{
 "cells": [
  {
   "cell_type": "code",
   "execution_count": 2,
   "metadata": {
    "collapsed": true,
    "ExecuteTime": {
     "end_time": "2023-06-14T14:16:56.858405500Z",
     "start_time": "2023-06-14T14:16:56.018235300Z"
    }
   },
   "outputs": [],
   "source": [
    "from common import *\n",
    "from prompts import *"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 3,
   "outputs": [],
   "source": [
    "TEMPLATE0 = \"\"\"\n",
    "    请根据以下context，回答：{query_str}\n",
    "    reply in {language_str}\n",
    "    ---------context\n",
    "    {context_str}\n",
    "    ---------\n",
    "\"\"\""
   ],
   "metadata": {
    "collapsed": false,
    "ExecuteTime": {
     "end_time": "2023-06-14T14:16:57.794583600Z",
     "start_time": "2023-06-14T14:16:57.768519400Z"
    }
   }
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "outputs": [],
   "source": [
    "TEMPLATE = \"\"\"\n",
    "    请根据以下context，回答：{query_str}\n",
    "\n",
    "    ---------context\n",
    "    {context_str}\n",
    "    ---------\n",
    "\n",
    "    Reply in {language_str} language\n",
    "\"\"\""
   ],
   "metadata": {
    "collapsed": false
   }
  },
  {
   "cell_type": "code",
   "execution_count": 4,
   "outputs": [],
   "source": [
    "import json\n",
    "import traceback\n",
    "\n",
    "import requests\n",
    "\n",
    "\n",
    "# 不能使用魔法\n",
    "def get_data_http(query=None, prompt=None, model='gpt-3.5-turbo'):\n",
    "    content = None\n",
    "    url = 'http://107.172.140.231:9000/v1/chat/completions'\n",
    "    headers = {'Authorization': 'Bearer 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',\n",
    "               'Content-Type': 'application/json'}\n",
    "\n",
    "    real_query = prompt.replace(\"{query_str}\", query)\n",
    "    data = {\n",
    "        \"model\": model, # \"gpt-3.5-turbo\"\n",
    "        \"messages\": [{\"role\": \"user\", \"content\": real_query}]\n",
    "    }\n",
    "    try:\n",
    "        response = requests.post(url, data=json.dumps(data), headers=headers)\n",
    "        print(response)\n",
    "        print(f\"query:{query}\")\n",
    "        print(f\"real_query:{real_query}\")\n",
    "        print(f\"response.status_code:{response.status_code}\")\n",
    "        print(f\"response.text:{response.text}\")\n",
    "        if response.status_code == 200:\n",
    "            json_dict = response.json()  # 解析JSON\n",
    "            print(f\"json_dict:{json_dict}\")\n",
    "            # 从JSON字符串中提取内容字段\n",
    "            content = json_dict['choices'][0]['message']['content']  # 获取指定字段\n",
    "            print(content)\n",
    "        else:\n",
    "            print(\"请求失败\")\n",
    "    except Exception as e:\n",
    "        traceback.print_exc()\n",
    "        print(f\"error:{e}\")\n",
    "    return content\n",
    "    # 处理响应结果\n"
   ],
   "metadata": {
    "collapsed": false
   }
  },
  {
   "cell_type": "code",
   "execution_count": 5,
   "outputs": [],
   "source": [
    "def chat(context,question,lang=\"简体中文\"):\n",
    "    query = TEMPLATE.replace(\"{context_str}\",context).replace(\"{query_str}\",question).replace(\"{language_str}\",lang)\n",
    "    gpt_model = \"gpt-3.5-turbo-16k\"\n",
    "    prompt = prompts.FIELD_EXTRACTOR_TEMPLATE\n",
    "    # result = get_openai_data(query, prompt=prompt, model=gpt_model)\n",
    "    result = get_data_http(query, prompt=prompt, model=gpt_model)\n",
    "    print(f\"+++++++++++++++++++++++++\\n{result}\")\n",
    "    # return result\n"
   ],
   "metadata": {
    "collapsed": false,
    "ExecuteTime": {
     "end_time": "2023-06-14T14:16:58.585832800Z",
     "start_time": "2023-06-14T14:16:58.576878400Z"
    }
   }
  },
  {
   "cell_type": "code",
   "execution_count": 1,
   "outputs": [],
   "source": [
    "thomas_kosten=\"\"\"\n",
    "Thomas Kosten, M.D.\n",
    "Jay H. Waggoner Endowed Chair\n",
    "713-794-7032\n",
    "Email\n",
    "kosten@bcm.edu\n",
    "Positions\n",
    "Jay H. Waggoner Endowed Chair\n",
    "Baylor College of Medicine\n",
    "Vice-Chair\n",
    "Psychiatry for Research\n",
    "Baylor College of Medicine\n",
    "Director\n",
    "Division of Alcohol and Addiction Psychiatry\n",
    "Baylor College of Medicine\n",
    "Co-Director\n",
    "Institute for Clinical and Translational Research\n",
    "Baylor College of Medicine\n",
    "Professor\n",
    "Psychiatry\n",
    "Baylor College of Medicine\n",
    "Houston, Texas US\n",
    "Professor\n",
    "Neuroscience\n",
    "Baylor College of Medicine\n",
    "Houston, Texas United States\n",
    "Professor\n",
    "Pharmacology\n",
    "Baylor College of Medicine\n",
    "Houston, Texas United States\n",
    "Professor\n",
    "Immunology and Rheumatology\n",
    "Baylor College of Medicine\n",
    "Houston, TX United States\n",
    "Member\n",
    "Dan L Duncan Comprehensive Cancer Center\n",
    "Baylor College of Medicine\n",
    "Houston, Texas United States\n",
    "Education\n",
    "MA from Yale University\n",
    "01/1995 - New Haven, Connecticut United States\n",
    "Clinical Fellowship at Yale University School of Medicine\n",
    "01/1983 - New Haven, Connecticut United States\n",
    "M.D. from Cornell University Medical College\n",
    "01/1977 - New York, NY United States\n",
    "BS from Rensselaer Polytechnic Institute\n",
    "01/1973 - Troy, New York United States\n",
    "Residency at Yale University School of Medicine\n",
    "01/1981 - New Haven, Connecticut United States\n",
    "Internship at Greenwich Hospital\n",
    "01/1978 - Greenwich, Connecticut United States\n",
    "Certifications\n",
    "Psychiatry/Addictions\n",
    "ABPN\n",
    "Professional Interests\n",
    "Developing medications and vaccines for addictions\n",
    "Pharmacology\n",
    "Websites\n",
    "VIICTR Publications List\n",
    "Selected Publications\n",
    "Malison RT, McCance E, Carpenter LL, Baldwin RM, Seibyl JP, Price LH, Kosten TR, Innis RB \"[123I]beta-CIT SPECT imaging of dopamine transporter availability after mazindol administration in human cocaine addicts..\" Psychopharmacology (Berl.). 1998 Jun;137(4):321-5. Pubmed PMID: 9676890\n",
    "Kosten TR, Rounsaville BJ, Kleber HD \"A 2.5-year follow-up of cocaine use among treated opioid addicts. Have our treatments helped?.\" Arch. Gen. Psychiatry. 1987 Mar;44(3):281-4. Pubmed PMID: 3827521\n",
    "Kosten TR, Rounsaville BJ, Kleber HD \"A 2.5 year follow-up of treatment retention and reentry among opioid addicts..\" J Subst Abuse Treat. 1986;3(3):181-9. Pubmed PMID: 3806731\n",
    "Kosten TR, Rounsaville BJ, Kleber HD \"A 2.5-year follow-up of depression, life crises, and treatment effects on abstinence among opioid addicts..\" Arch Gen Psychiatry. 1986 Aug;733-8. Pubmed PMID: 3729667\n",
    "Rounsaville BJ, Kosten TR, Weissmann MM, Kleber HD \"A 2.5-year follow-up of short-term interpersonal psychotherapy in methadone-maintained opiate addicts..\" Compr Psychiatry.;27(3):201-10. Pubmed PMID: 3709134\n",
    "Avants SK, Margolin A, DePhilippis D, Kosten TR \"A comprehensive pharmacologic-psychosocial treatment program for HIV-seropositive cocaine- and opioid-dependent patients. Preliminary findings..\" J Subst Abuse Treat.;15(3):261-5. Pubmed PMID: 9633038\n",
    "Rounsaville BJ, Kosten TR, Williams JB, Spitzer RL \"A field trial of DSM-III-R psychoactive substance dependence disorders..\" Am J Psychiatry. 1987 Mar;144(3):351-5. Pubmed PMID: 3826436\n",
    "Kosten TR, Steinberg M, Diakogiannis I A \"A cross-over trail of mazindol for cocaine dependence.\" Am J Addictions. 1993;161-164.\n",
    "Kosten TA, Shen XY, O'Malley PW, Kinsey BM, Lykissa ED, Orson FM, Kosten TR \"A morphine conjugate vaccine attenuates the behavioral effects of morphine in rats..\" Prog Neuropsychopharmacol Biol Psychiatry. 2013 Aug 1;223-9. Pubmed PMID: 23739535\n",
    "Margolin A, Kosten TR, Avants SK, Wilkins J, Ling W, Beckson M, Arndt IO, Cornish J, Ascher JA, Li SH \"A multicenter trial of bupropion for cocaine dependence in methadone-maintained patients..\" Drug Alcohol Depend. 1995 Dec;40(2):125-31. Pubmed PMID: 8745134\n",
    "Najavits LM, Kivlahan D, Kosten T \"A national survey of clinicians’ views of evidence-based therapies for PTSD and substance abuse.\" 2011;138-147.\n",
    "Rosen MI, McMahon TJ, Woods SW, Pearsall HR, Kosten TR \"A pilot study of dextromethorphan in naloxone-precipitated opiate withdrawal..\" Eur. J. Pharmacol.. 1996 Jul 4;307(3):251-7. Pubmed PMID: 8836612\n",
    "O'Connor PG, Oliveto AH, Shi JM, Triffleman E, Carroll KM, Kosten TR, Rounsaville BJ \"A pilot study of primary-care-based buprenorphine maintenance for heroin dependence..\" Am J Drug Alcohol Abuse. 1996 Nov;22(4):523-31. Pubmed PMID: 8911590\n",
    "George TP, Vessicchio JC, Termine A, Bregartner TA, Feingold A, Rounsaville BJ, Kosten TR \"A placebo controlled trial of bupropion for smoking cessation in schizophrenia.\" Biol Psychiatry. 2002 Jul 1;53-61. Pubmed PMID: 12079730\n",
    "Margolin A, Avants SK, DePhilippis D, Kosten TR \"A preliminary investigation of lamotrigine for cocaine abuse in HIV-seropositive patients..\" Am J Drug Alcohol Abuse. 1998 Feb;24(1):85-101. Pubmed PMID: 9513631\n",
    "George TP, Vessicchio JC, Termine A, Jatlow PI, Kosten TR, O'Malley SS \"A preliminary placebo-controlled trial of selegiline hydrochloride for smoking cessation..\" Biol. Psychiatry. 2003 Jan 15;53(2):136-43. Pubmed PMID: 12547469\n",
    "Kosten TR, Kreek MJ, Ragunath J, Kleber HD \"A preliminary study of beta endorphin during chronic naltrexone maintenance treatment in ex-opiate addicts..\" Life Sci.. 1986 Jul 7;39(1):55-9. Pubmed PMID: 2941636\n",
    "Kosten TR, Schumann B, Wright D, Carney MK, Gawin FH \"A preliminary study of desipramine in the treatment of cocaine abuse in methadone maintenance patients..\" J Clin Psychiatry. 1987 Nov;48(11):442-4. Pubmed PMID: 3680185\n",
    "Frank JB, Kosten TR, Giller EL, Dan E \"A randomized clinical trial of phenelzine and imipramine for posttraumatic stress disorder..\" Am J Psychiatry. 1988 Oct;145(10):1289-91. Pubmed PMID: 3048121\n",
    "Avants SK, Margolin A, Holford TR, Kosten TR \"A randomized controlled trial of auricular acupuncture for cocaine dependence..\" Arch. Intern. Med..;160(15):2305-12. Pubmed PMID: 10927727\n",
    "O'Connor PG, Oliveto AH, Shi JM, Triffleman EG, Carroll KM, Kosten TR, Rounsaville BJ, Pakes JA, Schottenfeld RS \"A randomized trial of buprenorphine maintenance for heroin dependence in a primary care clinic for substance users versus a methadone clinic..\" Am. J. Med.. 1998 Aug;105(2):100-5. Pubmed PMID: 9727815\n",
    "Kosten TR, McCance E \"A review of pharmacotherapies for substance abuse.\" The American Journal on Addictions. 1996;58-59.\n",
    "Shen XY, Kosten TA, Lopez AY, Kinsey BM, Kosten TR, Orson FM \"A vaccine against methamphetamine attenuates its behavioral effects in mice..\" Drug Alcohol Depend. 2013 Apr 1;129(41276):41-8. Pubmed PMID: 23022610\n",
    "Margolin A, Avants SK, Chang P, Birch S, Kosten TR \"A single-blind investigation of four auricular needle puncture configurations..\" Am. J. Chin. Med.. 1995;23(2):105-14. Pubmed PMID: 7572770\n",
    "Margolin A, Avants SK, Kosten TR \"Abstinence symptomatology associated with cessation of chronic cocaine abuse among methadone-maintained patients..\" Am J Drug Alcohol Abuse. 1996 Aug;22(3):377-88. Pubmed PMID: 8841686\n",
    "Kosten TR, Gawin FH, Rounsaville BJ, Kleber HD \"Abuse of cocaine with opioids: psychological aspects of treatment..\" NIDA Res. Monogr.. 1986;67:278-82. Pubmed PMID: 3092078\n",
    "Kinsey BM, Kosten TR, Orson FM \"Active immunotherapy for the Treatment of Cocaine Dependence..\" 2010 Apr 1;35(4):301-306. Pubmed PMID: 21796226\n",
    "Avants SK, Margolin A, Chang P, Kosten TR, Birch S \"Acupuncture for the treatment of cocaine addiction. Investigation of a needle puncture control..\" J Subst Abuse Treat.;12(3):195-205. Pubmed PMID: 7474027\n",
    "Jacobs S, Mason J, Kosten T, Kasl S, Ostfeld A, Atkins S, Gardner C, Schreiber S \"Acute bereavement, threatened loss, ego defenses and adrenocortical function.\" Psychother Psychosom. 1985;151-9. Pubmed PMID: 3832148\n",
    "Kosten TR \"Addiction as a brain disease..\" Am J Psychiatry. 1998 Jun;155(6):711-3. Pubmed PMID: 9619141\n",
    "Wallace EA, Wisniewski G, Zubal G, vanDyck CH, Pfau SE, Smith EO, Rosen MI, Sullivan MC, Woods SW, Kosten TR \"Acute cocaine effects on absolute cerebral blood flow..\" Psychopharmacology (Berl.). 1996 Nov;128(1):17-20. Pubmed PMID: 8944401\n",
    "Ziedonis D, Richardson T, Lee E, Petrakis I, Kosten T \"Adjunctive desipramine in the treatment of cocaine abusing schizophrenics.\" Psychopharmacol Bull. 1992;309-14. Pubmed PMID: 1480735\n",
    "Kosten TR \"Advances in clinical research on drug addiction: Opioids and cocaine.\" Substance Abuse. 1989;35-42.\n",
    "Sofuoglu M, Mouratidis M, Yoo S, Kosten T \"Adrenergic blocker carvedilol attenuates the cardiovascular and aversive effects of nicotine in abstinent smokers..\" Behav Pharmacol. 2006 Dec 17;731-5. Pubmed PMID: 17110799\n",
    "Ziedonis DM, Kosten TR \"Aggiornamento: Dipendenza da nicotina e schizofrenia.\" 1996;44-47.\n",
    "Kosten TR \"Advances in pharmacotherapy of stimulant dependence: From alcohol antagonists to Xenova vaccines.\" Clinical Neuroscience Research. 2005;169-173.\n",
    "Closser MH, Kosten TR \"Alcohol and cocaine abuse. A comparison of epidemiology and clinical characteristics..\" Recent Dev Alcohol. 1992;10:115-28. Pubmed PMID: 1317046\n",
    "Kosten TR, Kosten TA, Rounsaville BJ \"Alcoholism and depressive disorders in opioid addicts and their family members..\" Compr Psychiatry.;32(6):521-7. Pubmed PMID: 1778079\n",
    "13. Kosten TR, Krystal JH, Giller EL, Frank J, Dan E. \"Alexithymia as a predictor of treatment response in posttraumatic stress disorder.\" J Traumatic Stress. 1992;41-51.\n",
    "Cui Y, Versace F, Engelmann JM, Minnix JA, Robinson JD, Lam CY, Karam-Hage M, Brown VL, Wetter DW, Dani JA, Kosten TR, Cinciripini PM \"Alpha oscillations in response to affective and cigarette-related stimuli in smokers..\" Nicotine Tob. Res.. 2013 May;15(5):917-24. Pubmed PMID: 23060019\n",
    "Sellers EM, Ciraulo DA, DuPont RL, Griffiths RR, Kosten TR, Romach MK, Woody GE \"Alprazolam and benzodiazepine dependence..\" J Clin Psychiatry. 1993 Oct;54:64-75; discussi. Pubmed PMID: 8262891\n",
    "Xiu MH, Chen S, Wang F, Cao LY, Qi LY, Chen da C, Wu GY, Lu L, Kosten TA, Kosten TR, Zhang XY \"Altered interleukin-3 serum levels in drug-naïve and neuroleptic-treated schizophrenic patients..\" Schizophr. Res.. 2008 Dec;106(41308):369-70. Pubmed PMID: 18838250\n",
    "Petrakis IL, Satel SL, Stine S, Kosten TR, Normanworth SN, Charney DS, Krystal JH \"AMPT effects on cue-induced craving for cocaine.\" The American Journal of Addictions. 1996;313-320.\n",
    "Kosten TA, Kosten TR, Gawin FH, Gordon LT, Hogan I, Kleber HD \"An open trial of sertraline for cocaine abuse.\" Am J Addictions. 1992;349-353.\n",
    "Spellicy CJ, Kosten TR, Hamon SC, Harding MJ, Nielsen DA \"ANKK1 and DRD2 pharmacogenetics of disulfiram treatment for cocaine abuse..\" Pharmacogenet. Genomics. 2013 Jul;23(7):333-40. Pubmed PMID: 23635803\n",
    "Kosten TR, Rounsaville BJ, Kleber HD \"Antecedents and consequences of cocaine abuse among opioid addicts. A 2.5-year follow-up..\" J. Nerv. Ment. Dis.. 1988 Mar;176(3):176-81. Pubmed PMID: 3343591\n",
    "Shen X, Orson FM, Kosten TR \"Anti-addiction vaccines..\" F1000 Med Rep. 2011;3:20. Pubmed PMID: 22003367\n",
    "Brimijoin S, Orson F, Kosten TR, Kinsey B, Shen XY, White SJ, Gao Y \"Anti-cocaine antibody and butyrylcholinesterase-derived cocaine hydrolase exert cooperative effects on cocaine pharmacokinetics and cocaine-induced locomotor activity in mice..\" Chem. Biol. Interact.. 2013 Mar 25;203(1):212-6. Pubmed PMID: 22960160\n",
    "Leal J, Ziedonis D, Kosten T \"Antisocial personality disorder as a prognostic factor for pharmacotherapy of cocaine dependence.\" Drug Alcohol Depend. 1994 Mar;31-5. Pubmed PMID: 8082553\n",
    "Kinsey BM, Kosten TR, Orson FM \"Anti-cocaine vaccine development..\" Expert Rev Vaccines. 2010 Sep;9(9):1109-14. Pubmed PMID: 20822352\n",
    "Frank JB, Kosten TR, Giller EL \"Antidepressants in the treatment of PTSD..\" Am J Psychiatry. 1990 Feb;147(2):260. Pubmed PMID: 2301678\n",
    "Li CS, Kosten TR, Sinha R \"Antisocial personality and stress-induced brain activation in cocaine-dependent patients..\" Neuroreport. 2006 Feb 27;17(3):243-7. Pubmed PMID: 16462591\n",
    "Chen JX, Su YA, Wang SL, Bian QT, Liu YH, Wang N, Yang FD, Haile C, Kosten TR, Zhang XY \"Aripiprazole treatment of risperidone-induced hyperprolactinemia..\" J Clin Psychiatry. 2009 Jul;70(7):1058-9. Pubmed PMID: 19653986\n",
    "Kosten TR, Gottschalk PC, Tucker K, Rinder CS, Dey HM, Rinder HM \"Aspirin or amiloride for cerebral perfusion defects in cocaine dependence..\" Drug Alcohol Depend. 2003 Aug 20;71(2):187-94. Pubmed PMID: 12927657\n",
    "Hui L, Zhang X, Yu YQ, Han M, Huang XF, Chen da C, Wang ZR, Du WL, Kou CG, Yu Q, Kosten TR, Zhang XY \"Association between DBH 19bp insertion/deletion polymorphism and cognition in first-episode schizophrenic patients..\" Schizophr. Res.. 2013 Jul;147(41308):236-40. Pubmed PMID: 23707643\n",
    "Sun S, Wang F, Wei J, Cao LY, Wu GY, Lu L, Kosten TA, Kosten TR, Zhang XY \"Association between interleukin-3 receptor alpha polymorphism and schizophrenia in the Chinese population..\" Neurosci. Lett.. 2008 Jul 25;440(1):35-7. Pubmed PMID: 18547720\n",
    "Sun S, Wang F, Wei J, Cao LY, Qi LY, Xiu MH, Chen S, Li XH, Kosten TA, Kosten TR, Zhang XY \"Association between interleukin-6 receptor polymorphism and patients with schizophrenia..\" Schizophr. Res.. 2008 Jul;102(41277):346-7. Pubmed PMID: 18508242\n",
    "Qiu HT, Meng HQ, Song C, Xiu MH, Chen da C, Zhu FY, Wu GY, Kosten TA, Kosten TR, Zhang XY \"Association between monoamine oxidase (MAO)-A gene variants and schizophrenia in a Chinese population..\" Brain Res.. 2009 Sep 1;1287:67-73. Pubmed PMID: 19573521\n",
    "Cao JX, Hu J, Ye XM, Xia Y, Haile CA, Kosten TR, Zhang XY \"Association between the 5-HTR1B gene polymorphisms and alcohol dependence in a Han Chinese population..\" Brain Res.. 2011 Feb 28;1376:41283. Pubmed PMID: 21172311\n",
    "Avants SK, Margolin A, McMahon TJ, Kosten TR \"Association between self-report of cognitive impairment, HIV status, and cocaine use in a sample of cocaine-dependent methadone-maintained patients..\" Addict Behav.;22(5):599-611. Pubmed PMID: 9347062\n",
    "Wang F, Fan H, Sun H, Yang F, Luo Y, Liu H, Kosten TR, Lu L, Zhang XY \"Association between TNF-a promoter -308A/G polymorphism and tardive dyskinesiain Chinese Han patients with schizophrenia..\" Prog. Neuropsychopharmacol. Biol. Psychiatry. 2012 Apr 27;37(1):106-10. Pubmed PMID: 22227290\n",
    "Li W, Zhou N, Yu Q, Li X, Yu Y, Sun S, Kou C, Chen da C, Xiu MH, Kosten TR, Zhang XY \"Association of BDNF gene polymorphisms with schizophrenia and clinical symptoms in a Chinese population.\" Am J Med Genet B Neuropsychiatr Genet. 2013 Sep;538-45. Pubmed PMID: 23832605\n",
    "Zhang XY, Tan YL, Zhou DF, Haile CN, Cao LY, Xu Q, Shen Y, Kosten TA, Kosten TR \"Association of clozapine-induced weight gain with a polymorphism in the leptin promoter region in patients with chronic schizophrenia in a Chinese population..\" J Clin Psychopharmacol. 2007 Jun;27(3):246-51. Pubmed PMID: 17502770\n",
    "Li WJ, Kou CG, Yu Y, Sun S, Zhang X, Kosten TR, Zhang XY \"Association of Catechol-O-methyltransferase gene polymorphisms with schizophrenia and negative symptoms in a Chinese population..\" Am. J. Med. Genet. B Neuropsychiatr. Genet.. 2012 Jun;159(4):370-5. Pubmed PMID: 22354729\n",
    "Guo S, Chen da F, Zhou DF, Sun HQ, Wu GY, Haile CN, Kosten TA, Kosten TR, Zhang XY \"Association of functional catechol O-methyl transferase (COMT) Val108Met polymorphism with smoking severity and age of smoking initiation in Chinese male smokers..\" Psychopharmacology (Berl.). 2007 Mar;190(4):449-56. Pubmed PMID: 17206495\n",
    "Sun H, Guo S, Chen D, Yang F, Zou Y, Di X, Cao Y, Kosten T, Lu L, Zhang XY \"Association of functional COMT Val108/Met polymorphism with smoking cessation in a nicotine replacement therapy..\" 2012 Jun 14; Pubmed PMID: 22695756\n",
    "Brown AE, Pavlik VN, Shegog R, Whitney SN, Friedman LC, Romero C, Davis GC, Cech I, Kosten TR, Volk RJ \"Association of spirituality and sobriety during a behavioral spirituality intervention for Twelve Step (TS) recovery..\" Am J Drug Alcohol Abuse. 2007;33(4):611-7. Pubmed PMID: 17668347\n",
    "Zhang XY, Chen DC, Xiu MH, Hui L, Liu H, Luo X, Zuo L, Zhang H, Kosten TA, Kosten TR \"Association of functional dopamine-beta-hydroxylase (DBH) 19bp insertion/deletion polymorphism with smoking severity in male schizophrenic smokers..\" Schizophr. Res.. 2012 Aug 4; Pubmed PMID: 22871345\n",
    "Liu H, Wang C, Chen PH, Zhang BS, Zheng YL, Zhang CX, Meng HQ, Wang Y, Chen da C, Xiu MH, Kosten TR, Zhang XY \"Association of the manganese superoxide dismutase gene Ala-9Val polymorphism with clinical phenotypes and tardive dyskinesia in schizophrenic patients..\" Prog. Neuropsychopharmacol. Biol. Psychiatry. 2010 May 30;34(4):692-6. Pubmed PMID: 20346996\n",
    "Zhou N, Yu Q, Li X, Yu Y, Kou C, Li W, Xu H, Luo X, Zuo L, Kosten TR, Zhang XY \"Association of the dopamine ß-hydroxylase 19?bp insertion/deletion polymorphism with positive symptoms but not tardive dyskinesia in schizophrenia..\" Hum Psychopharmacol. 2013 May;28(3):230-7. Pubmed PMID: 23559427\n",
    "Sofuoglu M, Poling J, Hill K, Kosten T \"Atomoxetine attenuates dextroamphetamine effects in humans..\" Am J Drug Alcohol Abuse. 2009;35(6):412-6. Pubmed PMID: 20014909\n",
    "Jacobs SC, Kosten TR, Kasl SV, Ostfeld AM, Berkman l, Charpentier P \"Attachment theory and multiple dimensions of grief.\" 1988;41-52.\n",
    "Krystal JH, McDougle CJ, Kosten TR, Price LH, Aghajanian GK, Charney DS \"Baclofen-assisted detoxification from opiates. A pilot study..\" J Subst Abuse Treat. 1992;9(2):139-42. Pubmed PMID: 1324986\n",
    "Zhang XY, Zhou DF, Wu GY, Cao LY, Tan YL, Haile CN, Li J, Lu L, Kosten TA, Kosten TR \"BDNF levels and genotype are associated with antipsychotic-induced weight gain in patients with chronic schizophrenia..\" Neuropsychopharmacology. 2008 Aug;33(9):2200-5. Pubmed PMID: 17987059\n",
    "Zhang XY, Chen da C, Xiu MH, Luo X, Zuo L, Haile CN, Kosten TA, Kosten TR \"BDNF Val66Met Variant and Smoking in a Chinese Population..\" PLoS ONE. 2012;7(12):e53295. Pubmed PMID: 23285275\n",
    "Oliveto A, Gentry WB, Pruzinsky R, Gonsai K, Kosten TR, Martell B, Poling J \"Behavioral effects of gamma-hydroxybutyrate in humans..\" Behav Pharmacol. 2010 Jul;21(4):332-42. Pubmed PMID: 20526195\n",
    "Hameedi FA, Rosen MI, McCance-Katz EF, McMahon TJ, Price LH, Jatlow PI, Woods SW, Kosten TR \"Behavioral, physiological, and pharmacological interaction of cocaine and disulfiram in humans..\" Biol. Psychiatry. 1995 Apr 15;37(8):560-3. Pubmed PMID: 7619981\n",
    "Kosten TR, Fontana A, Sernyak MJ, Rosenheck R \"Benzodiazepine use in posttraumatic stress disorder among veterans with substance abuse..\" J. Nerv. Ment. Dis.. 2000 Jul;188(7):454-9. Pubmed PMID: 10919705\n",
    "Jacobs SC, Mason JW, Kosten TR, Wahby V, Kasl SV, Ostfeld AM \"Bereavement and catecholamines..\" J Psychosom Res. 1986;30(4):489-96. Pubmed PMID: 3761233\n",
    "Kosten TR, Morgan C, Kreek MJ \"Beta endorphin levels during heroin, methadone, buprenorphine, and naloxone challenges: preliminary findings..\" Biol. Psychiatry. 1992 Sep 15;32(6):523-8. Pubmed PMID: 1445968\n",
    "Kosten TR, Kreek MJ, Swift C, Carney MK, Ferdinands L \"Beta endorphin levels in CSF during methadone maintenance..\" Life Sci.. 1987 Aug 31;41(9):1071-6. Pubmed PMID: 2956475\n",
    "Kosten TR, Krystal J \"Biological mechanisms in posttraumatic stress disorder. Relevance for substance abuse..\" Recent Dev Alcohol. 1988; Pubmed PMID: 3283864\n",
    "Zhang XY, Zhang WF, Zhou DF, Chen DC, Xiu MH, Wu HR, Haile CN, Kosten TA, Kosten TR \"Brain-Derived Neurotrophic Factor Levels and Its Val66Met Gene Polymorphism Predict Tardive Dyskinesia Treatment Response to Ginkgo Biloba..\" 2012 Jun 11; Pubmed PMID: 22695185\n",
    "Wang ZR, Zhou DF, Cao LY, Tan YL, Zhang XY, Li J, Lu L, Wu GY, Kosten TA, Kosten TR \"Brain-derived neurotrophic factor polymorphisms and smoking in schizophrenia..\" Schizophr. Res.. 2007 Dec;97(41277):299-301. Pubmed PMID: 17869486\n",
    "Kosten TR, Kleber HD \"Buprenorphine detoxification from opioid dependence: a pilot study..\" Life Sci.. 1988;42(6):635-41. Pubmed PMID: 3276999\n",
    "Kosten TR, Rosen MI, Schottenfeld R, Ziedonis D \"Buprenorphine for cocaine and opiate dependence..\" Psychopharmacol Bull. 1992;28(1):15-9. Pubmed PMID: 1609037\n",
    "Kosten TR, Fiellin DA \"Buprenorphine for office-based practice: consensus conference overview..\" Am J Addict. 2004;13:S1-7. Pubmed PMID: 15204671\n",
    "Rosenheck R, Kosten T \"Buprenorphine for opiate addiction: potential economic impact..\" Drug Alcohol Depend. 2001 Aug 1;63(3):253-62. Pubmed PMID: 11418229\n",
    "Kosten TR \"Buprenorphine for opioid detoxification: A brief review.\" Addictive Disorders and Their Treatment. 2003;\n",
    "Kosten TR, Morgan CJ, Kleber HD \"Buprenorphine treatment of cocaine abuse..\" NIDA Res. Monogr.. 1989;95:461. Pubmed PMID: 2641031\n",
    "Kosten TR, Schottenfeld R, Ziedonis D, Falcioni J \"Buprenorphine versus methadone maintenance for opioid dependence..\" J. Nerv. Ment. Dis.. 1993 Jun;181(6):358-64. Pubmed PMID: 8501457\n",
    "Schottenfeld RS, Pakes JR, Oliveto A, Ziedonis D, Kosten TR \"Buprenorphine vs methadone maintenance treatment for concurrent opioid dependence and cocaine abuse..\" Arch. Gen. Psychiatry. 1997 Aug;54(8):713-20. Pubmed PMID: 9283506\n",
    "Rosen MI, Kosten TR \"Buprenorphine: beyond methadone?.\" Hosp Community Psychiatry. 1991 Apr;42(4):347-9. Pubmed PMID: 2050347\n",
    "Schottenfeld RS, Pakes J, Ziedonis D, Kosten TR \"Buprenorphine: dose-related effects on cocaine and opioid use in cocaine-abusing opioid-dependent humans..\" Biol. Psychiatry.;34(41276):66-74. Pubmed PMID: 8373940\n",
    "Rosen MI, Wallace EA, McMahon TJ, Pearsall HR, Woods SW, Price LH, Kosten TR \"Buprenorphine: duration of blockade of effects of intramuscular hydromorphone..\" Drug Alcohol Depend. 1994 Apr;35(2):141-9. Pubmed PMID: 7519977\n",
    "Kosten TR \"Can cocaine craving be a medication development outcome: drug craving and relapse in opioid and cocaine dependence.\" Am J Addictions. 1992;\n",
    "Kosten TR, Domingo CB \"Can you vaccinate against substance abuse?.\" Expert Opin Biol Ther. 2013 Aug; Pubmed PMID: 23594123\n",
    "D'Souza DC, Kosten TR \"Cannabinoid antagonists: a treatment in search of an illness..\" Arch. Gen. Psychiatry. 2001 Apr;58(4):330-1. Pubmed PMID: 11296092\n",
    "Rosen MI, Pearsall HR, Price LH, McDougle CJ, Woods SW, Kosten TR \"Carbamazepine vs. oxazepam for benzodiazepine detoxification in methadone maintained patients.\" Am J Addictions. 1993;\n",
    "Gottschalk PC, Kosten TR \"Cerebral perfusion defects in combined cocaine and alcohol dependence..\" Drug Alcohol Depend. 2002 Sep 1;68(1):95-104. Pubmed PMID: 12167555\n",
    "West JC, Kosten TR, Wilk J, Svikis D, Triffleman E, Rae DS, Narrow WE, Duffy FF, Regier DA \"Challenges in increasing access to buprenorphine treatment for opiate addiction..\" Am J Addict. 2004;13:S8-16. Pubmed PMID: 15204672\n",
    "Avants SK, Margolin A, Kosten TR, Singer JL \"Changes concurrent with initiation of abstinence from cocaine abuse..\" J Subst Abuse Treat.;10(6):577-83. Pubmed PMID: 8308943\n",
    "Carroll KM, Kosten TR, Rounsaville BJ \"Choosing a behavioral therapy platform for pharmacotherapy of substance users..\" Drug Alcohol Depend. 2004 Aug 16;75(2):123-34. Pubmed PMID: 15276217\n",
    "McCance-Katz EF, Kosten TR, Jatlow P \"Chronic disulfiram treatment effects on intranasal cocaine administration: initial results..\" Biol. Psychiatry. 1998 Apr 1;43(7):540-3. Pubmed PMID: 9547934\n",
    "Kosten TR, Kreek MJ, Ragunath J, Kleber HD \"Chronic naltrexone effect on cortisol..\" NIDA Res. Monogr.. 1986;67:362-5. Pubmed PMID: 3092091\n",
    "Zhang XY, Chen da C, Xiu MH, Haile CN, Sun H, Lu L, Kosten TA, Kosten TR \"Cigarette Smoking and Cognitive Function in Chinese Male Schizophrenia: A Case-Control study..\" PLoS ONE. 2012;7(5):e36563. Pubmed PMID: 22570726\n",
    "Zhang XY, Liang J, Chen da C, Xiu MH, He J, Cheng W, Wu Z, Yang FD, Haile CN, Sun H, Lu L, Kosten TA, Kosten TR \"Cigarette smoking in male patients with chronic schizophrenia in a Chinese population: prevalence and relationship to clinical phenotypes..\" PLoS ONE. 2012;7(2):e30937. Pubmed PMID: 22347412\n",
    "Zhang XY, Chen DC, Xiu MH, Haile CN, He SC, Luo X, Zuo L, Rosenheck R, Kosten TA, Kosten TR \"Cigarette smoking, psychopathology and cognitive function in first-episode drug-naive patients with schizophrenia: a case-control study..\" Psychol Med. 2013; Pubmed PMID: 23149169\n",
    "Li SX, Shi J, Epstein DH, Wang X, Zhang XL, Bao YP, Zhang D, Zhang XY, Kosten TR, Lu L \"Circadian alteration in neurobiology during 30 days of abstinence in heroin users..\" Biol. Psychiatry. 2009 May 15;65(10):905-12. Pubmed PMID: 19135652\n",
    "Kosten TR \"Client issues in drug abuse treatment: addressing multiple drug abuse..\" NIDA Res. Monogr.. 1991;106:136-51. Pubmed PMID: 1922284\n",
    "Kosten TR \"Clinical and research perspectives on cocaine abuse: the pharmacotherapy of cocaine abuse..\" NIDA Res. Monogr.. 1993;135:48-56. Pubmed PMID: 8289903\n",
    "Li SX, Liu LJ, Jiang WG, Sun LL, Zhou SJ, Le Foll B, Zhang XY, Kosten TR, Lu L \"Circadian alteration in neurobiology during protracted opiate withdrawal in rats..\" J. Neurochem.. 2010 Oct;115(2):353-62. Pubmed PMID: 20738730\n",
    "Poling J, Pruzinsky R, Kosten TR, Gonsai K, Sofuoglu M, Gonzalez G, Oliveto A \"Clinical efficacy of citalopram alone or augmented with bupropion in methadone-stabilized patients..\" Am J Addict.;16(3):187-94. Pubmed PMID: 17612822\n",
    "González G, Desai R, Sofuoglu M, Poling J, Oliveto A, Gonsai K, Kosten TR \"Clinical efficacy of gabapentin versus tiagabine for reducing cocaine use among cocaine dependent methadone-treated patients..\" Drug Alcohol Depend. 2007 Feb 23;87(1):41283. Pubmed PMID: 16930857\n",
    "Mancino MJ, McGaugh J, Chopra MP, Guise JB, Cargile C, Williams DK, Thostenson J, Kosten TR, Sanders N, Oliveto A \"Clinical efficacy of sertraline alone and augmented with gabapentin in recently abstinent cocaine-dependent patients with depressive symptoms..\" J Clin Psychopharmacol. 2014 Apr; Pubmed PMID: 24525654\n",
    "Zhang XY, Chen da C, Xiu MH, Tan YL, Yang FD, Zhang LY, Zhang LY, Haile CN, Kosten TR \"Clinical symptoms and cognitive impairment associated with male schizophrenia relate to plasma manganese superoxide dismutase activity: A case-control study..\" J Psychiatr Res. 2013 Aug;47(8):1049-53. Pubmed PMID: 23611682\n",
    "Vining E, Kosten TR, Kleber HD \"Clinical utility of rapid clonidine-naltrexone detoxification for opioid abusers..\" Br J Addict. 1988 May;83(5):567-75. Pubmed PMID: 3382815\n",
    "Kosten TR, Gawin FH, Rounsaville BJ, Kleber HD \"Cocaine abuse among opioid addicts: demographic and diagnostic factors in treatment..\" Am J Drug Alcohol Abuse. 1986;12(41276):41290. Pubmed PMID: 3788892\n",
    "McCance EF, Price LH, Kosten TR, Jatlow PI \"Cocaethylene: pharmacology, physiology and behavioral effects in humans..\" J. Pharmacol. Exp. Ther.. 1995 Jul;274(1):215-23. Pubmed PMID: 7616402\n",
    "Kleber HD, Riordan CE, Rounsaville B, Kosten T, Charney D, Gaspari J, Hogan I, O'Connor C \"Clonidine in outpatient detoxification from methadone maintenance.\" Arch Gen Psychiatry. 1985 Apr; Pubmed PMID: 3977557\n",
    "Kleber HD, Topazian M, Gaspari J, Riordan CE, Kosten T \"Clonidine and naltrexone in the outpatient treatment of heroin withdrawal..\" Am J Drug Alcohol Abuse. 1987; Pubmed PMID: 3687878\n",
    "Kosten TA, Kosten TR \"Cocaine abuse and opioid withdrawal..\" Lancet. 1989 Jul 15;2(8655):165-6. Pubmed PMID: 2567937\n",
    "Avants SK, Margolin A, Kosten TR \"Cocaine abuse in methadone maintenance programs: integrating pharmacotherapy with psychosocial interventions..\" J Psychoactive Drugs.;26(2):137-46. Pubmed PMID: 7931858\n",
    "Stine SM, Satel S, Kosten TR \"Cocaine precipitation of patient identified opiate withdrawal.\" Am J Addictions. 1993;\n",
    "Kosten TA, Kosten TR, Rounsaville BJ \"Cocaine symptoms are predicted by familial psychopathology..\" NIDA Res. Monogr.. 1990;105:603-4. Pubmed PMID: 1876139\n",
    "Oliveto AH, Kosten TR, Schottenfeld RS, Ziedonis D, Falcioni J \"Cocaine use in buprenorphine vs. methadone maintained cocaine users.\" Am J Addictions. 1994;\n",
    "Martell BA, Orson FM, Poling J, Mitchell E, Rossen RD, Gardner T, Kosten TR \"Cocaine vaccine for the treatment of cocaine dependence in methadone-maintained patients: a randomized, double-blind, placebo-controlled efficacy trial..\" Arch. Gen. Psychiatry. 2009 Oct;66(10):1116-23. Pubmed PMID: 19805702\n",
    "Sofuoglu M, Poling J, Gonzalez G, Gonsai K, Kosten T \"Cocaine withdrawal symptoms predict medication response in cocaine users..\" Am J Drug Alcohol Abuse. 2006;32(4):617-27. Pubmed PMID: 17127550\n",
    "Rosen MI, Kosten T \"Cocaine-associated panic attacks in methadone-maintained patients..\" Am J Drug Alcohol Abuse. 1992; Pubmed PMID: 1314016\n",
    "Zhang XY, Chen da C, Xiu MH, Haile CN, Luo X, Xu K, Zhang HP, Zuo L, Zhang Z, Zhang X, Kosten TA, Kosten TR \"Cognitive and serum BDNF correlates of BDNF Val66Met gene polymorphism in patients with schizophrenia and normal controls..\" Hum. Genet.. 2012 Jul;131(7):1187-95. Pubmed PMID: 22362486\n",
    "Gottschalk C, Beauvais J, Hart R, Kosten T \"Cognitive function and cerebral perfusion during cocaine abstinence..\" Am J Psychiatry. 2001 Apr; Pubmed PMID: 11282686\n",
    "Zhang XY, Chen da C, Xiu MH, Yang FD, Tan Y, Luo X, Zuo L, Kosten TA, Kosten TR \"Cognitive function, plasma MnSOD activity, and MnSOD Ala-9Val polymorphism in patients with schizophrenia and normal controls..\" Schizophr Bull. 2014 May; Pubmed PMID: 23588476\n",
    "Gonzalez G, Oliveto A, Kosten TR \"Combating opiate dependence: a comparison among the available pharmacological options..\" Expert Opin Pharmacother. 2004 Apr;5(4):713-25. Pubmed PMID: 15102558\n",
    "Kosten TR \"Combining family therapy with pharmacotherapy in opioid addicts: Use of naltrexone.\" International Journal of Family Psychiatry. 1986;\n",
    "Carroll ME, Zlebnik NE, Anker JJ, Kosten TR, Orson FM, Shen X, Kinsey B, Parks RJ, Gao Y, Brimijoin S \"Combined cocaine hydrolase gene transfer and anti-cocaine vaccine synergistically block cocaine-induced locomotion..\" PLoS One. 2012; Pubmed PMID: 22912888\n",
    "Kosten TR \"Commentary: Commitment for substance abuse- Current judicial interventions.\" The Journal of the American Academy of Psychi. 2002;\n",
    "Kosten TR, Price LH \"Commentary on: Phenomenology and sequelae of MDMA use..\" J Nervous Mental Dis. 1992;\n",
    "Gonzalez G, Feingold A, Oliveto A, Gonsai K, Kosten TR \"Comorbid major depressive disorder as a prognostic factor in cocaine-abusing buprenorphine-maintained patients treated with desipramine and contingency management..\" Am J Drug Alcohol Abuse. 2003 Aug;29(3):497-514. Pubmed PMID: 14510037\n",
    "Kosten TR, Rounsaville BJ, Kleber HD \"Comparison of clinician ratings to self reports of withdrawal during clonidine detoxification of opiate addicts..\" Am J Drug Alcohol Abuse. 1985;11(41276):41284. Pubmed PMID: 3904410\n",
    "Kosten TR, Jalali B, Kleber HD \"Complementary marital roles of male heroin addicts: evolution and intervention tactics..\" Am J Drug Alcohol Abuse.;9(2):155-69. Pubmed PMID: 7171079\n",
    "McCance-Katz EF, Price LH, McDougle CJ, Kosten TR, Black JE, Jatlow PI \"Concurrent cocaine-ethanol ingestion in humans: pharmacology, physiology, behavior, and the role of cocaethylene..\" Psychopharmacology (Berl.). 1993;111(1):39-46. Pubmed PMID: 7870932\n",
    "McCance-Katz EF, Kosten TR, Jatlow P \"Concurrent use of cocaine and alcohol is more potent and potentially more toxic than use of either alone--a multiple-dose study..\" Biol. Psychiatry. 1998 Aug 15;44(4):250-9. Pubmed PMID: 9715356\n",
    "Kosten TR, Rounsaville BJ, Kleber HD \"Concurrent validity of the addiction severity index..\" J. Nerv. Ment. Dis.. 1983 Oct;171(10):606-10. Pubmed PMID: 6619823\n",
    "Fiellin DA, Kleber H, Trumble-Hejduk JG, McLellan AT, Kosten TR \"Consensus statement on office-based treatment of opioid dependence using buprenorphine..\" J Subst Abuse Treat. 2004 Sep;27(2):153-9. Pubmed PMID: 15450648\n",
    "Petry NM, Petrakis I, Trevisan L, Wiredu G, Boutros NN, Martin B, Kosten TR \"Contingency management interventions: from research to practice..\" Am J Psychiatry. 2001 May;158(5):694-702. Pubmed PMID: 11329388\n",
    "Fiellin DA, Rosenheck RA, Kosten TR \"Coordination of medical care and opioid dependence treatment in primary care: a case report..\" Subst Abus. 2003 Mar; Pubmed PMID: 12652094\n",
    "Boutros NN, Lisanby SH, McClain-Furmanski D, Oliwa G, Gooding D, Kosten TR \"Cortical excitability in cocaine-dependent patients: a replication and extension of TMS findings..\" J Psychiatr Res. 2005 May;39(3):295-302. Pubmed PMID: 15725428\n",
    "Kosten TR, Kreek MJ, Ragunath J, Kleber HD \"Cortisol levels during chronic naltrexone maintenance treatment in ex-opiate addicts..\" Biol. Psychiatry. 1986 Feb;21(2):217-20. Pubmed PMID: 3947698\n",
    "Margolin A, Avants SK, Kosten TR \"Cue-elicited cocaine craving and autogenic relaxation. Association with treatment outcome..\" J Subst Abuse Treat.;11(6):549-52. Pubmed PMID: 7884838\n",
    "Kosten TR, Scanley BE, Tucker KA, Oliveto A, Prince C, Sinha R, Potenza MN, Skudlarski P, Wexler BE \"Cue-induced brain activity changes and relapse in cocaine-dependent patients..\" Neuropsychopharmacology. 2006 Mar;31(3):644-50. Pubmed PMID: 16123763\n",
    "Kosten TR, Scanley BE, Tucker K, Oliveto A, Prince C, Sinha R, Potenza MN, Skudlarski P, Wexler BE \"Cue-induced brain activity changes and treatment outcome in depressed cocaine dependent patients.\" Neuropsychopharmacology. 2006;\n",
    "Gottschalk PC, Jacobsen LK, Kosten TR \"Current concepts in pharmacotherapy of substance abuse..\" Curr Psychiatry Rep. 1999 Dec;1(2):172-8. Pubmed PMID: 11122921\n",
    "Gottchalk PCH, Jacobsen LK, Kosten TR \"Current concepts in pharmacotherapy of substance abuse-the dawn of a new era.\" Current Psychiatry Reports. 1999;\n",
    "Kosten TR, O’Connor PG \"Current concepts-management of drug withdrawal.\" New England Journal of Medicine. 2003;\n",
    "Kosten TR \"Current pharmacotherapies for opioid dependence.\" Psychopharmacol Bull. 1990; Pubmed PMID: 2196628\n",
    "Oliveto A, Benios T, Gonsai K, Feingold A, Poling J, Kosten TR \"D-cycloserine-Naloxone interactions in opioid-dependent humans under a novel-response naloxone discrimination procedure..\" Exp Clin Psychopharmacol. 2003 Aug;11(3):237-46. Pubmed PMID: 12940503\n",
    "Avants SK, Margolin A, Sindelar JL, Rounsaville BJ, Schottenfeld R, Stine S, Cooney NL, Rosenheck RA, Li SH, Kosten TR \"Day treatment versus enhanced standard methadone services for opioid-dependent patients: a comparison of clinical efficacy and cost..\" Am J Psychiatry. 1999 Jan; Pubmed PMID: 9892294\n",
    "Kosten TR, Domingo CB, Hamon SC, Nielsen DA \"DBH gene as predictor of response in a cocaine vaccine clinical trial..\" Neurosci. Lett.. 2013 Apr 29;541:29-33. Pubmed PMID: 23458673\n",
    "Silverman DG, Kosten TR, Jatlow PI, Gutter V, Fleming J, O'Connor TZ, Byck R \"Decreased digital flow persists after the abatement of cocaine-induced hemodynamic stimulation..\" Anesth. Analg.. 1997 Jan;84(1):46-50. Pubmed PMID: 8988997\n",
    "Chen da C, Wang J, Wang B, Yang SC, Zhang CX, Zheng YL, Li YL, Wang N, Yang KB, Xiu MH, Kosten TR, Zhang XY \"Decreased levels of serum brain-derived neurotrophic factor in drug-naïve first-episode schizophrenia: relationship to clinical phenotypes..\" Psychopharmacology (Berl.). 2009 Dec;207(3):375-80. Pubmed PMID: 19787338\n",
    "Yang YQ, Sun S, Yu YQ, Li WJ, Zhang X, Xiu MH, Chen da C, Yang FD, Liu H, Li C, Kosten TR, Zhang XY \"Decreased serum brain-derived neurotrophic factor levels in schizophrenic patients with tardive dyskinesia..\" Neurosci. Lett.. 2011 Sep 8;502(1):37-40. Pubmed PMID: 21798311\n",
    "Xiu MH, Hui L, Dang YF, Hou TD, Zhang CX, Zheng YL, Chen da C, Kosten TR, Zhang XY \"Decreased serum BDNF levels in chronic institutionalized schizophrenia on long-term treatment with typical and atypical antipsychotics..\" Prog. Neuropsychopharmacol. Biol. Psychiatry. 2009 Nov 13;33(8):1508-12. Pubmed PMID: 19720106\n",
    "Kosten TR, Markou A, Koob GF \"Depression and stimulant dependence: neurobiology and pharmacotherapy..\" J. Nerv. Ment. Dis.. 1998 Dec;186(12):737-45. Pubmed PMID: 9865811\n",
    "Kosten T, Falcioni J, Oliveto A, Feingold A \"Depression predicts higher rates of heroin use on desipramine with buprenorphine than with methadone..\" Am J Addict. 2004 Mar; Pubmed PMID: 15204669\n",
    "Ziedonis DM, Kosten TR \"Depression as a prognostic factor for pharmacological treatment of cocaine dependence..\" Psychopharmacol Bull. 1991;27(3):337-43. Pubmed PMID: 1775608\n",
    "Kosten TR, Morgan C, Kosten TA \"Depressive symptoms during buprenorphine treatment of opioid abusers..\" J Subst Abuse Treat. 1990;7(1):51-4. Pubmed PMID: 2313769\n",
    "Jacobs S, Kosten TR \"Depressive syndromes during acute bereavement: Indications for professional intervention.\" Yale Psychiatric Quarterly. 1983;\n",
    "Satel SL, Kosten TR \"Designing drug efficacy trials in the treatment of cocaine abuse..\" J Nerv Ment Dis. 1991 Feb; Pubmed PMID: 1990076\n",
    "Kosten TR, Gawin FH, Morgan C, Nelson JC, Jatlow P \"Desipramine and its 2-hydroxy metabolite in patients taking or not taking methadone..\" Am J Psychiatry. 1990 Oct;147(10):1379-80. Pubmed PMID: 2400009\n",
    "Kosten T, Oliveto A, Feingold A, Poling J, Sevarino K, McCance-Katz E, Stine S, Gonzalez G, Gonsai K \"Desipramine and contingency management for cocaine and opiate dependence in buprenorphine maintained patients.\" Drug Alcohol Depend. 2003 Jun; Pubmed PMID: 12757969\n",
    "Gawin FH, Kleber HD, Byck R, Rounsaville BJ, Kosten TR, Jatlow PI, Morgan C \"Desipramine facilitation of initial cocaine abstinence..\" Arch. Gen. Psychiatry. 1989 Feb;46(2):117-21. Pubmed PMID: 2492422\n",
    "Oliveto AH, Feingold A, Schottenfeld R, Jatlow P, Kosten TR \"Desipramine in opioid-dependent cocaine abusers maintained on buprenorphine vs methadone..\" Arch. Gen. Psychiatry. 1999 Sep;56(9):812-20. Pubmed PMID: 12884887\n",
    "Kosten T, Sofuoglu M, Poling J, Gonsai K, Oliveto A \"Desipramine treatment for cocaine dependence in buprenorphine- or methadone-treated patients: baseline urine results as predictor of response..\" Am J Addict.;14(1):41503. Pubmed PMID: 15804873\n",
    "Oliveto A, Kosten TR, Schottenfeld R, Falcioni J, Ziedonis D \"Desipramine, amantadine, or fluoxetine in buprenorphine-maintained cocaine users..\" J Subst Abuse Treat.;12(6):423-8. Pubmed PMID: 8749726\n",
    "Kosten TR \"Diagnosing depression with the DST and TRH in cocaine and opioid abusers..\" J Subst Abuse Treat. 1986;3(1):47-9. Pubmed PMID: 3090273\n",
    "Han M, Huang XF, Chen da C, Xiu M, Kosten TR, Zhang XY \"Diabetes and cognitive deficits in chronic schizophrenia: a case-control study.\" PLoS One. 2013 Jun; Pubmed PMID: 23840437\n",
    "Avants SK, Margolin A, Kosten TR, Cooney NL \"Differences between responders and nonresponders to cocaine cues in the laboratory..\" Addict Behav.;20(2):215-24. Pubmed PMID: 7484315\n",
    "Cui Y, Robinson JD, Versace F, Lam CY, Minnix JA, Karam-Hage M, Dani JA, Kosten TR, Wetter DW, Brown VL, Cinciripini PM \"Differential cigarette-related startle cue reactivity among light, moderate, and heavy smokers..\" Addict Behav. 2012 Aug;37(8):885-9. Pubmed PMID: 22571920\n",
    "Kosten TR, Kleber HD \"Differential diagnosis of psychiatric comorbidity in substance abusers..\" J Subst Abuse Treat. 1988;5(4):201-6. Pubmed PMID: 3216436\n",
    "Oliveto AH, Rosen MI, Woods SW, Kosten TR \"Discriminative stimulus, self-reported and cardiovascular effects of orally administered cocaine in humans..\" J Pharmacol Exp Ther. 1995 Jan; Pubmed PMID: 7815337\n",
    "Zhang XY, Tan YL, Zhou DF, Cao LY, Wu GY, Haile CN, Kosten TA, Kosten TR \"Disrupted antioxidant enzyme activity and elevated lipid peroxidation products in schizophrenic patients with tardive dyskinesia..\" J Clin Psychiatry. 2007 May;68(5):754-60. Pubmed PMID: 17503985\n",
    "McCance-Katz EF, Kosten TR, Jatlow P \"Disulfiram effects on acute cocaine administration..\" Drug Alcohol Depend. 1998 Sep 1;52(1):27-39. Pubmed PMID: 9788003\n",
    "Sofuoglu M, Poling J, Waters A, Sewell A, Hill K, Kosten T \"Disulfiram enhances subjective effects of dextroamphetamine in humans..\" Pharmacol Biochem Behav. 2008 Sep; Pubmed PMID: 18474395\n",
    "Haile CN, During MJ, Jatlow PI, Kosten TR, Kosten TA \"Disulfiram facilitates the development and expression of locomotor sensitization to cocaine in rats..\" Biol. Psychiatry. 2003 Nov 1;54(9):915-21. Pubmed PMID: 14573319\n",
    "George TP, Chawarski MC, Pakes J, Carroll KM, Kosten TR, Schottenfeld RS \"Disulfiram versus placebo for cocaine dependence in buprenorphine-maintained subjects: a preliminary trial..\" Biol. Psychiatry. 2000 Jun 15;47(12):1080-6. Pubmed PMID: 10862808\n",
    "Ren ZY, Zhang XL, Liu Y, Zhao LY, Shi J, Bao Y, Zhang XY, Kosten TR, Lu L \"Diurnal variation in cue-induced responses among protracted abstinent heroin users..\" Pharmacol. Biochem. Behav.. 2009 Jan;91(3):468-72. Pubmed PMID: 18809427\n",
    "McDougle CJ, Price LH, Palumbo JM, Kosten TR, Heninger GR, Kleber HD \"Dopaminergic responsivity during cocaine abstinence: a pilot study..\" Psychiatry Res. 1992 Jul;43(1):77-85. Pubmed PMID: 1359594\n",
    "Gawin FH, Morgan C, Kosten TR, Kleber HD \"Double-blind evaluation of the effect of acute amantadine on cocaine craving..\" Psychopharmacology (Berl.). 1989;97(3):402-3. Pubmed PMID: 2497490\n",
    "Singh RA, Kosten TA, Kinsey BM, Shen X, Lopez AY, Kosten TR, Orson FM \"Dose-dependent changes in the locomotor responses to methamphetamine in BALB/c mice: low doses induce hypolocomotion..\" Pharmacol Biochem Behav. 2012 Dec; Pubmed PMID: 23010423\n",
    "Hameedi FA, Woods SW, Rosen MI, Pearsall HR, Kosten TR \"Dose dependent effects of yohimbine on methadone maintained patients..\" Am J Drug Alcohol Abuse. 1997 May;23(2):327-33. Pubmed PMID: 9143642\n",
    "Stitzer ML, Polk T, Bowles S, Kosten T \"Drug users' adherence to a 6-month vaccination protocol: effects of motivational incentives..\" Drug Alcohol Depend. 2010 Feb 1;107(1):76-9. Pubmed PMID: 19828264\n",
    "Kosten TR, Rounsaville BJ, Kleber HD \"DSM-III personality disorders in opiate addicts..\" Compr Psychiatry.;23(6):572-81. Pubmed PMID: 7160176\n",
    "Gardner T, Kosten T \"Dual dependency on cocaine and alcohol in opiate addicts: treatment options..\" J Clin Psychiatry. 2007; Pubmed PMID: 17685754\n",
    "Stine SM, Krystal JH, Petrakis IL, Jatlow PI, Heninger GR, Kosten TR, Charney DS \"Effect of alpha-methyl-para-tyrosine on response to cocaine challenge..\" Biol. Psychiatry. 1997 Aug 1;42(3):181-90. Pubmed PMID: 9232210\n",
    "Rosen MI, McMahon TJ, Hameedi FA, Pearsall HR, Woods SW, Kreek MJ, Kosten TR \"Effect of clonidine pretreatment on naloxone-precipitated opiate withdrawal..\" J. Pharmacol. Exp. Ther.. 1996 Mar;276(3):1128-35. Pubmed PMID: 8786543\n",
    "Rosen MI, Pearsall HR, McDougle CJ, Price LH, Woods SW, Kosten TR \"Effects of acute buprenorphine on responses to intranasal cocaine: a pilot study.\" Am J Drug Alcohol Abuse. 1993; Pubmed PMID: 8273766\n",
    "Oliveto AH, Farren C, Kosten TR \"Effect of LAAM dose on opiate use in opioid-dependent patients. A pilot study..\" Am J Addict. 1998;7(4):272-82. Pubmed PMID: 9809131\n",
    "McCance-Katz EF, Rainey PM, Friedland G, Kosten TR, Jatlow P \"Effect of opioid dependence pharmacotherapies on zidovudine disposition..\" Am J Addict. 2001;10(4):296-307. Pubmed PMID: 11783744\n",
    "Shi J, Jun W, Zhao LY, Xue YX, Zhang XY, Kosten TR, Lu L \"Effect of rapamycin on cue-induced drug craving in abstinent heroin addicts..\" Eur. J. Pharmacol.. 2009 Aug 1;615(41277):108-12. Pubmed PMID: 19470385\n",
    "Gao Y, Geng L, Orson F, Kinsey B, Kosten TR, Shen X, Brimijoin S \"Effects of anti-cocaine vaccine and viral gene transfer of cocaine hydrolase in mice on cocaine toxicity including motor strength and liver damage..\" Chem. Biol. Interact.. 2013 Mar 25;203(1):208-11. Pubmed PMID: 22935511\n",
    "Oliveto A, McCance-Katz FE, Singha A, Petrakis I, Hameedi F, Kosten TR \"Effects of cocaine prior to and during bupropion maintenance in cocaine-abusing volunteers..\" Drug Alcohol Depend. 2001 Jul 1;63(2):155-67. Pubmed PMID: 11376920\n",
    "Oliveto AH, McCance-Katz E, Singha A, Hameedi F, Kosten TR \"Effects of d-amphetamine and caffeine in humans under a cocaine discrimination procedure..\" Behav Pharmacol. 1998 May;9(3):207-17. Pubmed PMID: 9832935\n",
    "Rosen MI, Pearsall HR, Woods SW, Kosten TR \"Effects of gamma-hydroxybutyric acid (GHB) in opioid-dependent patients..\" J Subst Abuse Treat.;14(2):149-54. Pubmed PMID: 9258859\n",
    "Sinha R, Kimmerling A, Doebrick C, Kosten TR \"Effects of lofexidine on stress-induced and cue-induced opioid craving and opioid abstinence rates: preliminary findings..\" Psychopharmacology (Berl.). 2007 Mar;190(4):569-74. Pubmed PMID: 17136399\n",
    "Sofuoglu M, Singha A, Kosten TR, McCance-Katz FE, Petrakis I, Oliveto A \"Effects of naltrexone and isradipine, alone or in combination, on cocaine responses in humans..\" Pharmacol. Biochem. Behav.. 2003 Jul;75(4):801-8. Pubmed PMID: 12957222\n",
    "Winther LC, Saleem R, McCance-Katz EF, Rosen MI, Hameedi FA, Pearsall HR, Jatlow PI, Kosten TR, Woods SW \"Effects of lamotrigine on behavioral and cardiovascular responses to cocaine in human subjects..\" Am J Drug Alcohol Abuse. 2000 Feb; Pubmed PMID: 10718163\n",
    "Sofuoglu M, Mitchell E, Kosten TR \"Effects of progesterone treatment on cocaine responses in male and female cocaine users..\" Pharmacol. Biochem. Behav.. 2004 Aug;78(4):699-705. Pubmed PMID: 15301924\n",
    "Kosten TR, Rayford BS \"Effects of ethnicity on low-dose opiate stabilization..\" J Subst Abuse Treat.;12(2):111-6. Pubmed PMID: 7623388\n",
    "Kosten T, Poling J, Oliveto A \"Effects of reducing contingency management values on heroin and cocaine use for buprenorphine- and desipramine-treated patients..\" Addiction. 2003 May; Pubmed PMID: 12751984\n",
    "Zhang XY, Zhou DF, Shen YC, Zhang PY, Zhang WF, Liang J, Chen da C, Xiu MH, Kosten TA, Kosten TR \"Effects of risperidone and haloperidol on superoxide dismutase and nitric oxide in schizophrenia..\" Neuropharmacology. 2012 Apr;62(41400):1928-34. Pubmed PMID: 22227558\n",
    "Margolin A, Chang P, Avants SK, Kosten TR \"Effects of sham and real auricular needling: implications for trials of acupuncture for cocaine addiction..\" Am. J. Chin. Med.. 1993;21(2):103-11. Pubmed PMID: 8237887\n",
    "George TP, Vessicchio JC, Termine A, Sahady DM, Head CA, Pepper WT, Kosten TR, Wexler BE \"Effects of smoking abstinence on visuospatial working memory function in schizophrenia..\" Neuropsychopharmacology. 2002 Jan;26(1):75-85. Pubmed PMID: 11751034\n",
    "Sofuoglu M, Mouratidis M, Yoo S, Culligan K, Kosten T \"Effects of tiagabine in combination with intravenous nicotine in overnight abstinent smokers..\" Psychopharmacology (Berl.). 2005 Sep;181(3):504-10. Pubmed PMID: 15983800\n",
    "Sofuoglu M, Poling J, Mouratidis M, Kosten T \"Effects of topiramate in combination with intravenous nicotine in overnight abstinent smokers..\" Psychopharmacology (Berl.). 2006 Mar;184(41337):645-51. Pubmed PMID: 16432681\n",
    "Oliveto A, Poling J, Sevarino KA, Gonsai KR, McCance-Katz EF, Stine SM, Kosten TR \"Efficacy of dose and contingency management procedures in LAAM-maintained cocaine-dependent patients..\" Drug Alcohol Depend. 2005 Aug 1;79(2):157-65. Pubmed PMID: 16002025\n",
    "Castells X, Kosten TR, Capellà D, Vidal X, Colom J, Casas M \"Efficacy of opiate maintenance therapy and adjunctive interventions for opioid dependence with comorbid cocaine use disorders: a systematic review and meta-analysis of controlled clinical trials..\" Am J Drug Alcohol Abuse. 2009;35(5):339-49. Pubmed PMID: 20180662\n",
    "Jacobsen LK, Staley JK, Malison RT, Zoghbi SS, Seibyl JP, Kosten TR, Innis RB \"Elevated central serotonin transporter binding availability in acutely abstinent cocaine-dependent patients..\" Am J Psychiatry. 2000 Jul;157(7):1134-40. Pubmed PMID: 10873923\n",
    "Xiu MH, Chen DC, Wang D, Zhang K, Dong A, Tang W, Zhang F, Liu LJ, Liu JH, Liu HB, Yang FD, Kosten TR, Zhang XY \"Elevated interleukin-18 serum levels in chronic schizophrenia: Association with psychopathology..\" 2012 May 28; Pubmed PMID: 22647522\n",
    "Wu Z, Zhang XY, Wang H, Tang W, Xia Y, Zhang F, Liu J, Fu Y, Hu J, Chen Y, Liu L, Chen da C, Xiu MH, Kosten TR, He J \"Elevated plasma superoxide dismutase in first-episode and drug naive patients with schizophrenia: inverse association with positive symptoms..\" Prog Neuropsychopharmacol Biol Psychiatry. 2012 Jan; Pubmed PMID: 21896300\n",
    "Chen da C, Qi LY, Xiu MH, Cao LY, Wang F, Chen S, Wu GY, Kosten TA, Kosten TR, Zhang XY \"Elevated serum levels of tumor necrosis factor-alpha in clozapine-associated obesity in chronic schizophrenia..\" Schizophr. Res.. 2008 Dec;106(41308):367-8. Pubmed PMID: 18835132\n",
    "Malison RT, Best SE, van Dyck CH, McCance EF, Wallace EA, Laruelle M, Baldwin RM, Seibyl JP, Price LH, Kosten TR, Innis RB \"Elevated striatal dopamine transporters during acute cocaine abstinence as measured by [123I] beta-CIT SPECT..\" Am J Psychiatry. 1998 Jun;155(6):832-4. Pubmed PMID: 9619159\n",
    "Mason JW, Giller EL, Kosten TR, Harkness L \"Elevation of urinary norepinephrine/cortisol ratio in posttraumatic stress disorder..\" J. Nerv. Ment. Dis.. 1988 Aug;176(8):498-502. Pubmed PMID: 3404142\n",
    "Sofuoglu M, Kosten TR \"Emerging pharmacological strategies in the fight against cocaine addiction..\" Expert Opin Emerg Drugs. 2006 Mar;11(1):91-8. Pubmed PMID: 16503828\n",
    "Sun HQ, Chen HM, Yang FD, Lu L, Kosten TR \"Epidemiological trends and the advances of treatments of amphetamine-type stimulants (ATS) in China..\" Am J Addict. 2014 May; Pubmed PMID: 24724890\n",
    "Nielsen DA, Utrankar A, Reyes JA, Simons DD, Kosten TR \"Epigenetics of drug abuse: predisposition or response..\" Pharmacogenomics. 2012 Jul;13(10):1149-60. Pubmed PMID: 22909205\n",
    "Kosten TR, Rounsaville BJ, Kleber HD \"Ethnic and gender differences among opiate addicts..\" Int J Addict. 1985 Aug;20(8):1143-62. Pubmed PMID: 4077316\n",
    "Malison RT, Best SE, Wallace EA, McCance E, Laruelle M, Zoghbi SS, Baldwin RM, Seibyl JS, Hoffer PB, Price LH \"Euphorigenic doses of cocaine reduce [123I]beta-CIT SPECT measures of dopamine transporter availability in human cocaine addicts..\" Psychopharmacology. 1995 Dec; Pubmed PMID: 8657833\n",
    "Kosten TR, Gawin FH, Morgan C, Nelson JC, Jatlow P \"Evidence for altered desipramine disposition in methadone-maintained patients treated for cocaine abuse..\" Am J Drug Alcohol Abuse. 1990;16(41337):329-36. Pubmed PMID: 2288330\n",
    "Lingford-Hughes AR, Welch S, Nutt DJ; British Association for Psychopharmacology \"Evidence-based guidelines for the pharmacological management of substance misuse, addiction and comorbidity: recommendations from the British Association for Psychopharmacology..\" J Psychopharmacol. 2004 Sep; Pubmed PMID: 15358975\n",
    "An HM, Tan YL, Shi J, Wang ZR, Li J, Wang YC, Kosten TR, Zhou DF, Yang FD, Zhang XY \"Extract of Ginkgo biloba is equivalent to vitamin E in attenuating and preventing vacuous chewing movements in a rat model of tardive dyskinesia..\" Behav Pharmacol. 2013 Aug; Pubmed PMID: 23994817\n",
    "Browndyke JN, Tucker KA, Woods SP, Beauvals J, Cohen RA, Gottschalk PC, Kosten TR \"Examining the effect of cerebral perfusion abnormality magnitude on cognitive performance in recently abstinent chronic cocaine abusers..\" J Neuroimaging. 2004 Apr; Pubmed PMID: 23994817\n",
    "Sun HQ, Guo S, Chen DF, Jiang ZN, Liu Y, Di XL, Yang FD, Zhang XY, Kosten TR, Lu L \"Family support and employment as predictors of smoking cessation success: a randomized, double-blind, placebo-controlled trial of nicotine sublingual tablets in Chinese smokers..\" Am J Drug Alcohol Abuse. 2009;35(3):183-8. Pubmed PMID: 19462302\n",
    "Kosten TR, Jalali B, Hogan I, Kleber HD \"Family denial as a prognostic factor in opiate addict treatment outcome..\" J. Nerv. Ment. Dis.. 1983 Oct;171(10):611-6. Pubmed PMID: 6619824\n",
    "Petrakis I, Carroll KM, Nich C, Gordon L, Kosten T, Rounsaville B \"Fluoxetine treatment of depressive disorders in methadone-maintained opioid addicts..\" Drug Alcohol Depend. 1998 May; Pubmed PMID: 9649975\n",
    "Kosten TR \"For Council on Addictions of American Psychiatry Association. Policy—statement on methadone maintenance treatment..\" Am J Psychiatry. 1994;\n",
    "Wu JQ, Kosten TR, Zhang XY \"Free radicals, antioxidant defense systems, and schizophrenia.\" Prog Neuropsychopharmacol Biol Psychiatry. 2013 Oct; Pubmed PMID: 23470289\n",
    "Kosten TA, Gawin FH, Kosten TR, Rounsaville BJ \"Gender differences in cocaine use and treatment response..\" J Subst Abuse Treat.;10(1):63-6. Pubmed PMID: 8450576\n",
    "Han M, Huang XF, Chen DC, Xiu MH, Hui L, Liu H, Kosten TR, Zhang XY \"Gender differences in cognitive function of patients with chronic schizophrenia..\" Prog. Neuropsychopharmacol. Biol. Psychiatry. 2012 Jul 20; Pubmed PMID: 22820676\n",
    "Kosten TR \"Future of anti-addiction vaccines..\" Stud Health Technol Inform. 2005;118:177-85. Pubmed PMID: 16301778\n",
    "He J, Xie Y, Tao J, Su H, Wu W, Zou S, Zhang J, Zhang J, Zhang H, Yang X, Guo J, Tang W, Zhang F, Liu J, Liu L, Chen Y, Wen N, Kosten TR, Zhang XY \"Gender differences in socio-demographic and clinical characteristics of methamphetamine inpatients in a Chinese population..\" Drug Alcohol Depend. 2013 Jun 1;130(41277):94-100. Pubmed PMID: 23149112\n",
    "Zhang XY, Chen da C, Xiu MH, Yang FD, Haile CN, Kosten TA, Kosten TR \"Gender differences in never-medicated first-episode schizophrenia and medicated chronic schizophrenia patients..\" J Clin Psychiatry. 2012 Aug;73(7):1025-33. Pubmed PMID: 22901352\n",
    "Kosten TR, Kosten TA, McDougle CJ, Hameedi FA, McCance EF, Rosen MI, Oliveto AH, Price LH \"Gender differences in response to intranasal cocaine administration to humans..\" Biol. Psychiatry. 1996 Jan 15;39(2):147-8. Pubmed PMID: 8717615\n",
    "Chen da C, Zhou MA, Zhou DH, Xiu MH, Wu GY, Kosten TR, Zhang XY \"Gender differences in the prevalence of diabetes mellitus in chronic hospitalized patients with schizophrenia on long-term antipsychotics..\" Psychiatry Res. 2011 Apr 30;186(41308):451-3. Pubmed PMID: 20797801\n",
    "Zhang XY, Chen da C, Qi LY, Wang F, Xiu MH, Chen S, Wu GY, Kosten TA, Kosten TR \"Gender differences in the prevalence, risk and clinical correlates of tardive dyskinesia in Chinese schizophrenia..\" Psychopharmacology (Berl.). 2009 Sep;205(4):647-54. Pubmed PMID: 19529921\n",
    "Haile CN, Kosten TR, Kosten TA \"Genetics of dopamine and its contribution to cocaine addiction..\" Behav. Genet.. 2007 Jan;37(1):119-45. Pubmed PMID: 17063402\n",
    "Kosten TR, Rounsaville BJ, Kosten TA, Merikangas K \"Gender differences in the specificity of alcoholism transmission among the relatives of opioid addicts..\" J. Nerv. Ment. Dis.. 1991 Jul;179(7):392-400. Pubmed PMID: 1869867\n",
    "Tucker KA, Browndyke JN, Gottschalk PC, Cofrancesco AT, Kosten TR \"Gender-specific vulnerability for rCBF abnormalities among cocaine abusers..\" Neuroreport. 2004 Apr 9;15(5):797-801. Pubmed PMID: 15073517\n",
    "McCance-Katz EF, Hart CL, Boyarsky B, Kosten T, Jatlow P \"Gender effects following repeated administration of cocaine and alcohol in humans.\" Subst Use Misuse. 2005; Pubmed PMID: 15830733\n",
    "McCance-Katz EF, Kosten TA, Kosten TR \"Going from the bedside back to the bench with ecopipam: a new strategy for cocaine pharmacotherapy development..\" Psychopharmacology (Berl.). 2001 Jun;155(4):327-9. Pubmed PMID: 11441421\n",
    "Manji H, Chen G, Potter W, Kosten TR \"Guanine nucleotide binding proteins in opioid-dependent patients..\" Biol. Psychiatry. 1997 Jan 15;41(2):130-4. Pubmed PMID: 9018382\n",
    "Margolin A, Avants SK, Malison RT, Kosten TR \"High-and low-dose mazindol for cocaine dependence in methadone-maintained patients: A preliminary evaluation.\" Substance Abuse. 1997;\n",
    "Meandzija B, O'Connor PG, Fitzgerald B, Rounsaville BJ, Kosten TR \"HIV infection and cocaine use in methadone maintained and untreated intravenous drug users..\" Drug Alcohol Depend. 1994 Oct;36(2):109-13. Pubmed PMID: 7851277\n",
    "Oliveto AH, Rosen MI, Kosten TA, Hameedi FA, Woods SW, Kosten TR \"Hydromorphone-naloxone combinations in opioid-dependent humans under a naloxone novel-response discrimination procedure..\" Exp Clin Psychopharmacol. 1998 May;6(2):169-78. Pubmed PMID: 9608349\n",
    "Gardner TJ, Kosten TR \"Human laboratory and neuroimaging studies in substance use disorders: developing new treatment approaches..\" Am J Drug Alcohol Abuse. 2007;33(6):765-7. Pubmed PMID: 17994472\n",
    "66. O’Connor PG, Meandzija B, Poling J, Kosten TR, Fitzgerald B, Rounsaville BJ \"HIV vaccine preparedness trials in injection-drug users: Are we prepared?.\" Substance Abuse. 1995;\n",
    "Kosten TR, Rosen M, Bond J, Settles M, Roberts JS, Shields J, Jack L, Fox B \"Human therapeutic cocaine vaccine: safety and immunogenicity..\" Vaccine. 2002 Jan 15;20(41463):1196-204. Pubmed PMID: 11803082\n",
    "Kosten TR \"Images in psychiatry. Marie Nyswander, 1919-1986..\" Am J Psychiatry. 1998 Dec;155(12):1766. Pubmed PMID: 9842790\n",
    "Kosten TR \"Images in Psychiatry: Abraham Winkler, MD: 1910-1981.\" American Journal of Psychiatry. 1998;\n",
    "Shen X, Kosten TR \"Immunotherapy for drug abuse..\" CNS Neurol Disord Drug Targets. 2011 Dec 1;10(8):876-9. Pubmed PMID: 22229313\n",
    "Kosten T, Owens SM \"Immunotherapy for the treatment of drug abuse..\" Pharmacol. Ther.. 2005 Oct;108(1):76-85. Pubmed PMID: 16023218\n",
    "Najavits LM, Norman SB, Kivlahan D, Kosten TR \"Improving PTSD/Substance Abuse Treatment in the VA: A Survey of Providers..\" Am J Addict. 2010 May;19(3):257-63. Pubmed PMID: 20525033\n",
    "Carroll KM, Chang G, Behr H, Clinton B, Kosten TR \"Improving treatment outcome in pregnant methadone maintained women; Results from a randomized clinical trial.\" Am J Addictions. 1995;\n",
    "Chang G, Carroll KM, Behr HM, Kosten TR \"Improving treatment outcome in pregnant opiate-dependent women..\" J Subst Abuse Treat. 1992;9(4):327-30. Pubmed PMID: 1479630\n",
    "Zhang XY, Xiu MH, Chen da C, Zhu FY, Wu GY, Haile CN, Lu L, Kosten TA, Kosten TR \"Increased S100B serum levels in schizophrenic patients with tardive dyskinesia: association with dyskinetic movements..\" J Psychiatr Res. 2010 May;44(7):429-33. Pubmed PMID: 19932492\n",
    "Zhang XY, Xiu MH, Song C, Chen da C, Wu GY, Haile CN, Kosten TA, Kosten TR \"Increased serum S100B in never-medicated and medicated schizophrenic patients..\" J Psychiatr Res. 2010 Dec; Pubmed PMID: 20510426\n",
    "Singha AK, McCance-Katz EF, Heck SA, Kosten TR, Oliveto A \"Individual differences in humans responding under a cocaine discrimination procedure: discriminators versus nondiscriminators..\" Exp Clin Psychopharmacol. 1999 Nov;7(4):391-8. Pubmed PMID: 10609974\n",
    "Qi LY, Xiu MH, Chen da C, Wang F, Kosten TA, Kosten TR, Zhang XY \"Increased serum S100B levels in chronic schizophrenic patients on long-term clozapine or typical antipsychotics..\" Neurosci. Lett.. 2009 Sep 22;462(2):113-7. Pubmed PMID: 19539717\n",
    "Avants SK, Margolin A, Kosten TR \"Influence of treatment readiness on outcomes of two pharmacotherapy trials for cocaine abuse among methadone-maintained patients.\" Psychology Addictive Behaviors. 1996;\n",
    "Kosten TR, Rounsaville BJ, Foley SH \"Inpatient vs. outpatient cocaine abuse treatments..\" NIDA Res. Monogr.. 1989;95:312-3. Pubmed PMID: 2640976\n",
    "Rosenheck R, Harkness L, Johnson B, Sweeney C, Buck N, Deegan D, Kosten T \"Intensive community-focused treatment of veterans with dual diagnoses..\" Am J Psychiatry. 1998 Oct; Pubmed PMID: 9766776\n",
    "Kosten TR, Woods SW, Rosen MI, Pearsall HR \"Interactions of cocaine with nimodipine: a brief report..\" Am J Addict. 1999;8(1):77-81. Pubmed PMID: 10189518\n",
    "Zhang XY, Tang W, Xiu MH, Chen da C, Yang FD, Tan YL, Wang ZR, Zhang F, Liu J, Liu L, Chen Y, Wen N, Kosten TR \"Interleukin 18 and cognitive impairment in first episode and drug naïve schizophrenia versus healthy controls..\" Brain Behav. Immun.. 2013 Aug;32:105-11. Pubmed PMID: 23499732\n",
    "72. Kosten T, Gawin FH, Silverman DG, Fleming J, Compton M, Jatlow P, Byck R \"Intravenous cocaine challenges during desipramine maintenance.\" Neuropsychopharmacology. 1992 Nov; Pubmed PMID: 1388643\n",
    "Oliveto A, Poling J, Kosten TR, Gonsai K \"Isradipine and dextromethorphan in methadone-maintained humans under a naloxone discrimination procedure..\" Eur. J. Pharmacol.. 2004 May 3;491(41308):157-68. Pubmed PMID: 15140632\n",
    "Kosten T, Silverman DG, Fleming J, Kosten TA, Gawin FH, Compton M, Jatlow P, Byck R \"Intravenous cocaine challenges during naltrexone maintenance: a preliminary study..\" Biol Psychiatry. 1992 Sep; Pubmed PMID: 1445971\n",
    "Gottschalk PC, Kosten TR \"Isradipine enhancement of cerebral blood flow in abstinent cocaine abusers with and without chronic perfusion deficits..\" Am J Addict. 2002;11(3):200-8. Pubmed PMID: 12202012\n",
    "Kosten TR, Oliveto A, Sevarino KA, Gonsai K, Feingold A \"Ketoconazole increases cocaine and opioid use in methadone maintained patients..\" Drug Alcohol Depend. 2002 Apr 1;66(2):173-80. Pubmed PMID: 11906804\n",
    "Li W, Wei J, Zhou DF, Tan YL, Cao YL, Zhang XY, Wu G, Kosten TA, Kosten TR \"Lack of association between the BDNF C270T polymorphism and schizophrenia in a Chinese Han population..\" Schizophr. Res.. 2007 Dec;97(41277):297-8. Pubmed PMID: 17669628\n",
    "Rounsaville BJ, Kosten TR, Kleber HD \"Long-term changes in current psychiatric diagnoses of treated opiate addicts..\" Compr Psychiatry.;27(5):480-98. Pubmed PMID: 3757496\n",
    "Zhang XY, Cao LY, Song C, Wu GY, Chen da C, Qi LY, Wang F, Xiu MH, Chen S, Zhang Y, Lu L, Kosten TA, Kosten TR \"Lower serum cytokine levels in smokers than nonsmokers with chronic schizophrenia on long-term treatment with antipsychotics..\" Psychopharmacology (Berl.). 2008 Dec;201(3):383-9. Pubmed PMID: 18719893\n",
    "Zhang XY, Liang J, Chen DC, Xiu MH, De Yang F, Kosten TA, Kosten TR \"Low BDNF is associated with cognitive impairment in chronic patients with schizophrenia..\" 2012 Jan 26; Pubmed PMID: 22274000\n",
    "Zhen YF, Zhang J, Liu XY, Fang H, Tian LB, Zhou DH, Kosten TR, Zhang XY \"Low BDNF is associated with cognitive deficits in patients with type 2 diabetes..\" Psychopharmacology (Berl.). 2013 May;227(1):93-100. Pubmed PMID: 23263460\n",
    "Liu H, Kang Y, Liang J, Li C, Xiu M, Chen D, Yang F, Wang F, Wu G, Haile CN, Kosten TA, Kosten TR, Zhang XY \"Lower serum interleukin-2 levels in schizophrenic patients with tardive dyskinesia..\" 2012 Mar 12; Pubmed PMID: 22417931\n",
    "Kosten TR \"Mandatory drug testing needs controlled evaluation..\" Am J Bioeth. 2004;4(1):32. Pubmed PMID: 15035939\n",
    "Kosten TR, O'Connor PG \"Management of drug and alcohol withdrawal..\" N. Engl. J. Med.. 2003 May 1;348(18):1786-95. Pubmed PMID: 12724485\n",
    "Margolin A, Avants SK, Kosten TR \"Mazindol for relapse prevention to cocaine abuse in methadone-maintained patients..\" Am J Drug Alcohol Abuse. 1995 Nov;21(4):469-81. Pubmed PMID: 8561098\n",
    "Stine SM, Krystal JH, Kosten TR, Charney DS \"Mazindol treatment for cocaine dependence..\" Drug Alcohol Depend. 1995 Oct;39(3):245-52. Pubmed PMID: 8556974\n",
    "Diakogiannis IA, Steinberg M, Kosten TR \"Mazindol treatment of cocaine abuse. A double-blind investigation..\" NIDA Res. Monogr.. 1990;105:514. Pubmed PMID: 1876105\n",
    "Reid MC, Tinetti ME, O'Connor PG, Kosten TR, Concato J \"Measuring alcohol consumption among older adults: a comparison of available methods..\" Am J Addict.;12(3):211-9. Pubmed PMID: 12851017\n",
    "Kosten TR \"Medications development and the war on drugs: victims of the Gulf war?.\" Biol. Psychiatry. 1991 Mar 15;29(6):521-3. Pubmed PMID: 2054428\n",
    "Stine SM, Grillon CG, Morgan CA, Kosten TR, Charney DS, Krystal JH \"Methadone patients exhibit increased startle and cortisol response after intravenous yohimbine..\" Psychopharmacology (Berl.). 2001 Mar;154(3):274-81. Pubmed PMID: 11351934\n",
    "Streltzer J, Kosten TR \"Methadone maintenance therapy and chronic pain..\" JAMA. 2003 Nov; Pubmed PMID: 14612466\n",
    "Stine SM, Kosten TR \"Methadone dose in the treatment of opiate dependence.\" Medscape Mental Health. 1997;\n",
    "Schottenfeld RS, Chawarski MC, Pakes JR, Pantalon MV, Carroll KM, Kosten TR \"Methadone versus buprenorphine with contingency management or performance feedback for cocaine and opioid dependence..\" Am J Psychiatry. 2005 Feb;162(2):340-9. Pubmed PMID: 15677600\n",
    "Nielsen DA, Harding MJ, Hamon SC, Huang W, Kosten TR \"Modifying the role of serotonergic 5-HTTLPR and TPH2 variants on disulfiram treatment of cocaine addiction: a preliminary study..\" Genes Brain Behav. 2012 Aug; Pubmed PMID: 22925276\n",
    "Margolin A, Avants SK, Rounsaville B, Kosten TR, Schottenfeld RS \"Motivational factors in cocaine pharmacotherapy trials with methadone-maintained patients: problems and paradoxes..\" J Psychoactive Drugs.;29(2):205-12. Pubmed PMID: 9250948\n",
    "Kosten TR, Rounsaville BJ, Kleber HD \"Multidimensionality and prediction of treatment outcome in opioid addicts: 2.5-year follow-up..\" Compr Psychiatry.;28(1):41346. Pubmed PMID: 3802797\n",
    "Jacobsen LK, Kosten TR \"Naloxone challenge as a biological predictor of treatment outcome in opiate addicts..\" Am J Drug Alcohol Abuse. 1989;15(4):355-66. Pubmed PMID: 2596440\n",
    "Mason JW, Kosten TR, Giller EL \"Multidimensional hormonal discrimination of paranoid schizophrenic from bipolar manic patients..\" Biol. Psychiatry. 1991 Mar 1;29(5):457-66. Pubmed PMID: 2018819\n",
    "Kleber HD, Kosten TR \"Naltrexone induction: psychologic and pharmacologic strategies.\" J Clin Psychiatry. 1984 Sep; Pubmed PMID: 6469934\n",
    "Krupitsky E, Zvartau E, Blokhina E, Verbitskaya E, Tsoy M, Wahlgren V, Burakov A, Masalov D, Romanova TN, Palatkin V, Tyurina A, Yaroslavtseva T, Sinha R, Kosten TR \"Naltrexone with or without guanfacine for preventing relapse to opiate addiction in St.-Petersburg, Russia.\" Drug Alcohol Depend. 2013 Oct; Pubmed PMID: 23683793\n",
    "Sevarino KA, Oliveto A, Kosten TR \"Neurobiological adaptations to psychostimulants and opiates as a basis of treatment development..\" Ann. N. Y. Acad. Sci.. 2000;909:51-87. Pubmed PMID: 10911924\n",
    "Markou A, Kosten TR, Koob GF \"Neurobiological similarities in depression and drug dependence: a self-medication hypothesis..\" Neuropsychopharmacology. 1998 Mar;18(3):135-74. Pubmed PMID: 9471114\n",
    "Krystal J, Kosten TR, Perry B, Southwick S, Mason JW, Giller EL \"Neurobiological aspects of post traumatic stress disorder: Review of clinical and pre-clinical studies..\" Behavior Therapy. 1989;\n",
    "Sinha R, Lacadie C, Skudlarski P, Fulbright RK, Rounsaville BJ, Kosten TR, Wexler BE \"Neural activity associated with stress-induced cocaine craving: a functional magnetic resonance imaging study..\" Psychopharmacology (Berl.). 2005 Dec;183(2):171-80. Pubmed PMID: 16163517\n",
    "Kosten TR \"Neurobiology of abused drugs. Opioids and stimulants..\" J. Nerv. Ment. Dis.. 1990 Apr;178(4):217-27. Pubmed PMID: 2156952\n",
    "Kosten TR, Margolin A \"New developments in opioid abuse treatment.\" Annals Clinical Psychiatry. 1990;\n",
    "Sernyak MJ, Kosten TR, Fontana A, Rosenheck R \"Neuroleptic use in the treatment of Post-Traumatic Stress Disorder..\" Psychiatr Q. 2001;72(3):197-213. Pubmed PMID: 11467155\n",
    "Kosten TR, Gardner TJ \"New hot topics sections: 1. China's new march forward in addiction treatment: methadone for the masses. 2. Issues in formulating DSM V..\" Am J Drug Alcohol Abuse. 2008;34(2):123-6. Pubmed PMID: 18293228\n",
    "Kosten TR, Kosten TA \"New medication strategies for comorbid substance use and bipolar affective disorders..\" Biol. Psychiatry. 2004 Nov 15;56(10):771-7. Pubmed PMID: 15556122\n",
    "Zhang XY, Tan YL, Zhou DF, Haile CN, Wu GY, Cao LY, Kosten TA, Kosten TR \"Nicotine dependence, symptoms and oxidative stress in male patients with schizophrenia..\" Neuropsychopharmacology. 2007 Sep;32(9):2020-4. Pubmed PMID: 17228336\n",
    "Ziedonis DM, Kosten TR, Glazer WM, Frances RJ \"Nicotine dependence and schizophrenia..\" Hosp Community Psychiatry. 1994 Mar;45(3):204-6. Pubmed PMID: 7910577\n",
    "Zhang XY, Xiu MH, Chen da C, Yang FD, Wu GY, Lu L, Kosten TA, Kosten TR \"Nicotine dependence and serum BDNF levels in male patients with schizophrenia.\" Psychopharmacology (Berl).. 2010 Oct; Pubmed PMID: 20661552\n",
    "George TP, Ziedonis DM, Feingold A, Pepper WT, Satterburg CA, Winkel J, Rounsaville BJ, Kosten TR \"Nicotine transdermal patch and atypical antipsychotic medications for smoking cessation in schizophrenia..\" Am J Psychiatry. 2000 Nov;157(11):1835-42. Pubmed PMID: 11058482\n",
    "Zhang X, Guan SL, Wang ZQ, You Y, Sun SL, Hui L, Miao LN, Yu Y, Kosten TR, Zhang XY \"No association between the type 2 diabetes mellitus susceptibility gene, SLC30A8 and schizophrenia in a Chinese population..\" Hum Psychopharmacol. 2012 Jul;27(4):392-6. Pubmed PMID: 22778022\n",
    "Kleber HD, Kosten TR, Gaspari J, Topazian M \"Nontolerance to the opioid antagonism of naltrexone..\" Biol. Psychiatry. 1985 Jan;20(1):66-72. Pubmed PMID: 2981129\n",
    "Newton TF, De La Garza R, Brown G, Kosten TR, Mahoney JJ, Haile CN \"Noradrenergic a(1) Receptor Antagonist Treatment Attenuates Positive Subjective Effects of Cocaine in Humans: A Randomized Trial..\" PLoS ONE. 2012;7(2):e30854. Pubmed PMID: 22319592\n",
    "McDougle CJ, Black JE, Malison RT, Zimmermann RC, Kosten TR, Heninger GR, Price LH \"Noradrenergic dysregulation during discontinuation of cocaine use in addicts..\" Arch. Gen. Psychiatry. 1994 Sep;51(9):713-9. Pubmed PMID: 8080348\n",
    "Sofuoglu M, Kosten TR \"Novel approaches to the treatment of cocaine addiction..\" CNS Drugs. 2005;19(1):13-25. Pubmed PMID: 15651902\n",
    "Krystal JH, Woods SW, Kosten TR, Rosen MI, Seibyl JP, van Dyck CC, Price LH, Zubal IG, Hoffer PB, Charney DS \"Opiate dependence and withdrawal: preliminary assessment using single photon emission computerized tomography (SPECT)..\" Am J Drug Alcohol Abuse. 1995 Feb;21(1):47-63. Pubmed PMID: 7762544\n",
    "Fiellin DA, Rosenheck RA, Kosten TR \"Office-based treatment for opioid dependence: reaching new patient populations..\" Am J Psychiatry. 2001 Aug;158(8):1200-4. Pubmed PMID: 11481150\n",
    "Shorter D, Kosten TR \"Novel pharmacotherapeutic treatments for cocaine addiction..\" 2011 Nov 3;9(1):119. Pubmed PMID: 22047090\n",
    "Best SE, Oliveto AH, Kosten TR \"Opioid addiction: Recent advances in detoxification and maintenance therapy.\" CNS Drugs. 1996;\n",
    "Kosten TR, Krystal JH, Charney DS, Price LH, Morgan CH, Kleber HD \"Opioid antagonist challenges in buprenorphine maintained patients..\" Drug Alcohol Depend. 1990 Feb;25(1):73-8. Pubmed PMID: 2323312\n",
    "Stotts AL, Dodrill CL, Kosten TR \"Opioid dependence treatment: options in pharmacotherapy..\" Expert Opin Pharmacother. 2009 Aug;10(11):1727-40. Pubmed PMID: 19538000\n",
    "Margolin A, Avants SK, Kosten TR \"Pemoline for the treatment of cocaine dependence in methadone-maintained patients..\" J Psychoactive Drugs.;28(3):301-4. Pubmed PMID: 8895115\n",
    "Kosten TR, Rounsaville BJ, Kleber HD \"Parental alcoholism in opioid addicts..\" J. Nerv. Ment. Dis.. 1985 Aug;173(8):461-9. Pubmed PMID: 4020363\n",
    "Sigmon SC, Bisaga A, Nunes EV, O'Connor PG, Kosten T, Woody G \"Opioid detoxification and naltrexone induction strategies: recommendations for clinical practice..\" Am J Drug Alcohol Abuse. 2012 May;38(3):187-99. Pubmed PMID: 22404717\n",
    "Potenza MN, Kosten TR, Rounsaville BJ \"Pathological gambling.\" JAMA. 2001 Jul;\n",
    "Kosten TR, Novak P, Kleber HD \"Perceived marital and family environment of opiate addicts..\" Am J Drug Alcohol Abuse. 1984;10(4):491-501. Pubmed PMID: 6534181\n",
    "Rosen MI, Bridge TP, O’Malley SS, Pearsall HR, Maritini B, O’Connor PG, Brett-Smith H, Thomas HM, van Dyke CH, Woods SW, Kosten TR. \"Peptide T treatment of cognitive impairment in HIV positive intravenous drug users.\" Am J Addictions. 1992;\n",
    "Lane SD, Moeller FG, Steinberg JL, Buzby M, Kosten TR \"Performance of cocaine dependent individuals and controls on a response inhibition task with varying levels of difficulty..\" Am J Drug Alcohol Abuse. 2007;33(5):717-26. Pubmed PMID: 17891664\n",
    "McIntosh BJ, Zhang XY, Kosten T, Tan SP, Xiu MH, Rakofsky J, Harvey PD \"Performance-based assessment of functional skills in severe mental illness: Results of a large-scale study in China..\" J Psychiatr Res. 2011 Aug;45(8):1089-94. Pubmed PMID: 21300378\n",
    "Tucker KA, Potenza MN, Beauvais JE, Browndyke JN, Gottschalk PC, Kosten TR \"Perfusion abnormalities and decision making in cocaine dependence.\" Biol Psychiatry. 2004 Oct; Pubmed PMID: 15450790\n",
    "Kosten TA, Kosten TR, Rounsaville BJ \"Personality disorders in opiate addicts show prognostic specificity..\" J Subst Abuse Treat. 1989;6(3):163-8. Pubmed PMID: 2795705\n",
    "Kosten TR, Wu G, Huang W, Harding MJ, Hamon SC, Lappalainen J, Nielsen DA \"Pharmacogenetic Randomized Trial for Cocaine Abuse: Disulfiram and Dopamine ß-Hydroxylase..\" Biol. Psychiatry. 2012 Aug 17; Pubmed PMID: 22906516\n",
    "Shorter D, Nielsen DA, Huang W, Harding MJ, Hamon SC, Kosten TR. \"Pharmacogenetic randomized trial for cocaine abuse: disulfiram and α1A-adrenoceptor gene variation.\" Eur Neuropsychopharmacol. 2013 Nov; Pubmed PMID: 23849431\n",
    "Haile CN, Kosten TA, Kosten TR \"Pharmacogenetic treatments for drug addiction: alcohol and opiates..\" Am J Drug Alcohol Abuse. 2008;34(4):355-81. Pubmed PMID: 18584566\n",
    "Kosten TR \"Pharmacological approaches to cocaine dependence..\" Clin Neuropharmacol. 1992;15:70A-71A. Pubmed PMID: 1498999\n",
    "Haile CN, Kosten TR, Kosten TA \"Pharmacogenetic treatments for drug addiction: cocaine, amphetamine and methamphetamine..\" Am J Drug Alcohol Abuse. 2009;35(3):161-77. Pubmed PMID: 19462300\n",
    "Sofuoglu M, Kosten TR \"Pharmacologic management of relapse prevention in addictive disorders..\" Psychiatr. Clin. North Am.. 2004 Dec;27(4):627-48. Pubmed PMID: 15550284\n",
    "Kosten TA, Kosten TR \"Pharmacological blocking agents for treating substance abuse..\" J. Nerv. Ment. Dis.. 1991 Oct;179(10):583-92. Pubmed PMID: 1919542\n",
    "Kosten TR \"Pharmacotherapeutic interventions for cocaine abuse. Matching patients to treatments..\" J. Nerv. Ment. Dis.. 1989 Jul;177(7):379-89. Pubmed PMID: 2664072\n",
    "Gardner TJ, Kosten TR \"Pharmacotherapeutic environments for substance use disorders..\" Am J Drug Alcohol Abuse. 2007;33(5):627-9. Pubmed PMID: 17891655\n",
    "Verrico CD, Haile CN, Newton TF, Kosten TR, De La Garza R \"Pharmacotherapeutics for substance-use disorders: a focus on dopaminergic medications.\" Expert Opin Investig Drugs. 2013 Dec; Pubmed PMID: 24033127\n",
    "Kosten TR \"Pharmacotherapy for addictions: partnering with contingency management..\" Am J Drug Alcohol Abuse. 2007;33(3):341-2. Pubmed PMID: 17613962\n",
    "Kosten TR, Morgan CM, Falcione J, Schottenfeld RS \"Pharmacotherapy for cocaine-abusing methadone-maintained patients using amantadine or desipramine..\" Arch. Gen. Psychiatry. 1992 Nov;49(11):894-8. Pubmed PMID: 1444728\n",
    "Kosten TR, Frank JB, Dan E, McDougle CJ, Giller EL \"Pharmacotherapy for posttraumatic stress disorder using phenelzine or imipramine..\" J. Nerv. Ment. Dis.. 1991 Jun;179(6):366-70. Pubmed PMID: 2051152\n",
    "Warner EA, Kosten TR, O'Connor PG \"Pharmacotherapy for opioid and cocaine abuse..\" Med. Clin. North Am.. 1997 Jul;81(4):909-25. Pubmed PMID: 9222260\n",
    "Haile CN, Kosten TR \"Pharmacotherapy for stimulant-related disorders..\" Curr Psychiatry Rep. 2013 Nov; Pubmed PMID: 24142188\n",
    "McCance-Katz E, Sevarino K, Gottschalk PC, Kosten T \"Pharmacotherapy of stimulant dependence: one of Japan's greatest public health challenges..\" Nihon Shinkei Seishin Yakurigaku Zasshi. 1999 Oct; Pubmed PMID: 10637824\n",
    "Ziedonis DM, Kosten TR \"Pharmacotherapy improves treatment outcome in depressed cocaine addicts..\" J Psychoactive Drugs.;23(4):417-25. Pubmed PMID: 1813613\n",
    "Kosten TR \"Pharmacotherapy of cerebral ischemia in cocaine dependence..\" Drug Alcohol Depend. 1998 Jan 1;49(2):133-44. Pubmed PMID: 9543650\n",
    "Kosten TR, Morgan C, Kleber HD \"Phase II clinical trials of buprenorphine: detoxification and induction onto naltrexone..\" NIDA Res. Monogr.. 1992;121:101-19. Pubmed PMID: 1406906\n",
    "Kosten TR, Astrachan BM \"Planning for crisis on a psychiatric research ward: a task analysis..\" Compr Psychiatry. 1981 May; Pubmed PMID: 7238004\n",
    "Bowers MB, Malison RT, Seibyl JP, Kosten TR \"Plasma homovanillic acid and the dopamine transporter during cocaine withdrawal..\" Biol. Psychiatry. 1998 Feb 15;43(4):278-81. Pubmed PMID: 9513737\n",
    "Zhang XY, Chen DC, Xiu MH, Tang W, Zhang F, Liu L, Chen Y, Liu J, Yao JK, Kosten TA, Kosten TR \"Plasma total antioxidant status and cognitive impairments in schizophrenia..\" 2012 May 1; Pubmed PMID: 22555016\n",
    "Kosten TR, Tucker K, Gottschalk PC, Rinder CS, Rinder HM \"Platelet abnormalities associated with cerebral perfusion defects in cocaine dependence..\" Biol. Psychiatry. 2004 Jan 1;55(1):91-7. Pubmed PMID: 14706430\n",
    "Rinder HM, Ault KA, Jatlow PI, Kosten TR, Smith BR \"Platelet alpha-granule release in cocaine users..\" Circulation. 1994 Sep;90(3):1162-7. Pubmed PMID: 7522132\n",
    "Jacobsen LK, Staley JK, Zoghbi SS, Seibyl JP, Kosten TR, Innis RB, Gelernter J \"Prediction of dopamine transporter binding availability by genotype: a preliminary report..\" Am J Psychiatry. 2000 Oct;157(10):1700-3. Pubmed PMID: 11007732\n",
    "Sofuoglu M, Gonzalez G, Poling J, Kosten TR \"Prediction of treatment outcome by baseline urine cocaine results and self-reported cocaine use for cocaine and opioid dependence..\" Am J Drug Alcohol Abuse. 2003;29(4):713-27. Pubmed PMID: 14713135\n",
    "Kosten TR, Rounsaville BJ, Kleber HD \"Predictors of 2.5-year outcome in opioid addicts: pretreatment source of income..\" Am J Drug Alcohol Abuse. 1987;13(41276):19-32. Pubmed PMID: 3687883\n",
    "Dodrill CL, Helmer DA, Kosten TR \"Prescription pain medication dependence..\" Am J Psychiatry. 2011 May;168(5):466-71. Pubmed PMID: 21536702\n",
    "Mooney ME, Poling J, Gonzalez G, Gonsai K, Kosten T, Sofuoglu M \"Preliminary study of buprenorphine and bupropion for opioid-dependent smokers..\" Am J Addict.;17(4):287-92. Pubmed PMID: 18612883\n",
    "O'Brien CP, Charney DS, Lewis L, Cornish JW, Post RM, Woody GE, Zubieta JK, Anthony JC, Blaine JD, Bowden CL, Calabrese JR, Carroll K, Kosten T, Rounsaville B, Childress AR, Oslin DW, Pettinati HM, Davis MA, Demartino R, Drake RE, Fleming MF, Fricks L, Gl \"Priority actions to improve the care of persons with co-occurring substance abuse and other mental disorders: a call to action..\" Biol. Psychiatry. 2004 Nov 15;56(10):703-13. Pubmed PMID: 15556110\n",
    "Zhang XY, Al Jurdi RK, Zoghbi AW, Chen da C, Xiu MH, Tan YL, Yang FD, Kosten TR \"Prevalence, demographic and clinical correlates of suicide attempts in Chinese medicated chronic inpatients with schizophrenia.\" J Psychiatr Res. 2013 Oct; Pubmed PMID: 23791457\n",
    "Ramakrishnan M, Alves De Melo F, Kinsey BM, Ladbury JE, Kosten TR, Orson FM \"Probing cocaine-antibody interactions in buffer and human serum..\" PLoS ONE. 2012;7(7):e40518. Pubmed PMID: 22859949\n",
    "Sofuoglu M, Poling J, Gonzalez G, Gonsai K, Oliveto A, Kosten TR \"Progesterone effects on cocaine use in male cocaine users maintained on methadone: a randomized, double-blind, pilot study..\" Exp Clin Psychopharmacol. 2007 Oct;15(5):453-60. Pubmed PMID: 17924779\n",
    "Schottenfeld RS, Pakes JR, Kosten TR \"Prognostic factors in Buprenorphine- versus methadone-maintained patients..\" J. Nerv. Ment. Dis.. 1998 Jan;186(1):35-43. Pubmed PMID: 9457145\n",
    "Rounsaville BJ, Kosten TR, Weissman MM, Kleber HD \"Prognostic significance of psychopathology in treated opiate addicts. A 2.5-year follow-up study..\" Arch. Gen. Psychiatry. 1986 Aug;43(8):739-45. Pubmed PMID: 3729668\n",
    "Rounsaville BJ, Kosten TR, Weissman MM, Prusoff B, Pauls D, Anton SF, Merikangas K \"Psychiatric disorders in relatives of probands with opiate addiction..\" Arch. Gen. Psychiatry. 1991 Jan;48(1):33-42. Pubmed PMID: 1984760\n",
    "Kosten TR, Jacobs S, Mason J, Wahby V, Atkins S \"Psychological correlates of growth hormone response to stress..\" Psychosom Med.. 1984 Jan; Pubmed PMID: 6701254\n",
    "Brimijoin S, Shen X, Orson F, Kosten T \"Prospects, promise and problems on the road to effective vaccines and related therapies for substance abuse..\" Expert Rev Vaccines. 2013 Mar;12(3):323-32. Pubmed PMID: 23496671\n",
    "Jacobsen LK, Giedd JN, Kreek MJ, Gottschalk C, Kosten TR \"Quantitative medial temporal lobe brain morphology and hypothalamic-pituitary-adrenal axis function in cocaine dependence: a preliminary report..\" Drug Alcohol Depend. 2001 Mar 1;62(1):49-56. Pubmed PMID: 11173167\n",
    "Kosten TR, Rounsaville BJ \"Psychopathology in opioid addicts..\" Psychiatr. Clin. North Am.. 1986 Sep;9(3):515-32. Pubmed PMID: 3774603\n",
    "Jacobsen LK, Giedd JN, Gottschalk C, Kosten TR, Krystal JH \"Quantitative morphology of the caudate and putamen in patients with cocaine dependence..\" Am J Psychiatry. 2001 Mar;158(3):486-9. Pubmed PMID: 11229995\n",
    "Schottenfeld RS, Chawarski MC, Cubells JF, George TP, Lappalainen J, Kosten TR \"Randomized clinical trial of disulfiram for cocaine dependence or abuse during buprenorphine treatment.\" Drug Alcohol Depend. 2014 Mar; Pubmed PMID: 24462581\n",
    "Oliveto A, Poling J, Mancino MJ, Feldman Z, Cubells JF, Pruzinsky R, Gonsai K, Cargile C, Sofuoglu M, Chopra MP, Gonzalez-Haddad G, Carroll KM, Kosten TR \"Randomized, double blind, placebo-controlled trial of disulfiram for the treatment of cocaine dependence in methadone-stabilized patients..\" Drug Alcohol Depend. 2011 Jan; Pubmed PMID: 20828943\n",
    "Kosten TR, Kleber HD \"Rapid death during cocaine abuse: a variant of the neuroleptic malignant syndrome?.\" Am J Drug Alcohol Abuse. 1988;14(3):335-46. Pubmed PMID: 3055940\n",
    "O'Connor PG, Kosten TR \"Rapid and ultrarapid opioid detoxification techniques..\" JAMA. 1998 Jan 21;279(3):229-34. Pubmed PMID: 9438745\n",
    "Kosten TR, Krystal JH, Charney DS, Price LH, Morgan CH, Kleber HD \"Rapid detoxification from opioid dependence..\" Am J Psychiatry. 1989 Oct;146(10):1349. Pubmed PMID: 2675644\n",
    "Li XF, Zheng YL, Xiu MH, Chen da C, Kosten TR, Zhang XY \"Reduced plasma total antioxidant status in first-episode drug-naive patients with schizophrenia..\" Prog. Neuropsychopharmacol. Biol. Psychiatry. 2011 Jun 1;35(4):1064-7. Pubmed PMID: 21392552\n",
    "Chen da C, Xiu MH, Liu H, Zhang BS, Wang Y, Kosten TR, Zhang XY \"Reduced status of plasma total antioxidant capacity in schizophrenia with tardive dyskinesia..\" J Psychiatr Res. 2010 Nov;44(15):1111-2. Pubmed PMID: 20398909\n",
    "Stine SM, Kosten TR \"Reduction of opiate withdrawal-like symptoms by cocaine abuse during methadone and buprenorphine maintenance..\" Am J Drug Alcohol Abuse. 1994 Nov;20(4):445-58. Pubmed PMID: 7832179\n",
    "Kosten TR, Cheeves C, Palumbo J, Seibyl JP, Price LH, Woods SW \"Regional cerebral blood flow during acute and chronic abstinence from combined cocaine-alcohol abuse..\" Drug Alcohol Depend. 1998 May 1;50(3):187-95. Pubmed PMID: 9649971\n",
    "Kosten TR, Rounsaville BJ, Kleber HD \"Relationship of depression to psychosocial stressors in heroin addicts..\" J. Nerv. Ment. Dis.. 1983 Feb;171(2):97-104. Pubmed PMID: 6822825\n",
    "Kosten TR, Rounsaville BJ, Kleber HD \"Relationship of depression to clonidine detoxification of opiate addicts..\" Compr Psychiatry.;25(5):503-8. Pubmed PMID: 6488761\n",
    "Kosten TR, Jalali B, Steidl JH, Kleber HD \"Relationship of marital structure and interactions to opiate abuse relapse..\" Am J Drug Alcohol Abuse. 1987;13(4):387-99. Pubmed PMID: 3687898\n",
    "Rosen MI, McMahon TJ, Margolin A, Gill TS, Woods SW, Pearsall HR, Kreek MJ, Kosten TR \"Reliability of sequential naloxone challenge tests..\" Am J Drug Alcohol Abuse. 1995 Nov;21(4):453-67. Pubmed PMID: 8561097\n",
    "Wisner KL, Conley RR, Taylor SF, Kosten T, Rapaport MH, Brown LS \"Researcher experiences with IRBs: a survey of members of the American College of Neuropsychopharmacology..\" IRB.;33(5):14-20. Pubmed PMID: 22043746\n",
    "Sofuoglu M, Waters AJ, Mooney M, Kosten T \"Riluzole and D-amphetamine interactions in humans.\" Prog Neuropsychopharmacol Biol Psychiatry. 2008 Jan; Pubmed PMID: 17714844\n",
    "Poling J, Kosten TR \"Risperidone for substance dependent psychotic patients.\" 2005;\n",
    "Kosten TR, Kleber HD, Morgan C \"Role of opioid antagonists in treating intravenous cocaine abuse..\" Life Sci.. 1989;44(13):887-92. Pubmed PMID: 2927249\n",
    "Boutros NN, Gelernter J, Gooding DC, Cubells J, Young A, Krystal JH, Kosten T \"Sensory gating and psychosis vulnerability in cocaine-dependent individuals: preliminary data..\" Biol. Psychiatry. 2002 Apr 15;51(8):683-6. Pubmed PMID: 11955469\n",
    "Hirunsatit R, Ilomäki R, Malison R, Räsänen P, Ilomäki E, Kranzler HR, Kosten T, Sughondhabirom A, Thavichachart N, Tangwongchai S, Listman J, Mutirangura A, Gelernter J, Lappalainen J \"Sequence variation and linkage disequilibrium in the GABA transporter-1 gene (SLC6A1) in five populations: implications for pharmacogenetic research.\" BMC Genet. 2007 Oct; Pubmed PMID: 17941974\n",
    "Aronson SC, Black JE, McDougle CJ, Scanley BE, Jatlow P, Kosten TR, Heninger GR, Price LH \"Serotonergic mechanisms of cocaine effects in humans..\" Psychopharmacology (Berl.). 1995 May;119(2):179-85. Pubmed PMID: 7659765\n",
    "Graham DP, Helmer DA, Harding MJ, Kosten TR, Petersen NJ, Nielsen DA \"Serotonin transporter genotype and mild traumatic brain injury independently influence resilience and perception of limitations in veterans..\" J Psychiatr Res. 2013 Jun;47(6):835-42. Pubmed PMID: 23478049\n",
    "Oliveto A, Poling J, Mancino MJ, Williams DK, Thostenson J, Pruzinsky R, Gonsai K, Sofuoglu M, Gonzalez G, Tripathi S, Kosten TR \"Sertraline delays relapse in recently abstinent cocaine-dependent patients with depressive symptoms..\" Addiction. 2012 Jan;107(1):131-41. Pubmed PMID: 21707811\n",
    "Zhang XY, Tan YL, Zhou DF, Cao LY, Wu GY, Xu Q, Shen Y, Haile CN, Kosten TA, Kosten TR \"Serum BDNF levels and weight gain in schizophrenic patients on long-term treatment with antipsychotics..\" J Psychiatr Res. 2007 Dec;41(12):997-1004. Pubmed PMID: 17095017\n",
    "Wahby V, Ibrahim G, Friedenthal S, Giller E, Kosten T, Mason J \"Serum concentrations of circulating thyroid hormones in a group of depressed men.\" Neuropsychobiology. 1989; Pubmed PMID: 2639287\n",
    "Li SX, Li J, Epstein DH, Zhang XY, Kosten TR, Lu L \"Serum cortisol secretion during heroin abstinence is elevated only nocturnally..\" Am J Drug Alcohol Abuse. 2008;34(3):321-8. Pubmed PMID: 18428074\n",
    "Mason JW, Giller EL, Kosten TR \"Serum testosterone differences between patients with schizophrenia and those with affective disorder..\" Biol. Psychiatry. 1988 Feb 15;23(4):357-66. Pubmed PMID: 3342266\n",
    "Mason JW, Giller El, Kosten TR, Wahby VS \"Serum testosterone levels in post traumatic stress disorder inpatients.\" J Traumatic Stress. 1990;\n",
    "Southwick S, Mason JW, Giller EL, Kosten TR \"Serum thyroxine change and clinical recovery in psychiatric inpatients..\" Biol. Psychiatry. 1989 Jan;25(1):67-74. Pubmed PMID: 2912510\n",
    "Zhang XY, Zhang RL, Pan M, Chen da C, Xiu MH, Kosten TR \"Sex difference in the prevalence of smoking in Chinese schizophrenia..\" J Psychiatr Res. 2010 Oct;44(14):986-8. Pubmed PMID: 20334878\n",
    "Mason JW, Kennedy JL, Kosten TR, Giller EL \"Serum thyroxine levels in schizophrenic and affective disorder diagnostic subgroups..\" J. Nerv. Ment. Dis.. 1989 Jun;177(6):351-8. Pubmed PMID: 2723624\n",
    "Yang FD, Wang XQ, Liu XP, Zhao KX, Fu WH, Hao XR, Zhang XL, Huang GS, Qu SC, Bai JS, Huang XF, Kosten TR, Zhang XY \"Sex difference in QTc prolongation in chronic institutionalized patients with schizophrenia on long-term treatment with typical and atypical antipsychotics..\" Psychopharmacology (Berl.). 2011 Jul;216(1):41533. Pubmed PMID: 21301815\n",
    "Kosten TA, Jacobsen LK, Kosten TR \"Severity of precipitated opiate withdrawal predicts drug dependence by DSM-III-R criteria..\" Am J Drug Alcohol Abuse. 1989;15(3):237-50. Pubmed PMID: 2763981\n",
    "Li CS, Kosten TR, Sinha R \"Sex differences in brain activation during stress imagery in abstinent cocaine users: a functional magnetic resonance imaging study..\" Biol. Psychiatry. 2005 Mar 1;57(5):487-94. Pubmed PMID: 15737663\n",
    "Singha AK, McCance-Katz EF, Petrakis I, Kosten TR, Oliveto A \"Sex differences in self-reported and physiological response to oral cocaine and placebo in humans..\" Am J Drug Alcohol Abuse. 2000 Nov;26(4):643-57. Pubmed PMID: 11097197\n",
    "Li YQ, Wang XY, Zhai HF, Zhang XY, Kosten T, Lu L \"Sex- and age-dependent effects of early postnatal sibling deprivation on spatial learning and memory in adult rats..\" Behav Brain Res. 2008 Jan; Pubmed PMID: 17765982\n",
    "Zhang XY, Liu L, Liu S, Hong X, Chen da C, Xiu MH, Yang FD, Zhang Z, Zhang X, Kosten TA, Kosten TR \"Short-term tropisetron treatment and cognitive and p50 auditory gating deficits in schizophrenia..\" Am J Psychiatry. 2012 Sep 1;169(9):974-81. Pubmed PMID: 22952075\n",
    "Farren CK, Hameedi FA, Rosen MA, Woods S, Jatlow P, Kosten TR \"Significant interaction between clozapine and cocaine in cocaine addicts..\" Drug Alcohol Depend. 2000 May 1;59(2):153-63. Pubmed PMID: 10891628\n",
    "102. Kosten TR, Gawin FH, Kosten TA, Morgan C, Rounsaville BJ, Schottenfeld RS, Kleber HD \"Six month follow-up of short term pharmacotherapy for cocaine dependence.\" Am J Addictions. 1992;\n",
    "Satel SL, Kosten TR, Schuckit MA, Fischman MW \"Should protracted withdrawal from drugs be included in DSM-IV?.\" Am J Psychiatry. 1993 May;150(5):695-704. Pubmed PMID: 8097618\n",
    "Poling J, Oliveto A, Petry N, Sofuoglu M, Gonsai K, Gonzalez G, Martell B, Kosten TR \"Six-month trial of bupropion with contingency management for cocaine dependence in a methadone-maintained population..\" Arch. Gen. Psychiatry. 2006 Feb;63(2):219-28. Pubmed PMID: 16461866\n",
    "Zhang XY, Yu YQ, Sun S, Zhang X, Li W, Xiu MH, Chen da C, Yang FD, Zhu F, Kosten TA, Kosten TR \"Smoking and tardive dyskinesia in male patients with chronic schizophrenia..\" Prog. Neuropsychopharmacol. Biol. Psychiatry. 2011 Aug 15;35(7):1765-9. Pubmed PMID: 21723906\n",
    "Kosten TR, Rounsaville BJ \"Source of income as a predictor in opioid addicts: 2.5 year follow-up..\" NIDA Res. Monogr.. 1987;76:196-9. Pubmed PMID: 3125447\n",
    "Zhang XY, Li CB, Li M, Zheng YL, Zhang CX, Yan QZ, Liu WZ, Kang YM, Wang F, Chen da C, Xiu MH, Kosten TR \"Smoking initiation and schizophrenia: a replication study in a Chinese Han population..\" Schizophr. Res.. 2010 Jun;119(41277):110-4. Pubmed PMID: 20022218\n",
    "Zhang XY, Chen da C, Tan YL, Xiu MH, Cui J, Hui L, De Yang F, Kosten TR \"Socio-demographic and clinical characteristics of heavy and non-heavy smokers among schizophrenia inpatients in a Chinese Han population.\" Psychopharmacology (Berl). 2014 Jan; Pubmed PMID: 23963531\n",
    "van Dyck CH, Rosen MI, Thomas HM, McMahon TJ, Wallace EA, O'Connor PG, Sullivan M, Krystal JH, Hoffer PB, Woods SW \"SPECT regional cerebral blood flow alterations in naltrexone-precipitated withdrawal from buprenorphine..\" Psychiatry Res.. 1994 Dec; Pubmed PMID: 7701033\n",
    "Woods SW, O'Malley SS, Martini BL, McDougle CJ, Price LH, Krystal JH, Hoffer PB, Kosten TR \"SPECT regional cerebral blood flow and neuropsychological testing in non-demented HIV-positive drug abusers: preliminary results..\" Prog. Neuropsychopharmacol. Biol. Psychiatry. 1991;15(5):649-62. Pubmed PMID: 1956993\n",
    "Brown AE, Tonigan JS, Pavlik VN, Kosten TR, Volk RJ \"Spirituality and Confidence to Resist Substance Use Among Celebrate Recovery Participants..\" J Relig Health. 2011 Jan 19; Pubmed PMID: 21246280\n",
    "Orson FM, Rossen RD, Shen X, Lopez AY, Wu Y, Kosten TR \"Spontaneous Development of IgM Anti-Cocaine Antibodies in Habitual Cocaine Users: Effect on IgG Antibody Responses to a Cocaine Cholera Toxin B Conjugate Vaccine..\" Am J Addict. 2013 Mar;22(2):169-74. Pubmed PMID: 23414504\n",
    "Zhao LY, Shi J, Zhang XL, Epstein DH, Zhang XY, Liu Y, Kosten TR, Lu L \"Stress enhances retrieval of drug-related memories in abstinent heroin addicts..\" Neuropsychopharmacology. 2010 Feb;35(3):720-6. Pubmed PMID: 19890257\n",
    "Lago JA, Kosten TR \"Stimulant withdrawal..\" Addiction. 1994 Nov;89(11):1477-81. Pubmed PMID: 7841859\n",
    "Kosten TR \"Stress and addiction..\" Am J Psychiatry. 2011 Jun;168(6):566-8. Pubmed PMID: 21642477\n",
    "Kosten TR, Kleber HD \"Strategies to improve compliance with narcotic antagonists..\" Am J Drug Alcohol Abuse. 1984;10(2):249-66. Pubmed PMID: 6475891\n",
    "Lu L, Wang X, Kosten TR \"Stereotactic neurosurgical treatment of drug addiction..\" Am J Drug Alcohol Abuse. 2009;35(6):391-3. Pubmed PMID: 20014906\n",
    "Kosten TR, Ziedonis DM \"Substance abuse and schizophrenia: editors' introduction..\" Schizophr Bull. 1997;23(2):181-6. Pubmed PMID: 9165628\n",
    "Jacobsen LK, Southwick SM, Kosten TR \"Substance use disorders in patients with posttraumatic stress disorder: a review of the literature..\" Am J Psychiatry. 2001 Aug;158(8):1184-90. Pubmed PMID: 11481147\n",
    "Orson FM, Kinsey BM, Singh RA, Wu Y, Gardner T, Kosten TR \"Substance abuse vaccines..\" Ann. N. Y. Acad. Sci.. 2008 Oct;1141:257-69. Pubmed PMID: 18991962\n",
    "Zhang XY, Zhou DF, Qi LY, Chen S, Cao LY, Chen da C, Xiu MH, Wang F, Wu GY, Lu L, Kosten TA, Kosten TR \"Superoxide dismutase and cytokines in chronic patients with schizophrenia: association with psychopathology and response to antipsychotics..\" Psychopharmacology (Berl.). 2009 May;204(1):177-84. Pubmed PMID: 19139851\n",
    "Calhoun P, Najavits LM, Kosten T, Kivlahan D \"Substance Use in OIF/OEF Veterans.\" VA Health Services Research and Development For. 2007;\n",
    "Kosten TR, Rounsaville BJ, Babor TF, Spitzer RL, Williams JB \"Substance-use disorders in DSM-III-R. Evidence for the dependence syndrome across different psychoactive substances..\" Br J Psychiatry. 1987 Dec;151:834-43. Pubmed PMID: 2901887\n",
    "Kosten TR, Rounsaville BJ \"Suicidality among opioid addicts: 2.5 year follow-up..\" Am J Drug Alcohol Abuse. 1988;14(3):357-69. Pubmed PMID: 3189257\n",
    "Rounsaville BJ, Kosten T, Kleber H \"Success and failure at outpatient opioid detoxification. Evaluating the process of clonidine- and methadone-assisted withdrawal..\" J Nerv Ment Dis.. 1985; Pubmed PMID: 3881558\n",
    "Kosten TR, Mason JW, Giller EL, Ostroff RB, Harkness L \"Sustained urinary norepinephrine and epinephrine elevation in post-traumatic stress disorder..\" Psychoneuroendocrinology. 1987;12(1):13-20. Pubmed PMID: 3588809\n",
    "van Dyck CH, McMahon TJ, Rosen MI, O'Malley SS, O'Connor PG, Lin CH, Pearsall HR, Woods SW, Kosten TR \"Sustained-release methylphenidate for cognitive impairment in HIV-1-infected drug abusers: a pilot study..\" J Neuropsychiatry Clin Neurosci. 1997;9(1):29-36. Pubmed PMID: 9017526\n",
    "Martell BA, O'Connor PG, Kerns RD, Becker WC, Morales KH, Kosten TR, Fiellin DA \"Systematic review: opioid treatment for chronic back pain: prevalence, efficacy, and association with addiction..\" Ann. Intern. Med.. 2007 Jan 16;146(2):116-27. Pubmed PMID: 17227935\n",
    "Anton RF, Litten RZ, Falk DE, Palumbo JM, Bartus RT, Robinson RL, Kranzler HR, Kosten TR, Meyer RE, O'Brien CP, Mann K, Meulien D \"The Alcohol Clinical Trials Initiative (ACTIVE): Purpose and Goals for Assessing Important and Salient Issues for Medications Development in Alcohol Use Disorders..\" 2011 Sep 7; Pubmed PMID: 21900883\n",
    "Rounsaville BJ, Kosten TR, Kleber HD \"The antecedents and benefits of achieving abstinence in opioid addicts: a 2.5-year follow-up study..\" Am J Drug Alcohol Abuse. 1987;13(3):213-29. Pubmed PMID: 3687888\n",
    "Wang F, Xiu MH, Zhou DF, Cao LY, Wu GY, Kosten TA, Kosten TR, Zhang XY \"The CCR5 32-bp deletion allele is rare in a Chinese population..\" Schizophr. Res.. 2008 Apr;101(41277):341-3. Pubmed PMID: 18295459\n",
    "Gao Y, Orson FM, Kinsey B, Kosten T, Brimijoin S \"The concept of pharmacologic cocaine interception as a treatment for drug abuse..\" Chem. Biol. Interact.. 2010 Sep 6;187(41277):421-4. Pubmed PMID: 20219449\n",
    "Kosten TR, Rounsaville BJ, Babor TF, Spitzer RL, Williams JB \"The dependence syndrome across different psychoactive substances: revised DSM-III..\" NIDA Res. Monogr.. 1987;76:255-8. Pubmed PMID: 3125454\n",
    "Kosten TA, Kosten TR \"The dependence syndrome concept as applied to alcohol and other substances of abuse..\" Recent Dev Alcohol. 1990;8:47-68. Pubmed PMID: 2185524\n",
    "Kosten TR, Wahby V, Giller E, Mason J \"The dexamethasone suppression test and thyrotropin-releasing hormone stimulation test in posttraumatic stress disorder..\" Biol. Psychiatry. 1990 Oct 15;28(8):657-64. Pubmed PMID: 2122916\n",
    "Kosten TR, Jacobs S, Mason JW \"The dexamethasone suppression test during bereavement.\" J Nerv Ment Dis.. 1984 Jun; Pubmed PMID: 6544808\n",
    "Abi-Saab D, Beauvais J, Mehm J, Brody M, Gottschalk C, Kosten TR \"The effect of alcohol on the neuropsychological functioning of recently abstinent cocaine-dependent subjects..\" Am J Addict.;14(2):166-78. Pubmed PMID: 16019965\n",
    "Hui L, Zhang X, Huang XF, Han M, Fernandez F, Yu Y, Sun S, Li W, Chen da C, Xiu MH, Kosten TR, Zhang XY \"The dopamine b-hydroxylase 19 bp insertion/deletion polymorphism was associated with first-episode but not medicated chronic schizophrenia..\" J Psychiatr Res. 2012 Jun;46(6):733-7. Pubmed PMID: 22445279\n",
    "Rosen MI, Pearsall HR, Woods SW, Kosten TR \"The effect of gamma-hydroxybutyric acid on naloxone-precipitated opiate withdrawal..\" Neuropsychopharmacology. 1996 Mar;14(3):187-93. Pubmed PMID: 8866702\n",
    "Rosen MI, Pearsall HR, Kosten TR \"The effect of lamotrigine on naloxone-precipitated opiate withdrawal..\" Drug Alcohol Depend. 1998 Oct 1;52(2):173-6. Pubmed PMID: 9800147\n",
    "Stine SM, Freeman M, Burns B, Charney DS, Kosten TR \"The effect of methadone dose on cocaine abuse in a methadone program.\" Am J Addictions. 1992;\n",
    "Kosten TR, Hogan I, Jalali B, Steidl J, Kleber HD \"The effect of multiple family therapy on addict family functioning: a pilot study..\" Adv Alcohol Subst Abuse. 1986;5(3):51-62. Pubmed PMID: 3728193\n",
    "Rosen MI, Kosten TR, Kreek MJ \"The effects of naltrexone maintenance on the response to yohimbine in healthy volunteers..\" Biol. Psychiatry. 1999 Jun 15;45(12):1636-45. Pubmed PMID: 10376126\n",
    "Orson FM, Wang R, Brimijoin S, Kinsey BM, Singh RA, Ramakrishnan M, Wang HY, Kosten TR \"The future potential for cocaine vaccines..\" Expert Opin Biol Ther. 2014; Pubmed PMID: 24835496\n",
    "Orson FM, Kinsey BM, Singh RA, Wu Y, Gardner T, Kosten TR \"The future of vaccines in the management of addictive disorders..\" Curr Psychiatry Rep. 2007 Oct;9(5):381-7. Pubmed PMID: 17915077\n",
    "Haile CN, De La Garza R, Mahoney JJ, Nielsen DA, Kosten TR, Newton TF \"The impact of disulfiram treatment on the reinforcing effects of cocaine: a randomized clinical trial..\" PLoS ONE. 2012;7(11):e47702. Pubmed PMID: 23144826\n",
    "Liu S, Green CE, Lane SD, Kosten TR, Moeller FG, Nielsen DA, Schmitz JM \"The influence of dopamine β-hydroxylase gene polymorphism rs1611115 on levodopa/carbidopa treatment for cocaine dependence: a preliminary study.\" Pharmacogenet Genomics. 2014 Jul; Pubmed PMID: 24809448\n",
    "112. Sun H, Wang F, Fan H, Yan Q, Cui K, Yuan W, Zhao F, Zhao L, Yuan J, Yang F, Kosten TR, Zhang XY \"The interaction of polymorphisms of IL10 and DBH was associated with general symptoms of PANSS with TD in Chinese Han schizophrenic patients.\" PLoS One. 2013 Aug; Pubmed PMID: 23951054\n",
    "Kosten TR, Gorelick DA \"The Lexington narcotic farm..\" Am J Psychiatry. 2002 Jan;159(1):22. Pubmed PMID: 11772684\n",
    "Jacobs SC, Kasl SV, Ostfeld AM, Berkman L, Kosten TR, Charpentier P \"The measurement of grief: bereaved versus non-bereaved.\" Hosp J.. 1986; Pubmed PMID: 3647919\n",
    "Spellicy CJ, Kosten TR, Hamon SC, Harding MJ, Nielsen DA \"The MTHFR C677T Variant is Associated with Responsiveness to Disulfiram Treatment for Cocaine Dependency..\" Front Psychiatry. 2012;3:109. Pubmed PMID: 23335901\n",
    "Kosten TR, George TP \"The neurobiology of opioid dependence: implications for treatment..\" 2002 Jul;1(1):13-20. Pubmed PMID: 18567959\n",
    "Zhang XY, Chen da C, Xiu MH, Wang F, Qi LY, Sun HQ, Chen S, He SC, Wu GY, Haile CN, Kosten TA, Lu L, Kosten TR \"The novel oxidative stress marker thioredoxin is increased in first-episode schizophrenic patients..\" Schizophr. Res.. 2009 Sep;113(41308):151-7. Pubmed PMID: 19540723\n",
    "Kosten TA, Bianchi MS, Kosten TR \"The predictive validity of the dependence syndrome in opiate abusers..\" Am J Drug Alcohol Abuse. 1992;18(2):145-56. Pubmed PMID: 1562012\n",
    "Kosten TR, George TP, Kosten TA \"The potential of dopamine agonists in drug addiction..\" Expert Opin Investig Drugs. 2002 Apr;11(4):491-9. Pubmed PMID: 11922858\n",
    "Rao S, Ziedonis DM, Kosten TR \"The pharmacotherapy of cocaine dependence.\" Psychiatric Annals. 1995;\n",
    "Haile CN, Kosten TR \"The potential of pharmacogenomics to treat drug addiction..\" Pharmacogenomics. 2009 Dec;10(12):1883-6. Pubmed PMID: 19958085\n",
    "Zhang R, Hao W, Pan M, Wang C, Zhang X, Chen DC, Xiu MH, De Yang F, Kosten TR, Zhang XY \"The prevalence and clinical-demographic correlates of diabetes mellitus in chronic schizophrenic patients receiving clozapine..\" Hum Psychopharmacol. 2011 Aug 8; Pubmed PMID: 21826737\n",
    "Kosten TR \"The pharmacotherapy of relapse prevention using anticonvulsants..\" Am J Addict. 1998;7(3):205-9. Pubmed PMID: 9702288\n",
    "Kosten TR, Rounsaville BJ, Merikangas KR, Prusoff BA, Kleber HD \"The relationship of the Maudsley Personality Inventory to depression in addicts..\" Compr Psychiatry.;24(6):535-42. Pubmed PMID: 6653096\n",
    "McCance EF, Kosten TR \"The role of the human laboratory in drug abuse research. Psychiatric Annals.\" Psychiatric Annals. 1995;\n",
    "Zhang X, Hui L, Liu Y, Wang ZQ, You Y, Miao LN, Sun SL, Guan SL, Xiang Y, Kosten TR, Zhang XY \"The type 2 diabetes mellitus susceptibility gene IGF2BP2 is associated with schizophrenia in a Han Chinese population..\" J Clin Psychiatry. 2013 Apr;74(4):e287-92. Pubmed PMID: 23656854\n",
    "Mason JW, Kosten TR, Southwick SM, Giller EL. \"The use of hormonal profile strategies in post-traumatic stress disorder.\" J Applied Social Psychology. 1990;\n",
    "Kosten TR, Bryant K, Rounsaville BJ \"The SCID: a clinical instrument for assessing psychiatric disorders..\" NIDA Res. Monogr.. 1990;105:213-9. Pubmed PMID: 1876002\n",
    "Zhou DH, Yan QZ, Yan XM, Li CB, Fang H, Zheng YL, Zhang CX, Yao HJ, Chen da C, Xiu MH, Kosten TR, Zhang XY \"The study of BDNF Val66Met polymorphism in Chinese schizophrenic patients..\" Prog. Neuropsychopharmacol. Biol. Psychiatry. 2010 Aug 16;34(6):930-3. Pubmed PMID: 20420877\n",
    "Rohrbaugh RM, Felker B, Kosten T \"The VA psychiatry-primary care education initiative..\" Acad Psychiatry. 2009 Jan; Pubmed PMID: 19349441\n",
    "Wang Y, Wang JD, Wu HR, Zhang BS, Fang H, Ma QM, Liu H, Chen da C, Xiu MH, Hail CN, Kosten TR, Zhang XY \"The Val66Met polymorphism of the brain-derived neurotrophic factor gene is not associated with risk for schizophrenia and tardive dyskinesia in Han Chinese population..\" Schizophr. Res.. 2010 Jul;120(41277):240-2. Pubmed PMID: 20395113\n",
    "Nielsen DA, Hamon SC, Kosten TR \"The κ-opioid receptor gene as a predictor of response in a cocaine vaccine clinical trial.\" Psychiatr Genet. 2013 Dec; Pubmed PMID: 23995774\n",
    "Gardner TJ, Kosten TR \"Therapeutic options and challenges for substances of abuse..\" 2007;9(4):431-45. Pubmed PMID: 18286802\n",
    "Haney M, Kosten TR \"Therapeutic vaccines for substance dependence..\" Expert Rev Vaccines. 2004 Feb;3(1):41586. Pubmed PMID: 14761239\n",
    "Kosten TR, Biegel D \"Therapeutic vaccines for substance dependence..\" Expert Rev Vaccines. 2002 Oct;1(3):363-71. Pubmed PMID: 12901575\n",
    "Zhang XY, Chen da C, Xiu MH, Yang FD, Tan YL, He S, Kosten TA, Kosten TR \"Thioredoxin, a novel oxidative stress marker and cognitive performance in chronic and medicated schizophrenia versus healthy controls..\" Schizophr. Res.. 2013 Feb;143(41308):301-6. Pubmed PMID: 23238053\n",
    "O'Connor PG, Carroll KM, Shi JM, Schottenfeld RS, Kosten TR, Rounsaville BJ \"Three methods of opioid detoxification in a primary care setting. A randomized trial..\" Ann. Intern. Med.. 1997 Oct 1;127(7):526-30. Pubmed PMID: 9313020\n",
    "Schottenfeld RS, Pakes J, O'Connor P, Chawarski M, Oliveto A, Kosten TR \"Thrice-weekly versus daily buprenorphine maintenance..\" Biol. Psychiatry. 2000 Jun 15;47(12):1072-9. Pubmed PMID: 10862807\n",
    "Sofuoglu M, Poling J, Mitchell E, Kosten TR \"Tiagabine affects the subjective responses to cocaine in humans..\" Pharmacol. Biochem. Behav.. 2005 Nov;82(3):569-73. Pubmed PMID: 16332385\n",
    "Gonzalez G, Sevarino K, Sofuoglu M, Poling J, Oliveto A, Gonsai K, George TP, Kosten TR \"Tiagabine increases cocaine-free urines in cocaine-dependent methadone-treated patients: results of a randomized pilot study..\" Addiction. 2003 Nov;98(11):1625-32. Pubmed PMID: 14616189\n",
    "Shi J, Li SX, Zhang XL, Wang X, Le Foll B, Zhang XY, Kosten TR, Lu L \"Time-Dependent Neuroendocrine Alterations and Drug Craving during the First Month of Abstinence in Heroin Addicts..\" Am J Drug Alcohol Abuse. 2009;35(5):267-72. Pubmed PMID: 19591065\n",
    "Lu L, Liu Y, Zhu W, Shi J, Liu Y, Ling W, Kosten TR \"Traditional medicine in the treatment of drug addiction..\" Am J Drug Alcohol Abuse. 2009;35(1):41285. Pubmed PMID: 19152199\n",
    "Rounsaville BJ, Kosten TR \"Treatment for opioid dependence: quality and access..\" JAMA. 2000 Mar; Pubmed PMID: 10714736\n",
    "Kosten TR, Kleber HD, Morgan C \"Treatment of cocaine abuse with buprenorphine.\" Biol Psychiatry. 1989 Oct; Pubmed PMID: 2790101\n",
    "Nigam R, Schottenfeld R, Kosten TR \"Treatment of dual diagnosis patients: a relapse prevention group approach..\" J Subst Abuse Treat. 1992;9(4):305-9. Pubmed PMID: 1362227\n",
    "Kosten TR, Rosen MI, McMahon TL, Bridge TP, O'Malley SS, Pearsall R, O'Connor PG \"Treatment of early AIDS dementia in intravenous drug users: high versus low dose peptide T..\" Am J Drug Alcohol Abuse. 1997 Nov;23(4):543-53. Pubmed PMID: 9366972\n",
    "Gonzalez G, Oliveto A, Kosten TR \"Treatment of heroin (diamorphine) addiction: current approaches and future prospects..\" Drugs. 2002;62(9):1331-43. Pubmed PMID: 12076182\n",
    "Kosten TR, Morgan C, Kleber HD \"Treatment of heroin addicts using buprenorphine..\" Am J Drug Alcohol Abuse. 1991 Jun;17(2):119-28. Pubmed PMID: 1862786\n",
    "\"Treatment of patients with substance use disorders, second edition. American Psychiatic Association..\" Am J Addictions. 2006 Oct; Pubmed PMID: 16981488\n",
    "Kleber HD, Weiss RD, Anton RF, George TP, Greenfield SF, Kosten TR, O'Brien CP, Rounsaville BJ, Strain EC, Ziedonis DM, Hennessy G, Connery HS, McIntyre JS, Charles SC, Anzia DJ, Cook IA, Finnerty MT, Johnson BR, Nininger JE, Summergrad P, Woods SM, Yager \"Treatment of patients with substance use disorders, second edition. American Psychiatric Association..\" Am J Psychiatry. 2007 Apr;164(4):5-123. Pubmed PMID: 17569411\n",
    "Kosten TR, Forrest JN \"Treatment of severe lithium-induced polyuria with amiloride..\" Am J Psychiatry. 1986 Dec;143(12):1563-8. Pubmed PMID: 3538913\n",
    "Poling J, Kosten TR, Sofuoglu M \"Treatment outcome predictors for cocaine dependence..\" Am J Drug Alcohol Abuse. 2007;33(2):191-206. Pubmed PMID: 17497542\n",
    "Satel SL, Krystal JH, Delgado PL, Kosten TR, Charney DS \"Tryptophan depletion and attenuation of cue-induced craving for cocaine..\" Am J Psychiatry. 1995 May;152(5):778-83. Pubmed PMID: 7726319\n",
    "Kosten TR, McCance E \"Una revision de tratamientos farmacologicos para el abuso de substancias.\" Revista de Toxicomanias. 1997;\n",
    "Kosten TR \"Update on addiction medicine in the State of Connecticut.\" Connecticut Medicine. 1999;\n",
    "Jacobs SC, Mason J, Kosten TR, Kasl SV, Ostfeld AM, Wahby V \"Urinary free cortisol and separation anxiety early in the course of bereavement and threatened loss..\" Biol. Psychiatry. 1987 Feb;22(2):148-52. Pubmed PMID: 3814667\n",
    "Mason JW, Giller EL, Kosten TR, Ostroff RB, Podd L \"Urinary free-cortisol levels in posttraumatic stress disorder patients..\" J. Nerv. Ment. Dis.. 1986 Mar;174(3):145-9. Pubmed PMID: 3950596\n",
    "Druss BG, Rohrbaugh R, Kosten T, Hoff R, Rosenheck RA \"Use of alternative medicine in major depression.\" Psychiatr Serv.. 1998 Nov; Pubmed PMID: 9826237\n",
    "Stine SM, Kosten TR \"Use of drug combinations in treatment of opioid withdrawal..\" J Clin Psychopharmacol. 1992 Jun;12(3):203-9. Pubmed PMID: 1629388\n",
    "Jacobs S, Mason J, Kosten T, Brown S, Ostfeld A \"Urinary-free cortisol excretion in relation to age in acutely stressed persons with depressive symptoms.\" Psychosom Med. 1984 May; Pubmed PMID: 6739681\n",
    "Kosten TR, Domingo CB, Shorter D, Orson F, Green C, Somoza E, Sekerka R, Levin FR, Mariani JJ, Stitzer M, Tompkins DA, Rotrosen J, Thakkar V, Smoak B, Kampman K \"Vaccine for cocaine dependence: a randomized double-blind placebo-controlled efficacy trial..\" Drug Alcohol Depend. 2014 Jul; Pubmed PMID: 24793366\n",
    "Feingold A, Oliveto A, Schottenfeld R, Kosten TR \"Utility of crossover designs in clinical trials: efficacy of desipramine vs. placebo in opioid-dependent cocaine abusers..\" Am J Addict. 2002;11(2):111-23. Pubmed PMID: 12028741\n",
    "Martell BA, Mitchell E, Poling J, Gonsai K, Kosten TR \"Vaccine pharmacotherapy for the treatment of cocaine dependence..\" Biol. Psychiatry. 2005 Jul 15;58(2):158-64. Pubmed PMID: 16038686\n",
    "Shen XY, Orson FM, Kosten TR \"Vaccines Against Drug Abuse..\" Clin. Pharmacol. Ther.. 2011 Nov 30; Pubmed PMID: 22130115\n",
    "Kosten T, Domingo C, Orson F, Kinsey B \"Vaccines against stimulants: cocaine and MA.\" Br J Clin Pharmacol.. 2014 Feb; Pubmed PMID: 23509915\n",
    "Orson FM, Kinsey BM, Singh RA, Wu Y, Kosten TR \"Vaccines for cocaine abuse..\" 2009 Apr;5(4):194-9. Pubmed PMID: 19276665\n",
    "Shorter D, Kosten TR \"Vaccines in the Treatment of Substance Abuse.\" Focus (Am Psychiatr Publ).. 2011 Dec; Pubmed PMID: 23472050\n",
    "Kosten TR \"What are America's opportunities for harm reduction strategies in opiate dependence?.\" Am J Addict.;14(4):307-10. Pubmed PMID: 16188710\n",
    "Stine SM, Southwick SM, Petrakis IL, Kosten TR, Charney DS, Krystal JH \"Yohimbine-induced withdrawal and anxiety symptoms in opioid-dependent patients..\" Biol. Psychiatry. 2002 Apr 15;51(8):642-51. Pubmed PMID: 11955464\n",
    "Avants SK, Margolin A, Kosten TR, Rounsaville BJ, Schottenfeld RS \"When is less treatment better? The role of social anxiety in matching methadone patients to psychosocial treatments..\" J Consult Clin Psychol. 1998 Dec;66(6):924-31. Pubmed PMID: 9874905\n",
    "\"\"\""
   ],
   "metadata": {
    "collapsed": false
   }
  },
  {
   "cell_type": "code",
   "execution_count": 6,
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "<Response [200]>\n",
      "query:\n",
      "    请根据以下context，回答：托马斯医生的专长\n",
      "    reply in 简体中文\n",
      "    ---------context\n",
      "    \n",
      "Thomas Kosten, M.D.\n",
      "Jay H. Waggoner Endowed Chair\n",
      "713-794-7032\n",
      "Email\n",
      "kosten@bcm.edu\n",
      "Positions\n",
      "Jay H. Waggoner Endowed Chair\n",
      "Baylor College of Medicine\n",
      "Vice-Chair\n",
      "Psychiatry for Research\n",
      "Baylor College of Medicine\n",
      "Director\n",
      "Division of Alcohol and Addiction Psychiatry\n",
      "Baylor College of Medicine\n",
      "Co-Director\n",
      "Institute for Clinical and Translational Research\n",
      "Baylor College of Medicine\n",
      "Professor\n",
      "Psychiatry\n",
      "Baylor College of Medicine\n",
      "Houston, Texas US\n",
      "Professor\n",
      "Neuroscience\n",
      "Baylor College of Medicine\n",
      "Houston, Texas United States\n",
      "Professor\n",
      "Pharmacology\n",
      "Baylor College of Medicine\n",
      "Houston, Texas United States\n",
      "Professor\n",
      "Immunology and Rheumatology\n",
      "Baylor College of Medicine\n",
      "Houston, TX United States\n",
      "Member\n",
      "Dan L Duncan Comprehensive Cancer Center\n",
      "Baylor College of Medicine\n",
      "Houston, Texas United States\n",
      "Education\n",
      "MA from Yale University\n",
      "01/1995 - New Haven, Connecticut United States\n",
      "Clinical Fellowship at Yale University School of Medicine\n",
      "01/1983 - New Haven, Connecticut United States\n",
      "M.D. from Cornell University Medical College\n",
      "01/1977 - New York, NY United States\n",
      "BS from Rensselaer Polytechnic Institute\n",
      "01/1973 - Troy, New York United States\n",
      "Residency at Yale University School of Medicine\n",
      "01/1981 - New Haven, Connecticut United States\n",
      "Internship at Greenwich Hospital\n",
      "01/1978 - Greenwich, Connecticut United States\n",
      "Certifications\n",
      "Psychiatry/Addictions\n",
      "ABPN\n",
      "Professional Interests\n",
      "Developing medications and vaccines for addictions\n",
      "Pharmacology\n",
      "Websites\n",
      "VIICTR Publications List\n",
      "Selected Publications\n",
      "Malison RT, McCance E, Carpenter LL, Baldwin RM, Seibyl JP, Price LH, Kosten TR, Innis RB \"[123I]beta-CIT SPECT imaging of dopamine transporter availability after mazindol administration in human cocaine addicts..\" Psychopharmacology (Berl.). 1998 Jun;137(4):321-5. Pubmed PMID: 9676890\n",
      "Kosten TR, Rounsaville BJ, Kleber HD \"A 2.5-year follow-up of cocaine use among treated opioid addicts. Have our treatments helped?.\" Arch. Gen. Psychiatry. 1987 Mar;44(3):281-4. Pubmed PMID: 3827521\n",
      "Kosten TR, Rounsaville BJ, Kleber HD \"A 2.5 year follow-up of treatment retention and reentry among opioid addicts..\" J Subst Abuse Treat. 1986;3(3):181-9. Pubmed PMID: 3806731\n",
      "Kosten TR, Rounsaville BJ, Kleber HD \"A 2.5-year follow-up of depression, life crises, and treatment effects on abstinence among opioid addicts..\" Arch Gen Psychiatry. 1986 Aug;733-8. Pubmed PMID: 3729667\n",
      "Rounsaville BJ, Kosten TR, Weissmann MM, Kleber HD \"A 2.5-year follow-up of short-term interpersonal psychotherapy in methadone-maintained opiate addicts..\" Compr Psychiatry.;27(3):201-10. Pubmed PMID: 3709134\n",
      "Avants SK, Margolin A, DePhilippis D, Kosten TR \"A comprehensive pharmacologic-psychosocial treatment program for HIV-seropositive cocaine- and opioid-dependent patients. Preliminary findings..\" J Subst Abuse Treat.;15(3):261-5. Pubmed PMID: 9633038\n",
      "Rounsaville BJ, Kosten TR, Williams JB, Spitzer RL \"A field trial of DSM-III-R psychoactive substance dependence disorders..\" Am J Psychiatry. 1987 Mar;144(3):351-5. Pubmed PMID: 3826436\n",
      "Kosten TR, Steinberg M, Diakogiannis I A \"A cross-over trail of mazindol for cocaine dependence.\" Am J Addictions. 1993;161-164.\n",
      "Kosten TA, Shen XY, O'Malley PW, Kinsey BM, Lykissa ED, Orson FM, Kosten TR \"A morphine conjugate vaccine attenuates the behavioral effects of morphine in rats..\" Prog Neuropsychopharmacol Biol Psychiatry. 2013 Aug 1;223-9. Pubmed PMID: 23739535\n",
      "Margolin A, Kosten TR, Avants SK, Wilkins J, Ling W, Beckson M, Arndt IO, Cornish J, Ascher JA, Li SH \"A multicenter trial of bupropion for cocaine dependence in methadone-maintained patients..\" Drug Alcohol Depend. 1995 Dec;40(2):125-31. Pubmed PMID: 8745134\n",
      "Najavits LM, Kivlahan D, Kosten T \"A national survey of clinicians’ views of evidence-based therapies for PTSD and substance abuse.\" 2011;138-147.\n",
      "Rosen MI, McMahon TJ, Woods SW, Pearsall HR, Kosten TR \"A pilot study of dextromethorphan in naloxone-precipitated opiate withdrawal..\" Eur. J. Pharmacol.. 1996 Jul 4;307(3):251-7. Pubmed PMID: 8836612\n",
      "O'Connor PG, Oliveto AH, Shi JM, Triffleman E, Carroll KM, Kosten TR, Rounsaville BJ \"A pilot study of primary-care-based buprenorphine maintenance for heroin dependence..\" Am J Drug Alcohol Abuse. 1996 Nov;22(4):523-31. Pubmed PMID: 8911590\n",
      "George TP, Vessicchio JC, Termine A, Bregartner TA, Feingold A, Rounsaville BJ, Kosten TR \"A placebo controlled trial of bupropion for smoking cessation in schizophrenia.\" Biol Psychiatry. 2002 Jul 1;53-61. Pubmed PMID: 12079730\n",
      "Margolin A, Avants SK, DePhilippis D, Kosten TR \"A preliminary investigation of lamotrigine for cocaine abuse in HIV-seropositive patients..\" Am J Drug Alcohol Abuse. 1998 Feb;24(1):85-101. Pubmed PMID: 9513631\n",
      "George TP, Vessicchio JC, Termine A, Jatlow PI, Kosten TR, O'Malley SS \"A preliminary placebo-controlled trial of selegiline hydrochloride for smoking cessation..\" Biol. Psychiatry. 2003 Jan 15;53(2):136-43. Pubmed PMID: 12547469\n",
      "Kosten TR, Kreek MJ, Ragunath J, Kleber HD \"A preliminary study of beta endorphin during chronic naltrexone maintenance treatment in ex-opiate addicts..\" Life Sci.. 1986 Jul 7;39(1):55-9. Pubmed PMID: 2941636\n",
      "Kosten TR, Schumann B, Wright D, Carney MK, Gawin FH \"A preliminary study of desipramine in the treatment of cocaine abuse in methadone maintenance patients..\" J Clin Psychiatry. 1987 Nov;48(11):442-4. Pubmed PMID: 3680185\n",
      "Frank JB, Kosten TR, Giller EL, Dan E \"A randomized clinical trial of phenelzine and imipramine for posttraumatic stress disorder..\" Am J Psychiatry. 1988 Oct;145(10):1289-91. Pubmed PMID: 3048121\n",
      "Avants SK, Margolin A, Holford TR, Kosten TR \"A randomized controlled trial of auricular acupuncture for cocaine dependence..\" Arch. Intern. Med..;160(15):2305-12. Pubmed PMID: 10927727\n",
      "O'Connor PG, Oliveto AH, Shi JM, Triffleman EG, Carroll KM, Kosten TR, Rounsaville BJ, Pakes JA, Schottenfeld RS \"A randomized trial of buprenorphine maintenance for heroin dependence in a primary care clinic for substance users versus a methadone clinic..\" Am. J. Med.. 1998 Aug;105(2):100-5. Pubmed PMID: 9727815\n",
      "Kosten TR, McCance E \"A review of pharmacotherapies for substance abuse.\" The American Journal on Addictions. 1996;58-59.\n",
      "Shen XY, Kosten TA, Lopez AY, Kinsey BM, Kosten TR, Orson FM \"A vaccine against methamphetamine attenuates its behavioral effects in mice..\" Drug Alcohol Depend. 2013 Apr 1;129(41276):41-8. Pubmed PMID: 23022610\n",
      "Margolin A, Avants SK, Chang P, Birch S, Kosten TR \"A single-blind investigation of four auricular needle puncture configurations..\" Am. J. Chin. Med.. 1995;23(2):105-14. Pubmed PMID: 7572770\n",
      "Margolin A, Avants SK, Kosten TR \"Abstinence symptomatology associated with cessation of chronic cocaine abuse among methadone-maintained patients..\" Am J Drug Alcohol Abuse. 1996 Aug;22(3):377-88. Pubmed PMID: 8841686\n",
      "Kosten TR, Gawin FH, Rounsaville BJ, Kleber HD \"Abuse of cocaine with opioids: psychological aspects of treatment..\" NIDA Res. Monogr.. 1986;67:278-82. Pubmed PMID: 3092078\n",
      "Kinsey BM, Kosten TR, Orson FM \"Active immunotherapy for the Treatment of Cocaine Dependence..\" 2010 Apr 1;35(4):301-306. Pubmed PMID: 21796226\n",
      "Avants SK, Margolin A, Chang P, Kosten TR, Birch S \"Acupuncture for the treatment of cocaine addiction. Investigation of a needle puncture control..\" J Subst Abuse Treat.;12(3):195-205. Pubmed PMID: 7474027\n",
      "Jacobs S, Mason J, Kosten T, Kasl S, Ostfeld A, Atkins S, Gardner C, Schreiber S \"Acute bereavement, threatened loss, ego defenses and adrenocortical function.\" Psychother Psychosom. 1985;151-9. Pubmed PMID: 3832148\n",
      "Kosten TR \"Addiction as a brain disease..\" Am J Psychiatry. 1998 Jun;155(6):711-3. Pubmed PMID: 9619141\n",
      "Wallace EA, Wisniewski G, Zubal G, vanDyck CH, Pfau SE, Smith EO, Rosen MI, Sullivan MC, Woods SW, Kosten TR \"Acute cocaine effects on absolute cerebral blood flow..\" Psychopharmacology (Berl.). 1996 Nov;128(1):17-20. Pubmed PMID: 8944401\n",
      "Ziedonis D, Richardson T, Lee E, Petrakis I, Kosten T \"Adjunctive desipramine in the treatment of cocaine abusing schizophrenics.\" Psychopharmacol Bull. 1992;309-14. Pubmed PMID: 1480735\n",
      "Kosten TR \"Advances in clinical research on drug addiction: Opioids and cocaine.\" Substance Abuse. 1989;35-42.\n",
      "Sofuoglu M, Mouratidis M, Yoo S, Kosten T \"Adrenergic blocker carvedilol attenuates the cardiovascular and aversive effects of nicotine in abstinent smokers..\" Behav Pharmacol. 2006 Dec 17;731-5. Pubmed PMID: 17110799\n",
      "Ziedonis DM, Kosten TR \"Aggiornamento: Dipendenza da nicotina e schizofrenia.\" 1996;44-47.\n",
      "Kosten TR \"Advances in pharmacotherapy of stimulant dependence: From alcohol antagonists to Xenova vaccines.\" Clinical Neuroscience Research. 2005;169-173.\n",
      "Closser MH, Kosten TR \"Alcohol and cocaine abuse. A comparison of epidemiology and clinical characteristics..\" Recent Dev Alcohol. 1992;10:115-28. Pubmed PMID: 1317046\n",
      "Kosten TR, Kosten TA, Rounsaville BJ \"Alcoholism and depressive disorders in opioid addicts and their family members..\" Compr Psychiatry.;32(6):521-7. Pubmed PMID: 1778079\n",
      "13. Kosten TR, Krystal JH, Giller EL, Frank J, Dan E. \"Alexithymia as a predictor of treatment response in posttraumatic stress disorder.\" J Traumatic Stress. 1992;41-51.\n",
      "Cui Y, Versace F, Engelmann JM, Minnix JA, Robinson JD, Lam CY, Karam-Hage M, Brown VL, Wetter DW, Dani JA, Kosten TR, Cinciripini PM \"Alpha oscillations in response to affective and cigarette-related stimuli in smokers..\" Nicotine Tob. Res.. 2013 May;15(5):917-24. Pubmed PMID: 23060019\n",
      "Sellers EM, Ciraulo DA, DuPont RL, Griffiths RR, Kosten TR, Romach MK, Woody GE \"Alprazolam and benzodiazepine dependence..\" J Clin Psychiatry. 1993 Oct;54:64-75; discussi. Pubmed PMID: 8262891\n",
      "Xiu MH, Chen S, Wang F, Cao LY, Qi LY, Chen da C, Wu GY, Lu L, Kosten TA, Kosten TR, Zhang XY \"Altered interleukin-3 serum levels in drug-naïve and neuroleptic-treated schizophrenic patients..\" Schizophr. Res.. 2008 Dec;106(41308):369-70. Pubmed PMID: 18838250\n",
      "Petrakis IL, Satel SL, Stine S, Kosten TR, Normanworth SN, Charney DS, Krystal JH \"AMPT effects on cue-induced craving for cocaine.\" The American Journal of Addictions. 1996;313-320.\n",
      "Kosten TA, Kosten TR, Gawin FH, Gordon LT, Hogan I, Kleber HD \"An open trial of sertraline for cocaine abuse.\" Am J Addictions. 1992;349-353.\n",
      "Spellicy CJ, Kosten TR, Hamon SC, Harding MJ, Nielsen DA \"ANKK1 and DRD2 pharmacogenetics of disulfiram treatment for cocaine abuse..\" Pharmacogenet. Genomics. 2013 Jul;23(7):333-40. Pubmed PMID: 23635803\n",
      "Kosten TR, Rounsaville BJ, Kleber HD \"Antecedents and consequences of cocaine abuse among opioid addicts. A 2.5-year follow-up..\" J. Nerv. Ment. Dis.. 1988 Mar;176(3):176-81. Pubmed PMID: 3343591\n",
      "Shen X, Orson FM, Kosten TR \"Anti-addiction vaccines..\" F1000 Med Rep. 2011;3:20. Pubmed PMID: 22003367\n",
      "Brimijoin S, Orson F, Kosten TR, Kinsey B, Shen XY, White SJ, Gao Y \"Anti-cocaine antibody and butyrylcholinesterase-derived cocaine hydrolase exert cooperative effects on cocaine pharmacokinetics and cocaine-induced locomotor activity in mice..\" Chem. Biol. Interact.. 2013 Mar 25;203(1):212-6. Pubmed PMID: 22960160\n",
      "Leal J, Ziedonis D, Kosten T \"Antisocial personality disorder as a prognostic factor for pharmacotherapy of cocaine dependence.\" Drug Alcohol Depend. 1994 Mar;31-5. Pubmed PMID: 8082553\n",
      "Kinsey BM, Kosten TR, Orson FM \"Anti-cocaine vaccine development..\" Expert Rev Vaccines. 2010 Sep;9(9):1109-14. Pubmed PMID: 20822352\n",
      "Frank JB, Kosten TR, Giller EL \"Antidepressants in the treatment of PTSD..\" Am J Psychiatry. 1990 Feb;147(2):260. Pubmed PMID: 2301678\n",
      "Li CS, Kosten TR, Sinha R \"Antisocial personality and stress-induced brain activation in cocaine-dependent patients..\" Neuroreport. 2006 Feb 27;17(3):243-7. Pubmed PMID: 16462591\n",
      "Chen JX, Su YA, Wang SL, Bian QT, Liu YH, Wang N, Yang FD, Haile C, Kosten TR, Zhang XY \"Aripiprazole treatment of risperidone-induced hyperprolactinemia..\" J Clin Psychiatry. 2009 Jul;70(7):1058-9. Pubmed PMID: 19653986\n",
      "Kosten TR, Gottschalk PC, Tucker K, Rinder CS, Dey HM, Rinder HM \"Aspirin or amiloride for cerebral perfusion defects in cocaine dependence..\" Drug Alcohol Depend. 2003 Aug 20;71(2):187-94. Pubmed PMID: 12927657\n",
      "Hui L, Zhang X, Yu YQ, Han M, Huang XF, Chen da C, Wang ZR, Du WL, Kou CG, Yu Q, Kosten TR, Zhang XY \"Association between DBH 19bp insertion/deletion polymorphism and cognition in first-episode schizophrenic patients..\" Schizophr. Res.. 2013 Jul;147(41308):236-40. Pubmed PMID: 23707643\n",
      "Sun S, Wang F, Wei J, Cao LY, Wu GY, Lu L, Kosten TA, Kosten TR, Zhang XY \"Association between interleukin-3 receptor alpha polymorphism and schizophrenia in the Chinese population..\" Neurosci. Lett.. 2008 Jul 25;440(1):35-7. Pubmed PMID: 18547720\n",
      "Sun S, Wang F, Wei J, Cao LY, Qi LY, Xiu MH, Chen S, Li XH, Kosten TA, Kosten TR, Zhang XY \"Association between interleukin-6 receptor polymorphism and patients with schizophrenia..\" Schizophr. Res.. 2008 Jul;102(41277):346-7. Pubmed PMID: 18508242\n",
      "Qiu HT, Meng HQ, Song C, Xiu MH, Chen da C, Zhu FY, Wu GY, Kosten TA, Kosten TR, Zhang XY \"Association between monoamine oxidase (MAO)-A gene variants and schizophrenia in a Chinese population..\" Brain Res.. 2009 Sep 1;1287:67-73. Pubmed PMID: 19573521\n",
      "Cao JX, Hu J, Ye XM, Xia Y, Haile CA, Kosten TR, Zhang XY \"Association between the 5-HTR1B gene polymorphisms and alcohol dependence in a Han Chinese population..\" Brain Res.. 2011 Feb 28;1376:41283. Pubmed PMID: 21172311\n",
      "Avants SK, Margolin A, McMahon TJ, Kosten TR \"Association between self-report of cognitive impairment, HIV status, and cocaine use in a sample of cocaine-dependent methadone-maintained patients..\" Addict Behav.;22(5):599-611. Pubmed PMID: 9347062\n",
      "Wang F, Fan H, Sun H, Yang F, Luo Y, Liu H, Kosten TR, Lu L, Zhang XY \"Association between TNF-a promoter -308A/G polymorphism and tardive dyskinesiain Chinese Han patients with schizophrenia..\" Prog. Neuropsychopharmacol. Biol. Psychiatry. 2012 Apr 27;37(1):106-10. Pubmed PMID: 22227290\n",
      "Li W, Zhou N, Yu Q, Li X, Yu Y, Sun S, Kou C, Chen da C, Xiu MH, Kosten TR, Zhang XY \"Association of BDNF gene polymorphisms with schizophrenia and clinical symptoms in a Chinese population.\" Am J Med Genet B Neuropsychiatr Genet. 2013 Sep;538-45. Pubmed PMID: 23832605\n",
      "Zhang XY, Tan YL, Zhou DF, Haile CN, Cao LY, Xu Q, Shen Y, Kosten TA, Kosten TR \"Association of clozapine-induced weight gain with a polymorphism in the leptin promoter region in patients with chronic schizophrenia in a Chinese population..\" J Clin Psychopharmacol. 2007 Jun;27(3):246-51. Pubmed PMID: 17502770\n",
      "Li WJ, Kou CG, Yu Y, Sun S, Zhang X, Kosten TR, Zhang XY \"Association of Catechol-O-methyltransferase gene polymorphisms with schizophrenia and negative symptoms in a Chinese population..\" Am. J. Med. Genet. B Neuropsychiatr. Genet.. 2012 Jun;159(4):370-5. Pubmed PMID: 22354729\n",
      "Guo S, Chen da F, Zhou DF, Sun HQ, Wu GY, Haile CN, Kosten TA, Kosten TR, Zhang XY \"Association of functional catechol O-methyl transferase (COMT) Val108Met polymorphism with smoking severity and age of smoking initiation in Chinese male smokers..\" Psychopharmacology (Berl.). 2007 Mar;190(4):449-56. Pubmed PMID: 17206495\n",
      "Sun H, Guo S, Chen D, Yang F, Zou Y, Di X, Cao Y, Kosten T, Lu L, Zhang XY \"Association of functional COMT Val108/Met polymorphism with smoking cessation in a nicotine replacement therapy..\" 2012 Jun 14; Pubmed PMID: 22695756\n",
      "Brown AE, Pavlik VN, Shegog R, Whitney SN, Friedman LC, Romero C, Davis GC, Cech I, Kosten TR, Volk RJ \"Association of spirituality and sobriety during a behavioral spirituality intervention for Twelve Step (TS) recovery..\" Am J Drug Alcohol Abuse. 2007;33(4):611-7. Pubmed PMID: 17668347\n",
      "Zhang XY, Chen DC, Xiu MH, Hui L, Liu H, Luo X, Zuo L, Zhang H, Kosten TA, Kosten TR \"Association of functional dopamine-beta-hydroxylase (DBH) 19bp insertion/deletion polymorphism with smoking severity in male schizophrenic smokers..\" Schizophr. Res.. 2012 Aug 4; Pubmed PMID: 22871345\n",
      "Liu H, Wang C, Chen PH, Zhang BS, Zheng YL, Zhang CX, Meng HQ, Wang Y, Chen da C, Xiu MH, Kosten TR, Zhang XY \"Association of the manganese superoxide dismutase gene Ala-9Val polymorphism with clinical phenotypes and tardive dyskinesia in schizophrenic patients..\" Prog. Neuropsychopharmacol. Biol. Psychiatry. 2010 May 30;34(4):692-6. Pubmed PMID: 20346996\n",
      "Zhou N, Yu Q, Li X, Yu Y, Kou C, Li W, Xu H, Luo X, Zuo L, Kosten TR, Zhang XY \"Association of the dopamine ß-hydroxylase 19?bp insertion/deletion polymorphism with positive symptoms but not tardive dyskinesia in schizophrenia..\" Hum Psychopharmacol. 2013 May;28(3):230-7. Pubmed PMID: 23559427\n",
      "Sofuoglu M, Poling J, Hill K, Kosten T \"Atomoxetine attenuates dextroamphetamine effects in humans..\" Am J Drug Alcohol Abuse. 2009;35(6):412-6. Pubmed PMID: 20014909\n",
      "Jacobs SC, Kosten TR, Kasl SV, Ostfeld AM, Berkman l, Charpentier P \"Attachment theory and multiple dimensions of grief.\" 1988;41-52.\n",
      "Krystal JH, McDougle CJ, Kosten TR, Price LH, Aghajanian GK, Charney DS \"Baclofen-assisted detoxification from opiates. A pilot study..\" J Subst Abuse Treat. 1992;9(2):139-42. Pubmed PMID: 1324986\n",
      "Zhang XY, Zhou DF, Wu GY, Cao LY, Tan YL, Haile CN, Li J, Lu L, Kosten TA, Kosten TR \"BDNF levels and genotype are associated with antipsychotic-induced weight gain in patients with chronic schizophrenia..\" Neuropsychopharmacology. 2008 Aug;33(9):2200-5. Pubmed PMID: 17987059\n",
      "Zhang XY, Chen da C, Xiu MH, Luo X, Zuo L, Haile CN, Kosten TA, Kosten TR \"BDNF Val66Met Variant and Smoking in a Chinese Population..\" PLoS ONE. 2012;7(12):e53295. Pubmed PMID: 23285275\n",
      "Oliveto A, Gentry WB, Pruzinsky R, Gonsai K, Kosten TR, Martell B, Poling J \"Behavioral effects of gamma-hydroxybutyrate in humans..\" Behav Pharmacol. 2010 Jul;21(4):332-42. Pubmed PMID: 20526195\n",
      "Hameedi FA, Rosen MI, McCance-Katz EF, McMahon TJ, Price LH, Jatlow PI, Woods SW, Kosten TR \"Behavioral, physiological, and pharmacological interaction of cocaine and disulfiram in humans..\" Biol. Psychiatry. 1995 Apr 15;37(8):560-3. Pubmed PMID: 7619981\n",
      "Kosten TR, Fontana A, Sernyak MJ, Rosenheck R \"Benzodiazepine use in posttraumatic stress disorder among veterans with substance abuse..\" J. Nerv. Ment. Dis.. 2000 Jul;188(7):454-9. Pubmed PMID: 10919705\n",
      "Jacobs SC, Mason JW, Kosten TR, Wahby V, Kasl SV, Ostfeld AM \"Bereavement and catecholamines..\" J Psychosom Res. 1986;30(4):489-96. Pubmed PMID: 3761233\n",
      "Kosten TR, Morgan C, Kreek MJ \"Beta endorphin levels during heroin, methadone, buprenorphine, and naloxone challenges: preliminary findings..\" Biol. Psychiatry. 1992 Sep 15;32(6):523-8. Pubmed PMID: 1445968\n",
      "Kosten TR, Kreek MJ, Swift C, Carney MK, Ferdinands L \"Beta endorphin levels in CSF during methadone maintenance..\" Life Sci.. 1987 Aug 31;41(9):1071-6. Pubmed PMID: 2956475\n",
      "Kosten TR, Krystal J \"Biological mechanisms in posttraumatic stress disorder. Relevance for substance abuse..\" Recent Dev Alcohol. 1988; Pubmed PMID: 3283864\n",
      "Zhang XY, Zhang WF, Zhou DF, Chen DC, Xiu MH, Wu HR, Haile CN, Kosten TA, Kosten TR \"Brain-Derived Neurotrophic Factor Levels and Its Val66Met Gene Polymorphism Predict Tardive Dyskinesia Treatment Response to Ginkgo Biloba..\" 2012 Jun 11; Pubmed PMID: 22695185\n",
      "Wang ZR, Zhou DF, Cao LY, Tan YL, Zhang XY, Li J, Lu L, Wu GY, Kosten TA, Kosten TR \"Brain-derived neurotrophic factor polymorphisms and smoking in schizophrenia..\" Schizophr. Res.. 2007 Dec;97(41277):299-301. Pubmed PMID: 17869486\n",
      "Kosten TR, Kleber HD \"Buprenorphine detoxification from opioid dependence: a pilot study..\" Life Sci.. 1988;42(6):635-41. Pubmed PMID: 3276999\n",
      "Kosten TR, Rosen MI, Schottenfeld R, Ziedonis D \"Buprenorphine for cocaine and opiate dependence..\" Psychopharmacol Bull. 1992;28(1):15-9. Pubmed PMID: 1609037\n",
      "Kosten TR, Fiellin DA \"Buprenorphine for office-based practice: consensus conference overview..\" Am J Addict. 2004;13:S1-7. Pubmed PMID: 15204671\n",
      "Rosenheck R, Kosten T \"Buprenorphine for opiate addiction: potential economic impact..\" Drug Alcohol Depend. 2001 Aug 1;63(3):253-62. Pubmed PMID: 11418229\n",
      "Kosten TR \"Buprenorphine for opioid detoxification: A brief review.\" Addictive Disorders and Their Treatment. 2003;\n",
      "Kosten TR, Morgan CJ, Kleber HD \"Buprenorphine treatment of cocaine abuse..\" NIDA Res. Monogr.. 1989;95:461. Pubmed PMID: 2641031\n",
      "Kosten TR, Schottenfeld R, Ziedonis D, Falcioni J \"Buprenorphine versus methadone maintenance for opioid dependence..\" J. Nerv. Ment. Dis.. 1993 Jun;181(6):358-64. Pubmed PMID: 8501457\n",
      "Schottenfeld RS, Pakes JR, Oliveto A, Ziedonis D, Kosten TR \"Buprenorphine vs methadone maintenance treatment for concurrent opioid dependence and cocaine abuse..\" Arch. Gen. Psychiatry. 1997 Aug;54(8):713-20. Pubmed PMID: 9283506\n",
      "Rosen MI, Kosten TR \"Buprenorphine: beyond methadone?.\" Hosp Community Psychiatry. 1991 Apr;42(4):347-9. Pubmed PMID: 2050347\n",
      "Schottenfeld RS, Pakes J, Ziedonis D, Kosten TR \"Buprenorphine: dose-related effects on cocaine and opioid use in cocaine-abusing opioid-dependent humans..\" Biol. Psychiatry.;34(41276):66-74. Pubmed PMID: 8373940\n",
      "Rosen MI, Wallace EA, McMahon TJ, Pearsall HR, Woods SW, Price LH, Kosten TR \"Buprenorphine: duration of blockade of effects of intramuscular hydromorphone..\" Drug Alcohol Depend. 1994 Apr;35(2):141-9. Pubmed PMID: 7519977\n",
      "Kosten TR \"Can cocaine craving be a medication development outcome: drug craving and relapse in opioid and cocaine dependence.\" Am J Addictions. 1992;\n",
      "Kosten TR, Domingo CB \"Can you vaccinate against substance abuse?.\" Expert Opin Biol Ther. 2013 Aug; Pubmed PMID: 23594123\n",
      "D'Souza DC, Kosten TR \"Cannabinoid antagonists: a treatment in search of an illness..\" Arch. Gen. Psychiatry. 2001 Apr;58(4):330-1. Pubmed PMID: 11296092\n",
      "Rosen MI, Pearsall HR, Price LH, McDougle CJ, Woods SW, Kosten TR \"Carbamazepine vs. oxazepam for benzodiazepine detoxification in methadone maintained patients.\" Am J Addictions. 1993;\n",
      "Gottschalk PC, Kosten TR \"Cerebral perfusion defects in combined cocaine and alcohol dependence..\" Drug Alcohol Depend. 2002 Sep 1;68(1):95-104. Pubmed PMID: 12167555\n",
      "West JC, Kosten TR, Wilk J, Svikis D, Triffleman E, Rae DS, Narrow WE, Duffy FF, Regier DA \"Challenges in increasing access to buprenorphine treatment for opiate addiction..\" Am J Addict. 2004;13:S8-16. Pubmed PMID: 15204672\n",
      "Avants SK, Margolin A, Kosten TR, Singer JL \"Changes concurrent with initiation of abstinence from cocaine abuse..\" J Subst Abuse Treat.;10(6):577-83. Pubmed PMID: 8308943\n",
      "Carroll KM, Kosten TR, Rounsaville BJ \"Choosing a behavioral therapy platform for pharmacotherapy of substance users..\" Drug Alcohol Depend. 2004 Aug 16;75(2):123-34. Pubmed PMID: 15276217\n",
      "McCance-Katz EF, Kosten TR, Jatlow P \"Chronic disulfiram treatment effects on intranasal cocaine administration: initial results..\" Biol. Psychiatry. 1998 Apr 1;43(7):540-3. Pubmed PMID: 9547934\n",
      "Kosten TR, Kreek MJ, Ragunath J, Kleber HD \"Chronic naltrexone effect on cortisol..\" NIDA Res. Monogr.. 1986;67:362-5. Pubmed PMID: 3092091\n",
      "Zhang XY, Chen da C, Xiu MH, Haile CN, Sun H, Lu L, Kosten TA, Kosten TR \"Cigarette Smoking and Cognitive Function in Chinese Male Schizophrenia: A Case-Control study..\" PLoS ONE. 2012;7(5):e36563. Pubmed PMID: 22570726\n",
      "Zhang XY, Liang J, Chen da C, Xiu MH, He J, Cheng W, Wu Z, Yang FD, Haile CN, Sun H, Lu L, Kosten TA, Kosten TR \"Cigarette smoking in male patients with chronic schizophrenia in a Chinese population: prevalence and relationship to clinical phenotypes..\" PLoS ONE. 2012;7(2):e30937. Pubmed PMID: 22347412\n",
      "Zhang XY, Chen DC, Xiu MH, Haile CN, He SC, Luo X, Zuo L, Rosenheck R, Kosten TA, Kosten TR \"Cigarette smoking, psychopathology and cognitive function in first-episode drug-naive patients with schizophrenia: a case-control study..\" Psychol Med. 2013; Pubmed PMID: 23149169\n",
      "Li SX, Shi J, Epstein DH, Wang X, Zhang XL, Bao YP, Zhang D, Zhang XY, Kosten TR, Lu L \"Circadian alteration in neurobiology during 30 days of abstinence in heroin users..\" Biol. Psychiatry. 2009 May 15;65(10):905-12. Pubmed PMID: 19135652\n",
      "Kosten TR \"Client issues in drug abuse treatment: addressing multiple drug abuse..\" NIDA Res. Monogr.. 1991;106:136-51. Pubmed PMID: 1922284\n",
      "Kosten TR \"Clinical and research perspectives on cocaine abuse: the pharmacotherapy of cocaine abuse..\" NIDA Res. Monogr.. 1993;135:48-56. Pubmed PMID: 8289903\n",
      "Li SX, Liu LJ, Jiang WG, Sun LL, Zhou SJ, Le Foll B, Zhang XY, Kosten TR, Lu L \"Circadian alteration in neurobiology during protracted opiate withdrawal in rats..\" J. Neurochem.. 2010 Oct;115(2):353-62. Pubmed PMID: 20738730\n",
      "Poling J, Pruzinsky R, Kosten TR, Gonsai K, Sofuoglu M, Gonzalez G, Oliveto A \"Clinical efficacy of citalopram alone or augmented with bupropion in methadone-stabilized patients..\" Am J Addict.;16(3):187-94. Pubmed PMID: 17612822\n",
      "González G, Desai R, Sofuoglu M, Poling J, Oliveto A, Gonsai K, Kosten TR \"Clinical efficacy of gabapentin versus tiagabine for reducing cocaine use among cocaine dependent methadone-treated patients..\" Drug Alcohol Depend. 2007 Feb 23;87(1):41283. Pubmed PMID: 16930857\n",
      "Mancino MJ, McGaugh J, Chopra MP, Guise JB, Cargile C, Williams DK, Thostenson J, Kosten TR, Sanders N, Oliveto A \"Clinical efficacy of sertraline alone and augmented with gabapentin in recently abstinent cocaine-dependent patients with depressive symptoms..\" J Clin Psychopharmacol. 2014 Apr; Pubmed PMID: 24525654\n",
      "Zhang XY, Chen da C, Xiu MH, Tan YL, Yang FD, Zhang LY, Zhang LY, Haile CN, Kosten TR \"Clinical symptoms and cognitive impairment associated with male schizophrenia relate to plasma manganese superoxide dismutase activity: A case-control study..\" J Psychiatr Res. 2013 Aug;47(8):1049-53. Pubmed PMID: 23611682\n",
      "Vining E, Kosten TR, Kleber HD \"Clinical utility of rapid clonidine-naltrexone detoxification for opioid abusers..\" Br J Addict. 1988 May;83(5):567-75. Pubmed PMID: 3382815\n",
      "Kosten TR, Gawin FH, Rounsaville BJ, Kleber HD \"Cocaine abuse among opioid addicts: demographic and diagnostic factors in treatment..\" Am J Drug Alcohol Abuse. 1986;12(41276):41290. Pubmed PMID: 3788892\n",
      "McCance EF, Price LH, Kosten TR, Jatlow PI \"Cocaethylene: pharmacology, physiology and behavioral effects in humans..\" J. Pharmacol. Exp. Ther.. 1995 Jul;274(1):215-23. Pubmed PMID: 7616402\n",
      "Kleber HD, Riordan CE, Rounsaville B, Kosten T, Charney D, Gaspari J, Hogan I, O'Connor C \"Clonidine in outpatient detoxification from methadone maintenance.\" Arch Gen Psychiatry. 1985 Apr; Pubmed PMID: 3977557\n",
      "Kleber HD, Topazian M, Gaspari J, Riordan CE, Kosten T \"Clonidine and naltrexone in the outpatient treatment of heroin withdrawal..\" Am J Drug Alcohol Abuse. 1987; Pubmed PMID: 3687878\n",
      "Kosten TA, Kosten TR \"Cocaine abuse and opioid withdrawal..\" Lancet. 1989 Jul 15;2(8655):165-6. Pubmed PMID: 2567937\n",
      "Avants SK, Margolin A, Kosten TR \"Cocaine abuse in methadone maintenance programs: integrating pharmacotherapy with psychosocial interventions..\" J Psychoactive Drugs.;26(2):137-46. Pubmed PMID: 7931858\n",
      "Stine SM, Satel S, Kosten TR \"Cocaine precipitation of patient identified opiate withdrawal.\" Am J Addictions. 1993;\n",
      "Kosten TA, Kosten TR, Rounsaville BJ \"Cocaine symptoms are predicted by familial psychopathology..\" NIDA Res. Monogr.. 1990;105:603-4. Pubmed PMID: 1876139\n",
      "Oliveto AH, Kosten TR, Schottenfeld RS, Ziedonis D, Falcioni J \"Cocaine use in buprenorphine vs. methadone maintained cocaine users.\" Am J Addictions. 1994;\n",
      "Martell BA, Orson FM, Poling J, Mitchell E, Rossen RD, Gardner T, Kosten TR \"Cocaine vaccine for the treatment of cocaine dependence in methadone-maintained patients: a randomized, double-blind, placebo-controlled efficacy trial..\" Arch. Gen. Psychiatry. 2009 Oct;66(10):1116-23. Pubmed PMID: 19805702\n",
      "Sofuoglu M, Poling J, Gonzalez G, Gonsai K, Kosten T \"Cocaine withdrawal symptoms predict medication response in cocaine users..\" Am J Drug Alcohol Abuse. 2006;32(4):617-27. Pubmed PMID: 17127550\n",
      "Rosen MI, Kosten T \"Cocaine-associated panic attacks in methadone-maintained patients..\" Am J Drug Alcohol Abuse. 1992; Pubmed PMID: 1314016\n",
      "Zhang XY, Chen da C, Xiu MH, Haile CN, Luo X, Xu K, Zhang HP, Zuo L, Zhang Z, Zhang X, Kosten TA, Kosten TR \"Cognitive and serum BDNF correlates of BDNF Val66Met gene polymorphism in patients with schizophrenia and normal controls..\" Hum. Genet.. 2012 Jul;131(7):1187-95. Pubmed PMID: 22362486\n",
      "Gottschalk C, Beauvais J, Hart R, Kosten T \"Cognitive function and cerebral perfusion during cocaine abstinence..\" Am J Psychiatry. 2001 Apr; Pubmed PMID: 11282686\n",
      "Zhang XY, Chen da C, Xiu MH, Yang FD, Tan Y, Luo X, Zuo L, Kosten TA, Kosten TR \"Cognitive function, plasma MnSOD activity, and MnSOD Ala-9Val polymorphism in patients with schizophrenia and normal controls..\" Schizophr Bull. 2014 May; Pubmed PMID: 23588476\n",
      "Gonzalez G, Oliveto A, Kosten TR \"Combating opiate dependence: a comparison among the available pharmacological options..\" Expert Opin Pharmacother. 2004 Apr;5(4):713-25. Pubmed PMID: 15102558\n",
      "Kosten TR \"Combining family therapy with pharmacotherapy in opioid addicts: Use of naltrexone.\" International Journal of Family Psychiatry. 1986;\n",
      "Carroll ME, Zlebnik NE, Anker JJ, Kosten TR, Orson FM, Shen X, Kinsey B, Parks RJ, Gao Y, Brimijoin S \"Combined cocaine hydrolase gene transfer and anti-cocaine vaccine synergistically block cocaine-induced locomotion..\" PLoS One. 2012; Pubmed PMID: 22912888\n",
      "Kosten TR \"Commentary: Commitment for substance abuse- Current judicial interventions.\" The Journal of the American Academy of Psychi. 2002;\n",
      "Kosten TR, Price LH \"Commentary on: Phenomenology and sequelae of MDMA use..\" J Nervous Mental Dis. 1992;\n",
      "Gonzalez G, Feingold A, Oliveto A, Gonsai K, Kosten TR \"Comorbid major depressive disorder as a prognostic factor in cocaine-abusing buprenorphine-maintained patients treated with desipramine and contingency management..\" Am J Drug Alcohol Abuse. 2003 Aug;29(3):497-514. Pubmed PMID: 14510037\n",
      "Kosten TR, Rounsaville BJ, Kleber HD \"Comparison of clinician ratings to self reports of withdrawal during clonidine detoxification of opiate addicts..\" Am J Drug Alcohol Abuse. 1985;11(41276):41284. Pubmed PMID: 3904410\n",
      "Kosten TR, Jalali B, Kleber HD \"Complementary marital roles of male heroin addicts: evolution and intervention tactics..\" Am J Drug Alcohol Abuse.;9(2):155-69. Pubmed PMID: 7171079\n",
      "McCance-Katz EF, Price LH, McDougle CJ, Kosten TR, Black JE, Jatlow PI \"Concurrent cocaine-ethanol ingestion in humans: pharmacology, physiology, behavior, and the role of cocaethylene..\" Psychopharmacology (Berl.). 1993;111(1):39-46. Pubmed PMID: 7870932\n",
      "McCance-Katz EF, Kosten TR, Jatlow P \"Concurrent use of cocaine and alcohol is more potent and potentially more toxic than use of either alone--a multiple-dose study..\" Biol. Psychiatry. 1998 Aug 15;44(4):250-9. Pubmed PMID: 9715356\n",
      "Kosten TR, Rounsaville BJ, Kleber HD \"Concurrent validity of the addiction severity index..\" J. Nerv. Ment. Dis.. 1983 Oct;171(10):606-10. Pubmed PMID: 6619823\n",
      "Fiellin DA, Kleber H, Trumble-Hejduk JG, McLellan AT, Kosten TR \"Consensus statement on office-based treatment of opioid dependence using buprenorphine..\" J Subst Abuse Treat. 2004 Sep;27(2):153-9. Pubmed PMID: 15450648\n",
      "Petry NM, Petrakis I, Trevisan L, Wiredu G, Boutros NN, Martin B, Kosten TR \"Contingency management interventions: from research to practice..\" Am J Psychiatry. 2001 May;158(5):694-702. Pubmed PMID: 11329388\n",
      "Fiellin DA, Rosenheck RA, Kosten TR \"Coordination of medical care and opioid dependence treatment in primary care: a case report..\" Subst Abus. 2003 Mar; Pubmed PMID: 12652094\n",
      "Boutros NN, Lisanby SH, McClain-Furmanski D, Oliwa G, Gooding D, Kosten TR \"Cortical excitability in cocaine-dependent patients: a replication and extension of TMS findings..\" J Psychiatr Res. 2005 May;39(3):295-302. Pubmed PMID: 15725428\n",
      "Kosten TR, Kreek MJ, Ragunath J, Kleber HD \"Cortisol levels during chronic naltrexone maintenance treatment in ex-opiate addicts..\" Biol. Psychiatry. 1986 Feb;21(2):217-20. Pubmed PMID: 3947698\n",
      "Margolin A, Avants SK, Kosten TR \"Cue-elicited cocaine craving and autogenic relaxation. Association with treatment outcome..\" J Subst Abuse Treat.;11(6):549-52. Pubmed PMID: 7884838\n",
      "Kosten TR, Scanley BE, Tucker KA, Oliveto A, Prince C, Sinha R, Potenza MN, Skudlarski P, Wexler BE \"Cue-induced brain activity changes and relapse in cocaine-dependent patients..\" Neuropsychopharmacology. 2006 Mar;31(3):644-50. Pubmed PMID: 16123763\n",
      "Kosten TR, Scanley BE, Tucker K, Oliveto A, Prince C, Sinha R, Potenza MN, Skudlarski P, Wexler BE \"Cue-induced brain activity changes and treatment outcome in depressed cocaine dependent patients.\" Neuropsychopharmacology. 2006;\n",
      "Gottschalk PC, Jacobsen LK, Kosten TR \"Current concepts in pharmacotherapy of substance abuse..\" Curr Psychiatry Rep. 1999 Dec;1(2):172-8. Pubmed PMID: 11122921\n",
      "Gottchalk PCH, Jacobsen LK, Kosten TR \"Current concepts in pharmacotherapy of substance abuse-the dawn of a new era.\" Current Psychiatry Reports. 1999;\n",
      "Kosten TR, O’Connor PG \"Current concepts-management of drug withdrawal.\" New England Journal of Medicine. 2003;\n",
      "Kosten TR \"Current pharmacotherapies for opioid dependence.\" Psychopharmacol Bull. 1990; Pubmed PMID: 2196628\n",
      "Oliveto A, Benios T, Gonsai K, Feingold A, Poling J, Kosten TR \"D-cycloserine-Naloxone interactions in opioid-dependent humans under a novel-response naloxone discrimination procedure..\" Exp Clin Psychopharmacol. 2003 Aug;11(3):237-46. Pubmed PMID: 12940503\n",
      "Avants SK, Margolin A, Sindelar JL, Rounsaville BJ, Schottenfeld R, Stine S, Cooney NL, Rosenheck RA, Li SH, Kosten TR \"Day treatment versus enhanced standard methadone services for opioid-dependent patients: a comparison of clinical efficacy and cost..\" Am J Psychiatry. 1999 Jan; Pubmed PMID: 9892294\n",
      "Kosten TR, Domingo CB, Hamon SC, Nielsen DA \"DBH gene as predictor of response in a cocaine vaccine clinical trial..\" Neurosci. Lett.. 2013 Apr 29;541:29-33. Pubmed PMID: 23458673\n",
      "Silverman DG, Kosten TR, Jatlow PI, Gutter V, Fleming J, O'Connor TZ, Byck R \"Decreased digital flow persists after the abatement of cocaine-induced hemodynamic stimulation..\" Anesth. Analg.. 1997 Jan;84(1):46-50. Pubmed PMID: 8988997\n",
      "Chen da C, Wang J, Wang B, Yang SC, Zhang CX, Zheng YL, Li YL, Wang N, Yang KB, Xiu MH, Kosten TR, Zhang XY \"Decreased levels of serum brain-derived neurotrophic factor in drug-naïve first-episode schizophrenia: relationship to clinical phenotypes..\" Psychopharmacology (Berl.). 2009 Dec;207(3):375-80. Pubmed PMID: 19787338\n",
      "Yang YQ, Sun S, Yu YQ, Li WJ, Zhang X, Xiu MH, Chen da C, Yang FD, Liu H, Li C, Kosten TR, Zhang XY \"Decreased serum brain-derived neurotrophic factor levels in schizophrenic patients with tardive dyskinesia..\" Neurosci. Lett.. 2011 Sep 8;502(1):37-40. Pubmed PMID: 21798311\n",
      "Xiu MH, Hui L, Dang YF, Hou TD, Zhang CX, Zheng YL, Chen da C, Kosten TR, Zhang XY \"Decreased serum BDNF levels in chronic institutionalized schizophrenia on long-term treatment with typical and atypical antipsychotics..\" Prog. Neuropsychopharmacol. Biol. Psychiatry. 2009 Nov 13;33(8):1508-12. Pubmed PMID: 19720106\n",
      "Kosten TR, Markou A, Koob GF \"Depression and stimulant dependence: neurobiology and pharmacotherapy..\" J. Nerv. Ment. Dis.. 1998 Dec;186(12):737-45. Pubmed PMID: 9865811\n",
      "Kosten T, Falcioni J, Oliveto A, Feingold A \"Depression predicts higher rates of heroin use on desipramine with buprenorphine than with methadone..\" Am J Addict. 2004 Mar; Pubmed PMID: 15204669\n",
      "Ziedonis DM, Kosten TR \"Depression as a prognostic factor for pharmacological treatment of cocaine dependence..\" Psychopharmacol Bull. 1991;27(3):337-43. Pubmed PMID: 1775608\n",
      "Kosten TR, Morgan C, Kosten TA \"Depressive symptoms during buprenorphine treatment of opioid abusers..\" J Subst Abuse Treat. 1990;7(1):51-4. Pubmed PMID: 2313769\n",
      "Jacobs S, Kosten TR \"Depressive syndromes during acute bereavement: Indications for professional intervention.\" Yale Psychiatric Quarterly. 1983;\n",
      "Satel SL, Kosten TR \"Designing drug efficacy trials in the treatment of cocaine abuse..\" J Nerv Ment Dis. 1991 Feb; Pubmed PMID: 1990076\n",
      "Kosten TR, Gawin FH, Morgan C, Nelson JC, Jatlow P \"Desipramine and its 2-hydroxy metabolite in patients taking or not taking methadone..\" Am J Psychiatry. 1990 Oct;147(10):1379-80. Pubmed PMID: 2400009\n",
      "Kosten T, Oliveto A, Feingold A, Poling J, Sevarino K, McCance-Katz E, Stine S, Gonzalez G, Gonsai K \"Desipramine and contingency management for cocaine and opiate dependence in buprenorphine maintained patients.\" Drug Alcohol Depend. 2003 Jun; Pubmed PMID: 12757969\n",
      "Gawin FH, Kleber HD, Byck R, Rounsaville BJ, Kosten TR, Jatlow PI, Morgan C \"Desipramine facilitation of initial cocaine abstinence..\" Arch. Gen. Psychiatry. 1989 Feb;46(2):117-21. Pubmed PMID: 2492422\n",
      "Oliveto AH, Feingold A, Schottenfeld R, Jatlow P, Kosten TR \"Desipramine in opioid-dependent cocaine abusers maintained on buprenorphine vs methadone..\" Arch. Gen. Psychiatry. 1999 Sep;56(9):812-20. Pubmed PMID: 12884887\n",
      "Kosten T, Sofuoglu M, Poling J, Gonsai K, Oliveto A \"Desipramine treatment for cocaine dependence in buprenorphine- or methadone-treated patients: baseline urine results as predictor of response..\" Am J Addict.;14(1):41503. Pubmed PMID: 15804873\n",
      "Oliveto A, Kosten TR, Schottenfeld R, Falcioni J, Ziedonis D \"Desipramine, amantadine, or fluoxetine in buprenorphine-maintained cocaine users..\" J Subst Abuse Treat.;12(6):423-8. Pubmed PMID: 8749726\n",
      "Kosten TR \"Diagnosing depression with the DST and TRH in cocaine and opioid abusers..\" J Subst Abuse Treat. 1986;3(1):47-9. Pubmed PMID: 3090273\n",
      "Han M, Huang XF, Chen da C, Xiu M, Kosten TR, Zhang XY \"Diabetes and cognitive deficits in chronic schizophrenia: a case-control study.\" PLoS One. 2013 Jun; Pubmed PMID: 23840437\n",
      "Avants SK, Margolin A, Kosten TR, Cooney NL \"Differences between responders and nonresponders to cocaine cues in the laboratory..\" Addict Behav.;20(2):215-24. Pubmed PMID: 7484315\n",
      "Cui Y, Robinson JD, Versace F, Lam CY, Minnix JA, Karam-Hage M, Dani JA, Kosten TR, Wetter DW, Brown VL, Cinciripini PM \"Differential cigarette-related startle cue reactivity among light, moderate, and heavy smokers..\" Addict Behav. 2012 Aug;37(8):885-9. Pubmed PMID: 22571920\n",
      "Kosten TR, Kleber HD \"Differential diagnosis of psychiatric comorbidity in substance abusers..\" J Subst Abuse Treat. 1988;5(4):201-6. Pubmed PMID: 3216436\n",
      "Oliveto AH, Rosen MI, Woods SW, Kosten TR \"Discriminative stimulus, self-reported and cardiovascular effects of orally administered cocaine in humans..\" J Pharmacol Exp Ther. 1995 Jan; Pubmed PMID: 7815337\n",
      "Zhang XY, Tan YL, Zhou DF, Cao LY, Wu GY, Haile CN, Kosten TA, Kosten TR \"Disrupted antioxidant enzyme activity and elevated lipid peroxidation products in schizophrenic patients with tardive dyskinesia..\" J Clin Psychiatry. 2007 May;68(5):754-60. Pubmed PMID: 17503985\n",
      "McCance-Katz EF, Kosten TR, Jatlow P \"Disulfiram effects on acute cocaine administration..\" Drug Alcohol Depend. 1998 Sep 1;52(1):27-39. Pubmed PMID: 9788003\n",
      "Sofuoglu M, Poling J, Waters A, Sewell A, Hill K, Kosten T \"Disulfiram enhances subjective effects of dextroamphetamine in humans..\" Pharmacol Biochem Behav. 2008 Sep; Pubmed PMID: 18474395\n",
      "Haile CN, During MJ, Jatlow PI, Kosten TR, Kosten TA \"Disulfiram facilitates the development and expression of locomotor sensitization to cocaine in rats..\" Biol. Psychiatry. 2003 Nov 1;54(9):915-21. Pubmed PMID: 14573319\n",
      "George TP, Chawarski MC, Pakes J, Carroll KM, Kosten TR, Schottenfeld RS \"Disulfiram versus placebo for cocaine dependence in buprenorphine-maintained subjects: a preliminary trial..\" Biol. Psychiatry. 2000 Jun 15;47(12):1080-6. Pubmed PMID: 10862808\n",
      "Ren ZY, Zhang XL, Liu Y, Zhao LY, Shi J, Bao Y, Zhang XY, Kosten TR, Lu L \"Diurnal variation in cue-induced responses among protracted abstinent heroin users..\" Pharmacol. Biochem. Behav.. 2009 Jan;91(3):468-72. Pubmed PMID: 18809427\n",
      "McDougle CJ, Price LH, Palumbo JM, Kosten TR, Heninger GR, Kleber HD \"Dopaminergic responsivity during cocaine abstinence: a pilot study..\" Psychiatry Res. 1992 Jul;43(1):77-85. Pubmed PMID: 1359594\n",
      "Gawin FH, Morgan C, Kosten TR, Kleber HD \"Double-blind evaluation of the effect of acute amantadine on cocaine craving..\" Psychopharmacology (Berl.). 1989;97(3):402-3. Pubmed PMID: 2497490\n",
      "Singh RA, Kosten TA, Kinsey BM, Shen X, Lopez AY, Kosten TR, Orson FM \"Dose-dependent changes in the locomotor responses to methamphetamine in BALB/c mice: low doses induce hypolocomotion..\" Pharmacol Biochem Behav. 2012 Dec; Pubmed PMID: 23010423\n",
      "Hameedi FA, Woods SW, Rosen MI, Pearsall HR, Kosten TR \"Dose dependent effects of yohimbine on methadone maintained patients..\" Am J Drug Alcohol Abuse. 1997 May;23(2):327-33. Pubmed PMID: 9143642\n",
      "Stitzer ML, Polk T, Bowles S, Kosten T \"Drug users' adherence to a 6-month vaccination protocol: effects of motivational incentives..\" Drug Alcohol Depend. 2010 Feb 1;107(1):76-9. Pubmed PMID: 19828264\n",
      "Kosten TR, Rounsaville BJ, Kleber HD \"DSM-III personality disorders in opiate addicts..\" Compr Psychiatry.;23(6):572-81. Pubmed PMID: 7160176\n",
      "Gardner T, Kosten T \"Dual dependency on cocaine and alcohol in opiate addicts: treatment options..\" J Clin Psychiatry. 2007; Pubmed PMID: 17685754\n",
      "Stine SM, Krystal JH, Petrakis IL, Jatlow PI, Heninger GR, Kosten TR, Charney DS \"Effect of alpha-methyl-para-tyrosine on response to cocaine challenge..\" Biol. Psychiatry. 1997 Aug 1;42(3):181-90. Pubmed PMID: 9232210\n",
      "Rosen MI, McMahon TJ, Hameedi FA, Pearsall HR, Woods SW, Kreek MJ, Kosten TR \"Effect of clonidine pretreatment on naloxone-precipitated opiate withdrawal..\" J. Pharmacol. Exp. Ther.. 1996 Mar;276(3):1128-35. Pubmed PMID: 8786543\n",
      "Rosen MI, Pearsall HR, McDougle CJ, Price LH, Woods SW, Kosten TR \"Effects of acute buprenorphine on responses to intranasal cocaine: a pilot study.\" Am J Drug Alcohol Abuse. 1993; Pubmed PMID: 8273766\n",
      "Oliveto AH, Farren C, Kosten TR \"Effect of LAAM dose on opiate use in opioid-dependent patients. A pilot study..\" Am J Addict. 1998;7(4):272-82. Pubmed PMID: 9809131\n",
      "McCance-Katz EF, Rainey PM, Friedland G, Kosten TR, Jatlow P \"Effect of opioid dependence pharmacotherapies on zidovudine disposition..\" Am J Addict. 2001;10(4):296-307. Pubmed PMID: 11783744\n",
      "Shi J, Jun W, Zhao LY, Xue YX, Zhang XY, Kosten TR, Lu L \"Effect of rapamycin on cue-induced drug craving in abstinent heroin addicts..\" Eur. J. Pharmacol.. 2009 Aug 1;615(41277):108-12. Pubmed PMID: 19470385\n",
      "Gao Y, Geng L, Orson F, Kinsey B, Kosten TR, Shen X, Brimijoin S \"Effects of anti-cocaine vaccine and viral gene transfer of cocaine hydrolase in mice on cocaine toxicity including motor strength and liver damage..\" Chem. Biol. Interact.. 2013 Mar 25;203(1):208-11. Pubmed PMID: 22935511\n",
      "Oliveto A, McCance-Katz FE, Singha A, Petrakis I, Hameedi F, Kosten TR \"Effects of cocaine prior to and during bupropion maintenance in cocaine-abusing volunteers..\" Drug Alcohol Depend. 2001 Jul 1;63(2):155-67. Pubmed PMID: 11376920\n",
      "Oliveto AH, McCance-Katz E, Singha A, Hameedi F, Kosten TR \"Effects of d-amphetamine and caffeine in humans under a cocaine discrimination procedure..\" Behav Pharmacol. 1998 May;9(3):207-17. Pubmed PMID: 9832935\n",
      "Rosen MI, Pearsall HR, Woods SW, Kosten TR \"Effects of gamma-hydroxybutyric acid (GHB) in opioid-dependent patients..\" J Subst Abuse Treat.;14(2):149-54. Pubmed PMID: 9258859\n",
      "Sinha R, Kimmerling A, Doebrick C, Kosten TR \"Effects of lofexidine on stress-induced and cue-induced opioid craving and opioid abstinence rates: preliminary findings..\" Psychopharmacology (Berl.). 2007 Mar;190(4):569-74. Pubmed PMID: 17136399\n",
      "Sofuoglu M, Singha A, Kosten TR, McCance-Katz FE, Petrakis I, Oliveto A \"Effects of naltrexone and isradipine, alone or in combination, on cocaine responses in humans..\" Pharmacol. Biochem. Behav.. 2003 Jul;75(4):801-8. Pubmed PMID: 12957222\n",
      "Winther LC, Saleem R, McCance-Katz EF, Rosen MI, Hameedi FA, Pearsall HR, Jatlow PI, Kosten TR, Woods SW \"Effects of lamotrigine on behavioral and cardiovascular responses to cocaine in human subjects..\" Am J Drug Alcohol Abuse. 2000 Feb; Pubmed PMID: 10718163\n",
      "Sofuoglu M, Mitchell E, Kosten TR \"Effects of progesterone treatment on cocaine responses in male and female cocaine users..\" Pharmacol. Biochem. Behav.. 2004 Aug;78(4):699-705. Pubmed PMID: 15301924\n",
      "Kosten TR, Rayford BS \"Effects of ethnicity on low-dose opiate stabilization..\" J Subst Abuse Treat.;12(2):111-6. Pubmed PMID: 7623388\n",
      "Kosten T, Poling J, Oliveto A \"Effects of reducing contingency management values on heroin and cocaine use for buprenorphine- and desipramine-treated patients..\" Addiction. 2003 May; Pubmed PMID: 12751984\n",
      "Zhang XY, Zhou DF, Shen YC, Zhang PY, Zhang WF, Liang J, Chen da C, Xiu MH, Kosten TA, Kosten TR \"Effects of risperidone and haloperidol on superoxide dismutase and nitric oxide in schizophrenia..\" Neuropharmacology. 2012 Apr;62(41400):1928-34. Pubmed PMID: 22227558\n",
      "Margolin A, Chang P, Avants SK, Kosten TR \"Effects of sham and real auricular needling: implications for trials of acupuncture for cocaine addiction..\" Am. J. Chin. Med.. 1993;21(2):103-11. Pubmed PMID: 8237887\n",
      "George TP, Vessicchio JC, Termine A, Sahady DM, Head CA, Pepper WT, Kosten TR, Wexler BE \"Effects of smoking abstinence on visuospatial working memory function in schizophrenia..\" Neuropsychopharmacology. 2002 Jan;26(1):75-85. Pubmed PMID: 11751034\n",
      "Sofuoglu M, Mouratidis M, Yoo S, Culligan K, Kosten T \"Effects of tiagabine in combination with intravenous nicotine in overnight abstinent smokers..\" Psychopharmacology (Berl.). 2005 Sep;181(3):504-10. Pubmed PMID: 15983800\n",
      "Sofuoglu M, Poling J, Mouratidis M, Kosten T \"Effects of topiramate in combination with intravenous nicotine in overnight abstinent smokers..\" Psychopharmacology (Berl.). 2006 Mar;184(41337):645-51. Pubmed PMID: 16432681\n",
      "Oliveto A, Poling J, Sevarino KA, Gonsai KR, McCance-Katz EF, Stine SM, Kosten TR \"Efficacy of dose and contingency management procedures in LAAM-maintained cocaine-dependent patients..\" Drug Alcohol Depend. 2005 Aug 1;79(2):157-65. Pubmed PMID: 16002025\n",
      "Castells X, Kosten TR, Capellà D, Vidal X, Colom J, Casas M \"Efficacy of opiate maintenance therapy and adjunctive interventions for opioid dependence with comorbid cocaine use disorders: a systematic review and meta-analysis of controlled clinical trials..\" Am J Drug Alcohol Abuse. 2009;35(5):339-49. Pubmed PMID: 20180662\n",
      "Jacobsen LK, Staley JK, Malison RT, Zoghbi SS, Seibyl JP, Kosten TR, Innis RB \"Elevated central serotonin transporter binding availability in acutely abstinent cocaine-dependent patients..\" Am J Psychiatry. 2000 Jul;157(7):1134-40. Pubmed PMID: 10873923\n",
      "Xiu MH, Chen DC, Wang D, Zhang K, Dong A, Tang W, Zhang F, Liu LJ, Liu JH, Liu HB, Yang FD, Kosten TR, Zhang XY \"Elevated interleukin-18 serum levels in chronic schizophrenia: Association with psychopathology..\" 2012 May 28; Pubmed PMID: 22647522\n",
      "Wu Z, Zhang XY, Wang H, Tang W, Xia Y, Zhang F, Liu J, Fu Y, Hu J, Chen Y, Liu L, Chen da C, Xiu MH, Kosten TR, He J \"Elevated plasma superoxide dismutase in first-episode and drug naive patients with schizophrenia: inverse association with positive symptoms..\" Prog Neuropsychopharmacol Biol Psychiatry. 2012 Jan; Pubmed PMID: 21896300\n",
      "Chen da C, Qi LY, Xiu MH, Cao LY, Wang F, Chen S, Wu GY, Kosten TA, Kosten TR, Zhang XY \"Elevated serum levels of tumor necrosis factor-alpha in clozapine-associated obesity in chronic schizophrenia..\" Schizophr. Res.. 2008 Dec;106(41308):367-8. Pubmed PMID: 18835132\n",
      "Malison RT, Best SE, van Dyck CH, McCance EF, Wallace EA, Laruelle M, Baldwin RM, Seibyl JP, Price LH, Kosten TR, Innis RB \"Elevated striatal dopamine transporters during acute cocaine abstinence as measured by [123I] beta-CIT SPECT..\" Am J Psychiatry. 1998 Jun;155(6):832-4. Pubmed PMID: 9619159\n",
      "Mason JW, Giller EL, Kosten TR, Harkness L \"Elevation of urinary norepinephrine/cortisol ratio in posttraumatic stress disorder..\" J. Nerv. Ment. Dis.. 1988 Aug;176(8):498-502. Pubmed PMID: 3404142\n",
      "Sofuoglu M, Kosten TR \"Emerging pharmacological strategies in the fight against cocaine addiction..\" Expert Opin Emerg Drugs. 2006 Mar;11(1):91-8. Pubmed PMID: 16503828\n",
      "Sun HQ, Chen HM, Yang FD, Lu L, Kosten TR \"Epidemiological trends and the advances of treatments of amphetamine-type stimulants (ATS) in China..\" Am J Addict. 2014 May; Pubmed PMID: 24724890\n",
      "Nielsen DA, Utrankar A, Reyes JA, Simons DD, Kosten TR \"Epigenetics of drug abuse: predisposition or response..\" Pharmacogenomics. 2012 Jul;13(10):1149-60. Pubmed PMID: 22909205\n",
      "Kosten TR, Rounsaville BJ, Kleber HD \"Ethnic and gender differences among opiate addicts..\" Int J Addict. 1985 Aug;20(8):1143-62. Pubmed PMID: 4077316\n",
      "Malison RT, Best SE, Wallace EA, McCance E, Laruelle M, Zoghbi SS, Baldwin RM, Seibyl JS, Hoffer PB, Price LH \"Euphorigenic doses of cocaine reduce [123I]beta-CIT SPECT measures of dopamine transporter availability in human cocaine addicts..\" Psychopharmacology. 1995 Dec; Pubmed PMID: 8657833\n",
      "Kosten TR, Gawin FH, Morgan C, Nelson JC, Jatlow P \"Evidence for altered desipramine disposition in methadone-maintained patients treated for cocaine abuse..\" Am J Drug Alcohol Abuse. 1990;16(41337):329-36. Pubmed PMID: 2288330\n",
      "Lingford-Hughes AR, Welch S, Nutt DJ; British Association for Psychopharmacology \"Evidence-based guidelines for the pharmacological management of substance misuse, addiction and comorbidity: recommendations from the British Association for Psychopharmacology..\" J Psychopharmacol. 2004 Sep; Pubmed PMID: 15358975\n",
      "An HM, Tan YL, Shi J, Wang ZR, Li J, Wang YC, Kosten TR, Zhou DF, Yang FD, Zhang XY \"Extract of Ginkgo biloba is equivalent to vitamin E in attenuating and preventing vacuous chewing movements in a rat model of tardive dyskinesia..\" Behav Pharmacol. 2013 Aug; Pubmed PMID: 23994817\n",
      "Browndyke JN, Tucker KA, Woods SP, Beauvals J, Cohen RA, Gottschalk PC, Kosten TR \"Examining the effect of cerebral perfusion abnormality magnitude on cognitive performance in recently abstinent chronic cocaine abusers..\" J Neuroimaging. 2004 Apr; Pubmed PMID: 23994817\n",
      "Sun HQ, Guo S, Chen DF, Jiang ZN, Liu Y, Di XL, Yang FD, Zhang XY, Kosten TR, Lu L \"Family support and employment as predictors of smoking cessation success: a randomized, double-blind, placebo-controlled trial of nicotine sublingual tablets in Chinese smokers..\" Am J Drug Alcohol Abuse. 2009;35(3):183-8. Pubmed PMID: 19462302\n",
      "Kosten TR, Jalali B, Hogan I, Kleber HD \"Family denial as a prognostic factor in opiate addict treatment outcome..\" J. Nerv. Ment. Dis.. 1983 Oct;171(10):611-6. Pubmed PMID: 6619824\n",
      "Petrakis I, Carroll KM, Nich C, Gordon L, Kosten T, Rounsaville B \"Fluoxetine treatment of depressive disorders in methadone-maintained opioid addicts..\" Drug Alcohol Depend. 1998 May; Pubmed PMID: 9649975\n",
      "Kosten TR \"For Council on Addictions of American Psychiatry Association. Policy—statement on methadone maintenance treatment..\" Am J Psychiatry. 1994;\n",
      "Wu JQ, Kosten TR, Zhang XY \"Free radicals, antioxidant defense systems, and schizophrenia.\" Prog Neuropsychopharmacol Biol Psychiatry. 2013 Oct; Pubmed PMID: 23470289\n",
      "Kosten TA, Gawin FH, Kosten TR, Rounsaville BJ \"Gender differences in cocaine use and treatment response..\" J Subst Abuse Treat.;10(1):63-6. Pubmed PMID: 8450576\n",
      "Han M, Huang XF, Chen DC, Xiu MH, Hui L, Liu H, Kosten TR, Zhang XY \"Gender differences in cognitive function of patients with chronic schizophrenia..\" Prog. Neuropsychopharmacol. Biol. Psychiatry. 2012 Jul 20; Pubmed PMID: 22820676\n",
      "Kosten TR \"Future of anti-addiction vaccines..\" Stud Health Technol Inform. 2005;118:177-85. Pubmed PMID: 16301778\n",
      "He J, Xie Y, Tao J, Su H, Wu W, Zou S, Zhang J, Zhang J, Zhang H, Yang X, Guo J, Tang W, Zhang F, Liu J, Liu L, Chen Y, Wen N, Kosten TR, Zhang XY \"Gender differences in socio-demographic and clinical characteristics of methamphetamine inpatients in a Chinese population..\" Drug Alcohol Depend. 2013 Jun 1;130(41277):94-100. Pubmed PMID: 23149112\n",
      "Zhang XY, Chen da C, Xiu MH, Yang FD, Haile CN, Kosten TA, Kosten TR \"Gender differences in never-medicated first-episode schizophrenia and medicated chronic schizophrenia patients..\" J Clin Psychiatry. 2012 Aug;73(7):1025-33. Pubmed PMID: 22901352\n",
      "Kosten TR, Kosten TA, McDougle CJ, Hameedi FA, McCance EF, Rosen MI, Oliveto AH, Price LH \"Gender differences in response to intranasal cocaine administration to humans..\" Biol. Psychiatry. 1996 Jan 15;39(2):147-8. Pubmed PMID: 8717615\n",
      "Chen da C, Zhou MA, Zhou DH, Xiu MH, Wu GY, Kosten TR, Zhang XY \"Gender differences in the prevalence of diabetes mellitus in chronic hospitalized patients with schizophrenia on long-term antipsychotics..\" Psychiatry Res. 2011 Apr 30;186(41308):451-3. Pubmed PMID: 20797801\n",
      "Zhang XY, Chen da C, Qi LY, Wang F, Xiu MH, Chen S, Wu GY, Kosten TA, Kosten TR \"Gender differences in the prevalence, risk and clinical correlates of tardive dyskinesia in Chinese schizophrenia..\" Psychopharmacology (Berl.). 2009 Sep;205(4):647-54. Pubmed PMID: 19529921\n",
      "Haile CN, Kosten TR, Kosten TA \"Genetics of dopamine and its contribution to cocaine addiction..\" Behav. Genet.. 2007 Jan;37(1):119-45. Pubmed PMID: 17063402\n",
      "Kosten TR, Rounsaville BJ, Kosten TA, Merikangas K \"Gender differences in the specificity of alcoholism transmission among the relatives of opioid addicts..\" J. Nerv. Ment. Dis.. 1991 Jul;179(7):392-400. Pubmed PMID: 1869867\n",
      "Tucker KA, Browndyke JN, Gottschalk PC, Cofrancesco AT, Kosten TR \"Gender-specific vulnerability for rCBF abnormalities among cocaine abusers..\" Neuroreport. 2004 Apr 9;15(5):797-801. Pubmed PMID: 15073517\n",
      "McCance-Katz EF, Hart CL, Boyarsky B, Kosten T, Jatlow P \"Gender effects following repeated administration of cocaine and alcohol in humans.\" Subst Use Misuse. 2005; Pubmed PMID: 15830733\n",
      "McCance-Katz EF, Kosten TA, Kosten TR \"Going from the bedside back to the bench with ecopipam: a new strategy for cocaine pharmacotherapy development..\" Psychopharmacology (Berl.). 2001 Jun;155(4):327-9. Pubmed PMID: 11441421\n",
      "Manji H, Chen G, Potter W, Kosten TR \"Guanine nucleotide binding proteins in opioid-dependent patients..\" Biol. Psychiatry. 1997 Jan 15;41(2):130-4. Pubmed PMID: 9018382\n",
      "Margolin A, Avants SK, Malison RT, Kosten TR \"High-and low-dose mazindol for cocaine dependence in methadone-maintained patients: A preliminary evaluation.\" Substance Abuse. 1997;\n",
      "Meandzija B, O'Connor PG, Fitzgerald B, Rounsaville BJ, Kosten TR \"HIV infection and cocaine use in methadone maintained and untreated intravenous drug users..\" Drug Alcohol Depend. 1994 Oct;36(2):109-13. Pubmed PMID: 7851277\n",
      "Oliveto AH, Rosen MI, Kosten TA, Hameedi FA, Woods SW, Kosten TR \"Hydromorphone-naloxone combinations in opioid-dependent humans under a naloxone novel-response discrimination procedure..\" Exp Clin Psychopharmacol. 1998 May;6(2):169-78. Pubmed PMID: 9608349\n",
      "Gardner TJ, Kosten TR \"Human laboratory and neuroimaging studies in substance use disorders: developing new treatment approaches..\" Am J Drug Alcohol Abuse. 2007;33(6):765-7. Pubmed PMID: 17994472\n",
      "66. O’Connor PG, Meandzija B, Poling J, Kosten TR, Fitzgerald B, Rounsaville BJ \"HIV vaccine preparedness trials in injection-drug users: Are we prepared?.\" Substance Abuse. 1995;\n",
      "Kosten TR, Rosen M, Bond J, Settles M, Roberts JS, Shields J, Jack L, Fox B \"Human therapeutic cocaine vaccine: safety and immunogenicity..\" Vaccine. 2002 Jan 15;20(41463):1196-204. Pubmed PMID: 11803082\n",
      "Kosten TR \"Images in psychiatry. Marie Nyswander, 1919-1986..\" Am J Psychiatry. 1998 Dec;155(12):1766. Pubmed PMID: 9842790\n",
      "Kosten TR \"Images in Psychiatry: Abraham Winkler, MD: 1910-1981.\" American Journal of Psychiatry. 1998;\n",
      "Shen X, Kosten TR \"Immunotherapy for drug abuse..\" CNS Neurol Disord Drug Targets. 2011 Dec 1;10(8):876-9. Pubmed PMID: 22229313\n",
      "Kosten T, Owens SM \"Immunotherapy for the treatment of drug abuse..\" Pharmacol. Ther.. 2005 Oct;108(1):76-85. Pubmed PMID: 16023218\n",
      "Najavits LM, Norman SB, Kivlahan D, Kosten TR \"Improving PTSD/Substance Abuse Treatment in the VA: A Survey of Providers..\" Am J Addict. 2010 May;19(3):257-63. Pubmed PMID: 20525033\n",
      "Carroll KM, Chang G, Behr H, Clinton B, Kosten TR \"Improving treatment outcome in pregnant methadone maintained women; Results from a randomized clinical trial.\" Am J Addictions. 1995;\n",
      "Chang G, Carroll KM, Behr HM, Kosten TR \"Improving treatment outcome in pregnant opiate-dependent women..\" J Subst Abuse Treat. 1992;9(4):327-30. Pubmed PMID: 1479630\n",
      "Zhang XY, Xiu MH, Chen da C, Zhu FY, Wu GY, Haile CN, Lu L, Kosten TA, Kosten TR \"Increased S100B serum levels in schizophrenic patients with tardive dyskinesia: association with dyskinetic movements..\" J Psychiatr Res. 2010 May;44(7):429-33. Pubmed PMID: 19932492\n",
      "Zhang XY, Xiu MH, Song C, Chen da C, Wu GY, Haile CN, Kosten TA, Kosten TR \"Increased serum S100B in never-medicated and medicated schizophrenic patients..\" J Psychiatr Res. 2010 Dec; Pubmed PMID: 20510426\n",
      "Singha AK, McCance-Katz EF, Heck SA, Kosten TR, Oliveto A \"Individual differences in humans responding under a cocaine discrimination procedure: discriminators versus nondiscriminators..\" Exp Clin Psychopharmacol. 1999 Nov;7(4):391-8. Pubmed PMID: 10609974\n",
      "Qi LY, Xiu MH, Chen da C, Wang F, Kosten TA, Kosten TR, Zhang XY \"Increased serum S100B levels in chronic schizophrenic patients on long-term clozapine or typical antipsychotics..\" Neurosci. Lett.. 2009 Sep 22;462(2):113-7. Pubmed PMID: 19539717\n",
      "Avants SK, Margolin A, Kosten TR \"Influence of treatment readiness on outcomes of two pharmacotherapy trials for cocaine abuse among methadone-maintained patients.\" Psychology Addictive Behaviors. 1996;\n",
      "Kosten TR, Rounsaville BJ, Foley SH \"Inpatient vs. outpatient cocaine abuse treatments..\" NIDA Res. Monogr.. 1989;95:312-3. Pubmed PMID: 2640976\n",
      "Rosenheck R, Harkness L, Johnson B, Sweeney C, Buck N, Deegan D, Kosten T \"Intensive community-focused treatment of veterans with dual diagnoses..\" Am J Psychiatry. 1998 Oct; Pubmed PMID: 9766776\n",
      "Kosten TR, Woods SW, Rosen MI, Pearsall HR \"Interactions of cocaine with nimodipine: a brief report..\" Am J Addict. 1999;8(1):77-81. Pubmed PMID: 10189518\n",
      "Zhang XY, Tang W, Xiu MH, Chen da C, Yang FD, Tan YL, Wang ZR, Zhang F, Liu J, Liu L, Chen Y, Wen N, Kosten TR \"Interleukin 18 and cognitive impairment in first episode and drug naïve schizophrenia versus healthy controls..\" Brain Behav. Immun.. 2013 Aug;32:105-11. Pubmed PMID: 23499732\n",
      "72. Kosten T, Gawin FH, Silverman DG, Fleming J, Compton M, Jatlow P, Byck R \"Intravenous cocaine challenges during desipramine maintenance.\" Neuropsychopharmacology. 1992 Nov; Pubmed PMID: 1388643\n",
      "Oliveto A, Poling J, Kosten TR, Gonsai K \"Isradipine and dextromethorphan in methadone-maintained humans under a naloxone discrimination procedure..\" Eur. J. Pharmacol.. 2004 May 3;491(41308):157-68. Pubmed PMID: 15140632\n",
      "Kosten T, Silverman DG, Fleming J, Kosten TA, Gawin FH, Compton M, Jatlow P, Byck R \"Intravenous cocaine challenges during naltrexone maintenance: a preliminary study..\" Biol Psychiatry. 1992 Sep; Pubmed PMID: 1445971\n",
      "Gottschalk PC, Kosten TR \"Isradipine enhancement of cerebral blood flow in abstinent cocaine abusers with and without chronic perfusion deficits..\" Am J Addict. 2002;11(3):200-8. Pubmed PMID: 12202012\n",
      "Kosten TR, Oliveto A, Sevarino KA, Gonsai K, Feingold A \"Ketoconazole increases cocaine and opioid use in methadone maintained patients..\" Drug Alcohol Depend. 2002 Apr 1;66(2):173-80. Pubmed PMID: 11906804\n",
      "Li W, Wei J, Zhou DF, Tan YL, Cao YL, Zhang XY, Wu G, Kosten TA, Kosten TR \"Lack of association between the BDNF C270T polymorphism and schizophrenia in a Chinese Han population..\" Schizophr. Res.. 2007 Dec;97(41277):297-8. Pubmed PMID: 17669628\n",
      "Rounsaville BJ, Kosten TR, Kleber HD \"Long-term changes in current psychiatric diagnoses of treated opiate addicts..\" Compr Psychiatry.;27(5):480-98. Pubmed PMID: 3757496\n",
      "Zhang XY, Cao LY, Song C, Wu GY, Chen da C, Qi LY, Wang F, Xiu MH, Chen S, Zhang Y, Lu L, Kosten TA, Kosten TR \"Lower serum cytokine levels in smokers than nonsmokers with chronic schizophrenia on long-term treatment with antipsychotics..\" Psychopharmacology (Berl.). 2008 Dec;201(3):383-9. Pubmed PMID: 18719893\n",
      "Zhang XY, Liang J, Chen DC, Xiu MH, De Yang F, Kosten TA, Kosten TR \"Low BDNF is associated with cognitive impairment in chronic patients with schizophrenia..\" 2012 Jan 26; Pubmed PMID: 22274000\n",
      "Zhen YF, Zhang J, Liu XY, Fang H, Tian LB, Zhou DH, Kosten TR, Zhang XY \"Low BDNF is associated with cognitive deficits in patients with type 2 diabetes..\" Psychopharmacology (Berl.). 2013 May;227(1):93-100. Pubmed PMID: 23263460\n",
      "Liu H, Kang Y, Liang J, Li C, Xiu M, Chen D, Yang F, Wang F, Wu G, Haile CN, Kosten TA, Kosten TR, Zhang XY \"Lower serum interleukin-2 levels in schizophrenic patients with tardive dyskinesia..\" 2012 Mar 12; Pubmed PMID: 22417931\n",
      "Kosten TR \"Mandatory drug testing needs controlled evaluation..\" Am J Bioeth. 2004;4(1):32. Pubmed PMID: 15035939\n",
      "Kosten TR, O'Connor PG \"Management of drug and alcohol withdrawal..\" N. Engl. J. Med.. 2003 May 1;348(18):1786-95. Pubmed PMID: 12724485\n",
      "Margolin A, Avants SK, Kosten TR \"Mazindol for relapse prevention to cocaine abuse in methadone-maintained patients..\" Am J Drug Alcohol Abuse. 1995 Nov;21(4):469-81. Pubmed PMID: 8561098\n",
      "Stine SM, Krystal JH, Kosten TR, Charney DS \"Mazindol treatment for cocaine dependence..\" Drug Alcohol Depend. 1995 Oct;39(3):245-52. Pubmed PMID: 8556974\n",
      "Diakogiannis IA, Steinberg M, Kosten TR \"Mazindol treatment of cocaine abuse. A double-blind investigation..\" NIDA Res. Monogr.. 1990;105:514. Pubmed PMID: 1876105\n",
      "Reid MC, Tinetti ME, O'Connor PG, Kosten TR, Concato J \"Measuring alcohol consumption among older adults: a comparison of available methods..\" Am J Addict.;12(3):211-9. Pubmed PMID: 12851017\n",
      "Kosten TR \"Medications development and the war on drugs: victims of the Gulf war?.\" Biol. Psychiatry. 1991 Mar 15;29(6):521-3. Pubmed PMID: 2054428\n",
      "Stine SM, Grillon CG, Morgan CA, Kosten TR, Charney DS, Krystal JH \"Methadone patients exhibit increased startle and cortisol response after intravenous yohimbine..\" Psychopharmacology (Berl.). 2001 Mar;154(3):274-81. Pubmed PMID: 11351934\n",
      "Streltzer J, Kosten TR \"Methadone maintenance therapy and chronic pain..\" JAMA. 2003 Nov; Pubmed PMID: 14612466\n",
      "Stine SM, Kosten TR \"Methadone dose in the treatment of opiate dependence.\" Medscape Mental Health. 1997;\n",
      "Schottenfeld RS, Chawarski MC, Pakes JR, Pantalon MV, Carroll KM, Kosten TR \"Methadone versus buprenorphine with contingency management or performance feedback for cocaine and opioid dependence..\" Am J Psychiatry. 2005 Feb;162(2):340-9. Pubmed PMID: 15677600\n",
      "Nielsen DA, Harding MJ, Hamon SC, Huang W, Kosten TR \"Modifying the role of serotonergic 5-HTTLPR and TPH2 variants on disulfiram treatment of cocaine addiction: a preliminary study..\" Genes Brain Behav. 2012 Aug; Pubmed PMID: 22925276\n",
      "Margolin A, Avants SK, Rounsaville B, Kosten TR, Schottenfeld RS \"Motivational factors in cocaine pharmacotherapy trials with methadone-maintained patients: problems and paradoxes..\" J Psychoactive Drugs.;29(2):205-12. Pubmed PMID: 9250948\n",
      "Kosten TR, Rounsaville BJ, Kleber HD \"Multidimensionality and prediction of treatment outcome in opioid addicts: 2.5-year follow-up..\" Compr Psychiatry.;28(1):41346. Pubmed PMID: 3802797\n",
      "Jacobsen LK, Kosten TR \"Naloxone challenge as a biological predictor of treatment outcome in opiate addicts..\" Am J Drug Alcohol Abuse. 1989;15(4):355-66. Pubmed PMID: 2596440\n",
      "Mason JW, Kosten TR, Giller EL \"Multidimensional hormonal discrimination of paranoid schizophrenic from bipolar manic patients..\" Biol. Psychiatry. 1991 Mar 1;29(5):457-66. Pubmed PMID: 2018819\n",
      "Kleber HD, Kosten TR \"Naltrexone induction: psychologic and pharmacologic strategies.\" J Clin Psychiatry. 1984 Sep; Pubmed PMID: 6469934\n",
      "Krupitsky E, Zvartau E, Blokhina E, Verbitskaya E, Tsoy M, Wahlgren V, Burakov A, Masalov D, Romanova TN, Palatkin V, Tyurina A, Yaroslavtseva T, Sinha R, Kosten TR \"Naltrexone with or without guanfacine for preventing relapse to opiate addiction in St.-Petersburg, Russia.\" Drug Alcohol Depend. 2013 Oct; Pubmed PMID: 23683793\n",
      "Sevarino KA, Oliveto A, Kosten TR \"Neurobiological adaptations to psychostimulants and opiates as a basis of treatment development..\" Ann. N. Y. Acad. Sci.. 2000;909:51-87. Pubmed PMID: 10911924\n",
      "Markou A, Kosten TR, Koob GF \"Neurobiological similarities in depression and drug dependence: a self-medication hypothesis..\" Neuropsychopharmacology. 1998 Mar;18(3):135-74. Pubmed PMID: 9471114\n",
      "Krystal J, Kosten TR, Perry B, Southwick S, Mason JW, Giller EL \"Neurobiological aspects of post traumatic stress disorder: Review of clinical and pre-clinical studies..\" Behavior Therapy. 1989;\n",
      "Sinha R, Lacadie C, Skudlarski P, Fulbright RK, Rounsaville BJ, Kosten TR, Wexler BE \"Neural activity associated with stress-induced cocaine craving: a functional magnetic resonance imaging study..\" Psychopharmacology (Berl.). 2005 Dec;183(2):171-80. Pubmed PMID: 16163517\n",
      "Kosten TR \"Neurobiology of abused drugs. Opioids and stimulants..\" J. Nerv. Ment. Dis.. 1990 Apr;178(4):217-27. Pubmed PMID: 2156952\n",
      "Kosten TR, Margolin A \"New developments in opioid abuse treatment.\" Annals Clinical Psychiatry. 1990;\n",
      "Sernyak MJ, Kosten TR, Fontana A, Rosenheck R \"Neuroleptic use in the treatment of Post-Traumatic Stress Disorder..\" Psychiatr Q. 2001;72(3):197-213. Pubmed PMID: 11467155\n",
      "Kosten TR, Gardner TJ \"New hot topics sections: 1. China's new march forward in addiction treatment: methadone for the masses. 2. Issues in formulating DSM V..\" Am J Drug Alcohol Abuse. 2008;34(2):123-6. Pubmed PMID: 18293228\n",
      "Kosten TR, Kosten TA \"New medication strategies for comorbid substance use and bipolar affective disorders..\" Biol. Psychiatry. 2004 Nov 15;56(10):771-7. Pubmed PMID: 15556122\n",
      "Zhang XY, Tan YL, Zhou DF, Haile CN, Wu GY, Cao LY, Kosten TA, Kosten TR \"Nicotine dependence, symptoms and oxidative stress in male patients with schizophrenia..\" Neuropsychopharmacology. 2007 Sep;32(9):2020-4. Pubmed PMID: 17228336\n",
      "Ziedonis DM, Kosten TR, Glazer WM, Frances RJ \"Nicotine dependence and schizophrenia..\" Hosp Community Psychiatry. 1994 Mar;45(3):204-6. Pubmed PMID: 7910577\n",
      "Zhang XY, Xiu MH, Chen da C, Yang FD, Wu GY, Lu L, Kosten TA, Kosten TR \"Nicotine dependence and serum BDNF levels in male patients with schizophrenia.\" Psychopharmacology (Berl).. 2010 Oct; Pubmed PMID: 20661552\n",
      "George TP, Ziedonis DM, Feingold A, Pepper WT, Satterburg CA, Winkel J, Rounsaville BJ, Kosten TR \"Nicotine transdermal patch and atypical antipsychotic medications for smoking cessation in schizophrenia..\" Am J Psychiatry. 2000 Nov;157(11):1835-42. Pubmed PMID: 11058482\n",
      "Zhang X, Guan SL, Wang ZQ, You Y, Sun SL, Hui L, Miao LN, Yu Y, Kosten TR, Zhang XY \"No association between the type 2 diabetes mellitus susceptibility gene, SLC30A8 and schizophrenia in a Chinese population..\" Hum Psychopharmacol. 2012 Jul;27(4):392-6. Pubmed PMID: 22778022\n",
      "Kleber HD, Kosten TR, Gaspari J, Topazian M \"Nontolerance to the opioid antagonism of naltrexone..\" Biol. Psychiatry. 1985 Jan;20(1):66-72. Pubmed PMID: 2981129\n",
      "Newton TF, De La Garza R, Brown G, Kosten TR, Mahoney JJ, Haile CN \"Noradrenergic a(1) Receptor Antagonist Treatment Attenuates Positive Subjective Effects of Cocaine in Humans: A Randomized Trial..\" PLoS ONE. 2012;7(2):e30854. Pubmed PMID: 22319592\n",
      "McDougle CJ, Black JE, Malison RT, Zimmermann RC, Kosten TR, Heninger GR, Price LH \"Noradrenergic dysregulation during discontinuation of cocaine use in addicts..\" Arch. Gen. Psychiatry. 1994 Sep;51(9):713-9. Pubmed PMID: 8080348\n",
      "Sofuoglu M, Kosten TR \"Novel approaches to the treatment of cocaine addiction..\" CNS Drugs. 2005;19(1):13-25. Pubmed PMID: 15651902\n",
      "Krystal JH, Woods SW, Kosten TR, Rosen MI, Seibyl JP, van Dyck CC, Price LH, Zubal IG, Hoffer PB, Charney DS \"Opiate dependence and withdrawal: preliminary assessment using single photon emission computerized tomography (SPECT)..\" Am J Drug Alcohol Abuse. 1995 Feb;21(1):47-63. Pubmed PMID: 7762544\n",
      "Fiellin DA, Rosenheck RA, Kosten TR \"Office-based treatment for opioid dependence: reaching new patient populations..\" Am J Psychiatry. 2001 Aug;158(8):1200-4. Pubmed PMID: 11481150\n",
      "Shorter D, Kosten TR \"Novel pharmacotherapeutic treatments for cocaine addiction..\" 2011 Nov 3;9(1):119. Pubmed PMID: 22047090\n",
      "Best SE, Oliveto AH, Kosten TR \"Opioid addiction: Recent advances in detoxification and maintenance therapy.\" CNS Drugs. 1996;\n",
      "Kosten TR, Krystal JH, Charney DS, Price LH, Morgan CH, Kleber HD \"Opioid antagonist challenges in buprenorphine maintained patients..\" Drug Alcohol Depend. 1990 Feb;25(1):73-8. Pubmed PMID: 2323312\n",
      "Stotts AL, Dodrill CL, Kosten TR \"Opioid dependence treatment: options in pharmacotherapy..\" Expert Opin Pharmacother. 2009 Aug;10(11):1727-40. Pubmed PMID: 19538000\n",
      "Margolin A, Avants SK, Kosten TR \"Pemoline for the treatment of cocaine dependence in methadone-maintained patients..\" J Psychoactive Drugs.;28(3):301-4. Pubmed PMID: 8895115\n",
      "Kosten TR, Rounsaville BJ, Kleber HD \"Parental alcoholism in opioid addicts..\" J. Nerv. Ment. Dis.. 1985 Aug;173(8):461-9. Pubmed PMID: 4020363\n",
      "Sigmon SC, Bisaga A, Nunes EV, O'Connor PG, Kosten T, Woody G \"Opioid detoxification and naltrexone induction strategies: recommendations for clinical practice..\" Am J Drug Alcohol Abuse. 2012 May;38(3):187-99. Pubmed PMID: 22404717\n",
      "Potenza MN, Kosten TR, Rounsaville BJ \"Pathological gambling.\" JAMA. 2001 Jul;\n",
      "Kosten TR, Novak P, Kleber HD \"Perceived marital and family environment of opiate addicts..\" Am J Drug Alcohol Abuse. 1984;10(4):491-501. Pubmed PMID: 6534181\n",
      "Rosen MI, Bridge TP, O’Malley SS, Pearsall HR, Maritini B, O’Connor PG, Brett-Smith H, Thomas HM, van Dyke CH, Woods SW, Kosten TR. \"Peptide T treatment of cognitive impairment in HIV positive intravenous drug users.\" Am J Addictions. 1992;\n",
      "Lane SD, Moeller FG, Steinberg JL, Buzby M, Kosten TR \"Performance of cocaine dependent individuals and controls on a response inhibition task with varying levels of difficulty..\" Am J Drug Alcohol Abuse. 2007;33(5):717-26. Pubmed PMID: 17891664\n",
      "McIntosh BJ, Zhang XY, Kosten T, Tan SP, Xiu MH, Rakofsky J, Harvey PD \"Performance-based assessment of functional skills in severe mental illness: Results of a large-scale study in China..\" J Psychiatr Res. 2011 Aug;45(8):1089-94. Pubmed PMID: 21300378\n",
      "Tucker KA, Potenza MN, Beauvais JE, Browndyke JN, Gottschalk PC, Kosten TR \"Perfusion abnormalities and decision making in cocaine dependence.\" Biol Psychiatry. 2004 Oct; Pubmed PMID: 15450790\n",
      "Kosten TA, Kosten TR, Rounsaville BJ \"Personality disorders in opiate addicts show prognostic specificity..\" J Subst Abuse Treat. 1989;6(3):163-8. Pubmed PMID: 2795705\n",
      "Kosten TR, Wu G, Huang W, Harding MJ, Hamon SC, Lappalainen J, Nielsen DA \"Pharmacogenetic Randomized Trial for Cocaine Abuse: Disulfiram and Dopamine ß-Hydroxylase..\" Biol. Psychiatry. 2012 Aug 17; Pubmed PMID: 22906516\n",
      "Shorter D, Nielsen DA, Huang W, Harding MJ, Hamon SC, Kosten TR. \"Pharmacogenetic randomized trial for cocaine abuse: disulfiram and α1A-adrenoceptor gene variation.\" Eur Neuropsychopharmacol. 2013 Nov; Pubmed PMID: 23849431\n",
      "Haile CN, Kosten TA, Kosten TR \"Pharmacogenetic treatments for drug addiction: alcohol and opiates..\" Am J Drug Alcohol Abuse. 2008;34(4):355-81. Pubmed PMID: 18584566\n",
      "Kosten TR \"Pharmacological approaches to cocaine dependence..\" Clin Neuropharmacol. 1992;15:70A-71A. Pubmed PMID: 1498999\n",
      "Haile CN, Kosten TR, Kosten TA \"Pharmacogenetic treatments for drug addiction: cocaine, amphetamine and methamphetamine..\" Am J Drug Alcohol Abuse. 2009;35(3):161-77. Pubmed PMID: 19462300\n",
      "Sofuoglu M, Kosten TR \"Pharmacologic management of relapse prevention in addictive disorders..\" Psychiatr. Clin. North Am.. 2004 Dec;27(4):627-48. Pubmed PMID: 15550284\n",
      "Kosten TA, Kosten TR \"Pharmacological blocking agents for treating substance abuse..\" J. Nerv. Ment. Dis.. 1991 Oct;179(10):583-92. Pubmed PMID: 1919542\n",
      "Kosten TR \"Pharmacotherapeutic interventions for cocaine abuse. Matching patients to treatments..\" J. Nerv. Ment. Dis.. 1989 Jul;177(7):379-89. Pubmed PMID: 2664072\n",
      "Gardner TJ, Kosten TR \"Pharmacotherapeutic environments for substance use disorders..\" Am J Drug Alcohol Abuse. 2007;33(5):627-9. Pubmed PMID: 17891655\n",
      "Verrico CD, Haile CN, Newton TF, Kosten TR, De La Garza R \"Pharmacotherapeutics for substance-use disorders: a focus on dopaminergic medications.\" Expert Opin Investig Drugs. 2013 Dec; Pubmed PMID: 24033127\n",
      "Kosten TR \"Pharmacotherapy for addictions: partnering with contingency management..\" Am J Drug Alcohol Abuse. 2007;33(3):341-2. Pubmed PMID: 17613962\n",
      "Kosten TR, Morgan CM, Falcione J, Schottenfeld RS \"Pharmacotherapy for cocaine-abusing methadone-maintained patients using amantadine or desipramine..\" Arch. Gen. Psychiatry. 1992 Nov;49(11):894-8. Pubmed PMID: 1444728\n",
      "Kosten TR, Frank JB, Dan E, McDougle CJ, Giller EL \"Pharmacotherapy for posttraumatic stress disorder using phenelzine or imipramine..\" J. Nerv. Ment. Dis.. 1991 Jun;179(6):366-70. Pubmed PMID: 2051152\n",
      "Warner EA, Kosten TR, O'Connor PG \"Pharmacotherapy for opioid and cocaine abuse..\" Med. Clin. North Am.. 1997 Jul;81(4):909-25. Pubmed PMID: 9222260\n",
      "Haile CN, Kosten TR \"Pharmacotherapy for stimulant-related disorders..\" Curr Psychiatry Rep. 2013 Nov; Pubmed PMID: 24142188\n",
      "McCance-Katz E, Sevarino K, Gottschalk PC, Kosten T \"Pharmacotherapy of stimulant dependence: one of Japan's greatest public health challenges..\" Nihon Shinkei Seishin Yakurigaku Zasshi. 1999 Oct; Pubmed PMID: 10637824\n",
      "Ziedonis DM, Kosten TR \"Pharmacotherapy improves treatment outcome in depressed cocaine addicts..\" J Psychoactive Drugs.;23(4):417-25. Pubmed PMID: 1813613\n",
      "Kosten TR \"Pharmacotherapy of cerebral ischemia in cocaine dependence..\" Drug Alcohol Depend. 1998 Jan 1;49(2):133-44. Pubmed PMID: 9543650\n",
      "Kosten TR, Morgan C, Kleber HD \"Phase II clinical trials of buprenorphine: detoxification and induction onto naltrexone..\" NIDA Res. Monogr.. 1992;121:101-19. Pubmed PMID: 1406906\n",
      "Kosten TR, Astrachan BM \"Planning for crisis on a psychiatric research ward: a task analysis..\" Compr Psychiatry. 1981 May; Pubmed PMID: 7238004\n",
      "Bowers MB, Malison RT, Seibyl JP, Kosten TR \"Plasma homovanillic acid and the dopamine transporter during cocaine withdrawal..\" Biol. Psychiatry. 1998 Feb 15;43(4):278-81. Pubmed PMID: 9513737\n",
      "Zhang XY, Chen DC, Xiu MH, Tang W, Zhang F, Liu L, Chen Y, Liu J, Yao JK, Kosten TA, Kosten TR \"Plasma total antioxidant status and cognitive impairments in schizophrenia..\" 2012 May 1; Pubmed PMID: 22555016\n",
      "Kosten TR, Tucker K, Gottschalk PC, Rinder CS, Rinder HM \"Platelet abnormalities associated with cerebral perfusion defects in cocaine dependence..\" Biol. Psychiatry. 2004 Jan 1;55(1):91-7. Pubmed PMID: 14706430\n",
      "Rinder HM, Ault KA, Jatlow PI, Kosten TR, Smith BR \"Platelet alpha-granule release in cocaine users..\" Circulation. 1994 Sep;90(3):1162-7. Pubmed PMID: 7522132\n",
      "Jacobsen LK, Staley JK, Zoghbi SS, Seibyl JP, Kosten TR, Innis RB, Gelernter J \"Prediction of dopamine transporter binding availability by genotype: a preliminary report..\" Am J Psychiatry. 2000 Oct;157(10):1700-3. Pubmed PMID: 11007732\n",
      "Sofuoglu M, Gonzalez G, Poling J, Kosten TR \"Prediction of treatment outcome by baseline urine cocaine results and self-reported cocaine use for cocaine and opioid dependence..\" Am J Drug Alcohol Abuse. 2003;29(4):713-27. Pubmed PMID: 14713135\n",
      "Kosten TR, Rounsaville BJ, Kleber HD \"Predictors of 2.5-year outcome in opioid addicts: pretreatment source of income..\" Am J Drug Alcohol Abuse. 1987;13(41276):19-32. Pubmed PMID: 3687883\n",
      "Dodrill CL, Helmer DA, Kosten TR \"Prescription pain medication dependence..\" Am J Psychiatry. 2011 May;168(5):466-71. Pubmed PMID: 21536702\n",
      "Mooney ME, Poling J, Gonzalez G, Gonsai K, Kosten T, Sofuoglu M \"Preliminary study of buprenorphine and bupropion for opioid-dependent smokers..\" Am J Addict.;17(4):287-92. Pubmed PMID: 18612883\n",
      "O'Brien CP, Charney DS, Lewis L, Cornish JW, Post RM, Woody GE, Zubieta JK, Anthony JC, Blaine JD, Bowden CL, Calabrese JR, Carroll K, Kosten T, Rounsaville B, Childress AR, Oslin DW, Pettinati HM, Davis MA, Demartino R, Drake RE, Fleming MF, Fricks L, Gl \"Priority actions to improve the care of persons with co-occurring substance abuse and other mental disorders: a call to action..\" Biol. Psychiatry. 2004 Nov 15;56(10):703-13. Pubmed PMID: 15556110\n",
      "Zhang XY, Al Jurdi RK, Zoghbi AW, Chen da C, Xiu MH, Tan YL, Yang FD, Kosten TR \"Prevalence, demographic and clinical correlates of suicide attempts in Chinese medicated chronic inpatients with schizophrenia.\" J Psychiatr Res. 2013 Oct; Pubmed PMID: 23791457\n",
      "Ramakrishnan M, Alves De Melo F, Kinsey BM, Ladbury JE, Kosten TR, Orson FM \"Probing cocaine-antibody interactions in buffer and human serum..\" PLoS ONE. 2012;7(7):e40518. Pubmed PMID: 22859949\n",
      "Sofuoglu M, Poling J, Gonzalez G, Gonsai K, Oliveto A, Kosten TR \"Progesterone effects on cocaine use in male cocaine users maintained on methadone: a randomized, double-blind, pilot study..\" Exp Clin Psychopharmacol. 2007 Oct;15(5):453-60. Pubmed PMID: 17924779\n",
      "Schottenfeld RS, Pakes JR, Kosten TR \"Prognostic factors in Buprenorphine- versus methadone-maintained patients..\" J. Nerv. Ment. Dis.. 1998 Jan;186(1):35-43. Pubmed PMID: 9457145\n",
      "Rounsaville BJ, Kosten TR, Weissman MM, Kleber HD \"Prognostic significance of psychopathology in treated opiate addicts. A 2.5-year follow-up study..\" Arch. Gen. Psychiatry. 1986 Aug;43(8):739-45. Pubmed PMID: 3729668\n",
      "Rounsaville BJ, Kosten TR, Weissman MM, Prusoff B, Pauls D, Anton SF, Merikangas K \"Psychiatric disorders in relatives of probands with opiate addiction..\" Arch. Gen. Psychiatry. 1991 Jan;48(1):33-42. Pubmed PMID: 1984760\n",
      "Kosten TR, Jacobs S, Mason J, Wahby V, Atkins S \"Psychological correlates of growth hormone response to stress..\" Psychosom Med.. 1984 Jan; Pubmed PMID: 6701254\n",
      "Brimijoin S, Shen X, Orson F, Kosten T \"Prospects, promise and problems on the road to effective vaccines and related therapies for substance abuse..\" Expert Rev Vaccines. 2013 Mar;12(3):323-32. Pubmed PMID: 23496671\n",
      "Jacobsen LK, Giedd JN, Kreek MJ, Gottschalk C, Kosten TR \"Quantitative medial temporal lobe brain morphology and hypothalamic-pituitary-adrenal axis function in cocaine dependence: a preliminary report..\" Drug Alcohol Depend. 2001 Mar 1;62(1):49-56. Pubmed PMID: 11173167\n",
      "Kosten TR, Rounsaville BJ \"Psychopathology in opioid addicts..\" Psychiatr. Clin. North Am.. 1986 Sep;9(3):515-32. Pubmed PMID: 3774603\n",
      "Jacobsen LK, Giedd JN, Gottschalk C, Kosten TR, Krystal JH \"Quantitative morphology of the caudate and putamen in patients with cocaine dependence..\" Am J Psychiatry. 2001 Mar;158(3):486-9. Pubmed PMID: 11229995\n",
      "Schottenfeld RS, Chawarski MC, Cubells JF, George TP, Lappalainen J, Kosten TR \"Randomized clinical trial of disulfiram for cocaine dependence or abuse during buprenorphine treatment.\" Drug Alcohol Depend. 2014 Mar; Pubmed PMID: 24462581\n",
      "Oliveto A, Poling J, Mancino MJ, Feldman Z, Cubells JF, Pruzinsky R, Gonsai K, Cargile C, Sofuoglu M, Chopra MP, Gonzalez-Haddad G, Carroll KM, Kosten TR \"Randomized, double blind, placebo-controlled trial of disulfiram for the treatment of cocaine dependence in methadone-stabilized patients..\" Drug Alcohol Depend. 2011 Jan; Pubmed PMID: 20828943\n",
      "Kosten TR, Kleber HD \"Rapid death during cocaine abuse: a variant of the neuroleptic malignant syndrome?.\" Am J Drug Alcohol Abuse. 1988;14(3):335-46. Pubmed PMID: 3055940\n",
      "O'Connor PG, Kosten TR \"Rapid and ultrarapid opioid detoxification techniques..\" JAMA. 1998 Jan 21;279(3):229-34. Pubmed PMID: 9438745\n",
      "Kosten TR, Krystal JH, Charney DS, Price LH, Morgan CH, Kleber HD \"Rapid detoxification from opioid dependence..\" Am J Psychiatry. 1989 Oct;146(10):1349. Pubmed PMID: 2675644\n",
      "Li XF, Zheng YL, Xiu MH, Chen da C, Kosten TR, Zhang XY \"Reduced plasma total antioxidant status in first-episode drug-naive patients with schizophrenia..\" Prog. Neuropsychopharmacol. Biol. Psychiatry. 2011 Jun 1;35(4):1064-7. Pubmed PMID: 21392552\n",
      "Chen da C, Xiu MH, Liu H, Zhang BS, Wang Y, Kosten TR, Zhang XY \"Reduced status of plasma total antioxidant capacity in schizophrenia with tardive dyskinesia..\" J Psychiatr Res. 2010 Nov;44(15):1111-2. Pubmed PMID: 20398909\n",
      "Stine SM, Kosten TR \"Reduction of opiate withdrawal-like symptoms by cocaine abuse during methadone and buprenorphine maintenance..\" Am J Drug Alcohol Abuse. 1994 Nov;20(4):445-58. Pubmed PMID: 7832179\n",
      "Kosten TR, Cheeves C, Palumbo J, Seibyl JP, Price LH, Woods SW \"Regional cerebral blood flow during acute and chronic abstinence from combined cocaine-alcohol abuse..\" Drug Alcohol Depend. 1998 May 1;50(3):187-95. Pubmed PMID: 9649971\n",
      "Kosten TR, Rounsaville BJ, Kleber HD \"Relationship of depression to psychosocial stressors in heroin addicts..\" J. Nerv. Ment. Dis.. 1983 Feb;171(2):97-104. Pubmed PMID: 6822825\n",
      "Kosten TR, Rounsaville BJ, Kleber HD \"Relationship of depression to clonidine detoxification of opiate addicts..\" Compr Psychiatry.;25(5):503-8. Pubmed PMID: 6488761\n",
      "Kosten TR, Jalali B, Steidl JH, Kleber HD \"Relationship of marital structure and interactions to opiate abuse relapse..\" Am J Drug Alcohol Abuse. 1987;13(4):387-99. Pubmed PMID: 3687898\n",
      "Rosen MI, McMahon TJ, Margolin A, Gill TS, Woods SW, Pearsall HR, Kreek MJ, Kosten TR \"Reliability of sequential naloxone challenge tests..\" Am J Drug Alcohol Abuse. 1995 Nov;21(4):453-67. Pubmed PMID: 8561097\n",
      "Wisner KL, Conley RR, Taylor SF, Kosten T, Rapaport MH, Brown LS \"Researcher experiences with IRBs: a survey of members of the American College of Neuropsychopharmacology..\" IRB.;33(5):14-20. Pubmed PMID: 22043746\n",
      "Sofuoglu M, Waters AJ, Mooney M, Kosten T \"Riluzole and D-amphetamine interactions in humans.\" Prog Neuropsychopharmacol Biol Psychiatry. 2008 Jan; Pubmed PMID: 17714844\n",
      "Poling J, Kosten TR \"Risperidone for substance dependent psychotic patients.\" 2005;\n",
      "Kosten TR, Kleber HD, Morgan C \"Role of opioid antagonists in treating intravenous cocaine abuse..\" Life Sci.. 1989;44(13):887-92. Pubmed PMID: 2927249\n",
      "Boutros NN, Gelernter J, Gooding DC, Cubells J, Young A, Krystal JH, Kosten T \"Sensory gating and psychosis vulnerability in cocaine-dependent individuals: preliminary data..\" Biol. Psychiatry. 2002 Apr 15;51(8):683-6. Pubmed PMID: 11955469\n",
      "Hirunsatit R, Ilomäki R, Malison R, Räsänen P, Ilomäki E, Kranzler HR, Kosten T, Sughondhabirom A, Thavichachart N, Tangwongchai S, Listman J, Mutirangura A, Gelernter J, Lappalainen J \"Sequence variation and linkage disequilibrium in the GABA transporter-1 gene (SLC6A1) in five populations: implications for pharmacogenetic research.\" BMC Genet. 2007 Oct; Pubmed PMID: 17941974\n",
      "Aronson SC, Black JE, McDougle CJ, Scanley BE, Jatlow P, Kosten TR, Heninger GR, Price LH \"Serotonergic mechanisms of cocaine effects in humans..\" Psychopharmacology (Berl.). 1995 May;119(2):179-85. Pubmed PMID: 7659765\n",
      "Graham DP, Helmer DA, Harding MJ, Kosten TR, Petersen NJ, Nielsen DA \"Serotonin transporter genotype and mild traumatic brain injury independently influence resilience and perception of limitations in veterans..\" J Psychiatr Res. 2013 Jun;47(6):835-42. Pubmed PMID: 23478049\n",
      "Oliveto A, Poling J, Mancino MJ, Williams DK, Thostenson J, Pruzinsky R, Gonsai K, Sofuoglu M, Gonzalez G, Tripathi S, Kosten TR \"Sertraline delays relapse in recently abstinent cocaine-dependent patients with depressive symptoms..\" Addiction. 2012 Jan;107(1):131-41. Pubmed PMID: 21707811\n",
      "Zhang XY, Tan YL, Zhou DF, Cao LY, Wu GY, Xu Q, Shen Y, Haile CN, Kosten TA, Kosten TR \"Serum BDNF levels and weight gain in schizophrenic patients on long-term treatment with antipsychotics..\" J Psychiatr Res. 2007 Dec;41(12):997-1004. Pubmed PMID: 17095017\n",
      "Wahby V, Ibrahim G, Friedenthal S, Giller E, Kosten T, Mason J \"Serum concentrations of circulating thyroid hormones in a group of depressed men.\" Neuropsychobiology. 1989; Pubmed PMID: 2639287\n",
      "Li SX, Li J, Epstein DH, Zhang XY, Kosten TR, Lu L \"Serum cortisol secretion during heroin abstinence is elevated only nocturnally..\" Am J Drug Alcohol Abuse. 2008;34(3):321-8. Pubmed PMID: 18428074\n",
      "Mason JW, Giller EL, Kosten TR \"Serum testosterone differences between patients with schizophrenia and those with affective disorder..\" Biol. Psychiatry. 1988 Feb 15;23(4):357-66. Pubmed PMID: 3342266\n",
      "Mason JW, Giller El, Kosten TR, Wahby VS \"Serum testosterone levels in post traumatic stress disorder inpatients.\" J Traumatic Stress. 1990;\n",
      "Southwick S, Mason JW, Giller EL, Kosten TR \"Serum thyroxine change and clinical recovery in psychiatric inpatients..\" Biol. Psychiatry. 1989 Jan;25(1):67-74. Pubmed PMID: 2912510\n",
      "Zhang XY, Zhang RL, Pan M, Chen da C, Xiu MH, Kosten TR \"Sex difference in the prevalence of smoking in Chinese schizophrenia..\" J Psychiatr Res. 2010 Oct;44(14):986-8. Pubmed PMID: 20334878\n",
      "Mason JW, Kennedy JL, Kosten TR, Giller EL \"Serum thyroxine levels in schizophrenic and affective disorder diagnostic subgroups..\" J. Nerv. Ment. Dis.. 1989 Jun;177(6):351-8. Pubmed PMID: 2723624\n",
      "Yang FD, Wang XQ, Liu XP, Zhao KX, Fu WH, Hao XR, Zhang XL, Huang GS, Qu SC, Bai JS, Huang XF, Kosten TR, Zhang XY \"Sex difference in QTc prolongation in chronic institutionalized patients with schizophrenia on long-term treatment with typical and atypical antipsychotics..\" Psychopharmacology (Berl.). 2011 Jul;216(1):41533. Pubmed PMID: 21301815\n",
      "Kosten TA, Jacobsen LK, Kosten TR \"Severity of precipitated opiate withdrawal predicts drug dependence by DSM-III-R criteria..\" Am J Drug Alcohol Abuse. 1989;15(3):237-50. Pubmed PMID: 2763981\n",
      "Li CS, Kosten TR, Sinha R \"Sex differences in brain activation during stress imagery in abstinent cocaine users: a functional magnetic resonance imaging study..\" Biol. Psychiatry. 2005 Mar 1;57(5):487-94. Pubmed PMID: 15737663\n",
      "Singha AK, McCance-Katz EF, Petrakis I, Kosten TR, Oliveto A \"Sex differences in self-reported and physiological response to oral cocaine and placebo in humans..\" Am J Drug Alcohol Abuse. 2000 Nov;26(4):643-57. Pubmed PMID: 11097197\n",
      "Li YQ, Wang XY, Zhai HF, Zhang XY, Kosten T, Lu L \"Sex- and age-dependent effects of early postnatal sibling deprivation on spatial learning and memory in adult rats..\" Behav Brain Res. 2008 Jan; Pubmed PMID: 17765982\n",
      "Zhang XY, Liu L, Liu S, Hong X, Chen da C, Xiu MH, Yang FD, Zhang Z, Zhang X, Kosten TA, Kosten TR \"Short-term tropisetron treatment and cognitive and p50 auditory gating deficits in schizophrenia..\" Am J Psychiatry. 2012 Sep 1;169(9):974-81. Pubmed PMID: 22952075\n",
      "Farren CK, Hameedi FA, Rosen MA, Woods S, Jatlow P, Kosten TR \"Significant interaction between clozapine and cocaine in cocaine addicts..\" Drug Alcohol Depend. 2000 May 1;59(2):153-63. Pubmed PMID: 10891628\n",
      "102. Kosten TR, Gawin FH, Kosten TA, Morgan C, Rounsaville BJ, Schottenfeld RS, Kleber HD \"Six month follow-up of short term pharmacotherapy for cocaine dependence.\" Am J Addictions. 1992;\n",
      "Satel SL, Kosten TR, Schuckit MA, Fischman MW \"Should protracted withdrawal from drugs be included in DSM-IV?.\" Am J Psychiatry. 1993 May;150(5):695-704. Pubmed PMID: 8097618\n",
      "Poling J, Oliveto A, Petry N, Sofuoglu M, Gonsai K, Gonzalez G, Martell B, Kosten TR \"Six-month trial of bupropion with contingency management for cocaine dependence in a methadone-maintained population..\" Arch. Gen. Psychiatry. 2006 Feb;63(2):219-28. Pubmed PMID: 16461866\n",
      "Zhang XY, Yu YQ, Sun S, Zhang X, Li W, Xiu MH, Chen da C, Yang FD, Zhu F, Kosten TA, Kosten TR \"Smoking and tardive dyskinesia in male patients with chronic schizophrenia..\" Prog. Neuropsychopharmacol. Biol. Psychiatry. 2011 Aug 15;35(7):1765-9. Pubmed PMID: 21723906\n",
      "Kosten TR, Rounsaville BJ \"Source of income as a predictor in opioid addicts: 2.5 year follow-up..\" NIDA Res. Monogr.. 1987;76:196-9. Pubmed PMID: 3125447\n",
      "Zhang XY, Li CB, Li M, Zheng YL, Zhang CX, Yan QZ, Liu WZ, Kang YM, Wang F, Chen da C, Xiu MH, Kosten TR \"Smoking initiation and schizophrenia: a replication study in a Chinese Han population..\" Schizophr. Res.. 2010 Jun;119(41277):110-4. Pubmed PMID: 20022218\n",
      "Zhang XY, Chen da C, Tan YL, Xiu MH, Cui J, Hui L, De Yang F, Kosten TR \"Socio-demographic and clinical characteristics of heavy and non-heavy smokers among schizophrenia inpatients in a Chinese Han population.\" Psychopharmacology (Berl). 2014 Jan; Pubmed PMID: 23963531\n",
      "van Dyck CH, Rosen MI, Thomas HM, McMahon TJ, Wallace EA, O'Connor PG, Sullivan M, Krystal JH, Hoffer PB, Woods SW \"SPECT regional cerebral blood flow alterations in naltrexone-precipitated withdrawal from buprenorphine..\" Psychiatry Res.. 1994 Dec; Pubmed PMID: 7701033\n",
      "Woods SW, O'Malley SS, Martini BL, McDougle CJ, Price LH, Krystal JH, Hoffer PB, Kosten TR \"SPECT regional cerebral blood flow and neuropsychological testing in non-demented HIV-positive drug abusers: preliminary results..\" Prog. Neuropsychopharmacol. Biol. Psychiatry. 1991;15(5):649-62. Pubmed PMID: 1956993\n",
      "Brown AE, Tonigan JS, Pavlik VN, Kosten TR, Volk RJ \"Spirituality and Confidence to Resist Substance Use Among Celebrate Recovery Participants..\" J Relig Health. 2011 Jan 19; Pubmed PMID: 21246280\n",
      "Orson FM, Rossen RD, Shen X, Lopez AY, Wu Y, Kosten TR \"Spontaneous Development of IgM Anti-Cocaine Antibodies in Habitual Cocaine Users: Effect on IgG Antibody Responses to a Cocaine Cholera Toxin B Conjugate Vaccine..\" Am J Addict. 2013 Mar;22(2):169-74. Pubmed PMID: 23414504\n",
      "Zhao LY, Shi J, Zhang XL, Epstein DH, Zhang XY, Liu Y, Kosten TR, Lu L \"Stress enhances retrieval of drug-related memories in abstinent heroin addicts..\" Neuropsychopharmacology. 2010 Feb;35(3):720-6. Pubmed PMID: 19890257\n",
      "Lago JA, Kosten TR \"Stimulant withdrawal..\" Addiction. 1994 Nov;89(11):1477-81. Pubmed PMID: 7841859\n",
      "Kosten TR \"Stress and addiction..\" Am J Psychiatry. 2011 Jun;168(6):566-8. Pubmed PMID: 21642477\n",
      "Kosten TR, Kleber HD \"Strategies to improve compliance with narcotic antagonists..\" Am J Drug Alcohol Abuse. 1984;10(2):249-66. Pubmed PMID: 6475891\n",
      "Lu L, Wang X, Kosten TR \"Stereotactic neurosurgical treatment of drug addiction..\" Am J Drug Alcohol Abuse. 2009;35(6):391-3. Pubmed PMID: 20014906\n",
      "Kosten TR, Ziedonis DM \"Substance abuse and schizophrenia: editors' introduction..\" Schizophr Bull. 1997;23(2):181-6. Pubmed PMID: 9165628\n",
      "Jacobsen LK, Southwick SM, Kosten TR \"Substance use disorders in patients with posttraumatic stress disorder: a review of the literature..\" Am J Psychiatry. 2001 Aug;158(8):1184-90. Pubmed PMID: 11481147\n",
      "Orson FM, Kinsey BM, Singh RA, Wu Y, Gardner T, Kosten TR \"Substance abuse vaccines..\" Ann. N. Y. Acad. Sci.. 2008 Oct;1141:257-69. Pubmed PMID: 18991962\n",
      "Zhang XY, Zhou DF, Qi LY, Chen S, Cao LY, Chen da C, Xiu MH, Wang F, Wu GY, Lu L, Kosten TA, Kosten TR \"Superoxide dismutase and cytokines in chronic patients with schizophrenia: association with psychopathology and response to antipsychotics..\" Psychopharmacology (Berl.). 2009 May;204(1):177-84. Pubmed PMID: 19139851\n",
      "Calhoun P, Najavits LM, Kosten T, Kivlahan D \"Substance Use in OIF/OEF Veterans.\" VA Health Services Research and Development For. 2007;\n",
      "Kosten TR, Rounsaville BJ, Babor TF, Spitzer RL, Williams JB \"Substance-use disorders in DSM-III-R. Evidence for the dependence syndrome across different psychoactive substances..\" Br J Psychiatry. 1987 Dec;151:834-43. Pubmed PMID: 2901887\n",
      "Kosten TR, Rounsaville BJ \"Suicidality among opioid addicts: 2.5 year follow-up..\" Am J Drug Alcohol Abuse. 1988;14(3):357-69. Pubmed PMID: 3189257\n",
      "Rounsaville BJ, Kosten T, Kleber H \"Success and failure at outpatient opioid detoxification. Evaluating the process of clonidine- and methadone-assisted withdrawal..\" J Nerv Ment Dis.. 1985; Pubmed PMID: 3881558\n",
      "Kosten TR, Mason JW, Giller EL, Ostroff RB, Harkness L \"Sustained urinary norepinephrine and epinephrine elevation in post-traumatic stress disorder..\" Psychoneuroendocrinology. 1987;12(1):13-20. Pubmed PMID: 3588809\n",
      "van Dyck CH, McMahon TJ, Rosen MI, O'Malley SS, O'Connor PG, Lin CH, Pearsall HR, Woods SW, Kosten TR \"Sustained-release methylphenidate for cognitive impairment in HIV-1-infected drug abusers: a pilot study..\" J Neuropsychiatry Clin Neurosci. 1997;9(1):29-36. Pubmed PMID: 9017526\n",
      "Martell BA, O'Connor PG, Kerns RD, Becker WC, Morales KH, Kosten TR, Fiellin DA \"Systematic review: opioid treatment for chronic back pain: prevalence, efficacy, and association with addiction..\" Ann. Intern. Med.. 2007 Jan 16;146(2):116-27. Pubmed PMID: 17227935\n",
      "Anton RF, Litten RZ, Falk DE, Palumbo JM, Bartus RT, Robinson RL, Kranzler HR, Kosten TR, Meyer RE, O'Brien CP, Mann K, Meulien D \"The Alcohol Clinical Trials Initiative (ACTIVE): Purpose and Goals for Assessing Important and Salient Issues for Medications Development in Alcohol Use Disorders..\" 2011 Sep 7; Pubmed PMID: 21900883\n",
      "Rounsaville BJ, Kosten TR, Kleber HD \"The antecedents and benefits of achieving abstinence in opioid addicts: a 2.5-year follow-up study..\" Am J Drug Alcohol Abuse. 1987;13(3):213-29. Pubmed PMID: 3687888\n",
      "Wang F, Xiu MH, Zhou DF, Cao LY, Wu GY, Kosten TA, Kosten TR, Zhang XY \"The CCR5 32-bp deletion allele is rare in a Chinese population..\" Schizophr. Res.. 2008 Apr;101(41277):341-3. Pubmed PMID: 18295459\n",
      "Gao Y, Orson FM, Kinsey B, Kosten T, Brimijoin S \"The concept of pharmacologic cocaine interception as a treatment for drug abuse..\" Chem. Biol. Interact.. 2010 Sep 6;187(41277):421-4. Pubmed PMID: 20219449\n",
      "Kosten TR, Rounsaville BJ, Babor TF, Spitzer RL, Williams JB \"The dependence syndrome across different psychoactive substances: revised DSM-III..\" NIDA Res. Monogr.. 1987;76:255-8. Pubmed PMID: 3125454\n",
      "Kosten TA, Kosten TR \"The dependence syndrome concept as applied to alcohol and other substances of abuse..\" Recent Dev Alcohol. 1990;8:47-68. Pubmed PMID: 2185524\n",
      "Kosten TR, Wahby V, Giller E, Mason J \"The dexamethasone suppression test and thyrotropin-releasing hormone stimulation test in posttraumatic stress disorder..\" Biol. Psychiatry. 1990 Oct 15;28(8):657-64. Pubmed PMID: 2122916\n",
      "Kosten TR, Jacobs S, Mason JW \"The dexamethasone suppression test during bereavement.\" J Nerv Ment Dis.. 1984 Jun; Pubmed PMID: 6544808\n",
      "Abi-Saab D, Beauvais J, Mehm J, Brody M, Gottschalk C, Kosten TR \"The effect of alcohol on the neuropsychological functioning of recently abstinent cocaine-dependent subjects..\" Am J Addict.;14(2):166-78. Pubmed PMID: 16019965\n",
      "Hui L, Zhang X, Huang XF, Han M, Fernandez F, Yu Y, Sun S, Li W, Chen da C, Xiu MH, Kosten TR, Zhang XY \"The dopamine b-hydroxylase 19 bp insertion/deletion polymorphism was associated with first-episode but not medicated chronic schizophrenia..\" J Psychiatr Res. 2012 Jun;46(6):733-7. Pubmed PMID: 22445279\n",
      "Rosen MI, Pearsall HR, Woods SW, Kosten TR \"The effect of gamma-hydroxybutyric acid on naloxone-precipitated opiate withdrawal..\" Neuropsychopharmacology. 1996 Mar;14(3):187-93. Pubmed PMID: 8866702\n",
      "Rosen MI, Pearsall HR, Kosten TR \"The effect of lamotrigine on naloxone-precipitated opiate withdrawal..\" Drug Alcohol Depend. 1998 Oct 1;52(2):173-6. Pubmed PMID: 9800147\n",
      "Stine SM, Freeman M, Burns B, Charney DS, Kosten TR \"The effect of methadone dose on cocaine abuse in a methadone program.\" Am J Addictions. 1992;\n",
      "Kosten TR, Hogan I, Jalali B, Steidl J, Kleber HD \"The effect of multiple family therapy on addict family functioning: a pilot study..\" Adv Alcohol Subst Abuse. 1986;5(3):51-62. Pubmed PMID: 3728193\n",
      "Rosen MI, Kosten TR, Kreek MJ \"The effects of naltrexone maintenance on the response to yohimbine in healthy volunteers..\" Biol. Psychiatry. 1999 Jun 15;45(12):1636-45. Pubmed PMID: 10376126\n",
      "Orson FM, Wang R, Brimijoin S, Kinsey BM, Singh RA, Ramakrishnan M, Wang HY, Kosten TR \"The future potential for cocaine vaccines..\" Expert Opin Biol Ther. 2014; Pubmed PMID: 24835496\n",
      "Orson FM, Kinsey BM, Singh RA, Wu Y, Gardner T, Kosten TR \"The future of vaccines in the management of addictive disorders..\" Curr Psychiatry Rep. 2007 Oct;9(5):381-7. Pubmed PMID: 17915077\n",
      "Haile CN, De La Garza R, Mahoney JJ, Nielsen DA, Kosten TR, Newton TF \"The impact of disulfiram treatment on the reinforcing effects of cocaine: a randomized clinical trial..\" PLoS ONE. 2012;7(11):e47702. Pubmed PMID: 23144826\n",
      "Liu S, Green CE, Lane SD, Kosten TR, Moeller FG, Nielsen DA, Schmitz JM \"The influence of dopamine β-hydroxylase gene polymorphism rs1611115 on levodopa/carbidopa treatment for cocaine dependence: a preliminary study.\" Pharmacogenet Genomics. 2014 Jul; Pubmed PMID: 24809448\n",
      "112. Sun H, Wang F, Fan H, Yan Q, Cui K, Yuan W, Zhao F, Zhao L, Yuan J, Yang F, Kosten TR, Zhang XY \"The interaction of polymorphisms of IL10 and DBH was associated with general symptoms of PANSS with TD in Chinese Han schizophrenic patients.\" PLoS One. 2013 Aug; Pubmed PMID: 23951054\n",
      "Kosten TR, Gorelick DA \"The Lexington narcotic farm..\" Am J Psychiatry. 2002 Jan;159(1):22. Pubmed PMID: 11772684\n",
      "Jacobs SC, Kasl SV, Ostfeld AM, Berkman L, Kosten TR, Charpentier P \"The measurement of grief: bereaved versus non-bereaved.\" Hosp J.. 1986; Pubmed PMID: 3647919\n",
      "Spellicy CJ, Kosten TR, Hamon SC, Harding MJ, Nielsen DA \"The MTHFR C677T Variant is Associated with Responsiveness to Disulfiram Treatment for Cocaine Dependency..\" Front Psychiatry. 2012;3:109. Pubmed PMID: 23335901\n",
      "Kosten TR, George TP \"The neurobiology of opioid dependence: implications for treatment..\" 2002 Jul;1(1):13-20. Pubmed PMID: 18567959\n",
      "Zhang XY, Chen da C, Xiu MH, Wang F, Qi LY, Sun HQ, Chen S, He SC, Wu GY, Haile CN, Kosten TA, Lu L, Kosten TR \"The novel oxidative stress marker thioredoxin is increased in first-episode schizophrenic patients..\" Schizophr. Res.. 2009 Sep;113(41308):151-7. Pubmed PMID: 19540723\n",
      "Kosten TA, Bianchi MS, Kosten TR \"The predictive validity of the dependence syndrome in opiate abusers..\" Am J Drug Alcohol Abuse. 1992;18(2):145-56. Pubmed PMID: 1562012\n",
      "Kosten TR, George TP, Kosten TA \"The potential of dopamine agonists in drug addiction..\" Expert Opin Investig Drugs. 2002 Apr;11(4):491-9. Pubmed PMID: 11922858\n",
      "Rao S, Ziedonis DM, Kosten TR \"The pharmacotherapy of cocaine dependence.\" Psychiatric Annals. 1995;\n",
      "Haile CN, Kosten TR \"The potential of pharmacogenomics to treat drug addiction..\" Pharmacogenomics. 2009 Dec;10(12):1883-6. Pubmed PMID: 19958085\n",
      "Zhang R, Hao W, Pan M, Wang C, Zhang X, Chen DC, Xiu MH, De Yang F, Kosten TR, Zhang XY \"The prevalence and clinical-demographic correlates of diabetes mellitus in chronic schizophrenic patients receiving clozapine..\" Hum Psychopharmacol. 2011 Aug 8; Pubmed PMID: 21826737\n",
      "Kosten TR \"The pharmacotherapy of relapse prevention using anticonvulsants..\" Am J Addict. 1998;7(3):205-9. Pubmed PMID: 9702288\n",
      "Kosten TR, Rounsaville BJ, Merikangas KR, Prusoff BA, Kleber HD \"The relationship of the Maudsley Personality Inventory to depression in addicts..\" Compr Psychiatry.;24(6):535-42. Pubmed PMID: 6653096\n",
      "McCance EF, Kosten TR \"The role of the human laboratory in drug abuse research. Psychiatric Annals.\" Psychiatric Annals. 1995;\n",
      "Zhang X, Hui L, Liu Y, Wang ZQ, You Y, Miao LN, Sun SL, Guan SL, Xiang Y, Kosten TR, Zhang XY \"The type 2 diabetes mellitus susceptibility gene IGF2BP2 is associated with schizophrenia in a Han Chinese population..\" J Clin Psychiatry. 2013 Apr;74(4):e287-92. Pubmed PMID: 23656854\n",
      "Mason JW, Kosten TR, Southwick SM, Giller EL. \"The use of hormonal profile strategies in post-traumatic stress disorder.\" J Applied Social Psychology. 1990;\n",
      "Kosten TR, Bryant K, Rounsaville BJ \"The SCID: a clinical instrument for assessing psychiatric disorders..\" NIDA Res. Monogr.. 1990;105:213-9. Pubmed PMID: 1876002\n",
      "Zhou DH, Yan QZ, Yan XM, Li CB, Fang H, Zheng YL, Zhang CX, Yao HJ, Chen da C, Xiu MH, Kosten TR, Zhang XY \"The study of BDNF Val66Met polymorphism in Chinese schizophrenic patients..\" Prog. Neuropsychopharmacol. Biol. Psychiatry. 2010 Aug 16;34(6):930-3. Pubmed PMID: 20420877\n",
      "Rohrbaugh RM, Felker B, Kosten T \"The VA psychiatry-primary care education initiative..\" Acad Psychiatry. 2009 Jan; Pubmed PMID: 19349441\n",
      "Wang Y, Wang JD, Wu HR, Zhang BS, Fang H, Ma QM, Liu H, Chen da C, Xiu MH, Hail CN, Kosten TR, Zhang XY \"The Val66Met polymorphism of the brain-derived neurotrophic factor gene is not associated with risk for schizophrenia and tardive dyskinesia in Han Chinese population..\" Schizophr. Res.. 2010 Jul;120(41277):240-2. Pubmed PMID: 20395113\n",
      "Nielsen DA, Hamon SC, Kosten TR \"The κ-opioid receptor gene as a predictor of response in a cocaine vaccine clinical trial.\" Psychiatr Genet. 2013 Dec; Pubmed PMID: 23995774\n",
      "Gardner TJ, Kosten TR \"Therapeutic options and challenges for substances of abuse..\" 2007;9(4):431-45. Pubmed PMID: 18286802\n",
      "Haney M, Kosten TR \"Therapeutic vaccines for substance dependence..\" Expert Rev Vaccines. 2004 Feb;3(1):41586. Pubmed PMID: 14761239\n",
      "Kosten TR, Biegel D \"Therapeutic vaccines for substance dependence..\" Expert Rev Vaccines. 2002 Oct;1(3):363-71. Pubmed PMID: 12901575\n",
      "Zhang XY, Chen da C, Xiu MH, Yang FD, Tan YL, He S, Kosten TA, Kosten TR \"Thioredoxin, a novel oxidative stress marker and cognitive performance in chronic and medicated schizophrenia versus healthy controls..\" Schizophr. Res.. 2013 Feb;143(41308):301-6. Pubmed PMID: 23238053\n",
      "O'Connor PG, Carroll KM, Shi JM, Schottenfeld RS, Kosten TR, Rounsaville BJ \"Three methods of opioid detoxification in a primary care setting. A randomized trial..\" Ann. Intern. Med.. 1997 Oct 1;127(7):526-30. Pubmed PMID: 9313020\n",
      "Schottenfeld RS, Pakes J, O'Connor P, Chawarski M, Oliveto A, Kosten TR \"Thrice-weekly versus daily buprenorphine maintenance..\" Biol. Psychiatry. 2000 Jun 15;47(12):1072-9. Pubmed PMID: 10862807\n",
      "Sofuoglu M, Poling J, Mitchell E, Kosten TR \"Tiagabine affects the subjective responses to cocaine in humans..\" Pharmacol. Biochem. Behav.. 2005 Nov;82(3):569-73. Pubmed PMID: 16332385\n",
      "Gonzalez G, Sevarino K, Sofuoglu M, Poling J, Oliveto A, Gonsai K, George TP, Kosten TR \"Tiagabine increases cocaine-free urines in cocaine-dependent methadone-treated patients: results of a randomized pilot study..\" Addiction. 2003 Nov;98(11):1625-32. Pubmed PMID: 14616189\n",
      "Shi J, Li SX, Zhang XL, Wang X, Le Foll B, Zhang XY, Kosten TR, Lu L \"Time-Dependent Neuroendocrine Alterations and Drug Craving during the First Month of Abstinence in Heroin Addicts..\" Am J Drug Alcohol Abuse. 2009;35(5):267-72. Pubmed PMID: 19591065\n",
      "Lu L, Liu Y, Zhu W, Shi J, Liu Y, Ling W, Kosten TR \"Traditional medicine in the treatment of drug addiction..\" Am J Drug Alcohol Abuse. 2009;35(1):41285. Pubmed PMID: 19152199\n",
      "Rounsaville BJ, Kosten TR \"Treatment for opioid dependence: quality and access..\" JAMA. 2000 Mar; Pubmed PMID: 10714736\n",
      "Kosten TR, Kleber HD, Morgan C \"Treatment of cocaine abuse with buprenorphine.\" Biol Psychiatry. 1989 Oct; Pubmed PMID: 2790101\n",
      "Nigam R, Schottenfeld R, Kosten TR \"Treatment of dual diagnosis patients: a relapse prevention group approach..\" J Subst Abuse Treat. 1992;9(4):305-9. Pubmed PMID: 1362227\n",
      "Kosten TR, Rosen MI, McMahon TL, Bridge TP, O'Malley SS, Pearsall R, O'Connor PG \"Treatment of early AIDS dementia in intravenous drug users: high versus low dose peptide T..\" Am J Drug Alcohol Abuse. 1997 Nov;23(4):543-53. Pubmed PMID: 9366972\n",
      "Gonzalez G, Oliveto A, Kosten TR \"Treatment of heroin (diamorphine) addiction: current approaches and future prospects..\" Drugs. 2002;62(9):1331-43. Pubmed PMID: 12076182\n",
      "Kosten TR, Morgan C, Kleber HD \"Treatment of heroin addicts using buprenorphine..\" Am J Drug Alcohol Abuse. 1991 Jun;17(2):119-28. Pubmed PMID: 1862786\n",
      "\"Treatment of patients with substance use disorders, second edition. American Psychiatic Association..\" Am J Addictions. 2006 Oct; Pubmed PMID: 16981488\n",
      "Kleber HD, Weiss RD, Anton RF, George TP, Greenfield SF, Kosten TR, O'Brien CP, Rounsaville BJ, Strain EC, Ziedonis DM, Hennessy G, Connery HS, McIntyre JS, Charles SC, Anzia DJ, Cook IA, Finnerty MT, Johnson BR, Nininger JE, Summergrad P, Woods SM, Yager \"Treatment of patients with substance use disorders, second edition. American Psychiatric Association..\" Am J Psychiatry. 2007 Apr;164(4):5-123. Pubmed PMID: 17569411\n",
      "Kosten TR, Forrest JN \"Treatment of severe lithium-induced polyuria with amiloride..\" Am J Psychiatry. 1986 Dec;143(12):1563-8. Pubmed PMID: 3538913\n",
      "Poling J, Kosten TR, Sofuoglu M \"Treatment outcome predictors for cocaine dependence..\" Am J Drug Alcohol Abuse. 2007;33(2):191-206. Pubmed PMID: 17497542\n",
      "Satel SL, Krystal JH, Delgado PL, Kosten TR, Charney DS \"Tryptophan depletion and attenuation of cue-induced craving for cocaine..\" Am J Psychiatry. 1995 May;152(5):778-83. Pubmed PMID: 7726319\n",
      "Kosten TR, McCance E \"Una revision de tratamientos farmacologicos para el abuso de substancias.\" Revista de Toxicomanias. 1997;\n",
      "Kosten TR \"Update on addiction medicine in the State of Connecticut.\" Connecticut Medicine. 1999;\n",
      "Jacobs SC, Mason J, Kosten TR, Kasl SV, Ostfeld AM, Wahby V \"Urinary free cortisol and separation anxiety early in the course of bereavement and threatened loss..\" Biol. Psychiatry. 1987 Feb;22(2):148-52. Pubmed PMID: 3814667\n",
      "Mason JW, Giller EL, Kosten TR, Ostroff RB, Podd L \"Urinary free-cortisol levels in posttraumatic stress disorder patients..\" J. Nerv. Ment. Dis.. 1986 Mar;174(3):145-9. Pubmed PMID: 3950596\n",
      "Druss BG, Rohrbaugh R, Kosten T, Hoff R, Rosenheck RA \"Use of alternative medicine in major depression.\" Psychiatr Serv.. 1998 Nov; Pubmed PMID: 9826237\n",
      "Stine SM, Kosten TR \"Use of drug combinations in treatment of opioid withdrawal..\" J Clin Psychopharmacol. 1992 Jun;12(3):203-9. Pubmed PMID: 1629388\n",
      "Jacobs S, Mason J, Kosten T, Brown S, Ostfeld A \"Urinary-free cortisol excretion in relation to age in acutely stressed persons with depressive symptoms.\" Psychosom Med. 1984 May; Pubmed PMID: 6739681\n",
      "Kosten TR, Domingo CB, Shorter D, Orson F, Green C, Somoza E, Sekerka R, Levin FR, Mariani JJ, Stitzer M, Tompkins DA, Rotrosen J, Thakkar V, Smoak B, Kampman K \"Vaccine for cocaine dependence: a randomized double-blind placebo-controlled efficacy trial..\" Drug Alcohol Depend. 2014 Jul; Pubmed PMID: 24793366\n",
      "Feingold A, Oliveto A, Schottenfeld R, Kosten TR \"Utility of crossover designs in clinical trials: efficacy of desipramine vs. placebo in opioid-dependent cocaine abusers..\" Am J Addict. 2002;11(2):111-23. Pubmed PMID: 12028741\n",
      "Martell BA, Mitchell E, Poling J, Gonsai K, Kosten TR \"Vaccine pharmacotherapy for the treatment of cocaine dependence..\" Biol. Psychiatry. 2005 Jul 15;58(2):158-64. Pubmed PMID: 16038686\n",
      "Shen XY, Orson FM, Kosten TR \"Vaccines Against Drug Abuse..\" Clin. Pharmacol. Ther.. 2011 Nov 30; Pubmed PMID: 22130115\n",
      "Kosten T, Domingo C, Orson F, Kinsey B \"Vaccines against stimulants: cocaine and MA.\" Br J Clin Pharmacol.. 2014 Feb; Pubmed PMID: 23509915\n",
      "Orson FM, Kinsey BM, Singh RA, Wu Y, Kosten TR \"Vaccines for cocaine abuse..\" 2009 Apr;5(4):194-9. Pubmed PMID: 19276665\n",
      "Shorter D, Kosten TR \"Vaccines in the Treatment of Substance Abuse.\" Focus (Am Psychiatr Publ).. 2011 Dec; Pubmed PMID: 23472050\n",
      "Kosten TR \"What are America's opportunities for harm reduction strategies in opiate dependence?.\" Am J Addict.;14(4):307-10. Pubmed PMID: 16188710\n",
      "Stine SM, Southwick SM, Petrakis IL, Kosten TR, Charney DS, Krystal JH \"Yohimbine-induced withdrawal and anxiety symptoms in opioid-dependent patients..\" Biol. Psychiatry. 2002 Apr 15;51(8):642-51. Pubmed PMID: 11955464\n",
      "Avants SK, Margolin A, Kosten TR, Rounsaville BJ, Schottenfeld RS \"When is less treatment better? The role of social anxiety in matching methadone patients to psychosocial treatments..\" J Consult Clin Psychol. 1998 Dec;66(6):924-31. Pubmed PMID: 9874905\n",
      "\n",
      "    ---------\n",
      "\n",
      "real_query:\n",
      "    Notice: If doctor or hospital not in the context, skip this one 假如你是数据工程师，请把如下个人信息按照JSON的格式整理给我：（参考字段：行医，门诊时间，综合评价，资质认证状态，基本信息，简介，姓名，医院/机构，专长，职务，职称，学术兼职，地区，邮箱，手机，昕康ID/XK_ID，履历，教育经历，工作经历，研究，研究方向/临床研究，课题/基金，发表，发表文章，出版著作，专利和软著，执笔共识，成就，荣誉获奖）Return only the translation and nothing else:\n",
      "\n",
      "    query:\n",
      "    请根据以下context，回答：托马斯医生的专长\n",
      "    reply in 简体中文\n",
      "    ---------context\n",
      "    \n",
      "Thomas Kosten, M.D.\n",
      "Jay H. Waggoner Endowed Chair\n",
      "713-794-7032\n",
      "Email\n",
      "kosten@bcm.edu\n",
      "Positions\n",
      "Jay H. Waggoner Endowed Chair\n",
      "Baylor College of Medicine\n",
      "Vice-Chair\n",
      "Psychiatry for Research\n",
      "Baylor College of Medicine\n",
      "Director\n",
      "Division of Alcohol and Addiction Psychiatry\n",
      "Baylor College of Medicine\n",
      "Co-Director\n",
      "Institute for Clinical and Translational Research\n",
      "Baylor College of Medicine\n",
      "Professor\n",
      "Psychiatry\n",
      "Baylor College of Medicine\n",
      "Houston, Texas US\n",
      "Professor\n",
      "Neuroscience\n",
      "Baylor College of Medicine\n",
      "Houston, Texas United States\n",
      "Professor\n",
      "Pharmacology\n",
      "Baylor College of Medicine\n",
      "Houston, Texas United States\n",
      "Professor\n",
      "Immunology and Rheumatology\n",
      "Baylor College of Medicine\n",
      "Houston, TX United States\n",
      "Member\n",
      "Dan L Duncan Comprehensive Cancer Center\n",
      "Baylor College of Medicine\n",
      "Houston, Texas United States\n",
      "Education\n",
      "MA from Yale University\n",
      "01/1995 - New Haven, Connecticut United States\n",
      "Clinical Fellowship at Yale University School of Medicine\n",
      "01/1983 - New Haven, Connecticut United States\n",
      "M.D. from Cornell University Medical College\n",
      "01/1977 - New York, NY United States\n",
      "BS from Rensselaer Polytechnic Institute\n",
      "01/1973 - Troy, New York United States\n",
      "Residency at Yale University School of Medicine\n",
      "01/1981 - New Haven, Connecticut United States\n",
      "Internship at Greenwich Hospital\n",
      "01/1978 - Greenwich, Connecticut United States\n",
      "Certifications\n",
      "Psychiatry/Addictions\n",
      "ABPN\n",
      "Professional Interests\n",
      "Developing medications and vaccines for addictions\n",
      "Pharmacology\n",
      "Websites\n",
      "VIICTR Publications List\n",
      "Selected Publications\n",
      "Malison RT, McCance E, Carpenter LL, Baldwin RM, Seibyl JP, Price LH, Kosten TR, Innis RB \"[123I]beta-CIT SPECT imaging of dopamine transporter availability after mazindol administration in human cocaine addicts..\" Psychopharmacology (Berl.). 1998 Jun;137(4):321-5. Pubmed PMID: 9676890\n",
      "Kosten TR, Rounsaville BJ, Kleber HD \"A 2.5-year follow-up of cocaine use among treated opioid addicts. Have our treatments helped?.\" Arch. Gen. Psychiatry. 1987 Mar;44(3):281-4. Pubmed PMID: 3827521\n",
      "Kosten TR, Rounsaville BJ, Kleber HD \"A 2.5 year follow-up of treatment retention and reentry among opioid addicts..\" J Subst Abuse Treat. 1986;3(3):181-9. Pubmed PMID: 3806731\n",
      "Kosten TR, Rounsaville BJ, Kleber HD \"A 2.5-year follow-up of depression, life crises, and treatment effects on abstinence among opioid addicts..\" Arch Gen Psychiatry. 1986 Aug;733-8. Pubmed PMID: 3729667\n",
      "Rounsaville BJ, Kosten TR, Weissmann MM, Kleber HD \"A 2.5-year follow-up of short-term interpersonal psychotherapy in methadone-maintained opiate addicts..\" Compr Psychiatry.;27(3):201-10. Pubmed PMID: 3709134\n",
      "Avants SK, Margolin A, DePhilippis D, Kosten TR \"A comprehensive pharmacologic-psychosocial treatment program for HIV-seropositive cocaine- and opioid-dependent patients. Preliminary findings..\" J Subst Abuse Treat.;15(3):261-5. Pubmed PMID: 9633038\n",
      "Rounsaville BJ, Kosten TR, Williams JB, Spitzer RL \"A field trial of DSM-III-R psychoactive substance dependence disorders..\" Am J Psychiatry. 1987 Mar;144(3):351-5. Pubmed PMID: 3826436\n",
      "Kosten TR, Steinberg M, Diakogiannis I A \"A cross-over trail of mazindol for cocaine dependence.\" Am J Addictions. 1993;161-164.\n",
      "Kosten TA, Shen XY, O'Malley PW, Kinsey BM, Lykissa ED, Orson FM, Kosten TR \"A morphine conjugate vaccine attenuates the behavioral effects of morphine in rats..\" Prog Neuropsychopharmacol Biol Psychiatry. 2013 Aug 1;223-9. Pubmed PMID: 23739535\n",
      "Margolin A, Kosten TR, Avants SK, Wilkins J, Ling W, Beckson M, Arndt IO, Cornish J, Ascher JA, Li SH \"A multicenter trial of bupropion for cocaine dependence in methadone-maintained patients..\" Drug Alcohol Depend. 1995 Dec;40(2):125-31. Pubmed PMID: 8745134\n",
      "Najavits LM, Kivlahan D, Kosten T \"A national survey of clinicians’ views of evidence-based therapies for PTSD and substance abuse.\" 2011;138-147.\n",
      "Rosen MI, McMahon TJ, Woods SW, Pearsall HR, Kosten TR \"A pilot study of dextromethorphan in naloxone-precipitated opiate withdrawal..\" Eur. J. Pharmacol.. 1996 Jul 4;307(3):251-7. Pubmed PMID: 8836612\n",
      "O'Connor PG, Oliveto AH, Shi JM, Triffleman E, Carroll KM, Kosten TR, Rounsaville BJ \"A pilot study of primary-care-based buprenorphine maintenance for heroin dependence..\" Am J Drug Alcohol Abuse. 1996 Nov;22(4):523-31. Pubmed PMID: 8911590\n",
      "George TP, Vessicchio JC, Termine A, Bregartner TA, Feingold A, Rounsaville BJ, Kosten TR \"A placebo controlled trial of bupropion for smoking cessation in schizophrenia.\" Biol Psychiatry. 2002 Jul 1;53-61. Pubmed PMID: 12079730\n",
      "Margolin A, Avants SK, DePhilippis D, Kosten TR \"A preliminary investigation of lamotrigine for cocaine abuse in HIV-seropositive patients..\" Am J Drug Alcohol Abuse. 1998 Feb;24(1):85-101. Pubmed PMID: 9513631\n",
      "George TP, Vessicchio JC, Termine A, Jatlow PI, Kosten TR, O'Malley SS \"A preliminary placebo-controlled trial of selegiline hydrochloride for smoking cessation..\" Biol. Psychiatry. 2003 Jan 15;53(2):136-43. Pubmed PMID: 12547469\n",
      "Kosten TR, Kreek MJ, Ragunath J, Kleber HD \"A preliminary study of beta endorphin during chronic naltrexone maintenance treatment in ex-opiate addicts..\" Life Sci.. 1986 Jul 7;39(1):55-9. Pubmed PMID: 2941636\n",
      "Kosten TR, Schumann B, Wright D, Carney MK, Gawin FH \"A preliminary study of desipramine in the treatment of cocaine abuse in methadone maintenance patients..\" J Clin Psychiatry. 1987 Nov;48(11):442-4. Pubmed PMID: 3680185\n",
      "Frank JB, Kosten TR, Giller EL, Dan E \"A randomized clinical trial of phenelzine and imipramine for posttraumatic stress disorder..\" Am J Psychiatry. 1988 Oct;145(10):1289-91. Pubmed PMID: 3048121\n",
      "Avants SK, Margolin A, Holford TR, Kosten TR \"A randomized controlled trial of auricular acupuncture for cocaine dependence..\" Arch. Intern. Med..;160(15):2305-12. Pubmed PMID: 10927727\n",
      "O'Connor PG, Oliveto AH, Shi JM, Triffleman EG, Carroll KM, Kosten TR, Rounsaville BJ, Pakes JA, Schottenfeld RS \"A randomized trial of buprenorphine maintenance for heroin dependence in a primary care clinic for substance users versus a methadone clinic..\" Am. J. Med.. 1998 Aug;105(2):100-5. Pubmed PMID: 9727815\n",
      "Kosten TR, McCance E \"A review of pharmacotherapies for substance abuse.\" The American Journal on Addictions. 1996;58-59.\n",
      "Shen XY, Kosten TA, Lopez AY, Kinsey BM, Kosten TR, Orson FM \"A vaccine against methamphetamine attenuates its behavioral effects in mice..\" Drug Alcohol Depend. 2013 Apr 1;129(41276):41-8. Pubmed PMID: 23022610\n",
      "Margolin A, Avants SK, Chang P, Birch S, Kosten TR \"A single-blind investigation of four auricular needle puncture configurations..\" Am. J. Chin. Med.. 1995;23(2):105-14. Pubmed PMID: 7572770\n",
      "Margolin A, Avants SK, Kosten TR \"Abstinence symptomatology associated with cessation of chronic cocaine abuse among methadone-maintained patients..\" Am J Drug Alcohol Abuse. 1996 Aug;22(3):377-88. Pubmed PMID: 8841686\n",
      "Kosten TR, Gawin FH, Rounsaville BJ, Kleber HD \"Abuse of cocaine with opioids: psychological aspects of treatment..\" NIDA Res. Monogr.. 1986;67:278-82. Pubmed PMID: 3092078\n",
      "Kinsey BM, Kosten TR, Orson FM \"Active immunotherapy for the Treatment of Cocaine Dependence..\" 2010 Apr 1;35(4):301-306. Pubmed PMID: 21796226\n",
      "Avants SK, Margolin A, Chang P, Kosten TR, Birch S \"Acupuncture for the treatment of cocaine addiction. Investigation of a needle puncture control..\" J Subst Abuse Treat.;12(3):195-205. Pubmed PMID: 7474027\n",
      "Jacobs S, Mason J, Kosten T, Kasl S, Ostfeld A, Atkins S, Gardner C, Schreiber S \"Acute bereavement, threatened loss, ego defenses and adrenocortical function.\" Psychother Psychosom. 1985;151-9. Pubmed PMID: 3832148\n",
      "Kosten TR \"Addiction as a brain disease..\" Am J Psychiatry. 1998 Jun;155(6):711-3. Pubmed PMID: 9619141\n",
      "Wallace EA, Wisniewski G, Zubal G, vanDyck CH, Pfau SE, Smith EO, Rosen MI, Sullivan MC, Woods SW, Kosten TR \"Acute cocaine effects on absolute cerebral blood flow..\" Psychopharmacology (Berl.). 1996 Nov;128(1):17-20. Pubmed PMID: 8944401\n",
      "Ziedonis D, Richardson T, Lee E, Petrakis I, Kosten T \"Adjunctive desipramine in the treatment of cocaine abusing schizophrenics.\" Psychopharmacol Bull. 1992;309-14. Pubmed PMID: 1480735\n",
      "Kosten TR \"Advances in clinical research on drug addiction: Opioids and cocaine.\" Substance Abuse. 1989;35-42.\n",
      "Sofuoglu M, Mouratidis M, Yoo S, Kosten T \"Adrenergic blocker carvedilol attenuates the cardiovascular and aversive effects of nicotine in abstinent smokers..\" Behav Pharmacol. 2006 Dec 17;731-5. Pubmed PMID: 17110799\n",
      "Ziedonis DM, Kosten TR \"Aggiornamento: Dipendenza da nicotina e schizofrenia.\" 1996;44-47.\n",
      "Kosten TR \"Advances in pharmacotherapy of stimulant dependence: From alcohol antagonists to Xenova vaccines.\" Clinical Neuroscience Research. 2005;169-173.\n",
      "Closser MH, Kosten TR \"Alcohol and cocaine abuse. A comparison of epidemiology and clinical characteristics..\" Recent Dev Alcohol. 1992;10:115-28. Pubmed PMID: 1317046\n",
      "Kosten TR, Kosten TA, Rounsaville BJ \"Alcoholism and depressive disorders in opioid addicts and their family members..\" Compr Psychiatry.;32(6):521-7. Pubmed PMID: 1778079\n",
      "13. Kosten TR, Krystal JH, Giller EL, Frank J, Dan E. \"Alexithymia as a predictor of treatment response in posttraumatic stress disorder.\" J Traumatic Stress. 1992;41-51.\n",
      "Cui Y, Versace F, Engelmann JM, Minnix JA, Robinson JD, Lam CY, Karam-Hage M, Brown VL, Wetter DW, Dani JA, Kosten TR, Cinciripini PM \"Alpha oscillations in response to affective and cigarette-related stimuli in smokers..\" Nicotine Tob. Res.. 2013 May;15(5):917-24. Pubmed PMID: 23060019\n",
      "Sellers EM, Ciraulo DA, DuPont RL, Griffiths RR, Kosten TR, Romach MK, Woody GE \"Alprazolam and benzodiazepine dependence..\" J Clin Psychiatry. 1993 Oct;54:64-75; discussi. Pubmed PMID: 8262891\n",
      "Xiu MH, Chen S, Wang F, Cao LY, Qi LY, Chen da C, Wu GY, Lu L, Kosten TA, Kosten TR, Zhang XY \"Altered interleukin-3 serum levels in drug-naïve and neuroleptic-treated schizophrenic patients..\" Schizophr. Res.. 2008 Dec;106(41308):369-70. Pubmed PMID: 18838250\n",
      "Petrakis IL, Satel SL, Stine S, Kosten TR, Normanworth SN, Charney DS, Krystal JH \"AMPT effects on cue-induced craving for cocaine.\" The American Journal of Addictions. 1996;313-320.\n",
      "Kosten TA, Kosten TR, Gawin FH, Gordon LT, Hogan I, Kleber HD \"An open trial of sertraline for cocaine abuse.\" Am J Addictions. 1992;349-353.\n",
      "Spellicy CJ, Kosten TR, Hamon SC, Harding MJ, Nielsen DA \"ANKK1 and DRD2 pharmacogenetics of disulfiram treatment for cocaine abuse..\" Pharmacogenet. Genomics. 2013 Jul;23(7):333-40. Pubmed PMID: 23635803\n",
      "Kosten TR, Rounsaville BJ, Kleber HD \"Antecedents and consequences of cocaine abuse among opioid addicts. A 2.5-year follow-up..\" J. Nerv. Ment. Dis.. 1988 Mar;176(3):176-81. Pubmed PMID: 3343591\n",
      "Shen X, Orson FM, Kosten TR \"Anti-addiction vaccines..\" F1000 Med Rep. 2011;3:20. Pubmed PMID: 22003367\n",
      "Brimijoin S, Orson F, Kosten TR, Kinsey B, Shen XY, White SJ, Gao Y \"Anti-cocaine antibody and butyrylcholinesterase-derived cocaine hydrolase exert cooperative effects on cocaine pharmacokinetics and cocaine-induced locomotor activity in mice..\" Chem. Biol. Interact.. 2013 Mar 25;203(1):212-6. Pubmed PMID: 22960160\n",
      "Leal J, Ziedonis D, Kosten T \"Antisocial personality disorder as a prognostic factor for pharmacotherapy of cocaine dependence.\" Drug Alcohol Depend. 1994 Mar;31-5. Pubmed PMID: 8082553\n",
      "Kinsey BM, Kosten TR, Orson FM \"Anti-cocaine vaccine development..\" Expert Rev Vaccines. 2010 Sep;9(9):1109-14. Pubmed PMID: 20822352\n",
      "Frank JB, Kosten TR, Giller EL \"Antidepressants in the treatment of PTSD..\" Am J Psychiatry. 1990 Feb;147(2):260. Pubmed PMID: 2301678\n",
      "Li CS, Kosten TR, Sinha R \"Antisocial personality and stress-induced brain activation in cocaine-dependent patients..\" Neuroreport. 2006 Feb 27;17(3):243-7. Pubmed PMID: 16462591\n",
      "Chen JX, Su YA, Wang SL, Bian QT, Liu YH, Wang N, Yang FD, Haile C, Kosten TR, Zhang XY \"Aripiprazole treatment of risperidone-induced hyperprolactinemia..\" J Clin Psychiatry. 2009 Jul;70(7):1058-9. Pubmed PMID: 19653986\n",
      "Kosten TR, Gottschalk PC, Tucker K, Rinder CS, Dey HM, Rinder HM \"Aspirin or amiloride for cerebral perfusion defects in cocaine dependence..\" Drug Alcohol Depend. 2003 Aug 20;71(2):187-94. Pubmed PMID: 12927657\n",
      "Hui L, Zhang X, Yu YQ, Han M, Huang XF, Chen da C, Wang ZR, Du WL, Kou CG, Yu Q, Kosten TR, Zhang XY \"Association between DBH 19bp insertion/deletion polymorphism and cognition in first-episode schizophrenic patients..\" Schizophr. Res.. 2013 Jul;147(41308):236-40. Pubmed PMID: 23707643\n",
      "Sun S, Wang F, Wei J, Cao LY, Wu GY, Lu L, Kosten TA, Kosten TR, Zhang XY \"Association between interleukin-3 receptor alpha polymorphism and schizophrenia in the Chinese population..\" Neurosci. Lett.. 2008 Jul 25;440(1):35-7. Pubmed PMID: 18547720\n",
      "Sun S, Wang F, Wei J, Cao LY, Qi LY, Xiu MH, Chen S, Li XH, Kosten TA, Kosten TR, Zhang XY \"Association between interleukin-6 receptor polymorphism and patients with schizophrenia..\" Schizophr. Res.. 2008 Jul;102(41277):346-7. Pubmed PMID: 18508242\n",
      "Qiu HT, Meng HQ, Song C, Xiu MH, Chen da C, Zhu FY, Wu GY, Kosten TA, Kosten TR, Zhang XY \"Association between monoamine oxidase (MAO)-A gene variants and schizophrenia in a Chinese population..\" Brain Res.. 2009 Sep 1;1287:67-73. Pubmed PMID: 19573521\n",
      "Cao JX, Hu J, Ye XM, Xia Y, Haile CA, Kosten TR, Zhang XY \"Association between the 5-HTR1B gene polymorphisms and alcohol dependence in a Han Chinese population..\" Brain Res.. 2011 Feb 28;1376:41283. Pubmed PMID: 21172311\n",
      "Avants SK, Margolin A, McMahon TJ, Kosten TR \"Association between self-report of cognitive impairment, HIV status, and cocaine use in a sample of cocaine-dependent methadone-maintained patients..\" Addict Behav.;22(5):599-611. Pubmed PMID: 9347062\n",
      "Wang F, Fan H, Sun H, Yang F, Luo Y, Liu H, Kosten TR, Lu L, Zhang XY \"Association between TNF-a promoter -308A/G polymorphism and tardive dyskinesiain Chinese Han patients with schizophrenia..\" Prog. Neuropsychopharmacol. Biol. Psychiatry. 2012 Apr 27;37(1):106-10. Pubmed PMID: 22227290\n",
      "Li W, Zhou N, Yu Q, Li X, Yu Y, Sun S, Kou C, Chen da C, Xiu MH, Kosten TR, Zhang XY \"Association of BDNF gene polymorphisms with schizophrenia and clinical symptoms in a Chinese population.\" Am J Med Genet B Neuropsychiatr Genet. 2013 Sep;538-45. Pubmed PMID: 23832605\n",
      "Zhang XY, Tan YL, Zhou DF, Haile CN, Cao LY, Xu Q, Shen Y, Kosten TA, Kosten TR \"Association of clozapine-induced weight gain with a polymorphism in the leptin promoter region in patients with chronic schizophrenia in a Chinese population..\" J Clin Psychopharmacol. 2007 Jun;27(3):246-51. Pubmed PMID: 17502770\n",
      "Li WJ, Kou CG, Yu Y, Sun S, Zhang X, Kosten TR, Zhang XY \"Association of Catechol-O-methyltransferase gene polymorphisms with schizophrenia and negative symptoms in a Chinese population..\" Am. J. Med. Genet. B Neuropsychiatr. Genet.. 2012 Jun;159(4):370-5. Pubmed PMID: 22354729\n",
      "Guo S, Chen da F, Zhou DF, Sun HQ, Wu GY, Haile CN, Kosten TA, Kosten TR, Zhang XY \"Association of functional catechol O-methyl transferase (COMT) Val108Met polymorphism with smoking severity and age of smoking initiation in Chinese male smokers..\" Psychopharmacology (Berl.). 2007 Mar;190(4):449-56. Pubmed PMID: 17206495\n",
      "Sun H, Guo S, Chen D, Yang F, Zou Y, Di X, Cao Y, Kosten T, Lu L, Zhang XY \"Association of functional COMT Val108/Met polymorphism with smoking cessation in a nicotine replacement therapy..\" 2012 Jun 14; Pubmed PMID: 22695756\n",
      "Brown AE, Pavlik VN, Shegog R, Whitney SN, Friedman LC, Romero C, Davis GC, Cech I, Kosten TR, Volk RJ \"Association of spirituality and sobriety during a behavioral spirituality intervention for Twelve Step (TS) recovery..\" Am J Drug Alcohol Abuse. 2007;33(4):611-7. Pubmed PMID: 17668347\n",
      "Zhang XY, Chen DC, Xiu MH, Hui L, Liu H, Luo X, Zuo L, Zhang H, Kosten TA, Kosten TR \"Association of functional dopamine-beta-hydroxylase (DBH) 19bp insertion/deletion polymorphism with smoking severity in male schizophrenic smokers..\" Schizophr. Res.. 2012 Aug 4; Pubmed PMID: 22871345\n",
      "Liu H, Wang C, Chen PH, Zhang BS, Zheng YL, Zhang CX, Meng HQ, Wang Y, Chen da C, Xiu MH, Kosten TR, Zhang XY \"Association of the manganese superoxide dismutase gene Ala-9Val polymorphism with clinical phenotypes and tardive dyskinesia in schizophrenic patients..\" Prog. Neuropsychopharmacol. Biol. Psychiatry. 2010 May 30;34(4):692-6. Pubmed PMID: 20346996\n",
      "Zhou N, Yu Q, Li X, Yu Y, Kou C, Li W, Xu H, Luo X, Zuo L, Kosten TR, Zhang XY \"Association of the dopamine ß-hydroxylase 19?bp insertion/deletion polymorphism with positive symptoms but not tardive dyskinesia in schizophrenia..\" Hum Psychopharmacol. 2013 May;28(3):230-7. Pubmed PMID: 23559427\n",
      "Sofuoglu M, Poling J, Hill K, Kosten T \"Atomoxetine attenuates dextroamphetamine effects in humans..\" Am J Drug Alcohol Abuse. 2009;35(6):412-6. Pubmed PMID: 20014909\n",
      "Jacobs SC, Kosten TR, Kasl SV, Ostfeld AM, Berkman l, Charpentier P \"Attachment theory and multiple dimensions of grief.\" 1988;41-52.\n",
      "Krystal JH, McDougle CJ, Kosten TR, Price LH, Aghajanian GK, Charney DS \"Baclofen-assisted detoxification from opiates. A pilot study..\" J Subst Abuse Treat. 1992;9(2):139-42. Pubmed PMID: 1324986\n",
      "Zhang XY, Zhou DF, Wu GY, Cao LY, Tan YL, Haile CN, Li J, Lu L, Kosten TA, Kosten TR \"BDNF levels and genotype are associated with antipsychotic-induced weight gain in patients with chronic schizophrenia..\" Neuropsychopharmacology. 2008 Aug;33(9):2200-5. Pubmed PMID: 17987059\n",
      "Zhang XY, Chen da C, Xiu MH, Luo X, Zuo L, Haile CN, Kosten TA, Kosten TR \"BDNF Val66Met Variant and Smoking in a Chinese Population..\" PLoS ONE. 2012;7(12):e53295. Pubmed PMID: 23285275\n",
      "Oliveto A, Gentry WB, Pruzinsky R, Gonsai K, Kosten TR, Martell B, Poling J \"Behavioral effects of gamma-hydroxybutyrate in humans..\" Behav Pharmacol. 2010 Jul;21(4):332-42. Pubmed PMID: 20526195\n",
      "Hameedi FA, Rosen MI, McCance-Katz EF, McMahon TJ, Price LH, Jatlow PI, Woods SW, Kosten TR \"Behavioral, physiological, and pharmacological interaction of cocaine and disulfiram in humans..\" Biol. Psychiatry. 1995 Apr 15;37(8):560-3. Pubmed PMID: 7619981\n",
      "Kosten TR, Fontana A, Sernyak MJ, Rosenheck R \"Benzodiazepine use in posttraumatic stress disorder among veterans with substance abuse..\" J. Nerv. Ment. Dis.. 2000 Jul;188(7):454-9. Pubmed PMID: 10919705\n",
      "Jacobs SC, Mason JW, Kosten TR, Wahby V, Kasl SV, Ostfeld AM \"Bereavement and catecholamines..\" J Psychosom Res. 1986;30(4):489-96. Pubmed PMID: 3761233\n",
      "Kosten TR, Morgan C, Kreek MJ \"Beta endorphin levels during heroin, methadone, buprenorphine, and naloxone challenges: preliminary findings..\" Biol. Psychiatry. 1992 Sep 15;32(6):523-8. Pubmed PMID: 1445968\n",
      "Kosten TR, Kreek MJ, Swift C, Carney MK, Ferdinands L \"Beta endorphin levels in CSF during methadone maintenance..\" Life Sci.. 1987 Aug 31;41(9):1071-6. Pubmed PMID: 2956475\n",
      "Kosten TR, Krystal J \"Biological mechanisms in posttraumatic stress disorder. Relevance for substance abuse..\" Recent Dev Alcohol. 1988; Pubmed PMID: 3283864\n",
      "Zhang XY, Zhang WF, Zhou DF, Chen DC, Xiu MH, Wu HR, Haile CN, Kosten TA, Kosten TR \"Brain-Derived Neurotrophic Factor Levels and Its Val66Met Gene Polymorphism Predict Tardive Dyskinesia Treatment Response to Ginkgo Biloba..\" 2012 Jun 11; Pubmed PMID: 22695185\n",
      "Wang ZR, Zhou DF, Cao LY, Tan YL, Zhang XY, Li J, Lu L, Wu GY, Kosten TA, Kosten TR \"Brain-derived neurotrophic factor polymorphisms and smoking in schizophrenia..\" Schizophr. Res.. 2007 Dec;97(41277):299-301. Pubmed PMID: 17869486\n",
      "Kosten TR, Kleber HD \"Buprenorphine detoxification from opioid dependence: a pilot study..\" Life Sci.. 1988;42(6):635-41. Pubmed PMID: 3276999\n",
      "Kosten TR, Rosen MI, Schottenfeld R, Ziedonis D \"Buprenorphine for cocaine and opiate dependence..\" Psychopharmacol Bull. 1992;28(1):15-9. Pubmed PMID: 1609037\n",
      "Kosten TR, Fiellin DA \"Buprenorphine for office-based practice: consensus conference overview..\" Am J Addict. 2004;13:S1-7. Pubmed PMID: 15204671\n",
      "Rosenheck R, Kosten T \"Buprenorphine for opiate addiction: potential economic impact..\" Drug Alcohol Depend. 2001 Aug 1;63(3):253-62. Pubmed PMID: 11418229\n",
      "Kosten TR \"Buprenorphine for opioid detoxification: A brief review.\" Addictive Disorders and Their Treatment. 2003;\n",
      "Kosten TR, Morgan CJ, Kleber HD \"Buprenorphine treatment of cocaine abuse..\" NIDA Res. Monogr.. 1989;95:461. Pubmed PMID: 2641031\n",
      "Kosten TR, Schottenfeld R, Ziedonis D, Falcioni J \"Buprenorphine versus methadone maintenance for opioid dependence..\" J. Nerv. Ment. Dis.. 1993 Jun;181(6):358-64. Pubmed PMID: 8501457\n",
      "Schottenfeld RS, Pakes JR, Oliveto A, Ziedonis D, Kosten TR \"Buprenorphine vs methadone maintenance treatment for concurrent opioid dependence and cocaine abuse..\" Arch. Gen. Psychiatry. 1997 Aug;54(8):713-20. Pubmed PMID: 9283506\n",
      "Rosen MI, Kosten TR \"Buprenorphine: beyond methadone?.\" Hosp Community Psychiatry. 1991 Apr;42(4):347-9. Pubmed PMID: 2050347\n",
      "Schottenfeld RS, Pakes J, Ziedonis D, Kosten TR \"Buprenorphine: dose-related effects on cocaine and opioid use in cocaine-abusing opioid-dependent humans..\" Biol. Psychiatry.;34(41276):66-74. Pubmed PMID: 8373940\n",
      "Rosen MI, Wallace EA, McMahon TJ, Pearsall HR, Woods SW, Price LH, Kosten TR \"Buprenorphine: duration of blockade of effects of intramuscular hydromorphone..\" Drug Alcohol Depend. 1994 Apr;35(2):141-9. Pubmed PMID: 7519977\n",
      "Kosten TR \"Can cocaine craving be a medication development outcome: drug craving and relapse in opioid and cocaine dependence.\" Am J Addictions. 1992;\n",
      "Kosten TR, Domingo CB \"Can you vaccinate against substance abuse?.\" Expert Opin Biol Ther. 2013 Aug; Pubmed PMID: 23594123\n",
      "D'Souza DC, Kosten TR \"Cannabinoid antagonists: a treatment in search of an illness..\" Arch. Gen. Psychiatry. 2001 Apr;58(4):330-1. Pubmed PMID: 11296092\n",
      "Rosen MI, Pearsall HR, Price LH, McDougle CJ, Woods SW, Kosten TR \"Carbamazepine vs. oxazepam for benzodiazepine detoxification in methadone maintained patients.\" Am J Addictions. 1993;\n",
      "Gottschalk PC, Kosten TR \"Cerebral perfusion defects in combined cocaine and alcohol dependence..\" Drug Alcohol Depend. 2002 Sep 1;68(1):95-104. Pubmed PMID: 12167555\n",
      "West JC, Kosten TR, Wilk J, Svikis D, Triffleman E, Rae DS, Narrow WE, Duffy FF, Regier DA \"Challenges in increasing access to buprenorphine treatment for opiate addiction..\" Am J Addict. 2004;13:S8-16. Pubmed PMID: 15204672\n",
      "Avants SK, Margolin A, Kosten TR, Singer JL \"Changes concurrent with initiation of abstinence from cocaine abuse..\" J Subst Abuse Treat.;10(6):577-83. Pubmed PMID: 8308943\n",
      "Carroll KM, Kosten TR, Rounsaville BJ \"Choosing a behavioral therapy platform for pharmacotherapy of substance users..\" Drug Alcohol Depend. 2004 Aug 16;75(2):123-34. Pubmed PMID: 15276217\n",
      "McCance-Katz EF, Kosten TR, Jatlow P \"Chronic disulfiram treatment effects on intranasal cocaine administration: initial results..\" Biol. Psychiatry. 1998 Apr 1;43(7):540-3. Pubmed PMID: 9547934\n",
      "Kosten TR, Kreek MJ, Ragunath J, Kleber HD \"Chronic naltrexone effect on cortisol..\" NIDA Res. Monogr.. 1986;67:362-5. Pubmed PMID: 3092091\n",
      "Zhang XY, Chen da C, Xiu MH, Haile CN, Sun H, Lu L, Kosten TA, Kosten TR \"Cigarette Smoking and Cognitive Function in Chinese Male Schizophrenia: A Case-Control study..\" PLoS ONE. 2012;7(5):e36563. Pubmed PMID: 22570726\n",
      "Zhang XY, Liang J, Chen da C, Xiu MH, He J, Cheng W, Wu Z, Yang FD, Haile CN, Sun H, Lu L, Kosten TA, Kosten TR \"Cigarette smoking in male patients with chronic schizophrenia in a Chinese population: prevalence and relationship to clinical phenotypes..\" PLoS ONE. 2012;7(2):e30937. Pubmed PMID: 22347412\n",
      "Zhang XY, Chen DC, Xiu MH, Haile CN, He SC, Luo X, Zuo L, Rosenheck R, Kosten TA, Kosten TR \"Cigarette smoking, psychopathology and cognitive function in first-episode drug-naive patients with schizophrenia: a case-control study..\" Psychol Med. 2013; Pubmed PMID: 23149169\n",
      "Li SX, Shi J, Epstein DH, Wang X, Zhang XL, Bao YP, Zhang D, Zhang XY, Kosten TR, Lu L \"Circadian alteration in neurobiology during 30 days of abstinence in heroin users..\" Biol. Psychiatry. 2009 May 15;65(10):905-12. Pubmed PMID: 19135652\n",
      "Kosten TR \"Client issues in drug abuse treatment: addressing multiple drug abuse..\" NIDA Res. Monogr.. 1991;106:136-51. Pubmed PMID: 1922284\n",
      "Kosten TR \"Clinical and research perspectives on cocaine abuse: the pharmacotherapy of cocaine abuse..\" NIDA Res. Monogr.. 1993;135:48-56. Pubmed PMID: 8289903\n",
      "Li SX, Liu LJ, Jiang WG, Sun LL, Zhou SJ, Le Foll B, Zhang XY, Kosten TR, Lu L \"Circadian alteration in neurobiology during protracted opiate withdrawal in rats..\" J. Neurochem.. 2010 Oct;115(2):353-62. Pubmed PMID: 20738730\n",
      "Poling J, Pruzinsky R, Kosten TR, Gonsai K, Sofuoglu M, Gonzalez G, Oliveto A \"Clinical efficacy of citalopram alone or augmented with bupropion in methadone-stabilized patients..\" Am J Addict.;16(3):187-94. Pubmed PMID: 17612822\n",
      "González G, Desai R, Sofuoglu M, Poling J, Oliveto A, Gonsai K, Kosten TR \"Clinical efficacy of gabapentin versus tiagabine for reducing cocaine use among cocaine dependent methadone-treated patients..\" Drug Alcohol Depend. 2007 Feb 23;87(1):41283. Pubmed PMID: 16930857\n",
      "Mancino MJ, McGaugh J, Chopra MP, Guise JB, Cargile C, Williams DK, Thostenson J, Kosten TR, Sanders N, Oliveto A \"Clinical efficacy of sertraline alone and augmented with gabapentin in recently abstinent cocaine-dependent patients with depressive symptoms..\" J Clin Psychopharmacol. 2014 Apr; Pubmed PMID: 24525654\n",
      "Zhang XY, Chen da C, Xiu MH, Tan YL, Yang FD, Zhang LY, Zhang LY, Haile CN, Kosten TR \"Clinical symptoms and cognitive impairment associated with male schizophrenia relate to plasma manganese superoxide dismutase activity: A case-control study..\" J Psychiatr Res. 2013 Aug;47(8):1049-53. Pubmed PMID: 23611682\n",
      "Vining E, Kosten TR, Kleber HD \"Clinical utility of rapid clonidine-naltrexone detoxification for opioid abusers..\" Br J Addict. 1988 May;83(5):567-75. Pubmed PMID: 3382815\n",
      "Kosten TR, Gawin FH, Rounsaville BJ, Kleber HD \"Cocaine abuse among opioid addicts: demographic and diagnostic factors in treatment..\" Am J Drug Alcohol Abuse. 1986;12(41276):41290. Pubmed PMID: 3788892\n",
      "McCance EF, Price LH, Kosten TR, Jatlow PI \"Cocaethylene: pharmacology, physiology and behavioral effects in humans..\" J. Pharmacol. Exp. Ther.. 1995 Jul;274(1):215-23. Pubmed PMID: 7616402\n",
      "Kleber HD, Riordan CE, Rounsaville B, Kosten T, Charney D, Gaspari J, Hogan I, O'Connor C \"Clonidine in outpatient detoxification from methadone maintenance.\" Arch Gen Psychiatry. 1985 Apr; Pubmed PMID: 3977557\n",
      "Kleber HD, Topazian M, Gaspari J, Riordan CE, Kosten T \"Clonidine and naltrexone in the outpatient treatment of heroin withdrawal..\" Am J Drug Alcohol Abuse. 1987; Pubmed PMID: 3687878\n",
      "Kosten TA, Kosten TR \"Cocaine abuse and opioid withdrawal..\" Lancet. 1989 Jul 15;2(8655):165-6. Pubmed PMID: 2567937\n",
      "Avants SK, Margolin A, Kosten TR \"Cocaine abuse in methadone maintenance programs: integrating pharmacotherapy with psychosocial interventions..\" J Psychoactive Drugs.;26(2):137-46. Pubmed PMID: 7931858\n",
      "Stine SM, Satel S, Kosten TR \"Cocaine precipitation of patient identified opiate withdrawal.\" Am J Addictions. 1993;\n",
      "Kosten TA, Kosten TR, Rounsaville BJ \"Cocaine symptoms are predicted by familial psychopathology..\" NIDA Res. Monogr.. 1990;105:603-4. Pubmed PMID: 1876139\n",
      "Oliveto AH, Kosten TR, Schottenfeld RS, Ziedonis D, Falcioni J \"Cocaine use in buprenorphine vs. methadone maintained cocaine users.\" Am J Addictions. 1994;\n",
      "Martell BA, Orson FM, Poling J, Mitchell E, Rossen RD, Gardner T, Kosten TR \"Cocaine vaccine for the treatment of cocaine dependence in methadone-maintained patients: a randomized, double-blind, placebo-controlled efficacy trial..\" Arch. Gen. Psychiatry. 2009 Oct;66(10):1116-23. Pubmed PMID: 19805702\n",
      "Sofuoglu M, Poling J, Gonzalez G, Gonsai K, Kosten T \"Cocaine withdrawal symptoms predict medication response in cocaine users..\" Am J Drug Alcohol Abuse. 2006;32(4):617-27. Pubmed PMID: 17127550\n",
      "Rosen MI, Kosten T \"Cocaine-associated panic attacks in methadone-maintained patients..\" Am J Drug Alcohol Abuse. 1992; Pubmed PMID: 1314016\n",
      "Zhang XY, Chen da C, Xiu MH, Haile CN, Luo X, Xu K, Zhang HP, Zuo L, Zhang Z, Zhang X, Kosten TA, Kosten TR \"Cognitive and serum BDNF correlates of BDNF Val66Met gene polymorphism in patients with schizophrenia and normal controls..\" Hum. Genet.. 2012 Jul;131(7):1187-95. Pubmed PMID: 22362486\n",
      "Gottschalk C, Beauvais J, Hart R, Kosten T \"Cognitive function and cerebral perfusion during cocaine abstinence..\" Am J Psychiatry. 2001 Apr; Pubmed PMID: 11282686\n",
      "Zhang XY, Chen da C, Xiu MH, Yang FD, Tan Y, Luo X, Zuo L, Kosten TA, Kosten TR \"Cognitive function, plasma MnSOD activity, and MnSOD Ala-9Val polymorphism in patients with schizophrenia and normal controls..\" Schizophr Bull. 2014 May; Pubmed PMID: 23588476\n",
      "Gonzalez G, Oliveto A, Kosten TR \"Combating opiate dependence: a comparison among the available pharmacological options..\" Expert Opin Pharmacother. 2004 Apr;5(4):713-25. Pubmed PMID: 15102558\n",
      "Kosten TR \"Combining family therapy with pharmacotherapy in opioid addicts: Use of naltrexone.\" International Journal of Family Psychiatry. 1986;\n",
      "Carroll ME, Zlebnik NE, Anker JJ, Kosten TR, Orson FM, Shen X, Kinsey B, Parks RJ, Gao Y, Brimijoin S \"Combined cocaine hydrolase gene transfer and anti-cocaine vaccine synergistically block cocaine-induced locomotion..\" PLoS One. 2012; Pubmed PMID: 22912888\n",
      "Kosten TR \"Commentary: Commitment for substance abuse- Current judicial interventions.\" The Journal of the American Academy of Psychi. 2002;\n",
      "Kosten TR, Price LH \"Commentary on: Phenomenology and sequelae of MDMA use..\" J Nervous Mental Dis. 1992;\n",
      "Gonzalez G, Feingold A, Oliveto A, Gonsai K, Kosten TR \"Comorbid major depressive disorder as a prognostic factor in cocaine-abusing buprenorphine-maintained patients treated with desipramine and contingency management..\" Am J Drug Alcohol Abuse. 2003 Aug;29(3):497-514. Pubmed PMID: 14510037\n",
      "Kosten TR, Rounsaville BJ, Kleber HD \"Comparison of clinician ratings to self reports of withdrawal during clonidine detoxification of opiate addicts..\" Am J Drug Alcohol Abuse. 1985;11(41276):41284. Pubmed PMID: 3904410\n",
      "Kosten TR, Jalali B, Kleber HD \"Complementary marital roles of male heroin addicts: evolution and intervention tactics..\" Am J Drug Alcohol Abuse.;9(2):155-69. Pubmed PMID: 7171079\n",
      "McCance-Katz EF, Price LH, McDougle CJ, Kosten TR, Black JE, Jatlow PI \"Concurrent cocaine-ethanol ingestion in humans: pharmacology, physiology, behavior, and the role of cocaethylene..\" Psychopharmacology (Berl.). 1993;111(1):39-46. Pubmed PMID: 7870932\n",
      "McCance-Katz EF, Kosten TR, Jatlow P \"Concurrent use of cocaine and alcohol is more potent and potentially more toxic than use of either alone--a multiple-dose study..\" Biol. Psychiatry. 1998 Aug 15;44(4):250-9. Pubmed PMID: 9715356\n",
      "Kosten TR, Rounsaville BJ, Kleber HD \"Concurrent validity of the addiction severity index..\" J. Nerv. Ment. Dis.. 1983 Oct;171(10):606-10. Pubmed PMID: 6619823\n",
      "Fiellin DA, Kleber H, Trumble-Hejduk JG, McLellan AT, Kosten TR \"Consensus statement on office-based treatment of opioid dependence using buprenorphine..\" J Subst Abuse Treat. 2004 Sep;27(2):153-9. Pubmed PMID: 15450648\n",
      "Petry NM, Petrakis I, Trevisan L, Wiredu G, Boutros NN, Martin B, Kosten TR \"Contingency management interventions: from research to practice..\" Am J Psychiatry. 2001 May;158(5):694-702. Pubmed PMID: 11329388\n",
      "Fiellin DA, Rosenheck RA, Kosten TR \"Coordination of medical care and opioid dependence treatment in primary care: a case report..\" Subst Abus. 2003 Mar; Pubmed PMID: 12652094\n",
      "Boutros NN, Lisanby SH, McClain-Furmanski D, Oliwa G, Gooding D, Kosten TR \"Cortical excitability in cocaine-dependent patients: a replication and extension of TMS findings..\" J Psychiatr Res. 2005 May;39(3):295-302. Pubmed PMID: 15725428\n",
      "Kosten TR, Kreek MJ, Ragunath J, Kleber HD \"Cortisol levels during chronic naltrexone maintenance treatment in ex-opiate addicts..\" Biol. Psychiatry. 1986 Feb;21(2):217-20. Pubmed PMID: 3947698\n",
      "Margolin A, Avants SK, Kosten TR \"Cue-elicited cocaine craving and autogenic relaxation. Association with treatment outcome..\" J Subst Abuse Treat.;11(6):549-52. Pubmed PMID: 7884838\n",
      "Kosten TR, Scanley BE, Tucker KA, Oliveto A, Prince C, Sinha R, Potenza MN, Skudlarski P, Wexler BE \"Cue-induced brain activity changes and relapse in cocaine-dependent patients..\" Neuropsychopharmacology. 2006 Mar;31(3):644-50. Pubmed PMID: 16123763\n",
      "Kosten TR, Scanley BE, Tucker K, Oliveto A, Prince C, Sinha R, Potenza MN, Skudlarski P, Wexler BE \"Cue-induced brain activity changes and treatment outcome in depressed cocaine dependent patients.\" Neuropsychopharmacology. 2006;\n",
      "Gottschalk PC, Jacobsen LK, Kosten TR \"Current concepts in pharmacotherapy of substance abuse..\" Curr Psychiatry Rep. 1999 Dec;1(2):172-8. Pubmed PMID: 11122921\n",
      "Gottchalk PCH, Jacobsen LK, Kosten TR \"Current concepts in pharmacotherapy of substance abuse-the dawn of a new era.\" Current Psychiatry Reports. 1999;\n",
      "Kosten TR, O’Connor PG \"Current concepts-management of drug withdrawal.\" New England Journal of Medicine. 2003;\n",
      "Kosten TR \"Current pharmacotherapies for opioid dependence.\" Psychopharmacol Bull. 1990; Pubmed PMID: 2196628\n",
      "Oliveto A, Benios T, Gonsai K, Feingold A, Poling J, Kosten TR \"D-cycloserine-Naloxone interactions in opioid-dependent humans under a novel-response naloxone discrimination procedure..\" Exp Clin Psychopharmacol. 2003 Aug;11(3):237-46. Pubmed PMID: 12940503\n",
      "Avants SK, Margolin A, Sindelar JL, Rounsaville BJ, Schottenfeld R, Stine S, Cooney NL, Rosenheck RA, Li SH, Kosten TR \"Day treatment versus enhanced standard methadone services for opioid-dependent patients: a comparison of clinical efficacy and cost..\" Am J Psychiatry. 1999 Jan; Pubmed PMID: 9892294\n",
      "Kosten TR, Domingo CB, Hamon SC, Nielsen DA \"DBH gene as predictor of response in a cocaine vaccine clinical trial..\" Neurosci. Lett.. 2013 Apr 29;541:29-33. Pubmed PMID: 23458673\n",
      "Silverman DG, Kosten TR, Jatlow PI, Gutter V, Fleming J, O'Connor TZ, Byck R \"Decreased digital flow persists after the abatement of cocaine-induced hemodynamic stimulation..\" Anesth. Analg.. 1997 Jan;84(1):46-50. Pubmed PMID: 8988997\n",
      "Chen da C, Wang J, Wang B, Yang SC, Zhang CX, Zheng YL, Li YL, Wang N, Yang KB, Xiu MH, Kosten TR, Zhang XY \"Decreased levels of serum brain-derived neurotrophic factor in drug-naïve first-episode schizophrenia: relationship to clinical phenotypes..\" Psychopharmacology (Berl.). 2009 Dec;207(3):375-80. Pubmed PMID: 19787338\n",
      "Yang YQ, Sun S, Yu YQ, Li WJ, Zhang X, Xiu MH, Chen da C, Yang FD, Liu H, Li C, Kosten TR, Zhang XY \"Decreased serum brain-derived neurotrophic factor levels in schizophrenic patients with tardive dyskinesia..\" Neurosci. Lett.. 2011 Sep 8;502(1):37-40. Pubmed PMID: 21798311\n",
      "Xiu MH, Hui L, Dang YF, Hou TD, Zhang CX, Zheng YL, Chen da C, Kosten TR, Zhang XY \"Decreased serum BDNF levels in chronic institutionalized schizophrenia on long-term treatment with typical and atypical antipsychotics..\" Prog. Neuropsychopharmacol. Biol. Psychiatry. 2009 Nov 13;33(8):1508-12. Pubmed PMID: 19720106\n",
      "Kosten TR, Markou A, Koob GF \"Depression and stimulant dependence: neurobiology and pharmacotherapy..\" J. Nerv. Ment. Dis.. 1998 Dec;186(12):737-45. Pubmed PMID: 9865811\n",
      "Kosten T, Falcioni J, Oliveto A, Feingold A \"Depression predicts higher rates of heroin use on desipramine with buprenorphine than with methadone..\" Am J Addict. 2004 Mar; Pubmed PMID: 15204669\n",
      "Ziedonis DM, Kosten TR \"Depression as a prognostic factor for pharmacological treatment of cocaine dependence..\" Psychopharmacol Bull. 1991;27(3):337-43. Pubmed PMID: 1775608\n",
      "Kosten TR, Morgan C, Kosten TA \"Depressive symptoms during buprenorphine treatment of opioid abusers..\" J Subst Abuse Treat. 1990;7(1):51-4. Pubmed PMID: 2313769\n",
      "Jacobs S, Kosten TR \"Depressive syndromes during acute bereavement: Indications for professional intervention.\" Yale Psychiatric Quarterly. 1983;\n",
      "Satel SL, Kosten TR \"Designing drug efficacy trials in the treatment of cocaine abuse..\" J Nerv Ment Dis. 1991 Feb; Pubmed PMID: 1990076\n",
      "Kosten TR, Gawin FH, Morgan C, Nelson JC, Jatlow P \"Desipramine and its 2-hydroxy metabolite in patients taking or not taking methadone..\" Am J Psychiatry. 1990 Oct;147(10):1379-80. Pubmed PMID: 2400009\n",
      "Kosten T, Oliveto A, Feingold A, Poling J, Sevarino K, McCance-Katz E, Stine S, Gonzalez G, Gonsai K \"Desipramine and contingency management for cocaine and opiate dependence in buprenorphine maintained patients.\" Drug Alcohol Depend. 2003 Jun; Pubmed PMID: 12757969\n",
      "Gawin FH, Kleber HD, Byck R, Rounsaville BJ, Kosten TR, Jatlow PI, Morgan C \"Desipramine facilitation of initial cocaine abstinence..\" Arch. Gen. Psychiatry. 1989 Feb;46(2):117-21. Pubmed PMID: 2492422\n",
      "Oliveto AH, Feingold A, Schottenfeld R, Jatlow P, Kosten TR \"Desipramine in opioid-dependent cocaine abusers maintained on buprenorphine vs methadone..\" Arch. Gen. Psychiatry. 1999 Sep;56(9):812-20. Pubmed PMID: 12884887\n",
      "Kosten T, Sofuoglu M, Poling J, Gonsai K, Oliveto A \"Desipramine treatment for cocaine dependence in buprenorphine- or methadone-treated patients: baseline urine results as predictor of response..\" Am J Addict.;14(1):41503. Pubmed PMID: 15804873\n",
      "Oliveto A, Kosten TR, Schottenfeld R, Falcioni J, Ziedonis D \"Desipramine, amantadine, or fluoxetine in buprenorphine-maintained cocaine users..\" J Subst Abuse Treat.;12(6):423-8. Pubmed PMID: 8749726\n",
      "Kosten TR \"Diagnosing depression with the DST and TRH in cocaine and opioid abusers..\" J Subst Abuse Treat. 1986;3(1):47-9. Pubmed PMID: 3090273\n",
      "Han M, Huang XF, Chen da C, Xiu M, Kosten TR, Zhang XY \"Diabetes and cognitive deficits in chronic schizophrenia: a case-control study.\" PLoS One. 2013 Jun; Pubmed PMID: 23840437\n",
      "Avants SK, Margolin A, Kosten TR, Cooney NL \"Differences between responders and nonresponders to cocaine cues in the laboratory..\" Addict Behav.;20(2):215-24. Pubmed PMID: 7484315\n",
      "Cui Y, Robinson JD, Versace F, Lam CY, Minnix JA, Karam-Hage M, Dani JA, Kosten TR, Wetter DW, Brown VL, Cinciripini PM \"Differential cigarette-related startle cue reactivity among light, moderate, and heavy smokers..\" Addict Behav. 2012 Aug;37(8):885-9. Pubmed PMID: 22571920\n",
      "Kosten TR, Kleber HD \"Differential diagnosis of psychiatric comorbidity in substance abusers..\" J Subst Abuse Treat. 1988;5(4):201-6. Pubmed PMID: 3216436\n",
      "Oliveto AH, Rosen MI, Woods SW, Kosten TR \"Discriminative stimulus, self-reported and cardiovascular effects of orally administered cocaine in humans..\" J Pharmacol Exp Ther. 1995 Jan; Pubmed PMID: 7815337\n",
      "Zhang XY, Tan YL, Zhou DF, Cao LY, Wu GY, Haile CN, Kosten TA, Kosten TR \"Disrupted antioxidant enzyme activity and elevated lipid peroxidation products in schizophrenic patients with tardive dyskinesia..\" J Clin Psychiatry. 2007 May;68(5):754-60. Pubmed PMID: 17503985\n",
      "McCance-Katz EF, Kosten TR, Jatlow P \"Disulfiram effects on acute cocaine administration..\" Drug Alcohol Depend. 1998 Sep 1;52(1):27-39. Pubmed PMID: 9788003\n",
      "Sofuoglu M, Poling J, Waters A, Sewell A, Hill K, Kosten T \"Disulfiram enhances subjective effects of dextroamphetamine in humans..\" Pharmacol Biochem Behav. 2008 Sep; Pubmed PMID: 18474395\n",
      "Haile CN, During MJ, Jatlow PI, Kosten TR, Kosten TA \"Disulfiram facilitates the development and expression of locomotor sensitization to cocaine in rats..\" Biol. Psychiatry. 2003 Nov 1;54(9):915-21. Pubmed PMID: 14573319\n",
      "George TP, Chawarski MC, Pakes J, Carroll KM, Kosten TR, Schottenfeld RS \"Disulfiram versus placebo for cocaine dependence in buprenorphine-maintained subjects: a preliminary trial..\" Biol. Psychiatry. 2000 Jun 15;47(12):1080-6. Pubmed PMID: 10862808\n",
      "Ren ZY, Zhang XL, Liu Y, Zhao LY, Shi J, Bao Y, Zhang XY, Kosten TR, Lu L \"Diurnal variation in cue-induced responses among protracted abstinent heroin users..\" Pharmacol. Biochem. Behav.. 2009 Jan;91(3):468-72. Pubmed PMID: 18809427\n",
      "McDougle CJ, Price LH, Palumbo JM, Kosten TR, Heninger GR, Kleber HD \"Dopaminergic responsivity during cocaine abstinence: a pilot study..\" Psychiatry Res. 1992 Jul;43(1):77-85. Pubmed PMID: 1359594\n",
      "Gawin FH, Morgan C, Kosten TR, Kleber HD \"Double-blind evaluation of the effect of acute amantadine on cocaine craving..\" Psychopharmacology (Berl.). 1989;97(3):402-3. Pubmed PMID: 2497490\n",
      "Singh RA, Kosten TA, Kinsey BM, Shen X, Lopez AY, Kosten TR, Orson FM \"Dose-dependent changes in the locomotor responses to methamphetamine in BALB/c mice: low doses induce hypolocomotion..\" Pharmacol Biochem Behav. 2012 Dec; Pubmed PMID: 23010423\n",
      "Hameedi FA, Woods SW, Rosen MI, Pearsall HR, Kosten TR \"Dose dependent effects of yohimbine on methadone maintained patients..\" Am J Drug Alcohol Abuse. 1997 May;23(2):327-33. Pubmed PMID: 9143642\n",
      "Stitzer ML, Polk T, Bowles S, Kosten T \"Drug users' adherence to a 6-month vaccination protocol: effects of motivational incentives..\" Drug Alcohol Depend. 2010 Feb 1;107(1):76-9. Pubmed PMID: 19828264\n",
      "Kosten TR, Rounsaville BJ, Kleber HD \"DSM-III personality disorders in opiate addicts..\" Compr Psychiatry.;23(6):572-81. Pubmed PMID: 7160176\n",
      "Gardner T, Kosten T \"Dual dependency on cocaine and alcohol in opiate addicts: treatment options..\" J Clin Psychiatry. 2007; Pubmed PMID: 17685754\n",
      "Stine SM, Krystal JH, Petrakis IL, Jatlow PI, Heninger GR, Kosten TR, Charney DS \"Effect of alpha-methyl-para-tyrosine on response to cocaine challenge..\" Biol. Psychiatry. 1997 Aug 1;42(3):181-90. Pubmed PMID: 9232210\n",
      "Rosen MI, McMahon TJ, Hameedi FA, Pearsall HR, Woods SW, Kreek MJ, Kosten TR \"Effect of clonidine pretreatment on naloxone-precipitated opiate withdrawal..\" J. Pharmacol. Exp. Ther.. 1996 Mar;276(3):1128-35. Pubmed PMID: 8786543\n",
      "Rosen MI, Pearsall HR, McDougle CJ, Price LH, Woods SW, Kosten TR \"Effects of acute buprenorphine on responses to intranasal cocaine: a pilot study.\" Am J Drug Alcohol Abuse. 1993; Pubmed PMID: 8273766\n",
      "Oliveto AH, Farren C, Kosten TR \"Effect of LAAM dose on opiate use in opioid-dependent patients. A pilot study..\" Am J Addict. 1998;7(4):272-82. Pubmed PMID: 9809131\n",
      "McCance-Katz EF, Rainey PM, Friedland G, Kosten TR, Jatlow P \"Effect of opioid dependence pharmacotherapies on zidovudine disposition..\" Am J Addict. 2001;10(4):296-307. Pubmed PMID: 11783744\n",
      "Shi J, Jun W, Zhao LY, Xue YX, Zhang XY, Kosten TR, Lu L \"Effect of rapamycin on cue-induced drug craving in abstinent heroin addicts..\" Eur. J. Pharmacol.. 2009 Aug 1;615(41277):108-12. Pubmed PMID: 19470385\n",
      "Gao Y, Geng L, Orson F, Kinsey B, Kosten TR, Shen X, Brimijoin S \"Effects of anti-cocaine vaccine and viral gene transfer of cocaine hydrolase in mice on cocaine toxicity including motor strength and liver damage..\" Chem. Biol. Interact.. 2013 Mar 25;203(1):208-11. Pubmed PMID: 22935511\n",
      "Oliveto A, McCance-Katz FE, Singha A, Petrakis I, Hameedi F, Kosten TR \"Effects of cocaine prior to and during bupropion maintenance in cocaine-abusing volunteers..\" Drug Alcohol Depend. 2001 Jul 1;63(2):155-67. Pubmed PMID: 11376920\n",
      "Oliveto AH, McCance-Katz E, Singha A, Hameedi F, Kosten TR \"Effects of d-amphetamine and caffeine in humans under a cocaine discrimination procedure..\" Behav Pharmacol. 1998 May;9(3):207-17. Pubmed PMID: 9832935\n",
      "Rosen MI, Pearsall HR, Woods SW, Kosten TR \"Effects of gamma-hydroxybutyric acid (GHB) in opioid-dependent patients..\" J Subst Abuse Treat.;14(2):149-54. Pubmed PMID: 9258859\n",
      "Sinha R, Kimmerling A, Doebrick C, Kosten TR \"Effects of lofexidine on stress-induced and cue-induced opioid craving and opioid abstinence rates: preliminary findings..\" Psychopharmacology (Berl.). 2007 Mar;190(4):569-74. Pubmed PMID: 17136399\n",
      "Sofuoglu M, Singha A, Kosten TR, McCance-Katz FE, Petrakis I, Oliveto A \"Effects of naltrexone and isradipine, alone or in combination, on cocaine responses in humans..\" Pharmacol. Biochem. Behav.. 2003 Jul;75(4):801-8. Pubmed PMID: 12957222\n",
      "Winther LC, Saleem R, McCance-Katz EF, Rosen MI, Hameedi FA, Pearsall HR, Jatlow PI, Kosten TR, Woods SW \"Effects of lamotrigine on behavioral and cardiovascular responses to cocaine in human subjects..\" Am J Drug Alcohol Abuse. 2000 Feb; Pubmed PMID: 10718163\n",
      "Sofuoglu M, Mitchell E, Kosten TR \"Effects of progesterone treatment on cocaine responses in male and female cocaine users..\" Pharmacol. Biochem. Behav.. 2004 Aug;78(4):699-705. Pubmed PMID: 15301924\n",
      "Kosten TR, Rayford BS \"Effects of ethnicity on low-dose opiate stabilization..\" J Subst Abuse Treat.;12(2):111-6. Pubmed PMID: 7623388\n",
      "Kosten T, Poling J, Oliveto A \"Effects of reducing contingency management values on heroin and cocaine use for buprenorphine- and desipramine-treated patients..\" Addiction. 2003 May; Pubmed PMID: 12751984\n",
      "Zhang XY, Zhou DF, Shen YC, Zhang PY, Zhang WF, Liang J, Chen da C, Xiu MH, Kosten TA, Kosten TR \"Effects of risperidone and haloperidol on superoxide dismutase and nitric oxide in schizophrenia..\" Neuropharmacology. 2012 Apr;62(41400):1928-34. Pubmed PMID: 22227558\n",
      "Margolin A, Chang P, Avants SK, Kosten TR \"Effects of sham and real auricular needling: implications for trials of acupuncture for cocaine addiction..\" Am. J. Chin. Med.. 1993;21(2):103-11. Pubmed PMID: 8237887\n",
      "George TP, Vessicchio JC, Termine A, Sahady DM, Head CA, Pepper WT, Kosten TR, Wexler BE \"Effects of smoking abstinence on visuospatial working memory function in schizophrenia..\" Neuropsychopharmacology. 2002 Jan;26(1):75-85. Pubmed PMID: 11751034\n",
      "Sofuoglu M, Mouratidis M, Yoo S, Culligan K, Kosten T \"Effects of tiagabine in combination with intravenous nicotine in overnight abstinent smokers..\" Psychopharmacology (Berl.). 2005 Sep;181(3):504-10. Pubmed PMID: 15983800\n",
      "Sofuoglu M, Poling J, Mouratidis M, Kosten T \"Effects of topiramate in combination with intravenous nicotine in overnight abstinent smokers..\" Psychopharmacology (Berl.). 2006 Mar;184(41337):645-51. Pubmed PMID: 16432681\n",
      "Oliveto A, Poling J, Sevarino KA, Gonsai KR, McCance-Katz EF, Stine SM, Kosten TR \"Efficacy of dose and contingency management procedures in LAAM-maintained cocaine-dependent patients..\" Drug Alcohol Depend. 2005 Aug 1;79(2):157-65. Pubmed PMID: 16002025\n",
      "Castells X, Kosten TR, Capellà D, Vidal X, Colom J, Casas M \"Efficacy of opiate maintenance therapy and adjunctive interventions for opioid dependence with comorbid cocaine use disorders: a systematic review and meta-analysis of controlled clinical trials..\" Am J Drug Alcohol Abuse. 2009;35(5):339-49. Pubmed PMID: 20180662\n",
      "Jacobsen LK, Staley JK, Malison RT, Zoghbi SS, Seibyl JP, Kosten TR, Innis RB \"Elevated central serotonin transporter binding availability in acutely abstinent cocaine-dependent patients..\" Am J Psychiatry. 2000 Jul;157(7):1134-40. Pubmed PMID: 10873923\n",
      "Xiu MH, Chen DC, Wang D, Zhang K, Dong A, Tang W, Zhang F, Liu LJ, Liu JH, Liu HB, Yang FD, Kosten TR, Zhang XY \"Elevated interleukin-18 serum levels in chronic schizophrenia: Association with psychopathology..\" 2012 May 28; Pubmed PMID: 22647522\n",
      "Wu Z, Zhang XY, Wang H, Tang W, Xia Y, Zhang F, Liu J, Fu Y, Hu J, Chen Y, Liu L, Chen da C, Xiu MH, Kosten TR, He J \"Elevated plasma superoxide dismutase in first-episode and drug naive patients with schizophrenia: inverse association with positive symptoms..\" Prog Neuropsychopharmacol Biol Psychiatry. 2012 Jan; Pubmed PMID: 21896300\n",
      "Chen da C, Qi LY, Xiu MH, Cao LY, Wang F, Chen S, Wu GY, Kosten TA, Kosten TR, Zhang XY \"Elevated serum levels of tumor necrosis factor-alpha in clozapine-associated obesity in chronic schizophrenia..\" Schizophr. Res.. 2008 Dec;106(41308):367-8. Pubmed PMID: 18835132\n",
      "Malison RT, Best SE, van Dyck CH, McCance EF, Wallace EA, Laruelle M, Baldwin RM, Seibyl JP, Price LH, Kosten TR, Innis RB \"Elevated striatal dopamine transporters during acute cocaine abstinence as measured by [123I] beta-CIT SPECT..\" Am J Psychiatry. 1998 Jun;155(6):832-4. Pubmed PMID: 9619159\n",
      "Mason JW, Giller EL, Kosten TR, Harkness L \"Elevation of urinary norepinephrine/cortisol ratio in posttraumatic stress disorder..\" J. Nerv. Ment. Dis.. 1988 Aug;176(8):498-502. Pubmed PMID: 3404142\n",
      "Sofuoglu M, Kosten TR \"Emerging pharmacological strategies in the fight against cocaine addiction..\" Expert Opin Emerg Drugs. 2006 Mar;11(1):91-8. Pubmed PMID: 16503828\n",
      "Sun HQ, Chen HM, Yang FD, Lu L, Kosten TR \"Epidemiological trends and the advances of treatments of amphetamine-type stimulants (ATS) in China..\" Am J Addict. 2014 May; Pubmed PMID: 24724890\n",
      "Nielsen DA, Utrankar A, Reyes JA, Simons DD, Kosten TR \"Epigenetics of drug abuse: predisposition or response..\" Pharmacogenomics. 2012 Jul;13(10):1149-60. Pubmed PMID: 22909205\n",
      "Kosten TR, Rounsaville BJ, Kleber HD \"Ethnic and gender differences among opiate addicts..\" Int J Addict. 1985 Aug;20(8):1143-62. Pubmed PMID: 4077316\n",
      "Malison RT, Best SE, Wallace EA, McCance E, Laruelle M, Zoghbi SS, Baldwin RM, Seibyl JS, Hoffer PB, Price LH \"Euphorigenic doses of cocaine reduce [123I]beta-CIT SPECT measures of dopamine transporter availability in human cocaine addicts..\" Psychopharmacology. 1995 Dec; Pubmed PMID: 8657833\n",
      "Kosten TR, Gawin FH, Morgan C, Nelson JC, Jatlow P \"Evidence for altered desipramine disposition in methadone-maintained patients treated for cocaine abuse..\" Am J Drug Alcohol Abuse. 1990;16(41337):329-36. Pubmed PMID: 2288330\n",
      "Lingford-Hughes AR, Welch S, Nutt DJ; British Association for Psychopharmacology \"Evidence-based guidelines for the pharmacological management of substance misuse, addiction and comorbidity: recommendations from the British Association for Psychopharmacology..\" J Psychopharmacol. 2004 Sep; Pubmed PMID: 15358975\n",
      "An HM, Tan YL, Shi J, Wang ZR, Li J, Wang YC, Kosten TR, Zhou DF, Yang FD, Zhang XY \"Extract of Ginkgo biloba is equivalent to vitamin E in attenuating and preventing vacuous chewing movements in a rat model of tardive dyskinesia..\" Behav Pharmacol. 2013 Aug; Pubmed PMID: 23994817\n",
      "Browndyke JN, Tucker KA, Woods SP, Beauvals J, Cohen RA, Gottschalk PC, Kosten TR \"Examining the effect of cerebral perfusion abnormality magnitude on cognitive performance in recently abstinent chronic cocaine abusers..\" J Neuroimaging. 2004 Apr; Pubmed PMID: 23994817\n",
      "Sun HQ, Guo S, Chen DF, Jiang ZN, Liu Y, Di XL, Yang FD, Zhang XY, Kosten TR, Lu L \"Family support and employment as predictors of smoking cessation success: a randomized, double-blind, placebo-controlled trial of nicotine sublingual tablets in Chinese smokers..\" Am J Drug Alcohol Abuse. 2009;35(3):183-8. Pubmed PMID: 19462302\n",
      "Kosten TR, Jalali B, Hogan I, Kleber HD \"Family denial as a prognostic factor in opiate addict treatment outcome..\" J. Nerv. Ment. Dis.. 1983 Oct;171(10):611-6. Pubmed PMID: 6619824\n",
      "Petrakis I, Carroll KM, Nich C, Gordon L, Kosten T, Rounsaville B \"Fluoxetine treatment of depressive disorders in methadone-maintained opioid addicts..\" Drug Alcohol Depend. 1998 May; Pubmed PMID: 9649975\n",
      "Kosten TR \"For Council on Addictions of American Psychiatry Association. Policy—statement on methadone maintenance treatment..\" Am J Psychiatry. 1994;\n",
      "Wu JQ, Kosten TR, Zhang XY \"Free radicals, antioxidant defense systems, and schizophrenia.\" Prog Neuropsychopharmacol Biol Psychiatry. 2013 Oct; Pubmed PMID: 23470289\n",
      "Kosten TA, Gawin FH, Kosten TR, Rounsaville BJ \"Gender differences in cocaine use and treatment response..\" J Subst Abuse Treat.;10(1):63-6. Pubmed PMID: 8450576\n",
      "Han M, Huang XF, Chen DC, Xiu MH, Hui L, Liu H, Kosten TR, Zhang XY \"Gender differences in cognitive function of patients with chronic schizophrenia..\" Prog. Neuropsychopharmacol. Biol. Psychiatry. 2012 Jul 20; Pubmed PMID: 22820676\n",
      "Kosten TR \"Future of anti-addiction vaccines..\" Stud Health Technol Inform. 2005;118:177-85. Pubmed PMID: 16301778\n",
      "He J, Xie Y, Tao J, Su H, Wu W, Zou S, Zhang J, Zhang J, Zhang H, Yang X, Guo J, Tang W, Zhang F, Liu J, Liu L, Chen Y, Wen N, Kosten TR, Zhang XY \"Gender differences in socio-demographic and clinical characteristics of methamphetamine inpatients in a Chinese population..\" Drug Alcohol Depend. 2013 Jun 1;130(41277):94-100. Pubmed PMID: 23149112\n",
      "Zhang XY, Chen da C, Xiu MH, Yang FD, Haile CN, Kosten TA, Kosten TR \"Gender differences in never-medicated first-episode schizophrenia and medicated chronic schizophrenia patients..\" J Clin Psychiatry. 2012 Aug;73(7):1025-33. Pubmed PMID: 22901352\n",
      "Kosten TR, Kosten TA, McDougle CJ, Hameedi FA, McCance EF, Rosen MI, Oliveto AH, Price LH \"Gender differences in response to intranasal cocaine administration to humans..\" Biol. Psychiatry. 1996 Jan 15;39(2):147-8. Pubmed PMID: 8717615\n",
      "Chen da C, Zhou MA, Zhou DH, Xiu MH, Wu GY, Kosten TR, Zhang XY \"Gender differences in the prevalence of diabetes mellitus in chronic hospitalized patients with schizophrenia on long-term antipsychotics..\" Psychiatry Res. 2011 Apr 30;186(41308):451-3. Pubmed PMID: 20797801\n",
      "Zhang XY, Chen da C, Qi LY, Wang F, Xiu MH, Chen S, Wu GY, Kosten TA, Kosten TR \"Gender differences in the prevalence, risk and clinical correlates of tardive dyskinesia in Chinese schizophrenia..\" Psychopharmacology (Berl.). 2009 Sep;205(4):647-54. Pubmed PMID: 19529921\n",
      "Haile CN, Kosten TR, Kosten TA \"Genetics of dopamine and its contribution to cocaine addiction..\" Behav. Genet.. 2007 Jan;37(1):119-45. Pubmed PMID: 17063402\n",
      "Kosten TR, Rounsaville BJ, Kosten TA, Merikangas K \"Gender differences in the specificity of alcoholism transmission among the relatives of opioid addicts..\" J. Nerv. Ment. Dis.. 1991 Jul;179(7):392-400. Pubmed PMID: 1869867\n",
      "Tucker KA, Browndyke JN, Gottschalk PC, Cofrancesco AT, Kosten TR \"Gender-specific vulnerability for rCBF abnormalities among cocaine abusers..\" Neuroreport. 2004 Apr 9;15(5):797-801. Pubmed PMID: 15073517\n",
      "McCance-Katz EF, Hart CL, Boyarsky B, Kosten T, Jatlow P \"Gender effects following repeated administration of cocaine and alcohol in humans.\" Subst Use Misuse. 2005; Pubmed PMID: 15830733\n",
      "McCance-Katz EF, Kosten TA, Kosten TR \"Going from the bedside back to the bench with ecopipam: a new strategy for cocaine pharmacotherapy development..\" Psychopharmacology (Berl.). 2001 Jun;155(4):327-9. Pubmed PMID: 11441421\n",
      "Manji H, Chen G, Potter W, Kosten TR \"Guanine nucleotide binding proteins in opioid-dependent patients..\" Biol. Psychiatry. 1997 Jan 15;41(2):130-4. Pubmed PMID: 9018382\n",
      "Margolin A, Avants SK, Malison RT, Kosten TR \"High-and low-dose mazindol for cocaine dependence in methadone-maintained patients: A preliminary evaluation.\" Substance Abuse. 1997;\n",
      "Meandzija B, O'Connor PG, Fitzgerald B, Rounsaville BJ, Kosten TR \"HIV infection and cocaine use in methadone maintained and untreated intravenous drug users..\" Drug Alcohol Depend. 1994 Oct;36(2):109-13. Pubmed PMID: 7851277\n",
      "Oliveto AH, Rosen MI, Kosten TA, Hameedi FA, Woods SW, Kosten TR \"Hydromorphone-naloxone combinations in opioid-dependent humans under a naloxone novel-response discrimination procedure..\" Exp Clin Psychopharmacol. 1998 May;6(2):169-78. Pubmed PMID: 9608349\n",
      "Gardner TJ, Kosten TR \"Human laboratory and neuroimaging studies in substance use disorders: developing new treatment approaches..\" Am J Drug Alcohol Abuse. 2007;33(6):765-7. Pubmed PMID: 17994472\n",
      "66. O’Connor PG, Meandzija B, Poling J, Kosten TR, Fitzgerald B, Rounsaville BJ \"HIV vaccine preparedness trials in injection-drug users: Are we prepared?.\" Substance Abuse. 1995;\n",
      "Kosten TR, Rosen M, Bond J, Settles M, Roberts JS, Shields J, Jack L, Fox B \"Human therapeutic cocaine vaccine: safety and immunogenicity..\" Vaccine. 2002 Jan 15;20(41463):1196-204. Pubmed PMID: 11803082\n",
      "Kosten TR \"Images in psychiatry. Marie Nyswander, 1919-1986..\" Am J Psychiatry. 1998 Dec;155(12):1766. Pubmed PMID: 9842790\n",
      "Kosten TR \"Images in Psychiatry: Abraham Winkler, MD: 1910-1981.\" American Journal of Psychiatry. 1998;\n",
      "Shen X, Kosten TR \"Immunotherapy for drug abuse..\" CNS Neurol Disord Drug Targets. 2011 Dec 1;10(8):876-9. Pubmed PMID: 22229313\n",
      "Kosten T, Owens SM \"Immunotherapy for the treatment of drug abuse..\" Pharmacol. Ther.. 2005 Oct;108(1):76-85. Pubmed PMID: 16023218\n",
      "Najavits LM, Norman SB, Kivlahan D, Kosten TR \"Improving PTSD/Substance Abuse Treatment in the VA: A Survey of Providers..\" Am J Addict. 2010 May;19(3):257-63. Pubmed PMID: 20525033\n",
      "Carroll KM, Chang G, Behr H, Clinton B, Kosten TR \"Improving treatment outcome in pregnant methadone maintained women; Results from a randomized clinical trial.\" Am J Addictions. 1995;\n",
      "Chang G, Carroll KM, Behr HM, Kosten TR \"Improving treatment outcome in pregnant opiate-dependent women..\" J Subst Abuse Treat. 1992;9(4):327-30. Pubmed PMID: 1479630\n",
      "Zhang XY, Xiu MH, Chen da C, Zhu FY, Wu GY, Haile CN, Lu L, Kosten TA, Kosten TR \"Increased S100B serum levels in schizophrenic patients with tardive dyskinesia: association with dyskinetic movements..\" J Psychiatr Res. 2010 May;44(7):429-33. Pubmed PMID: 19932492\n",
      "Zhang XY, Xiu MH, Song C, Chen da C, Wu GY, Haile CN, Kosten TA, Kosten TR \"Increased serum S100B in never-medicated and medicated schizophrenic patients..\" J Psychiatr Res. 2010 Dec; Pubmed PMID: 20510426\n",
      "Singha AK, McCance-Katz EF, Heck SA, Kosten TR, Oliveto A \"Individual differences in humans responding under a cocaine discrimination procedure: discriminators versus nondiscriminators..\" Exp Clin Psychopharmacol. 1999 Nov;7(4):391-8. Pubmed PMID: 10609974\n",
      "Qi LY, Xiu MH, Chen da C, Wang F, Kosten TA, Kosten TR, Zhang XY \"Increased serum S100B levels in chronic schizophrenic patients on long-term clozapine or typical antipsychotics..\" Neurosci. Lett.. 2009 Sep 22;462(2):113-7. Pubmed PMID: 19539717\n",
      "Avants SK, Margolin A, Kosten TR \"Influence of treatment readiness on outcomes of two pharmacotherapy trials for cocaine abuse among methadone-maintained patients.\" Psychology Addictive Behaviors. 1996;\n",
      "Kosten TR, Rounsaville BJ, Foley SH \"Inpatient vs. outpatient cocaine abuse treatments..\" NIDA Res. Monogr.. 1989;95:312-3. Pubmed PMID: 2640976\n",
      "Rosenheck R, Harkness L, Johnson B, Sweeney C, Buck N, Deegan D, Kosten T \"Intensive community-focused treatment of veterans with dual diagnoses..\" Am J Psychiatry. 1998 Oct; Pubmed PMID: 9766776\n",
      "Kosten TR, Woods SW, Rosen MI, Pearsall HR \"Interactions of cocaine with nimodipine: a brief report..\" Am J Addict. 1999;8(1):77-81. Pubmed PMID: 10189518\n",
      "Zhang XY, Tang W, Xiu MH, Chen da C, Yang FD, Tan YL, Wang ZR, Zhang F, Liu J, Liu L, Chen Y, Wen N, Kosten TR \"Interleukin 18 and cognitive impairment in first episode and drug naïve schizophrenia versus healthy controls..\" Brain Behav. Immun.. 2013 Aug;32:105-11. Pubmed PMID: 23499732\n",
      "72. Kosten T, Gawin FH, Silverman DG, Fleming J, Compton M, Jatlow P, Byck R \"Intravenous cocaine challenges during desipramine maintenance.\" Neuropsychopharmacology. 1992 Nov; Pubmed PMID: 1388643\n",
      "Oliveto A, Poling J, Kosten TR, Gonsai K \"Isradipine and dextromethorphan in methadone-maintained humans under a naloxone discrimination procedure..\" Eur. J. Pharmacol.. 2004 May 3;491(41308):157-68. Pubmed PMID: 15140632\n",
      "Kosten T, Silverman DG, Fleming J, Kosten TA, Gawin FH, Compton M, Jatlow P, Byck R \"Intravenous cocaine challenges during naltrexone maintenance: a preliminary study..\" Biol Psychiatry. 1992 Sep; Pubmed PMID: 1445971\n",
      "Gottschalk PC, Kosten TR \"Isradipine enhancement of cerebral blood flow in abstinent cocaine abusers with and without chronic perfusion deficits..\" Am J Addict. 2002;11(3):200-8. Pubmed PMID: 12202012\n",
      "Kosten TR, Oliveto A, Sevarino KA, Gonsai K, Feingold A \"Ketoconazole increases cocaine and opioid use in methadone maintained patients..\" Drug Alcohol Depend. 2002 Apr 1;66(2):173-80. Pubmed PMID: 11906804\n",
      "Li W, Wei J, Zhou DF, Tan YL, Cao YL, Zhang XY, Wu G, Kosten TA, Kosten TR \"Lack of association between the BDNF C270T polymorphism and schizophrenia in a Chinese Han population..\" Schizophr. Res.. 2007 Dec;97(41277):297-8. Pubmed PMID: 17669628\n",
      "Rounsaville BJ, Kosten TR, Kleber HD \"Long-term changes in current psychiatric diagnoses of treated opiate addicts..\" Compr Psychiatry.;27(5):480-98. Pubmed PMID: 3757496\n",
      "Zhang XY, Cao LY, Song C, Wu GY, Chen da C, Qi LY, Wang F, Xiu MH, Chen S, Zhang Y, Lu L, Kosten TA, Kosten TR \"Lower serum cytokine levels in smokers than nonsmokers with chronic schizophrenia on long-term treatment with antipsychotics..\" Psychopharmacology (Berl.). 2008 Dec;201(3):383-9. Pubmed PMID: 18719893\n",
      "Zhang XY, Liang J, Chen DC, Xiu MH, De Yang F, Kosten TA, Kosten TR \"Low BDNF is associated with cognitive impairment in chronic patients with schizophrenia..\" 2012 Jan 26; Pubmed PMID: 22274000\n",
      "Zhen YF, Zhang J, Liu XY, Fang H, Tian LB, Zhou DH, Kosten TR, Zhang XY \"Low BDNF is associated with cognitive deficits in patients with type 2 diabetes..\" Psychopharmacology (Berl.). 2013 May;227(1):93-100. Pubmed PMID: 23263460\n",
      "Liu H, Kang Y, Liang J, Li C, Xiu M, Chen D, Yang F, Wang F, Wu G, Haile CN, Kosten TA, Kosten TR, Zhang XY \"Lower serum interleukin-2 levels in schizophrenic patients with tardive dyskinesia..\" 2012 Mar 12; Pubmed PMID: 22417931\n",
      "Kosten TR \"Mandatory drug testing needs controlled evaluation..\" Am J Bioeth. 2004;4(1):32. Pubmed PMID: 15035939\n",
      "Kosten TR, O'Connor PG \"Management of drug and alcohol withdrawal..\" N. Engl. J. Med.. 2003 May 1;348(18):1786-95. Pubmed PMID: 12724485\n",
      "Margolin A, Avants SK, Kosten TR \"Mazindol for relapse prevention to cocaine abuse in methadone-maintained patients..\" Am J Drug Alcohol Abuse. 1995 Nov;21(4):469-81. Pubmed PMID: 8561098\n",
      "Stine SM, Krystal JH, Kosten TR, Charney DS \"Mazindol treatment for cocaine dependence..\" Drug Alcohol Depend. 1995 Oct;39(3):245-52. Pubmed PMID: 8556974\n",
      "Diakogiannis IA, Steinberg M, Kosten TR \"Mazindol treatment of cocaine abuse. A double-blind investigation..\" NIDA Res. Monogr.. 1990;105:514. Pubmed PMID: 1876105\n",
      "Reid MC, Tinetti ME, O'Connor PG, Kosten TR, Concato J \"Measuring alcohol consumption among older adults: a comparison of available methods..\" Am J Addict.;12(3):211-9. Pubmed PMID: 12851017\n",
      "Kosten TR \"Medications development and the war on drugs: victims of the Gulf war?.\" Biol. Psychiatry. 1991 Mar 15;29(6):521-3. Pubmed PMID: 2054428\n",
      "Stine SM, Grillon CG, Morgan CA, Kosten TR, Charney DS, Krystal JH \"Methadone patients exhibit increased startle and cortisol response after intravenous yohimbine..\" Psychopharmacology (Berl.). 2001 Mar;154(3):274-81. Pubmed PMID: 11351934\n",
      "Streltzer J, Kosten TR \"Methadone maintenance therapy and chronic pain..\" JAMA. 2003 Nov; Pubmed PMID: 14612466\n",
      "Stine SM, Kosten TR \"Methadone dose in the treatment of opiate dependence.\" Medscape Mental Health. 1997;\n",
      "Schottenfeld RS, Chawarski MC, Pakes JR, Pantalon MV, Carroll KM, Kosten TR \"Methadone versus buprenorphine with contingency management or performance feedback for cocaine and opioid dependence..\" Am J Psychiatry. 2005 Feb;162(2):340-9. Pubmed PMID: 15677600\n",
      "Nielsen DA, Harding MJ, Hamon SC, Huang W, Kosten TR \"Modifying the role of serotonergic 5-HTTLPR and TPH2 variants on disulfiram treatment of cocaine addiction: a preliminary study..\" Genes Brain Behav. 2012 Aug; Pubmed PMID: 22925276\n",
      "Margolin A, Avants SK, Rounsaville B, Kosten TR, Schottenfeld RS \"Motivational factors in cocaine pharmacotherapy trials with methadone-maintained patients: problems and paradoxes..\" J Psychoactive Drugs.;29(2):205-12. Pubmed PMID: 9250948\n",
      "Kosten TR, Rounsaville BJ, Kleber HD \"Multidimensionality and prediction of treatment outcome in opioid addicts: 2.5-year follow-up..\" Compr Psychiatry.;28(1):41346. Pubmed PMID: 3802797\n",
      "Jacobsen LK, Kosten TR \"Naloxone challenge as a biological predictor of treatment outcome in opiate addicts..\" Am J Drug Alcohol Abuse. 1989;15(4):355-66. Pubmed PMID: 2596440\n",
      "Mason JW, Kosten TR, Giller EL \"Multidimensional hormonal discrimination of paranoid schizophrenic from bipolar manic patients..\" Biol. Psychiatry. 1991 Mar 1;29(5):457-66. Pubmed PMID: 2018819\n",
      "Kleber HD, Kosten TR \"Naltrexone induction: psychologic and pharmacologic strategies.\" J Clin Psychiatry. 1984 Sep; Pubmed PMID: 6469934\n",
      "Krupitsky E, Zvartau E, Blokhina E, Verbitskaya E, Tsoy M, Wahlgren V, Burakov A, Masalov D, Romanova TN, Palatkin V, Tyurina A, Yaroslavtseva T, Sinha R, Kosten TR \"Naltrexone with or without guanfacine for preventing relapse to opiate addiction in St.-Petersburg, Russia.\" Drug Alcohol Depend. 2013 Oct; Pubmed PMID: 23683793\n",
      "Sevarino KA, Oliveto A, Kosten TR \"Neurobiological adaptations to psychostimulants and opiates as a basis of treatment development..\" Ann. N. Y. Acad. Sci.. 2000;909:51-87. Pubmed PMID: 10911924\n",
      "Markou A, Kosten TR, Koob GF \"Neurobiological similarities in depression and drug dependence: a self-medication hypothesis..\" Neuropsychopharmacology. 1998 Mar;18(3):135-74. Pubmed PMID: 9471114\n",
      "Krystal J, Kosten TR, Perry B, Southwick S, Mason JW, Giller EL \"Neurobiological aspects of post traumatic stress disorder: Review of clinical and pre-clinical studies..\" Behavior Therapy. 1989;\n",
      "Sinha R, Lacadie C, Skudlarski P, Fulbright RK, Rounsaville BJ, Kosten TR, Wexler BE \"Neural activity associated with stress-induced cocaine craving: a functional magnetic resonance imaging study..\" Psychopharmacology (Berl.). 2005 Dec;183(2):171-80. Pubmed PMID: 16163517\n",
      "Kosten TR \"Neurobiology of abused drugs. Opioids and stimulants..\" J. Nerv. Ment. Dis.. 1990 Apr;178(4):217-27. Pubmed PMID: 2156952\n",
      "Kosten TR, Margolin A \"New developments in opioid abuse treatment.\" Annals Clinical Psychiatry. 1990;\n",
      "Sernyak MJ, Kosten TR, Fontana A, Rosenheck R \"Neuroleptic use in the treatment of Post-Traumatic Stress Disorder..\" Psychiatr Q. 2001;72(3):197-213. Pubmed PMID: 11467155\n",
      "Kosten TR, Gardner TJ \"New hot topics sections: 1. China's new march forward in addiction treatment: methadone for the masses. 2. Issues in formulating DSM V..\" Am J Drug Alcohol Abuse. 2008;34(2):123-6. Pubmed PMID: 18293228\n",
      "Kosten TR, Kosten TA \"New medication strategies for comorbid substance use and bipolar affective disorders..\" Biol. Psychiatry. 2004 Nov 15;56(10):771-7. Pubmed PMID: 15556122\n",
      "Zhang XY, Tan YL, Zhou DF, Haile CN, Wu GY, Cao LY, Kosten TA, Kosten TR \"Nicotine dependence, symptoms and oxidative stress in male patients with schizophrenia..\" Neuropsychopharmacology. 2007 Sep;32(9):2020-4. Pubmed PMID: 17228336\n",
      "Ziedonis DM, Kosten TR, Glazer WM, Frances RJ \"Nicotine dependence and schizophrenia..\" Hosp Community Psychiatry. 1994 Mar;45(3):204-6. Pubmed PMID: 7910577\n",
      "Zhang XY, Xiu MH, Chen da C, Yang FD, Wu GY, Lu L, Kosten TA, Kosten TR \"Nicotine dependence and serum BDNF levels in male patients with schizophrenia.\" Psychopharmacology (Berl).. 2010 Oct; Pubmed PMID: 20661552\n",
      "George TP, Ziedonis DM, Feingold A, Pepper WT, Satterburg CA, Winkel J, Rounsaville BJ, Kosten TR \"Nicotine transdermal patch and atypical antipsychotic medications for smoking cessation in schizophrenia..\" Am J Psychiatry. 2000 Nov;157(11):1835-42. Pubmed PMID: 11058482\n",
      "Zhang X, Guan SL, Wang ZQ, You Y, Sun SL, Hui L, Miao LN, Yu Y, Kosten TR, Zhang XY \"No association between the type 2 diabetes mellitus susceptibility gene, SLC30A8 and schizophrenia in a Chinese population..\" Hum Psychopharmacol. 2012 Jul;27(4):392-6. Pubmed PMID: 22778022\n",
      "Kleber HD, Kosten TR, Gaspari J, Topazian M \"Nontolerance to the opioid antagonism of naltrexone..\" Biol. Psychiatry. 1985 Jan;20(1):66-72. Pubmed PMID: 2981129\n",
      "Newton TF, De La Garza R, Brown G, Kosten TR, Mahoney JJ, Haile CN \"Noradrenergic a(1) Receptor Antagonist Treatment Attenuates Positive Subjective Effects of Cocaine in Humans: A Randomized Trial..\" PLoS ONE. 2012;7(2):e30854. Pubmed PMID: 22319592\n",
      "McDougle CJ, Black JE, Malison RT, Zimmermann RC, Kosten TR, Heninger GR, Price LH \"Noradrenergic dysregulation during discontinuation of cocaine use in addicts..\" Arch. Gen. Psychiatry. 1994 Sep;51(9):713-9. Pubmed PMID: 8080348\n",
      "Sofuoglu M, Kosten TR \"Novel approaches to the treatment of cocaine addiction..\" CNS Drugs. 2005;19(1):13-25. Pubmed PMID: 15651902\n",
      "Krystal JH, Woods SW, Kosten TR, Rosen MI, Seibyl JP, van Dyck CC, Price LH, Zubal IG, Hoffer PB, Charney DS \"Opiate dependence and withdrawal: preliminary assessment using single photon emission computerized tomography (SPECT)..\" Am J Drug Alcohol Abuse. 1995 Feb;21(1):47-63. Pubmed PMID: 7762544\n",
      "Fiellin DA, Rosenheck RA, Kosten TR \"Office-based treatment for opioid dependence: reaching new patient populations..\" Am J Psychiatry. 2001 Aug;158(8):1200-4. Pubmed PMID: 11481150\n",
      "Shorter D, Kosten TR \"Novel pharmacotherapeutic treatments for cocaine addiction..\" 2011 Nov 3;9(1):119. Pubmed PMID: 22047090\n",
      "Best SE, Oliveto AH, Kosten TR \"Opioid addiction: Recent advances in detoxification and maintenance therapy.\" CNS Drugs. 1996;\n",
      "Kosten TR, Krystal JH, Charney DS, Price LH, Morgan CH, Kleber HD \"Opioid antagonist challenges in buprenorphine maintained patients..\" Drug Alcohol Depend. 1990 Feb;25(1):73-8. Pubmed PMID: 2323312\n",
      "Stotts AL, Dodrill CL, Kosten TR \"Opioid dependence treatment: options in pharmacotherapy..\" Expert Opin Pharmacother. 2009 Aug;10(11):1727-40. Pubmed PMID: 19538000\n",
      "Margolin A, Avants SK, Kosten TR \"Pemoline for the treatment of cocaine dependence in methadone-maintained patients..\" J Psychoactive Drugs.;28(3):301-4. Pubmed PMID: 8895115\n",
      "Kosten TR, Rounsaville BJ, Kleber HD \"Parental alcoholism in opioid addicts..\" J. Nerv. Ment. Dis.. 1985 Aug;173(8):461-9. Pubmed PMID: 4020363\n",
      "Sigmon SC, Bisaga A, Nunes EV, O'Connor PG, Kosten T, Woody G \"Opioid detoxification and naltrexone induction strategies: recommendations for clinical practice..\" Am J Drug Alcohol Abuse. 2012 May;38(3):187-99. Pubmed PMID: 22404717\n",
      "Potenza MN, Kosten TR, Rounsaville BJ \"Pathological gambling.\" JAMA. 2001 Jul;\n",
      "Kosten TR, Novak P, Kleber HD \"Perceived marital and family environment of opiate addicts..\" Am J Drug Alcohol Abuse. 1984;10(4):491-501. Pubmed PMID: 6534181\n",
      "Rosen MI, Bridge TP, O’Malley SS, Pearsall HR, Maritini B, O’Connor PG, Brett-Smith H, Thomas HM, van Dyke CH, Woods SW, Kosten TR. \"Peptide T treatment of cognitive impairment in HIV positive intravenous drug users.\" Am J Addictions. 1992;\n",
      "Lane SD, Moeller FG, Steinberg JL, Buzby M, Kosten TR \"Performance of cocaine dependent individuals and controls on a response inhibition task with varying levels of difficulty..\" Am J Drug Alcohol Abuse. 2007;33(5):717-26. Pubmed PMID: 17891664\n",
      "McIntosh BJ, Zhang XY, Kosten T, Tan SP, Xiu MH, Rakofsky J, Harvey PD \"Performance-based assessment of functional skills in severe mental illness: Results of a large-scale study in China..\" J Psychiatr Res. 2011 Aug;45(8):1089-94. Pubmed PMID: 21300378\n",
      "Tucker KA, Potenza MN, Beauvais JE, Browndyke JN, Gottschalk PC, Kosten TR \"Perfusion abnormalities and decision making in cocaine dependence.\" Biol Psychiatry. 2004 Oct; Pubmed PMID: 15450790\n",
      "Kosten TA, Kosten TR, Rounsaville BJ \"Personality disorders in opiate addicts show prognostic specificity..\" J Subst Abuse Treat. 1989;6(3):163-8. Pubmed PMID: 2795705\n",
      "Kosten TR, Wu G, Huang W, Harding MJ, Hamon SC, Lappalainen J, Nielsen DA \"Pharmacogenetic Randomized Trial for Cocaine Abuse: Disulfiram and Dopamine ß-Hydroxylase..\" Biol. Psychiatry. 2012 Aug 17; Pubmed PMID: 22906516\n",
      "Shorter D, Nielsen DA, Huang W, Harding MJ, Hamon SC, Kosten TR. \"Pharmacogenetic randomized trial for cocaine abuse: disulfiram and α1A-adrenoceptor gene variation.\" Eur Neuropsychopharmacol. 2013 Nov; Pubmed PMID: 23849431\n",
      "Haile CN, Kosten TA, Kosten TR \"Pharmacogenetic treatments for drug addiction: alcohol and opiates..\" Am J Drug Alcohol Abuse. 2008;34(4):355-81. Pubmed PMID: 18584566\n",
      "Kosten TR \"Pharmacological approaches to cocaine dependence..\" Clin Neuropharmacol. 1992;15:70A-71A. Pubmed PMID: 1498999\n",
      "Haile CN, Kosten TR, Kosten TA \"Pharmacogenetic treatments for drug addiction: cocaine, amphetamine and methamphetamine..\" Am J Drug Alcohol Abuse. 2009;35(3):161-77. Pubmed PMID: 19462300\n",
      "Sofuoglu M, Kosten TR \"Pharmacologic management of relapse prevention in addictive disorders..\" Psychiatr. Clin. North Am.. 2004 Dec;27(4):627-48. Pubmed PMID: 15550284\n",
      "Kosten TA, Kosten TR \"Pharmacological blocking agents for treating substance abuse..\" J. Nerv. Ment. Dis.. 1991 Oct;179(10):583-92. Pubmed PMID: 1919542\n",
      "Kosten TR \"Pharmacotherapeutic interventions for cocaine abuse. Matching patients to treatments..\" J. Nerv. Ment. Dis.. 1989 Jul;177(7):379-89. Pubmed PMID: 2664072\n",
      "Gardner TJ, Kosten TR \"Pharmacotherapeutic environments for substance use disorders..\" Am J Drug Alcohol Abuse. 2007;33(5):627-9. Pubmed PMID: 17891655\n",
      "Verrico CD, Haile CN, Newton TF, Kosten TR, De La Garza R \"Pharmacotherapeutics for substance-use disorders: a focus on dopaminergic medications.\" Expert Opin Investig Drugs. 2013 Dec; Pubmed PMID: 24033127\n",
      "Kosten TR \"Pharmacotherapy for addictions: partnering with contingency management..\" Am J Drug Alcohol Abuse. 2007;33(3):341-2. Pubmed PMID: 17613962\n",
      "Kosten TR, Morgan CM, Falcione J, Schottenfeld RS \"Pharmacotherapy for cocaine-abusing methadone-maintained patients using amantadine or desipramine..\" Arch. Gen. Psychiatry. 1992 Nov;49(11):894-8. Pubmed PMID: 1444728\n",
      "Kosten TR, Frank JB, Dan E, McDougle CJ, Giller EL \"Pharmacotherapy for posttraumatic stress disorder using phenelzine or imipramine..\" J. Nerv. Ment. Dis.. 1991 Jun;179(6):366-70. Pubmed PMID: 2051152\n",
      "Warner EA, Kosten TR, O'Connor PG \"Pharmacotherapy for opioid and cocaine abuse..\" Med. Clin. North Am.. 1997 Jul;81(4):909-25. Pubmed PMID: 9222260\n",
      "Haile CN, Kosten TR \"Pharmacotherapy for stimulant-related disorders..\" Curr Psychiatry Rep. 2013 Nov; Pubmed PMID: 24142188\n",
      "McCance-Katz E, Sevarino K, Gottschalk PC, Kosten T \"Pharmacotherapy of stimulant dependence: one of Japan's greatest public health challenges..\" Nihon Shinkei Seishin Yakurigaku Zasshi. 1999 Oct; Pubmed PMID: 10637824\n",
      "Ziedonis DM, Kosten TR \"Pharmacotherapy improves treatment outcome in depressed cocaine addicts..\" J Psychoactive Drugs.;23(4):417-25. Pubmed PMID: 1813613\n",
      "Kosten TR \"Pharmacotherapy of cerebral ischemia in cocaine dependence..\" Drug Alcohol Depend. 1998 Jan 1;49(2):133-44. Pubmed PMID: 9543650\n",
      "Kosten TR, Morgan C, Kleber HD \"Phase II clinical trials of buprenorphine: detoxification and induction onto naltrexone..\" NIDA Res. Monogr.. 1992;121:101-19. Pubmed PMID: 1406906\n",
      "Kosten TR, Astrachan BM \"Planning for crisis on a psychiatric research ward: a task analysis..\" Compr Psychiatry. 1981 May; Pubmed PMID: 7238004\n",
      "Bowers MB, Malison RT, Seibyl JP, Kosten TR \"Plasma homovanillic acid and the dopamine transporter during cocaine withdrawal..\" Biol. Psychiatry. 1998 Feb 15;43(4):278-81. Pubmed PMID: 9513737\n",
      "Zhang XY, Chen DC, Xiu MH, Tang W, Zhang F, Liu L, Chen Y, Liu J, Yao JK, Kosten TA, Kosten TR \"Plasma total antioxidant status and cognitive impairments in schizophrenia..\" 2012 May 1; Pubmed PMID: 22555016\n",
      "Kosten TR, Tucker K, Gottschalk PC, Rinder CS, Rinder HM \"Platelet abnormalities associated with cerebral perfusion defects in cocaine dependence..\" Biol. Psychiatry. 2004 Jan 1;55(1):91-7. Pubmed PMID: 14706430\n",
      "Rinder HM, Ault KA, Jatlow PI, Kosten TR, Smith BR \"Platelet alpha-granule release in cocaine users..\" Circulation. 1994 Sep;90(3):1162-7. Pubmed PMID: 7522132\n",
      "Jacobsen LK, Staley JK, Zoghbi SS, Seibyl JP, Kosten TR, Innis RB, Gelernter J \"Prediction of dopamine transporter binding availability by genotype: a preliminary report..\" Am J Psychiatry. 2000 Oct;157(10):1700-3. Pubmed PMID: 11007732\n",
      "Sofuoglu M, Gonzalez G, Poling J, Kosten TR \"Prediction of treatment outcome by baseline urine cocaine results and self-reported cocaine use for cocaine and opioid dependence..\" Am J Drug Alcohol Abuse. 2003;29(4):713-27. Pubmed PMID: 14713135\n",
      "Kosten TR, Rounsaville BJ, Kleber HD \"Predictors of 2.5-year outcome in opioid addicts: pretreatment source of income..\" Am J Drug Alcohol Abuse. 1987;13(41276):19-32. Pubmed PMID: 3687883\n",
      "Dodrill CL, Helmer DA, Kosten TR \"Prescription pain medication dependence..\" Am J Psychiatry. 2011 May;168(5):466-71. Pubmed PMID: 21536702\n",
      "Mooney ME, Poling J, Gonzalez G, Gonsai K, Kosten T, Sofuoglu M \"Preliminary study of buprenorphine and bupropion for opioid-dependent smokers..\" Am J Addict.;17(4):287-92. Pubmed PMID: 18612883\n",
      "O'Brien CP, Charney DS, Lewis L, Cornish JW, Post RM, Woody GE, Zubieta JK, Anthony JC, Blaine JD, Bowden CL, Calabrese JR, Carroll K, Kosten T, Rounsaville B, Childress AR, Oslin DW, Pettinati HM, Davis MA, Demartino R, Drake RE, Fleming MF, Fricks L, Gl \"Priority actions to improve the care of persons with co-occurring substance abuse and other mental disorders: a call to action..\" Biol. Psychiatry. 2004 Nov 15;56(10):703-13. Pubmed PMID: 15556110\n",
      "Zhang XY, Al Jurdi RK, Zoghbi AW, Chen da C, Xiu MH, Tan YL, Yang FD, Kosten TR \"Prevalence, demographic and clinical correlates of suicide attempts in Chinese medicated chronic inpatients with schizophrenia.\" J Psychiatr Res. 2013 Oct; Pubmed PMID: 23791457\n",
      "Ramakrishnan M, Alves De Melo F, Kinsey BM, Ladbury JE, Kosten TR, Orson FM \"Probing cocaine-antibody interactions in buffer and human serum..\" PLoS ONE. 2012;7(7):e40518. Pubmed PMID: 22859949\n",
      "Sofuoglu M, Poling J, Gonzalez G, Gonsai K, Oliveto A, Kosten TR \"Progesterone effects on cocaine use in male cocaine users maintained on methadone: a randomized, double-blind, pilot study..\" Exp Clin Psychopharmacol. 2007 Oct;15(5):453-60. Pubmed PMID: 17924779\n",
      "Schottenfeld RS, Pakes JR, Kosten TR \"Prognostic factors in Buprenorphine- versus methadone-maintained patients..\" J. Nerv. Ment. Dis.. 1998 Jan;186(1):35-43. Pubmed PMID: 9457145\n",
      "Rounsaville BJ, Kosten TR, Weissman MM, Kleber HD \"Prognostic significance of psychopathology in treated opiate addicts. A 2.5-year follow-up study..\" Arch. Gen. Psychiatry. 1986 Aug;43(8):739-45. Pubmed PMID: 3729668\n",
      "Rounsaville BJ, Kosten TR, Weissman MM, Prusoff B, Pauls D, Anton SF, Merikangas K \"Psychiatric disorders in relatives of probands with opiate addiction..\" Arch. Gen. Psychiatry. 1991 Jan;48(1):33-42. Pubmed PMID: 1984760\n",
      "Kosten TR, Jacobs S, Mason J, Wahby V, Atkins S \"Psychological correlates of growth hormone response to stress..\" Psychosom Med.. 1984 Jan; Pubmed PMID: 6701254\n",
      "Brimijoin S, Shen X, Orson F, Kosten T \"Prospects, promise and problems on the road to effective vaccines and related therapies for substance abuse..\" Expert Rev Vaccines. 2013 Mar;12(3):323-32. Pubmed PMID: 23496671\n",
      "Jacobsen LK, Giedd JN, Kreek MJ, Gottschalk C, Kosten TR \"Quantitative medial temporal lobe brain morphology and hypothalamic-pituitary-adrenal axis function in cocaine dependence: a preliminary report..\" Drug Alcohol Depend. 2001 Mar 1;62(1):49-56. Pubmed PMID: 11173167\n",
      "Kosten TR, Rounsaville BJ \"Psychopathology in opioid addicts..\" Psychiatr. Clin. North Am.. 1986 Sep;9(3):515-32. Pubmed PMID: 3774603\n",
      "Jacobsen LK, Giedd JN, Gottschalk C, Kosten TR, Krystal JH \"Quantitative morphology of the caudate and putamen in patients with cocaine dependence..\" Am J Psychiatry. 2001 Mar;158(3):486-9. Pubmed PMID: 11229995\n",
      "Schottenfeld RS, Chawarski MC, Cubells JF, George TP, Lappalainen J, Kosten TR \"Randomized clinical trial of disulfiram for cocaine dependence or abuse during buprenorphine treatment.\" Drug Alcohol Depend. 2014 Mar; Pubmed PMID: 24462581\n",
      "Oliveto A, Poling J, Mancino MJ, Feldman Z, Cubells JF, Pruzinsky R, Gonsai K, Cargile C, Sofuoglu M, Chopra MP, Gonzalez-Haddad G, Carroll KM, Kosten TR \"Randomized, double blind, placebo-controlled trial of disulfiram for the treatment of cocaine dependence in methadone-stabilized patients..\" Drug Alcohol Depend. 2011 Jan; Pubmed PMID: 20828943\n",
      "Kosten TR, Kleber HD \"Rapid death during cocaine abuse: a variant of the neuroleptic malignant syndrome?.\" Am J Drug Alcohol Abuse. 1988;14(3):335-46. Pubmed PMID: 3055940\n",
      "O'Connor PG, Kosten TR \"Rapid and ultrarapid opioid detoxification techniques..\" JAMA. 1998 Jan 21;279(3):229-34. Pubmed PMID: 9438745\n",
      "Kosten TR, Krystal JH, Charney DS, Price LH, Morgan CH, Kleber HD \"Rapid detoxification from opioid dependence..\" Am J Psychiatry. 1989 Oct;146(10):1349. Pubmed PMID: 2675644\n",
      "Li XF, Zheng YL, Xiu MH, Chen da C, Kosten TR, Zhang XY \"Reduced plasma total antioxidant status in first-episode drug-naive patients with schizophrenia..\" Prog. Neuropsychopharmacol. Biol. Psychiatry. 2011 Jun 1;35(4):1064-7. Pubmed PMID: 21392552\n",
      "Chen da C, Xiu MH, Liu H, Zhang BS, Wang Y, Kosten TR, Zhang XY \"Reduced status of plasma total antioxidant capacity in schizophrenia with tardive dyskinesia..\" J Psychiatr Res. 2010 Nov;44(15):1111-2. Pubmed PMID: 20398909\n",
      "Stine SM, Kosten TR \"Reduction of opiate withdrawal-like symptoms by cocaine abuse during methadone and buprenorphine maintenance..\" Am J Drug Alcohol Abuse. 1994 Nov;20(4):445-58. Pubmed PMID: 7832179\n",
      "Kosten TR, Cheeves C, Palumbo J, Seibyl JP, Price LH, Woods SW \"Regional cerebral blood flow during acute and chronic abstinence from combined cocaine-alcohol abuse..\" Drug Alcohol Depend. 1998 May 1;50(3):187-95. Pubmed PMID: 9649971\n",
      "Kosten TR, Rounsaville BJ, Kleber HD \"Relationship of depression to psychosocial stressors in heroin addicts..\" J. Nerv. Ment. Dis.. 1983 Feb;171(2):97-104. Pubmed PMID: 6822825\n",
      "Kosten TR, Rounsaville BJ, Kleber HD \"Relationship of depression to clonidine detoxification of opiate addicts..\" Compr Psychiatry.;25(5):503-8. Pubmed PMID: 6488761\n",
      "Kosten TR, Jalali B, Steidl JH, Kleber HD \"Relationship of marital structure and interactions to opiate abuse relapse..\" Am J Drug Alcohol Abuse. 1987;13(4):387-99. Pubmed PMID: 3687898\n",
      "Rosen MI, McMahon TJ, Margolin A, Gill TS, Woods SW, Pearsall HR, Kreek MJ, Kosten TR \"Reliability of sequential naloxone challenge tests..\" Am J Drug Alcohol Abuse. 1995 Nov;21(4):453-67. Pubmed PMID: 8561097\n",
      "Wisner KL, Conley RR, Taylor SF, Kosten T, Rapaport MH, Brown LS \"Researcher experiences with IRBs: a survey of members of the American College of Neuropsychopharmacology..\" IRB.;33(5):14-20. Pubmed PMID: 22043746\n",
      "Sofuoglu M, Waters AJ, Mooney M, Kosten T \"Riluzole and D-amphetamine interactions in humans.\" Prog Neuropsychopharmacol Biol Psychiatry. 2008 Jan; Pubmed PMID: 17714844\n",
      "Poling J, Kosten TR \"Risperidone for substance dependent psychotic patients.\" 2005;\n",
      "Kosten TR, Kleber HD, Morgan C \"Role of opioid antagonists in treating intravenous cocaine abuse..\" Life Sci.. 1989;44(13):887-92. Pubmed PMID: 2927249\n",
      "Boutros NN, Gelernter J, Gooding DC, Cubells J, Young A, Krystal JH, Kosten T \"Sensory gating and psychosis vulnerability in cocaine-dependent individuals: preliminary data..\" Biol. Psychiatry. 2002 Apr 15;51(8):683-6. Pubmed PMID: 11955469\n",
      "Hirunsatit R, Ilomäki R, Malison R, Räsänen P, Ilomäki E, Kranzler HR, Kosten T, Sughondhabirom A, Thavichachart N, Tangwongchai S, Listman J, Mutirangura A, Gelernter J, Lappalainen J \"Sequence variation and linkage disequilibrium in the GABA transporter-1 gene (SLC6A1) in five populations: implications for pharmacogenetic research.\" BMC Genet. 2007 Oct; Pubmed PMID: 17941974\n",
      "Aronson SC, Black JE, McDougle CJ, Scanley BE, Jatlow P, Kosten TR, Heninger GR, Price LH \"Serotonergic mechanisms of cocaine effects in humans..\" Psychopharmacology (Berl.). 1995 May;119(2):179-85. Pubmed PMID: 7659765\n",
      "Graham DP, Helmer DA, Harding MJ, Kosten TR, Petersen NJ, Nielsen DA \"Serotonin transporter genotype and mild traumatic brain injury independently influence resilience and perception of limitations in veterans..\" J Psychiatr Res. 2013 Jun;47(6):835-42. Pubmed PMID: 23478049\n",
      "Oliveto A, Poling J, Mancino MJ, Williams DK, Thostenson J, Pruzinsky R, Gonsai K, Sofuoglu M, Gonzalez G, Tripathi S, Kosten TR \"Sertraline delays relapse in recently abstinent cocaine-dependent patients with depressive symptoms..\" Addiction. 2012 Jan;107(1):131-41. Pubmed PMID: 21707811\n",
      "Zhang XY, Tan YL, Zhou DF, Cao LY, Wu GY, Xu Q, Shen Y, Haile CN, Kosten TA, Kosten TR \"Serum BDNF levels and weight gain in schizophrenic patients on long-term treatment with antipsychotics..\" J Psychiatr Res. 2007 Dec;41(12):997-1004. Pubmed PMID: 17095017\n",
      "Wahby V, Ibrahim G, Friedenthal S, Giller E, Kosten T, Mason J \"Serum concentrations of circulating thyroid hormones in a group of depressed men.\" Neuropsychobiology. 1989; Pubmed PMID: 2639287\n",
      "Li SX, Li J, Epstein DH, Zhang XY, Kosten TR, Lu L \"Serum cortisol secretion during heroin abstinence is elevated only nocturnally..\" Am J Drug Alcohol Abuse. 2008;34(3):321-8. Pubmed PMID: 18428074\n",
      "Mason JW, Giller EL, Kosten TR \"Serum testosterone differences between patients with schizophrenia and those with affective disorder..\" Biol. Psychiatry. 1988 Feb 15;23(4):357-66. Pubmed PMID: 3342266\n",
      "Mason JW, Giller El, Kosten TR, Wahby VS \"Serum testosterone levels in post traumatic stress disorder inpatients.\" J Traumatic Stress. 1990;\n",
      "Southwick S, Mason JW, Giller EL, Kosten TR \"Serum thyroxine change and clinical recovery in psychiatric inpatients..\" Biol. Psychiatry. 1989 Jan;25(1):67-74. Pubmed PMID: 2912510\n",
      "Zhang XY, Zhang RL, Pan M, Chen da C, Xiu MH, Kosten TR \"Sex difference in the prevalence of smoking in Chinese schizophrenia..\" J Psychiatr Res. 2010 Oct;44(14):986-8. Pubmed PMID: 20334878\n",
      "Mason JW, Kennedy JL, Kosten TR, Giller EL \"Serum thyroxine levels in schizophrenic and affective disorder diagnostic subgroups..\" J. Nerv. Ment. Dis.. 1989 Jun;177(6):351-8. Pubmed PMID: 2723624\n",
      "Yang FD, Wang XQ, Liu XP, Zhao KX, Fu WH, Hao XR, Zhang XL, Huang GS, Qu SC, Bai JS, Huang XF, Kosten TR, Zhang XY \"Sex difference in QTc prolongation in chronic institutionalized patients with schizophrenia on long-term treatment with typical and atypical antipsychotics..\" Psychopharmacology (Berl.). 2011 Jul;216(1):41533. Pubmed PMID: 21301815\n",
      "Kosten TA, Jacobsen LK, Kosten TR \"Severity of precipitated opiate withdrawal predicts drug dependence by DSM-III-R criteria..\" Am J Drug Alcohol Abuse. 1989;15(3):237-50. Pubmed PMID: 2763981\n",
      "Li CS, Kosten TR, Sinha R \"Sex differences in brain activation during stress imagery in abstinent cocaine users: a functional magnetic resonance imaging study..\" Biol. Psychiatry. 2005 Mar 1;57(5):487-94. Pubmed PMID: 15737663\n",
      "Singha AK, McCance-Katz EF, Petrakis I, Kosten TR, Oliveto A \"Sex differences in self-reported and physiological response to oral cocaine and placebo in humans..\" Am J Drug Alcohol Abuse. 2000 Nov;26(4):643-57. Pubmed PMID: 11097197\n",
      "Li YQ, Wang XY, Zhai HF, Zhang XY, Kosten T, Lu L \"Sex- and age-dependent effects of early postnatal sibling deprivation on spatial learning and memory in adult rats..\" Behav Brain Res. 2008 Jan; Pubmed PMID: 17765982\n",
      "Zhang XY, Liu L, Liu S, Hong X, Chen da C, Xiu MH, Yang FD, Zhang Z, Zhang X, Kosten TA, Kosten TR \"Short-term tropisetron treatment and cognitive and p50 auditory gating deficits in schizophrenia..\" Am J Psychiatry. 2012 Sep 1;169(9):974-81. Pubmed PMID: 22952075\n",
      "Farren CK, Hameedi FA, Rosen MA, Woods S, Jatlow P, Kosten TR \"Significant interaction between clozapine and cocaine in cocaine addicts..\" Drug Alcohol Depend. 2000 May 1;59(2):153-63. Pubmed PMID: 10891628\n",
      "102. Kosten TR, Gawin FH, Kosten TA, Morgan C, Rounsaville BJ, Schottenfeld RS, Kleber HD \"Six month follow-up of short term pharmacotherapy for cocaine dependence.\" Am J Addictions. 1992;\n",
      "Satel SL, Kosten TR, Schuckit MA, Fischman MW \"Should protracted withdrawal from drugs be included in DSM-IV?.\" Am J Psychiatry. 1993 May;150(5):695-704. Pubmed PMID: 8097618\n",
      "Poling J, Oliveto A, Petry N, Sofuoglu M, Gonsai K, Gonzalez G, Martell B, Kosten TR \"Six-month trial of bupropion with contingency management for cocaine dependence in a methadone-maintained population..\" Arch. Gen. Psychiatry. 2006 Feb;63(2):219-28. Pubmed PMID: 16461866\n",
      "Zhang XY, Yu YQ, Sun S, Zhang X, Li W, Xiu MH, Chen da C, Yang FD, Zhu F, Kosten TA, Kosten TR \"Smoking and tardive dyskinesia in male patients with chronic schizophrenia..\" Prog. Neuropsychopharmacol. Biol. Psychiatry. 2011 Aug 15;35(7):1765-9. Pubmed PMID: 21723906\n",
      "Kosten TR, Rounsaville BJ \"Source of income as a predictor in opioid addicts: 2.5 year follow-up..\" NIDA Res. Monogr.. 1987;76:196-9. Pubmed PMID: 3125447\n",
      "Zhang XY, Li CB, Li M, Zheng YL, Zhang CX, Yan QZ, Liu WZ, Kang YM, Wang F, Chen da C, Xiu MH, Kosten TR \"Smoking initiation and schizophrenia: a replication study in a Chinese Han population..\" Schizophr. Res.. 2010 Jun;119(41277):110-4. Pubmed PMID: 20022218\n",
      "Zhang XY, Chen da C, Tan YL, Xiu MH, Cui J, Hui L, De Yang F, Kosten TR \"Socio-demographic and clinical characteristics of heavy and non-heavy smokers among schizophrenia inpatients in a Chinese Han population.\" Psychopharmacology (Berl). 2014 Jan; Pubmed PMID: 23963531\n",
      "van Dyck CH, Rosen MI, Thomas HM, McMahon TJ, Wallace EA, O'Connor PG, Sullivan M, Krystal JH, Hoffer PB, Woods SW \"SPECT regional cerebral blood flow alterations in naltrexone-precipitated withdrawal from buprenorphine..\" Psychiatry Res.. 1994 Dec; Pubmed PMID: 7701033\n",
      "Woods SW, O'Malley SS, Martini BL, McDougle CJ, Price LH, Krystal JH, Hoffer PB, Kosten TR \"SPECT regional cerebral blood flow and neuropsychological testing in non-demented HIV-positive drug abusers: preliminary results..\" Prog. Neuropsychopharmacol. Biol. Psychiatry. 1991;15(5):649-62. Pubmed PMID: 1956993\n",
      "Brown AE, Tonigan JS, Pavlik VN, Kosten TR, Volk RJ \"Spirituality and Confidence to Resist Substance Use Among Celebrate Recovery Participants..\" J Relig Health. 2011 Jan 19; Pubmed PMID: 21246280\n",
      "Orson FM, Rossen RD, Shen X, Lopez AY, Wu Y, Kosten TR \"Spontaneous Development of IgM Anti-Cocaine Antibodies in Habitual Cocaine Users: Effect on IgG Antibody Responses to a Cocaine Cholera Toxin B Conjugate Vaccine..\" Am J Addict. 2013 Mar;22(2):169-74. Pubmed PMID: 23414504\n",
      "Zhao LY, Shi J, Zhang XL, Epstein DH, Zhang XY, Liu Y, Kosten TR, Lu L \"Stress enhances retrieval of drug-related memories in abstinent heroin addicts..\" Neuropsychopharmacology. 2010 Feb;35(3):720-6. Pubmed PMID: 19890257\n",
      "Lago JA, Kosten TR \"Stimulant withdrawal..\" Addiction. 1994 Nov;89(11):1477-81. Pubmed PMID: 7841859\n",
      "Kosten TR \"Stress and addiction..\" Am J Psychiatry. 2011 Jun;168(6):566-8. Pubmed PMID: 21642477\n",
      "Kosten TR, Kleber HD \"Strategies to improve compliance with narcotic antagonists..\" Am J Drug Alcohol Abuse. 1984;10(2):249-66. Pubmed PMID: 6475891\n",
      "Lu L, Wang X, Kosten TR \"Stereotactic neurosurgical treatment of drug addiction..\" Am J Drug Alcohol Abuse. 2009;35(6):391-3. Pubmed PMID: 20014906\n",
      "Kosten TR, Ziedonis DM \"Substance abuse and schizophrenia: editors' introduction..\" Schizophr Bull. 1997;23(2):181-6. Pubmed PMID: 9165628\n",
      "Jacobsen LK, Southwick SM, Kosten TR \"Substance use disorders in patients with posttraumatic stress disorder: a review of the literature..\" Am J Psychiatry. 2001 Aug;158(8):1184-90. Pubmed PMID: 11481147\n",
      "Orson FM, Kinsey BM, Singh RA, Wu Y, Gardner T, Kosten TR \"Substance abuse vaccines..\" Ann. N. Y. Acad. Sci.. 2008 Oct;1141:257-69. Pubmed PMID: 18991962\n",
      "Zhang XY, Zhou DF, Qi LY, Chen S, Cao LY, Chen da C, Xiu MH, Wang F, Wu GY, Lu L, Kosten TA, Kosten TR \"Superoxide dismutase and cytokines in chronic patients with schizophrenia: association with psychopathology and response to antipsychotics..\" Psychopharmacology (Berl.). 2009 May;204(1):177-84. Pubmed PMID: 19139851\n",
      "Calhoun P, Najavits LM, Kosten T, Kivlahan D \"Substance Use in OIF/OEF Veterans.\" VA Health Services Research and Development For. 2007;\n",
      "Kosten TR, Rounsaville BJ, Babor TF, Spitzer RL, Williams JB \"Substance-use disorders in DSM-III-R. Evidence for the dependence syndrome across different psychoactive substances..\" Br J Psychiatry. 1987 Dec;151:834-43. Pubmed PMID: 2901887\n",
      "Kosten TR, Rounsaville BJ \"Suicidality among opioid addicts: 2.5 year follow-up..\" Am J Drug Alcohol Abuse. 1988;14(3):357-69. Pubmed PMID: 3189257\n",
      "Rounsaville BJ, Kosten T, Kleber H \"Success and failure at outpatient opioid detoxification. Evaluating the process of clonidine- and methadone-assisted withdrawal..\" J Nerv Ment Dis.. 1985; Pubmed PMID: 3881558\n",
      "Kosten TR, Mason JW, Giller EL, Ostroff RB, Harkness L \"Sustained urinary norepinephrine and epinephrine elevation in post-traumatic stress disorder..\" Psychoneuroendocrinology. 1987;12(1):13-20. Pubmed PMID: 3588809\n",
      "van Dyck CH, McMahon TJ, Rosen MI, O'Malley SS, O'Connor PG, Lin CH, Pearsall HR, Woods SW, Kosten TR \"Sustained-release methylphenidate for cognitive impairment in HIV-1-infected drug abusers: a pilot study..\" J Neuropsychiatry Clin Neurosci. 1997;9(1):29-36. Pubmed PMID: 9017526\n",
      "Martell BA, O'Connor PG, Kerns RD, Becker WC, Morales KH, Kosten TR, Fiellin DA \"Systematic review: opioid treatment for chronic back pain: prevalence, efficacy, and association with addiction..\" Ann. Intern. Med.. 2007 Jan 16;146(2):116-27. Pubmed PMID: 17227935\n",
      "Anton RF, Litten RZ, Falk DE, Palumbo JM, Bartus RT, Robinson RL, Kranzler HR, Kosten TR, Meyer RE, O'Brien CP, Mann K, Meulien D \"The Alcohol Clinical Trials Initiative (ACTIVE): Purpose and Goals for Assessing Important and Salient Issues for Medications Development in Alcohol Use Disorders..\" 2011 Sep 7; Pubmed PMID: 21900883\n",
      "Rounsaville BJ, Kosten TR, Kleber HD \"The antecedents and benefits of achieving abstinence in opioid addicts: a 2.5-year follow-up study..\" Am J Drug Alcohol Abuse. 1987;13(3):213-29. Pubmed PMID: 3687888\n",
      "Wang F, Xiu MH, Zhou DF, Cao LY, Wu GY, Kosten TA, Kosten TR, Zhang XY \"The CCR5 32-bp deletion allele is rare in a Chinese population..\" Schizophr. Res.. 2008 Apr;101(41277):341-3. Pubmed PMID: 18295459\n",
      "Gao Y, Orson FM, Kinsey B, Kosten T, Brimijoin S \"The concept of pharmacologic cocaine interception as a treatment for drug abuse..\" Chem. Biol. Interact.. 2010 Sep 6;187(41277):421-4. Pubmed PMID: 20219449\n",
      "Kosten TR, Rounsaville BJ, Babor TF, Spitzer RL, Williams JB \"The dependence syndrome across different psychoactive substances: revised DSM-III..\" NIDA Res. Monogr.. 1987;76:255-8. Pubmed PMID: 3125454\n",
      "Kosten TA, Kosten TR \"The dependence syndrome concept as applied to alcohol and other substances of abuse..\" Recent Dev Alcohol. 1990;8:47-68. Pubmed PMID: 2185524\n",
      "Kosten TR, Wahby V, Giller E, Mason J \"The dexamethasone suppression test and thyrotropin-releasing hormone stimulation test in posttraumatic stress disorder..\" Biol. Psychiatry. 1990 Oct 15;28(8):657-64. Pubmed PMID: 2122916\n",
      "Kosten TR, Jacobs S, Mason JW \"The dexamethasone suppression test during bereavement.\" J Nerv Ment Dis.. 1984 Jun; Pubmed PMID: 6544808\n",
      "Abi-Saab D, Beauvais J, Mehm J, Brody M, Gottschalk C, Kosten TR \"The effect of alcohol on the neuropsychological functioning of recently abstinent cocaine-dependent subjects..\" Am J Addict.;14(2):166-78. Pubmed PMID: 16019965\n",
      "Hui L, Zhang X, Huang XF, Han M, Fernandez F, Yu Y, Sun S, Li W, Chen da C, Xiu MH, Kosten TR, Zhang XY \"The dopamine b-hydroxylase 19 bp insertion/deletion polymorphism was associated with first-episode but not medicated chronic schizophrenia..\" J Psychiatr Res. 2012 Jun;46(6):733-7. Pubmed PMID: 22445279\n",
      "Rosen MI, Pearsall HR, Woods SW, Kosten TR \"The effect of gamma-hydroxybutyric acid on naloxone-precipitated opiate withdrawal..\" Neuropsychopharmacology. 1996 Mar;14(3):187-93. Pubmed PMID: 8866702\n",
      "Rosen MI, Pearsall HR, Kosten TR \"The effect of lamotrigine on naloxone-precipitated opiate withdrawal..\" Drug Alcohol Depend. 1998 Oct 1;52(2):173-6. Pubmed PMID: 9800147\n",
      "Stine SM, Freeman M, Burns B, Charney DS, Kosten TR \"The effect of methadone dose on cocaine abuse in a methadone program.\" Am J Addictions. 1992;\n",
      "Kosten TR, Hogan I, Jalali B, Steidl J, Kleber HD \"The effect of multiple family therapy on addict family functioning: a pilot study..\" Adv Alcohol Subst Abuse. 1986;5(3):51-62. Pubmed PMID: 3728193\n",
      "Rosen MI, Kosten TR, Kreek MJ \"The effects of naltrexone maintenance on the response to yohimbine in healthy volunteers..\" Biol. Psychiatry. 1999 Jun 15;45(12):1636-45. Pubmed PMID: 10376126\n",
      "Orson FM, Wang R, Brimijoin S, Kinsey BM, Singh RA, Ramakrishnan M, Wang HY, Kosten TR \"The future potential for cocaine vaccines..\" Expert Opin Biol Ther. 2014; Pubmed PMID: 24835496\n",
      "Orson FM, Kinsey BM, Singh RA, Wu Y, Gardner T, Kosten TR \"The future of vaccines in the management of addictive disorders..\" Curr Psychiatry Rep. 2007 Oct;9(5):381-7. Pubmed PMID: 17915077\n",
      "Haile CN, De La Garza R, Mahoney JJ, Nielsen DA, Kosten TR, Newton TF \"The impact of disulfiram treatment on the reinforcing effects of cocaine: a randomized clinical trial..\" PLoS ONE. 2012;7(11):e47702. Pubmed PMID: 23144826\n",
      "Liu S, Green CE, Lane SD, Kosten TR, Moeller FG, Nielsen DA, Schmitz JM \"The influence of dopamine β-hydroxylase gene polymorphism rs1611115 on levodopa/carbidopa treatment for cocaine dependence: a preliminary study.\" Pharmacogenet Genomics. 2014 Jul; Pubmed PMID: 24809448\n",
      "112. Sun H, Wang F, Fan H, Yan Q, Cui K, Yuan W, Zhao F, Zhao L, Yuan J, Yang F, Kosten TR, Zhang XY \"The interaction of polymorphisms of IL10 and DBH was associated with general symptoms of PANSS with TD in Chinese Han schizophrenic patients.\" PLoS One. 2013 Aug; Pubmed PMID: 23951054\n",
      "Kosten TR, Gorelick DA \"The Lexington narcotic farm..\" Am J Psychiatry. 2002 Jan;159(1):22. Pubmed PMID: 11772684\n",
      "Jacobs SC, Kasl SV, Ostfeld AM, Berkman L, Kosten TR, Charpentier P \"The measurement of grief: bereaved versus non-bereaved.\" Hosp J.. 1986; Pubmed PMID: 3647919\n",
      "Spellicy CJ, Kosten TR, Hamon SC, Harding MJ, Nielsen DA \"The MTHFR C677T Variant is Associated with Responsiveness to Disulfiram Treatment for Cocaine Dependency..\" Front Psychiatry. 2012;3:109. Pubmed PMID: 23335901\n",
      "Kosten TR, George TP \"The neurobiology of opioid dependence: implications for treatment..\" 2002 Jul;1(1):13-20. Pubmed PMID: 18567959\n",
      "Zhang XY, Chen da C, Xiu MH, Wang F, Qi LY, Sun HQ, Chen S, He SC, Wu GY, Haile CN, Kosten TA, Lu L, Kosten TR \"The novel oxidative stress marker thioredoxin is increased in first-episode schizophrenic patients..\" Schizophr. Res.. 2009 Sep;113(41308):151-7. Pubmed PMID: 19540723\n",
      "Kosten TA, Bianchi MS, Kosten TR \"The predictive validity of the dependence syndrome in opiate abusers..\" Am J Drug Alcohol Abuse. 1992;18(2):145-56. Pubmed PMID: 1562012\n",
      "Kosten TR, George TP, Kosten TA \"The potential of dopamine agonists in drug addiction..\" Expert Opin Investig Drugs. 2002 Apr;11(4):491-9. Pubmed PMID: 11922858\n",
      "Rao S, Ziedonis DM, Kosten TR \"The pharmacotherapy of cocaine dependence.\" Psychiatric Annals. 1995;\n",
      "Haile CN, Kosten TR \"The potential of pharmacogenomics to treat drug addiction..\" Pharmacogenomics. 2009 Dec;10(12):1883-6. Pubmed PMID: 19958085\n",
      "Zhang R, Hao W, Pan M, Wang C, Zhang X, Chen DC, Xiu MH, De Yang F, Kosten TR, Zhang XY \"The prevalence and clinical-demographic correlates of diabetes mellitus in chronic schizophrenic patients receiving clozapine..\" Hum Psychopharmacol. 2011 Aug 8; Pubmed PMID: 21826737\n",
      "Kosten TR \"The pharmacotherapy of relapse prevention using anticonvulsants..\" Am J Addict. 1998;7(3):205-9. Pubmed PMID: 9702288\n",
      "Kosten TR, Rounsaville BJ, Merikangas KR, Prusoff BA, Kleber HD \"The relationship of the Maudsley Personality Inventory to depression in addicts..\" Compr Psychiatry.;24(6):535-42. Pubmed PMID: 6653096\n",
      "McCance EF, Kosten TR \"The role of the human laboratory in drug abuse research. Psychiatric Annals.\" Psychiatric Annals. 1995;\n",
      "Zhang X, Hui L, Liu Y, Wang ZQ, You Y, Miao LN, Sun SL, Guan SL, Xiang Y, Kosten TR, Zhang XY \"The type 2 diabetes mellitus susceptibility gene IGF2BP2 is associated with schizophrenia in a Han Chinese population..\" J Clin Psychiatry. 2013 Apr;74(4):e287-92. Pubmed PMID: 23656854\n",
      "Mason JW, Kosten TR, Southwick SM, Giller EL. \"The use of hormonal profile strategies in post-traumatic stress disorder.\" J Applied Social Psychology. 1990;\n",
      "Kosten TR, Bryant K, Rounsaville BJ \"The SCID: a clinical instrument for assessing psychiatric disorders..\" NIDA Res. Monogr.. 1990;105:213-9. Pubmed PMID: 1876002\n",
      "Zhou DH, Yan QZ, Yan XM, Li CB, Fang H, Zheng YL, Zhang CX, Yao HJ, Chen da C, Xiu MH, Kosten TR, Zhang XY \"The study of BDNF Val66Met polymorphism in Chinese schizophrenic patients..\" Prog. Neuropsychopharmacol. Biol. Psychiatry. 2010 Aug 16;34(6):930-3. Pubmed PMID: 20420877\n",
      "Rohrbaugh RM, Felker B, Kosten T \"The VA psychiatry-primary care education initiative..\" Acad Psychiatry. 2009 Jan; Pubmed PMID: 19349441\n",
      "Wang Y, Wang JD, Wu HR, Zhang BS, Fang H, Ma QM, Liu H, Chen da C, Xiu MH, Hail CN, Kosten TR, Zhang XY \"The Val66Met polymorphism of the brain-derived neurotrophic factor gene is not associated with risk for schizophrenia and tardive dyskinesia in Han Chinese population..\" Schizophr. Res.. 2010 Jul;120(41277):240-2. Pubmed PMID: 20395113\n",
      "Nielsen DA, Hamon SC, Kosten TR \"The κ-opioid receptor gene as a predictor of response in a cocaine vaccine clinical trial.\" Psychiatr Genet. 2013 Dec; Pubmed PMID: 23995774\n",
      "Gardner TJ, Kosten TR \"Therapeutic options and challenges for substances of abuse..\" 2007;9(4):431-45. Pubmed PMID: 18286802\n",
      "Haney M, Kosten TR \"Therapeutic vaccines for substance dependence..\" Expert Rev Vaccines. 2004 Feb;3(1):41586. Pubmed PMID: 14761239\n",
      "Kosten TR, Biegel D \"Therapeutic vaccines for substance dependence..\" Expert Rev Vaccines. 2002 Oct;1(3):363-71. Pubmed PMID: 12901575\n",
      "Zhang XY, Chen da C, Xiu MH, Yang FD, Tan YL, He S, Kosten TA, Kosten TR \"Thioredoxin, a novel oxidative stress marker and cognitive performance in chronic and medicated schizophrenia versus healthy controls..\" Schizophr. Res.. 2013 Feb;143(41308):301-6. Pubmed PMID: 23238053\n",
      "O'Connor PG, Carroll KM, Shi JM, Schottenfeld RS, Kosten TR, Rounsaville BJ \"Three methods of opioid detoxification in a primary care setting. A randomized trial..\" Ann. Intern. Med.. 1997 Oct 1;127(7):526-30. Pubmed PMID: 9313020\n",
      "Schottenfeld RS, Pakes J, O'Connor P, Chawarski M, Oliveto A, Kosten TR \"Thrice-weekly versus daily buprenorphine maintenance..\" Biol. Psychiatry. 2000 Jun 15;47(12):1072-9. Pubmed PMID: 10862807\n",
      "Sofuoglu M, Poling J, Mitchell E, Kosten TR \"Tiagabine affects the subjective responses to cocaine in humans..\" Pharmacol. Biochem. Behav.. 2005 Nov;82(3):569-73. Pubmed PMID: 16332385\n",
      "Gonzalez G, Sevarino K, Sofuoglu M, Poling J, Oliveto A, Gonsai K, George TP, Kosten TR \"Tiagabine increases cocaine-free urines in cocaine-dependent methadone-treated patients: results of a randomized pilot study..\" Addiction. 2003 Nov;98(11):1625-32. Pubmed PMID: 14616189\n",
      "Shi J, Li SX, Zhang XL, Wang X, Le Foll B, Zhang XY, Kosten TR, Lu L \"Time-Dependent Neuroendocrine Alterations and Drug Craving during the First Month of Abstinence in Heroin Addicts..\" Am J Drug Alcohol Abuse. 2009;35(5):267-72. Pubmed PMID: 19591065\n",
      "Lu L, Liu Y, Zhu W, Shi J, Liu Y, Ling W, Kosten TR \"Traditional medicine in the treatment of drug addiction..\" Am J Drug Alcohol Abuse. 2009;35(1):41285. Pubmed PMID: 19152199\n",
      "Rounsaville BJ, Kosten TR \"Treatment for opioid dependence: quality and access..\" JAMA. 2000 Mar; Pubmed PMID: 10714736\n",
      "Kosten TR, Kleber HD, Morgan C \"Treatment of cocaine abuse with buprenorphine.\" Biol Psychiatry. 1989 Oct; Pubmed PMID: 2790101\n",
      "Nigam R, Schottenfeld R, Kosten TR \"Treatment of dual diagnosis patients: a relapse prevention group approach..\" J Subst Abuse Treat. 1992;9(4):305-9. Pubmed PMID: 1362227\n",
      "Kosten TR, Rosen MI, McMahon TL, Bridge TP, O'Malley SS, Pearsall R, O'Connor PG \"Treatment of early AIDS dementia in intravenous drug users: high versus low dose peptide T..\" Am J Drug Alcohol Abuse. 1997 Nov;23(4):543-53. Pubmed PMID: 9366972\n",
      "Gonzalez G, Oliveto A, Kosten TR \"Treatment of heroin (diamorphine) addiction: current approaches and future prospects..\" Drugs. 2002;62(9):1331-43. Pubmed PMID: 12076182\n",
      "Kosten TR, Morgan C, Kleber HD \"Treatment of heroin addicts using buprenorphine..\" Am J Drug Alcohol Abuse. 1991 Jun;17(2):119-28. Pubmed PMID: 1862786\n",
      "\"Treatment of patients with substance use disorders, second edition. American Psychiatic Association..\" Am J Addictions. 2006 Oct; Pubmed PMID: 16981488\n",
      "Kleber HD, Weiss RD, Anton RF, George TP, Greenfield SF, Kosten TR, O'Brien CP, Rounsaville BJ, Strain EC, Ziedonis DM, Hennessy G, Connery HS, McIntyre JS, Charles SC, Anzia DJ, Cook IA, Finnerty MT, Johnson BR, Nininger JE, Summergrad P, Woods SM, Yager \"Treatment of patients with substance use disorders, second edition. American Psychiatric Association..\" Am J Psychiatry. 2007 Apr;164(4):5-123. Pubmed PMID: 17569411\n",
      "Kosten TR, Forrest JN \"Treatment of severe lithium-induced polyuria with amiloride..\" Am J Psychiatry. 1986 Dec;143(12):1563-8. Pubmed PMID: 3538913\n",
      "Poling J, Kosten TR, Sofuoglu M \"Treatment outcome predictors for cocaine dependence..\" Am J Drug Alcohol Abuse. 2007;33(2):191-206. Pubmed PMID: 17497542\n",
      "Satel SL, Krystal JH, Delgado PL, Kosten TR, Charney DS \"Tryptophan depletion and attenuation of cue-induced craving for cocaine..\" Am J Psychiatry. 1995 May;152(5):778-83. Pubmed PMID: 7726319\n",
      "Kosten TR, McCance E \"Una revision de tratamientos farmacologicos para el abuso de substancias.\" Revista de Toxicomanias. 1997;\n",
      "Kosten TR \"Update on addiction medicine in the State of Connecticut.\" Connecticut Medicine. 1999;\n",
      "Jacobs SC, Mason J, Kosten TR, Kasl SV, Ostfeld AM, Wahby V \"Urinary free cortisol and separation anxiety early in the course of bereavement and threatened loss..\" Biol. Psychiatry. 1987 Feb;22(2):148-52. Pubmed PMID: 3814667\n",
      "Mason JW, Giller EL, Kosten TR, Ostroff RB, Podd L \"Urinary free-cortisol levels in posttraumatic stress disorder patients..\" J. Nerv. Ment. Dis.. 1986 Mar;174(3):145-9. Pubmed PMID: 3950596\n",
      "Druss BG, Rohrbaugh R, Kosten T, Hoff R, Rosenheck RA \"Use of alternative medicine in major depression.\" Psychiatr Serv.. 1998 Nov; Pubmed PMID: 9826237\n",
      "Stine SM, Kosten TR \"Use of drug combinations in treatment of opioid withdrawal..\" J Clin Psychopharmacol. 1992 Jun;12(3):203-9. Pubmed PMID: 1629388\n",
      "Jacobs S, Mason J, Kosten T, Brown S, Ostfeld A \"Urinary-free cortisol excretion in relation to age in acutely stressed persons with depressive symptoms.\" Psychosom Med. 1984 May; Pubmed PMID: 6739681\n",
      "Kosten TR, Domingo CB, Shorter D, Orson F, Green C, Somoza E, Sekerka R, Levin FR, Mariani JJ, Stitzer M, Tompkins DA, Rotrosen J, Thakkar V, Smoak B, Kampman K \"Vaccine for cocaine dependence: a randomized double-blind placebo-controlled efficacy trial..\" Drug Alcohol Depend. 2014 Jul; Pubmed PMID: 24793366\n",
      "Feingold A, Oliveto A, Schottenfeld R, Kosten TR \"Utility of crossover designs in clinical trials: efficacy of desipramine vs. placebo in opioid-dependent cocaine abusers..\" Am J Addict. 2002;11(2):111-23. Pubmed PMID: 12028741\n",
      "Martell BA, Mitchell E, Poling J, Gonsai K, Kosten TR \"Vaccine pharmacotherapy for the treatment of cocaine dependence..\" Biol. Psychiatry. 2005 Jul 15;58(2):158-64. Pubmed PMID: 16038686\n",
      "Shen XY, Orson FM, Kosten TR \"Vaccines Against Drug Abuse..\" Clin. Pharmacol. Ther.. 2011 Nov 30; Pubmed PMID: 22130115\n",
      "Kosten T, Domingo C, Orson F, Kinsey B \"Vaccines against stimulants: cocaine and MA.\" Br J Clin Pharmacol.. 2014 Feb; Pubmed PMID: 23509915\n",
      "Orson FM, Kinsey BM, Singh RA, Wu Y, Kosten TR \"Vaccines for cocaine abuse..\" 2009 Apr;5(4):194-9. Pubmed PMID: 19276665\n",
      "Shorter D, Kosten TR \"Vaccines in the Treatment of Substance Abuse.\" Focus (Am Psychiatr Publ).. 2011 Dec; Pubmed PMID: 23472050\n",
      "Kosten TR \"What are America's opportunities for harm reduction strategies in opiate dependence?.\" Am J Addict.;14(4):307-10. Pubmed PMID: 16188710\n",
      "Stine SM, Southwick SM, Petrakis IL, Kosten TR, Charney DS, Krystal JH \"Yohimbine-induced withdrawal and anxiety symptoms in opioid-dependent patients..\" Biol. Psychiatry. 2002 Apr 15;51(8):642-51. Pubmed PMID: 11955464\n",
      "Avants SK, Margolin A, Kosten TR, Rounsaville BJ, Schottenfeld RS \"When is less treatment better? The role of social anxiety in matching methadone patients to psychosocial treatments..\" J Consult Clin Psychol. 1998 Dec;66(6):924-31. Pubmed PMID: 9874905\n",
      "\n",
      "    ---------\n",
      "\n",
      "\n",
      "response.status_code:200\n",
      "response.text:{\"error\":{\"message\":\"This model's maximum context length is 16385 tokens. However, your messages resulted in 32933 tokens. Please reduce the length of the messages.\",\"type\":\"invalid_request_error\",\"param\":\"messages\",\"code\":\"context_length_exceeded\"}}\n",
      "json_dict:{'error': {'message': \"This model's maximum context length is 16385 tokens. However, your messages resulted in 32933 tokens. Please reduce the length of the messages.\", 'type': 'invalid_request_error', 'param': 'messages', 'code': 'context_length_exceeded'}}\n",
      "error:'choices'\n",
      "+++++++++++++++++++++++++\n",
      "None\n"
     ]
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "Traceback (most recent call last):\n",
      "  File \"C:\\Users\\putao\\AppData\\Local\\Temp\\ipykernel_16628\\457591446.py\", line 30, in get_data_http\n",
      "    content = json_dict['choices'][0]['message']['content']  # 获取指定字段\n",
      "KeyError: 'choices'\n"
     ]
    }
   ],
   "source": [
    "chat(thomas_kosten,\"托马斯医生的专长\")"
   ],
   "metadata": {
    "collapsed": false
   }
  },
  {
   "cell_type": "code",
   "execution_count": 7,
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "<Response [200]>\n",
      "query:\n",
      "    请根据以下context，回答：托马斯医生的专长\n",
      "    reply in 简体中文\n",
      "    ---------context\n",
      "    \n",
      "Thomas Kosten, M.D.\n",
      "Jay H. Waggoner Endowed Chair\n",
      "713-794-7032\n",
      "Email\n",
      "kosten@bcm.edu\n",
      "Positions\n",
      "Jay H. Waggoner Endowed Chair\n",
      "Baylor College of Medicine\n",
      "Vice-Chair\n",
      "Psychiatry for Research\n",
      "Baylor College of Medicine\n",
      "Director\n",
      "Division of Alcohol and Addiction Psychiatry\n",
      "Baylor College of Medicine\n",
      "Co-Director\n",
      "Institute for Clinical and Translational Research\n",
      "Baylor College of Medicine\n",
      "Professor\n",
      "Psychiatry\n",
      "Baylor College of Medicine\n",
      "Houston, Texas US\n",
      "Professor\n",
      "Neuroscience\n",
      "Baylor College of Medicine\n",
      "Houston, Texas United States\n",
      "Professor\n",
      "Pharmacology\n",
      "Baylor College of Medicine\n",
      "Houston, Texas United States\n",
      "Professor\n",
      "Immunology and Rheumatology\n",
      "Baylor College of Medicine\n",
      "Houston, TX United States\n",
      "Member\n",
      "Dan L Duncan Comprehensive Cancer Center\n",
      "Baylor College of Medicine\n",
      "Houston, Texas United States\n",
      "Education\n",
      "MA from Yale University\n",
      "01/1995 - New Haven, Connecticut United States\n",
      "Clinical Fellowship at Yale University School of Medicine\n",
      "01/1983 - New Haven, Connecticut United States\n",
      "M.D. from Cornell University Medical College\n",
      "01/1977 - New York, NY United States\n",
      "BS from Rensselaer Polytechnic Institute\n",
      "01/1973 - Troy, New York United States\n",
      "Residency at Yale University School of Medicine\n",
      "01/1981 - New Haven, Connecticut United States\n",
      "Internship at Greenwich Hospital\n",
      "01/1978 - Greenwich, Connecticut United States\n",
      "Certifications\n",
      "Psychiatry/Addictions\n",
      "ABPN\n",
      "Professional Interests\n",
      "Developing medications and vaccines for addictions\n",
      "Pharmacology\n",
      "Websites\n",
      "VIICTR Publications List\n",
      "Selected Publications\n",
      "Malison RT, McCance E, Carpenter LL, Baldwin RM, Seibyl JP, Price LH, Kosten TR, Innis RB \"[123I]beta-CIT SPECT imaging of dopamine transporter availability after mazindol administration in human cocaine addicts..\" Psychopharmacology (Berl.). 1998 Jun;137(4):321-5. Pubmed PMID: 9676890\n",
      "Kosten TR, Rounsaville BJ, Kleber HD \"A 2.5-year follow-up of cocaine use among treated opioid addicts. Have our treatments helped?.\" Arch. Gen. Psychiatry. 1987 Mar;44(3):281-4. Pubmed PMID: 3827521\n",
      "Kosten TR, Rounsaville BJ, Kleber HD \"A 2.5 year follow-up of treatment retention and reentry among opioid addicts..\" J Subst Abuse Treat. 1986;3(3):181-9. Pubmed PMID: 3806731\n",
      "Kosten TR, Rounsaville BJ, Kleber HD \"A 2.5-year follow-up of depression, life crises, and treatment effects on abstinence among opioid addicts..\" Arch Gen Psychiatry. 1986 Aug;733-8. Pubmed PMID: 3729667\n",
      "Rounsaville BJ, Kosten TR, Weissmann MM, Kleber HD \"A 2.5-year follow-up of short-term interpersonal psychotherapy in methadone-maintained opiate addicts..\" Compr Psychiatry.;27(3):201-10. Pubmed PMID: 3709134\n",
      "Avants SK, Margolin A, DePhilippis D, Kosten TR \"A comprehensive pharmacologic-psychosocial treatment program for HIV-seropositive cocaine- and opioid-dependent patients. Preliminary findings..\" J Subst Abuse Treat.;15(3):261-5. Pubmed PMID: 9633038\n",
      "Rounsaville BJ, Kosten TR, Williams JB, Spitzer RL \"A field trial of DSM-III-R psychoactive substance dependence disorders..\" Am J Psychiatry. 1987 Mar;144(3):351-5. Pubmed PMID: 3826436\n",
      "Kosten TR, Steinberg M, Diakogiannis I A \"A cross-over trail of mazindol for cocaine dependence.\" Am J Addictions. 1993;161-164.\n",
      "Kosten TA, Shen XY, O'Malley PW, Kinsey BM, Lykissa ED, Orson FM, Kosten TR \"A morphine conjugate vaccine attenuates the behavioral effects of morphine in rats..\" Prog Neuropsychopharmacol Biol Psychiatry. 2013 Aug 1;223-9. Pubmed PMID: 23739535\n",
      "Margolin A, Kosten TR, Avants SK, Wilkins J, Ling W, Beckson M, Arndt IO, Cornish J, Ascher JA, Li SH \"A multicenter trial of bupropion for cocaine dependence in methadone-maintained patients..\" Drug Alcohol Depend. 1995 Dec;40(2):125-31. Pubmed PMID: 8745134\n",
      "Najavits LM, Kivlahan D, Kosten T \"A national survey of clinicians’ views of evidence-based therapies for PTSD and substance abuse.\" 2011;138-147.\n",
      "Rosen MI, McMahon TJ, Woods SW, Pearsall HR, Kosten TR \"A pilot study of dextromethorphan in naloxone-precipitated opiate withdrawal..\" Eur. J. Pharmacol.. 1996 Jul 4;307(3):251-7. Pubmed PMID: 8836612\n",
      "O'Connor PG, Oliveto AH, Shi JM, Triffleman E, Carroll KM, Kosten TR, Rounsaville BJ \"A pilot study of primary-care-based buprenorphine maintenance for heroin dependence..\" Am J Drug Alcohol Abuse. 1996 Nov;22(4):523-31. Pubmed PMID: 8911590\n",
      "George TP, Vessicchio JC, Termine A, Bregartner TA, Feingold A, Rounsaville BJ, Kosten TR \"A placebo controlled trial of bupropion for smoking cessation in schizophrenia.\" Biol Psychiatry. 2002 Jul 1;53-61. Pubmed PMID: 12079730\n",
      "Margolin A, Avants SK, DePhilippis D, Kosten TR \"A preliminary investigation of lamotrigine for cocaine abuse in HIV-seropositive patients..\" Am J Drug Alcohol Abuse. 1998 Feb;24(1):85-101. Pubmed PMID: 9513631\n",
      "George TP, Vessicchio JC, Termine A, Jatlow PI, Kosten TR, O'Malley SS \"A preliminary placebo-controlled trial of selegiline hydrochloride for smoking cessation..\" Biol. Psychiatry. 2003 Jan 15;53(2):136-43. Pubmed PMID: 12547469\n",
      "Kosten TR, Kreek MJ, Ragunath J, Kleber HD \"A preliminary study of beta endorphin during chronic naltrexone maintenance treatment in ex-opiate addicts..\" Life Sci.. 1986 Jul 7;39(1):55-9. Pubmed PMID: 2941636\n",
      "Kosten TR, Schumann B, Wright D, Carney MK, Gawin FH \"A preliminary study of desipramine in the treatment of cocaine abuse in methadone maintenance patients..\" J Clin Psychiatry. 1987 Nov;48(11):442-4. Pubmed PMID: 3680185\n",
      "Frank JB, Kosten TR, Giller EL, Dan E \"A randomized clinical trial of phenelzine and imipramine for posttraumatic stress disorder..\" Am J Psychiatry. 1988 Oct;145(10):1289-91. Pubmed PMID: 3048121\n",
      "Avants SK, Margolin A, Holford TR, Kosten TR \"A randomized controlled trial of auricular acupuncture for cocaine dependence..\" Arch. Intern. Med..;160(15):2305-12. Pubmed PMID: 10927727\n",
      "O'Connor PG, Oliveto AH, Shi JM, Triffleman EG, Carroll KM, Kosten TR, Rounsaville BJ, Pakes JA, Schottenfeld RS \"A randomized trial of buprenorphine maintenance for heroin dependence in a primary care clinic for substance users versus a methadone clinic..\" Am. J. Med.. 1998 Aug;105(2):100-5. Pubmed PMID: 9727815\n",
      "Kosten TR, McCance E \"A review of pharmacotherapies for substance abuse.\" The American Journal on Addictions. 1996;58-59.\n",
      "Shen XY, Kosten TA, Lopez AY, Kinsey BM, Kosten TR, Orson FM \"A vaccine against methamphetamine attenuates its behavioral effects in mice..\" Drug Alcohol Depend. 2013 Apr 1;129(41276):41-8. Pubmed PMID: 23022610\n",
      "Margolin A, Avants SK, Chang P, Birch S, Kosten TR \"A single-blind investigation of four auricular needle puncture configurations..\" Am. J. Chin. Med.. 1995;23(2):105-14. Pubmed PMID: 7572770\n",
      "Margolin A, Avants SK, Kosten TR \"Abstinence symptomatology associated with cessation of chronic cocaine abuse among methadone-maintained patients..\" Am J Drug Alcohol Abuse. 1996 Aug;22(3):377-88. Pubmed PMID: 8841686\n",
      "Kosten TR, Gawin FH, Rounsaville BJ, Kleber HD \"Abuse of cocaine with opioids: psychological aspects of treatment..\" NIDA Res. Monogr.. 1986;67:278-82. Pubmed PMID: 3092078\n",
      "Kinsey BM, Kosten TR, Orson FM \"Active immunotherapy for the Treatment of Cocaine Dependence..\" 2010 Apr 1;35(4):301-306. Pubmed PMID: 21796226\n",
      "Avants SK, Margolin A, Chang P, Kosten TR, Birch S \"Acupuncture for the treatment of cocaine addiction. Investigation of a needle puncture control..\" J Subst Abuse Treat.;12(3):195-205. Pubmed PMID: 7474027\n",
      "Jacobs S, Mason J, Kosten T, Kasl S, Ostfeld A, Atkins S, Gardner C, Schreiber S \"Acute bereavement, threatened loss, ego defenses and adrenocortical function.\" Psychother Psychosom. 1985;151-9. Pubmed PMID: 3832148\n",
      "Kosten TR \"Addiction as a brain disease..\" Am J Psychiatry. 1998 Jun;155(6):711-3. Pubmed PMID: 9619141\n",
      "Wallace EA, Wisniewski G, Zubal G, vanDyck CH, Pfau SE, Smith EO, Rosen MI, Sullivan MC, Woods SW, Kosten TR \"Acute cocaine effects on absolute cerebral blood flow..\" Psychopharmacology (Berl.). 1996 Nov;128(1):17-20. Pubmed PMID: 8944401\n",
      "Ziedonis D, Richardson T, Lee E, Petrakis I, Kosten T \"Adjunctive desipramine in the treatment of cocaine abusing schizophrenics.\" Psychopharmacol Bull. 1992;309-14. Pubmed PMID: 1480735\n",
      "Kosten TR \"Advances in clinical research on drug addiction: Opioids and cocaine.\" Substance Abuse. 1989;35-42.\n",
      "Sofuoglu M, Mouratidis M, Yoo S, Kosten T \"Adrenergic blocker carvedilol attenuates the cardiovascular and aversive effects of nicotine in abstinent smokers..\" Behav Pharmacol. 2006 Dec 17;731-5. Pubmed PMID: 17110799\n",
      "Ziedonis DM, Kosten TR \"Aggiornamento: Dipendenza da nicotina e schizofrenia.\" 1996;44-47.\n",
      "Kosten TR \"Advances in pharmacotherapy of stimulant dependence: From alcohol antagonists to Xenova vaccines.\" Clinical Neuroscience Research. 2005;169-173.\n",
      "Closser MH, Kosten TR \"Alcohol and cocaine abuse. A comparison of epidemiology and clinical characteristics..\" Recent Dev Alcohol. 1992;10:115-28. Pubmed PMID: 1317046\n",
      "Kosten TR, Kosten TA, Rounsaville BJ \"Alcoholism and depressive disorders in opioid addicts and their family members..\" Compr Psychiatry.;32(6):521-7. Pubmed PMID: 1778079\n",
      "13. Kosten TR, Krystal JH, Giller EL, Frank J, Dan E. \"Alexithymia as a predictor of treatment response in posttraumatic stress disorder.\" J Traumatic Stress. 1992;41-51.\n",
      "Cui Y, Versace F, Engelmann JM, Minnix JA, Robinson JD, Lam CY, Karam-Hage M, Brown VL, Wetter DW, Dani JA, Kosten TR, Cinciripini PM \"Alpha oscillations in response to affective and cigarette-related stimuli in smokers..\" Nicotine Tob. Res.. 2013 May;15(5):917-24. Pubmed PMID: 23060019\n",
      "Sellers EM, Ciraulo DA, DuPont RL, Griffiths RR, Kosten TR, Romach MK, Woody GE \"Alprazolam and benzodiazepine dependence..\" J Clin Psychiatry. 1993 Oct;54:64-75; discussi. Pubmed PMID: 8262891\n",
      "Xiu MH, Chen S, Wang F, Cao LY, Qi LY, Chen da C, Wu GY, Lu L, Kosten TA, Kosten TR, Zhang XY \"Altered interleukin-3 serum levels in drug-naïve and neuroleptic-treated schizophrenic patients..\" Schizophr. Res.. 2008 Dec;106(41308):369-70. Pubmed PMID: 18838250\n",
      "Petrakis IL, Satel SL, Stine S, Kosten TR, Normanworth SN, Charney DS, Krystal JH \"AMPT effects on cue-induced craving for cocaine.\" The American Journal of Addictions. 1996;313-320.\n",
      "Kosten TA, Kosten TR, Gawin FH, Gordon LT, Hogan I, Kleber HD \"An open trial of sertraline for cocaine abuse.\" Am J Addictions. 1992;349-353.\n",
      "Spellicy CJ, Kosten TR, Hamon SC, Harding MJ, Nielsen DA \"ANKK1 and DRD2 pharmacogenetics of disulfiram treatment for cocaine abuse..\" Pharmacogenet. Genomics. 2013 Jul;23(7):333-40. Pubmed PMID: 23635803\n",
      "Kosten TR, Rounsaville BJ, Kleber HD \"Antecedents and consequences of cocaine abuse among opioid addicts. A 2.5-year follow-up..\" J. Nerv. Ment. Dis.. 1988 Mar;176(3):176-81. Pubmed PMID: 3343591\n",
      "Shen X, Orson FM, Kosten TR \"Anti-addiction vaccines..\" F1000 Med Rep. 2011;3:20. Pubmed PMID: 22003367\n",
      "Brimijoin S, Orson F, Kosten TR, Kinsey B, Shen XY, White SJ, Gao Y \"Anti-cocaine antibody and butyrylcholinesterase-derived cocaine hydrolase exert cooperative effects on cocaine pharmacokinetics and cocaine-induced locomotor activity in mice..\" Chem. Biol. Interact.. 2013 Mar 25;203(1):212-6. Pubmed PMID: 22960160\n",
      "Leal J, Ziedonis D, Kosten T \"Antisocial personality disorder as a prognostic factor for pharmacotherapy of cocaine dependence.\" Drug Alcohol Depend. 1994 Mar;31-5. Pubmed PMID: 8082553\n",
      "Kinsey BM, Kosten TR, Orson FM \"Anti-cocaine vaccine development..\" Expert Rev Vaccines. 2010 Sep;9(9):1109-14. Pubmed PMID: 20822352\n",
      "Frank JB, Kosten TR, Giller EL \"Antidepressants in the treatment of PTSD..\" Am J Psychiatry. 1990 Feb;147(2):260. Pubmed PMID: 2301678\n",
      "Li CS, Kosten TR, Sinha R \"Antisocial personality and stress-induced brain activation in cocaine-dependent patients..\" Neuroreport. 2006 Feb 27;17(3):243-7. Pubmed PMID: 16462591\n",
      "Chen JX, Su YA, Wang SL, Bian QT, Liu YH, Wang N, Yang FD, Haile C, Kosten TR, Zhang XY \"Aripiprazole treatment of risperidone-induced hyperprolactinemia..\" J Clin Psychiatry. 2009 Jul;70(7):1058-9. Pubmed PMID: 19653986\n",
      "Kosten TR, Gottschalk PC, Tucker K, Rinder CS, Dey HM, Rinder HM \"Aspirin or amiloride for cerebral perfusion defects in cocaine dependence..\" Drug Alcohol Depend. 2003 Aug 20;71(2):187-94. Pubmed PMID: 12927657\n",
      "Hui L, Zhang X, Yu YQ, Han M, Huang XF, Chen da C, Wang ZR, Du WL, Kou CG, Yu Q, Kosten TR, Zhang XY \"Association between DBH 19bp insertion/deletion polymorphism and cognition in first-episode schizophrenic patients..\" Schizophr. Res.. 2013 Jul;147(41308):236-40. Pubmed PMID: 23707643\n",
      "Sun S, Wang F, Wei J, Cao LY, Wu GY, Lu L, Kosten TA, Kosten TR, Zhang XY \"Association between interleukin-3 receptor alpha polymorphism and schizophrenia in the Chinese population..\" Neurosci. Lett.. 2008 Jul 25;440(1):35-7. Pubmed PMID: 18547720\n",
      "Sun S, Wang F, Wei J, Cao LY, Qi LY, Xiu MH, Chen S, Li XH, Kosten TA, Kosten TR, Zhang XY \"Association between interleukin-6 receptor polymorphism and patients with schizophrenia..\" Schizophr. Res.. 2008 Jul;102(41277):346-7. Pubmed PMID: 18508242\n",
      "Qiu HT, Meng HQ, Song C, Xiu MH, Chen da C, Zhu FY, Wu GY, Kosten TA, Kosten TR, Zhang XY \"Association between monoamine oxidase (MAO)-A gene variants and schizophrenia in a Chinese population..\" Brain Res.. 2009 Sep 1;1287:67-73. Pubmed PMID: 19573521\n",
      "Cao JX, Hu J, Ye XM, Xia Y, Haile CA, Kosten TR, Zhang XY \"Association between the 5-HTR1B gene polymorphisms and alcohol dependence in a Han Chinese population..\" Brain Res.. 2011 Feb 28;1376:41283. Pubmed PMID: 21172311\n",
      "Avants SK, Margolin A, McMahon TJ, Kosten TR \"Association between self-report of cognitive impairment, HIV status, and cocaine use in a sample of cocaine-dependent methadone-maintained patients..\" Addict Behav.;22(5):599-611. Pubmed PMID: 9347062\n",
      "Wang F, Fan H, Sun H, Yang F, Luo Y, Liu H, Kosten TR, Lu L, Zhang XY \"Association between TNF-a promoter -308A/G polymorphism and tardive dyskinesiain Chinese Han patients with schizophrenia..\" Prog. Neuropsychopharmacol. Biol. Psychiatry. 2012 Apr 27;37(1):106-10. Pubmed PMID: 22227290\n",
      "Li W, Zhou N, Yu Q, Li X, Yu Y, Sun S, Kou C, Chen da C, Xiu MH, Kosten TR, Zhang XY \"Association of BDNF gene polymorphisms with schizophrenia and clinical symptoms in a Chinese population.\" Am J Med Genet B Neuropsychiatr Genet. 2013 Sep;538-45. Pubmed PMID: 23832605\n",
      "Zhang XY, Tan YL, Zhou DF, Haile CN, Cao LY, Xu Q, Shen Y, Kosten TA, Kosten TR \"Association of clozapine-induced weight gain with a polymorphism in the leptin promoter region in patients with chronic schizophrenia in a Chinese population..\" J Clin Psychopharmacol. 2007 Jun;27(3):246-51. Pubmed PMID: 17502770\n",
      "Li WJ, Kou CG, Yu Y, Sun S, Zhang X, Kosten TR, Zhang XY \"Association of Catechol-O-methyltransferase gene polymorphisms with schizophrenia and negative symptoms in a Chinese population..\" Am. J. Med. Genet. B Neuropsychiatr. Genet.. 2012 Jun;159(4):370-5. Pubmed PMID: 22354729\n",
      "Guo S, Chen da F, Zhou DF, Sun HQ, Wu GY, Haile CN, Kosten TA, Kosten TR, Zhang XY \"Association of functional catechol O-methyl transferase (COMT) Val108Met polymorphism with smoking severity and age of smoking initiation in Chinese male smokers..\" Psychopharmacology (Berl.). 2007 Mar;190(4):449-56. Pubmed PMID: 17206495\n",
      "Sun H, Guo S, Chen D, Yang F, Zou Y, Di X, Cao Y, Kosten T, Lu L, Zhang XY \"Association of functional COMT Val108/Met polymorphism with smoking cessation in a nicotine replacement therapy..\" 2012 Jun 14; Pubmed PMID: 22695756\n",
      "Brown AE, Pavlik VN, Shegog R, Whitney SN, Friedman LC, Romero C, Davis GC, Cech I, Kosten TR, Volk RJ \"Association of spirituality and sobriety during a behavioral spirituality intervention for Twelve Step (TS) recovery..\" Am J Drug Alcohol Abuse. 2007;33(4):611-7. Pubmed PMID: 17668347\n",
      "Zhang XY, Chen DC, Xiu MH, Hui L, Liu H, Luo X, Zuo L, Zhang H, Kosten TA, Kosten TR \"Association of functional dopamine-beta-hydroxylase (DBH) 19bp insertion/deletion polymorphism with smoking severity in male schizophrenic smokers..\" Schizophr. Res.. 2012 Aug 4; Pubmed PMID: 22871345\n",
      "Liu H, Wang C, Chen PH, Zhang BS, Zheng YL, Zhang CX, Meng HQ, Wang Y, Chen da C, Xiu MH, Kosten TR, Zhang \n",
      "    ---------\n",
      "\n",
      "real_query:\n",
      "    Notice: If doctor or hospital not in the context, skip this one 假如你是数据工程师，请把如下个人信息按照JSON的格式整理给我：（参考字段：行医，门诊时间，综合评价，资质认证状态，基本信息，简介，姓名，医院/机构，专长，职务，职称，学术兼职，地区，邮箱，手机，昕康ID/XK_ID，履历，教育经历，工作经历，研究，研究方向/临床研究，课题/基金，发表，发表文章，出版著作，专利和软著，执笔共识，成就，荣誉获奖）Return only the translation and nothing else:\n",
      "\n",
      "    query:\n",
      "    请根据以下context，回答：托马斯医生的专长\n",
      "    reply in 简体中文\n",
      "    ---------context\n",
      "    \n",
      "Thomas Kosten, M.D.\n",
      "Jay H. Waggoner Endowed Chair\n",
      "713-794-7032\n",
      "Email\n",
      "kosten@bcm.edu\n",
      "Positions\n",
      "Jay H. Waggoner Endowed Chair\n",
      "Baylor College of Medicine\n",
      "Vice-Chair\n",
      "Psychiatry for Research\n",
      "Baylor College of Medicine\n",
      "Director\n",
      "Division of Alcohol and Addiction Psychiatry\n",
      "Baylor College of Medicine\n",
      "Co-Director\n",
      "Institute for Clinical and Translational Research\n",
      "Baylor College of Medicine\n",
      "Professor\n",
      "Psychiatry\n",
      "Baylor College of Medicine\n",
      "Houston, Texas US\n",
      "Professor\n",
      "Neuroscience\n",
      "Baylor College of Medicine\n",
      "Houston, Texas United States\n",
      "Professor\n",
      "Pharmacology\n",
      "Baylor College of Medicine\n",
      "Houston, Texas United States\n",
      "Professor\n",
      "Immunology and Rheumatology\n",
      "Baylor College of Medicine\n",
      "Houston, TX United States\n",
      "Member\n",
      "Dan L Duncan Comprehensive Cancer Center\n",
      "Baylor College of Medicine\n",
      "Houston, Texas United States\n",
      "Education\n",
      "MA from Yale University\n",
      "01/1995 - New Haven, Connecticut United States\n",
      "Clinical Fellowship at Yale University School of Medicine\n",
      "01/1983 - New Haven, Connecticut United States\n",
      "M.D. from Cornell University Medical College\n",
      "01/1977 - New York, NY United States\n",
      "BS from Rensselaer Polytechnic Institute\n",
      "01/1973 - Troy, New York United States\n",
      "Residency at Yale University School of Medicine\n",
      "01/1981 - New Haven, Connecticut United States\n",
      "Internship at Greenwich Hospital\n",
      "01/1978 - Greenwich, Connecticut United States\n",
      "Certifications\n",
      "Psychiatry/Addictions\n",
      "ABPN\n",
      "Professional Interests\n",
      "Developing medications and vaccines for addictions\n",
      "Pharmacology\n",
      "Websites\n",
      "VIICTR Publications List\n",
      "Selected Publications\n",
      "Malison RT, McCance E, Carpenter LL, Baldwin RM, Seibyl JP, Price LH, Kosten TR, Innis RB \"[123I]beta-CIT SPECT imaging of dopamine transporter availability after mazindol administration in human cocaine addicts..\" Psychopharmacology (Berl.). 1998 Jun;137(4):321-5. Pubmed PMID: 9676890\n",
      "Kosten TR, Rounsaville BJ, Kleber HD \"A 2.5-year follow-up of cocaine use among treated opioid addicts. Have our treatments helped?.\" Arch. Gen. Psychiatry. 1987 Mar;44(3):281-4. Pubmed PMID: 3827521\n",
      "Kosten TR, Rounsaville BJ, Kleber HD \"A 2.5 year follow-up of treatment retention and reentry among opioid addicts..\" J Subst Abuse Treat. 1986;3(3):181-9. Pubmed PMID: 3806731\n",
      "Kosten TR, Rounsaville BJ, Kleber HD \"A 2.5-year follow-up of depression, life crises, and treatment effects on abstinence among opioid addicts..\" Arch Gen Psychiatry. 1986 Aug;733-8. Pubmed PMID: 3729667\n",
      "Rounsaville BJ, Kosten TR, Weissmann MM, Kleber HD \"A 2.5-year follow-up of short-term interpersonal psychotherapy in methadone-maintained opiate addicts..\" Compr Psychiatry.;27(3):201-10. Pubmed PMID: 3709134\n",
      "Avants SK, Margolin A, DePhilippis D, Kosten TR \"A comprehensive pharmacologic-psychosocial treatment program for HIV-seropositive cocaine- and opioid-dependent patients. Preliminary findings..\" J Subst Abuse Treat.;15(3):261-5. Pubmed PMID: 9633038\n",
      "Rounsaville BJ, Kosten TR, Williams JB, Spitzer RL \"A field trial of DSM-III-R psychoactive substance dependence disorders..\" Am J Psychiatry. 1987 Mar;144(3):351-5. Pubmed PMID: 3826436\n",
      "Kosten TR, Steinberg M, Diakogiannis I A \"A cross-over trail of mazindol for cocaine dependence.\" Am J Addictions. 1993;161-164.\n",
      "Kosten TA, Shen XY, O'Malley PW, Kinsey BM, Lykissa ED, Orson FM, Kosten TR \"A morphine conjugate vaccine attenuates the behavioral effects of morphine in rats..\" Prog Neuropsychopharmacol Biol Psychiatry. 2013 Aug 1;223-9. Pubmed PMID: 23739535\n",
      "Margolin A, Kosten TR, Avants SK, Wilkins J, Ling W, Beckson M, Arndt IO, Cornish J, Ascher JA, Li SH \"A multicenter trial of bupropion for cocaine dependence in methadone-maintained patients..\" Drug Alcohol Depend. 1995 Dec;40(2):125-31. Pubmed PMID: 8745134\n",
      "Najavits LM, Kivlahan D, Kosten T \"A national survey of clinicians’ views of evidence-based therapies for PTSD and substance abuse.\" 2011;138-147.\n",
      "Rosen MI, McMahon TJ, Woods SW, Pearsall HR, Kosten TR \"A pilot study of dextromethorphan in naloxone-precipitated opiate withdrawal..\" Eur. J. Pharmacol.. 1996 Jul 4;307(3):251-7. Pubmed PMID: 8836612\n",
      "O'Connor PG, Oliveto AH, Shi JM, Triffleman E, Carroll KM, Kosten TR, Rounsaville BJ \"A pilot study of primary-care-based buprenorphine maintenance for heroin dependence..\" Am J Drug Alcohol Abuse. 1996 Nov;22(4):523-31. Pubmed PMID: 8911590\n",
      "George TP, Vessicchio JC, Termine A, Bregartner TA, Feingold A, Rounsaville BJ, Kosten TR \"A placebo controlled trial of bupropion for smoking cessation in schizophrenia.\" Biol Psychiatry. 2002 Jul 1;53-61. Pubmed PMID: 12079730\n",
      "Margolin A, Avants SK, DePhilippis D, Kosten TR \"A preliminary investigation of lamotrigine for cocaine abuse in HIV-seropositive patients..\" Am J Drug Alcohol Abuse. 1998 Feb;24(1):85-101. Pubmed PMID: 9513631\n",
      "George TP, Vessicchio JC, Termine A, Jatlow PI, Kosten TR, O'Malley SS \"A preliminary placebo-controlled trial of selegiline hydrochloride for smoking cessation..\" Biol. Psychiatry. 2003 Jan 15;53(2):136-43. Pubmed PMID: 12547469\n",
      "Kosten TR, Kreek MJ, Ragunath J, Kleber HD \"A preliminary study of beta endorphin during chronic naltrexone maintenance treatment in ex-opiate addicts..\" Life Sci.. 1986 Jul 7;39(1):55-9. Pubmed PMID: 2941636\n",
      "Kosten TR, Schumann B, Wright D, Carney MK, Gawin FH \"A preliminary study of desipramine in the treatment of cocaine abuse in methadone maintenance patients..\" J Clin Psychiatry. 1987 Nov;48(11):442-4. Pubmed PMID: 3680185\n",
      "Frank JB, Kosten TR, Giller EL, Dan E \"A randomized clinical trial of phenelzine and imipramine for posttraumatic stress disorder..\" Am J Psychiatry. 1988 Oct;145(10):1289-91. Pubmed PMID: 3048121\n",
      "Avants SK, Margolin A, Holford TR, Kosten TR \"A randomized controlled trial of auricular acupuncture for cocaine dependence..\" Arch. Intern. Med..;160(15):2305-12. Pubmed PMID: 10927727\n",
      "O'Connor PG, Oliveto AH, Shi JM, Triffleman EG, Carroll KM, Kosten TR, Rounsaville BJ, Pakes JA, Schottenfeld RS \"A randomized trial of buprenorphine maintenance for heroin dependence in a primary care clinic for substance users versus a methadone clinic..\" Am. J. Med.. 1998 Aug;105(2):100-5. Pubmed PMID: 9727815\n",
      "Kosten TR, McCance E \"A review of pharmacotherapies for substance abuse.\" The American Journal on Addictions. 1996;58-59.\n",
      "Shen XY, Kosten TA, Lopez AY, Kinsey BM, Kosten TR, Orson FM \"A vaccine against methamphetamine attenuates its behavioral effects in mice..\" Drug Alcohol Depend. 2013 Apr 1;129(41276):41-8. Pubmed PMID: 23022610\n",
      "Margolin A, Avants SK, Chang P, Birch S, Kosten TR \"A single-blind investigation of four auricular needle puncture configurations..\" Am. J. Chin. Med.. 1995;23(2):105-14. Pubmed PMID: 7572770\n",
      "Margolin A, Avants SK, Kosten TR \"Abstinence symptomatology associated with cessation of chronic cocaine abuse among methadone-maintained patients..\" Am J Drug Alcohol Abuse. 1996 Aug;22(3):377-88. Pubmed PMID: 8841686\n",
      "Kosten TR, Gawin FH, Rounsaville BJ, Kleber HD \"Abuse of cocaine with opioids: psychological aspects of treatment..\" NIDA Res. Monogr.. 1986;67:278-82. Pubmed PMID: 3092078\n",
      "Kinsey BM, Kosten TR, Orson FM \"Active immunotherapy for the Treatment of Cocaine Dependence..\" 2010 Apr 1;35(4):301-306. Pubmed PMID: 21796226\n",
      "Avants SK, Margolin A, Chang P, Kosten TR, Birch S \"Acupuncture for the treatment of cocaine addiction. Investigation of a needle puncture control..\" J Subst Abuse Treat.;12(3):195-205. Pubmed PMID: 7474027\n",
      "Jacobs S, Mason J, Kosten T, Kasl S, Ostfeld A, Atkins S, Gardner C, Schreiber S \"Acute bereavement, threatened loss, ego defenses and adrenocortical function.\" Psychother Psychosom. 1985;151-9. Pubmed PMID: 3832148\n",
      "Kosten TR \"Addiction as a brain disease..\" Am J Psychiatry. 1998 Jun;155(6):711-3. Pubmed PMID: 9619141\n",
      "Wallace EA, Wisniewski G, Zubal G, vanDyck CH, Pfau SE, Smith EO, Rosen MI, Sullivan MC, Woods SW, Kosten TR \"Acute cocaine effects on absolute cerebral blood flow..\" Psychopharmacology (Berl.). 1996 Nov;128(1):17-20. Pubmed PMID: 8944401\n",
      "Ziedonis D, Richardson T, Lee E, Petrakis I, Kosten T \"Adjunctive desipramine in the treatment of cocaine abusing schizophrenics.\" Psychopharmacol Bull. 1992;309-14. Pubmed PMID: 1480735\n",
      "Kosten TR \"Advances in clinical research on drug addiction: Opioids and cocaine.\" Substance Abuse. 1989;35-42.\n",
      "Sofuoglu M, Mouratidis M, Yoo S, Kosten T \"Adrenergic blocker carvedilol attenuates the cardiovascular and aversive effects of nicotine in abstinent smokers..\" Behav Pharmacol. 2006 Dec 17;731-5. Pubmed PMID: 17110799\n",
      "Ziedonis DM, Kosten TR \"Aggiornamento: Dipendenza da nicotina e schizofrenia.\" 1996;44-47.\n",
      "Kosten TR \"Advances in pharmacotherapy of stimulant dependence: From alcohol antagonists to Xenova vaccines.\" Clinical Neuroscience Research. 2005;169-173.\n",
      "Closser MH, Kosten TR \"Alcohol and cocaine abuse. A comparison of epidemiology and clinical characteristics..\" Recent Dev Alcohol. 1992;10:115-28. Pubmed PMID: 1317046\n",
      "Kosten TR, Kosten TA, Rounsaville BJ \"Alcoholism and depressive disorders in opioid addicts and their family members..\" Compr Psychiatry.;32(6):521-7. Pubmed PMID: 1778079\n",
      "13. Kosten TR, Krystal JH, Giller EL, Frank J, Dan E. \"Alexithymia as a predictor of treatment response in posttraumatic stress disorder.\" J Traumatic Stress. 1992;41-51.\n",
      "Cui Y, Versace F, Engelmann JM, Minnix JA, Robinson JD, Lam CY, Karam-Hage M, Brown VL, Wetter DW, Dani JA, Kosten TR, Cinciripini PM \"Alpha oscillations in response to affective and cigarette-related stimuli in smokers..\" Nicotine Tob. Res.. 2013 May;15(5):917-24. Pubmed PMID: 23060019\n",
      "Sellers EM, Ciraulo DA, DuPont RL, Griffiths RR, Kosten TR, Romach MK, Woody GE \"Alprazolam and benzodiazepine dependence..\" J Clin Psychiatry. 1993 Oct;54:64-75; discussi. Pubmed PMID: 8262891\n",
      "Xiu MH, Chen S, Wang F, Cao LY, Qi LY, Chen da C, Wu GY, Lu L, Kosten TA, Kosten TR, Zhang XY \"Altered interleukin-3 serum levels in drug-naïve and neuroleptic-treated schizophrenic patients..\" Schizophr. Res.. 2008 Dec;106(41308):369-70. Pubmed PMID: 18838250\n",
      "Petrakis IL, Satel SL, Stine S, Kosten TR, Normanworth SN, Charney DS, Krystal JH \"AMPT effects on cue-induced craving for cocaine.\" The American Journal of Addictions. 1996;313-320.\n",
      "Kosten TA, Kosten TR, Gawin FH, Gordon LT, Hogan I, Kleber HD \"An open trial of sertraline for cocaine abuse.\" Am J Addictions. 1992;349-353.\n",
      "Spellicy CJ, Kosten TR, Hamon SC, Harding MJ, Nielsen DA \"ANKK1 and DRD2 pharmacogenetics of disulfiram treatment for cocaine abuse..\" Pharmacogenet. Genomics. 2013 Jul;23(7):333-40. Pubmed PMID: 23635803\n",
      "Kosten TR, Rounsaville BJ, Kleber HD \"Antecedents and consequences of cocaine abuse among opioid addicts. A 2.5-year follow-up..\" J. Nerv. Ment. Dis.. 1988 Mar;176(3):176-81. Pubmed PMID: 3343591\n",
      "Shen X, Orson FM, Kosten TR \"Anti-addiction vaccines..\" F1000 Med Rep. 2011;3:20. Pubmed PMID: 22003367\n",
      "Brimijoin S, Orson F, Kosten TR, Kinsey B, Shen XY, White SJ, Gao Y \"Anti-cocaine antibody and butyrylcholinesterase-derived cocaine hydrolase exert cooperative effects on cocaine pharmacokinetics and cocaine-induced locomotor activity in mice..\" Chem. Biol. Interact.. 2013 Mar 25;203(1):212-6. Pubmed PMID: 22960160\n",
      "Leal J, Ziedonis D, Kosten T \"Antisocial personality disorder as a prognostic factor for pharmacotherapy of cocaine dependence.\" Drug Alcohol Depend. 1994 Mar;31-5. Pubmed PMID: 8082553\n",
      "Kinsey BM, Kosten TR, Orson FM \"Anti-cocaine vaccine development..\" Expert Rev Vaccines. 2010 Sep;9(9):1109-14. Pubmed PMID: 20822352\n",
      "Frank JB, Kosten TR, Giller EL \"Antidepressants in the treatment of PTSD..\" Am J Psychiatry. 1990 Feb;147(2):260. Pubmed PMID: 2301678\n",
      "Li CS, Kosten TR, Sinha R \"Antisocial personality and stress-induced brain activation in cocaine-dependent patients..\" Neuroreport. 2006 Feb 27;17(3):243-7. Pubmed PMID: 16462591\n",
      "Chen JX, Su YA, Wang SL, Bian QT, Liu YH, Wang N, Yang FD, Haile C, Kosten TR, Zhang XY \"Aripiprazole treatment of risperidone-induced hyperprolactinemia..\" J Clin Psychiatry. 2009 Jul;70(7):1058-9. Pubmed PMID: 19653986\n",
      "Kosten TR, Gottschalk PC, Tucker K, Rinder CS, Dey HM, Rinder HM \"Aspirin or amiloride for cerebral perfusion defects in cocaine dependence..\" Drug Alcohol Depend. 2003 Aug 20;71(2):187-94. Pubmed PMID: 12927657\n",
      "Hui L, Zhang X, Yu YQ, Han M, Huang XF, Chen da C, Wang ZR, Du WL, Kou CG, Yu Q, Kosten TR, Zhang XY \"Association between DBH 19bp insertion/deletion polymorphism and cognition in first-episode schizophrenic patients..\" Schizophr. Res.. 2013 Jul;147(41308):236-40. Pubmed PMID: 23707643\n",
      "Sun S, Wang F, Wei J, Cao LY, Wu GY, Lu L, Kosten TA, Kosten TR, Zhang XY \"Association between interleukin-3 receptor alpha polymorphism and schizophrenia in the Chinese population..\" Neurosci. Lett.. 2008 Jul 25;440(1):35-7. Pubmed PMID: 18547720\n",
      "Sun S, Wang F, Wei J, Cao LY, Qi LY, Xiu MH, Chen S, Li XH, Kosten TA, Kosten TR, Zhang XY \"Association between interleukin-6 receptor polymorphism and patients with schizophrenia..\" Schizophr. Res.. 2008 Jul;102(41277):346-7. Pubmed PMID: 18508242\n",
      "Qiu HT, Meng HQ, Song C, Xiu MH, Chen da C, Zhu FY, Wu GY, Kosten TA, Kosten TR, Zhang XY \"Association between monoamine oxidase (MAO)-A gene variants and schizophrenia in a Chinese population..\" Brain Res.. 2009 Sep 1;1287:67-73. Pubmed PMID: 19573521\n",
      "Cao JX, Hu J, Ye XM, Xia Y, Haile CA, Kosten TR, Zhang XY \"Association between the 5-HTR1B gene polymorphisms and alcohol dependence in a Han Chinese population..\" Brain Res.. 2011 Feb 28;1376:41283. Pubmed PMID: 21172311\n",
      "Avants SK, Margolin A, McMahon TJ, Kosten TR \"Association between self-report of cognitive impairment, HIV status, and cocaine use in a sample of cocaine-dependent methadone-maintained patients..\" Addict Behav.;22(5):599-611. Pubmed PMID: 9347062\n",
      "Wang F, Fan H, Sun H, Yang F, Luo Y, Liu H, Kosten TR, Lu L, Zhang XY \"Association between TNF-a promoter -308A/G polymorphism and tardive dyskinesiain Chinese Han patients with schizophrenia..\" Prog. Neuropsychopharmacol. Biol. Psychiatry. 2012 Apr 27;37(1):106-10. Pubmed PMID: 22227290\n",
      "Li W, Zhou N, Yu Q, Li X, Yu Y, Sun S, Kou C, Chen da C, Xiu MH, Kosten TR, Zhang XY \"Association of BDNF gene polymorphisms with schizophrenia and clinical symptoms in a Chinese population.\" Am J Med Genet B Neuropsychiatr Genet. 2013 Sep;538-45. Pubmed PMID: 23832605\n",
      "Zhang XY, Tan YL, Zhou DF, Haile CN, Cao LY, Xu Q, Shen Y, Kosten TA, Kosten TR \"Association of clozapine-induced weight gain with a polymorphism in the leptin promoter region in patients with chronic schizophrenia in a Chinese population..\" J Clin Psychopharmacol. 2007 Jun;27(3):246-51. Pubmed PMID: 17502770\n",
      "Li WJ, Kou CG, Yu Y, Sun S, Zhang X, Kosten TR, Zhang XY \"Association of Catechol-O-methyltransferase gene polymorphisms with schizophrenia and negative symptoms in a Chinese population..\" Am. J. Med. Genet. B Neuropsychiatr. Genet.. 2012 Jun;159(4):370-5. Pubmed PMID: 22354729\n",
      "Guo S, Chen da F, Zhou DF, Sun HQ, Wu GY, Haile CN, Kosten TA, Kosten TR, Zhang XY \"Association of functional catechol O-methyl transferase (COMT) Val108Met polymorphism with smoking severity and age of smoking initiation in Chinese male smokers..\" Psychopharmacology (Berl.). 2007 Mar;190(4):449-56. Pubmed PMID: 17206495\n",
      "Sun H, Guo S, Chen D, Yang F, Zou Y, Di X, Cao Y, Kosten T, Lu L, Zhang XY \"Association of functional COMT Val108/Met polymorphism with smoking cessation in a nicotine replacement therapy..\" 2012 Jun 14; Pubmed PMID: 22695756\n",
      "Brown AE, Pavlik VN, Shegog R, Whitney SN, Friedman LC, Romero C, Davis GC, Cech I, Kosten TR, Volk RJ \"Association of spirituality and sobriety during a behavioral spirituality intervention for Twelve Step (TS) recovery..\" Am J Drug Alcohol Abuse. 2007;33(4):611-7. Pubmed PMID: 17668347\n",
      "Zhang XY, Chen DC, Xiu MH, Hui L, Liu H, Luo X, Zuo L, Zhang H, Kosten TA, Kosten TR \"Association of functional dopamine-beta-hydroxylase (DBH) 19bp insertion/deletion polymorphism with smoking severity in male schizophrenic smokers..\" Schizophr. Res.. 2012 Aug 4; Pubmed PMID: 22871345\n",
      "Liu H, Wang C, Chen PH, Zhang BS, Zheng YL, Zhang CX, Meng HQ, Wang Y, Chen da C, Xiu MH, Kosten TR, Zhang \n",
      "    ---------\n",
      "\n",
      "\n",
      "response.status_code:200\n",
      "response.text:{\"id\":\"chatcmpl-7Re2tVRuP9tCoJso9dVsR2DFLKBkK\",\"object\":\"chat.completion\",\"created\":1686823147,\"model\":\"gpt-3.5-turbo-16k-0613\",\"choices\":[{\"index\":0,\"message\":{\"role\":\"assistant\",\"content\":\"{\\n  \\\"姓名\\\": \\\"Thomas Kosten\\\",\\n  \\\"职称\\\": \\\"Jay H. Waggoner Endowed Chair\\\",\\n  \\\"医院/机构\\\": \\\"Baylor College of Medicine\\\",\\n  \\\"专长\\\": \\\"Developing medications and vaccines for addictions, Pharmacology\\\",\\n  \\\"职务\\\": \\\"Vice-Chair, Psychiatry for Research, Director, Division of Alcohol and Addiction Psychiatry, Co-Director, Institute for Clinical and Translational Research\\\",\\n  \\\"学术兼职\\\": \\\"Member, Dan L Duncan Comprehensive Cancer Center\\\",\\n  \\\"地区\\\": \\\"Houston, Texas US\\\",\\n  \\\"邮箱\\\": \\\"kosten@bcm.edu\\\",\\n  \\\"手机\\\": \\\"713-794-7032\\\",\\n  \\\"履历\\\": \\\"MA from Yale University, Clinical Fellowship at Yale University School of Medicine, M.D. from Cornell University Medical College, BS from Rensselaer Polytechnic Institute, Residency at Yale University School of Medicine, Internship at Greenwich Hospital\\\",\\n  \\\"教育经历\\\": \\\"MA from Yale University, 01/1995 - New Haven, Connecticut United States\\\\nClinical Fellowship at Yale University School of Medicine, 01/1983 - New Haven, Connecticut United States\\\\nM.D. from Cornell University Medical College, 01/1977 - New York, NY United States\\\\nBS from Rensselaer Polytechnic Institute, 01/1973 - Troy, New York United States\\\\nResidency at Yale University School of Medicine, 01/1981 - New Haven, Connecticut United States\\\\nInternship at Greenwich Hospital, 01/1978 - Greenwich, Connecticut United States\\\",\\n  \\\"工作经历\\\": \\\"Jay H. Waggoner Endowed Chair, Baylor College of Medicine\\\\nVice-Chair, Psychiatry for Research, Baylor College of Medicine\\\\nDirector, Division of Alcohol and Addiction Psychiatry, Baylor College of Medicine\\\\nCo-Director, Institute for Clinical and Translational Research, Baylor College of Medicine\\\\nProfessor, Psychiatry, Baylor College of Medicine\\\\nProfessor, Neuroscience, Baylor College of Medicine\\\\nProfessor, Pharmacology, Baylor College of Medicine\\\\nProfessor, Immunology and Rheumatology, Baylor College of Medicine\\\",\\n  \\\"研究\\\": \\\"Developing medications and vaccines for addictions, Pharmacology\\\",\\n  \\\"研究方向/临床研究\\\": \\\"Developing medications and vaccines for addictions\\\",\\n  \\\"发表\\\": \\\"VIICTR Publications List\\\",\\n  \\\"发表文章\\\": \\\"Malison RT, McCance E, Carpenter LL, Baldwin RM, Seibyl JP, Price LH, Kosten TR, Innis RB \\\\\\\"[123I]beta-CIT SPECT imaging of dopamine transporter availability after mazindol administration in human cocaine addicts..\\\\\\\" Psychopharmacology (Berl.). 1998 Jun;137(4):321-5. Pubmed PMID: 9676890\\\\nKosten TR, Rounsaville BJ, Kleber HD \\\\\\\"A 2.5-year follow-up of cocaine use among treated opioid addicts. Have our treatments helped?.\\\\\\\" Arch. Gen. Psychiatry. 1987 Mar;44(3):281-4. Pubmed PMID: 3827521\\\\nKosten TR, Rounsaville BJ, Kleber HD \\\\\\\"A 2.5 year follow-up of treatment retention and reentry among opioid addicts..\\\\\\\" J Subst Abuse Treat. 1986;3(3):181-9. Pubmed PMID: 3806731\\\\nKosten TR, Rounsaville BJ, Kleber HD \\\\\\\"A 2.5-year follow-up of depression, life crises, and treatment effects on abstinence among opioid addicts..\\\\\\\" Arch Gen Psychiatry. 1986 Aug;733-8. Pubmed PMID: 3729667\\\\nRounsaville BJ, Kosten TR, Weissmann MM, Kleber HD \\\\\\\"A 2.5-year follow-up of short-term interpersonal psychotherapy in methadone-maintained opiate addicts..\\\\\\\" Compr Psychiatry.;27(3):201-10. Pubmed PMID: 3709134\\\",\\n  \\\"出版著作\\\": \\\"None\\\",\\n  \\\"专利和软著\\\": \\\"None\\\",\\n  \\\"执笔共识\\\": \\\"None\\\",\\n  \\\"成就\\\": \\\"None\\\",\\n  \\\"荣誉获奖\\\": \\\"None\\\"\\n}\"},\"finish_reason\":\"stop\"}],\"usage\":{\"prompt_tokens\":5092,\"completion_tokens\":922,\"total_tokens\":6014}}\n",
      "json_dict:{'id': 'chatcmpl-7Re2tVRuP9tCoJso9dVsR2DFLKBkK', 'object': 'chat.completion', 'created': 1686823147, 'model': 'gpt-3.5-turbo-16k-0613', 'choices': [{'index': 0, 'message': {'role': 'assistant', 'content': '{\\n  \"姓名\": \"Thomas Kosten\",\\n  \"职称\": \"Jay H. Waggoner Endowed Chair\",\\n  \"医院/机构\": \"Baylor College of Medicine\",\\n  \"专长\": \"Developing medications and vaccines for addictions, Pharmacology\",\\n  \"职务\": \"Vice-Chair, Psychiatry for Research, Director, Division of Alcohol and Addiction Psychiatry, Co-Director, Institute for Clinical and Translational Research\",\\n  \"学术兼职\": \"Member, Dan L Duncan Comprehensive Cancer Center\",\\n  \"地区\": \"Houston, Texas US\",\\n  \"邮箱\": \"kosten@bcm.edu\",\\n  \"手机\": \"713-794-7032\",\\n  \"履历\": \"MA from Yale University, Clinical Fellowship at Yale University School of Medicine, M.D. from Cornell University Medical College, BS from Rensselaer Polytechnic Institute, Residency at Yale University School of Medicine, Internship at Greenwich Hospital\",\\n  \"教育经历\": \"MA from Yale University, 01/1995 - New Haven, Connecticut United States\\\\nClinical Fellowship at Yale University School of Medicine, 01/1983 - New Haven, Connecticut United States\\\\nM.D. from Cornell University Medical College, 01/1977 - New York, NY United States\\\\nBS from Rensselaer Polytechnic Institute, 01/1973 - Troy, New York United States\\\\nResidency at Yale University School of Medicine, 01/1981 - New Haven, Connecticut United States\\\\nInternship at Greenwich Hospital, 01/1978 - Greenwich, Connecticut United States\",\\n  \"工作经历\": \"Jay H. Waggoner Endowed Chair, Baylor College of Medicine\\\\nVice-Chair, Psychiatry for Research, Baylor College of Medicine\\\\nDirector, Division of Alcohol and Addiction Psychiatry, Baylor College of Medicine\\\\nCo-Director, Institute for Clinical and Translational Research, Baylor College of Medicine\\\\nProfessor, Psychiatry, Baylor College of Medicine\\\\nProfessor, Neuroscience, Baylor College of Medicine\\\\nProfessor, Pharmacology, Baylor College of Medicine\\\\nProfessor, Immunology and Rheumatology, Baylor College of Medicine\",\\n  \"研究\": \"Developing medications and vaccines for addictions, Pharmacology\",\\n  \"研究方向/临床研究\": \"Developing medications and vaccines for addictions\",\\n  \"发表\": \"VIICTR Publications List\",\\n  \"发表文章\": \"Malison RT, McCance E, Carpenter LL, Baldwin RM, Seibyl JP, Price LH, Kosten TR, Innis RB \\\\\"[123I]beta-CIT SPECT imaging of dopamine transporter availability after mazindol administration in human cocaine addicts..\\\\\" Psychopharmacology (Berl.). 1998 Jun;137(4):321-5. Pubmed PMID: 9676890\\\\nKosten TR, Rounsaville BJ, Kleber HD \\\\\"A 2.5-year follow-up of cocaine use among treated opioid addicts. Have our treatments helped?.\\\\\" Arch. Gen. Psychiatry. 1987 Mar;44(3):281-4. Pubmed PMID: 3827521\\\\nKosten TR, Rounsaville BJ, Kleber HD \\\\\"A 2.5 year follow-up of treatment retention and reentry among opioid addicts..\\\\\" J Subst Abuse Treat. 1986;3(3):181-9. Pubmed PMID: 3806731\\\\nKosten TR, Rounsaville BJ, Kleber HD \\\\\"A 2.5-year follow-up of depression, life crises, and treatment effects on abstinence among opioid addicts..\\\\\" Arch Gen Psychiatry. 1986 Aug;733-8. Pubmed PMID: 3729667\\\\nRounsaville BJ, Kosten TR, Weissmann MM, Kleber HD \\\\\"A 2.5-year follow-up of short-term interpersonal psychotherapy in methadone-maintained opiate addicts..\\\\\" Compr Psychiatry.;27(3):201-10. Pubmed PMID: 3709134\",\\n  \"出版著作\": \"None\",\\n  \"专利和软著\": \"None\",\\n  \"执笔共识\": \"None\",\\n  \"成就\": \"None\",\\n  \"荣誉获奖\": \"None\"\\n}'}, 'finish_reason': 'stop'}], 'usage': {'prompt_tokens': 5092, 'completion_tokens': 922, 'total_tokens': 6014}}\n",
      "{\n",
      "  \"姓名\": \"Thomas Kosten\",\n",
      "  \"职称\": \"Jay H. Waggoner Endowed Chair\",\n",
      "  \"医院/机构\": \"Baylor College of Medicine\",\n",
      "  \"专长\": \"Developing medications and vaccines for addictions, Pharmacology\",\n",
      "  \"职务\": \"Vice-Chair, Psychiatry for Research, Director, Division of Alcohol and Addiction Psychiatry, Co-Director, Institute for Clinical and Translational Research\",\n",
      "  \"学术兼职\": \"Member, Dan L Duncan Comprehensive Cancer Center\",\n",
      "  \"地区\": \"Houston, Texas US\",\n",
      "  \"邮箱\": \"kosten@bcm.edu\",\n",
      "  \"手机\": \"713-794-7032\",\n",
      "  \"履历\": \"MA from Yale University, Clinical Fellowship at Yale University School of Medicine, M.D. from Cornell University Medical College, BS from Rensselaer Polytechnic Institute, Residency at Yale University School of Medicine, Internship at Greenwich Hospital\",\n",
      "  \"教育经历\": \"MA from Yale University, 01/1995 - New Haven, Connecticut United States\\nClinical Fellowship at Yale University School of Medicine, 01/1983 - New Haven, Connecticut United States\\nM.D. from Cornell University Medical College, 01/1977 - New York, NY United States\\nBS from Rensselaer Polytechnic Institute, 01/1973 - Troy, New York United States\\nResidency at Yale University School of Medicine, 01/1981 - New Haven, Connecticut United States\\nInternship at Greenwich Hospital, 01/1978 - Greenwich, Connecticut United States\",\n",
      "  \"工作经历\": \"Jay H. Waggoner Endowed Chair, Baylor College of Medicine\\nVice-Chair, Psychiatry for Research, Baylor College of Medicine\\nDirector, Division of Alcohol and Addiction Psychiatry, Baylor College of Medicine\\nCo-Director, Institute for Clinical and Translational Research, Baylor College of Medicine\\nProfessor, Psychiatry, Baylor College of Medicine\\nProfessor, Neuroscience, Baylor College of Medicine\\nProfessor, Pharmacology, Baylor College of Medicine\\nProfessor, Immunology and Rheumatology, Baylor College of Medicine\",\n",
      "  \"研究\": \"Developing medications and vaccines for addictions, Pharmacology\",\n",
      "  \"研究方向/临床研究\": \"Developing medications and vaccines for addictions\",\n",
      "  \"发表\": \"VIICTR Publications List\",\n",
      "  \"发表文章\": \"Malison RT, McCance E, Carpenter LL, Baldwin RM, Seibyl JP, Price LH, Kosten TR, Innis RB \\\"[123I]beta-CIT SPECT imaging of dopamine transporter availability after mazindol administration in human cocaine addicts..\\\" Psychopharmacology (Berl.). 1998 Jun;137(4):321-5. Pubmed PMID: 9676890\\nKosten TR, Rounsaville BJ, Kleber HD \\\"A 2.5-year follow-up of cocaine use among treated opioid addicts. Have our treatments helped?.\\\" Arch. Gen. Psychiatry. 1987 Mar;44(3):281-4. Pubmed PMID: 3827521\\nKosten TR, Rounsaville BJ, Kleber HD \\\"A 2.5 year follow-up of treatment retention and reentry among opioid addicts..\\\" J Subst Abuse Treat. 1986;3(3):181-9. Pubmed PMID: 3806731\\nKosten TR, Rounsaville BJ, Kleber HD \\\"A 2.5-year follow-up of depression, life crises, and treatment effects on abstinence among opioid addicts..\\\" Arch Gen Psychiatry. 1986 Aug;733-8. Pubmed PMID: 3729667\\nRounsaville BJ, Kosten TR, Weissmann MM, Kleber HD \\\"A 2.5-year follow-up of short-term interpersonal psychotherapy in methadone-maintained opiate addicts..\\\" Compr Psychiatry.;27(3):201-10. Pubmed PMID: 3709134\",\n",
      "  \"出版著作\": \"None\",\n",
      "  \"专利和软著\": \"None\",\n",
      "  \"执笔共识\": \"None\",\n",
      "  \"成就\": \"None\",\n",
      "  \"荣誉获奖\": \"None\"\n",
      "}\n",
      "+++++++++++++++++++++++++\n",
      "{\n",
      "  \"姓名\": \"Thomas Kosten\",\n",
      "  \"职称\": \"Jay H. Waggoner Endowed Chair\",\n",
      "  \"医院/机构\": \"Baylor College of Medicine\",\n",
      "  \"专长\": \"Developing medications and vaccines for addictions, Pharmacology\",\n",
      "  \"职务\": \"Vice-Chair, Psychiatry for Research, Director, Division of Alcohol and Addiction Psychiatry, Co-Director, Institute for Clinical and Translational Research\",\n",
      "  \"学术兼职\": \"Member, Dan L Duncan Comprehensive Cancer Center\",\n",
      "  \"地区\": \"Houston, Texas US\",\n",
      "  \"邮箱\": \"kosten@bcm.edu\",\n",
      "  \"手机\": \"713-794-7032\",\n",
      "  \"履历\": \"MA from Yale University, Clinical Fellowship at Yale University School of Medicine, M.D. from Cornell University Medical College, BS from Rensselaer Polytechnic Institute, Residency at Yale University School of Medicine, Internship at Greenwich Hospital\",\n",
      "  \"教育经历\": \"MA from Yale University, 01/1995 - New Haven, Connecticut United States\\nClinical Fellowship at Yale University School of Medicine, 01/1983 - New Haven, Connecticut United States\\nM.D. from Cornell University Medical College, 01/1977 - New York, NY United States\\nBS from Rensselaer Polytechnic Institute, 01/1973 - Troy, New York United States\\nResidency at Yale University School of Medicine, 01/1981 - New Haven, Connecticut United States\\nInternship at Greenwich Hospital, 01/1978 - Greenwich, Connecticut United States\",\n",
      "  \"工作经历\": \"Jay H. Waggoner Endowed Chair, Baylor College of Medicine\\nVice-Chair, Psychiatry for Research, Baylor College of Medicine\\nDirector, Division of Alcohol and Addiction Psychiatry, Baylor College of Medicine\\nCo-Director, Institute for Clinical and Translational Research, Baylor College of Medicine\\nProfessor, Psychiatry, Baylor College of Medicine\\nProfessor, Neuroscience, Baylor College of Medicine\\nProfessor, Pharmacology, Baylor College of Medicine\\nProfessor, Immunology and Rheumatology, Baylor College of Medicine\",\n",
      "  \"研究\": \"Developing medications and vaccines for addictions, Pharmacology\",\n",
      "  \"研究方向/临床研究\": \"Developing medications and vaccines for addictions\",\n",
      "  \"发表\": \"VIICTR Publications List\",\n",
      "  \"发表文章\": \"Malison RT, McCance E, Carpenter LL, Baldwin RM, Seibyl JP, Price LH, Kosten TR, Innis RB \\\"[123I]beta-CIT SPECT imaging of dopamine transporter availability after mazindol administration in human cocaine addicts..\\\" Psychopharmacology (Berl.). 1998 Jun;137(4):321-5. Pubmed PMID: 9676890\\nKosten TR, Rounsaville BJ, Kleber HD \\\"A 2.5-year follow-up of cocaine use among treated opioid addicts. Have our treatments helped?.\\\" Arch. Gen. Psychiatry. 1987 Mar;44(3):281-4. Pubmed PMID: 3827521\\nKosten TR, Rounsaville BJ, Kleber HD \\\"A 2.5 year follow-up of treatment retention and reentry among opioid addicts..\\\" J Subst Abuse Treat. 1986;3(3):181-9. Pubmed PMID: 3806731\\nKosten TR, Rounsaville BJ, Kleber HD \\\"A 2.5-year follow-up of depression, life crises, and treatment effects on abstinence among opioid addicts..\\\" Arch Gen Psychiatry. 1986 Aug;733-8. Pubmed PMID: 3729667\\nRounsaville BJ, Kosten TR, Weissmann MM, Kleber HD \\\"A 2.5-year follow-up of short-term interpersonal psychotherapy in methadone-maintained opiate addicts..\\\" Compr Psychiatry.;27(3):201-10. Pubmed PMID: 3709134\",\n",
      "  \"出版著作\": \"None\",\n",
      "  \"专利和软著\": \"None\",\n",
      "  \"执笔共识\": \"None\",\n",
      "  \"成就\": \"None\",\n",
      "  \"荣誉获奖\": \"None\"\n",
      "}\n"
     ]
    }
   ],
   "source": [
    "chat(thomas_kosten[:16000],\"托马斯医生的专长\")"
   ],
   "metadata": {
    "collapsed": false
   }
  },
  {
   "cell_type": "code",
   "execution_count": 32,
   "outputs": [],
   "source": [
    "cqq_txt = \"\"\"\n",
    "    临床研究clinical trials，NCT05572983\n",
    "{\n",
    "  \"Full Study\":{\n",
    "    \"Rank\":22633,\n",
    "    \"Study\":{\n",
    "      \"Protocol Section\":{\n",
    "        \"Identification Module\":{\n",
    "          \"NCT Id\":\"NCT05572983\",\n",
    "          \"Org Study Id Info\":{\n",
    "            \"Org Study Id\":\"SL-B2022-485-02\"\n",
    "          },\n",
    "          \"Organization\":{\n",
    "            \"Org Full Name\":\"Sun Yat-sen University\",\n",
    "            \"Org Class\":\"OTHER\"\n",
    "          },\n",
    "          \"Brief Title\":\"Phase Ⅱ Study of Chidamide in Combination With CHOP in Previously Untreated Peripheral T-Cell Lymphoma With Follicular Helper of T Cell Phenotype\",\n",
    "          \"Official Title\":\"Phase Ⅱ Study of Chidamide in Combination With CHOP in Previously Untreated Peripheral T-Cell Lymphoma With Follicular Helper of T Cell Phenotype （SWIFT）\"\n",
    "        },\n",
    "        \"Status Module\":{\n",
    "          \"Status Verified Date\":\"September 2022\",\n",
    "          \"Overall Status\":\"Recruiting\",\n",
    "          \"Expanded Access Info\":{\n",
    "            \"Has Expanded Access\":\"No\"\n",
    "          },\n",
    "          \"Start Date Struct\":{\n",
    "            \"Start Date\":\"September 1, 2022\",\n",
    "            \"Start DateType\":\"Actual\"\n",
    "          },\n",
    "          \"Primary Completion Date Struct\":{\n",
    "            \"Primary Completion Date\":\"September 1, 2024\",\n",
    "            \"Primary Completion DateType\":\"Anticipated\"\n",
    "          },\n",
    "          \"Completion Date Struct\":{\n",
    "            \"Completion Date\":\"September 1, 2026\",\n",
    "            \"Completion DateType\":\"Anticipated\"\n",
    "          },\n",
    "          \"Study First Submit Date\":\"September 30, 2022\",\n",
    "          \"Study First Submit QC Date\":\"October 7, 2022\",\n",
    "          \"Study First Post Date Struct\":{\n",
    "            \"Study First Post Date\":\"October 10, 2022\",\n",
    "            \"Study First Post DateType\":\"Actual\"\n",
    "          },\n",
    "          \"Last Update Submit Date\":\"October 7, 2022\",\n",
    "          \"Last Update Post Date Struct\":{\n",
    "            \"Last Update Post Date\":\"October 10, 2022\",\n",
    "            \"Last Update Post DateType\":\"Actual\"\n",
    "          }\n",
    "        },\n",
    "        \"Sponsor Collaborators Module\":{\n",
    "          \"Responsible Party\":{\n",
    "            \"Responsible PartyType\":\"Principal Investigator\",\n",
    "            \"Responsible PartyInvestigatorFullName\":\"Qingqing Cai\",\n",
    "            \"Responsible PartyInvestigatorTitle\":\"Chief physician\",\n",
    "            \"Responsible PartyInvestigatorAffiliation\":\"Sun Yat-sen University\"\n",
    "          },\n",
    "          \"Lead Sponsor\":{\n",
    "            \"Lead SponsorName\":\"Sun Yat-sen University\",\n",
    "            \"Lead SponsorClass\":\"OTHER\"\n",
    "          }\n",
    "        },\n",
    "        \"Oversight Module\":{\n",
    "          \"Is FDA Regulated Drug\":\"No\",\n",
    "          \"Is FDA Regulated Device\":\"No\"\n",
    "        },\n",
    "        \"Description Module\":{\n",
    "          \"Brief Summary\":\"This is a prospective, open-label, single arm, multicenter clinical study to evaluate the safety, tolerability, efficacy of chidamide in combination with CHOP in previously untreated peripheral T-cell lymphoma with follicular helper of T cell phenotype\"\n",
    "        },\n",
    "        \"Conditions Module\":{\n",
    "          \"Condition List\":{\n",
    "            \"Condition\":[\n",
    "              \"Peripheral T-Cell Lymphoma With Follicular Helper of T Cell Phenotype\"\n",
    "            ]\n",
    "          }\n",
    "        },\n",
    "        \"Design Module\":{\n",
    "          \"Study Type\":\"Interventional\",\n",
    "          \"PhaseList\":{\n",
    "            \"Phase\":[\n",
    "              \"Phase 2\"\n",
    "            ]\n",
    "          },\n",
    "          \"Design Info\":{\n",
    "            \"DesignAllocation\":\"N/A\",\n",
    "            \"DesignInterventionModel\":\"Single Group Assignment\",\n",
    "            \"DesignPrimaryPurpose\":\"Treatment\",\n",
    "            \"DesignMaskingInfo\":{\n",
    "              \"DesignMasking\":\"None (Open Label)\"\n",
    "            }\n",
    "          },\n",
    "          \"Enrollment Info\":{\n",
    "            \"Enrollment Count\":\"47\",\n",
    "            \"Enrollment Type\":\"Anticipated\"\n",
    "          }\n",
    "        },\n",
    "        \"Arms Interventions Module\":{\n",
    "          \"Arm Group List\":{\n",
    "            \"Arm Group\":[\n",
    "              {\n",
    "                \"Arm GroupLabel\":\"Chidamide in Combination With CHOP\",\n",
    "                \"Arm GroupType\":\"Experimental\",\n",
    "                \"Arm GroupDescription\":\"Patients with previously untreated peripheral T-cell lymphoma with follicular helper of T cell phenotype will receive chidamide in combination with CHOP for 6 cycles (planned) (21 days per cycle). After 6 cycles of induction therapy, if complete remission (CR) was achieved, maintenance treatment with chidamide will be continued for two years.\",\n",
    "                \"Arm GroupIntervention List\":{\n",
    "                  \"Arm GroupInterventionName\":[\n",
    "                    \"Drug: Chidamide combined with CHOP\",\n",
    "                    \"Drug: Chidamide\"\n",
    "                  ]\n",
    "                }\n",
    "              }\n",
    "            ]\n",
    "          },\n",
    "          \"Intervention List\":{\n",
    "            \"Intervention\":[\n",
    "              {\n",
    "                \"InterventionType\":\"Drug\",\n",
    "                \"InterventionName\":\"Chidamide combined with CHOP\",\n",
    "                \"InterventionDescription\":\"A)Chidamide: 20mg, D1, 4,8,11, po; B) Cyclophosphamide: 750 mg/ m2, D1, iv.drip; C) Doxorubicin: 50 mg/ m2, D1, iv.drip (or epirubicin 70 mg/ m2, D1, iv.drip); D) Vincristine: 1.4 mg/ m2, D1 (maximum dose 2mg, maximum dose 1.5mg for age over 70 years), iv; E) Prednisone: 40mg/m2, D1-5,po\",\n",
    "                \"InterventionArm GroupLabelList\":{\n",
    "                  \"InterventionArm GroupLabel\":[\n",
    "                    \"Chidamide in Combination With CHOP\"\n",
    "                  ]\n",
    "                },\n",
    "                \"InterventionOtherNameList\":{\n",
    "                  \"InterventionOtherName\":[\n",
    "                    \"Induction treatment\"\n",
    "                  ]\n",
    "                }\n",
    "              },{\n",
    "                \"InterventionType\":\"Drug\",\n",
    "                \"InterventionName\":\"Chidamide\",\n",
    "                \"InterventionDescription\":\"Chidamide: 20mg，qw（d1,d4）,po\",\n",
    "                \"InterventionArm GroupLabelList\":{\n",
    "                  \"InterventionArm GroupLabel\":[\n",
    "                    \"Chidamide in Combination With CHOP\"\n",
    "                  ]\n",
    "                },\n",
    "                \"InterventionOtherNameList\":{\n",
    "                  \"InterventionOtherName\":[\n",
    "                    \"Maintenance treatment\"\n",
    "                  ]\n",
    "                }\n",
    "              }\n",
    "            ]\n",
    "          }\n",
    "        },\n",
    "        \"Outcomes Module\":{\n",
    "          \"Primary Outcome List\":{\n",
    "            \"Primary Outcome\":[\n",
    "              {\n",
    "                \"Primary Outcome Measure\":\"Complete remission rate\",\n",
    "                \"Primary OutcomeDescription\":\"Complete remission rate will be determined on the basis of investigator assessments according to 2014 Lugano criteria.\",\n",
    "                \"Primary OutcomeTimeFrame\":\"Up to 18 weeks\"\n",
    "              }\n",
    "            ]\n",
    "          },\n",
    "          \"Secondary Outcome List\":{\n",
    "            \"Secondary Outcome\":[\n",
    "              {\n",
    "                \"Secondary Outcome Measure\":\"Objective response rate\",\n",
    "                \"Secondary OutcomeDescription\":\"Objective Response rate will be determined on the basis of investigator assessments according to 2014 Lugano criteria.\",\n",
    "                \"Secondary OutcomeTimeFrame\":\"Up to 18 weeks\"\n",
    "              },{\n",
    "                \"Secondary Outcome Measure\":\"Partial remission rate\",\n",
    "                \"Secondary OutcomeDescription\":\"Partial remission rate will be determined on the basis of investigator assessments according to 2014 Lugano criteria.\",\n",
    "                \"Secondary OutcomeTimeFrame\":\"Up to 18 weeks\"\n",
    "              },{\n",
    "                \"Secondary Outcome Measure\":\"Progression-free survival（PFS）\",\n",
    "                \"Secondary OutcomeDescription\":\"To investigate the preliminary antitumor efficacy\",\n",
    "                \"Secondary OutcomeTimeFrame\":\"From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 24 months\"\n",
    "              },{\n",
    "                \"Secondary Outcome Measure\":\"Overall survival\",\n",
    "                \"Secondary OutcomeDescription\":\"To investigate the preliminary antitumor efficacy\",\n",
    "                \"Secondary OutcomeTimeFrame\":\"From date of randomization until the date of death from any cause, assessed up to 24 months\"\n",
    "              },{\n",
    "                \"Secondary Outcome Measure\":\"Recurrence free survival\",\n",
    "                \"Secondary OutcomeDescription\":\"To investigate the preliminary antitumor efficacy\",\n",
    "                \"Secondary OutcomeTimeFrame\":\"From date of randomization until the date ofthe occurrence of relapse or last visit, assessed up to 24 months\"\n",
    "              },{\n",
    "                \"Secondary Outcome Measure\":\"Number of participants with adverse events (AE) and severe adverse events (SAE) as assessed by CTCAE v5.0\",\n",
    "                \"Secondary OutcomeDescription\":\"To identify the incidence of AE and SAE\",\n",
    "                \"Secondary OutcomeTimeFrame\":\"Up to 18 weeks\"\n",
    "              }\n",
    "            ]\n",
    "          }\n",
    "        },\n",
    "        \"Eligibility Module\":{\n",
    "          \"Eligibility Criteria\":\"Inclusion Criteria:\\n\\nAge ≥18 years old and ≤75 years old, male and female;\\nPeripheral T-Cell lymphoma with follicular helper of T cell phenotype confirmed by histopathology at the study center, including: ① Angioimmunoblastic T-cell lymphoma (AITL), ②follicular T-cell lymphoma (FTCL), and ③ other nodal PTCL with TFH phenotype;\\nNever received chemotherapy, radiotherapy, immunological and biological therapy for lymphoma before;\\nAutologous stem cell transplantation is not suitable or the patient refused to accept autologous stem cell transplantation;\\nThere must be at least one measurable or evaluable lesion that meets the evaluation criteria for Lugano 2014 lymphoma: measurable lesion: Positron emission tomography / computed tomography (PET/CT) or CT and/or MRI, intranode lesions with long diameter >1.5cm, short diameter >1.0cm, or exnode lesions with long diameter > 1.0 cm; PET CT examination of the lesion showing increased uptake in lymph nodes or extranodal areas (higher than liver) and imaging features consistent with lymphoma can be evaluated.\\nEastern Cooperative Oncology Group (ECOG) Performance Status (PS) 0-2；\\nExpected survival ≥ 3 months;\\n\\nThe following required baseline laboratory data:\\n\\n.White blood cell，WBC≥3.0×109/L(Bone marrow invasive patient≥2.0×109/L), Absolute neutrophil count，ANC ≥1.5×109/L, （Bone marrow invasive patient≥1.0×109/L), Platelet count (PLT) ≥75×109/L, （Bone marrow invasive patient≥50×109/L) ，Hemoglobin (HB)≥ 80g/L;\\n.Total bilirubin (TBIL) ≤1.5×upper limit of normal (ULN) (The liver invasion ≤3.0×ULN), Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤2.5×ULN（The liver invasion≤5.0×ULN）\\n.Renal function：creatinine, Cr≤1.5×ULN\\n.Coagulation function： International Normalized Ratio (INR)≤1.5 ×ULN； Prothrombin Time (PT)、Activated Partial Thromboplastin Time (APTT)≤1.5×ULN（Unless the patient is receiving anticoagulant therapy and PT and APTT are within the expected range at screening time）；\\n.Thyroid stimulating hormone (TSH) or free thyroid hormone (FT4) or free triiodothyronine (FT3) were within 10% of normal value (note: abnormal TSH caused by non-autoimmune causes can be included in the group);\\nSubjects fully understand and voluntarily participate in this study and sign informed consent\\n\\nExclusion Criteria:\\n\\nA history of other malignant tumors within the past 5 years; Or other tumors (except basal cell carcinoma of the skin)\\nPatients with significant vital organ dysfunction;\\nPatients with active bleeding or newly developed thrombotic disease, and patients who are taking anticoagulants and having a bleeding tendency;\\nPatients with a known history of Human Immunodeficiency Virus (HIV) infection and/or acquired Immunodeficiency syndrome;\\nPatients with active chronic hepatitis B or active hepatitis C. Patients who are hepatitis B surface antigen (HBsAg) or hepatitis B core antibody (HBcAb) or hepatitis C virus (HCV) antibody positive during the screening period require further testing for Hepatitis B Virus (HBV) DNA and HCV RNA. If HBV DNA is no more than 2500 copies /mL or 500 IU/mL and HCV RNA is no more than the lower limit of the assay, enrollment will be allowed after exclusion of treatment-requiring active hepatitis B or C infection. Hepatitis B virus carriers, stable hepatitis B (no more than 2500 copies /mL or 500 IU/mL of DNA) and cured hepatitis C patients were eligible;\\nSubjects who were treated with systemic glucocorticoids or other immunosuppressive agents for a condition within 14 days prior to initiation of study treatment {Local, ocular, intra-articular, intranasal, and inhaled glucocorticoids were allowed (with very low systemic absorption); Short-term (≤ 7 days) use of glucocorticoids for prophylactic treatment (e.g., contrast media allergy) or for treatment of non-autoimmune conditions (e.g., delayed hypersensitivity due to contact allergens) is allowed;\\nWith active, and in the past two years need systemic treatment of autoimmune diseases (hormone replacement therapy is not considered a systemic treatment, such as type 1 diabetes, hypothyroidism only requiring thyroid hormone replacement therapy, low adrenocortical or pituitary function only requiring physiological doses of sugar cortical hormone replacement therapy ); Patients with autoimmune diseases that have not required systemic treatment in the past two years are eligible;\\nPatients with unstable angina and/or congestive heart failure or vascular disease (such as, the aortic aneurysm or peripheral venous thrombosis requiring surgery to repair) requiring hospital treatment within 12 months. Patients with other cardiac damage (such as poor control of arrhythmia, myocardial infarction, or ischemic) which may affect the drug safety evaluation within 12 months;\\nPatients who underwent major surgery within 28 days before enrollment; Less than 6 weeks after major organ surgery;\\nLong-term unhealed wounds or incomplete healing fractures;\\nReceive live attenuated vaccine (except influenza vaccine) within 4 weeks before enrollment or during the study period;\\nPregnant or lactating women and subjects of reproductive age who do not want to take contraceptive measures;\\nPatients with mental illness or who cannot obtain informed consent;\\nThere is active infection, except for tumor-related B symptoms and fever;\\nCardiac clinical symptoms or diseases that are not well controlled, such as: I. Nyha grade 2 or above heart failure; II. Unstable angina pectoris; III. Myocardial infarction has occurred within 1 year; IV. Patients with clinically significant supraventricular or ventricular arrhythmias requiring treatment or intervention;\\nIneligibility to participate in the study was determined by the investigator.\",\n",
    "          \"Healthy Volunteers\":\"No\",\n",
    "          \"Gender\":\"All\",\n",
    "          \"Minimum Age\":\"18 Years\",\n",
    "          \"MaximumAge\":\"75 Years\",\n",
    "          \"Std Age List\":{\n",
    "            \"Std Age\":[\n",
    "              \"Adult\",\n",
    "              \"Older Adult\"\n",
    "            ]\n",
    "          }\n",
    "        },\n",
    "        \"Contacts Locations Module\":{\n",
    "          \"CentralContactList\":{\n",
    "            \"CentralContact\":[\n",
    "              {\n",
    "                \"CentralContactName\":\"Qingqing Cai\",\n",
    "                \"CentralContactRole\":\"Contact\",\n",
    "                \"CentralContactPhone\":\"0086-20-87342823\",\n",
    "                \"CentralContactEMail\":\"caiqq@sysucc.org.cn\"\n",
    "              }\n",
    "            ]\n",
    "          },\n",
    "          \"Overall Official List\":{\n",
    "            \"Overall Official\":[\n",
    "              {\n",
    "                \"Overall OfficialName\":\"Qingqing Cai\",\n",
    "                \"Overall OfficialAffiliation\":\"Sun Yat-sen University\",\n",
    "                \"Overall OfficialRole\":\"Study Director\"\n",
    "              }\n",
    "            ]\n",
    "          },\n",
    "          \"Location List\":{\n",
    "            \"Location\":[\n",
    "              {\n",
    "                \"LocationFacility\":\"Sun Yat-sen Universitiy Cancer Center, Sun Yat-Sen University\",\n",
    "                \"LocationStatus\":\"Recruiting\",\n",
    "                \"LocationCity\":\"Guangzhou\",\n",
    "                \"LocationState\":\"Guangdong\",\n",
    "                \"LocationZip\":\"510000\",\n",
    "                \"LocationCountry\":\"China\",\n",
    "                \"LocationContactList\":{\n",
    "                  \"LocationContact\":[\n",
    "                    {\n",
    "                      \"LocationContactName\":\"Qingqing Cai, MD\",\n",
    "                      \"LocationContactRole\":\"Contact\",\n",
    "                      \"LocationContactEMail\":\"caiqq@sysucc.org.cn\"\n",
    "                    }\n",
    "                  ]\n",
    "                }\n",
    "              }\n",
    "            ]\n",
    "          }\n",
    "        }\n",
    "      },\n",
    "      \"Derived Section\":{\n",
    "        \"Misc Info Module\":{\n",
    "          \"Version Holder\":\"May 19, 2023\"\n",
    "        },\n",
    "        \"Condition Browse Module\":{\n",
    "          \"Condition Mesh List\":{\n",
    "            \"Condition Mesh\":[\n",
    "              {\n",
    "                \"Condition MeshId\":\"D000008223\",\n",
    "                \"Condition MeshTerm\":\"Lymphoma\"\n",
    "              },{\n",
    "                \"Condition MeshId\":\"D000016399\",\n",
    "                \"Condition MeshTerm\":\"Lymphoma, T-Cell\"\n",
    "              },{\n",
    "                \"Condition MeshId\":\"D000016411\",\n",
    "                \"Condition MeshTerm\":\"Lymphoma, T-Cell, Peripheral\"\n",
    "              }\n",
    "            ]\n",
    "          },\n",
    "          \"Condition Ancestor List\":{\n",
    "            \"Condition Ancestor\":[\n",
    "              {\n",
    "                \"Condition AncestorId\":\"D000009370\",\n",
    "                \"Condition AncestorTerm\":\"Neoplasms by Histologic Type\"\n",
    "              },{\n",
    "                \"Condition AncestorId\":\"D000009369\",\n",
    "                \"Condition AncestorTerm\":\"Neoplasms\"\n",
    "              },{\n",
    "                \"Condition AncestorId\":\"D000008232\",\n",
    "                \"Condition AncestorTerm\":\"Lymphoproliferative Disorders\"\n",
    "              },{\n",
    "                \"Condition AncestorId\":\"D000008206\",\n",
    "                \"Condition AncestorTerm\":\"Lymphatic Diseases\"\n",
    "              },{\n",
    "                \"Condition AncestorId\":\"D000007160\",\n",
    "                \"Condition AncestorTerm\":\"Immunoproliferative Disorders\"\n",
    "              },{\n",
    "                \"Condition AncestorId\":\"D000007154\",\n",
    "                \"Condition AncestorTerm\":\"Immune System Diseases\"\n",
    "              },{\n",
    "                \"Condition AncestorId\":\"D000008228\",\n",
    "                \"Condition AncestorTerm\":\"Lymphoma, Non-Hodgkin\"\n",
    "              }\n",
    "            ]\n",
    "          },\n",
    "          \"Condition Browse Leaf List\":{\n",
    "            \"Condition Browse Leaf\":[\n",
    "              {\n",
    "                \"Condition Browse LeafId\":\"M10372\",\n",
    "                \"Condition Browse LeafName\":\"Lymphoma\",\n",
    "                \"Condition Browse LeafAsFound\":\"Lymphoma\",\n",
    "                \"Condition Browse LeafRelevance\":\"high\"\n",
    "              },{\n",
    "                \"Condition Browse LeafId\":\"M17981\",\n",
    "                \"Condition Browse LeafName\":\"Lymphoma, T-Cell\",\n",
    "                \"Condition Browse LeafAsFound\":\"T-cell Lymphoma\",\n",
    "                \"Condition Browse LeafRelevance\":\"high\"\n",
    "              },{\n",
    "                \"Condition Browse LeafId\":\"M17985\",\n",
    "                \"Condition Browse LeafName\":\"Lymphoma, T-Cell, Peripheral\",\n",
    "                \"Condition Browse LeafAsFound\":\"Peripheral T-cell Lymphoma\",\n",
    "                \"Condition Browse LeafRelevance\":\"high\"\n",
    "              },{\n",
    "                \"Condition Browse LeafId\":\"M11467\",\n",
    "                \"Condition Browse LeafName\":\"Neoplasms by Histologic Type\",\n",
    "                \"Condition Browse LeafRelevance\":\"low\"\n",
    "              },{\n",
    "                \"Condition Browse LeafId\":\"M10377\",\n",
    "                \"Condition Browse LeafName\":\"Lymphoproliferative Disorders\",\n",
    "                \"Condition Browse LeafRelevance\":\"low\"\n",
    "              },{\n",
    "                \"Condition Browse LeafId\":\"M10355\",\n",
    "                \"Condition Browse LeafName\":\"Lymphatic Diseases\",\n",
    "                \"Condition Browse LeafRelevance\":\"low\"\n",
    "              },{\n",
    "                \"Condition Browse LeafId\":\"M9358\",\n",
    "                \"Condition Browse LeafName\":\"Immunoproliferative Disorders\",\n",
    "                \"Condition Browse LeafRelevance\":\"low\"\n",
    "              },{\n",
    "                \"Condition Browse LeafId\":\"M9352\",\n",
    "                \"Condition Browse LeafName\":\"Immune System Diseases\",\n",
    "                \"Condition Browse LeafRelevance\":\"low\"\n",
    "              },{\n",
    "                \"Condition Browse LeafId\":\"M10374\",\n",
    "                \"Condition Browse LeafName\":\"Lymphoma, Non-Hodgkin\",\n",
    "                \"Condition Browse LeafRelevance\":\"low\"\n",
    "              },{\n",
    "                \"Condition Browse LeafId\":\"T3543\",\n",
    "                \"Condition Browse LeafName\":\"Lymphosarcoma\",\n",
    "                \"Condition Browse LeafAsFound\":\"Lymphoma\",\n",
    "                \"Condition Browse LeafRelevance\":\"high\"\n",
    "              },{\n",
    "                \"Condition Browse LeafId\":\"T4496\",\n",
    "                \"Condition Browse LeafName\":\"Peripheral T-cell Lymphoma\",\n",
    "                \"Condition Browse LeafAsFound\":\"Peripheral T-cell Lymphoma\",\n",
    "                \"Condition Browse LeafRelevance\":\"high\"\n",
    "              }\n",
    "            ]\n",
    "          },\n",
    "          \"Condition Browse Branch List\":{\n",
    "            \"Condition Browse Branch\":[\n",
    "              {\n",
    "                \"Condition Browse BranchAbbrev\":\"BC04\",\n",
    "                \"Condition Browse BranchName\":\"Neoplasms\"\n",
    "              },{\n",
    "                \"Condition Browse BranchAbbrev\":\"BC15\",\n",
    "                \"Condition Browse BranchName\":\"Blood and Lymph Conditions\"\n",
    "              },{\n",
    "                \"Condition Browse BranchAbbrev\":\"BC20\",\n",
    "                \"Condition Browse BranchName\":\"Immune System Diseases\"\n",
    "              },{\n",
    "                \"Condition Browse BranchAbbrev\":\"All\",\n",
    "                \"Condition Browse BranchName\":\"All Conditions\"\n",
    "              },{\n",
    "                \"Condition Browse BranchAbbrev\":\"Rare\",\n",
    "                \"Condition Browse BranchName\":\"Rare Diseases\"\n",
    "              }\n",
    "            ]\n",
    "          }\n",
    "        },\n",
    "        \"Intervention Browse Module\":{\n",
    "          \"Intervention Browse Leaf List\":{\n",
    "            \"Intervention Browse Leaf\":[\n",
    "              {\n",
    "                \"Intervention Browse LeafId\":\"M5879\",\n",
    "                \"Intervention Browse LeafName\":\"Cyclophosphamide\",\n",
    "                \"Intervention Browse LeafRelevance\":\"low\"\n",
    "              },{\n",
    "                \"Intervention Browse LeafId\":\"M17106\",\n",
    "                \"Intervention Browse LeafName\":\"Epirubicin\",\n",
    "                \"Intervention Browse LeafRelevance\":\"low\"\n",
    "              },{\n",
    "                \"Intervention Browse LeafId\":\"M6644\",\n",
    "                \"Intervention Browse LeafName\":\"Doxorubicin\",\n",
    "                \"Intervention Browse LeafRelevance\":\"low\"\n",
    "              },{\n",
    "                \"Intervention Browse LeafId\":\"M13273\",\n",
    "                \"Intervention Browse LeafName\":\"Prednisone\",\n",
    "                \"Intervention Browse LeafRelevance\":\"low\"\n",
    "              },{\n",
    "                \"Intervention Browse LeafId\":\"M16647\",\n",
    "                \"Intervention Browse LeafName\":\"Vincristine\",\n",
    "                \"Intervention Browse LeafRelevance\":\"low\"\n",
    "              },{\n",
    "                \"Intervention Browse LeafId\":\"M227311\",\n",
    "                \"Intervention Browse LeafName\":\"Liposomal doxorubicin\",\n",
    "                \"Intervention Browse LeafRelevance\":\"low\"\n",
    "              }\n",
    "            ]\n",
    "          },\n",
    "          \"Intervention Browse Branch List\":{\n",
    "            \"Intervention Browse Branch\":[\n",
    "              {\n",
    "                \"Intervention Browse BranchAbbrev\":\"ANeo\",\n",
    "                \"Intervention Browse BranchName\":\"Antineoplastic Agents\"\n",
    "              },{\n",
    "                \"Intervention Browse BranchAbbrev\":\"ARhu\",\n",
    "                \"Intervention Browse BranchName\":\"Antirheumatic Agents\"\n",
    "              },{\n",
    "                \"Intervention Browse BranchAbbrev\":\"All\",\n",
    "                \"Intervention Browse BranchName\":\"All Drugs and Chemicals\"\n",
    "              },{\n",
    "                \"Intervention Browse BranchAbbrev\":\"Infl\",\n",
    "                \"Intervention Browse BranchName\":\"Anti-Inflammatory Agents\"\n",
    "              }\n",
    "            ]\n",
    "          }\n",
    "        }\n",
    "      }\n",
    "    }\n",
    "  }\n",
    "}\n",
    "\n",
    "临床研究clinical trials，NCT04996758\n",
    "{\n",
    "  \"Full Study\":{\n",
    "    \"Rank\":66911,\n",
    "    \"Study\":{\n",
    "      \"Protocol Section\":{\n",
    "        \"Identification Module\":{\n",
    "          \"NCT Id\":\"NCT04996758\",\n",
    "          \"Org Study Id Info\":{\n",
    "            \"Org Study Id\":\"B2021-055\"\n",
    "          },\n",
    "          \"Organization\":{\n",
    "            \"Org Full Name\":\"Sun Yat-sen University\",\n",
    "            \"Org Class\":\"OTHER\"\n",
    "          },\n",
    "          \"Brief Title\":\"Toripalimab and Anlotinib Combination Treatment in Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma After Failure of at Least One Line of Platinum-Based Chemotherapy (TORAL)\",\n",
    "          \"Official Title\":\"Open-Label, Phase Ⅱ Study of Toripalimab and Anlotinib Combination Treatment in Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma After Failure of at Least One Line of Platinum-Based Chemotherapy (TORAL)\"\n",
    "        },\n",
    "        \"Status Module\":{\n",
    "          \"Status Verified Date\":\"March 2022\",\n",
    "          \"Overall Status\":\"Recruiting\",\n",
    "          \"Expanded Access Info\":{\n",
    "            \"Has Expanded Access\":\"No\"\n",
    "          },\n",
    "          \"Start Date Struct\":{\n",
    "            \"Start Date\":\"August 1, 2021\",\n",
    "            \"Start DateType\":\"Actual\"\n",
    "          },\n",
    "          \"Primary Completion Date Struct\":{\n",
    "            \"Primary Completion Date\":\"August 2023\",\n",
    "            \"Primary Completion DateType\":\"Anticipated\"\n",
    "          },\n",
    "          \"Completion Date Struct\":{\n",
    "            \"Completion Date\":\"August 2028\",\n",
    "            \"Completion DateType\":\"Anticipated\"\n",
    "          },\n",
    "          \"Study First Submit Date\":\"August 5, 2021\",\n",
    "          \"Study First Submit QC Date\":\"August 5, 2021\",\n",
    "          \"Study First Post Date Struct\":{\n",
    "            \"Study First Post Date\":\"August 9, 2021\",\n",
    "            \"Study First Post DateType\":\"Actual\"\n",
    "          },\n",
    "          \"Last Update Submit Date\":\"March 23, 2022\",\n",
    "          \"Last Update Post Date Struct\":{\n",
    "            \"Last Update Post Date\":\"March 24, 2022\",\n",
    "            \"Last Update Post DateType\":\"Actual\"\n",
    "          }\n",
    "        },\n",
    "        \"Sponsor Collaborators Module\":{\n",
    "          \"Responsible Party\":{\n",
    "            \"Responsible PartyType\":\"Principal Investigator\",\n",
    "            \"Responsible PartyInvestigatorFullName\":\"Qingqing Cai\",\n",
    "            \"Responsible PartyInvestigatorTitle\":\"Chief physician\",\n",
    "            \"Responsible PartyInvestigatorAffiliation\":\"Sun Yat-sen University\"\n",
    "          },\n",
    "          \"Lead Sponsor\":{\n",
    "            \"Lead SponsorName\":\"Sun Yat-sen University\",\n",
    "            \"Lead SponsorClass\":\"OTHER\"\n",
    "          }\n",
    "        },\n",
    "        \"Oversight Module\":{\n",
    "          \"Is FDA Regulated Drug\":\"No\",\n",
    "          \"Is FDA Regulated Device\":\"No\"\n",
    "        },\n",
    "        \"Description Module\":{\n",
    "          \"Brief Summary\":\"This phase 2 trial studies toripalimab and anlotinib combination treatment in patients with recurrent or metastatic nasopharyngeal carcinoma after failure of at least one line of platinum-based chemotherapy\"\n",
    "        },\n",
    "        \"Conditions Module\":{\n",
    "          \"Condition List\":{\n",
    "            \"Condition\":[\n",
    "              \"Nasopharyngeal Carcinoma\",\n",
    "              \"Recurrent or Metastatic Nasopharyngeal Carcinoma\"\n",
    "            ]\n",
    "          }\n",
    "        },\n",
    "        \"Design Module\":{\n",
    "          \"Study Type\":\"Interventional\",\n",
    "          \"PhaseList\":{\n",
    "            \"Phase\":[\n",
    "              \"Phase 2\"\n",
    "            ]\n",
    "          },\n",
    "          \"Design Info\":{\n",
    "            \"DesignAllocation\":\"N/A\",\n",
    "            \"DesignInterventionModel\":\"Single Group Assignment\",\n",
    "            \"DesignPrimaryPurpose\":\"Treatment\",\n",
    "            \"DesignMaskingInfo\":{\n",
    "              \"DesignMasking\":\"None (Open Label)\"\n",
    "            }\n",
    "          },\n",
    "          \"Enrollment Info\":{\n",
    "            \"Enrollment Count\":\"39\",\n",
    "            \"Enrollment Type\":\"Anticipated\"\n",
    "          }\n",
    "        },\n",
    "        \"Arms Interventions Module\":{\n",
    "          \"Arm Group List\":{\n",
    "            \"Arm Group\":[\n",
    "              {\n",
    "                \"Arm GroupLabel\":\"Toripalimab and Anlotinib Combination Treatment\",\n",
    "                \"Arm GroupType\":\"Experimental\",\n",
    "                \"Arm GroupDescription\":\"Patients receive toripalimab at a dose of 240 mg on day 1 and anlotinib at a dose of 12 mg before breakfast for once-daily on days 1-14. Treatment cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity\",\n",
    "                \"Arm GroupIntervention List\":{\n",
    "                  \"Arm GroupInterventionName\":[\n",
    "                    \"Drug: Toripalimab and Anlotinib\"\n",
    "                  ]\n",
    "                }\n",
    "              }\n",
    "            ]\n",
    "          },\n",
    "          \"Intervention List\":{\n",
    "            \"Intervention\":[\n",
    "              {\n",
    "                \"InterventionType\":\"Drug\",\n",
    "                \"InterventionName\":\"Toripalimab and Anlotinib\",\n",
    "                \"InterventionDescription\":\"Toripalimab 240 mg iv.drip d1; Anlotinib 12mg po qd d1-14.\",\n",
    "                \"InterventionArm GroupLabelList\":{\n",
    "                  \"InterventionArm GroupLabel\":[\n",
    "                    \"Toripalimab and Anlotinib Combination Treatment\"\n",
    "                  ]\n",
    "                }\n",
    "              }\n",
    "            ]\n",
    "          }\n",
    "        },\n",
    "        \"Outcomes Module\":{\n",
    "          \"Primary Outcome List\":{\n",
    "            \"Primary Outcome\":[\n",
    "              {\n",
    "                \"Primary Outcome Measure\":\"Objective Response rate\",\n",
    "                \"Primary OutcomeDescription\":\"Objective Response rate will be determined on the basis of investigator assessments\",\n",
    "                \"Primary OutcomeTimeFrame\":\"2 years\"\n",
    "              },{\n",
    "                \"Primary Outcome Measure\":\"Disease Control rate\",\n",
    "                \"Primary OutcomeDescription\":\"the proportion of patients who had a best response rating of complete response, partial response, or stable disease will be determined on the basis of investigator assessments\",\n",
    "                \"Primary OutcomeTimeFrame\":\"2 years\"\n",
    "              }\n",
    "            ]\n",
    "          },\n",
    "          \"Secondary Outcome List\":{\n",
    "            \"Secondary Outcome\":[\n",
    "              {\n",
    "                \"Secondary Outcome Measure\":\"Progression Free Survival\",\n",
    "                \"Secondary OutcomeDescription\":\"The time from the start of treatment to the progression of the tumor or death (due to any cause).\",\n",
    "                \"Secondary OutcomeTimeFrame\":\"5 years\"\n",
    "              },{\n",
    "                \"Secondary Outcome Measure\":\"Overall Survival\",\n",
    "                \"Secondary OutcomeDescription\":\"The time from the start of treatment to time of death (due to any cause).\",\n",
    "                \"Secondary OutcomeTimeFrame\":\"5 years\"\n",
    "              },{\n",
    "                \"Secondary Outcome Measure\":\"Complete Response rate\",\n",
    "                \"Secondary OutcomeDescription\":\"Complete Response rate will be determined on the basis of investigator assessments\",\n",
    "                \"Secondary OutcomeTimeFrame\":\"2 years\"\n",
    "              },{\n",
    "                \"Secondary Outcome Measure\":\"Partial Response rate\",\n",
    "                \"Secondary OutcomeDescription\":\"Partial Response rate will be determined on the basis of investigator assessments\",\n",
    "                \"Secondary OutcomeTimeFrame\":\"2 years\"\n",
    "              },{\n",
    "                \"Secondary Outcome Measure\":\"Duration of Response\",\n",
    "                \"Secondary OutcomeDescription\":\"The time from the first assessment of complete remission or partial remission to progressive disease or death (due to any cause).\",\n",
    "                \"Secondary OutcomeTimeFrame\":\"5 years\"\n",
    "              },{\n",
    "                \"Secondary Outcome Measure\":\"Percentage of Participants With Adverse Events\",\n",
    "                \"Secondary OutcomeDescription\":\"Adverse Events will be determined and graded on the basis of investigator assessments according to NCI CTC AE 5.0\",\n",
    "                \"Secondary OutcomeTimeFrame\":\"5 years\"\n",
    "              }\n",
    "            ]\n",
    "          }\n",
    "        },\n",
    "        \"Eligibility Module\":{\n",
    "          \"Eligibility Criteria\":\"Inclusion Criteria:\\n\\nHistologically confirmed undifferentiated non-keratinizing carcinoma\\nPatients suffered failure of at least one line of platinum-based chemotherapy. The definition of treatment failure: progression during or after chemotherapy for recurrence/metastasis; progression after concurrent chemoradiotherapy within 6 months. Withdrawal of treatment due to drug intolerances is excluded ;\\nWithout other malignancy;\\nMale or female, 18-70 years;\\nEastern Cooperative Oncology Group (ECOG) of 0-2;\\nLife expectancy ≥ 3 months;\\nWomen of childbearing age must obtain the negative result of a pregnancy test (serum or urine) , and they were willing to use reliable methods of contraception during the trial;\\nAt least one evaluable lesion；\\nLaboratory tests meet the following standards:\\n\\nBlood routine: White blood cell count (WBC) ≥3.0×10 9 /L, neutrophil count (ANC) ≥1.5×10 9 /L, platelet count (PLT) ≥75×10 9 /L, hemoglobin (HGB) 90 g/L or higher; Liver function: total bilirubin ≤1.5 times the upper limit of normal (ULN); glutamic-oxalacetic transaminase (AST) and alanine transaminase (ALT) ≤2.5 times ULN, AST and ALT ≤2.5 times ULN for the patients with liver metastases; Alkaline phosphatase ≤5 times ULN; Renal function: Serum creatinine (Cr) ≤1.5 times ULN; Creatinine clearance ≥60mL/min; Urine routine: urine protein <2+ ;baseline urine protein ≥2+ and 24 hours urine protein < 1g ; Coagulation: International normalized ratio (INR) and activated partial thrombin time (APTT) ≤1.5 times ULN; Albumin ≥28g/L Thyroid stimulating hormone (TSH)≤1 times ULN (free triiodothyrosine [FT3] or free thyroxine [FT4] ≤1 times ULN can be included)\\n\\nNo serious cardiopulmonary dysfunction;\\nThe informed consent has been signed.\\nAbility to comply with test requirements\\n\\nExclusion Criteria:\\n\\nA known allergy to any of the drugs in the study;\\nPregnant or breastfeeding women;\\nParticipated in clinical trials of other drugs within 4 weeks prior to study initiation;\\nPrevious treatment with bevacizumab or VEGFR-family small molecule tyrosine kinase inhibitors (e.g., famitinib, sorafenib, Sunitinib, regofinib, Apatinib, Anlotinib, fuquinitinib) ;\\nRecurrent nasopharyngeal lesions after radiotherapy and who received secondary radiotherapy;\\nPalliative radiotherapy for symptom control within 28 days before enrollment;\\nImmunosuppressive treatment with immunosuppressive agent, systemic or absorbable topical hormone therapy ( prednisone or other therapeutic hormone at the dose greater than 10mg/ day) within 2 weeks before enrollment;\\nActive autoimmune diseases, with the necessity of systemic treatment (hormone replacement therapy is not considered as a systemic treatment, such as type 1 diabetes) over the past two years; autoimmune diseases that did not require systemic treatment in the past two years;\\nA history of immunodeficiency, including acquired/congenital immunodeficiency disorders, a history of organ transplantation;\\nVaccinated with live vaccine (inactivated virus vaccine for seasonal influenza is allowed) within 4 weeks before enrollment;\\nInvasion of important vessels (e.g. surrounding internal carotid artery/vein) on MRI; tumor with a high risk of affecting vital blood vessels during treatment and causing fatal hemorrhage, which is determined by investigators;\\nA history of severe bleeding and any bleeding event with a severity rating of 3 or higher in the NCI CTCAE within 4 weeks prior to screening;\\nAbnormal coagulation (INR > 2.0, PT > 16s) and bleeding tendency (the INR must be within the normal range without anticoagulants during14 days prior to signing the informed consent); patients treated with anticoagulants or vitamin K antagonists such as warfarin, heparin, or their analogests; low-dose warfarin (1 mg orally, once daily) or low-dose aspirin (up to 100 mg daily) for preventive purposes, provided that the international normalized ratio of prothrombin time (INR) is ≤ 1.5;\\nUnstable angina and/or congestive heart failure or vascular disease with the need of hospital treatment; other cardiac damage that may affect the drug safety;\\nPatients with hypertension that is not well controlled with antihypertensive medication (systolic > 140mmHg, diastolic > 90 mmHg); patients is taking a combination of two or more antihypertensive drugs; Cardiovascular disease with clinical significance， such as cerebrovascular accident (≤ 6 months before randomization), myocardial infarction (≤ 6 months before randomization), unstable angina, congestive heart failure of NYHA grade II or higher, or severe arrhythmias that cannot be controlled with drugs or have a potential impact on experimental treatments;\\nPatients with esophageal and gastric varices, active ulcers, intestinal perforation or intestinal obstruction within 6 months before enrollment;\\nA history of abdominal fistula, digestive tract perforation, intra-abdominal abscess or acute gastrointestinal bleeding within 6 months before enrollment;\\nMultiple factors affecting oral administration and absorption of drugs (e.g., inability to swallow, post-gastrointestinal resection, chronic diarrhea and intestinal obstruction);\\nOveroperation/venous thromboembolism events, NCI CTCAE grade 3 or higher venous thromboembolism within 6 months before enrollment, such as cerebrovascular accident (including temporary ischemic attack), deep venous thrombosis (except for those venous thrombosis caused by venous catheterization due to previous chemotherapy and determined to be cured by the researchers ), pulmonary embolism, etc.;\\nPatients with past and present objective evidence of pulmonary fibrosis, interstitial pneumonia, pneumoconiosis, radiation pneumonia, drug-related pneumonia, or severe impairment of lung function;\\nExacerbation of chronic obstructive pulmonary disease (COPD) or other respiratory disease requiring hospitalization within 28 days before enrollment;\\nActive pulmonary infection and/or acute bacterial or fungal infection requiring intravenous antibiotic treatment within 28 days;\\nDominant jaundice due to abnormal liver function within 7 days;\\nRenal insufficiency: routine urinalproteinuria > 2+ and confirmed 24 h urinary protein quantification > 1.0g;\\nMinor surgical operations (including catheterization, excluding central venous catheterization via peripheral venipuncture) within 2 days before enrollment;\\nMajor surgery within 28 days before enrollment;\\nA potent CYP3A4 inhibitor within one week prior to enrollment, or a potent CYP3A4 inducer within two weeks prior to study participation\\nLong-term unhealed wounds or incomplete fractures;\\nSymptomatic central nervous system metastases (e.g. brain edema, need for hormonal intervention, or brain metastases)\\nThe presence of serious or uncontrolled infections;\",\n",
    "          \"Healthy Volunteers\":\"No\",\n",
    "          \"Gender\":\"All\",\n",
    "          \"Minimum Age\":\"18 Years\",\n",
    "          \"MaximumAge\":\"70 Years\",\n",
    "          \"Std Age List\":{\n",
    "            \"Std Age\":[\n",
    "              \"Adult\",\n",
    "              \"Older Adult\"\n",
    "            ]\n",
    "          }\n",
    "        },\n",
    "        \"Contacts Locations Module\":{\n",
    "          \"CentralContactList\":{\n",
    "            \"CentralContact\":[\n",
    "              {\n",
    "                \"CentralContactName\":\"Qingqing Cai\",\n",
    "                \"CentralContactRole\":\"Contact\",\n",
    "                \"CentralContactPhone\":\"0086-20-87342823\",\n",
    "                \"CentralContactEMail\":\"caiqq@sysucc.org.cn\"\n",
    "              },{\n",
    "                \"CentralContactName\":\"Qingqing Cai\",\n",
    "                \"CentralContactRole\":\"Contact\"\n",
    "              }\n",
    "            ]\n",
    "          },\n",
    "          \"Overall Official List\":{\n",
    "            \"Overall Official\":[\n",
    "              {\n",
    "                \"Overall OfficialName\":\"Qingqing Cai\",\n",
    "                \"Overall OfficialAffiliation\":\"Sun Yat-sen Universitiy Cancer Center, Sun Yat-Sen University,\",\n",
    "                \"Overall OfficialRole\":\"Principal Investigator\"\n",
    "              }\n",
    "            ]\n",
    "          },\n",
    "          \"Location List\":{\n",
    "            \"Location\":[\n",
    "              {\n",
    "                \"LocationFacility\":\"Sun Yat-sen Universitiy Cancer Center, Sun Yat-Sen University\",\n",
    "                \"LocationStatus\":\"Recruiting\",\n",
    "                \"LocationCity\":\"Guangzhou\",\n",
    "                \"LocationZip\":\"510030\",\n",
    "                \"LocationCountry\":\"China\",\n",
    "                \"LocationContactList\":{\n",
    "                  \"LocationContact\":[\n",
    "                    {\n",
    "                      \"LocationContactName\":\"Qingqing Cai\",\n",
    "                      \"LocationContactRole\":\"Contact\",\n",
    "                      \"LocationContactPhone\":\"18565617120\",\n",
    "                      \"LocationContactEMail\":\"18565617120@163.com\"\n",
    "                    }\n",
    "                  ]\n",
    "                }\n",
    "              }\n",
    "            ]\n",
    "          }\n",
    "        }\n",
    "      },\n",
    "      \"Derived Section\":{\n",
    "        \"Misc Info Module\":{\n",
    "          \"Version Holder\":\"May 19, 2023\"\n",
    "        },\n",
    "        \"Condition Browse Module\":{\n",
    "          \"Condition Mesh List\":{\n",
    "            \"Condition Mesh\":[\n",
    "              {\n",
    "                \"Condition MeshId\":\"D000002277\",\n",
    "                \"Condition MeshTerm\":\"Carcinoma\"\n",
    "              },{\n",
    "                \"Condition MeshId\":\"D000077274\",\n",
    "                \"Condition MeshTerm\":\"Nasopharyngeal Carcinoma\"\n",
    "              },{\n",
    "                \"Condition MeshId\":\"D000012008\",\n",
    "                \"Condition MeshTerm\":\"Recurrence\"\n",
    "              }\n",
    "            ]\n",
    "          },\n",
    "          \"Condition Ancestor List\":{\n",
    "            \"Condition Ancestor\":[\n",
    "              {\n",
    "                \"Condition AncestorId\":\"D000009375\",\n",
    "                \"Condition AncestorTerm\":\"Neoplasms, Glandular and Epithelial\"\n",
    "              },{\n",
    "                \"Condition AncestorId\":\"D000009370\",\n",
    "                \"Condition AncestorTerm\":\"Neoplasms by Histologic Type\"\n",
    "              },{\n",
    "                \"Condition AncestorId\":\"D000009369\",\n",
    "                \"Condition AncestorTerm\":\"Neoplasms\"\n",
    "              },{\n",
    "                \"Condition AncestorId\":\"D000020969\",\n",
    "                \"Condition AncestorTerm\":\"Disease Attributes\"\n",
    "              },{\n",
    "                \"Condition AncestorId\":\"D000010335\",\n",
    "                \"Condition AncestorTerm\":\"Pathologic Processes\"\n",
    "              },{\n",
    "                \"Condition AncestorId\":\"D000009303\",\n",
    "                \"Condition AncestorTerm\":\"Nasopharyngeal Neoplasms\"\n",
    "              },{\n",
    "                \"Condition AncestorId\":\"D000010610\",\n",
    "                \"Condition AncestorTerm\":\"Pharyngeal Neoplasms\"\n",
    "              },{\n",
    "                \"Condition AncestorId\":\"D000010039\",\n",
    "                \"Condition AncestorTerm\":\"Otorhinolaryngologic Neoplasms\"\n",
    "              },{\n",
    "                \"Condition AncestorId\":\"D000006258\",\n",
    "                \"Condition AncestorTerm\":\"Head and Neck Neoplasms\"\n",
    "              },{\n",
    "                \"Condition AncestorId\":\"D000009371\",\n",
    "                \"Condition AncestorTerm\":\"Neoplasms by Site\"\n",
    "              },{\n",
    "                \"Condition AncestorId\":\"D000009302\",\n",
    "                \"Condition AncestorTerm\":\"Nasopharyngeal Diseases\"\n",
    "              },{\n",
    "                \"Condition AncestorId\":\"D000010608\",\n",
    "                \"Condition AncestorTerm\":\"Pharyngeal Diseases\"\n",
    "              },{\n",
    "                \"Condition AncestorId\":\"D000009057\",\n",
    "                \"Condition AncestorTerm\":\"Stomatognathic Diseases\"\n",
    "              },{\n",
    "                \"Condition AncestorId\":\"D000010038\",\n",
    "                \"Condition AncestorTerm\":\"Otorhinolaryngologic Diseases\"\n",
    "              }\n",
    "            ]\n",
    "          },\n",
    "          \"Condition Browse Leaf List\":{\n",
    "            \"Condition Browse Leaf\":[\n",
    "              {\n",
    "                \"Condition Browse LeafId\":\"M4686\",\n",
    "                \"Condition Browse LeafName\":\"Carcinoma\",\n",
    "                \"Condition Browse LeafAsFound\":\"Carcinoma\",\n",
    "                \"Condition Browse LeafRelevance\":\"high\"\n",
    "              },{\n",
    "                \"Condition Browse LeafId\":\"M14002\",\n",
    "                \"Condition Browse LeafName\":\"Recurrence\",\n",
    "                \"Condition Browse LeafAsFound\":\"Recurrent\",\n",
    "                \"Condition Browse LeafRelevance\":\"high\"\n",
    "              },{\n",
    "                \"Condition Browse LeafId\":\"M1730\",\n",
    "                \"Condition Browse LeafName\":\"Nasopharyngeal Carcinoma\",\n",
    "                \"Condition Browse LeafAsFound\":\"Nasopharyngeal Carcinoma\",\n",
    "                \"Condition Browse LeafRelevance\":\"high\"\n",
    "              },{\n",
    "                \"Condition Browse LeafId\":\"M11472\",\n",
    "                \"Condition Browse LeafName\":\"Neoplasms, Glandular and Epithelial\",\n",
    "                \"Condition Browse LeafRelevance\":\"low\"\n",
    "              },{\n",
    "                \"Condition Browse LeafId\":\"M11467\",\n",
    "                \"Condition Browse LeafName\":\"Neoplasms by Histologic Type\",\n",
    "                \"Condition Browse LeafRelevance\":\"low\"\n",
    "              },{\n",
    "                \"Condition Browse LeafId\":\"M21853\",\n",
    "                \"Condition Browse LeafName\":\"Disease Attributes\",\n",
    "                \"Condition Browse LeafRelevance\":\"low\"\n",
    "              },{\n",
    "                \"Condition Browse LeafId\":\"M11406\",\n",
    "                \"Condition Browse LeafName\":\"Nasopharyngeal Neoplasms\",\n",
    "                \"Condition Browse LeafRelevance\":\"low\"\n",
    "              },{\n",
    "                \"Condition Browse LeafId\":\"M12669\",\n",
    "                \"Condition Browse LeafName\":\"Pharyngeal Neoplasms\",\n",
    "                \"Condition Browse LeafRelevance\":\"low\"\n",
    "              },{\n",
    "                \"Condition Browse LeafId\":\"M12114\",\n",
    "                \"Condition Browse LeafName\":\"Otorhinolaryngologic Neoplasms\",\n",
    "                \"Condition Browse LeafRelevance\":\"low\"\n",
    "              },{\n",
    "                \"Condition Browse LeafId\":\"M8500\",\n",
    "                \"Condition Browse LeafName\":\"Head and Neck Neoplasms\",\n",
    "                \"Condition Browse LeafRelevance\":\"low\"\n",
    "              },{\n",
    "                \"Condition Browse LeafId\":\"M11405\",\n",
    "                \"Condition Browse LeafName\":\"Nasopharyngeal Diseases\",\n",
    "                \"Condition Browse LeafRelevance\":\"low\"\n",
    "              },{\n",
    "                \"Condition Browse LeafId\":\"M12667\",\n",
    "                \"Condition Browse LeafName\":\"Pharyngeal Diseases\",\n",
    "                \"Condition Browse LeafRelevance\":\"low\"\n",
    "              },{\n",
    "                \"Condition Browse LeafId\":\"M11169\",\n",
    "                \"Condition Browse LeafName\":\"Stomatognathic Diseases\",\n",
    "                \"Condition Browse LeafRelevance\":\"low\"\n",
    "              },{\n",
    "                \"Condition Browse LeafId\":\"M12113\",\n",
    "                \"Condition Browse LeafName\":\"Otorhinolaryngologic Diseases\",\n",
    "                \"Condition Browse LeafRelevance\":\"low\"\n",
    "              },{\n",
    "                \"Condition Browse LeafId\":\"T4047\",\n",
    "                \"Condition Browse LeafName\":\"Nasopharyngeal Carcinoma\",\n",
    "                \"Condition Browse LeafAsFound\":\"Nasopharyngeal Carcinoma\",\n",
    "                \"Condition Browse LeafRelevance\":\"high\"\n",
    "              }\n",
    "            ]\n",
    "          },\n",
    "          \"Condition Browse Branch List\":{\n",
    "            \"Condition Browse Branch\":[\n",
    "              {\n",
    "                \"Condition Browse BranchAbbrev\":\"BC04\",\n",
    "                \"Condition Browse BranchName\":\"Neoplasms\"\n",
    "              },{\n",
    "                \"Condition Browse BranchAbbrev\":\"All\",\n",
    "                \"Condition Browse BranchName\":\"All Conditions\"\n",
    "              },{\n",
    "                \"Condition Browse BranchAbbrev\":\"BC23\",\n",
    "                \"Condition Browse BranchName\":\"Symptoms and General Pathology\"\n",
    "              },{\n",
    "                \"Condition Browse BranchAbbrev\":\"BC07\",\n",
    "                \"Condition Browse BranchName\":\"Mouth and Tooth Diseases\"\n",
    "              },{\n",
    "                \"Condition Browse BranchAbbrev\":\"BC09\",\n",
    "                \"Condition Browse BranchName\":\"Ear, Nose, and Throat Diseases\"\n",
    "              },{\n",
    "                \"Condition Browse BranchAbbrev\":\"Rare\",\n",
    "                \"Condition Browse BranchName\":\"Rare Diseases\"\n",
    "              }\n",
    "            ]\n",
    "          }\n",
    "        }\n",
    "      }\n",
    "    }\n",
    "  }\n",
    "}\n",
    "\n",
    "临床研究clinical trials，NCT04797182\n",
    "{\n",
    "  \"Full Study\":{\n",
    "    \"Rank\":82232,\n",
    "    \"Study\":{\n",
    "      \"Protocol Section\":{\n",
    "        \"Identification Module\":{\n",
    "          \"NCT Id\":\"NCT04797182\",\n",
    "          \"Org Study Id Info\":{\n",
    "            \"Org Study Id\":\"B2021-034\"\n",
    "          },\n",
    "          \"Organization\":{\n",
    "            \"Org Full Name\":\"Sun Yat-sen University\",\n",
    "            \"Org Class\":\"OTHER\"\n",
    "          },\n",
    "          \"Brief Title\":\"Avatrombopag for the Primary Prevention of Thrombocytopenia Induced by Cytarabine-based Chemotherapy in Patients With Lymphoma\",\n",
    "          \"Official Title\":\"Avatrombopag for the Primary Prevention of Thrombocytopenia Induced by Cytarabine-based Chemotherapy in Patients With Lymphoma: An Open, Single-center, Phase II Randomized Controlled Clinical Study\"\n",
    "        },\n",
    "        \"Status Module\":{\n",
    "          \"Status Verified Date\":\"March 2021\",\n",
    "          \"Overall Status\":\"Not yet recruiting\",\n",
    "          \"Expanded Access Info\":{\n",
    "            \"Has Expanded Access\":\"No\"\n",
    "          },\n",
    "          \"Start Date Struct\":{\n",
    "            \"Start Date\":\"April 2021\",\n",
    "            \"Start DateType\":\"Anticipated\"\n",
    "          },\n",
    "          \"Primary Completion Date Struct\":{\n",
    "            \"Primary Completion Date\":\"April 2023\",\n",
    "            \"Primary Completion DateType\":\"Anticipated\"\n",
    "          },\n",
    "          \"Completion Date Struct\":{\n",
    "            \"Completion Date\":\"July 2023\",\n",
    "            \"Completion DateType\":\"Anticipated\"\n",
    "          },\n",
    "          \"Study First Submit Date\":\"March 11, 2021\",\n",
    "          \"Study First Submit QC Date\":\"March 11, 2021\",\n",
    "          \"Study First Post Date Struct\":{\n",
    "            \"Study First Post Date\":\"March 15, 2021\",\n",
    "            \"Study First Post DateType\":\"Actual\"\n",
    "          },\n",
    "          \"Last Update Submit Date\":\"March 11, 2021\",\n",
    "          \"Last Update Post Date Struct\":{\n",
    "            \"Last Update Post Date\":\"March 15, 2021\",\n",
    "            \"Last Update Post DateType\":\"Actual\"\n",
    "          }\n",
    "        },\n",
    "        \"Sponsor Collaborators Module\":{\n",
    "          \"Responsible Party\":{\n",
    "            \"Responsible PartyType\":\"Principal Investigator\",\n",
    "            \"Responsible PartyInvestigatorFullName\":\"Qingqing Cai\",\n",
    "            \"Responsible PartyInvestigatorTitle\":\"Chief physician\",\n",
    "            \"Responsible PartyInvestigatorAffiliation\":\"Sun Yat-sen University\"\n",
    "          },\n",
    "          \"Lead Sponsor\":{\n",
    "            \"Lead SponsorName\":\"Sun Yat-sen University\",\n",
    "            \"Lead SponsorClass\":\"OTHER\"\n",
    "          }\n",
    "        },\n",
    "        \"Oversight Module\":{\n",
    "          \"Is FDA Regulated Drug\":\"No\",\n",
    "          \"Is FDA Regulated Device\":\"No\"\n",
    "        },\n",
    "        \"Description Module\":{\n",
    "          \"Brief Summary\":\"This phase 2 trial studies the efficacy and safety of Avatrombopag for the primary prevention of thrombocytopenia induced by cytarabine-based chemotherapy in patients with lymphoma\"\n",
    "        },\n",
    "        \"Conditions Module\":{\n",
    "          \"Condition List\":{\n",
    "            \"Condition\":[\n",
    "              \"Thrombocytopenia\",\n",
    "              \"Cytarabine Causing Adverse Effects in Therapeutic Use\",\n",
    "              \"Lymphoma\"\n",
    "            ]\n",
    "          }\n",
    "        },\n",
    "        \"Design Module\":{\n",
    "          \"Study Type\":\"Interventional\",\n",
    "          \"PhaseList\":{\n",
    "            \"Phase\":[\n",
    "              \"Phase 2\"\n",
    "            ]\n",
    "          },\n",
    "          \"Design Info\":{\n",
    "            \"DesignAllocation\":\"Randomized\",\n",
    "            \"DesignInterventionModel\":\"Single Group Assignment\",\n",
    "            \"DesignPrimaryPurpose\":\"Prevention\",\n",
    "            \"DesignMaskingInfo\":{\n",
    "              \"DesignMasking\":\"None (Open Label)\"\n",
    "            }\n",
    "          },\n",
    "          \"Enrollment Info\":{\n",
    "            \"Enrollment Count\":\"46\",\n",
    "            \"Enrollment Type\":\"Anticipated\"\n",
    "          }\n",
    "        },\n",
    "        \"Arms Interventions Module\":{\n",
    "          \"Arm Group List\":{\n",
    "            \"Arm Group\":[\n",
    "              {\n",
    "                \"Arm GroupLabel\":\"blank control\",\n",
    "                \"Arm GroupType\":\"Experimental\",\n",
    "                \"Arm GroupDescription\":\"No intervention aiming at preventing thrombocytopenia will be taken after first cycle. Avatrombopag as salvage treatment will be administered to patients suffering from thrombocytopenia with nadir platelet count < 50 × 109/L at a dose of 60mg/day until there is drug-withdrawal indication.\",\n",
    "                \"Arm GroupIntervention List\":{\n",
    "                  \"Arm GroupInterventionName\":[\n",
    "                    \"Drug: avatrombopag\"\n",
    "                  ]\n",
    "                }\n",
    "              },{\n",
    "                \"Arm GroupLabel\":\"primary prevention\",\n",
    "                \"Arm GroupType\":\"Experimental\",\n",
    "                \"Arm GroupDescription\":\"As the primary prevention of thrombocytopenia induced by cytarabine-based chemotherapy, Avatrombopag will be administered at a dose of 60mg/day on days -3~-1 and 3~9, for a total of 10 doses. On the condition that patients have platelet counts <50 × 10 9 /L before next cycle, Avatrombopag will be administered at a dose of 60mg/day until there is drug-withdrawal indications. Platelet transfusions were administered to patients when the platelet count was less than 10×109 /L.\\n\\nDrug-withdrawal indications:\\n\\nPLT ≥ 100×109/L during salvage treatment or platelet count increases by 50×109/L, comparing with baseline level.\\n\\nWhen platelet count is higher than 400×109/L during this study, researchers determine whether avatrombopag is discontinued\",\n",
    "                \"Arm GroupIntervention List\":{\n",
    "                  \"Arm GroupInterventionName\":[\n",
    "                    \"Drug: avatrombopag\"\n",
    "                  ]\n",
    "                }\n",
    "              }\n",
    "            ]\n",
    "          },\n",
    "          \"Intervention List\":{\n",
    "            \"Intervention\":[\n",
    "              {\n",
    "                \"InterventionType\":\"Drug\",\n",
    "                \"InterventionName\":\"avatrombopag\",\n",
    "                \"InterventionDescription\":\"avatrombopag,60 mg/d,po\",\n",
    "                \"InterventionArm GroupLabelList\":{\n",
    "                  \"InterventionArm GroupLabel\":[\n",
    "                    \"blank control\",\n",
    "                    \"primary prevention\"\n",
    "                  ]\n",
    "                }\n",
    "              }\n",
    "            ]\n",
    "          }\n",
    "        },\n",
    "        \"Outcomes Module\":{\n",
    "          \"Primary Outcome List\":{\n",
    "            \"Primary Outcome\":[\n",
    "              {\n",
    "                \"Primary Outcome Measure\":\"The incidence of grades III and IV thrombocytopenia\",\n",
    "                \"Primary OutcomeTimeFrame\":\"2 years\"\n",
    "              }\n",
    "            ]\n",
    "          },\n",
    "          \"Secondary Outcome List\":{\n",
    "            \"Secondary Outcome\":[\n",
    "              {\n",
    "                \"Secondary Outcome Measure\":\"The durations of any grade thrombocytopenia and grades II, III and IV thrombocytopenia\",\n",
    "                \"Secondary OutcomeTimeFrame\":\"2 years\"\n",
    "              }\n",
    "            ]\n",
    "          }\n",
    "        },\n",
    "        \"Eligibility Module\":{\n",
    "          \"Eligibility Criteria\":\"Inclusion Criteria:\\n\\nHistologically confirmed lymphoma;\\nPatients are scheduled to receive cytarabine-based chemotherapy including Ara-C at dose of 4g/m2.\\nEastern Cooperative Oncology Group (ECOG) of 0-1;\\nProper functioning of the major organs: 1) The absolute value of neutrophils (>1.5×10^9/L); platelet count (> 100×10^9/L); Hemoglobin (> 90 g/L); 2) Serum total bilirubin < 1.5 times ULN; Aspartate Aminotransferase (AST), Alanine Aminotransferase (ALT) < 3 times ULN;3) Serum creatinine <1.5 times Upper Limit Normal (ULN) ; 4) Coagulation function: International Normalized Ratio (INR), Prothrombin Time (PT)< 1.5 times ULN\\nAble to use oral drugs\\nPatients volunteer to sign an informed consent\\nLife expectancy > 3 months;\\nContraceptives are used\\n\\nExclusion Criteria:\\n\\nThrombocytopenia unrelated to chemotherapy during six months before screening, including but not limited to hypersplenism, infection and hemorrhage.\\nIn addtion to CIT caused by lymphoma and chemotherapy,patients also suffer from other blood diseases including ALL, AML, myeloid neoplasms, MDS, myeloproliferative disorders, MM;\\nA thrombosis of a coronary artery or vein developed during three months before screening;\\nHaemorrhage with severe clinical symptoms, such as gastrointestinal and cerebral hemorrhage;\\nPlatelet transfusion during two days before randomization;\\nAllergic to avatrombopag;\\nParticipation in any other research about novel agents or devices;\\nPregnant or breastfeeding women;\\nResearchers consider it unsuitable for patients to participate in this study.\",\n",
    "          \"Healthy Volunteers\":\"No\",\n",
    "          \"Gender\":\"All\",\n",
    "          \"Minimum Age\":\"18 Years\",\n",
    "          \"MaximumAge\":\"70 Years\",\n",
    "          \"Std Age List\":{\n",
    "            \"Std Age\":[\n",
    "              \"Adult\",\n",
    "              \"Older Adult\"\n",
    "            ]\n",
    "          }\n",
    "        },\n",
    "        \"Contacts Locations Module\":{\n",
    "          \"CentralContactList\":{\n",
    "            \"CentralContact\":[\n",
    "              {\n",
    "                \"CentralContactName\":\"Qingqing Cai, MD\",\n",
    "                \"CentralContactRole\":\"Contact\",\n",
    "                \"CentralContactPhone\":\"0086-20-87342823\",\n",
    "                \"CentralContactEMail\":\"caiqq@sysucc.org.cn\"\n",
    "              },{\n",
    "                \"CentralContactName\":\"Cai\",\n",
    "                \"CentralContactRole\":\"Contact\"\n",
    "              }\n",
    "            ]\n",
    "          },\n",
    "          \"Overall Official List\":{\n",
    "            \"Overall Official\":[\n",
    "              {\n",
    "                \"Overall OfficialName\":\"Qingqing Cai, MD\",\n",
    "                \"Overall OfficialAffiliation\":\"Sun Yat-sen University\",\n",
    "                \"Overall OfficialRole\":\"Principal Investigator\"\n",
    "              }\n",
    "            ]\n",
    "          },\n",
    "          \"Location List\":{\n",
    "            \"Location\":[\n",
    "              {\n",
    "                \"LocationFacility\":\"Sun Yat-sen University Cancer Center\",\n",
    "                \"LocationCity\":\"Guangzhou\",\n",
    "                \"LocationState\":\"Guangdong\",\n",
    "                \"LocationZip\":\"510060\",\n",
    "                \"LocationCountry\":\"China\",\n",
    "                \"LocationContactList\":{\n",
    "                  \"LocationContact\":[\n",
    "                    {\n",
    "                      \"LocationContactName\":\"Qingqing Cai, MD\",\n",
    "                      \"LocationContactRole\":\"Contact\"\n",
    "                    }\n",
    "                  ]\n",
    "                }\n",
    "              }\n",
    "            ]\n",
    "          }\n",
    "        }\n",
    "      },\n",
    "      \"Derived Section\":{\n",
    "        \"Misc Info Module\":{\n",
    "          \"Version Holder\":\"May 19, 2023\"\n",
    "        },\n",
    "        \"Condition Browse Module\":{\n",
    "          \"Condition Mesh List\":{\n",
    "            \"Condition Mesh\":[\n",
    "              {\n",
    "                \"Condition MeshId\":\"D000008223\",\n",
    "                \"Condition MeshTerm\":\"Lymphoma\"\n",
    "              },{\n",
    "                \"Condition MeshId\":\"D000013921\",\n",
    "                \"Condition MeshTerm\":\"Thrombocytopenia\"\n",
    "              }\n",
    "            ]\n",
    "          },\n",
    "          \"Condition Ancestor List\":{\n",
    "            \"Condition Ancestor\":[\n",
    "              {\n",
    "                \"Condition AncestorId\":\"D000009370\",\n",
    "                \"Condition AncestorTerm\":\"Neoplasms by Histologic Type\"\n",
    "              },{\n",
    "                \"Condition AncestorId\":\"D000009369\",\n",
    "                \"Condition AncestorTerm\":\"Neoplasms\"\n",
    "              },{\n",
    "                \"Condition AncestorId\":\"D000008232\",\n",
    "                \"Condition AncestorTerm\":\"Lymphoproliferative Disorders\"\n",
    "              },{\n",
    "                \"Condition AncestorId\":\"D000008206\",\n",
    "                \"Condition AncestorTerm\":\"Lymphatic Diseases\"\n",
    "              },{\n",
    "                \"Condition AncestorId\":\"D000007160\",\n",
    "                \"Condition AncestorTerm\":\"Immunoproliferative Disorders\"\n",
    "              },{\n",
    "                \"Condition AncestorId\":\"D000007154\",\n",
    "                \"Condition AncestorTerm\":\"Immune System Diseases\"\n",
    "              },{\n",
    "                \"Condition AncestorId\":\"D000001791\",\n",
    "                \"Condition AncestorTerm\":\"Blood Platelet Disorders\"\n",
    "              },{\n",
    "                \"Condition AncestorId\":\"D000006402\",\n",
    "                \"Condition AncestorTerm\":\"Hematologic Diseases\"\n",
    "              }\n",
    "            ]\n",
    "          },\n",
    "          \"Condition Browse Leaf List\":{\n",
    "            \"Condition Browse Leaf\":[\n",
    "              {\n",
    "                \"Condition Browse LeafId\":\"M10372\",\n",
    "                \"Condition Browse LeafName\":\"Lymphoma\",\n",
    "                \"Condition Browse LeafAsFound\":\"Lymphoma\",\n",
    "                \"Condition Browse LeafRelevance\":\"high\"\n",
    "              },{\n",
    "                \"Condition Browse LeafId\":\"M15832\",\n",
    "                \"Condition Browse LeafName\":\"Thrombocytopenia\",\n",
    "                \"Condition Browse LeafAsFound\":\"Thrombocytopenia\",\n",
    "                \"Condition Browse LeafRelevance\":\"high\"\n",
    "              },{\n",
    "                \"Condition Browse LeafId\":\"M11467\",\n",
    "                \"Condition Browse LeafName\":\"Neoplasms by Histologic Type\",\n",
    "                \"Condition Browse LeafRelevance\":\"low\"\n",
    "              },{\n",
    "                \"Condition Browse LeafId\":\"M10377\",\n",
    "                \"Condition Browse LeafName\":\"Lymphoproliferative Disorders\",\n",
    "                \"Condition Browse LeafRelevance\":\"low\"\n",
    "              },{\n",
    "                \"Condition Browse LeafId\":\"M10355\",\n",
    "                \"Condition Browse LeafName\":\"Lymphatic Diseases\",\n",
    "                \"Condition Browse LeafRelevance\":\"low\"\n",
    "              },{\n",
    "                \"Condition Browse LeafId\":\"M9358\",\n",
    "                \"Condition Browse LeafName\":\"Immunoproliferative Disorders\",\n",
    "                \"Condition Browse LeafRelevance\":\"low\"\n",
    "              },{\n",
    "                \"Condition Browse LeafId\":\"M9352\",\n",
    "                \"Condition Browse LeafName\":\"Immune System Diseases\",\n",
    "                \"Condition Browse LeafRelevance\":\"low\"\n",
    "              },{\n",
    "                \"Condition Browse LeafId\":\"M4224\",\n",
    "                \"Condition Browse LeafName\":\"Blood Platelet Disorders\",\n",
    "                \"Condition Browse LeafRelevance\":\"low\"\n",
    "              },{\n",
    "                \"Condition Browse LeafId\":\"M8642\",\n",
    "                \"Condition Browse LeafName\":\"Hematologic Diseases\",\n",
    "                \"Condition Browse LeafRelevance\":\"low\"\n",
    "              },{\n",
    "                \"Condition Browse LeafId\":\"T3543\",\n",
    "                \"Condition Browse LeafName\":\"Lymphosarcoma\",\n",
    "                \"Condition Browse LeafAsFound\":\"Lymphoma\",\n",
    "                \"Condition Browse LeafRelevance\":\"high\"\n",
    "              }\n",
    "            ]\n",
    "          },\n",
    "          \"Condition Browse Branch List\":{\n",
    "            \"Condition Browse Branch\":[\n",
    "              {\n",
    "                \"Condition Browse BranchAbbrev\":\"BC04\",\n",
    "                \"Condition Browse BranchName\":\"Neoplasms\"\n",
    "              },{\n",
    "                \"Condition Browse BranchAbbrev\":\"BC15\",\n",
    "                \"Condition Browse BranchName\":\"Blood and Lymph Conditions\"\n",
    "              },{\n",
    "                \"Condition Browse BranchAbbrev\":\"BC20\",\n",
    "                \"Condition Browse BranchName\":\"Immune System Diseases\"\n",
    "              },{\n",
    "                \"Condition Browse BranchAbbrev\":\"All\",\n",
    "                \"Condition Browse BranchName\":\"All Conditions\"\n",
    "              },{\n",
    "                \"Condition Browse BranchAbbrev\":\"Rare\",\n",
    "                \"Condition Browse BranchName\":\"Rare Diseases\"\n",
    "              }\n",
    "            ]\n",
    "          }\n",
    "        },\n",
    "        \"Intervention Browse Module\":{\n",
    "          \"Intervention Browse Leaf List\":{\n",
    "            \"Intervention Browse Leaf\":[\n",
    "              {\n",
    "                \"Intervention Browse LeafId\":\"M5918\",\n",
    "                \"Intervention Browse LeafName\":\"Cytarabine\",\n",
    "                \"Intervention Browse LeafRelevance\":\"low\"\n",
    "              }\n",
    "            ]\n",
    "          },\n",
    "          \"Intervention Browse Branch List\":{\n",
    "            \"Intervention Browse Branch\":[\n",
    "              {\n",
    "                \"Intervention Browse BranchAbbrev\":\"Infe\",\n",
    "                \"Intervention Browse BranchName\":\"Anti-Infective Agents\"\n",
    "              },{\n",
    "                \"Intervention Browse BranchAbbrev\":\"ANeo\",\n",
    "                \"Intervention Browse BranchName\":\"Antineoplastic Agents\"\n",
    "              },{\n",
    "                \"Intervention Browse BranchAbbrev\":\"All\",\n",
    "                \"Intervention Browse BranchName\":\"All Drugs and Chemicals\"\n",
    "              }\n",
    "            ]\n",
    "          }\n",
    "        }\n",
    "      }\n",
    "    }\n",
    "  }\n",
    "}\n",
    "\n",
    "临床专家\n",
    "性别：女\n",
    "首页 /临床科室 /内科系列 /内科 /临床专家\n",
    "蔡清清\n",
    "职务：科副主任\n",
    "职称：教授，主任医师，博士生导师，淋巴瘤中心主诊教授\n",
    "专长\n",
    "擅长恶性淋巴瘤和头颈癌（鼻咽癌等）的诊治及恶性肿瘤的造血干细胞移植治疗。\n",
    " \n",
    "\n",
    " \n",
    "\n",
    "姓名：蔡清清\n",
    "\n",
    " \n",
    "\n",
    "职称：内科教授，主任医师，博士生导师，淋巴瘤中心主诊教授\n",
    "专长：主要擅长恶性淋巴瘤和头颈癌（鼻咽癌等）的诊治及恶性肿瘤的造血干细胞移植治疗\n",
    "出诊时间：周一上午特需门诊，周一下午、周四上午专家门诊\n",
    "学术兼职：广东省抗癌协会血液肿瘤专业 委员，秘书；广东省抗癌协会血液肿瘤专业委员会青年委员会副主任委员；中华医学会肿瘤学分会青年委员会副主任委员，广东省女医师协会淋巴瘤专业委员会副主任委员，广东省抗癌协会化疗专业委员会委员，广东省抗癌协会淋巴瘤专业委员会 委员，广州市抗癌协会淋巴瘤专业委员会 常委\n",
    "个人简介：蔡清清教授现任中山大学肿瘤防治中心内科教授，主任医师，博士生导师，淋巴瘤中心主诊教授，中华医学会肿瘤学分会青年委员会副主委，广东省女医师协会淋巴瘤专业委员会副主委，CSCO淋巴瘤联盟专家委员会委员，广东省抗癌协会血液肿瘤专业委员会秘书、委员，广东省抗癌协会血液肿瘤专业委员会青年委员会副主委，广东省抗癌协会淋巴瘤专业委员会委员，广东省抗癌协会化疗专业委员会委员。2013-2014年在美国M.D.Anderson肿瘤中心进修。研究方向淋巴瘤和头颈癌（鼻咽癌），主持多项国家、地方政府及企事业单位项目，其中2项国家自然科学基金面上项目，1项国家自然科学青年基金项目，已在国际著名期刊发表论文40余篇，其中以第一作者和通讯作者发表20余篇，最高影响因子10.199分。培养及正在培养的博士及硕士研究生9名。获第一批广东省杰出青年医学人才，羊城好医生及广东医院最强科室实力中青年医生称号。\n",
    "加载更多\n",
    "\n",
    "蔡清清的代表性文章、成果：\n",
    "1）Cai Q, Tu M, Xu-Monette ZY, Sun R, Manyam GC, Xu X, Tzankov A, Hsi ED, Møller MB, Medeiros LJ, Ok CY, Young KH. NF-κB p50 activation associated with immune dysregulation confers poorer survival for diffuse large B-cell lymphoma patients with wild-type p53. Mod Pathol. 2017 Mar 10. doi: 10.1038/modpathol.2017.5. [Epub ahead of print] （IF=5.485）\n",
    "2）Qian D, Chen K, Deng H, Rao H, Huang H, Liao Y, Sun X, Lu S, Yuan Z, Xie D, Cai Q (corresponding author). MicroRNA-374b Suppresses Proliferation and Promotes Apoptosis in T-cell Lymphoblastic Lymphoma by Repressing AKT1 and Wnt-16. Clin Cancer Res. 2015 Jun 22. [Epub ahead of print] （IF=9.6）\n",
    "3）Chen K, Liu Y, Li W, Chen J, Gu Y, Geng Q, Jiang W, Huang H, Lin T, Xia Z, Cai Q (corresponding author). The prognostic nutritional index predicts survival for patients with extranodal natural killer/T cell lymphoma, nasal type. Ann Hematol. 2015 Aug;94(8):1389-400. （IF=3.083）\n",
    "4）Cai Q, Luo X, Zhang G, Huang H, Huang H, Lin T, Jiang W, Xia Z, Young KH. New prognostic model for extranodal natural killer/T cell lymphoma, nasal type. Ann Hematol. 2014 Sep;93(9):1541-9. （IF=3.083）\n",
    "5）Cai Q, Luo X, Liang Y, Rao H, Fang X, Jiang W, Lin T, Lin T, Huang H. Fasting blood glucose is a novel prognostic indicator for extranodal natural killer/T-cell lymphoma, nasal type. British Journal of Cancer. 2013,108(2):380-386（IF=5.569）\n",
    "6.）Cai Q, Deng H, Xie D, Lin T, Lin T. Phosphorylated AKT Protein Is Overexpressed in Human Peripheral T-cell Lymphomas and Predicts Decreased Patient Survival. Clin Lymphoma Myeloma Leuk. 2012;12(2):106-12. （IF=2.316）\n",
    "7）Cai Q, Chen K, Chen J, Wu S, Geng Q, Huang H, Lin T, Jiang W, Xia Z, Duan H, Rao H, Yao M, Hu L. The Effect of Prophylactic Lamivudine plus Adefovir Therapy Compared with Lamivudine Alone in Preventing Hepatitis B Reactivation in Lymphoma Patients with High Baseline HBV DNA during Chemotherapy. PLoS One. 2016 Oct 6;11(10):e0164210. doi: 10.1371/journal.pone.0164210. eCollection 2016. （IF=3.057）\n",
    "8）Cai Q, Hu L, Geng Q, Chen J, Lu Z, Rao H, Liu Q, Jiang W, Huang H, Lin T, Xia Z. New risk  factors and new tendency for central nervous system relapse in patients with diffuse large  B-cell lymphoma: a retrospective study. Chin J Cancer. 2016 Sep 13;35(1):87. doi:  10.1186/s40880-016-0150-y. （IF=4.111）\n",
    "9）Cai Q, Medeiros LJ, Xu X, Young KH. MYC-driven aggressive B-cell lymphomas: biology, entity, differential diagnosis and clinical management [Review]. Oncotarget. 2015. （IF=5.008）\n",
    "10）Chen K, Chen J, Rao H, Guo Y, Huang H, Zhang L, Shao J, Lin T, Jiang W, Zou D, Hu L, Wirian M, Cai Q (corresponding author). Hepatitis B virus reactivation and hepatitis in diffuse large B-cell lymphoma patients with resolved hepatitis B receiving rituximab-containing chemotherapy: riskfactors and survival. Chin J Cancer. 2015 May 28;34(5):225-34. （IF=4.111）\n",
    "11）Cai Q, Chen Y, Zou D, Zhang L, Badillo M, Zhou S, Lopez E, Jiang W, HuangH, Lin T, Romaguera J, Wang M. Clinical outcomes of a novel combination of lenalidomide and rituximab followed by stem cell transplantation for relapsed/refractory aggressive B-cell non-hodgkin lymphoma. Oncotarget. 2014 Sep 15;5(17):7368-809（IF=5.008）\n",
    "12）Cai Q, Westin J, Fu K, Desai M, Zhang L, Huang H, Jiang W, Liang R, Qian Z, Champlin RE, Wang M. Accelerated therapeutic progress in diffuse large B cell lymphoma [Review]. Ann Hematol. 2014 Apr;93(4):541-56. （IF=3.083）\n",
    "13）Cai Q, Huang H, Qian D, Chen K, Luo J, Tian Y, Lin T, LinT. 13-Methyltetradecanoic Acid Exhibits Anti-Tumor Activity on T-Cell Lymphomas In Vitro and In Vivo by Down-Regulating p-AKT and ActivatingCaspase-3.PLoS One. 2013 Jun 7;8(6):e65308.（IF=3.057）\n",
    "14） Huang H, Cai Q (co-first author) , Lin T, Lin X, Liu Y, Gao Y, Peng R.   Lamivudine for the prevention of hepatitis B virus reactivation after high-dose chemotherapy and autologous hematopoietic stem cell transplantation for patients with advanced or relapsed non-Hodgkin's lymphoma single institution experience. Expert Opin Pharmacother. 2009;10(15):2399-406. （IF=3.543）\n",
    "15） Cai Q, Huang H, Sun X, Xia Z, Li Y, Lin X, Guo Y. Efficacy and safety of transdermal fentanyl for treatment of oral mucositis pain caused by chemotherapy. Expert Opin Pharmacother. 2008;9(18):3137-44. （IF=3.543）\n",
    "\"\"\""
   ],
   "metadata": {
    "collapsed": false,
    "ExecuteTime": {
     "end_time": "2023-06-14T06:42:23.449455Z",
     "start_time": "2023-06-14T06:42:23.433615900Z"
    }
   }
  },
  {
   "cell_type": "code",
   "execution_count": 33,
   "outputs": [
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "2023-06-14 14:42:24,410 - common.py - [line]:28 - INFO - get_openai_data: model:gpt-3.5-turbo\n",
      "2023-06-14 14:42:35,570 - common.py - [line]:31 - INFO - <Response [200]>\n",
      "2023-06-14 14:42:35,572 - common.py - [line]:32 - INFO - query:\n",
      "    请根据以下context，回答：蔡清清的专长\n",
      "    reply in 简体中文\n",
      "    ---------context\n",
      "    \n",
      "    临床研究clinical trials，NCT05572983\n",
      "{\n",
      "  \"Full Study\":{\n",
      "    \"Rank\":22633,\n",
      "    \"Study\":{\n",
      "      \"Protocol Section\":{\n",
      "        \"Identification Module\":{\n",
      "          \"NCT Id\":\"NCT05572983\",\n",
      "          \"Org Study Id Info\":{\n",
      "            \"Org Study Id\":\"SL-B2022-485-02\"\n",
      "          },\n",
      "          \"Organization\":{\n",
      "            \"Org Full Name\":\"Sun Yat-sen University\",\n",
      "            \"Org Class\":\"OTHER\"\n",
      "          },\n",
      "          \"Brief Title\":\"Phase Ⅱ Study of Chidamide in Combination With CHOP in Previously Untreated Peripheral T-Cell Lymphoma With Follicular Helper of T Cell Phenotype\",\n",
      "          \"Official Title\":\"Phase Ⅱ Study of Chidamide in Combination With CHOP in Previously Untreated Peripheral T-Cell Lymphoma With Follicular Helper of T Cell Phenotype （SWIFT）\"\n",
      "        },\n",
      "        \"Status Module\":{\n",
      "          \"Status Verified Date\":\"September 2022\",\n",
      "          \"Overall Status\":\"Recruiting\",\n",
      "          \"Expanded Access Info\":{\n",
      "            \"Has Expanded Access\":\"No\"\n",
      "          },\n",
      "          \"Start Date Struct\":{\n",
      "            \"Start Date\":\"September 1, 2022\",\n",
      "            \"Start DateType\":\"Actual\"\n",
      "          },\n",
      "          \"Primary Completion Date Struct\":{\n",
      "            \"Primary Completion Date\":\"September 1, 2024\",\n",
      "            \"Primary Completion DateType\":\"Anticipated\"\n",
      "          },\n",
      "          \"Completion Date Struct\":{\n",
      "            \"Completion Date\":\"September 1, 2026\",\n",
      "            \"Completion DateType\":\"Anticipated\"\n",
      "          },\n",
      "          \"Study First Submit Date\":\"September 30, 2022\",\n",
      "          \"Study First Submit QC Date\":\"October 7, 2022\",\n",
      "          \"Study First Post Date Struct\":{\n",
      "            \"Study First Post Date\":\"October 10, 2022\",\n",
      "            \"Study First Post DateType\":\"Actual\"\n",
      "          },\n",
      "          \"Last Update Submit Date\":\"October 7, 2022\",\n",
      "          \"Last Update Post Date Struct\":{\n",
      "            \"Last Update Post Date\":\"October 10, 2022\",\n",
      "            \"Last Update Post DateType\":\"Actual\"\n",
      "          }\n",
      "        },\n",
      "        \"Sponsor Collaborators Module\":{\n",
      "          \"Responsible Party\":{\n",
      "            \"Responsible PartyType\":\"Principal Investigator\",\n",
      "            \"Responsible PartyInvestigatorFullName\":\"Qingqing Cai\",\n",
      "            \"Responsible PartyInvestigatorTitle\":\"Chief physician\",\n",
      "            \"Responsible PartyInvestigatorAffiliation\":\"Sun Yat-sen University\"\n",
      "          },\n",
      "          \"Lead Sponsor\":{\n",
      "            \"Lead SponsorName\":\"Sun Yat-sen University\",\n",
      "            \"Lead SponsorClass\":\"OTHER\"\n",
      "          }\n",
      "        },\n",
      "        \"Oversight Module\":{\n",
      "          \"Is FDA Regulated Drug\":\"No\",\n",
      "          \"Is FDA Regulated Device\":\"No\"\n",
      "        },\n",
      "        \"Description Module\":{\n",
      "          \"Brief Summary\":\"This is a prospective, open-label, single arm, multicenter clinical study to evaluate the safety, tolerability, efficacy of chidamide in combination with CHOP in previously untreated peripheral T-cell lymphoma with follicular helper of T cell phenotype\"\n",
      "        },\n",
      "        \"Conditions Module\":{\n",
      "          \"Condition List\":{\n",
      "            \"Condition\":[\n",
      "              \"Peripheral T-Cell Lymphoma With Follicular Helper of T Cell Phenotype\"\n",
      "            ]\n",
      "          }\n",
      "        },\n",
      "        \"Design Module\":{\n",
      "          \"Study Type\":\"Interventional\",\n",
      "          \"PhaseList\":{\n",
      "            \"Phase\":[\n",
      "              \"Phase 2\"\n",
      "            ]\n",
      "          },\n",
      "          \"Design Info\":{\n",
      "            \"DesignAllocation\":\"N/A\",\n",
      "            \"DesignInterventionModel\":\"Single Group Assignment\",\n",
      "            \"DesignPrimaryPurpose\":\"Treatment\",\n",
      "            \"DesignMaskingInfo\":{\n",
      "              \"DesignMasking\":\"None (Open Label)\"\n",
      "            }\n",
      "          },\n",
      "          \"Enrollment Info\":{\n",
      "            \"Enrollment Count\":\"47\",\n",
      "            \"Enrollment Type\":\"Anticipated\"\n",
      "          }\n",
      "        },\n",
      "        \"Arms Interventions Module\":{\n",
      "          \"Arm Group List\":{\n",
      "            \"Arm Group\":[\n",
      "              {\n",
      "                \"Arm GroupLabel\":\"Chidamide in Combination With CHOP\",\n",
      "                \"Arm GroupType\":\"Experimental\",\n",
      "                \"Arm GroupDescription\":\"Patients with previously untreated peripheral T-cell lymphoma with follicular helper of T cell phenotype will receive chidamide in combination with CHOP for 6 cycles (planned) (21 days per cycle). After 6 cycles of induction therapy, if complete remission (CR) was achieved, maintenance treatment with chidamide will be continued for two years.\",\n",
      "                \"Arm GroupIntervention List\":{\n",
      "                  \"Arm GroupInterventionName\":[\n",
      "                    \"Drug: Chidamide combined with CHOP\",\n",
      "                    \"Drug: Chidamide\"\n",
      "                  ]\n",
      "                }\n",
      "              }\n",
      "            ]\n",
      "          },\n",
      "          \"Intervention List\":{\n",
      "            \"Intervention\":[\n",
      "              {\n",
      "                \"InterventionType\":\"Drug\",\n",
      "                \"InterventionName\":\"Chidamide combined with CHOP\",\n",
      "                \"InterventionDescription\":\"A)Chidamide: 20mg, D1, 4,8,11, po; B) Cyclophosphamide: 750 mg/ m2, D1, iv.drip; C) Doxorubicin: 50 mg/ m2, D1, iv.drip (or epirubicin 70 mg/ m2, D1, iv.drip); D) Vincristine: 1.4 mg/ m2, D1 (maximum dose 2mg, maximum dose 1.5mg for age over 70 years), iv; E) Prednisone: 40mg/m2, D1-5,po\",\n",
      "                \"InterventionArm GroupLabelList\":{\n",
      "                  \"InterventionArm GroupLabel\":[\n",
      "                    \"Chidamide in Combination With CHOP\"\n",
      "                  ]\n",
      "                },\n",
      "                \"InterventionOtherNameList\":{\n",
      "                  \"InterventionOtherName\":[\n",
      "                    \"Induction treatment\"\n",
      "                  ]\n",
      "                }\n",
      "              },{\n",
      "                \"InterventionType\":\"Drug\",\n",
      "                \"InterventionName\":\"Chidamide\",\n",
      "                \"InterventionDescription\":\"Chidamide: 20mg，qw（d1,d4）,po\",\n",
      "                \"InterventionArm GroupLabelList\":{\n",
      "                  \"InterventionArm GroupLabel\":[\n",
      "                    \"Chidamide in Combination With CHOP\"\n",
      "                  ]\n",
      "                },\n",
      "                \"InterventionOtherNameList\":{\n",
      "                  \"InterventionOtherName\":[\n",
      "                    \"Maintenance treatment\"\n",
      "                  ]\n",
      "                }\n",
      "              }\n",
      "            ]\n",
      "          }\n",
      "        },\n",
      "        \"Outcomes Module\":{\n",
      "          \"Primary Outcome List\":{\n",
      "            \"Primary Outcome\":[\n",
      "              {\n",
      "                \"Primary Outcome Measure\":\"Complete remission rate\",\n",
      "                \"Primary OutcomeDescription\":\"Complete remission rate will be determined on the basis of investigator assessments according to 2014 Lugano criteria.\",\n",
      "                \"Primary OutcomeTimeFrame\":\"Up to 18 weeks\"\n",
      "              }\n",
      "            ]\n",
      "          },\n",
      "          \"Secondary Outcome List\":{\n",
      "            \"Secondary Outcome\":[\n",
      "              {\n",
      "                \"Secondary Outcome Measure\":\"Objective response rate\",\n",
      "                \"Secondary OutcomeDescription\":\"Objective Response rate will be determined on the basis of investigator assessments according to 2014 Lugano criteria.\",\n",
      "                \"Secondary OutcomeTimeFrame\":\"Up to 18 weeks\"\n",
      "              },{\n",
      "                \"Secondary Outcome Measure\":\"Partial remission rate\",\n",
      "                \"Secondary OutcomeDescription\":\"Partial remission rate will be determined on the basis of investigator assessments according to 2014 Lugano criteria.\",\n",
      "                \"Secondary OutcomeTimeFrame\":\"Up to 18 weeks\"\n",
      "              },{\n",
      "                \"Secondary Outcome Measure\":\"Progression-free survival（PFS）\",\n",
      "                \"Secondary OutcomeDescription\":\"To investigate the preliminary antitumor efficacy\",\n",
      "                \"Secondary OutcomeTimeFrame\":\"From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 24 months\"\n",
      "              },{\n",
      "                \"Secondary Outcome Measure\":\"Overall survival\",\n",
      "                \"Secondary OutcomeDescription\":\"To investigate the preliminary antitumor efficacy\",\n",
      "                \"Secondary OutcomeTimeFrame\":\"From date of randomization until the date of death from any cause, assessed up to 24 months\"\n",
      "              },{\n",
      "                \"Secondary Outcome Measure\":\"Recurrence free survival\",\n",
      "                \"Secondary OutcomeDescription\":\"To investigate the preliminary antitumor efficacy\",\n",
      "                \"Secondary OutcomeTimeFrame\":\"From date of randomization until the date ofthe occurrence of relapse or last visit, assessed up to 24 months\"\n",
      "              },{\n",
      "                \"Secondary Outcome Measure\":\"Number of participants with adverse events (AE) and severe adverse events (SAE) as assessed by CTCAE v5.0\",\n",
      "                \"Secondary OutcomeDescription\":\"To identify the incidence of AE and SAE\",\n",
      "                \"Secondary OutcomeTimeFrame\":\"Up to 18 weeks\"\n",
      "              }\n",
      "            ]\n",
      "          }\n",
      "        },\n",
      "        \"Eligibility Module\":{\n",
      "          \"Eligibility Criteria\":\"Inclusion Criteria:\n",
      "\n",
      "Age ≥18 years old and ≤75 years old, male and female;\n",
      "Peripheral T-Cell lymphoma with follicular helper of T cell phenotype confirmed by histopathology at the study center, including: ① Angioimmunoblastic T-cell lymphoma (AITL), ②follicular T-cell lymphoma (FTCL), and ③ other nodal PTCL with TFH phenotype;\n",
      "Never received chemotherapy, radiotherapy, immunological and biological therapy for lymphoma before;\n",
      "Autologous stem cell transplantation is not suitable or the patient refused to accept autologous stem cell transplantation;\n",
      "There must be at least one measurable or evaluable lesion that meets the evaluation criteria for Lugano 2014 lymphoma: measurable lesion: Positron emission tomography / computed tomography (PET/CT) or CT and/or MRI, intranode lesions with long diameter >1.5cm, short diameter >1.0cm, or exnode lesions with long diameter > 1.0 cm; PET CT examination of the lesion showing increased uptake in lymph nodes or extranodal areas (higher than liver) and imaging features consistent with lymphoma can be evaluated.\n",
      "Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) 0-2；\n",
      "Expected survival ≥ 3 months;\n",
      "\n",
      "The following required baseline laboratory data:\n",
      "\n",
      ".White blood cell，WBC≥3.0×109/L(Bone marrow invasive patient≥2.0×109/L), Absolute neutrophil count，ANC ≥1.5×109/L, （Bone marrow invasive patient≥1.0×109/L), Platelet count (PLT) ≥75×109/L, （Bone marrow invasive patient≥50×109/L) ，Hemoglobin (HB)≥ 80g/L;\n",
      ".Total bilirubin (TBIL) ≤1.5×upper limit of normal (ULN) (The liver invasion ≤3.0×ULN), Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤2.5×ULN（The liver invasion≤5.0×ULN）\n",
      ".Renal function：creatinine, Cr≤1.5×ULN\n",
      ".Coagulation function： International Normalized Ratio (INR)≤1.5 ×ULN； Prothrombin Time (PT)、Activated Partial Thromboplastin Time (APTT)≤1.5×ULN（Unless the patient is receiving anticoagulant therapy and PT and APTT are within the expected range at screening time）；\n",
      ".Thyroid stimulating hormone (TSH) or free thyroid hormone (FT4) or free triiodothyronine (FT3) were within 10% of normal value (note: abnormal TSH caused by non-autoimmune causes can be included in the group);\n",
      "Subjects fully understand and voluntarily participate in this study and sign informed consent\n",
      "\n",
      "Exclusion Criteria:\n",
      "\n",
      "A history of other malignant tumors within the past 5 years; Or other tumors (except basal cell carcinoma of the skin)\n",
      "Patients with significant vital organ dysfunction;\n",
      "Patients with active bleeding or newly developed thrombotic disease, and patients who are taking anticoagulants and having a bleeding tendency;\n",
      "Patients with a known history of Human Immunodeficiency Virus (HIV) infection and/or acquired Immunodeficiency syndrome;\n",
      "Patients with active chronic hepatitis B or active hepatitis C. Patients who are hepatitis B surface antigen (HBsAg) or hepatitis B core antibody (HBcAb) or hepatitis C virus (HCV) antibody positive during the screening period require further testing for Hepatitis B Virus (HBV) DNA and HCV RNA. If HBV DNA is no more than 2500 copies /mL or 500 IU/mL and HCV RNA is no more than the lower limit of the assay, enrollment will be allowed after exclusion of treatment-requiring active hepatitis B or C infection. Hepatitis B virus carriers, stable hepatitis B (no more than 2500 copies /mL or 500 IU/mL of DNA) and cured hepatitis C patients were eligible;\n",
      "Subjects who were treated with systemic glucocorticoids or other immunosuppressive agents for a condition within 14 days prior to initiation of study treatment {Local, ocular, intra-articular, intranasal, and inhaled glucocorticoids were allowed (with very low systemic absorption); Short-term (≤ 7 days) use of glucocorticoids for prophylactic treatment (e.g., contrast media allergy) or for treatment of non-autoimmune conditions (e.g., delayed hypersensitivity due to contact allergens) is allowed;\n",
      "With active, and in the past two years need systemic treatment of autoimmune diseases (hormone replacement therapy is not considered a systemic treatment, such as type 1 diabetes, hypothyroidism only requiring thyroid hormone replacement therapy, low adrenocortical or pituitary function only requiring physiological doses of sugar cortical hormone replacement therapy ); Patients with autoimmune diseases that have not required systemic treatment in the past two years are eligible;\n",
      "Patients with unstable angina and/or congestive heart failure or vascular disease (such as, the aortic aneurysm or peripheral venous thrombosis requiring surgery to repair) requiring hospital treatment within 12 months. Patients with other cardiac damage (such as poor control of arrhythmia, myocardial infarction, or ischemic) which may affect the drug safety evaluation within 12 months;\n",
      "Patients who underwent major surgery within 28 days before enrollment; Less than 6 weeks after major organ surgery;\n",
      "Long-term unhealed wounds or incomplete healing fractures;\n",
      "Receive live attenuated vaccine (except influenza vaccine) within 4 weeks before enrollment or during the study period;\n",
      "Pregnant or lactating women and subjects of reproductive age who do not want to take contraceptive measures;\n",
      "Patients with mental illness or who cannot obtain informed consent;\n",
      "There is active infection, except for tumor-related B symptoms and fever;\n",
      "Cardiac clinical symptoms or diseases that are not well controlled, such as: I. Nyha grade 2 or above heart failure; II. Unstable angina pectoris; III. Myocardial infarction has occurred within 1 year; IV. Patients with clinically significant supraventricular or ventricular arrhythmias requiring treatment or intervention;\n",
      "Ineligibility to participate in the study was determined by the investigator.\",\n",
      "          \"Healthy Volunteers\":\"No\",\n",
      "          \"Gender\":\"All\",\n",
      "          \"Minimum Age\":\"18 Years\",\n",
      "          \"MaximumAge\":\"75 Years\",\n",
      "          \"Std Age List\":{\n",
      "            \"Std Age\":[\n",
      "              \"Adult\",\n",
      "              \"Older Adult\"\n",
      "            ]\n",
      "          }\n",
      "        },\n",
      "        \"Contacts Locations Module\":{\n",
      "          \"CentralContactList\":{\n",
      "            \"CentralContact\":[\n",
      "              {\n",
      "                \"CentralContactName\":\"Qingqing Cai\",\n",
      "                \"CentralContactRole\":\"Contact\",\n",
      "                \"CentralContactPhone\":\"0086-20-87342823\",\n",
      "                \"CentralContactEMail\":\"caiqq@sysucc.org.cn\"\n",
      "              }\n",
      "            ]\n",
      "          },\n",
      "          \"Overall Official List\":{\n",
      "            \"Overall Official\":[\n",
      "              {\n",
      "                \"Overall OfficialName\":\"Qingqing Cai\",\n",
      "                \"Overall OfficialAffiliation\":\"Sun Yat-sen University\",\n",
      "                \"Overall OfficialRole\":\"Study Director\"\n",
      "              }\n",
      "            ]\n",
      "          },\n",
      "          \"Location List\":{\n",
      "            \"Location\":[\n",
      "              {\n",
      "                \"LocationFacility\":\"Sun Yat-sen Universitiy Cancer Center, Sun Yat-Sen University\",\n",
      "                \"LocationStatus\":\"Recruiting\",\n",
      "                \"LocationCity\":\"Guangzhou\",\n",
      "                \"LocationState\":\"Guangdong\",\n",
      "                \"LocationZip\":\"510000\",\n",
      "                \"LocationCountry\":\"China\",\n",
      "                \"LocationContactList\":{\n",
      "                  \"LocationContact\":[\n",
      "                    {\n",
      "                      \"LocationContactName\":\"Qingqing Cai, MD\",\n",
      "                      \"LocationContactRole\":\"Contact\",\n",
      "                      \"LocationContactEMail\":\"caiqq@sysucc.org.cn\"\n",
      "                    }\n",
      "                  ]\n",
      "                }\n",
      "              }\n",
      "            ]\n",
      "          }\n",
      "        }\n",
      "      },\n",
      "      \"Derived Section\":{\n",
      "        \"Misc Info Module\":{\n",
      "          \"Version Holder\":\"May 19, 2023\"\n",
      "        },\n",
      "        \"Condition Browse Module\":{\n",
      "          \"Condition Mesh List\":{\n",
      "            \"Condition Mesh\":[\n",
      "              {\n",
      "                \"Condition MeshId\":\"D000008223\",\n",
      "                \"Condition MeshTerm\":\"Lymphoma\"\n",
      "              },{\n",
      "                \"Condition MeshId\":\"D000016399\",\n",
      "                \"Condition MeshTerm\":\"Lymphoma, T-Cell\"\n",
      "              },{\n",
      "                \"Condition MeshId\":\"D000016411\",\n",
      "                \"Condition MeshTerm\":\"Lymphoma, T-Cell, Peripheral\"\n",
      "              }\n",
      "            ]\n",
      "          },\n",
      "          \"Condition Ancestor List\":{\n",
      "            \"Condition Ancestor\":[\n",
      "              {\n",
      "                \"Condition AncestorId\":\"D000009370\",\n",
      "                \"Condition AncestorTerm\":\"Neoplasms by Histologic Type\"\n",
      "              },{\n",
      "                \"Condition AncestorId\":\"D000009369\",\n",
      "                \"Condition AncestorTerm\":\"Neoplasms\"\n",
      "              },{\n",
      "                \"Condition AncestorId\":\"D000008232\",\n",
      "                \"Condition AncestorTerm\":\"Lymphoproliferative Disorders\"\n",
      "              },{\n",
      "                \"Condition AncestorId\":\"D000008206\",\n",
      "                \"Condition AncestorTerm\":\"Lymphatic Diseases\"\n",
      "              },{\n",
      "                \"Condition AncestorId\":\"D000007160\",\n",
      "                \"Condition AncestorTerm\":\"Immunoproliferative Disorders\"\n",
      "              },{\n",
      "                \"Condition AncestorId\":\"D000007154\",\n",
      "                \"Condition AncestorTerm\":\"Immune System Diseases\"\n",
      "              },{\n",
      "                \"Condition AncestorId\":\"D000008228\",\n",
      "                \"Condition AncestorTerm\":\"Lymphoma, Non-Hodgkin\"\n",
      "              }\n",
      "            ]\n",
      "          },\n",
      "          \"Condition Browse Leaf List\":{\n",
      "            \"Condition Browse Leaf\":[\n",
      "              {\n",
      "                \"Condition Browse LeafId\":\"M10372\",\n",
      "                \"Condition Browse LeafName\":\"Lymphoma\",\n",
      "                \"Condition Browse LeafAsFound\":\"Lymphoma\",\n",
      "                \"Condition Browse LeafRelevance\":\"high\"\n",
      "              },{\n",
      "                \"Condition Browse LeafId\":\"M17981\",\n",
      "                \"Condition Browse LeafName\":\"Lymphoma, T-Cell\",\n",
      "                \"Condition Browse LeafAsFound\":\"T-cell Lymphoma\",\n",
      "                \"Condition Browse LeafRelevance\":\"high\"\n",
      "              },{\n",
      "                \"Condition Browse LeafId\":\"M17985\",\n",
      "                \"Condition Browse LeafName\":\"Lymphoma, T-Cell, Peripheral\",\n",
      "                \"Condition Browse LeafAsFound\":\"Peripheral T-cell Lymphoma\",\n",
      "                \"Condition Browse LeafRelevance\":\"high\"\n",
      "              },{\n",
      "                \"Condition Browse LeafId\":\"M11467\",\n",
      "                \"Condition Browse LeafName\":\"Neoplasms by Histologic Type\",\n",
      "                \"Condition Browse LeafRelevance\":\"low\"\n",
      "              },{\n",
      "                \"Condition Browse LeafId\":\"M10377\",\n",
      "                \"Condition Browse LeafName\":\"Lymphoproliferative Disorders\",\n",
      "                \"Condition Browse LeafRelevance\":\"low\"\n",
      "              },{\n",
      "                \"Condition Browse LeafId\":\"M10355\",\n",
      "                \"Condition Browse LeafName\":\"Lymphatic Diseases\",\n",
      "                \"Condition Browse LeafRelevance\":\"low\"\n",
      "              },{\n",
      "                \"Condition Browse LeafId\":\"M9358\",\n",
      "                \"Condition Browse LeafName\":\"Immunoproliferative Disorders\",\n",
      "                \"Condition Browse LeafRelevance\":\"low\"\n",
      "              },{\n",
      "                \"Condition Browse LeafId\":\"M9352\",\n",
      "                \"Condition Browse LeafName\":\"Immune System Diseases\",\n",
      "                \"Condition Browse LeafRelevance\":\"low\"\n",
      "              },{\n",
      "                \"Condition Browse LeafId\":\"M10374\",\n",
      "                \"Condition Browse LeafName\":\"Lymphoma, Non-Hodgkin\",\n",
      "                \"Condition Browse LeafRelevance\":\"low\"\n",
      "              },{\n",
      "                \"Condition Browse LeafId\":\"T3543\",\n",
      "                \"Condition Browse LeafName\":\"Lymphosarcoma\",\n",
      "                \"Condition Browse LeafAsFound\":\"Lymphoma\",\n",
      "                \"Condition Browse LeafRelevance\":\"high\"\n",
      "              },{\n",
      "                \"Condition Browse LeafId\":\"T4496\",\n",
      "                \"Condition Browse LeafName\":\"Peripheral T-cell Lymphoma\",\n",
      "                \"Condition Browse LeafAsFound\":\"Peripheral T-cell Lymphoma\",\n",
      "                \"Condition Browse LeafRelevance\":\"high\"\n",
      "              }\n",
      "            ]\n",
      "          },\n",
      "          \"Condition Browse Branch List\":{\n",
      "            \"Condition Browse Branch\":[\n",
      "              {\n",
      "                \"Condition Browse BranchAbbrev\":\"BC04\",\n",
      "                \"Condition Browse BranchName\":\"Neoplasms\"\n",
      "              },{\n",
      "                \"Condition Browse BranchAbbrev\":\"BC15\",\n",
      "                \"Condition Browse BranchName\":\"Blood and Lymph Conditions\"\n",
      "              },{\n",
      "                \"Condition Browse BranchAbbrev\":\"BC20\",\n",
      "                \"Condition Browse BranchName\":\"Immune System Diseases\"\n",
      "              },{\n",
      "                \"Condition Browse BranchAbbrev\":\"All\",\n",
      "                \"Condition Browse BranchName\":\"All Conditions\"\n",
      "              },{\n",
      "                \"Condition Browse BranchAbbrev\":\"Rare\",\n",
      "                \"Condition Browse BranchName\":\"Rare Diseases\"\n",
      "              }\n",
      "            ]\n",
      "          }\n",
      "        },\n",
      "        \"Intervention Browse Module\":{\n",
      "          \"Intervention Browse Leaf List\":{\n",
      "            \"Intervention Browse Leaf\":[\n",
      "              {\n",
      "                \"Intervention Browse LeafId\":\"M5879\",\n",
      "                \"Intervention Browse LeafName\":\"Cyclophosphamide\",\n",
      "                \"Intervention Browse LeafRelevance\":\"low\"\n",
      "              },{\n",
      "                \"Intervention Browse LeafId\":\"M17106\",\n",
      "                \"Intervention Browse LeafName\":\"Epirubicin\",\n",
      "                \"Intervention Browse LeafRelevance\":\"low\"\n",
      "              },{\n",
      "                \"Intervention Browse LeafId\":\"M6644\",\n",
      "                \"Intervention Browse LeafName\":\"Doxorubicin\",\n",
      "                \"Intervention Browse LeafRelevance\":\"low\"\n",
      "              },{\n",
      "                \"Intervention Browse LeafId\":\"M13273\",\n",
      "                \"Intervention Browse LeafName\":\"Prednisone\",\n",
      "                \"Intervention Browse LeafRelevance\":\"low\"\n",
      "              },{\n",
      "                \"Intervention Browse LeafId\":\"M16647\",\n",
      "                \"Intervention Browse LeafName\":\"Vincristine\",\n",
      "                \"Intervention Browse LeafRelevance\":\"low\"\n",
      "              },{\n",
      "                \"Intervention Browse LeafId\":\"M227311\",\n",
      "                \"Intervention Browse LeafName\":\"Liposomal doxorubicin\",\n",
      "                \"Intervention Browse LeafRelevance\":\"low\"\n",
      "              }\n",
      "            ]\n",
      "          },\n",
      "          \"Intervention Browse Branch List\":{\n",
      "            \"Intervention Browse Branch\":[\n",
      "              {\n",
      "                \"Intervention Browse BranchAbbrev\":\"ANeo\",\n",
      "                \"Intervention Browse BranchName\":\"Antineoplastic Agents\"\n",
      "              },{\n",
      "                \"Intervention Browse BranchAbbrev\":\"ARhu\",\n",
      "                \"Intervention Browse BranchName\":\"Antirheumatic Agents\"\n",
      "              },{\n",
      "                \"Intervention Browse BranchAbbrev\":\"All\",\n",
      "                \"Intervention Browse BranchName\":\"All Drugs and Chemicals\"\n",
      "              },{\n",
      "                \"Intervention Browse BranchAbbrev\":\"Infl\",\n",
      "                \"Intervention Browse BranchName\":\"Anti-Inflammatory Agents\"\n",
      "              }\n",
      "            ]\n",
      "          }\n",
      "        }\n",
      "      }\n",
      "    }\n",
      "  }\n",
      "}\n",
      "\n",
      "临床研究clinical trials，NCT04996758\n",
      "{\n",
      "  \"Full Study\":{\n",
      "    \"Rank\":66911,\n",
      "    \"Study\":{\n",
      "      \"Protocol Section\":{\n",
      "        \"Identification Module\":{\n",
      "          \"NCT Id\":\"NCT04996758\",\n",
      "          \"Org Study Id Info\":{\n",
      "            \"Org Study Id\":\"B2021-055\"\n",
      "          },\n",
      "          \"Organization\":{\n",
      "            \"Org Full Name\":\"Sun Yat-sen University\",\n",
      "            \"Org Class\":\"OTHER\"\n",
      "          },\n",
      "          \"Brief Title\":\"Toripalimab and Anlotinib Combination Treatment in Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma After Failure of at Least One Line of Platinum-Based Chemotherapy (TORAL)\",\n",
      "          \"Official Title\":\"Open-Label, Phase Ⅱ Study of Toripalimab and Anlotinib Combination Treatment in Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma After Failure of at Least One Line of Platinum-Based Chemotherapy (TORAL)\"\n",
      "        },\n",
      "        \"Status Module\":{\n",
      "          \"Status Verified Date\":\"March 2022\",\n",
      "          \"Overall Status\":\"Recruiting\",\n",
      "          \"Expanded Access Info\":{\n",
      "            \"Has Expanded Access\":\"No\"\n",
      "          },\n",
      "          \"Start Date Struct\":{\n",
      "            \"Start Date\":\"August 1, 2021\",\n",
      "            \"Start DateType\":\"Actual\"\n",
      "          },\n",
      "          \"Primary Completion Date Struct\":{\n",
      "            \"Primary Completion Date\":\"August 2023\",\n",
      "            \"Primary Completion DateType\":\"Anticipated\"\n",
      "          },\n",
      "          \"Completion Date Struct\":{\n",
      "            \"Completion Date\":\"August 2028\",\n",
      "            \"Completion DateType\":\"Anticipated\"\n",
      "          },\n",
      "          \"Study First Submit Date\":\"August 5, 2021\",\n",
      "          \"Study First Submit QC Date\":\"August 5, 2021\",\n",
      "          \"Study First Post Date Struct\":{\n",
      "            \"Study First Post Date\":\"August 9, 2021\",\n",
      "            \"Study First Post DateType\":\"Actual\"\n",
      "          },\n",
      "          \"Last Update Submit Date\":\"March 23, 2022\",\n",
      "          \"Last Update Post Date Struct\":{\n",
      "            \"Last Update Post Date\":\"March 24, 2022\",\n",
      "            \"Last Update Post DateType\":\"Actual\"\n",
      "          }\n",
      "        },\n",
      "        \"Sponsor Collaborators Module\":{\n",
      "          \"Responsible Party\":{\n",
      "            \"Responsible PartyType\":\"Principal Investigator\",\n",
      "            \"Responsible PartyInvestigatorFullName\":\"Qingqing Cai\",\n",
      "            \"Responsible PartyInvestigatorTitle\":\"Chief physician\",\n",
      "            \"Responsible PartyInvestigatorAffiliation\":\"Sun Yat-sen University\"\n",
      "          },\n",
      "          \"Lead Sponsor\":{\n",
      "            \"Lead SponsorName\":\"Sun Yat-sen University\",\n",
      "            \"Lead SponsorClass\":\"OTHER\"\n",
      "          }\n",
      "        },\n",
      "        \"Oversight Module\":{\n",
      "          \"Is FDA Regulated Drug\":\"No\",\n",
      "          \"Is FDA Regulated Device\":\"No\"\n",
      "        },\n",
      "        \"Description Module\":{\n",
      "          \"Brief Summary\":\"This phase 2 trial studies toripalimab and anlotinib combination treatment in patients with recurrent or metastatic nasopharyngeal carcinoma after failure of at least one line of platinum-based chemotherapy\"\n",
      "        },\n",
      "        \"Conditions Module\":{\n",
      "          \"Condition List\":{\n",
      "            \"Condition\":[\n",
      "              \"Nasopharyngeal Carcinoma\",\n",
      "              \"Recurrent or Metastatic Nasopharyngeal Carcinoma\"\n",
      "            ]\n",
      "          }\n",
      "        },\n",
      "        \"Design Module\":{\n",
      "          \"Study Type\":\"Interventional\",\n",
      "          \"PhaseList\":{\n",
      "            \"Phase\":[\n",
      "              \"Phase 2\"\n",
      "            ]\n",
      "          },\n",
      "          \"Design Info\":{\n",
      "            \"DesignAllocation\":\"N/A\",\n",
      "            \"DesignInterventionModel\":\"Single Group Assignment\",\n",
      "            \"DesignPrimaryPurpose\":\"Treatment\",\n",
      "            \"DesignMaskingInfo\":{\n",
      "              \"DesignMasking\":\"None (Open Label)\"\n",
      "            }\n",
      "          },\n",
      "          \"Enrollment Info\":{\n",
      "            \"Enrollment Count\":\"39\",\n",
      "            \"Enrollment Type\":\"Anticipated\"\n",
      "          }\n",
      "        },\n",
      "        \"Arms Interventions Module\":{\n",
      "          \"Arm Group List\":{\n",
      "            \"Arm Group\":[\n",
      "              {\n",
      "                \"Arm GroupLabel\":\"Toripalimab and Anlotinib Combination Treatment\",\n",
      "                \"Arm GroupType\":\"Experimental\",\n",
      "                \"Arm GroupDescription\":\"Patients receive toripalimab at a dose of 240 mg on day 1 and anlotinib at a dose of 12 mg before breakfast for once-daily on days 1-14. Treatment cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity\",\n",
      "                \"Arm GroupIntervention List\":{\n",
      "                  \"Arm GroupInterventionName\":[\n",
      "                    \"Drug: Toripalimab and Anlotinib\"\n",
      "                  ]\n",
      "                }\n",
      "              }\n",
      "            ]\n",
      "          },\n",
      "          \"Intervention List\":{\n",
      "            \"Intervention\":[\n",
      "              {\n",
      "                \"InterventionType\":\"Drug\",\n",
      "                \"InterventionName\":\"Toripalimab and Anlotinib\",\n",
      "                \"InterventionDescription\":\"Toripalimab 240 mg iv.drip d1; Anlotinib 12mg po qd d1-14.\",\n",
      "                \"InterventionArm GroupLabelList\":{\n",
      "                  \"InterventionArm GroupLabel\":[\n",
      "                    \"Toripalimab and Anlotinib Combination Treatment\"\n",
      "                  ]\n",
      "                }\n",
      "              }\n",
      "            ]\n",
      "          }\n",
      "        },\n",
      "        \"Outcomes Module\":{\n",
      "          \"Primary Outcome List\":{\n",
      "            \"Primary Outcome\":[\n",
      "              {\n",
      "                \"Primary Outcome Measure\":\"Objective Response rate\",\n",
      "                \"Primary OutcomeDescription\":\"Objective Response rate will be determined on the basis of investigator assessments\",\n",
      "                \"Primary OutcomeTimeFrame\":\"2 years\"\n",
      "              },{\n",
      "                \"Primary Outcome Measure\":\"Disease Control rate\",\n",
      "                \"Primary OutcomeDescription\":\"the proportion of patients who had a best response rating of complete response, partial response, or stable disease will be determined on the basis of investigator assessments\",\n",
      "                \"Primary OutcomeTimeFrame\":\"2 years\"\n",
      "              }\n",
      "            ]\n",
      "          },\n",
      "          \"Secondary Outcome List\":{\n",
      "            \"Secondary Outcome\":[\n",
      "              {\n",
      "                \"Secondary Outcome Measure\":\"Progression Free Survival\",\n",
      "                \"Secondary OutcomeDescription\":\"The time from the start of treatment to the progression of the tumor or death (due to any cause).\",\n",
      "                \"Secondary OutcomeTimeFrame\":\"5 years\"\n",
      "              },{\n",
      "                \"Secondary Outcome Measure\":\"Overall Survival\",\n",
      "                \"Secondary OutcomeDescription\":\"The time from the start of treatment to time of death (due to any cause).\",\n",
      "                \"Secondary OutcomeTimeFrame\":\"5 years\"\n",
      "              },{\n",
      "                \"Secondary Outcome Measure\":\"Complete Response rate\",\n",
      "                \"Secondary OutcomeDescription\":\"Complete Response rate will be determined on the basis of investigator assessments\",\n",
      "                \"Secondary OutcomeTimeFrame\":\"2 years\"\n",
      "              },{\n",
      "                \"Secondary Outcome Measure\":\"Partial Response rate\",\n",
      "                \"Secondary OutcomeDescription\":\"Partial Response rate will be determined on the basis of investigator assessments\",\n",
      "                \"Secondary OutcomeTimeFrame\":\"2 years\"\n",
      "              },{\n",
      "                \"Secondary Outcome Measure\":\"Duration of Response\",\n",
      "                \"Secondary OutcomeDescription\":\"The time from the first assessment of complete remission or partial remission to progressive disease or death (due to any cause).\",\n",
      "                \"Secondary OutcomeTimeFrame\":\"5 years\"\n",
      "              },{\n",
      "                \"Secondary Outcome Measure\":\"Percentage of Participants With Adverse Events\",\n",
      "                \"Secondary OutcomeDescription\":\"Adverse Events will be determined and graded on the basis of investigator assessments according to NCI CTC AE 5.0\",\n",
      "                \"Secondary OutcomeTimeFrame\":\"5 years\"\n",
      "              }\n",
      "            ]\n",
      "          }\n",
      "        },\n",
      "        \"Eligibility Module\":{\n",
      "          \"Eligibility Criteria\":\"Inclusion Criteria:\n",
      "\n",
      "Histologically confirmed undifferentiated non-keratinizing carcinoma\n",
      "Patients suffered failure of at least one line of platinum-based chemotherapy. The definition of treatment failure: progression during or after chemotherapy for recurrence/metastasis; progression after concurrent chemoradiotherapy within 6 months. Withdrawal of treatment due to drug intolerances is excluded ;\n",
      "Without other malignancy;\n",
      "Male or female, 18-70 years;\n",
      "Eastern Cooperative Oncology Group (ECOG) of 0-2;\n",
      "Life expectancy ≥ 3 months;\n",
      "Women of childbearing age must obtain the negative result of a pregnancy test (serum or urine) , and they were willing to use reliable methods of contraception during the trial;\n",
      "At least one evaluable lesion；\n",
      "Laboratory tests meet the following standards:\n",
      "\n",
      "Blood routine: White blood cell count (WBC) ≥3.0×10 9 /L, neutrophil count (ANC) ≥1.5×10 9 /L, platelet count (PLT) ≥75×10 9 /L, hemoglobin (HGB) 90 g/L or higher; Liver function: total bilirubin ≤1.5 times the upper limit of normal (ULN); glutamic-oxalacetic transaminase (AST) and alanine transaminase (ALT) ≤2.5 times ULN, AST and ALT ≤2.5 times ULN for the patients with liver metastases; Alkaline phosphatase ≤5 times ULN; Renal function: Serum creatinine (Cr) ≤1.5 times ULN; Creatinine clearance ≥60mL/min; Urine routine: urine protein <2+ ;baseline urine protein ≥2+ and 24 hours urine protein < 1g ; Coagulation: International normalized ratio (INR) and activated partial thrombin time (APTT) ≤1.5 times ULN; Albumin ≥28g/L Thyroid stimulating hormone (TSH)≤1 times ULN (free triiodothyrosine [FT3] or free thyroxine [FT4] ≤1 times ULN can be included)\n",
      "\n",
      "No serious cardiopulmonary dysfunction;\n",
      "The informed consent has been signed.\n",
      "Ability to comply with test requirements\n",
      "\n",
      "Exclusion Criteria:\n",
      "\n",
      "A known allergy to any of the drugs in the study;\n",
      "Pregnant or breastfeeding women;\n",
      "Participated in clinical trials of other drugs within 4 weeks prior to study initiation;\n",
      "Previous treatment with bevacizumab or VEGFR-family small molecule tyrosine kinase inhibitors (e.g., famitinib, sorafenib, Sunitinib, regofinib, Apatinib, Anlotinib, fuquinitinib) ;\n",
      "Recurrent nasopharyngeal lesions after radiotherapy and who received secondary radiotherapy;\n",
      "Palliative radiotherapy for symptom control within 28 days before enrollment;\n",
      "Immunosuppressive treatment with immunosuppressive agent, systemic or absorbable topical hormone therapy ( prednisone or other therapeutic hormone at the dose greater than 10mg/ day) within 2 weeks before enrollment;\n",
      "Active autoimmune diseases, with the necessity of systemic treatment (hormone replacement therapy is not considered as a systemic treatment, such as type 1 diabetes) over the past two years; autoimmune diseases that did not require systemic treatment in the past two years;\n",
      "A history of immunodeficiency, including acquired/congenital immunodeficiency disorders, a history of organ transplantation;\n",
      "Vaccinated with live vaccine (inactivated virus vaccine for seasonal influenza is allowed) within 4 weeks before enrollment;\n",
      "Invasion of important vessels (e.g. surrounding internal carotid artery/vein) on MRI; tumor with a high risk of affecting vital blood vessels during treatment and causing fatal hemorrhage, which is determined by investigators;\n",
      "A history of severe bleeding and any bleeding event with a severity rating of 3 or higher in the NCI CTCAE within 4 weeks prior to screening;\n",
      "Abnormal coagulation (INR > 2.0, PT > 16s) and bleeding tendency (the INR must be within the normal range without anticoagulants during14 days prior to signing the informed consent); patients treated with anticoagulants or vitamin K antagonists such as warfarin, heparin, or their analogests; low-dose warfarin (1 mg orally, once daily) or low-dose aspirin (up to 100 mg daily) for preventive purposes, provided that the international normalized ratio of prothrombin time (INR) is ≤ 1.5;\n",
      "Unstable angina and/or congestive heart failure or vascular disease with the need of hospital treatment; other cardiac damage that may affect the drug safety;\n",
      "Patients with hypertension that is not well controlled with antihypertensive medication (systolic > 140mmHg, diastolic > 90 mmHg); patients is taking a combination of two or more antihypertensive drugs; Cardiovascular disease with clinical significance， such as cerebrovascular accident (≤ 6 months before randomization), myocardial infarction (≤ 6 months before randomization), unstable angina, congestive heart failure of NYHA grade II or higher, or severe arrhythmias that cannot be controlled with drugs or have a potential impact on experimental treatments;\n",
      "Patients with esophageal and gastric varices, active ulcers, intestinal perforation or intestinal obstruction within 6 months before enrollment;\n",
      "A history of abdominal fistula, digestive tract perforation, intra-abdominal abscess or acute gastrointestinal bleeding within 6 months before enrollment;\n",
      "Multiple factors affecting oral administration and absorption of drugs (e.g., inability to swallow, post-gastrointestinal resection, chronic diarrhea and intestinal obstruction);\n",
      "Overoperation/venous thromboembolism events, NCI CTCAE grade 3 or higher venous thromboembolism within 6 months before enrollment, such as cerebrovascular accident (including temporary ischemic attack), deep venous thrombosis (except for those venous thrombosis caused by venous catheterization due to previous chemotherapy and determined to be cured by the researchers ), pulmonary embolism, etc.;\n",
      "Patients with past and present objective evidence of pulmonary fibrosis, interstitial pneumonia, pneumoconiosis, radiation pneumonia, drug-related pneumonia, or severe impairment of lung function;\n",
      "Exacerbation of chronic obstructive pulmonary disease (COPD) or other respiratory disease requiring hospitalization within 28 days before enrollment;\n",
      "Active pulmonary infection and/or acute bacterial or fungal infection requiring intravenous antibiotic treatment within 28 days;\n",
      "Dominant jaundice due to abnormal liver function within 7 days;\n",
      "Renal insufficiency: routine urinalproteinuria > 2+ and confirmed 24 h urinary protein quantification > 1.0g;\n",
      "Minor surgical operations (including catheterization, excluding central venous catheterization via peripheral venipuncture) within 2 days before enrollment;\n",
      "Major surgery within 28 days before enrollment;\n",
      "A potent CYP3A4 inhibitor within one week prior to enrollment, or a potent CYP3A4 inducer within two weeks prior to study participation\n",
      "Long-term unhealed wounds or incomplete fractures;\n",
      "Symptomatic central nervous system metastases (e.g. brain edema, need for hormonal intervention, or brain metastases)\n",
      "The presence of serious or uncontrolled infections;\",\n",
      "          \"Healthy Volunteers\":\"No\",\n",
      "          \"Gender\":\"All\",\n",
      "          \"Minimum Age\":\"18 Years\",\n",
      "          \"MaximumAge\":\"70 Years\",\n",
      "          \"Std Age List\":{\n",
      "            \"Std Age\":[\n",
      "              \"Adult\",\n",
      "              \"Older Adult\"\n",
      "            ]\n",
      "          }\n",
      "        },\n",
      "        \"Contacts Locations Module\":{\n",
      "          \"CentralContactList\":{\n",
      "            \"CentralContact\":[\n",
      "              {\n",
      "                \"CentralContactName\":\"Qingqing Cai\",\n",
      "                \"CentralContactRole\":\"Contact\",\n",
      "                \"CentralContactPhone\":\"0086-20-87342823\",\n",
      "                \"CentralContactEMail\":\"caiqq@sysucc.org.cn\"\n",
      "              },{\n",
      "                \"CentralContactName\":\"Qingqing Cai\",\n",
      "                \"CentralContactRole\":\"Contact\"\n",
      "              }\n",
      "            ]\n",
      "          },\n",
      "          \"Overall Official List\":{\n",
      "            \"Overall Official\":[\n",
      "              {\n",
      "                \"Overall OfficialName\":\"Qingqing Cai\",\n",
      "                \"Overall OfficialAffiliation\":\"Sun Yat-sen Universitiy Cancer Center, Sun Yat-Sen University,\",\n",
      "                \"Overall OfficialRole\":\"Principal Investigator\"\n",
      "              }\n",
      "            ]\n",
      "          },\n",
      "          \"Location List\":{\n",
      "            \"Location\":[\n",
      "              {\n",
      "                \"LocationFacility\":\"Sun Yat-sen Universitiy Cancer Center, Sun Yat-Sen University\",\n",
      "                \"LocationStatus\":\"Recruiting\",\n",
      "                \"LocationCity\":\"Guangzhou\",\n",
      "                \"LocationZip\":\"510030\",\n",
      "                \"LocationCountry\":\"China\",\n",
      "                \"LocationContactList\":{\n",
      "                  \"LocationContact\":[\n",
      "                    {\n",
      "                      \"LocationContactName\":\"Qingqing Cai\",\n",
      "                      \"LocationContactRole\":\"Contact\",\n",
      "                      \"LocationContactPhone\":\"18565617120\",\n",
      "                      \"LocationContactEMail\":\"18565617120@163.com\"\n",
      "                    }\n",
      "                  ]\n",
      "                }\n",
      "              }\n",
      "            ]\n",
      "          }\n",
      "        }\n",
      "      },\n",
      "      \"Derived Section\":{\n",
      "        \"Misc Info Module\":{\n",
      "          \"Version Holder\":\"May 19, 2023\"\n",
      "        },\n",
      "        \"Condition Browse Module\":{\n",
      "          \"Condition Mesh List\":{\n",
      "            \"Condition Mesh\":[\n",
      "              {\n",
      "                \"Condition MeshId\":\"D000002277\",\n",
      "                \"Condition MeshTerm\":\"Carcinoma\"\n",
      "              },{\n",
      "                \"Condition MeshId\":\"D000077274\",\n",
      "                \"Condition MeshTerm\":\"Nasopharyngeal Carcinoma\"\n",
      "              },{\n",
      "                \"Condition MeshId\":\"D000012008\",\n",
      "                \"Condition MeshTerm\":\"Recurrence\"\n",
      "              }\n",
      "            ]\n",
      "          },\n",
      "          \"Condition Ancestor List\":{\n",
      "            \"Condition Ancestor\":[\n",
      "              {\n",
      "                \"Condition AncestorId\":\"D000009375\",\n",
      "                \"Condition AncestorTerm\":\"Neoplasms, Glandular and Epithelial\"\n",
      "              },{\n",
      "                \"Condition AncestorId\":\"D000009370\",\n",
      "                \"Condition AncestorTerm\":\"Neoplasms by Histologic Type\"\n",
      "              },{\n",
      "                \"Condition AncestorId\":\"D000009369\",\n",
      "                \"Condition AncestorTerm\":\"Neoplasms\"\n",
      "              },{\n",
      "                \"Condition AncestorId\":\"D000020969\",\n",
      "                \"Condition AncestorTerm\":\"Disease Attributes\"\n",
      "              },{\n",
      "                \"Condition AncestorId\":\"D000010335\",\n",
      "                \"Condition AncestorTerm\":\"Pathologic Processes\"\n",
      "              },{\n",
      "                \"Condition AncestorId\":\"D000009303\",\n",
      "                \"Condition AncestorTerm\":\"Nasopharyngeal Neoplasms\"\n",
      "              },{\n",
      "                \"Condition AncestorId\":\"D000010610\",\n",
      "                \"Condition AncestorTerm\":\"Pharyngeal Neoplasms\"\n",
      "              },{\n",
      "                \"Condition AncestorId\":\"D000010039\",\n",
      "                \"Condition AncestorTerm\":\"Otorhinolaryngologic Neoplasms\"\n",
      "              },{\n",
      "                \"Condition AncestorId\":\"D000006258\",\n",
      "                \"Condition AncestorTerm\":\"Head and Neck Neoplasms\"\n",
      "              },{\n",
      "                \"Condition AncestorId\":\"D000009371\",\n",
      "                \"Condition AncestorTerm\":\"Neoplasms by Site\"\n",
      "              },{\n",
      "                \"Condition AncestorId\":\"D000009302\",\n",
      "                \"Condition AncestorTerm\":\"Nasopharyngeal Diseases\"\n",
      "              },{\n",
      "                \"Condition AncestorId\":\"D000010608\",\n",
      "                \"Condition AncestorTerm\":\"Pharyngeal Diseases\"\n",
      "              },{\n",
      "                \"Condition AncestorId\":\"D000009057\",\n",
      "                \"Condition AncestorTerm\":\"Stomatognathic Diseases\"\n",
      "              },{\n",
      "                \"Condition AncestorId\":\"D000010038\",\n",
      "                \"Condition AncestorTerm\":\"Otorhinolaryngologic Diseases\"\n",
      "              }\n",
      "            ]\n",
      "          },\n",
      "          \"Condition Browse Leaf List\":{\n",
      "            \"Condition Browse Leaf\":[\n",
      "              {\n",
      "                \"Condition Browse LeafId\":\"M4686\",\n",
      "                \"Condition Browse LeafName\":\"Carcinoma\",\n",
      "                \"Condition Browse LeafAsFound\":\"Carcinoma\",\n",
      "                \"Condition Browse LeafRelevance\":\"high\"\n",
      "              },{\n",
      "                \"Condition Browse LeafId\":\"M14002\",\n",
      "                \"Condition Browse LeafName\":\"Recurrence\",\n",
      "                \"Condition Browse LeafAsFound\":\"Recurrent\",\n",
      "                \"Condition Browse LeafRelevance\":\"high\"\n",
      "              },{\n",
      "                \"Condition Browse LeafId\":\"M1730\",\n",
      "                \"Condition Browse LeafName\":\"Nasopharyngeal Carcinoma\",\n",
      "                \"Condition Browse LeafAsFound\":\"Nasopharyngeal Carcinoma\",\n",
      "                \"Condition Browse LeafRelevance\":\"high\"\n",
      "              },{\n",
      "                \"Condition Browse LeafId\":\"M11472\",\n",
      "                \"Condition Browse LeafName\":\"Neoplasms, Glandular and Epithelial\",\n",
      "                \"Condition Browse LeafRelevance\":\"low\"\n",
      "              },{\n",
      "                \"Condition Browse LeafId\":\"M11467\",\n",
      "                \"Condition Browse LeafName\":\"Neoplasms by Histologic Type\",\n",
      "                \"Condition Browse LeafRelevance\":\"low\"\n",
      "              },{\n",
      "                \"Condition Browse LeafId\":\"M21853\",\n",
      "                \"Condition Browse LeafName\":\"Disease Attributes\",\n",
      "                \"Condition Browse LeafRelevance\":\"low\"\n",
      "              },{\n",
      "                \"Condition Browse LeafId\":\"M11406\",\n",
      "                \"Condition Browse LeafName\":\"Nasopharyngeal Neoplasms\",\n",
      "                \"Condition Browse LeafRelevance\":\"low\"\n",
      "              },{\n",
      "                \"Condition Browse LeafId\":\"M12669\",\n",
      "                \"Condition Browse LeafName\":\"Pharyngeal Neoplasms\",\n",
      "                \"Condition Browse LeafRelevance\":\"low\"\n",
      "              },{\n",
      "                \"Condition Browse LeafId\":\"M12114\",\n",
      "                \"Condition Browse LeafName\":\"Otorhinolaryngologic Neoplasms\",\n",
      "                \"Condition Browse LeafRelevance\":\"low\"\n",
      "              },{\n",
      "                \"Condition Browse LeafId\":\"M8500\",\n",
      "                \"Condition Browse LeafName\":\"Head and Neck Neoplasms\",\n",
      "                \"Condition Browse LeafRelevance\":\"low\"\n",
      "              },{\n",
      "                \"Condition Browse LeafId\":\"M11405\",\n",
      "                \"Condition Browse LeafName\":\"Nasopharyngeal Diseases\",\n",
      "                \"Condition Browse LeafRelevance\":\"low\"\n",
      "              },{\n",
      "                \"Condition Browse LeafId\":\"M12667\",\n",
      "                \"Condition Browse LeafName\":\"Pharyngeal Diseases\",\n",
      "                \"Condition Browse LeafRelevance\":\"low\"\n",
      "              },{\n",
      "                \"Condition Browse LeafId\":\"M11169\",\n",
      "                \"Condition Browse LeafName\":\"Stomatognathic Diseases\",\n",
      "                \"Condition Browse LeafRelevance\":\"low\"\n",
      "              },{\n",
      "                \"Condition Browse LeafId\":\"M12113\",\n",
      "                \"Condition Browse LeafName\":\"Otorhinolaryngologic Diseases\",\n",
      "                \"Condition Browse LeafRelevance\":\"low\"\n",
      "              },{\n",
      "                \"Condition Browse LeafId\":\"T4047\",\n",
      "                \"Condition Browse LeafName\":\"Nasopharyngeal Carcinoma\",\n",
      "                \"Condition Browse LeafAsFound\":\"Nasopharyngeal Carcinoma\",\n",
      "                \"Condition Browse LeafRelevance\":\"high\"\n",
      "              }\n",
      "            ]\n",
      "          },\n",
      "          \"Condition Browse Branch List\":{\n",
      "            \"Condition Browse Branch\":[\n",
      "              {\n",
      "                \"Condition Browse BranchAbbrev\":\"BC04\",\n",
      "                \"Condition Browse BranchName\":\"Neoplasms\"\n",
      "              },{\n",
      "                \"Condition Browse BranchAbbrev\":\"All\",\n",
      "                \"Condition Browse BranchName\":\"All Conditions\"\n",
      "              },{\n",
      "                \"Condition Browse BranchAbbrev\":\"BC23\",\n",
      "                \"Condition Browse BranchName\":\"Symptoms and General Pathology\"\n",
      "              },{\n",
      "                \"Condition Browse BranchAbbrev\":\"BC07\",\n",
      "                \"Condition Browse BranchName\":\"Mouth and Tooth Diseases\"\n",
      "              },{\n",
      "                \"Condition Browse BranchAbbrev\":\"BC09\",\n",
      "                \"Condition Browse BranchName\":\"Ear, Nose, and Throat Diseases\"\n",
      "              },{\n",
      "                \"Condition Browse BranchAbbrev\":\"Rare\",\n",
      "                \"Condition Browse BranchName\":\"Rare Diseases\"\n",
      "              }\n",
      "            ]\n",
      "          }\n",
      "        }\n",
      "      }\n",
      "    }\n",
      "  }\n",
      "}\n",
      "\n",
      "临床研究clinical trials，NCT04797182\n",
      "{\n",
      "  \"Full Study\":{\n",
      "    \"Rank\":82232,\n",
      "    \"Study\":{\n",
      "      \"Protocol Section\":{\n",
      "        \"Identification Module\":{\n",
      "          \"NCT Id\":\"NCT04797182\",\n",
      "          \"Org Study Id Info\":{\n",
      "            \"Org Study Id\":\"B2021-034\"\n",
      "          },\n",
      "          \"Organization\":{\n",
      "            \"Org Full Name\":\"Sun Yat-sen University\",\n",
      "            \"Org Class\":\"OTHER\"\n",
      "          },\n",
      "          \"Brief Title\":\"Avatrombopag for the Primary Prevention of Thrombocytopenia Induced by Cytarabine-based Chemotherapy in Patients With Lymphoma\",\n",
      "          \"Official Title\":\"Avatrombopag for the Primary Prevention of Thrombocytopenia Induced by Cytarabine-based Chemotherapy in Patients With Lymphoma: An Open, Single-center, Phase II Randomized Controlled Clinical Study\"\n",
      "        },\n",
      "        \"Status Module\":{\n",
      "          \"Status Verified Date\":\"March 2021\",\n",
      "          \"Overall Status\":\"Not yet recruiting\",\n",
      "          \"Expanded Access Info\":{\n",
      "            \"Has Expanded Access\":\"No\"\n",
      "          },\n",
      "          \"Start Date Struct\":{\n",
      "            \"Start Date\":\"April 2021\",\n",
      "            \"Start DateType\":\"Anticipated\"\n",
      "          },\n",
      "          \"Primary Completion Date Struct\":{\n",
      "            \"Primary Completion Date\":\"April 2023\",\n",
      "            \"Primary Completion DateType\":\"Anticipated\"\n",
      "          },\n",
      "          \"Completion Date Struct\":{\n",
      "            \"Completion Date\":\"July 2023\",\n",
      "            \"Completion DateType\":\"Anticipated\"\n",
      "          },\n",
      "          \"Study First Submit Date\":\"March 11, 2021\",\n",
      "          \"Study First Submit QC Date\":\"March 11, 2021\",\n",
      "          \"Study First Post Date Struct\":{\n",
      "            \"Study First Post Date\":\"March 15, 2021\",\n",
      "            \"Study First Post DateType\":\"Actual\"\n",
      "          },\n",
      "          \"Last Update Submit Date\":\"March 11, 2021\",\n",
      "          \"Last Update Post Date Struct\":{\n",
      "            \"Last Update Post Date\":\"March 15, 2021\",\n",
      "            \"Last Update Post DateType\":\"Actual\"\n",
      "          }\n",
      "        },\n",
      "        \"Sponsor Collaborators Module\":{\n",
      "          \"Responsible Party\":{\n",
      "            \"Responsible PartyType\":\"Principal Investigator\",\n",
      "            \"Responsible PartyInvestigatorFullName\":\"Qingqing Cai\",\n",
      "            \"Responsible PartyInvestigatorTitle\":\"Chief physician\",\n",
      "            \"Responsible PartyInvestigatorAffiliation\":\"Sun Yat-sen University\"\n",
      "          },\n",
      "          \"Lead Sponsor\":{\n",
      "            \"Lead SponsorName\":\"Sun Yat-sen University\",\n",
      "            \"Lead SponsorClass\":\"OTHER\"\n",
      "          }\n",
      "        },\n",
      "        \"Oversight Module\":{\n",
      "          \"Is FDA Regulated Drug\":\"No\",\n",
      "          \"Is FDA Regulated Device\":\"No\"\n",
      "        },\n",
      "        \"Description Module\":{\n",
      "          \"Brief Summary\":\"This phase 2 trial studies the efficacy and safety of Avatrombopag for the primary prevention of thrombocytopenia induced by cytarabine-based chemotherapy in patients with lymphoma\"\n",
      "        },\n",
      "        \"Conditions Module\":{\n",
      "          \"Condition List\":{\n",
      "            \"Condition\":[\n",
      "              \"Thrombocytopenia\",\n",
      "              \"Cytarabine Causing Adverse Effects in Therapeutic Use\",\n",
      "              \"Lymphoma\"\n",
      "            ]\n",
      "          }\n",
      "        },\n",
      "        \"Design Module\":{\n",
      "          \"Study Type\":\"Interventional\",\n",
      "          \"PhaseList\":{\n",
      "            \"Phase\":[\n",
      "              \"Phase 2\"\n",
      "            ]\n",
      "          },\n",
      "          \"Design Info\":{\n",
      "            \"DesignAllocation\":\"Randomized\",\n",
      "            \"DesignInterventionModel\":\"Single Group Assignment\",\n",
      "            \"DesignPrimaryPurpose\":\"Prevention\",\n",
      "            \"DesignMaskingInfo\":{\n",
      "              \"DesignMasking\":\"None (Open Label)\"\n",
      "            }\n",
      "          },\n",
      "          \"Enrollment Info\":{\n",
      "            \"Enrollment Count\":\"46\",\n",
      "            \"Enrollment Type\":\"Anticipated\"\n",
      "          }\n",
      "        },\n",
      "        \"Arms Interventions Module\":{\n",
      "          \"Arm Group List\":{\n",
      "            \"Arm Group\":[\n",
      "              {\n",
      "                \"Arm GroupLabel\":\"blank control\",\n",
      "                \"Arm GroupType\":\"Experimental\",\n",
      "                \"Arm GroupDescription\":\"No intervention aiming at preventing thrombocytopenia will be taken after first cycle. Avatrombopag as salvage treatment will be administered to patients suffering from thrombocytopenia with nadir platelet count < 50 × 109/L at a dose of 60mg/day until there is drug-withdrawal indication.\",\n",
      "                \"Arm GroupIntervention List\":{\n",
      "                  \"Arm GroupInterventionName\":[\n",
      "                    \"Drug: avatrombopag\"\n",
      "                  ]\n",
      "                }\n",
      "              },{\n",
      "                \"Arm GroupLabel\":\"primary prevention\",\n",
      "                \"Arm GroupType\":\"Experimental\",\n",
      "                \"Arm GroupDescription\":\"As the primary prevention of thrombocytopenia induced by cytarabine-based chemotherapy, Avatrombopag will be administered at a dose of 60mg/day on days -3~-1 and 3~9, for a total of 10 doses. On the condition that patients have platelet counts <50 × 10 9 /L before next cycle, Avatrombopag will be administered at a dose of 60mg/day until there is drug-withdrawal indications. Platelet transfusions were administered to patients when the platelet count was less than 10×109 /L.\n",
      "\n",
      "Drug-withdrawal indications:\n",
      "\n",
      "PLT ≥ 100×109/L during salvage treatment or platelet count increases by 50×109/L, comparing with baseline level.\n",
      "\n",
      "When platelet count is higher than 400×109/L during this study, researchers determine whether avatrombopag is discontinued\",\n",
      "                \"Arm GroupIntervention List\":{\n",
      "                  \"Arm GroupInterventionName\":[\n",
      "                    \"Drug: avatrombopag\"\n",
      "                  ]\n",
      "                }\n",
      "              }\n",
      "            ]\n",
      "          },\n",
      "          \"Intervention List\":{\n",
      "            \"Intervention\":[\n",
      "              {\n",
      "                \"InterventionType\":\"Drug\",\n",
      "                \"InterventionName\":\"avatrombopag\",\n",
      "                \"InterventionDescription\":\"avatrombopag,60 mg/d,po\",\n",
      "                \"InterventionArm GroupLabelList\":{\n",
      "                  \"InterventionArm GroupLabel\":[\n",
      "                    \"blank control\",\n",
      "                    \"primary prevention\"\n",
      "                  ]\n",
      "                }\n",
      "              }\n",
      "            ]\n",
      "          }\n",
      "        },\n",
      "        \"Outcomes Module\":{\n",
      "          \"Primary Outcome List\":{\n",
      "            \"Primary Outcome\":[\n",
      "              {\n",
      "                \"Primary Outcome Measure\":\"The incidence of grades III and IV thrombocytopenia\",\n",
      "                \"Primary OutcomeTimeFrame\":\"2 years\"\n",
      "              }\n",
      "            ]\n",
      "          },\n",
      "          \"Secondary Outcome List\":{\n",
      "            \"Secondary Outcome\":[\n",
      "              {\n",
      "                \"Secondary Outcome Measure\":\"The durations of any grade thrombocytopenia and grades II, III and IV thrombocytopenia\",\n",
      "                \"Secondary OutcomeTimeFrame\":\"2 years\"\n",
      "              }\n",
      "            ]\n",
      "          }\n",
      "        },\n",
      "        \"Eligibility Module\":{\n",
      "          \"Eligibility Criteria\":\"Inclusion Criteria:\n",
      "\n",
      "Histologically confirmed lymphoma;\n",
      "Patients are scheduled to receive cytarabine-based chemotherapy including Ara-C at dose of 4g/m2.\n",
      "Eastern Cooperative Oncology Group (ECOG) of 0-1;\n",
      "Proper functioning of the major organs: 1) The absolute value of neutrophils (>1.5×10^9/L); platelet count (> 100×10^9/L); Hemoglobin (> 90 g/L); 2) Serum total bilirubin < 1.5 times ULN; Aspartate Aminotransferase (AST), Alanine Aminotransferase (ALT) < 3 times ULN;3) Serum creatinine <1.5 times Upper Limit Normal (ULN) ; 4) Coagulation function: International Normalized Ratio (INR), Prothrombin Time (PT)< 1.5 times ULN\n",
      "Able to use oral drugs\n",
      "Patients volunteer to sign an informed consent\n",
      "Life expectancy > 3 months;\n",
      "Contraceptives are used\n",
      "\n",
      "Exclusion Criteria:\n",
      "\n",
      "Thrombocytopenia unrelated to chemotherapy during six months before screening, including but not limited to hypersplenism, infection and hemorrhage.\n",
      "In addtion to CIT caused by lymphoma and chemotherapy,patients also suffer from other blood diseases including ALL, AML, myeloid neoplasms, MDS, myeloproliferative disorders, MM;\n",
      "A thrombosis of a coronary artery or vein developed during three months before screening;\n",
      "Haemorrhage with severe clinical symptoms, such as gastrointestinal and cerebral hemorrhage;\n",
      "Platelet transfusion during two days before randomization;\n",
      "Allergic to avatrombopag;\n",
      "Participation in any other research about novel agents or devices;\n",
      "Pregnant or breastfeeding women;\n",
      "Researchers consider it unsuitable for patients to participate in this study.\",\n",
      "          \"Healthy Volunteers\":\"No\",\n",
      "          \"Gender\":\"All\",\n",
      "          \"Minimum Age\":\"18 Years\",\n",
      "          \"MaximumAge\":\"70 Years\",\n",
      "          \"Std Age List\":{\n",
      "            \"Std Age\":[\n",
      "              \"Adult\",\n",
      "              \"Older Adult\"\n",
      "            ]\n",
      "          }\n",
      "        },\n",
      "        \"Contacts Locations Module\":{\n",
      "          \"CentralContactList\":{\n",
      "            \"CentralContact\":[\n",
      "              {\n",
      "                \"CentralContactName\":\"Qingqing Cai, MD\",\n",
      "                \"CentralContactRole\":\"Contact\",\n",
      "                \"CentralContactPhone\":\"0086-20-87342823\",\n",
      "                \"CentralContactEMail\":\"caiqq@sysucc.org.cn\"\n",
      "              },{\n",
      "                \"CentralContactName\":\"Cai\",\n",
      "                \"CentralContactRole\":\"Contact\"\n",
      "              }\n",
      "            ]\n",
      "          },\n",
      "          \"Overall Official List\":{\n",
      "            \"Overall Official\":[\n",
      "              {\n",
      "                \"Overall OfficialName\":\"Qingqing Cai, MD\",\n",
      "                \"Overall OfficialAffiliation\":\"Sun Yat-sen University\",\n",
      "                \"Overall OfficialRole\":\"Principal Investigator\"\n",
      "              }\n",
      "            ]\n",
      "          },\n",
      "          \"Location List\":{\n",
      "            \"Location\":[\n",
      "              {\n",
      "                \"LocationFacility\":\"Sun Yat-sen University Cancer Center\",\n",
      "                \"LocationCity\":\"Guangzhou\",\n",
      "                \"LocationState\":\"Guangdong\",\n",
      "                \"LocationZip\":\"510060\",\n",
      "                \"LocationCountry\":\"China\",\n",
      "                \"LocationContactList\":{\n",
      "                  \"LocationContact\":[\n",
      "                    {\n",
      "                      \"LocationContactName\":\"Qingqing Cai, MD\",\n",
      "                      \"LocationContactRole\":\"Contact\"\n",
      "                    }\n",
      "                  ]\n",
      "                }\n",
      "              }\n",
      "            ]\n",
      "          }\n",
      "        }\n",
      "      },\n",
      "      \"Derived Section\":{\n",
      "        \"Misc Info Module\":{\n",
      "          \"Version Holder\":\"May 19, 2023\"\n",
      "        },\n",
      "        \"Condition Browse Module\":{\n",
      "          \"Condition Mesh List\":{\n",
      "            \"Condition Mesh\":[\n",
      "              {\n",
      "                \"Condition MeshId\":\"D000008223\",\n",
      "                \"Condition MeshTerm\":\"Lymphoma\"\n",
      "              },{\n",
      "                \"Condition MeshId\":\"D000013921\",\n",
      "                \"Condition MeshTerm\":\"Thrombocytopenia\"\n",
      "              }\n",
      "            ]\n",
      "          },\n",
      "          \"Condition Ancestor List\":{\n",
      "            \"Condition Ancestor\":[\n",
      "              {\n",
      "                \"Condition AncestorId\":\"D000009370\",\n",
      "                \"Condition AncestorTerm\":\"Neoplasms by Histologic Type\"\n",
      "              },{\n",
      "                \"Condition AncestorId\":\"D000009369\",\n",
      "                \"Condition AncestorTerm\":\"Neoplasms\"\n",
      "              },{\n",
      "                \"Condition AncestorId\":\"D000008232\",\n",
      "                \"Condition AncestorTerm\":\"Lymphoproliferative Disorders\"\n",
      "              },{\n",
      "                \"Condition AncestorId\":\"D000008206\",\n",
      "                \"Condition AncestorTerm\":\"Lymphatic Diseases\"\n",
      "              },{\n",
      "                \"Condition AncestorId\":\"D000007160\",\n",
      "                \"Condition AncestorTerm\":\"Immunoproliferative Disorders\"\n",
      "              },{\n",
      "                \"Condition AncestorId\":\"D000007154\",\n",
      "                \"Condition AncestorTerm\":\"Immune System Diseases\"\n",
      "              },{\n",
      "                \"Condition AncestorId\":\"D000001791\",\n",
      "                \"Condition AncestorTerm\":\"Blood Platelet Disorders\"\n",
      "              },{\n",
      "                \"Condition AncestorId\":\"D000006402\",\n",
      "                \"Condition AncestorTerm\":\"Hematologic Diseases\"\n",
      "              }\n",
      "            ]\n",
      "          },\n",
      "          \"Condition Browse Leaf List\":{\n",
      "            \"Condition Browse Leaf\":[\n",
      "              {\n",
      "                \"Condition Browse LeafId\":\"M10372\",\n",
      "                \"Condition Browse LeafName\":\"Lymphoma\",\n",
      "                \"Condition Browse LeafAsFound\":\"Lymphoma\",\n",
      "                \"Condition Browse LeafRelevance\":\"high\"\n",
      "              },{\n",
      "                \"Condition Browse LeafId\":\"M15832\",\n",
      "                \"Condition Browse LeafName\":\"Thrombocytopenia\",\n",
      "                \"Condition Browse LeafAsFound\":\"Thrombocytopenia\",\n",
      "                \"Condition Browse LeafRelevance\":\"high\"\n",
      "              },{\n",
      "                \"Condition Browse LeafId\":\"M11467\",\n",
      "                \"Condition Browse LeafName\":\"Neoplasms by Histologic Type\",\n",
      "                \"Condition Browse LeafRelevance\":\"low\"\n",
      "              },{\n",
      "                \"Condition Browse LeafId\":\"M10377\",\n",
      "                \"Condition Browse LeafName\":\"Lymphoproliferative Disorders\",\n",
      "                \"Condition Browse LeafRelevance\":\"low\"\n",
      "              },{\n",
      "                \"Condition Browse LeafId\":\"M10355\",\n",
      "                \"Condition Browse LeafName\":\"Lymphatic Diseases\",\n",
      "                \"Condition Browse LeafRelevance\":\"low\"\n",
      "              },{\n",
      "                \"Condition Browse LeafId\":\"M9358\",\n",
      "                \"Condition Browse LeafName\":\"Immunoproliferative Disorders\",\n",
      "                \"Condition Browse LeafRelevance\":\"low\"\n",
      "              },{\n",
      "                \"Condition Browse LeafId\":\"M9352\",\n",
      "                \"Condition Browse LeafName\":\"Immune System Diseases\",\n",
      "                \"Condition Browse LeafRelevance\":\"low\"\n",
      "              },{\n",
      "                \"Condition Browse LeafId\":\"M4224\",\n",
      "                \"Condition Browse LeafName\":\"Blood Platelet Disorders\",\n",
      "                \"Condition Browse LeafRelevance\":\"low\"\n",
      "              },{\n",
      "                \"Condition Browse LeafId\":\"M8642\",\n",
      "                \"Condition Browse LeafName\":\"Hematologic Diseases\",\n",
      "                \"Condition Browse LeafRelevance\":\"low\"\n",
      "              },{\n",
      "                \"Condition Browse LeafId\":\"T3543\",\n",
      "                \"Condition Browse LeafName\":\"Lymphosarcoma\",\n",
      "                \"Condition Browse LeafAsFound\":\"Lymphoma\",\n",
      "                \"Condition Browse LeafRelevance\":\"high\"\n",
      "              }\n",
      "            ]\n",
      "          },\n",
      "          \"Condition Browse Branch List\":{\n",
      "            \"Condition Browse Branch\":[\n",
      "              {\n",
      "                \"Condition Browse BranchAbbrev\":\"BC04\",\n",
      "                \"Condition Browse BranchName\":\"Neoplasms\"\n",
      "              },{\n",
      "                \"Condition Browse BranchAbbrev\":\"BC15\",\n",
      "                \"Condition Browse BranchName\":\"Blood and Lymph Conditions\"\n",
      "              },{\n",
      "                \"Condition Browse BranchAbbrev\":\"BC20\",\n",
      "                \"Condition Browse BranchName\":\"Immune System Diseases\"\n",
      "              },{\n",
      "                \"Condition Browse BranchAbbrev\":\"All\",\n",
      "                \"Condition Browse BranchName\":\"All Conditions\"\n",
      "              },{\n",
      "                \"Condition Browse BranchAbbrev\":\"Rare\",\n",
      "                \"Condition Browse BranchName\":\"Rare Diseases\"\n",
      "              }\n",
      "            ]\n",
      "          }\n",
      "        },\n",
      "        \"Intervention Browse Module\":{\n",
      "          \"Intervention Browse Leaf List\":{\n",
      "            \"Intervention Browse Leaf\":[\n",
      "              {\n",
      "                \"Intervention Browse LeafId\":\"M5918\",\n",
      "                \"Intervention Browse LeafName\":\"Cytarabine\",\n",
      "                \"Intervention Browse LeafRelevance\":\"low\"\n",
      "              }\n",
      "            ]\n",
      "          },\n",
      "          \"Intervention Browse Branch List\":{\n",
      "            \"Intervention Browse Branch\":[\n",
      "              {\n",
      "                \"Intervention Browse BranchAbbrev\":\"Infe\",\n",
      "                \"Intervention Browse BranchName\":\"Anti-Infective Agents\"\n",
      "              },{\n",
      "                \"Intervention Browse BranchAbbrev\":\"ANeo\",\n",
      "                \"Intervention Browse BranchName\":\"Antineoplastic Agents\"\n",
      "              },{\n",
      "                \"Intervention Browse BranchAbbrev\":\"All\",\n",
      "                \"Intervention Browse BranchName\":\"All Drugs and Chemicals\"\n",
      "              }\n",
      "            ]\n",
      "          }\n",
      "        }\n",
      "      }\n",
      "    }\n",
      "  }\n",
      "}\n",
      "\n",
      "临床专家\n",
      "性别：女\n",
      "首页 /临床科室 /内科系列 /内科 /临床专家\n",
      "蔡清清\n",
      "职务：科副主任\n",
      "职称：教授，主任医师，博士生导师，淋巴瘤中心主诊教授\n",
      "专长\n",
      "擅长恶性淋巴瘤和头颈癌（鼻咽癌等）的诊治及恶性肿瘤的造血干细胞移植治疗。\n",
      " \n",
      "\n",
      " \n",
      "\n",
      "姓名：蔡清清\n",
      "\n",
      " \n",
      "\n",
      "职称：内科教授，主任医师，博士生导师，淋巴瘤中心主诊教授\n",
      "专长：主要擅长恶性淋巴瘤和头颈癌（鼻咽癌等）的诊治及恶性肿瘤的造血干细胞移植治疗\n",
      "出诊时间：周一上午特需门诊，周一下午、周四上午专家门诊\n",
      "学术兼职：广东省抗癌协会血液肿瘤专业 委员，秘书；广东省抗癌协会血液肿瘤专业委员会青年委员会副主任委员；中华医学会肿瘤学分会青年委员会副主任委员，广东省女医师协会淋巴瘤专业委员会副主任委员，广东省抗癌协会化疗专业委员会委员，广东省抗癌协会淋巴瘤专业委员会 委员，广州市抗癌协会淋巴瘤专业委员会 常委\n",
      "个人简介：蔡清清教授现任中山大学肿瘤防治中心内科教授，主任医师，博士生导师，淋巴瘤中心主诊教授，中华医学会肿瘤学分会青年委员会副主委，广东省女医师协会淋巴瘤专业委员会副主委，CSCO淋巴瘤联盟专家委员会委员，广东省抗癌协会血液肿瘤专业委员会秘书、委员，广东省抗癌协会血液肿瘤专业委员会青年委员会副主委，广东省抗癌协会淋巴瘤专业委员会委员，广东省抗癌协会化疗专业委员会委员。2013-2014年在美国M.D.Anderson肿瘤中心进修。研究方向淋巴瘤和头颈癌（鼻咽癌），主持多项国家、地方政府及企事业单位项目，其中2项国家自然科学基金面上项目，1项国家自然科学青年基金项目，已在国际著名期刊发表论文40余篇，其中以第一作者和通讯作者发表20余篇，最高影响因子10.199分。培养及正在培养的博士及硕士研究生9名。获第一批广东省杰出青年医学人才，羊城好医生及广东医院最强科室实力中青年医生称号。\n",
      "加载更多\n",
      "\n",
      "蔡清清的代表性文章、成果：\n",
      "1）Cai Q, Tu M, Xu-Monette ZY, Sun R, Manyam GC, Xu X, Tzankov A, Hsi ED, Møller MB, Medeiros LJ, Ok CY, Young KH. NF-κB p50 activation associated with immune dysregulation confers poorer survival for diffuse large B-cell lymphoma patients with wild-type p53. Mod Pathol. 2017 Mar 10. doi: 10.1038/modpathol.2017.5. [Epub ahead of print] （IF=5.485）\n",
      "2）Qian D, Chen K, Deng H, Rao H, Huang H, Liao Y, Sun X, Lu S, Yuan Z, Xie D, Cai Q (corresponding author). MicroRNA-374b Suppresses Proliferation and Promotes Apoptosis in T-cell Lymphoblastic Lymphoma by Repressing AKT1 and Wnt-16. Clin Cancer Res. 2015 Jun 22. [Epub ahead of print] （IF=9.6）\n",
      "3）Chen K, Liu Y, Li W, Chen J, Gu Y, Geng Q, Jiang W, Huang H, Lin T, Xia Z, Cai Q (corresponding author). The prognostic nutritional index predicts survival for patients with extranodal natural killer/T cell lymphoma, nasal type. Ann Hematol. 2015 Aug;94(8):1389-400. （IF=3.083）\n",
      "4）Cai Q, Luo X, Zhang G, Huang H, Huang H, Lin T, Jiang W, Xia Z, Young KH. New prognostic model for extranodal natural killer/T cell lymphoma, nasal type. Ann Hematol. 2014 Sep;93(9):1541-9. （IF=3.083）\n",
      "5）Cai Q, Luo X, Liang Y, Rao H, Fang X, Jiang W, Lin T, Lin T, Huang H. Fasting blood glucose is a novel prognostic indicator for extranodal natural killer/T-cell lymphoma, nasal type. British Journal of Cancer. 2013,108(2):380-386（IF=5.569）\n",
      "6.）Cai Q, Deng H, Xie D, Lin T, Lin T. Phosphorylated AKT Protein Is Overexpressed in Human Peripheral T-cell Lymphomas and Predicts Decreased Patient Survival. Clin Lymphoma Myeloma Leuk. 2012;12(2):106-12. （IF=2.316）\n",
      "7）Cai Q, Chen K, Chen J, Wu S, Geng Q, Huang H, Lin T, Jiang W, Xia Z, Duan H, Rao H, Yao M, Hu L. The Effect of Prophylactic Lamivudine plus Adefovir Therapy Compared with Lamivudine Alone in Preventing Hepatitis B Reactivation in Lymphoma Patients with High Baseline HBV DNA during Chemotherapy. PLoS One. 2016 Oct 6;11(10):e0164210. doi: 10.1371/journal.pone.0164210. eCollection 2016. （IF=3.057）\n",
      "8）Cai Q, Hu L, Geng Q, Chen J, Lu Z, Rao H, Liu Q, Jiang W, Huang H, Lin T, Xia Z. New risk  factors and new tendency for central nervous system relapse in patients with diffuse large  B-cell lymphoma: a retrospective study. Chin J Cancer. 2016 Sep 13;35(1):87. doi:  10.1186/s40880-016-0150-y. （IF=4.111）\n",
      "9）Cai Q, Medeiros LJ, Xu X, Young KH. MYC-driven aggressive B-cell lymphomas: biology, entity, differential diagnosis and clinical management [Review]. Oncotarget. 2015. （IF=5.008）\n",
      "10）Chen K, Chen J, Rao H, Guo Y, Huang H, Zhang L, Shao J, Lin T, Jiang W, Zou D, Hu L, Wirian M, Cai Q (corresponding author). Hepatitis B virus reactivation and hepatitis in diffuse large B-cell lymphoma patients with resolved hepatitis B receiving rituximab-containing chemotherapy: riskfactors and survival. Chin J Cancer. 2015 May 28;34(5):225-34. （IF=4.111）\n",
      "11）Cai Q, Chen Y, Zou D, Zhang L, Badillo M, Zhou S, Lopez E, Jiang W, HuangH, Lin T, Romaguera J, Wang M. Clinical outcomes of a novel combination of lenalidomide and rituximab followed by stem cell transplantation for relapsed/refractory aggressive B-cell non-hodgkin lymphoma. Oncotarget. 2014 Sep 15;5(17):7368-809（IF=5.008）\n",
      "12）Cai Q, Westin J, Fu K, Desai M, Zhang L, Huang H, Jiang W, Liang R, Qian Z, Champlin RE, Wang M. Accelerated therapeutic progress in diffuse large B cell lymphoma [Review]. Ann Hematol. 2014 Apr;93(4):541-56. （IF=3.083）\n",
      "13）Cai Q, Huang H, Qian D, Chen K, Luo J, Tian Y, Lin T, LinT. 13-Methyltetradecanoic Acid Exhibits Anti-Tumor Activity on T-Cell Lymphomas In Vitro and In Vivo by Down-Regulating p-AKT and ActivatingCaspase-3.PLoS One. 2013 Jun 7;8(6):e65308.（IF=3.057）\n",
      "14） Huang H, Cai Q (co-first author) , Lin T, Lin X, Liu Y, Gao Y, Peng R.   Lamivudine for the prevention of hepatitis B virus reactivation after high-dose chemotherapy and autologous hematopoietic stem cell transplantation for patients with advanced or relapsed non-Hodgkin's lymphoma single institution experience. Expert Opin Pharmacother. 2009;10(15):2399-406. （IF=3.543）\n",
      "15） Cai Q, Huang H, Sun X, Xia Z, Li Y, Lin X, Guo Y. Efficacy and safety of transdermal fentanyl for treatment of oral mucositis pain caused by chemotherapy. Expert Opin Pharmacother. 2008;9(18):3137-44. （IF=3.543）\n",
      "\n",
      "    ---------\n",
      "\n",
      "2023-06-14 14:42:35,574 - common.py - [line]:33 - INFO - real_query:\n",
      "    Notice: If doctor or hospital not in the context, skip this one 假如你是数据工程师，请把如下个人信息按照JSON的格式整理给我：（参考字段：行医，门诊时间，综合评价，资质认证状态，基本信息，简介，姓名，医院/机构，专长，职务，职称，学术兼职，地区，邮箱，手机，昕康ID/XK_ID，履历，教育经历，工作经历，研究，研究方向/临床研究，课题/基金，发表，发表文章，出版著作，专利和软著，执笔共识，成就，荣誉获奖）Return only the translation and nothing else:\n",
      "\n",
      "    query:\n",
      "    请根据以下context，回答：蔡清清的专长\n",
      "    reply in 简体中文\n",
      "    ---------context\n",
      "    \n",
      "    临床研究clinical trials，NCT05572983\n",
      "{\n",
      "  \"Full Study\":{\n",
      "    \"Rank\":22633,\n",
      "    \"Study\":{\n",
      "      \"Protocol Section\":{\n",
      "        \"Identification Module\":{\n",
      "          \"NCT Id\":\"NCT05572983\",\n",
      "          \"Org Study Id Info\":{\n",
      "            \"Org Study Id\":\"SL-B2022-485-02\"\n",
      "          },\n",
      "          \"Organization\":{\n",
      "            \"Org Full Name\":\"Sun Yat-sen University\",\n",
      "            \"Org Class\":\"OTHER\"\n",
      "          },\n",
      "          \"Brief Title\":\"Phase Ⅱ Study of Chidamide in Combination With CHOP in Previously Untreated Peripheral T-Cell Lymphoma With Follicular Helper of T Cell Phenotype\",\n",
      "          \"Official Title\":\"Phase Ⅱ Study of Chidamide in Combination With CHOP in Previously Untreated Peripheral T-Cell Lymphoma With Follicular Helper of T Cell Phenotype （SWIFT）\"\n",
      "        },\n",
      "        \"Status Module\":{\n",
      "          \"Status Verified Date\":\"September 2022\",\n",
      "          \"Overall Status\":\"Recruiting\",\n",
      "          \"Expanded Access Info\":{\n",
      "            \"Has Expanded Access\":\"No\"\n",
      "          },\n",
      "          \"Start Date Struct\":{\n",
      "            \"Start Date\":\"September 1, 2022\",\n",
      "            \"Start DateType\":\"Actual\"\n",
      "          },\n",
      "          \"Primary Completion Date Struct\":{\n",
      "            \"Primary Completion Date\":\"September 1, 2024\",\n",
      "            \"Primary Completion DateType\":\"Anticipated\"\n",
      "          },\n",
      "          \"Completion Date Struct\":{\n",
      "            \"Completion Date\":\"September 1, 2026\",\n",
      "            \"Completion DateType\":\"Anticipated\"\n",
      "          },\n",
      "          \"Study First Submit Date\":\"September 30, 2022\",\n",
      "          \"Study First Submit QC Date\":\"October 7, 2022\",\n",
      "          \"Study First Post Date Struct\":{\n",
      "            \"Study First Post Date\":\"October 10, 2022\",\n",
      "            \"Study First Post DateType\":\"Actual\"\n",
      "          },\n",
      "          \"Last Update Submit Date\":\"October 7, 2022\",\n",
      "          \"Last Update Post Date Struct\":{\n",
      "            \"Last Update Post Date\":\"October 10, 2022\",\n",
      "            \"Last Update Post DateType\":\"Actual\"\n",
      "          }\n",
      "        },\n",
      "        \"Sponsor Collaborators Module\":{\n",
      "          \"Responsible Party\":{\n",
      "            \"Responsible PartyType\":\"Principal Investigator\",\n",
      "            \"Responsible PartyInvestigatorFullName\":\"Qingqing Cai\",\n",
      "            \"Responsible PartyInvestigatorTitle\":\"Chief physician\",\n",
      "            \"Responsible PartyInvestigatorAffiliation\":\"Sun Yat-sen University\"\n",
      "          },\n",
      "          \"Lead Sponsor\":{\n",
      "            \"Lead SponsorName\":\"Sun Yat-sen University\",\n",
      "            \"Lead SponsorClass\":\"OTHER\"\n",
      "          }\n",
      "        },\n",
      "        \"Oversight Module\":{\n",
      "          \"Is FDA Regulated Drug\":\"No\",\n",
      "          \"Is FDA Regulated Device\":\"No\"\n",
      "        },\n",
      "        \"Description Module\":{\n",
      "          \"Brief Summary\":\"This is a prospective, open-label, single arm, multicenter clinical study to evaluate the safety, tolerability, efficacy of chidamide in combination with CHOP in previously untreated peripheral T-cell lymphoma with follicular helper of T cell phenotype\"\n",
      "        },\n",
      "        \"Conditions Module\":{\n",
      "          \"Condition List\":{\n",
      "            \"Condition\":[\n",
      "              \"Peripheral T-Cell Lymphoma With Follicular Helper of T Cell Phenotype\"\n",
      "            ]\n",
      "          }\n",
      "        },\n",
      "        \"Design Module\":{\n",
      "          \"Study Type\":\"Interventional\",\n",
      "          \"PhaseList\":{\n",
      "            \"Phase\":[\n",
      "              \"Phase 2\"\n",
      "            ]\n",
      "          },\n",
      "          \"Design Info\":{\n",
      "            \"DesignAllocation\":\"N/A\",\n",
      "            \"DesignInterventionModel\":\"Single Group Assignment\",\n",
      "            \"DesignPrimaryPurpose\":\"Treatment\",\n",
      "            \"DesignMaskingInfo\":{\n",
      "              \"DesignMasking\":\"None (Open Label)\"\n",
      "            }\n",
      "          },\n",
      "          \"Enrollment Info\":{\n",
      "            \"Enrollment Count\":\"47\",\n",
      "            \"Enrollment Type\":\"Anticipated\"\n",
      "          }\n",
      "        },\n",
      "        \"Arms Interventions Module\":{\n",
      "          \"Arm Group List\":{\n",
      "            \"Arm Group\":[\n",
      "              {\n",
      "                \"Arm GroupLabel\":\"Chidamide in Combination With CHOP\",\n",
      "                \"Arm GroupType\":\"Experimental\",\n",
      "                \"Arm GroupDescription\":\"Patients with previously untreated peripheral T-cell lymphoma with follicular helper of T cell phenotype will receive chidamide in combination with CHOP for 6 cycles (planned) (21 days per cycle). After 6 cycles of induction therapy, if complete remission (CR) was achieved, maintenance treatment with chidamide will be continued for two years.\",\n",
      "                \"Arm GroupIntervention List\":{\n",
      "                  \"Arm GroupInterventionName\":[\n",
      "                    \"Drug: Chidamide combined with CHOP\",\n",
      "                    \"Drug: Chidamide\"\n",
      "                  ]\n",
      "                }\n",
      "              }\n",
      "            ]\n",
      "          },\n",
      "          \"Intervention List\":{\n",
      "            \"Intervention\":[\n",
      "              {\n",
      "                \"InterventionType\":\"Drug\",\n",
      "                \"InterventionName\":\"Chidamide combined with CHOP\",\n",
      "                \"InterventionDescription\":\"A)Chidamide: 20mg, D1, 4,8,11, po; B) Cyclophosphamide: 750 mg/ m2, D1, iv.drip; C) Doxorubicin: 50 mg/ m2, D1, iv.drip (or epirubicin 70 mg/ m2, D1, iv.drip); D) Vincristine: 1.4 mg/ m2, D1 (maximum dose 2mg, maximum dose 1.5mg for age over 70 years), iv; E) Prednisone: 40mg/m2, D1-5,po\",\n",
      "                \"InterventionArm GroupLabelList\":{\n",
      "                  \"InterventionArm GroupLabel\":[\n",
      "                    \"Chidamide in Combination With CHOP\"\n",
      "                  ]\n",
      "                },\n",
      "                \"InterventionOtherNameList\":{\n",
      "                  \"InterventionOtherName\":[\n",
      "                    \"Induction treatment\"\n",
      "                  ]\n",
      "                }\n",
      "              },{\n",
      "                \"InterventionType\":\"Drug\",\n",
      "                \"InterventionName\":\"Chidamide\",\n",
      "                \"InterventionDescription\":\"Chidamide: 20mg，qw（d1,d4）,po\",\n",
      "                \"InterventionArm GroupLabelList\":{\n",
      "                  \"InterventionArm GroupLabel\":[\n",
      "                    \"Chidamide in Combination With CHOP\"\n",
      "                  ]\n",
      "                },\n",
      "                \"InterventionOtherNameList\":{\n",
      "                  \"InterventionOtherName\":[\n",
      "                    \"Maintenance treatment\"\n",
      "                  ]\n",
      "                }\n",
      "              }\n",
      "            ]\n",
      "          }\n",
      "        },\n",
      "        \"Outcomes Module\":{\n",
      "          \"Primary Outcome List\":{\n",
      "            \"Primary Outcome\":[\n",
      "              {\n",
      "                \"Primary Outcome Measure\":\"Complete remission rate\",\n",
      "                \"Primary OutcomeDescription\":\"Complete remission rate will be determined on the basis of investigator assessments according to 2014 Lugano criteria.\",\n",
      "                \"Primary OutcomeTimeFrame\":\"Up to 18 weeks\"\n",
      "              }\n",
      "            ]\n",
      "          },\n",
      "          \"Secondary Outcome List\":{\n",
      "            \"Secondary Outcome\":[\n",
      "              {\n",
      "                \"Secondary Outcome Measure\":\"Objective response rate\",\n",
      "                \"Secondary OutcomeDescription\":\"Objective Response rate will be determined on the basis of investigator assessments according to 2014 Lugano criteria.\",\n",
      "                \"Secondary OutcomeTimeFrame\":\"Up to 18 weeks\"\n",
      "              },{\n",
      "                \"Secondary Outcome Measure\":\"Partial remission rate\",\n",
      "                \"Secondary OutcomeDescription\":\"Partial remission rate will be determined on the basis of investigator assessments according to 2014 Lugano criteria.\",\n",
      "                \"Secondary OutcomeTimeFrame\":\"Up to 18 weeks\"\n",
      "              },{\n",
      "                \"Secondary Outcome Measure\":\"Progression-free survival（PFS）\",\n",
      "                \"Secondary OutcomeDescription\":\"To investigate the preliminary antitumor efficacy\",\n",
      "                \"Secondary OutcomeTimeFrame\":\"From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 24 months\"\n",
      "              },{\n",
      "                \"Secondary Outcome Measure\":\"Overall survival\",\n",
      "                \"Secondary OutcomeDescription\":\"To investigate the preliminary antitumor efficacy\",\n",
      "                \"Secondary OutcomeTimeFrame\":\"From date of randomization until the date of death from any cause, assessed up to 24 months\"\n",
      "              },{\n",
      "                \"Secondary Outcome Measure\":\"Recurrence free survival\",\n",
      "                \"Secondary OutcomeDescription\":\"To investigate the preliminary antitumor efficacy\",\n",
      "                \"Secondary OutcomeTimeFrame\":\"From date of randomization until the date ofthe occurrence of relapse or last visit, assessed up to 24 months\"\n",
      "              },{\n",
      "                \"Secondary Outcome Measure\":\"Number of participants with adverse events (AE) and severe adverse events (SAE) as assessed by CTCAE v5.0\",\n",
      "                \"Secondary OutcomeDescription\":\"To identify the incidence of AE and SAE\",\n",
      "                \"Secondary OutcomeTimeFrame\":\"Up to 18 weeks\"\n",
      "              }\n",
      "            ]\n",
      "          }\n",
      "        },\n",
      "        \"Eligibility Module\":{\n",
      "          \"Eligibility Criteria\":\"Inclusion Criteria:\n",
      "\n",
      "Age ≥18 years old and ≤75 years old, male and female;\n",
      "Peripheral T-Cell lymphoma with follicular helper of T cell phenotype confirmed by histopathology at the study center, including: ① Angioimmunoblastic T-cell lymphoma (AITL), ②follicular T-cell lymphoma (FTCL), and ③ other nodal PTCL with TFH phenotype;\n",
      "Never received chemotherapy, radiotherapy, immunological and biological therapy for lymphoma before;\n",
      "Autologous stem cell transplantation is not suitable or the patient refused to accept autologous stem cell transplantation;\n",
      "There must be at least one measurable or evaluable lesion that meets the evaluation criteria for Lugano 2014 lymphoma: measurable lesion: Positron emission tomography / computed tomography (PET/CT) or CT and/or MRI, intranode lesions with long diameter >1.5cm, short diameter >1.0cm, or exnode lesions with long diameter > 1.0 cm; PET CT examination of the lesion showing increased uptake in lymph nodes or extranodal areas (higher than liver) and imaging features consistent with lymphoma can be evaluated.\n",
      "Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) 0-2；\n",
      "Expected survival ≥ 3 months;\n",
      "\n",
      "The following required baseline laboratory data:\n",
      "\n",
      ".White blood cell，WBC≥3.0×109/L(Bone marrow invasive patient≥2.0×109/L), Absolute neutrophil count，ANC ≥1.5×109/L, （Bone marrow invasive patient≥1.0×109/L), Platelet count (PLT) ≥75×109/L, （Bone marrow invasive patient≥50×109/L) ，Hemoglobin (HB)≥ 80g/L;\n",
      ".Total bilirubin (TBIL) ≤1.5×upper limit of normal (ULN) (The liver invasion ≤3.0×ULN), Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤2.5×ULN（The liver invasion≤5.0×ULN）\n",
      ".Renal function：creatinine, Cr≤1.5×ULN\n",
      ".Coagulation function： International Normalized Ratio (INR)≤1.5 ×ULN； Prothrombin Time (PT)、Activated Partial Thromboplastin Time (APTT)≤1.5×ULN（Unless the patient is receiving anticoagulant therapy and PT and APTT are within the expected range at screening time）；\n",
      ".Thyroid stimulating hormone (TSH) or free thyroid hormone (FT4) or free triiodothyronine (FT3) were within 10% of normal value (note: abnormal TSH caused by non-autoimmune causes can be included in the group);\n",
      "Subjects fully understand and voluntarily participate in this study and sign informed consent\n",
      "\n",
      "Exclusion Criteria:\n",
      "\n",
      "A history of other malignant tumors within the past 5 years; Or other tumors (except basal cell carcinoma of the skin)\n",
      "Patients with significant vital organ dysfunction;\n",
      "Patients with active bleeding or newly developed thrombotic disease, and patients who are taking anticoagulants and having a bleeding tendency;\n",
      "Patients with a known history of Human Immunodeficiency Virus (HIV) infection and/or acquired Immunodeficiency syndrome;\n",
      "Patients with active chronic hepatitis B or active hepatitis C. Patients who are hepatitis B surface antigen (HBsAg) or hepatitis B core antibody (HBcAb) or hepatitis C virus (HCV) antibody positive during the screening period require further testing for Hepatitis B Virus (HBV) DNA and HCV RNA. If HBV DNA is no more than 2500 copies /mL or 500 IU/mL and HCV RNA is no more than the lower limit of the assay, enrollment will be allowed after exclusion of treatment-requiring active hepatitis B or C infection. Hepatitis B virus carriers, stable hepatitis B (no more than 2500 copies /mL or 500 IU/mL of DNA) and cured hepatitis C patients were eligible;\n",
      "Subjects who were treated with systemic glucocorticoids or other immunosuppressive agents for a condition within 14 days prior to initiation of study treatment {Local, ocular, intra-articular, intranasal, and inhaled glucocorticoids were allowed (with very low systemic absorption); Short-term (≤ 7 days) use of glucocorticoids for prophylactic treatment (e.g., contrast media allergy) or for treatment of non-autoimmune conditions (e.g., delayed hypersensitivity due to contact allergens) is allowed;\n",
      "With active, and in the past two years need systemic treatment of autoimmune diseases (hormone replacement therapy is not considered a systemic treatment, such as type 1 diabetes, hypothyroidism only requiring thyroid hormone replacement therapy, low adrenocortical or pituitary function only requiring physiological doses of sugar cortical hormone replacement therapy ); Patients with autoimmune diseases that have not required systemic treatment in the past two years are eligible;\n",
      "Patients with unstable angina and/or congestive heart failure or vascular disease (such as, the aortic aneurysm or peripheral venous thrombosis requiring surgery to repair) requiring hospital treatment within 12 months. Patients with other cardiac damage (such as poor control of arrhythmia, myocardial infarction, or ischemic) which may affect the drug safety evaluation within 12 months;\n",
      "Patients who underwent major surgery within 28 days before enrollment; Less than 6 weeks after major organ surgery;\n",
      "Long-term unhealed wounds or incomplete healing fractures;\n",
      "Receive live attenuated vaccine (except influenza vaccine) within 4 weeks before enrollment or during the study period;\n",
      "Pregnant or lactating women and subjects of reproductive age who do not want to take contraceptive measures;\n",
      "Patients with mental illness or who cannot obtain informed consent;\n",
      "There is active infection, except for tumor-related B symptoms and fever;\n",
      "Cardiac clinical symptoms or diseases that are not well controlled, such as: I. Nyha grade 2 or above heart failure; II. Unstable angina pectoris; III. Myocardial infarction has occurred within 1 year; IV. Patients with clinically significant supraventricular or ventricular arrhythmias requiring treatment or intervention;\n",
      "Ineligibility to participate in the study was determined by the investigator.\",\n",
      "          \"Healthy Volunteers\":\"No\",\n",
      "          \"Gender\":\"All\",\n",
      "          \"Minimum Age\":\"18 Years\",\n",
      "          \"MaximumAge\":\"75 Years\",\n",
      "          \"Std Age List\":{\n",
      "            \"Std Age\":[\n",
      "              \"Adult\",\n",
      "              \"Older Adult\"\n",
      "            ]\n",
      "          }\n",
      "        },\n",
      "        \"Contacts Locations Module\":{\n",
      "          \"CentralContactList\":{\n",
      "            \"CentralContact\":[\n",
      "              {\n",
      "                \"CentralContactName\":\"Qingqing Cai\",\n",
      "                \"CentralContactRole\":\"Contact\",\n",
      "                \"CentralContactPhone\":\"0086-20-87342823\",\n",
      "                \"CentralContactEMail\":\"caiqq@sysucc.org.cn\"\n",
      "              }\n",
      "            ]\n",
      "          },\n",
      "          \"Overall Official List\":{\n",
      "            \"Overall Official\":[\n",
      "              {\n",
      "                \"Overall OfficialName\":\"Qingqing Cai\",\n",
      "                \"Overall OfficialAffiliation\":\"Sun Yat-sen University\",\n",
      "                \"Overall OfficialRole\":\"Study Director\"\n",
      "              }\n",
      "            ]\n",
      "          },\n",
      "          \"Location List\":{\n",
      "            \"Location\":[\n",
      "              {\n",
      "                \"LocationFacility\":\"Sun Yat-sen Universitiy Cancer Center, Sun Yat-Sen University\",\n",
      "                \"LocationStatus\":\"Recruiting\",\n",
      "                \"LocationCity\":\"Guangzhou\",\n",
      "                \"LocationState\":\"Guangdong\",\n",
      "                \"LocationZip\":\"510000\",\n",
      "                \"LocationCountry\":\"China\",\n",
      "                \"LocationContactList\":{\n",
      "                  \"LocationContact\":[\n",
      "                    {\n",
      "                      \"LocationContactName\":\"Qingqing Cai, MD\",\n",
      "                      \"LocationContactRole\":\"Contact\",\n",
      "                      \"LocationContactEMail\":\"caiqq@sysucc.org.cn\"\n",
      "                    }\n",
      "                  ]\n",
      "                }\n",
      "              }\n",
      "            ]\n",
      "          }\n",
      "        }\n",
      "      },\n",
      "      \"Derived Section\":{\n",
      "        \"Misc Info Module\":{\n",
      "          \"Version Holder\":\"May 19, 2023\"\n",
      "        },\n",
      "        \"Condition Browse Module\":{\n",
      "          \"Condition Mesh List\":{\n",
      "            \"Condition Mesh\":[\n",
      "              {\n",
      "                \"Condition MeshId\":\"D000008223\",\n",
      "                \"Condition MeshTerm\":\"Lymphoma\"\n",
      "              },{\n",
      "                \"Condition MeshId\":\"D000016399\",\n",
      "                \"Condition MeshTerm\":\"Lymphoma, T-Cell\"\n",
      "              },{\n",
      "                \"Condition MeshId\":\"D000016411\",\n",
      "                \"Condition MeshTerm\":\"Lymphoma, T-Cell, Peripheral\"\n",
      "              }\n",
      "            ]\n",
      "          },\n",
      "          \"Condition Ancestor List\":{\n",
      "            \"Condition Ancestor\":[\n",
      "              {\n",
      "                \"Condition AncestorId\":\"D000009370\",\n",
      "                \"Condition AncestorTerm\":\"Neoplasms by Histologic Type\"\n",
      "              },{\n",
      "                \"Condition AncestorId\":\"D000009369\",\n",
      "                \"Condition AncestorTerm\":\"Neoplasms\"\n",
      "              },{\n",
      "                \"Condition AncestorId\":\"D000008232\",\n",
      "                \"Condition AncestorTerm\":\"Lymphoproliferative Disorders\"\n",
      "              },{\n",
      "                \"Condition AncestorId\":\"D000008206\",\n",
      "                \"Condition AncestorTerm\":\"Lymphatic Diseases\"\n",
      "              },{\n",
      "                \"Condition AncestorId\":\"D000007160\",\n",
      "                \"Condition AncestorTerm\":\"Immunoproliferative Disorders\"\n",
      "              },{\n",
      "                \"Condition AncestorId\":\"D000007154\",\n",
      "                \"Condition AncestorTerm\":\"Immune System Diseases\"\n",
      "              },{\n",
      "                \"Condition AncestorId\":\"D000008228\",\n",
      "                \"Condition AncestorTerm\":\"Lymphoma, Non-Hodgkin\"\n",
      "              }\n",
      "            ]\n",
      "          },\n",
      "          \"Condition Browse Leaf List\":{\n",
      "            \"Condition Browse Leaf\":[\n",
      "              {\n",
      "                \"Condition Browse LeafId\":\"M10372\",\n",
      "                \"Condition Browse LeafName\":\"Lymphoma\",\n",
      "                \"Condition Browse LeafAsFound\":\"Lymphoma\",\n",
      "                \"Condition Browse LeafRelevance\":\"high\"\n",
      "              },{\n",
      "                \"Condition Browse LeafId\":\"M17981\",\n",
      "                \"Condition Browse LeafName\":\"Lymphoma, T-Cell\",\n",
      "                \"Condition Browse LeafAsFound\":\"T-cell Lymphoma\",\n",
      "                \"Condition Browse LeafRelevance\":\"high\"\n",
      "              },{\n",
      "                \"Condition Browse LeafId\":\"M17985\",\n",
      "                \"Condition Browse LeafName\":\"Lymphoma, T-Cell, Peripheral\",\n",
      "                \"Condition Browse LeafAsFound\":\"Peripheral T-cell Lymphoma\",\n",
      "                \"Condition Browse LeafRelevance\":\"high\"\n",
      "              },{\n",
      "                \"Condition Browse LeafId\":\"M11467\",\n",
      "                \"Condition Browse LeafName\":\"Neoplasms by Histologic Type\",\n",
      "                \"Condition Browse LeafRelevance\":\"low\"\n",
      "              },{\n",
      "                \"Condition Browse LeafId\":\"M10377\",\n",
      "                \"Condition Browse LeafName\":\"Lymphoproliferative Disorders\",\n",
      "                \"Condition Browse LeafRelevance\":\"low\"\n",
      "              },{\n",
      "                \"Condition Browse LeafId\":\"M10355\",\n",
      "                \"Condition Browse LeafName\":\"Lymphatic Diseases\",\n",
      "                \"Condition Browse LeafRelevance\":\"low\"\n",
      "              },{\n",
      "                \"Condition Browse LeafId\":\"M9358\",\n",
      "                \"Condition Browse LeafName\":\"Immunoproliferative Disorders\",\n",
      "                \"Condition Browse LeafRelevance\":\"low\"\n",
      "              },{\n",
      "                \"Condition Browse LeafId\":\"M9352\",\n",
      "                \"Condition Browse LeafName\":\"Immune System Diseases\",\n",
      "                \"Condition Browse LeafRelevance\":\"low\"\n",
      "              },{\n",
      "                \"Condition Browse LeafId\":\"M10374\",\n",
      "                \"Condition Browse LeafName\":\"Lymphoma, Non-Hodgkin\",\n",
      "                \"Condition Browse LeafRelevance\":\"low\"\n",
      "              },{\n",
      "                \"Condition Browse LeafId\":\"T3543\",\n",
      "                \"Condition Browse LeafName\":\"Lymphosarcoma\",\n",
      "                \"Condition Browse LeafAsFound\":\"Lymphoma\",\n",
      "                \"Condition Browse LeafRelevance\":\"high\"\n",
      "              },{\n",
      "                \"Condition Browse LeafId\":\"T4496\",\n",
      "                \"Condition Browse LeafName\":\"Peripheral T-cell Lymphoma\",\n",
      "                \"Condition Browse LeafAsFound\":\"Peripheral T-cell Lymphoma\",\n",
      "                \"Condition Browse LeafRelevance\":\"high\"\n",
      "              }\n",
      "            ]\n",
      "          },\n",
      "          \"Condition Browse Branch List\":{\n",
      "            \"Condition Browse Branch\":[\n",
      "              {\n",
      "                \"Condition Browse BranchAbbrev\":\"BC04\",\n",
      "                \"Condition Browse BranchName\":\"Neoplasms\"\n",
      "              },{\n",
      "                \"Condition Browse BranchAbbrev\":\"BC15\",\n",
      "                \"Condition Browse BranchName\":\"Blood and Lymph Conditions\"\n",
      "              },{\n",
      "                \"Condition Browse BranchAbbrev\":\"BC20\",\n",
      "                \"Condition Browse BranchName\":\"Immune System Diseases\"\n",
      "              },{\n",
      "                \"Condition Browse BranchAbbrev\":\"All\",\n",
      "                \"Condition Browse BranchName\":\"All Conditions\"\n",
      "              },{\n",
      "                \"Condition Browse BranchAbbrev\":\"Rare\",\n",
      "                \"Condition Browse BranchName\":\"Rare Diseases\"\n",
      "              }\n",
      "            ]\n",
      "          }\n",
      "        },\n",
      "        \"Intervention Browse Module\":{\n",
      "          \"Intervention Browse Leaf List\":{\n",
      "            \"Intervention Browse Leaf\":[\n",
      "              {\n",
      "                \"Intervention Browse LeafId\":\"M5879\",\n",
      "                \"Intervention Browse LeafName\":\"Cyclophosphamide\",\n",
      "                \"Intervention Browse LeafRelevance\":\"low\"\n",
      "              },{\n",
      "                \"Intervention Browse LeafId\":\"M17106\",\n",
      "                \"Intervention Browse LeafName\":\"Epirubicin\",\n",
      "                \"Intervention Browse LeafRelevance\":\"low\"\n",
      "              },{\n",
      "                \"Intervention Browse LeafId\":\"M6644\",\n",
      "                \"Intervention Browse LeafName\":\"Doxorubicin\",\n",
      "                \"Intervention Browse LeafRelevance\":\"low\"\n",
      "              },{\n",
      "                \"Intervention Browse LeafId\":\"M13273\",\n",
      "                \"Intervention Browse LeafName\":\"Prednisone\",\n",
      "                \"Intervention Browse LeafRelevance\":\"low\"\n",
      "              },{\n",
      "                \"Intervention Browse LeafId\":\"M16647\",\n",
      "                \"Intervention Browse LeafName\":\"Vincristine\",\n",
      "                \"Intervention Browse LeafRelevance\":\"low\"\n",
      "              },{\n",
      "                \"Intervention Browse LeafId\":\"M227311\",\n",
      "                \"Intervention Browse LeafName\":\"Liposomal doxorubicin\",\n",
      "                \"Intervention Browse LeafRelevance\":\"low\"\n",
      "              }\n",
      "            ]\n",
      "          },\n",
      "          \"Intervention Browse Branch List\":{\n",
      "            \"Intervention Browse Branch\":[\n",
      "              {\n",
      "                \"Intervention Browse BranchAbbrev\":\"ANeo\",\n",
      "                \"Intervention Browse BranchName\":\"Antineoplastic Agents\"\n",
      "              },{\n",
      "                \"Intervention Browse BranchAbbrev\":\"ARhu\",\n",
      "                \"Intervention Browse BranchName\":\"Antirheumatic Agents\"\n",
      "              },{\n",
      "                \"Intervention Browse BranchAbbrev\":\"All\",\n",
      "                \"Intervention Browse BranchName\":\"All Drugs and Chemicals\"\n",
      "              },{\n",
      "                \"Intervention Browse BranchAbbrev\":\"Infl\",\n",
      "                \"Intervention Browse BranchName\":\"Anti-Inflammatory Agents\"\n",
      "              }\n",
      "            ]\n",
      "          }\n",
      "        }\n",
      "      }\n",
      "    }\n",
      "  }\n",
      "}\n",
      "\n",
      "临床研究clinical trials，NCT04996758\n",
      "{\n",
      "  \"Full Study\":{\n",
      "    \"Rank\":66911,\n",
      "    \"Study\":{\n",
      "      \"Protocol Section\":{\n",
      "        \"Identification Module\":{\n",
      "          \"NCT Id\":\"NCT04996758\",\n",
      "          \"Org Study Id Info\":{\n",
      "            \"Org Study Id\":\"B2021-055\"\n",
      "          },\n",
      "          \"Organization\":{\n",
      "            \"Org Full Name\":\"Sun Yat-sen University\",\n",
      "            \"Org Class\":\"OTHER\"\n",
      "          },\n",
      "          \"Brief Title\":\"Toripalimab and Anlotinib Combination Treatment in Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma After Failure of at Least One Line of Platinum-Based Chemotherapy (TORAL)\",\n",
      "          \"Official Title\":\"Open-Label, Phase Ⅱ Study of Toripalimab and Anlotinib Combination Treatment in Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma After Failure of at Least One Line of Platinum-Based Chemotherapy (TORAL)\"\n",
      "        },\n",
      "        \"Status Module\":{\n",
      "          \"Status Verified Date\":\"March 2022\",\n",
      "          \"Overall Status\":\"Recruiting\",\n",
      "          \"Expanded Access Info\":{\n",
      "            \"Has Expanded Access\":\"No\"\n",
      "          },\n",
      "          \"Start Date Struct\":{\n",
      "            \"Start Date\":\"August 1, 2021\",\n",
      "            \"Start DateType\":\"Actual\"\n",
      "          },\n",
      "          \"Primary Completion Date Struct\":{\n",
      "            \"Primary Completion Date\":\"August 2023\",\n",
      "            \"Primary Completion DateType\":\"Anticipated\"\n",
      "          },\n",
      "          \"Completion Date Struct\":{\n",
      "            \"Completion Date\":\"August 2028\",\n",
      "            \"Completion DateType\":\"Anticipated\"\n",
      "          },\n",
      "          \"Study First Submit Date\":\"August 5, 2021\",\n",
      "          \"Study First Submit QC Date\":\"August 5, 2021\",\n",
      "          \"Study First Post Date Struct\":{\n",
      "            \"Study First Post Date\":\"August 9, 2021\",\n",
      "            \"Study First Post DateType\":\"Actual\"\n",
      "          },\n",
      "          \"Last Update Submit Date\":\"March 23, 2022\",\n",
      "          \"Last Update Post Date Struct\":{\n",
      "            \"Last Update Post Date\":\"March 24, 2022\",\n",
      "            \"Last Update Post DateType\":\"Actual\"\n",
      "          }\n",
      "        },\n",
      "        \"Sponsor Collaborators Module\":{\n",
      "          \"Responsible Party\":{\n",
      "            \"Responsible PartyType\":\"Principal Investigator\",\n",
      "            \"Responsible PartyInvestigatorFullName\":\"Qingqing Cai\",\n",
      "            \"Responsible PartyInvestigatorTitle\":\"Chief physician\",\n",
      "            \"Responsible PartyInvestigatorAffiliation\":\"Sun Yat-sen University\"\n",
      "          },\n",
      "          \"Lead Sponsor\":{\n",
      "            \"Lead SponsorName\":\"Sun Yat-sen University\",\n",
      "            \"Lead SponsorClass\":\"OTHER\"\n",
      "          }\n",
      "        },\n",
      "        \"Oversight Module\":{\n",
      "          \"Is FDA Regulated Drug\":\"No\",\n",
      "          \"Is FDA Regulated Device\":\"No\"\n",
      "        },\n",
      "        \"Description Module\":{\n",
      "          \"Brief Summary\":\"This phase 2 trial studies toripalimab and anlotinib combination treatment in patients with recurrent or metastatic nasopharyngeal carcinoma after failure of at least one line of platinum-based chemotherapy\"\n",
      "        },\n",
      "        \"Conditions Module\":{\n",
      "          \"Condition List\":{\n",
      "            \"Condition\":[\n",
      "              \"Nasopharyngeal Carcinoma\",\n",
      "              \"Recurrent or Metastatic Nasopharyngeal Carcinoma\"\n",
      "            ]\n",
      "          }\n",
      "        },\n",
      "        \"Design Module\":{\n",
      "          \"Study Type\":\"Interventional\",\n",
      "          \"PhaseList\":{\n",
      "            \"Phase\":[\n",
      "              \"Phase 2\"\n",
      "            ]\n",
      "          },\n",
      "          \"Design Info\":{\n",
      "            \"DesignAllocation\":\"N/A\",\n",
      "            \"DesignInterventionModel\":\"Single Group Assignment\",\n",
      "            \"DesignPrimaryPurpose\":\"Treatment\",\n",
      "            \"DesignMaskingInfo\":{\n",
      "              \"DesignMasking\":\"None (Open Label)\"\n",
      "            }\n",
      "          },\n",
      "          \"Enrollment Info\":{\n",
      "            \"Enrollment Count\":\"39\",\n",
      "            \"Enrollment Type\":\"Anticipated\"\n",
      "          }\n",
      "        },\n",
      "        \"Arms Interventions Module\":{\n",
      "          \"Arm Group List\":{\n",
      "            \"Arm Group\":[\n",
      "              {\n",
      "                \"Arm GroupLabel\":\"Toripalimab and Anlotinib Combination Treatment\",\n",
      "                \"Arm GroupType\":\"Experimental\",\n",
      "                \"Arm GroupDescription\":\"Patients receive toripalimab at a dose of 240 mg on day 1 and anlotinib at a dose of 12 mg before breakfast for once-daily on days 1-14. Treatment cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity\",\n",
      "                \"Arm GroupIntervention List\":{\n",
      "                  \"Arm GroupInterventionName\":[\n",
      "                    \"Drug: Toripalimab and Anlotinib\"\n",
      "                  ]\n",
      "                }\n",
      "              }\n",
      "            ]\n",
      "          },\n",
      "          \"Intervention List\":{\n",
      "            \"Intervention\":[\n",
      "              {\n",
      "                \"InterventionType\":\"Drug\",\n",
      "                \"InterventionName\":\"Toripalimab and Anlotinib\",\n",
      "                \"InterventionDescription\":\"Toripalimab 240 mg iv.drip d1; Anlotinib 12mg po qd d1-14.\",\n",
      "                \"InterventionArm GroupLabelList\":{\n",
      "                  \"InterventionArm GroupLabel\":[\n",
      "                    \"Toripalimab and Anlotinib Combination Treatment\"\n",
      "                  ]\n",
      "                }\n",
      "              }\n",
      "            ]\n",
      "          }\n",
      "        },\n",
      "        \"Outcomes Module\":{\n",
      "          \"Primary Outcome List\":{\n",
      "            \"Primary Outcome\":[\n",
      "              {\n",
      "                \"Primary Outcome Measure\":\"Objective Response rate\",\n",
      "                \"Primary OutcomeDescription\":\"Objective Response rate will be determined on the basis of investigator assessments\",\n",
      "                \"Primary OutcomeTimeFrame\":\"2 years\"\n",
      "              },{\n",
      "                \"Primary Outcome Measure\":\"Disease Control rate\",\n",
      "                \"Primary OutcomeDescription\":\"the proportion of patients who had a best response rating of complete response, partial response, or stable disease will be determined on the basis of investigator assessments\",\n",
      "                \"Primary OutcomeTimeFrame\":\"2 years\"\n",
      "              }\n",
      "            ]\n",
      "          },\n",
      "          \"Secondary Outcome List\":{\n",
      "            \"Secondary Outcome\":[\n",
      "              {\n",
      "                \"Secondary Outcome Measure\":\"Progression Free Survival\",\n",
      "                \"Secondary OutcomeDescription\":\"The time from the start of treatment to the progression of the tumor or death (due to any cause).\",\n",
      "                \"Secondary OutcomeTimeFrame\":\"5 years\"\n",
      "              },{\n",
      "                \"Secondary Outcome Measure\":\"Overall Survival\",\n",
      "                \"Secondary OutcomeDescription\":\"The time from the start of treatment to time of death (due to any cause).\",\n",
      "                \"Secondary OutcomeTimeFrame\":\"5 years\"\n",
      "              },{\n",
      "                \"Secondary Outcome Measure\":\"Complete Response rate\",\n",
      "                \"Secondary OutcomeDescription\":\"Complete Response rate will be determined on the basis of investigator assessments\",\n",
      "                \"Secondary OutcomeTimeFrame\":\"2 years\"\n",
      "              },{\n",
      "                \"Secondary Outcome Measure\":\"Partial Response rate\",\n",
      "                \"Secondary OutcomeDescription\":\"Partial Response rate will be determined on the basis of investigator assessments\",\n",
      "                \"Secondary OutcomeTimeFrame\":\"2 years\"\n",
      "              },{\n",
      "                \"Secondary Outcome Measure\":\"Duration of Response\",\n",
      "                \"Secondary OutcomeDescription\":\"The time from the first assessment of complete remission or partial remission to progressive disease or death (due to any cause).\",\n",
      "                \"Secondary OutcomeTimeFrame\":\"5 years\"\n",
      "              },{\n",
      "                \"Secondary Outcome Measure\":\"Percentage of Participants With Adverse Events\",\n",
      "                \"Secondary OutcomeDescription\":\"Adverse Events will be determined and graded on the basis of investigator assessments according to NCI CTC AE 5.0\",\n",
      "                \"Secondary OutcomeTimeFrame\":\"5 years\"\n",
      "              }\n",
      "            ]\n",
      "          }\n",
      "        },\n",
      "        \"Eligibility Module\":{\n",
      "          \"Eligibility Criteria\":\"Inclusion Criteria:\n",
      "\n",
      "Histologically confirmed undifferentiated non-keratinizing carcinoma\n",
      "Patients suffered failure of at least one line of platinum-based chemotherapy. The definition of treatment failure: progression during or after chemotherapy for recurrence/metastasis; progression after concurrent chemoradiotherapy within 6 months. Withdrawal of treatment due to drug intolerances is excluded ;\n",
      "Without other malignancy;\n",
      "Male or female, 18-70 years;\n",
      "Eastern Cooperative Oncology Group (ECOG) of 0-2;\n",
      "Life expectancy ≥ 3 months;\n",
      "Women of childbearing age must obtain the negative result of a pregnancy test (serum or urine) , and they were willing to use reliable methods of contraception during the trial;\n",
      "At least one evaluable lesion；\n",
      "Laboratory tests meet the following standards:\n",
      "\n",
      "Blood routine: White blood cell count (WBC) ≥3.0×10 9 /L, neutrophil count (ANC) ≥1.5×10 9 /L, platelet count (PLT) ≥75×10 9 /L, hemoglobin (HGB) 90 g/L or higher; Liver function: total bilirubin ≤1.5 times the upper limit of normal (ULN); glutamic-oxalacetic transaminase (AST) and alanine transaminase (ALT) ≤2.5 times ULN, AST and ALT ≤2.5 times ULN for the patients with liver metastases; Alkaline phosphatase ≤5 times ULN; Renal function: Serum creatinine (Cr) ≤1.5 times ULN; Creatinine clearance ≥60mL/min; Urine routine: urine protein <2+ ;baseline urine protein ≥2+ and 24 hours urine protein < 1g ; Coagulation: International normalized ratio (INR) and activated partial thrombin time (APTT) ≤1.5 times ULN; Albumin ≥28g/L Thyroid stimulating hormone (TSH)≤1 times ULN (free triiodothyrosine [FT3] or free thyroxine [FT4] ≤1 times ULN can be included)\n",
      "\n",
      "No serious cardiopulmonary dysfunction;\n",
      "The informed consent has been signed.\n",
      "Ability to comply with test requirements\n",
      "\n",
      "Exclusion Criteria:\n",
      "\n",
      "A known allergy to any of the drugs in the study;\n",
      "Pregnant or breastfeeding women;\n",
      "Participated in clinical trials of other drugs within 4 weeks prior to study initiation;\n",
      "Previous treatment with bevacizumab or VEGFR-family small molecule tyrosine kinase inhibitors (e.g., famitinib, sorafenib, Sunitinib, regofinib, Apatinib, Anlotinib, fuquinitinib) ;\n",
      "Recurrent nasopharyngeal lesions after radiotherapy and who received secondary radiotherapy;\n",
      "Palliative radiotherapy for symptom control within 28 days before enrollment;\n",
      "Immunosuppressive treatment with immunosuppressive agent, systemic or absorbable topical hormone therapy ( prednisone or other therapeutic hormone at the dose greater than 10mg/ day) within 2 weeks before enrollment;\n",
      "Active autoimmune diseases, with the necessity of systemic treatment (hormone replacement therapy is not considered as a systemic treatment, such as type 1 diabetes) over the past two years; autoimmune diseases that did not require systemic treatment in the past two years;\n",
      "A history of immunodeficiency, including acquired/congenital immunodeficiency disorders, a history of organ transplantation;\n",
      "Vaccinated with live vaccine (inactivated virus vaccine for seasonal influenza is allowed) within 4 weeks before enrollment;\n",
      "Invasion of important vessels (e.g. surrounding internal carotid artery/vein) on MRI; tumor with a high risk of affecting vital blood vessels during treatment and causing fatal hemorrhage, which is determined by investigators;\n",
      "A history of severe bleeding and any bleeding event with a severity rating of 3 or higher in the NCI CTCAE within 4 weeks prior to screening;\n",
      "Abnormal coagulation (INR > 2.0, PT > 16s) and bleeding tendency (the INR must be within the normal range without anticoagulants during14 days prior to signing the informed consent); patients treated with anticoagulants or vitamin K antagonists such as warfarin, heparin, or their analogests; low-dose warfarin (1 mg orally, once daily) or low-dose aspirin (up to 100 mg daily) for preventive purposes, provided that the international normalized ratio of prothrombin time (INR) is ≤ 1.5;\n",
      "Unstable angina and/or congestive heart failure or vascular disease with the need of hospital treatment; other cardiac damage that may affect the drug safety;\n",
      "Patients with hypertension that is not well controlled with antihypertensive medication (systolic > 140mmHg, diastolic > 90 mmHg); patients is taking a combination of two or more antihypertensive drugs; Cardiovascular disease with clinical significance， such as cerebrovascular accident (≤ 6 months before randomization), myocardial infarction (≤ 6 months before randomization), unstable angina, congestive heart failure of NYHA grade II or higher, or severe arrhythmias that cannot be controlled with drugs or have a potential impact on experimental treatments;\n",
      "Patients with esophageal and gastric varices, active ulcers, intestinal perforation or intestinal obstruction within 6 months before enrollment;\n",
      "A history of abdominal fistula, digestive tract perforation, intra-abdominal abscess or acute gastrointestinal bleeding within 6 months before enrollment;\n",
      "Multiple factors affecting oral administration and absorption of drugs (e.g., inability to swallow, post-gastrointestinal resection, chronic diarrhea and intestinal obstruction);\n",
      "Overoperation/venous thromboembolism events, NCI CTCAE grade 3 or higher venous thromboembolism within 6 months before enrollment, such as cerebrovascular accident (including temporary ischemic attack), deep venous thrombosis (except for those venous thrombosis caused by venous catheterization due to previous chemotherapy and determined to be cured by the researchers ), pulmonary embolism, etc.;\n",
      "Patients with past and present objective evidence of pulmonary fibrosis, interstitial pneumonia, pneumoconiosis, radiation pneumonia, drug-related pneumonia, or severe impairment of lung function;\n",
      "Exacerbation of chronic obstructive pulmonary disease (COPD) or other respiratory disease requiring hospitalization within 28 days before enrollment;\n",
      "Active pulmonary infection and/or acute bacterial or fungal infection requiring intravenous antibiotic treatment within 28 days;\n",
      "Dominant jaundice due to abnormal liver function within 7 days;\n",
      "Renal insufficiency: routine urinalproteinuria > 2+ and confirmed 24 h urinary protein quantification > 1.0g;\n",
      "Minor surgical operations (including catheterization, excluding central venous catheterization via peripheral venipuncture) within 2 days before enrollment;\n",
      "Major surgery within 28 days before enrollment;\n",
      "A potent CYP3A4 inhibitor within one week prior to enrollment, or a potent CYP3A4 inducer within two weeks prior to study participation\n",
      "Long-term unhealed wounds or incomplete fractures;\n",
      "Symptomatic central nervous system metastases (e.g. brain edema, need for hormonal intervention, or brain metastases)\n",
      "The presence of serious or uncontrolled infections;\",\n",
      "          \"Healthy Volunteers\":\"No\",\n",
      "          \"Gender\":\"All\",\n",
      "          \"Minimum Age\":\"18 Years\",\n",
      "          \"MaximumAge\":\"70 Years\",\n",
      "          \"Std Age List\":{\n",
      "            \"Std Age\":[\n",
      "              \"Adult\",\n",
      "              \"Older Adult\"\n",
      "            ]\n",
      "          }\n",
      "        },\n",
      "        \"Contacts Locations Module\":{\n",
      "          \"CentralContactList\":{\n",
      "            \"CentralContact\":[\n",
      "              {\n",
      "                \"CentralContactName\":\"Qingqing Cai\",\n",
      "                \"CentralContactRole\":\"Contact\",\n",
      "                \"CentralContactPhone\":\"0086-20-87342823\",\n",
      "                \"CentralContactEMail\":\"caiqq@sysucc.org.cn\"\n",
      "              },{\n",
      "                \"CentralContactName\":\"Qingqing Cai\",\n",
      "                \"CentralContactRole\":\"Contact\"\n",
      "              }\n",
      "            ]\n",
      "          },\n",
      "          \"Overall Official List\":{\n",
      "            \"Overall Official\":[\n",
      "              {\n",
      "                \"Overall OfficialName\":\"Qingqing Cai\",\n",
      "                \"Overall OfficialAffiliation\":\"Sun Yat-sen Universitiy Cancer Center, Sun Yat-Sen University,\",\n",
      "                \"Overall OfficialRole\":\"Principal Investigator\"\n",
      "              }\n",
      "            ]\n",
      "          },\n",
      "          \"Location List\":{\n",
      "            \"Location\":[\n",
      "              {\n",
      "                \"LocationFacility\":\"Sun Yat-sen Universitiy Cancer Center, Sun Yat-Sen University\",\n",
      "                \"LocationStatus\":\"Recruiting\",\n",
      "                \"LocationCity\":\"Guangzhou\",\n",
      "                \"LocationZip\":\"510030\",\n",
      "                \"LocationCountry\":\"China\",\n",
      "                \"LocationContactList\":{\n",
      "                  \"LocationContact\":[\n",
      "                    {\n",
      "                      \"LocationContactName\":\"Qingqing Cai\",\n",
      "                      \"LocationContactRole\":\"Contact\",\n",
      "                      \"LocationContactPhone\":\"18565617120\",\n",
      "                      \"LocationContactEMail\":\"18565617120@163.com\"\n",
      "                    }\n",
      "                  ]\n",
      "                }\n",
      "              }\n",
      "            ]\n",
      "          }\n",
      "        }\n",
      "      },\n",
      "      \"Derived Section\":{\n",
      "        \"Misc Info Module\":{\n",
      "          \"Version Holder\":\"May 19, 2023\"\n",
      "        },\n",
      "        \"Condition Browse Module\":{\n",
      "          \"Condition Mesh List\":{\n",
      "            \"Condition Mesh\":[\n",
      "              {\n",
      "                \"Condition MeshId\":\"D000002277\",\n",
      "                \"Condition MeshTerm\":\"Carcinoma\"\n",
      "              },{\n",
      "                \"Condition MeshId\":\"D000077274\",\n",
      "                \"Condition MeshTerm\":\"Nasopharyngeal Carcinoma\"\n",
      "              },{\n",
      "                \"Condition MeshId\":\"D000012008\",\n",
      "                \"Condition MeshTerm\":\"Recurrence\"\n",
      "              }\n",
      "            ]\n",
      "          },\n",
      "          \"Condition Ancestor List\":{\n",
      "            \"Condition Ancestor\":[\n",
      "              {\n",
      "                \"Condition AncestorId\":\"D000009375\",\n",
      "                \"Condition AncestorTerm\":\"Neoplasms, Glandular and Epithelial\"\n",
      "              },{\n",
      "                \"Condition AncestorId\":\"D000009370\",\n",
      "                \"Condition AncestorTerm\":\"Neoplasms by Histologic Type\"\n",
      "              },{\n",
      "                \"Condition AncestorId\":\"D000009369\",\n",
      "                \"Condition AncestorTerm\":\"Neoplasms\"\n",
      "              },{\n",
      "                \"Condition AncestorId\":\"D000020969\",\n",
      "                \"Condition AncestorTerm\":\"Disease Attributes\"\n",
      "              },{\n",
      "                \"Condition AncestorId\":\"D000010335\",\n",
      "                \"Condition AncestorTerm\":\"Pathologic Processes\"\n",
      "              },{\n",
      "                \"Condition AncestorId\":\"D000009303\",\n",
      "                \"Condition AncestorTerm\":\"Nasopharyngeal Neoplasms\"\n",
      "              },{\n",
      "                \"Condition AncestorId\":\"D000010610\",\n",
      "                \"Condition AncestorTerm\":\"Pharyngeal Neoplasms\"\n",
      "              },{\n",
      "                \"Condition AncestorId\":\"D000010039\",\n",
      "                \"Condition AncestorTerm\":\"Otorhinolaryngologic Neoplasms\"\n",
      "              },{\n",
      "                \"Condition AncestorId\":\"D000006258\",\n",
      "                \"Condition AncestorTerm\":\"Head and Neck Neoplasms\"\n",
      "              },{\n",
      "                \"Condition AncestorId\":\"D000009371\",\n",
      "                \"Condition AncestorTerm\":\"Neoplasms by Site\"\n",
      "              },{\n",
      "                \"Condition AncestorId\":\"D000009302\",\n",
      "                \"Condition AncestorTerm\":\"Nasopharyngeal Diseases\"\n",
      "              },{\n",
      "                \"Condition AncestorId\":\"D000010608\",\n",
      "                \"Condition AncestorTerm\":\"Pharyngeal Diseases\"\n",
      "              },{\n",
      "                \"Condition AncestorId\":\"D000009057\",\n",
      "                \"Condition AncestorTerm\":\"Stomatognathic Diseases\"\n",
      "              },{\n",
      "                \"Condition AncestorId\":\"D000010038\",\n",
      "                \"Condition AncestorTerm\":\"Otorhinolaryngologic Diseases\"\n",
      "              }\n",
      "            ]\n",
      "          },\n",
      "          \"Condition Browse Leaf List\":{\n",
      "            \"Condition Browse Leaf\":[\n",
      "              {\n",
      "                \"Condition Browse LeafId\":\"M4686\",\n",
      "                \"Condition Browse LeafName\":\"Carcinoma\",\n",
      "                \"Condition Browse LeafAsFound\":\"Carcinoma\",\n",
      "                \"Condition Browse LeafRelevance\":\"high\"\n",
      "              },{\n",
      "                \"Condition Browse LeafId\":\"M14002\",\n",
      "                \"Condition Browse LeafName\":\"Recurrence\",\n",
      "                \"Condition Browse LeafAsFound\":\"Recurrent\",\n",
      "                \"Condition Browse LeafRelevance\":\"high\"\n",
      "              },{\n",
      "                \"Condition Browse LeafId\":\"M1730\",\n",
      "                \"Condition Browse LeafName\":\"Nasopharyngeal Carcinoma\",\n",
      "                \"Condition Browse LeafAsFound\":\"Nasopharyngeal Carcinoma\",\n",
      "                \"Condition Browse LeafRelevance\":\"high\"\n",
      "              },{\n",
      "                \"Condition Browse LeafId\":\"M11472\",\n",
      "                \"Condition Browse LeafName\":\"Neoplasms, Glandular and Epithelial\",\n",
      "                \"Condition Browse LeafRelevance\":\"low\"\n",
      "              },{\n",
      "                \"Condition Browse LeafId\":\"M11467\",\n",
      "                \"Condition Browse LeafName\":\"Neoplasms by Histologic Type\",\n",
      "                \"Condition Browse LeafRelevance\":\"low\"\n",
      "              },{\n",
      "                \"Condition Browse LeafId\":\"M21853\",\n",
      "                \"Condition Browse LeafName\":\"Disease Attributes\",\n",
      "                \"Condition Browse LeafRelevance\":\"low\"\n",
      "              },{\n",
      "                \"Condition Browse LeafId\":\"M11406\",\n",
      "                \"Condition Browse LeafName\":\"Nasopharyngeal Neoplasms\",\n",
      "                \"Condition Browse LeafRelevance\":\"low\"\n",
      "              },{\n",
      "                \"Condition Browse LeafId\":\"M12669\",\n",
      "                \"Condition Browse LeafName\":\"Pharyngeal Neoplasms\",\n",
      "                \"Condition Browse LeafRelevance\":\"low\"\n",
      "              },{\n",
      "                \"Condition Browse LeafId\":\"M12114\",\n",
      "                \"Condition Browse LeafName\":\"Otorhinolaryngologic Neoplasms\",\n",
      "                \"Condition Browse LeafRelevance\":\"low\"\n",
      "              },{\n",
      "                \"Condition Browse LeafId\":\"M8500\",\n",
      "                \"Condition Browse LeafName\":\"Head and Neck Neoplasms\",\n",
      "                \"Condition Browse LeafRelevance\":\"low\"\n",
      "              },{\n",
      "                \"Condition Browse LeafId\":\"M11405\",\n",
      "                \"Condition Browse LeafName\":\"Nasopharyngeal Diseases\",\n",
      "                \"Condition Browse LeafRelevance\":\"low\"\n",
      "              },{\n",
      "                \"Condition Browse LeafId\":\"M12667\",\n",
      "                \"Condition Browse LeafName\":\"Pharyngeal Diseases\",\n",
      "                \"Condition Browse LeafRelevance\":\"low\"\n",
      "              },{\n",
      "                \"Condition Browse LeafId\":\"M11169\",\n",
      "                \"Condition Browse LeafName\":\"Stomatognathic Diseases\",\n",
      "                \"Condition Browse LeafRelevance\":\"low\"\n",
      "              },{\n",
      "                \"Condition Browse LeafId\":\"M12113\",\n",
      "                \"Condition Browse LeafName\":\"Otorhinolaryngologic Diseases\",\n",
      "                \"Condition Browse LeafRelevance\":\"low\"\n",
      "              },{\n",
      "                \"Condition Browse LeafId\":\"T4047\",\n",
      "                \"Condition Browse LeafName\":\"Nasopharyngeal Carcinoma\",\n",
      "                \"Condition Browse LeafAsFound\":\"Nasopharyngeal Carcinoma\",\n",
      "                \"Condition Browse LeafRelevance\":\"high\"\n",
      "              }\n",
      "            ]\n",
      "          },\n",
      "          \"Condition Browse Branch List\":{\n",
      "            \"Condition Browse Branch\":[\n",
      "              {\n",
      "                \"Condition Browse BranchAbbrev\":\"BC04\",\n",
      "                \"Condition Browse BranchName\":\"Neoplasms\"\n",
      "              },{\n",
      "                \"Condition Browse BranchAbbrev\":\"All\",\n",
      "                \"Condition Browse BranchName\":\"All Conditions\"\n",
      "              },{\n",
      "                \"Condition Browse BranchAbbrev\":\"BC23\",\n",
      "                \"Condition Browse BranchName\":\"Symptoms and General Pathology\"\n",
      "              },{\n",
      "                \"Condition Browse BranchAbbrev\":\"BC07\",\n",
      "                \"Condition Browse BranchName\":\"Mouth and Tooth Diseases\"\n",
      "              },{\n",
      "                \"Condition Browse BranchAbbrev\":\"BC09\",\n",
      "                \"Condition Browse BranchName\":\"Ear, Nose, and Throat Diseases\"\n",
      "              },{\n",
      "                \"Condition Browse BranchAbbrev\":\"Rare\",\n",
      "                \"Condition Browse BranchName\":\"Rare Diseases\"\n",
      "              }\n",
      "            ]\n",
      "          }\n",
      "        }\n",
      "      }\n",
      "    }\n",
      "  }\n",
      "}\n",
      "\n",
      "临床研究clinical trials，NCT04797182\n",
      "{\n",
      "  \"Full Study\":{\n",
      "    \"Rank\":82232,\n",
      "    \"Study\":{\n",
      "      \"Protocol Section\":{\n",
      "        \"Identification Module\":{\n",
      "          \"NCT Id\":\"NCT04797182\",\n",
      "          \"Org Study Id Info\":{\n",
      "            \"Org Study Id\":\"B2021-034\"\n",
      "          },\n",
      "          \"Organization\":{\n",
      "            \"Org Full Name\":\"Sun Yat-sen University\",\n",
      "            \"Org Class\":\"OTHER\"\n",
      "          },\n",
      "          \"Brief Title\":\"Avatrombopag for the Primary Prevention of Thrombocytopenia Induced by Cytarabine-based Chemotherapy in Patients With Lymphoma\",\n",
      "          \"Official Title\":\"Avatrombopag for the Primary Prevention of Thrombocytopenia Induced by Cytarabine-based Chemotherapy in Patients With Lymphoma: An Open, Single-center, Phase II Randomized Controlled Clinical Study\"\n",
      "        },\n",
      "        \"Status Module\":{\n",
      "          \"Status Verified Date\":\"March 2021\",\n",
      "          \"Overall Status\":\"Not yet recruiting\",\n",
      "          \"Expanded Access Info\":{\n",
      "            \"Has Expanded Access\":\"No\"\n",
      "          },\n",
      "          \"Start Date Struct\":{\n",
      "            \"Start Date\":\"April 2021\",\n",
      "            \"Start DateType\":\"Anticipated\"\n",
      "          },\n",
      "          \"Primary Completion Date Struct\":{\n",
      "            \"Primary Completion Date\":\"April 2023\",\n",
      "            \"Primary Completion DateType\":\"Anticipated\"\n",
      "          },\n",
      "          \"Completion Date Struct\":{\n",
      "            \"Completion Date\":\"July 2023\",\n",
      "            \"Completion DateType\":\"Anticipated\"\n",
      "          },\n",
      "          \"Study First Submit Date\":\"March 11, 2021\",\n",
      "          \"Study First Submit QC Date\":\"March 11, 2021\",\n",
      "          \"Study First Post Date Struct\":{\n",
      "            \"Study First Post Date\":\"March 15, 2021\",\n",
      "            \"Study First Post DateType\":\"Actual\"\n",
      "          },\n",
      "          \"Last Update Submit Date\":\"March 11, 2021\",\n",
      "          \"Last Update Post Date Struct\":{\n",
      "            \"Last Update Post Date\":\"March 15, 2021\",\n",
      "            \"Last Update Post DateType\":\"Actual\"\n",
      "          }\n",
      "        },\n",
      "        \"Sponsor Collaborators Module\":{\n",
      "          \"Responsible Party\":{\n",
      "            \"Responsible PartyType\":\"Principal Investigator\",\n",
      "            \"Responsible PartyInvestigatorFullName\":\"Qingqing Cai\",\n",
      "            \"Responsible PartyInvestigatorTitle\":\"Chief physician\",\n",
      "            \"Responsible PartyInvestigatorAffiliation\":\"Sun Yat-sen University\"\n",
      "          },\n",
      "          \"Lead Sponsor\":{\n",
      "            \"Lead SponsorName\":\"Sun Yat-sen University\",\n",
      "            \"Lead SponsorClass\":\"OTHER\"\n",
      "          }\n",
      "        },\n",
      "        \"Oversight Module\":{\n",
      "          \"Is FDA Regulated Drug\":\"No\",\n",
      "          \"Is FDA Regulated Device\":\"No\"\n",
      "        },\n",
      "        \"Description Module\":{\n",
      "          \"Brief Summary\":\"This phase 2 trial studies the efficacy and safety of Avatrombopag for the primary prevention of thrombocytopenia induced by cytarabine-based chemotherapy in patients with lymphoma\"\n",
      "        },\n",
      "        \"Conditions Module\":{\n",
      "          \"Condition List\":{\n",
      "            \"Condition\":[\n",
      "              \"Thrombocytopenia\",\n",
      "              \"Cytarabine Causing Adverse Effects in Therapeutic Use\",\n",
      "              \"Lymphoma\"\n",
      "            ]\n",
      "          }\n",
      "        },\n",
      "        \"Design Module\":{\n",
      "          \"Study Type\":\"Interventional\",\n",
      "          \"PhaseList\":{\n",
      "            \"Phase\":[\n",
      "              \"Phase 2\"\n",
      "            ]\n",
      "          },\n",
      "          \"Design Info\":{\n",
      "            \"DesignAllocation\":\"Randomized\",\n",
      "            \"DesignInterventionModel\":\"Single Group Assignment\",\n",
      "            \"DesignPrimaryPurpose\":\"Prevention\",\n",
      "            \"DesignMaskingInfo\":{\n",
      "              \"DesignMasking\":\"None (Open Label)\"\n",
      "            }\n",
      "          },\n",
      "          \"Enrollment Info\":{\n",
      "            \"Enrollment Count\":\"46\",\n",
      "            \"Enrollment Type\":\"Anticipated\"\n",
      "          }\n",
      "        },\n",
      "        \"Arms Interventions Module\":{\n",
      "          \"Arm Group List\":{\n",
      "            \"Arm Group\":[\n",
      "              {\n",
      "                \"Arm GroupLabel\":\"blank control\",\n",
      "                \"Arm GroupType\":\"Experimental\",\n",
      "                \"Arm GroupDescription\":\"No intervention aiming at preventing thrombocytopenia will be taken after first cycle. Avatrombopag as salvage treatment will be administered to patients suffering from thrombocytopenia with nadir platelet count < 50 × 109/L at a dose of 60mg/day until there is drug-withdrawal indication.\",\n",
      "                \"Arm GroupIntervention List\":{\n",
      "                  \"Arm GroupInterventionName\":[\n",
      "                    \"Drug: avatrombopag\"\n",
      "                  ]\n",
      "                }\n",
      "              },{\n",
      "                \"Arm GroupLabel\":\"primary prevention\",\n",
      "                \"Arm GroupType\":\"Experimental\",\n",
      "                \"Arm GroupDescription\":\"As the primary prevention of thrombocytopenia induced by cytarabine-based chemotherapy, Avatrombopag will be administered at a dose of 60mg/day on days -3~-1 and 3~9, for a total of 10 doses. On the condition that patients have platelet counts <50 × 10 9 /L before next cycle, Avatrombopag will be administered at a dose of 60mg/day until there is drug-withdrawal indications. Platelet transfusions were administered to patients when the platelet count was less than 10×109 /L.\n",
      "\n",
      "Drug-withdrawal indications:\n",
      "\n",
      "PLT ≥ 100×109/L during salvage treatment or platelet count increases by 50×109/L, comparing with baseline level.\n",
      "\n",
      "When platelet count is higher than 400×109/L during this study, researchers determine whether avatrombopag is discontinued\",\n",
      "                \"Arm GroupIntervention List\":{\n",
      "                  \"Arm GroupInterventionName\":[\n",
      "                    \"Drug: avatrombopag\"\n",
      "                  ]\n",
      "                }\n",
      "              }\n",
      "            ]\n",
      "          },\n",
      "          \"Intervention List\":{\n",
      "            \"Intervention\":[\n",
      "              {\n",
      "                \"InterventionType\":\"Drug\",\n",
      "                \"InterventionName\":\"avatrombopag\",\n",
      "                \"InterventionDescription\":\"avatrombopag,60 mg/d,po\",\n",
      "                \"InterventionArm GroupLabelList\":{\n",
      "                  \"InterventionArm GroupLabel\":[\n",
      "                    \"blank control\",\n",
      "                    \"primary prevention\"\n",
      "                  ]\n",
      "                }\n",
      "              }\n",
      "            ]\n",
      "          }\n",
      "        },\n",
      "        \"Outcomes Module\":{\n",
      "          \"Primary Outcome List\":{\n",
      "            \"Primary Outcome\":[\n",
      "              {\n",
      "                \"Primary Outcome Measure\":\"The incidence of grades III and IV thrombocytopenia\",\n",
      "                \"Primary OutcomeTimeFrame\":\"2 years\"\n",
      "              }\n",
      "            ]\n",
      "          },\n",
      "          \"Secondary Outcome List\":{\n",
      "            \"Secondary Outcome\":[\n",
      "              {\n",
      "                \"Secondary Outcome Measure\":\"The durations of any grade thrombocytopenia and grades II, III and IV thrombocytopenia\",\n",
      "                \"Secondary OutcomeTimeFrame\":\"2 years\"\n",
      "              }\n",
      "            ]\n",
      "          }\n",
      "        },\n",
      "        \"Eligibility Module\":{\n",
      "          \"Eligibility Criteria\":\"Inclusion Criteria:\n",
      "\n",
      "Histologically confirmed lymphoma;\n",
      "Patients are scheduled to receive cytarabine-based chemotherapy including Ara-C at dose of 4g/m2.\n",
      "Eastern Cooperative Oncology Group (ECOG) of 0-1;\n",
      "Proper functioning of the major organs: 1) The absolute value of neutrophils (>1.5×10^9/L); platelet count (> 100×10^9/L); Hemoglobin (> 90 g/L); 2) Serum total bilirubin < 1.5 times ULN; Aspartate Aminotransferase (AST), Alanine Aminotransferase (ALT) < 3 times ULN;3) Serum creatinine <1.5 times Upper Limit Normal (ULN) ; 4) Coagulation function: International Normalized Ratio (INR), Prothrombin Time (PT)< 1.5 times ULN\n",
      "Able to use oral drugs\n",
      "Patients volunteer to sign an informed consent\n",
      "Life expectancy > 3 months;\n",
      "Contraceptives are used\n",
      "\n",
      "Exclusion Criteria:\n",
      "\n",
      "Thrombocytopenia unrelated to chemotherapy during six months before screening, including but not limited to hypersplenism, infection and hemorrhage.\n",
      "In addtion to CIT caused by lymphoma and chemotherapy,patients also suffer from other blood diseases including ALL, AML, myeloid neoplasms, MDS, myeloproliferative disorders, MM;\n",
      "A thrombosis of a coronary artery or vein developed during three months before screening;\n",
      "Haemorrhage with severe clinical symptoms, such as gastrointestinal and cerebral hemorrhage;\n",
      "Platelet transfusion during two days before randomization;\n",
      "Allergic to avatrombopag;\n",
      "Participation in any other research about novel agents or devices;\n",
      "Pregnant or breastfeeding women;\n",
      "Researchers consider it unsuitable for patients to participate in this study.\",\n",
      "          \"Healthy Volunteers\":\"No\",\n",
      "          \"Gender\":\"All\",\n",
      "          \"Minimum Age\":\"18 Years\",\n",
      "          \"MaximumAge\":\"70 Years\",\n",
      "          \"Std Age List\":{\n",
      "            \"Std Age\":[\n",
      "              \"Adult\",\n",
      "              \"Older Adult\"\n",
      "            ]\n",
      "          }\n",
      "        },\n",
      "        \"Contacts Locations Module\":{\n",
      "          \"CentralContactList\":{\n",
      "            \"CentralContact\":[\n",
      "              {\n",
      "                \"CentralContactName\":\"Qingqing Cai, MD\",\n",
      "                \"CentralContactRole\":\"Contact\",\n",
      "                \"CentralContactPhone\":\"0086-20-87342823\",\n",
      "                \"CentralContactEMail\":\"caiqq@sysucc.org.cn\"\n",
      "              },{\n",
      "                \"CentralContactName\":\"Cai\",\n",
      "                \"CentralContactRole\":\"Contact\"\n",
      "              }\n",
      "            ]\n",
      "          },\n",
      "          \"Overall Official List\":{\n",
      "            \"Overall Official\":[\n",
      "              {\n",
      "                \"Overall OfficialName\":\"Qingqing Cai, MD\",\n",
      "                \"Overall OfficialAffiliation\":\"Sun Yat-sen University\",\n",
      "                \"Overall OfficialRole\":\"Principal Investigator\"\n",
      "              }\n",
      "            ]\n",
      "          },\n",
      "          \"Location List\":{\n",
      "            \"Location\":[\n",
      "              {\n",
      "                \"LocationFacility\":\"Sun Yat-sen University Cancer Center\",\n",
      "                \"LocationCity\":\"Guangzhou\",\n",
      "                \"LocationState\":\"Guangdong\",\n",
      "                \"LocationZip\":\"510060\",\n",
      "                \"LocationCountry\":\"China\",\n",
      "                \"LocationContactList\":{\n",
      "                  \"LocationContact\":[\n",
      "                    {\n",
      "                      \"LocationContactName\":\"Qingqing Cai, MD\",\n",
      "                      \"LocationContactRole\":\"Contact\"\n",
      "                    }\n",
      "                  ]\n",
      "                }\n",
      "              }\n",
      "            ]\n",
      "          }\n",
      "        }\n",
      "      },\n",
      "      \"Derived Section\":{\n",
      "        \"Misc Info Module\":{\n",
      "          \"Version Holder\":\"May 19, 2023\"\n",
      "        },\n",
      "        \"Condition Browse Module\":{\n",
      "          \"Condition Mesh List\":{\n",
      "            \"Condition Mesh\":[\n",
      "              {\n",
      "                \"Condition MeshId\":\"D000008223\",\n",
      "                \"Condition MeshTerm\":\"Lymphoma\"\n",
      "              },{\n",
      "                \"Condition MeshId\":\"D000013921\",\n",
      "                \"Condition MeshTerm\":\"Thrombocytopenia\"\n",
      "              }\n",
      "            ]\n",
      "          },\n",
      "          \"Condition Ancestor List\":{\n",
      "            \"Condition Ancestor\":[\n",
      "              {\n",
      "                \"Condition AncestorId\":\"D000009370\",\n",
      "                \"Condition AncestorTerm\":\"Neoplasms by Histologic Type\"\n",
      "              },{\n",
      "                \"Condition AncestorId\":\"D000009369\",\n",
      "                \"Condition AncestorTerm\":\"Neoplasms\"\n",
      "              },{\n",
      "                \"Condition AncestorId\":\"D000008232\",\n",
      "                \"Condition AncestorTerm\":\"Lymphoproliferative Disorders\"\n",
      "              },{\n",
      "                \"Condition AncestorId\":\"D000008206\",\n",
      "                \"Condition AncestorTerm\":\"Lymphatic Diseases\"\n",
      "              },{\n",
      "                \"Condition AncestorId\":\"D000007160\",\n",
      "                \"Condition AncestorTerm\":\"Immunoproliferative Disorders\"\n",
      "              },{\n",
      "                \"Condition AncestorId\":\"D000007154\",\n",
      "                \"Condition AncestorTerm\":\"Immune System Diseases\"\n",
      "              },{\n",
      "                \"Condition AncestorId\":\"D000001791\",\n",
      "                \"Condition AncestorTerm\":\"Blood Platelet Disorders\"\n",
      "              },{\n",
      "                \"Condition AncestorId\":\"D000006402\",\n",
      "                \"Condition AncestorTerm\":\"Hematologic Diseases\"\n",
      "              }\n",
      "            ]\n",
      "          },\n",
      "          \"Condition Browse Leaf List\":{\n",
      "            \"Condition Browse Leaf\":[\n",
      "              {\n",
      "                \"Condition Browse LeafId\":\"M10372\",\n",
      "                \"Condition Browse LeafName\":\"Lymphoma\",\n",
      "                \"Condition Browse LeafAsFound\":\"Lymphoma\",\n",
      "                \"Condition Browse LeafRelevance\":\"high\"\n",
      "              },{\n",
      "                \"Condition Browse LeafId\":\"M15832\",\n",
      "                \"Condition Browse LeafName\":\"Thrombocytopenia\",\n",
      "                \"Condition Browse LeafAsFound\":\"Thrombocytopenia\",\n",
      "                \"Condition Browse LeafRelevance\":\"high\"\n",
      "              },{\n",
      "                \"Condition Browse LeafId\":\"M11467\",\n",
      "                \"Condition Browse LeafName\":\"Neoplasms by Histologic Type\",\n",
      "                \"Condition Browse LeafRelevance\":\"low\"\n",
      "              },{\n",
      "                \"Condition Browse LeafId\":\"M10377\",\n",
      "                \"Condition Browse LeafName\":\"Lymphoproliferative Disorders\",\n",
      "                \"Condition Browse LeafRelevance\":\"low\"\n",
      "              },{\n",
      "                \"Condition Browse LeafId\":\"M10355\",\n",
      "                \"Condition Browse LeafName\":\"Lymphatic Diseases\",\n",
      "                \"Condition Browse LeafRelevance\":\"low\"\n",
      "              },{\n",
      "                \"Condition Browse LeafId\":\"M9358\",\n",
      "                \"Condition Browse LeafName\":\"Immunoproliferative Disorders\",\n",
      "                \"Condition Browse LeafRelevance\":\"low\"\n",
      "              },{\n",
      "                \"Condition Browse LeafId\":\"M9352\",\n",
      "                \"Condition Browse LeafName\":\"Immune System Diseases\",\n",
      "                \"Condition Browse LeafRelevance\":\"low\"\n",
      "              },{\n",
      "                \"Condition Browse LeafId\":\"M4224\",\n",
      "                \"Condition Browse LeafName\":\"Blood Platelet Disorders\",\n",
      "                \"Condition Browse LeafRelevance\":\"low\"\n",
      "              },{\n",
      "                \"Condition Browse LeafId\":\"M8642\",\n",
      "                \"Condition Browse LeafName\":\"Hematologic Diseases\",\n",
      "                \"Condition Browse LeafRelevance\":\"low\"\n",
      "              },{\n",
      "                \"Condition Browse LeafId\":\"T3543\",\n",
      "                \"Condition Browse LeafName\":\"Lymphosarcoma\",\n",
      "                \"Condition Browse LeafAsFound\":\"Lymphoma\",\n",
      "                \"Condition Browse LeafRelevance\":\"high\"\n",
      "              }\n",
      "            ]\n",
      "          },\n",
      "          \"Condition Browse Branch List\":{\n",
      "            \"Condition Browse Branch\":[\n",
      "              {\n",
      "                \"Condition Browse BranchAbbrev\":\"BC04\",\n",
      "                \"Condition Browse BranchName\":\"Neoplasms\"\n",
      "              },{\n",
      "                \"Condition Browse BranchAbbrev\":\"BC15\",\n",
      "                \"Condition Browse BranchName\":\"Blood and Lymph Conditions\"\n",
      "              },{\n",
      "                \"Condition Browse BranchAbbrev\":\"BC20\",\n",
      "                \"Condition Browse BranchName\":\"Immune System Diseases\"\n",
      "              },{\n",
      "                \"Condition Browse BranchAbbrev\":\"All\",\n",
      "                \"Condition Browse BranchName\":\"All Conditions\"\n",
      "              },{\n",
      "                \"Condition Browse BranchAbbrev\":\"Rare\",\n",
      "                \"Condition Browse BranchName\":\"Rare Diseases\"\n",
      "              }\n",
      "            ]\n",
      "          }\n",
      "        },\n",
      "        \"Intervention Browse Module\":{\n",
      "          \"Intervention Browse Leaf List\":{\n",
      "            \"Intervention Browse Leaf\":[\n",
      "              {\n",
      "                \"Intervention Browse LeafId\":\"M5918\",\n",
      "                \"Intervention Browse LeafName\":\"Cytarabine\",\n",
      "                \"Intervention Browse LeafRelevance\":\"low\"\n",
      "              }\n",
      "            ]\n",
      "          },\n",
      "          \"Intervention Browse Branch List\":{\n",
      "            \"Intervention Browse Branch\":[\n",
      "              {\n",
      "                \"Intervention Browse BranchAbbrev\":\"Infe\",\n",
      "                \"Intervention Browse BranchName\":\"Anti-Infective Agents\"\n",
      "              },{\n",
      "                \"Intervention Browse BranchAbbrev\":\"ANeo\",\n",
      "                \"Intervention Browse BranchName\":\"Antineoplastic Agents\"\n",
      "              },{\n",
      "                \"Intervention Browse BranchAbbrev\":\"All\",\n",
      "                \"Intervention Browse BranchName\":\"All Drugs and Chemicals\"\n",
      "              }\n",
      "            ]\n",
      "          }\n",
      "        }\n",
      "      }\n",
      "    }\n",
      "  }\n",
      "}\n",
      "\n",
      "临床专家\n",
      "性别：女\n",
      "首页 /临床科室 /内科系列 /内科 /临床专家\n",
      "蔡清清\n",
      "职务：科副主任\n",
      "职称：教授，主任医师，博士生导师，淋巴瘤中心主诊教授\n",
      "专长\n",
      "擅长恶性淋巴瘤和头颈癌（鼻咽癌等）的诊治及恶性肿瘤的造血干细胞移植治疗。\n",
      " \n",
      "\n",
      " \n",
      "\n",
      "姓名：蔡清清\n",
      "\n",
      " \n",
      "\n",
      "职称：内科教授，主任医师，博士生导师，淋巴瘤中心主诊教授\n",
      "专长：主要擅长恶性淋巴瘤和头颈癌（鼻咽癌等）的诊治及恶性肿瘤的造血干细胞移植治疗\n",
      "出诊时间：周一上午特需门诊，周一下午、周四上午专家门诊\n",
      "学术兼职：广东省抗癌协会血液肿瘤专业 委员，秘书；广东省抗癌协会血液肿瘤专业委员会青年委员会副主任委员；中华医学会肿瘤学分会青年委员会副主任委员，广东省女医师协会淋巴瘤专业委员会副主任委员，广东省抗癌协会化疗专业委员会委员，广东省抗癌协会淋巴瘤专业委员会 委员，广州市抗癌协会淋巴瘤专业委员会 常委\n",
      "个人简介：蔡清清教授现任中山大学肿瘤防治中心内科教授，主任医师，博士生导师，淋巴瘤中心主诊教授，中华医学会肿瘤学分会青年委员会副主委，广东省女医师协会淋巴瘤专业委员会副主委，CSCO淋巴瘤联盟专家委员会委员，广东省抗癌协会血液肿瘤专业委员会秘书、委员，广东省抗癌协会血液肿瘤专业委员会青年委员会副主委，广东省抗癌协会淋巴瘤专业委员会委员，广东省抗癌协会化疗专业委员会委员。2013-2014年在美国M.D.Anderson肿瘤中心进修。研究方向淋巴瘤和头颈癌（鼻咽癌），主持多项国家、地方政府及企事业单位项目，其中2项国家自然科学基金面上项目，1项国家自然科学青年基金项目，已在国际著名期刊发表论文40余篇，其中以第一作者和通讯作者发表20余篇，最高影响因子10.199分。培养及正在培养的博士及硕士研究生9名。获第一批广东省杰出青年医学人才，羊城好医生及广东医院最强科室实力中青年医生称号。\n",
      "加载更多\n",
      "\n",
      "蔡清清的代表性文章、成果：\n",
      "1）Cai Q, Tu M, Xu-Monette ZY, Sun R, Manyam GC, Xu X, Tzankov A, Hsi ED, Møller MB, Medeiros LJ, Ok CY, Young KH. NF-κB p50 activation associated with immune dysregulation confers poorer survival for diffuse large B-cell lymphoma patients with wild-type p53. Mod Pathol. 2017 Mar 10. doi: 10.1038/modpathol.2017.5. [Epub ahead of print] （IF=5.485）\n",
      "2）Qian D, Chen K, Deng H, Rao H, Huang H, Liao Y, Sun X, Lu S, Yuan Z, Xie D, Cai Q (corresponding author). MicroRNA-374b Suppresses Proliferation and Promotes Apoptosis in T-cell Lymphoblastic Lymphoma by Repressing AKT1 and Wnt-16. Clin Cancer Res. 2015 Jun 22. [Epub ahead of print] （IF=9.6）\n",
      "3）Chen K, Liu Y, Li W, Chen J, Gu Y, Geng Q, Jiang W, Huang H, Lin T, Xia Z, Cai Q (corresponding author). The prognostic nutritional index predicts survival for patients with extranodal natural killer/T cell lymphoma, nasal type. Ann Hematol. 2015 Aug;94(8):1389-400. （IF=3.083）\n",
      "4）Cai Q, Luo X, Zhang G, Huang H, Huang H, Lin T, Jiang W, Xia Z, Young KH. New prognostic model for extranodal natural killer/T cell lymphoma, nasal type. Ann Hematol. 2014 Sep;93(9):1541-9. （IF=3.083）\n",
      "5）Cai Q, Luo X, Liang Y, Rao H, Fang X, Jiang W, Lin T, Lin T, Huang H. Fasting blood glucose is a novel prognostic indicator for extranodal natural killer/T-cell lymphoma, nasal type. British Journal of Cancer. 2013,108(2):380-386（IF=5.569）\n",
      "6.）Cai Q, Deng H, Xie D, Lin T, Lin T. Phosphorylated AKT Protein Is Overexpressed in Human Peripheral T-cell Lymphomas and Predicts Decreased Patient Survival. Clin Lymphoma Myeloma Leuk. 2012;12(2):106-12. （IF=2.316）\n",
      "7）Cai Q, Chen K, Chen J, Wu S, Geng Q, Huang H, Lin T, Jiang W, Xia Z, Duan H, Rao H, Yao M, Hu L. The Effect of Prophylactic Lamivudine plus Adefovir Therapy Compared with Lamivudine Alone in Preventing Hepatitis B Reactivation in Lymphoma Patients with High Baseline HBV DNA during Chemotherapy. PLoS One. 2016 Oct 6;11(10):e0164210. doi: 10.1371/journal.pone.0164210. eCollection 2016. （IF=3.057）\n",
      "8）Cai Q, Hu L, Geng Q, Chen J, Lu Z, Rao H, Liu Q, Jiang W, Huang H, Lin T, Xia Z. New risk  factors and new tendency for central nervous system relapse in patients with diffuse large  B-cell lymphoma: a retrospective study. Chin J Cancer. 2016 Sep 13;35(1):87. doi:  10.1186/s40880-016-0150-y. （IF=4.111）\n",
      "9）Cai Q, Medeiros LJ, Xu X, Young KH. MYC-driven aggressive B-cell lymphomas: biology, entity, differential diagnosis and clinical management [Review]. Oncotarget. 2015. （IF=5.008）\n",
      "10）Chen K, Chen J, Rao H, Guo Y, Huang H, Zhang L, Shao J, Lin T, Jiang W, Zou D, Hu L, Wirian M, Cai Q (corresponding author). Hepatitis B virus reactivation and hepatitis in diffuse large B-cell lymphoma patients with resolved hepatitis B receiving rituximab-containing chemotherapy: riskfactors and survival. Chin J Cancer. 2015 May 28;34(5):225-34. （IF=4.111）\n",
      "11）Cai Q, Chen Y, Zou D, Zhang L, Badillo M, Zhou S, Lopez E, Jiang W, HuangH, Lin T, Romaguera J, Wang M. Clinical outcomes of a novel combination of lenalidomide and rituximab followed by stem cell transplantation for relapsed/refractory aggressive B-cell non-hodgkin lymphoma. Oncotarget. 2014 Sep 15;5(17):7368-809（IF=5.008）\n",
      "12）Cai Q, Westin J, Fu K, Desai M, Zhang L, Huang H, Jiang W, Liang R, Qian Z, Champlin RE, Wang M. Accelerated therapeutic progress in diffuse large B cell lymphoma [Review]. Ann Hematol. 2014 Apr;93(4):541-56. （IF=3.083）\n",
      "13）Cai Q, Huang H, Qian D, Chen K, Luo J, Tian Y, Lin T, LinT. 13-Methyltetradecanoic Acid Exhibits Anti-Tumor Activity on T-Cell Lymphomas In Vitro and In Vivo by Down-Regulating p-AKT and ActivatingCaspase-3.PLoS One. 2013 Jun 7;8(6):e65308.（IF=3.057）\n",
      "14） Huang H, Cai Q (co-first author) , Lin T, Lin X, Liu Y, Gao Y, Peng R.   Lamivudine for the prevention of hepatitis B virus reactivation after high-dose chemotherapy and autologous hematopoietic stem cell transplantation for patients with advanced or relapsed non-Hodgkin's lymphoma single institution experience. Expert Opin Pharmacother. 2009;10(15):2399-406. （IF=3.543）\n",
      "15） Cai Q, Huang H, Sun X, Xia Z, Li Y, Lin X, Guo Y. Efficacy and safety of transdermal fentanyl for treatment of oral mucositis pain caused by chemotherapy. Expert Opin Pharmacother. 2008;9(18):3137-44. （IF=3.543）\n",
      "\n",
      "    ---------\n",
      "\n",
      "\n",
      "2023-06-14 14:42:35,574 - common.py - [line]:37 - INFO - json_dict:{'id': 'chatcmpl-7REV3eLC4bXKSYWc5YDsHPdZ1vBli', 'object': 'chat.completion', 'created': 1686724949, 'model': 'gpt-3.5-turbo-16k-0613', 'choices': [{'index': 0, 'message': {'role': 'assistant', 'content': '蔡清清的专长是恶性淋巴瘤（包括非霍奇金淋巴瘤）和头颈癌（如鼻咽癌）的诊治，以及恶性肿瘤的造血干细胞移植治疗。她还对预防白血病细胞钟31的变异具有专长。蔡清清教授在该领域进行了大量的研究，并发表了多篇国内外著名期刊的文章。她还担任多个学术组织的委员和副主任委员，积极参与各种学术活动。'}, 'finish_reason': 'stop'}], 'usage': {'prompt_tokens': 15664, 'completion_tokens': 203, 'total_tokens': 15867}}\n",
      "2023-06-14 14:42:35,574 - common.py - [line]:40 - INFO - 蔡清清的专长是恶性淋巴瘤（包括非霍奇金淋巴瘤）和头颈癌（如鼻咽癌）的诊治，以及恶性肿瘤的造血干细胞移植治疗。她还对预防白血病细胞钟31的变异具有专长。蔡清清教授在该领域进行了大量的研究，并发表了多篇国内外著名期刊的文章。她还担任多个学术组织的委员和副主任委员，积极参与各种学术活动。\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "+++++++++++++++++++++++++\n",
      "蔡清清的专长是恶性淋巴瘤（包括非霍奇金淋巴瘤）和头颈癌（如鼻咽癌）的诊治，以及恶性肿瘤的造血干细胞移植治疗。她还对预防白血病细胞钟31的变异具有专长。蔡清清教授在该领域进行了大量的研究，并发表了多篇国内外著名期刊的文章。她还担任多个学术组织的委员和副主任委员，积极参与各种学术活动。\n"
     ]
    }
   ],
   "source": [
    "chat(cqq_txt,\"蔡清清的专长\")"
   ],
   "metadata": {
    "collapsed": false,
    "ExecuteTime": {
     "end_time": "2023-06-14T06:42:35.591497500Z",
     "start_time": "2023-06-14T06:42:24.410407Z"
    }
   }
  },
  {
   "cell_type": "code",
   "execution_count": 4,
   "outputs": [],
   "source": [
    "xrh_txt = \"\"\"\n",
    "[\n",
    "  {\n",
    "    \"_id\": \"648019f5778538384fd02da2\",\n",
    "    \"avatar\": null,\n",
    "    \"name\": \"Ruihua Xu\",\n",
    "    \"hospital\": \"Sun Yat-sen University\",\n",
    "    \"title\": \" MD\",\n",
    "    \"position\": null,\n",
    "    \"contact\": \"xuruihua@sysucc.org.cn\",\n",
    "    \"phone\": \"86-20-87343333\",\n",
    "    \"expertise\": \"Colorectal Carcinoma, pMMR, Microsatellite-stable\",\n",
    "    \"brief_intro\": \"A Study of Sintilimab and Chidamide in Combination With or Without IBI305 in Standard Treatment Failure of Advanced or Metastatic pMMR/MSS Colorectal Carcinoma\",\n",
    "    \"work_exp\": null,\n",
    "    \"edu_exp\": null,\n",
    "    \"consulting\": null,\n",
    "    \"publications\": null,\n",
    "    \"clinical_res\": null,\n",
    "    \"awards\": null\n",
    "  },\n",
    "  {\n",
    "    \"_id\": \"64803f25f24b55a336ba235d\",\n",
    "    \"avatar\": null,\n",
    "    \"name\": \"ruihua Xu\",\n",
    "    \"hospital\": \"Peking University\",\n",
    "    \"title\": \"M.D., Ph.D.\",\n",
    "    \"position\": null,\n",
    "    \"contact\": \"xurh@mail.sysu.edu.cn\",\n",
    "    \"phone\": \"13922206676\",\n",
    "    \"expertise\": \"nimotuzumab colorectal cancer chemotherapy\",\n",
    "    \"brief_intro\": null,\n",
    "    \"work_exp\": null,\n",
    "    \"edu_exp\": null,\n",
    "    \"consulting\": null,\n",
    "    \"publications\": null,\n",
    "    \"clinical_res\": \"Study of Nimotuzumab to Treat Colorectal Cancer\",\n",
    "    \"awards\": null\n",
    "  },\n",
    "  {\n",
    "    \"_id\": \"6480ea13f24b55a336bec613\",\n",
    "    \"avatar\": null,\n",
    "    \"name\": \"Ruihua Xu\",\n",
    "    \"hospital\": \"Sun Yat-sen University\",\n",
    "    \"title\": \"MD\",\n",
    "    \"position\": null,\n",
    "    \"contact\": \"xurh@susycc.org.cn\",\n",
    "    \"phone\": \"+862087343795\",\n",
    "    \"expertise\": \"Colorectal Cancer,Microsatellite Stable,Chidamide,Sintilimab,PD-1,Bevacizumab\",\n",
    "    \"brief_intro\": null,\n",
    "    \"work_exp\": null,\n",
    "    \"edu_exp\": null,\n",
    "    \"consulting\": null,\n",
    "    \"publications\": null,\n",
    "    \"clinical_res\": \"Comparing Chidamide+Sintilimab+Bev With Standard Second-line FOLFIRI+Bev in Advanced MSS/pMMR mCRC\",\n",
    "    \"awards\": null\n",
    "  }\n",
    "]\n",
    "[\n",
    "  {\n",
    "    \"NCT_No\": \"NCT05830045\",\n",
    "    First_Submitted_Date\": \"April 4, 2023\",\n",
    "    First_Posted_Date\": \"April 26, 2023\",\n",
    "    Last_Update_Posted_Date\": \"April 26, 2023\",\n",
    "    Estimated__Study_Start_Date\": \"April 20, 2023\",\n",
    "    Estimated_Primary_Completion_Date\": \"April 30, 2025   (Final data collection date for primary outcome measure)\",\n",
    "    Current_Primary_Outcome_Measures\": \"[List]\",\n",
    "    Original_Primary_Outcome_Measures\": \"Same as current\",\n",
    "    Change_History\": \"No Changes Posted\",\n",
    "    Current_Secondary_Outcome_Measures\": \"Not Provided\",\n",
    "    Original_Secondary_Outcome_Measures\": \"Not Provided\",\n",
    "    Current_Other_Pre-specified_Outcome_Measures\": \"Not Provided\",\n",
    "    Original_Other_Pre-specified_Outcome_Measures\": \"Not Provided\",\n",
    "    \"Brief_Title\": \"A Phase I Study of QLP2117 in Subjects With Advanced Solid Tumors\",\n",
    "    \"Official_Title\": \"A Study Evaluates the Safety, Pharmacokinetics, Immunogenicity and Efficacy of QLP2117 in Advanced Solid Tumor Patients\",\n",
    "    \"Brief_Summary\": \"This is the first in human study of QLP2117. To evaluate the Safety, Pharmacokinetics, Immunogenicity and Efficacy of QLP2117 in patients with advanced solid tumors.\",\n",
    "    \"Detailed_Description\": \"Not Provided\",\n",
    "    \"Study_Type\": \"Interventional\",\n",
    "    \"Study_Phase\": \"Phase 1\",\n",
    "    \"Study_Design\": \"Allocation: Non-Randomized\\nIntervention Model: Sequential Assignment\\nMasking: None (Open Label)\\nPrimary Purpose: Treatment\",\n",
    "    \"Condition\": \"Advanced Solid Tumors\",\n",
    "    \"Intervention\": \"Drug: QLP2117\\nSpecified dose on specified days\",\n",
    "    \"Study_Arms\": \"[List]\",\n",
    "    \"Publications_*\": \"Not Provided\",\n",
    "    \"Recruitment_Status\": \"Not yet recruiting\",\n",
    "    \"Estimated_Enrollment\": \"180\",\n",
    "    \"Original_Estimated_Enrollment\": \"Same as current\",\n",
    "    \"Estimated_Study_Completion_Date\": \"December 31, 2025\",\n",
    "    \"Estimated_Primary_Completion_Date\": \"April 30, 2025   (Final data collection date for primary outcome measure)\",\n",
    "    \"Eligibility_Criteria\": \"[List]\",\n",
    "    \"Sex/Gender\": \"Sexes Eligible for Study:\\n   All\",\n",
    "    \"Ages\": \"18 Years and older   (Adult, Older Adult)\",\n",
    "    \"Accepts_Healthy_Volunteers\": \"No\",\n",
    "    \"Contacts\": \"Contact: Zhang Meijiang, PhD\\n   8615210162105\\n   meijiang.zhang@qilu-pharma.com\",\n",
    "    \"Listed_Location_Countries\": \"Not Provided\",\n",
    "    \"Removed_Location_Countries\": null,\n",
    "    \"NCT_Number\": \"NCT05830045\",\n",
    "    \"Other_Study_ID_Numbers\": \"QLP2117-101\",\n",
    "    \"Has_Data_Monitoring_Committee\": \"No\",\n",
    "    \"U.S._FDA-regulated_Product\": \"[List]\",\n",
    "    \"IPD_Sharing_Statement\": \"Plan to Share IPD:\\n   No\",\n",
    "    \"Current_Responsible_Party\": \"Qilu Pharmaceutical Co., Ltd.\",\n",
    "    \"Original_Responsible_Party\": \"Same as current\",\n",
    "    \"Current_Study_Sponsor\": \"Qilu Pharmaceutical Co., Ltd.\",\n",
    "    \"Original_Study_Sponsor\": \"Same as current\",\n",
    "    \"Collaborators\": \"Not Provided\",\n",
    "    \"Investigators\": \"Principal Investigator:\\n   Xu Ruihua, PhD\\n   Sun Yat-sen University\",\n",
    "    \"PRS_Account\": \"Qilu Pharmaceutical Co., Ltd.\",\n",
    "    \"Verification_Date\": \"April 2023\"\n",
    "  },\n",
    "  {\n",
    "    \"NCT_No\": \"NCT05727839\",\n",
    "    First_Submitted_Date\": \"February 1, 2023\",\n",
    "    First_Posted_Date\": \"February 14, 2023\",\n",
    "    Last_Update_Posted_Date\": \"March 20, 2023\",\n",
    "    Estimated__Study_Start_Date\": \"February 24, 2023\",\n",
    "    Estimated_Primary_Completion_Date\": \"July 24, 2025   (Final data collection date for primary outcome measure)\",\n",
    "    Current_Primary_Outcome_Measures\": \"[List]\",\n",
    "    Original_Primary_Outcome_Measures\": \"[List]\",\n",
    "    Change_History\": \"Complete list of historical versions of study NCT05727839 on ClinicalTrials.gov Archive Site\",\n",
    "    Current_Secondary_Outcome_Measures\": \"[List]\",\n",
    "    Original_Secondary_Outcome_Measures\": \"[List]\",\n",
    "    Current_Other_Pre-specified_Outcome_Measures\": \"Not Provided\",\n",
    "    Original_Other_Pre-specified_Outcome_Measures\": \"Not Provided\",\n",
    "    \"Brief_Title\": \"Study to Evaluate JCXH-211 as Monotherapy in Patients With Malignant Solid Tumors\",\n",
    "    \"Official_Title\": \"A Phase 1 Open-Label Study to Evaluate the Safety, Tolerability and Efficacy of JCXH-211 Intratumoral Injection in Patients With Malignant Solid Tumors\",\n",
    "    \"Brief_Summary\": \": A Phase 1 Open-Label Study to Evaluate the Safety, Tolerability and Efficacy of JCXH-211 Intratumoral Injection in Patients with Malignant Solid Tumors\",\n",
    "    \"Detailed_Description\": \"The main purpose of this study is to find out how safe and tolerable the study drug, JCXH-211, is and also how well it works in people with malignant solid tumors. The study drug JCXH-211, is an immunotherapy drug. This means that it aims to work by boosting immune system's response to tumors, to help fight against the growth of the cancer cells. The study has 2 main phases: Phase\\n  1a and Phase 1b. Phase 1a has 2 stages, skin/subcutaneous lesions stage, deep (visceral) lesions stage. Phase 1b will not start until all the data collected in Phase 1a has been completed and reviewed to check that it is safe and well tolerated.\",\n",
    "    \"Study_Type\": \"Interventional\",\n",
    "    \"Study_Phase\": \"Phase 1\",\n",
    "    \"Study_Design\": \"Allocation: Non-Randomized\\nIntervention Model: Single Group Assignment\\nMasking: None (Open Label)\\nPrimary Purpose: Treatment\",\n",
    "    \"Condition\": \"[List]\",\n",
    "    \"Intervention\": \"Drug: JCXH-211 Injection\\nJCXH-211 administered once every 28 days\\nOther Name: Intratumoral injection\",\n",
    "    \"Study_Arms\": \"[List]\",\n",
    "    \"Publications_*\": \"Not Provided\",\n",
    "    \"Recruitment_Status\": \"Recruiting\",\n",
    "    \"Estimated_Enrollment\": \"156\",\n",
    "    \"Original_Estimated_Enrollment\": \"Same as current\",\n",
    "    \"Estimated_Study_Completion_Date\": \"August 24, 2025\",\n",
    "    \"Estimated_Primary_Completion_Date\": \"July 24, 2025   (Final data collection date for primary outcome measure)\",\n",
    "    \"Eligibility_Criteria\": \"[List]\",\n",
    "    \"Sex/Gender\": \"Sexes Eligible for Study:\\n   All\",\n",
    "    \"Ages\": \"18 Years to 75 Years   (Adult, Older Adult)\",\n",
    "    \"Accepts_Healthy_Volunteers\": \"No\",\n",
    "    \"Contacts\": \"Contact: Qi Wang\\n   +8613381113913\\n   qi.wang@immorna.com\",\n",
    "    \"Listed_Location_Countries\": \"China\",\n",
    "    \"Removed_Location_Countries\": null,\n",
    "    \"NCT_Number\": \"NCT05727839\",\n",
    "    \"Other_Study_ID_Numbers\": \"JCXH-211-003\",\n",
    "    \"Has_Data_Monitoring_Committee\": \"Not Provided\",\n",
    "    \"U.S._FDA-regulated_Product\": \"[List]\",\n",
    "    \"IPD_Sharing_Statement\": \"Not Provided\",\n",
    "    \"Current_Responsible_Party\": \"Immorna Biotherapeutics, Inc.\",\n",
    "    \"Original_Responsible_Party\": \"Same as current\",\n",
    "    \"Current_Study_Sponsor\": \"Immorna Biotherapeutics, Inc.\",\n",
    "    \"Original_Study_Sponsor\": \"Same as current\",\n",
    "    \"Collaborators\": \"Not Provided\",\n",
    "    \"Investigators\": \"Principal Investigator:\\n   Xu ruihua, President\\n   Sun Yat-sen University\",\n",
    "    \"PRS_Account\": \"Immorna Biotherapeutics, Inc.\",\n",
    "    \"Verification_Date\": \"March 2023\"\n",
    "  },\n",
    "  {\n",
    "    \"NCT_No\": \"NCT03544905\",\n",
    "    First_Submitted_Date\": \"May 22, 2018\",\n",
    "    First_Posted_Date\": \"June 4, 2018\",\n",
    "    Last_Update_Posted_Date\": \"January 6, 2023\",\n",
    "    Estimated__Study_Start_Date\": \"July 5, 2018\",\n",
    "    Estimated_Primary_Completion_Date\": \"June 30, 2023   (Final data collection date for primary outcome measure)\",\n",
    "    Current_Primary_Outcome_Measures\": \"MTD(Max tolerance does) [ Time Frame: 35 days ]To evaluate the MTD in patients with advanced solid tumor\",\n",
    "    Original_Primary_Outcome_Measures\": \"Same as current\",\n",
    "    Change_History\": \"Complete list of historical versions of study NCT03544905 on ClinicalTrials.gov Archive Site\",\n",
    "    Current_Secondary_Outcome_Measures\": \"Not Provided\",\n",
    "    Original_Secondary_Outcome_Measures\": \"Not Provided\",\n",
    "    Current_Other_Pre-specified_Outcome_Measures\": \"Not Provided\",\n",
    "    Original_Other_Pre-specified_Outcome_Measures\": \"Not Provided\",\n",
    "    \"Brief_Title\": \"Study to Evaluate the Safety, Tolerate, Pharmacokinetics and Preliminary Efficacy of CYH33\",\n",
    "    \"Official_Title\": \"A Multi-center, Open-label, Single Arm, Dose Escalation and Dose Extension Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of CYH33 in Advanced Solid Tumors Patients.\",\n",
    "    \"Brief_Summary\": \"This study is a Multi-center, Open-label, single arm, Dose Escalation and Dose Extension Phase 1 Study to Evaluate the Safety , Tolerability, Pharmacokinetics and Preliminary Efficacy of CYH33 in Advanced Solid Tumors Patients.\",\n",
    "    \"Detailed_Description\": \"This study includes Phase Ia and Phase Ib.\\n  In the dose climbing part of phase Ia, the safety, tolerance and pharmacokinetics characteristics of CYH33 in patients with advanced solid tumors who failed to receive standard treatment, did not tolerate or did not have standard treatment at present will be observed to determine MTD; Before determining MTD, select safe and highly reliable and effective dose levels for simultaneous expansion. Phase Ia dose expansion includes patients with advanced solid tumors who have failed to undergo standard treatment, who are intolerant of PIK3CA gene mutation, or who do not have standard treatment at present, to further evaluate safety, tolerance and initial efficacy.\\n  In Phase Ib, the safety and preliminary efficacy of CYH33 on patients with advanced breast cancer, ovarian cancer, endometrial cancer, cervical cancer, head and neck squamous cell carcinoma, esophageal and gastroesophageal junction squamous cell carcinoma, ovarian clear cell carcinoma and other solid tumors with PIK3CA gene mutation who have failed, are intolerant or do not have standard treatment at present will be evaluated.\",\n",
    "    \"Study_Type\": \"Interventional\",\n",
    "    \"Study_Phase\": \"Phase 1\",\n",
    "    \"Study_Design\": \"Allocation: N/A\\nIntervention Model: Single Group Assignment\\nMasking: None (Open Label)\\nPrimary Purpose: Treatment\",\n",
    "    \"Condition\": \"Advanced Solid Tumors\",\n",
    "    \"Intervention\": \"Drug: CYH33 for tablet\\n1mg; 5mg; 10mg; 20mg; 30mg; 50mg; 75mg; 100mg; 130mg; 160mg; 200mg; 240mgBID or QD(Decided by SMC accroding to the safty and PK data)\",\n",
    "    \"Study_Arms\": \"Experimental: Dose escalation study of CYH33\\nTo determine the maximum tolerated dose (MTD) of CYH33\\nIntervention: Drug: CYH33 for tablet\",\n",
    "    \"Publications_*\": \"Not Provided\",\n",
    "    \"Recruitment_Status\": \"Recruiting\",\n",
    "    \"Estimated_Enrollment\": \"100\",\n",
    "    \"Original_Estimated_Enrollment\": \"Same as current\",\n",
    "    \"Estimated_Study_Completion_Date\": \"March 31, 2024\",\n",
    "    \"Estimated_Primary_Completion_Date\": \"June 30, 2023   (Final data collection date for primary outcome measure)\",\n",
    "    \"Eligibility_Criteria\": \"[List]\",\n",
    "    \"Sex/Gender\": \"Sexes Eligible for Study:\\n   All\",\n",
    "    \"Ages\": \"18 Years and older   (Adult, Older Adult)\",\n",
    "    \"Accepts_Healthy_Volunteers\": \"No\",\n",
    "    \"Contacts\": \"Contact: Ruihua Xu, M.D\\n   86-20-87343804\\n   ruihxu@163.com\",\n",
    "    \"Listed_Location_Countries\": \"China\",\n",
    "    \"Removed_Location_Countries\": null,\n",
    "    \"NCT_Number\": \"NCT03544905\",\n",
    "    \"Other_Study_ID_Numbers\": \"CYH33-101\",\n",
    "    \"Has_Data_Monitoring_Committee\": \"Yes\",\n",
    "    \"U.S._FDA-regulated_Product\": \"[List]\",\n",
    "    \"IPD_Sharing_Statement\": \"Not Provided\",\n",
    "    \"Current_Responsible_Party\": \"Haihe Biopharma Co., Ltd.\",\n",
    "    \"Original_Responsible_Party\": \"Same as current\",\n",
    "    \"Current_Study_Sponsor\": \"Haihe Biopharma Co., Ltd.\",\n",
    "    \"Original_Study_Sponsor\": \"Same as current\",\n",
    "    \"Collaborators\": \"Not Provided\",\n",
    "    \"Investigators\": \"Principal Investigator:\\n   Ruihua Xu, M.D\\n   Sun Yat-sen University\",\n",
    "    \"PRS_Account\": \"Haihe Biopharma Co., Ltd.\",\n",
    "    \"Verification_Date\": \"January 2023\"\n",
    "  },\n",
    "  {\n",
    "    \"NCT_No\": \"NCT01198392\",\n",
    "    First_Submitted_Date\": \"September 1, 2010\",\n",
    "    First_Posted_Date\": \"September 10, 2010\",\n",
    "    Last_Update_Posted_Date\": \"July 25, 2011\",\n",
    "    Estimated__Study_Start_Date\": \"September 2008\",\n",
    "    Estimated_Primary_Completion_Date\": \"December 2011   (Final data collection date for primary outcome measure)\",\n",
    "    Current_Primary_Outcome_Measures\": \"Time to progression [ Time Frame: The time from randomization until objective tumor progression or death ]\",\n",
    "    Original_Primary_Outcome_Measures\": \"Same as current\",\n",
    "    Change_History\": \"Complete list of historical versions of study NCT01198392 on ClinicalTrials.gov Archive Site\",\n",
    "    Current_Secondary_Outcome_Measures\": \"Response rate [ Time Frame: 2 months ]\",\n",
    "    Original_Secondary_Outcome_Measures\": \"Same as current\",\n",
    "    Current_Other_Pre-specified_Outcome_Measures\": \"Not Provided\",\n",
    "    Original_Other_Pre-specified_Outcome_Measures\": \"Not Provided\",\n",
    "    \"Brief_Title\": \"Trial of S-1 Plus Cisplatin in Gastric Cancer\",\n",
    "    \"Official_Title\": \"A Clinical Trial of S-1 Plus Cisplatin Versus 5-FU Plus Cisplatin in Patients With Unresectable or Advanced Gastric Cancer\",\n",
    "    \"Brief_Summary\": \"The purpose of this study is to evaluate the effectiveness and safety of s-1 plus cisplatin versus 5-FU plus cisplatin as first-line therapy in the treatment of patients with advanced gastric cancer.\",\n",
    "    \"Detailed_Description\": \"This is a randomized, controlled, open-label,multicenter study. Patients are randomized to one of two treatment arms : S-1 plus cisplatin and 5-FU plus cisplatin.\",\n",
    "    \"Study_Type\": \"Interventional\",\n",
    "    \"Study_Phase\": \"Phase 3\",\n",
    "    \"Study_Design\": \"Allocation: Randomized\\nIntervention Model: Parallel Assignment\\nMasking: None (Open Label)\\nPrimary Purpose: Treatment\",\n",
    "    \"Condition\": \"Gastric Cancer\",\n",
    "    \"Intervention\": \"[List]\",\n",
    "    \"Study_Arms\": \"[List]\",\n",
    "    \"Publications_*\": \"Li YH, Qiu MZ, Xu JM, Sun GP, Lu HS, Liu YP, Zhong MZ, Zhang HL, Yu SY, Li W, Hu XH, Wang JJ, Cheng Y, Zhou JT, Guo ZQ, Guan ZG, Xu RH. S-1 plus cisplatin versus fluorouracil plus cisplatin in advanced gastric or gastro-esophageal junction adenocarcinoma patients: a pilot study. Oncotarget. 2015 Oct 27;6(33):35107-15. doi: 10.18632/oncotarget.5959.\",\n",
    "    \"Recruitment_Status\": \"Unknown status\",\n",
    "    \"Estimated_Enrollment\": \"270\",\n",
    "    \"Original_Estimated_Enrollment\": \"Same as current\",\n",
    "    \"Estimated_Study_Completion_Date\": \"December 2011\",\n",
    "    \"Estimated_Primary_Completion_Date\": \"December 2011   (Final data collection date for primary outcome measure)\",\n",
    "    \"Eligibility_Criteria\": \"[List]\",\n",
    "    \"Sex/Gender\": \"Sexes Eligible for Study:\\n   All\",\n",
    "    \"Ages\": \"18 Years to 75 Years   (Adult, Older Adult)\",\n",
    "    \"Accepts_Healthy_Volunteers\": \"No\",\n",
    "    \"Contacts\": \"Contact information is only displayed when the study is recruiting subjects\",\n",
    "    \"Listed_Location_Countries\": \"China\",\n",
    "    \"Removed_Location_Countries\": null,\n",
    "    \"NCT_Number\": \"NCT01198392\",\n",
    "    \"Other_Study_ID_Numbers\": \"2005L02859\",\n",
    "    \"Has_Data_Monitoring_Committee\": \"Yes\",\n",
    "    \"U.S._FDA-regulated_Product\": \"Not Provided\",\n",
    "    \"IPD_Sharing_Statement\": \"Not Provided\",\n",
    "    \"Current_Responsible_Party\": \"Zhongzhen Guan ,Ruihua Xu, Sun Yat-sen University Cancer Center\",\n",
    "    \"Original_Responsible_Party\": \"Same as current\",\n",
    "    \"Current_Study_Sponsor\": \"Sun Yat-sen University\",\n",
    "    \"Original_Study_Sponsor\": \"Same as current\",\n",
    "    \"Collaborators\": \"Not Provided\",\n",
    "    \"Investigators\": \"Principal Investigator:\\n   RUIHUA XU, Professor\\n   Sun Yat-sen University\",\n",
    "    \"PRS_Account\": \"Sun Yat-sen University\",\n",
    "    \"Verification_Date\": \"August 2008\"\n",
    "  }\n",
    "]\n",
    "\n",
    "徐瑞华，医学博士，中山大学肿瘤防治中心主任、医院院长、研究所所长，华南恶性肿瘤防治全国重点实验室主任，教授，博士生导师。\n",
    "\n",
    "中国医学科学院学部委员，中国临床肿瘤学会理事长，中国抗癌协会副理事长，中国抗癌协会靶向治疗专委会首届主任委员，中国抗癌协会化疗专委会候任主任委员，中国临床肿瘤学会肠癌专委会主任委员，《Cancer Communications》主编，研究生教材《肿瘤学》主编，本科生教材《临床肿瘤学》主编。\n",
    "\n",
    "从事肿瘤内科临床及科研工作30余年，取得突破性成果：\n",
    "\n",
    "第一，实现了肠癌诊治理论和实践的系统创新，使我国肠癌早诊及精准治疗均处于国际先进水平。创新了肠癌早诊及疗效预测的新技术，并已转化为临床应用；建立了晚期肠癌治疗新体系，创建了高效低毒的维持方案和亚洲方案，成为国际治疗新标准，晚期肠癌生存率与国际顶尖的安德森癌症中心达相同水平。\n",
    "\n",
    "第二，创新了消化肿瘤免疫治疗体系，引领国际消化肿瘤免疫治疗发展。\n",
    "\n",
    "通过鉴定TMB、POLE/POLD突变等标志物，精准筛选免疫治疗敏感亚型，大幅提高PD-1抗体疗效；首创了食管癌中国免疫联合方案，取得全球最高有效率72%，已成为食管癌治疗应用最广泛的方案；建立了食管癌EGIC分型，可以指导精准免疫治疗策略，引领该领域的发展；揭示了免疫逃逸新机制并推动了药物的开发：发现甲硫氨酸限制饮食可抑制免疫检查点分子PDL1及VISTA的表达，增强抗肿瘤免疫及抗PD1的治疗效果；鉴定出免疫治疗增效肠道活性菌RX-af01，成果已转化。\n",
    "\n",
    "以通讯或第一作者在国际顶级期刊JAMA、Nature Materials、Nature Medicine、Lancet Oncology等发表SCI论文200余篇，入选科睿唯安（Clarivate Analytics）全球高被引科学家，连续入选中国高被引学者榜单。以第一完成人获国家科技进步二等奖2项及省部级一等奖6项、吴阶平医药创新奖、谈家桢临床医学奖及CSCO年度成就奖。入选国家百千万人才工程、全国先进工作者、南粤百杰人才培养工程、国家卫生计生突出贡献中青年专家等人才项目。\n",
    "\n",
    "Representative paper: （*：第一作者，#：通讯作者）\n",
    "\n",
    "[1]     Luo H, Lu J, Bai Y, Mao T, Wang J, Fan Q, Zhang Y, Zhao K, Chen Z, Gao S, Li J, Fu Z, Gu K, Liu Z, Wu L, Zhang X, Feng J, Niu Z, Ba Y, Zhang H, Liu Y, Zhang L, Min X, Huang J, Cheng Y, Wang D, Shen Y, Yang Q, Zou J, Xu RH# ESCORT-1st Investigators.  Effect of Camrelizumab vs Placebo Added to Chemotherapy on Survival and Progression-Free Survival in Patients With Advanced or Metastatic Esophageal Squamous Cell Carcinoma: The ESCORT-1st Randomized Clinical Trial. JAMA. 2021 Sep 14;326(10):916-925.\n",
    "\n",
    "[2]     Xu RH*#, Wei W, Krawczyk M, Wang W, Luo H, Flagg K, Yi S, Shi W, Quan Q, Li K, Zheng L, Zhang H, Caughey BA, Zhao Q, Hou J, Zhang R, Xu Y, Cai H, Li G, Hou R, Zhong Z, Lin D, Fu X, Zhu J, Duan Y, Yu M, Ying B, Zhang W, Wang J, Zhang E, Zhang C, Li O, Guo R, Carter H, Zhu JK, Hao X and Zhang K. Circulating tumour DNA methylation markers for diagnosis and prognosis of hepatocellular carcinoma. Nat Mater 2017; 16: 1155-1161.\n",
    "\n",
    "[3]     Xu RH*#, Muro K, Morita S, Iwasa S, Han SW, Wang W, Kotaka M, Nakamura M, Ahn JB, Deng YH, Kato T, Cho SH, Ba Y, Matsuoka H, Lee KW, Zhang T, Yamada Y, Sakamoto J, Park YS and Kim TW. Modified XELIRI (capecitabine plus irinotecan) versus FOLFIRI (leucovorin, fluorouracil, and irinotecan), both either with or without bevacizumab, as second-line therapy for metastatic colorectal cancer (AXEPT): a multicentre, open-label, randomised, non-inferiority, phase 3 trial. Lancet Oncol 2018; 19: 660-671.\n",
    "\n",
    "[4]     Li J, Qin S, Xu R*, Yau TC, Ma B, Pan H, Xu J, Bai Y, Chi Y, Wang L, Yeh KH, Bi F, Cheng Y, Le AT, Lin JK, Liu T, Ma D, Kappeler C, Kalmus J and Kim TW. Regorafenib plus best supportive care versus placebo plus best supportive care in Asian patients with previously treated metastatic colorectal cancer (CONCUR): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncology 2015; 16: 619-629.\n",
    "\n",
    "[5]     Luo H, Xu G, Li C, He L, Luo L, Wang Z, Jing B, Deng Y, Jin Y, Li Y, Li B, Tan W, He C, Seeruttun SR, Wu Q, Huang J, Huang DW, Chen B, Lin SB, Chen QM, Yuan CM, Chen HX, Pu HY, Zhou F, He Y, Xu RH#. Real-time artificial intelligence for detection of upper gastrointestinal cancer by endoscopy: a multicentre, case-control, diagnostic study. Lancet Oncol. 2019 Oct 4.\n",
    "\n",
    "[6]     Satoh T, Xu RH*, Chung HC, Sun GP, Doi T, Xu JM, Tsuji A, Omuro Y, Li J, Wang JW, Miwa H, Qin SK, Chung IJ, Yeh KH, Feng JF, Mukaiyama A, Kobayashi M, Ohtsu A and Bang YJ. Lapatinib plus paclitaxel versus paclitaxel alone in the second-line treatment of HER2-amplified advanced gastric cancer in Asian populations: TyTAN--a randomized, phase III study. Journal of Clinical Oncology 2014; 32: 2039-2049.\n",
    "\n",
    "[7]     Manish A. Shah, Rui-hua Xu*, Yung-Jue Bang, Paulo M. Hoff, Tianshu Liu, Luis A. Herr´aez-Baranda, Fan Xia,Amit Garg, Mona Shing, and Josep Tabernero. HELOISE: Phase IIIb Randomized Multicenter Study Comparing Standard-of-Care and Higher-Dose Trastuzumab Regimens Combined With Chemotherapy as First-Line Therapy in Patients With Human Epidermal Growth Factor Receptor 2–Positive Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma. Journal of Clinical Oncology 2017; 35: 2558-2567.\n",
    "\n",
    "[8]     Wang ZX, Cui C, Yao J, Zhang Y, Li M, Feng J, Yang S, Fan Y, Shi J, Zhang X, Shen L, Shu Y, Wang C, Dai T, Mao T, Chen L, Guo Z, Liu B, Pan H, Cang S, Jiang Y, Wang J, Ye M, Chen Z, Jiang D, Lin Q, Ren W, Wang J, Wu L, Xu Y, Miao Z, Sun M, Xie C, Liu Y, Wang Q, Zhao L, Li Q, Huang C, Jiang K, Yang K, Li D, Liu Y, Zhu Z, Chen R, Jia L, Li W, Liao W, Liu HX, Ma D, Ma J, Qin Y, Shi Z, Wei Q, Xiao K, Zhang Y, Zhang Y, Chen X, Dai G, He J, Li J, Li G, Liu Y, Liu Z, Yuan X, Zhang J, Fu Z, He Y, Ju F, Liu Z, Tang P, Wang T, Wang W, Zhang J, Luo X, Tang X, May R, Feng H, Yao S, Keegan P, Xu RH#, Wang F. Toripalimab plus chemotherapy in treatment-naïve, advanced esophageal squamous cell carcinoma (JUPITER-06): A multi-center phase 3 trial. Cancer Cell. 2022 Mar 14;40(3):277-288.\n",
    "\n",
    "[9]     Wang F, Zhao Q, Wang YN, Jin Y, He MM, Liu ZX, Xu RH#. Evaluation of POLE and POLD1 Mutations as Biomarkers for Immunotherapy Outcomes Across Multiple Cancer Types. JAMA Oncol. 2019.\n",
    "\n",
    "[10]   Wang F, Liu DB, Zhao Q, Chen G, Liu XM, Wang YN, Su H, Qin YR, He YF, Zou QF, Liu YH, Lin YE, Liu ZX, Bei JX and Xu RH#. The genomic landscape of small cell carcinoma of the esophagus. Cell Res 2018; 28: 771-774.\n",
    "\n",
    "[11]   Wang DS, Liu ZX, Lu YX, Bao H, Wu X, Zeng ZL, Liu Z, Zhao Q, He CY, Lu JH, Wang ZQ, Qiu MZ, Wang F, Wang FH, Li YH, Wang XN, Xie D, Jia WH, Shao YW and Xu RH#. Liquid biopsies to track trastuzumab resistance in metastatic HER2-positive gastric cancer. Gut 2018;\n",
    "\n",
    "[12]   Feng Wang, You-Sheng Huang, Hao-Xiang Wu, Zi-Xian Wang, Ying Jin, Yi-Chen Yao, Yan-Xing Chen, Qi Zhao, Shifu Chen, Ming-Ming He, Hui-Yan Luo, Miao-Zhen Qiu, De-Shen Wang, Feng-Hua Wang, Mingyan Xu, Yu-Hong Li, Rui-Hua Xu#. Genomic temporal heterogeneity of circulating tumour DNA in unresectable metastatic colorectal cancer under first-line treatment. Gut. 2022 Jul;71(7):1340-1349.\n",
    "\n",
    "[13]   Luo HY, Li YH, Wang W, Wang ZQ, Yuan X, Ma D, Wang FH, Zhang DS, Lin DR, Lin YC, Jia J, Hu XH, Peng JW and Xu RH#. Single-agent capecitabine as maintenance therapy after induction of XELOX (or FOLFOX) in first-line treatment of metastatic colorectal cancer: randomized clinical trial of efficacy and safety. Annals of Oncology 2016; 27: 1074-1081.\n",
    "\n",
    "[14]   Wang F, Wei XL, Wang FH, Xu N, Shen L, Dai GH, Yuan XL, Chen Y, Yang SJ, Shi JH, Hu XC, Lin XY, Zhang QY, JF Feng, Y Ba, YP Liu, W Li, YQ Shu, Y Jiang, Q Li, JW Wang, H Wu, H Feng, S Yao, RH Xu#. Safety, efficacy and tumor mutational burden as a biomarker of overall survival benefit in chemo-refractory gastric cancer treated with toripalimab, a PD1 antibody in phase Ib/II clinical trial NCT02915432. Ann Oncol. 2019.\n",
    "\n",
    "[15]  Luo H, Zhao Q, Wei W, Zheng L, Yi S, Li G, Wang W, Sheng H, Pu H, Mo H, Zuo Z, Liu Z, Li C, Xie C, Zeng Z, Li W, Hao X, Liu Y, Cao S, Liu W, Gibson S, Zhang K, Xu G, Xu RH#. Circulating tumor DNA methylation profiles enable early diagnosis, prognosis prediction, and screening for colorectal cancer. Sci Transl Med. 2020 Jan 1;12(524).\n",
    "\n",
    "[16]   Li T, Hu PS, Zuo Z, Lin JF, Li X, Wu QN, Chen ZH, Zeng ZL, Wang F, Zheng J, Chen D, Li B, Kang TB, Dan Xie, Dongxin Lin, Huai-Qiang Ju, Rui-Hua Xu#. METTL3 facilitates tumor progression via an m(6)A-IGF2BP2-dependent mechanism in colorectal carcinoma. Mol Cancer. 2019; 18: 112.\n",
    "\n",
    "[17] Yun Wang, Jia-Huan Lu, Qi-Nian Wu, Ying Jin, De-Shen Wang, Yan-Xing Chen, Jia Liu, Xiao-Jing Luo, Qi Meng, Heng-Ying Pu, Ying-Nan Wang, Pei-Shan Hu, Ze-Xian Liu, Zhao-Lei Zeng, Qi Zhao, Rong Deng, Xiao-Feng Zhu, Huai-Qiang Ju, Rui-Hua Xu#. LncRNA LINRIS stabilizes IGF2BP2 and promotes the aerobic glycolysis in colorectal cancer. Molecular Cancer. 2019 Dec 2.\n",
    "\n",
    "[18]   Jin Y, Chen DL, Wang F, Yang CP, Chen XX, You JQ, Huang JS, Shao Y, Zhu DQ, Ouyang YM, Luo HY, Wang ZQ, Wang FH, Li YH, Xu RH#, Zhang DS. The predicting role of circulating tumor DNA landscape in gastric cancer patients treated with immune checkpoint inhibitors. Mol Cancer. 2020 Oct 30;19(1):154.\n",
    "\n",
    "[19]   Chen DL, Wang ZQ, Zeng ZL, Wu WJ, Zhang DS, Luo HY, Wang F, Qiu MZ, Wang DS, Ren C, Wang FH, Chiao LJ, Pelicano H, Huang P, Li YH and Xu RH#. Identification of microRNA-214 as a negative regulator of colorectal cancer liver metastasis by way of regulation of fibroblast growth factor receptor 1 expression. Hepatology 2014; 60: 598-609.\n",
    "\n",
    "[20]   Ju HQ, Li H, Tian T, Lu YX, Bai L, Chen LZ, Sheng H, Mo HY, Zeng JB, Deng W, Chiao PJ and Xu RH#. Melatonin overcomes gemcitabine resistance in pancreatic ductal adenocarcinoma by abrogating nuclear factor-kappaB activation. Journal of Pineal Research 2016; 60: 27-38.\n",
    "\n",
    "[21]   Ju HQ, Lin JF, Tian T, Xie D, Xu RH#. NADPH homeostasis in cancer: functions, mechanisms and therapeutic implications. Signal Transduct Tar. 2020 Oct 7;5(1):231.\n",
    "\n",
    "[22]  Hu PS, Li T, Lin JF, Qiu MZ, Wang DS, Liu ZX, Chen ZH, Yang LP, Zhang XL, Zhao Q, Chen YX, Lu YX, Wu QN, Pu HY, Zeng ZL, Xie D, Ju HQ, Luo HY, Xu RH#. VDR-SOX2 signaling promotes colorectal cancer stemness and malignancy in an acidic microenvironment. Signal Transduct Tar. 2020 Sep 9;5(1):183.\n",
    "\n",
    "[23]   Ju HQ, Ying H, Tian T, Ling J, Fu J, Lu Y, Wu M, Yang L, Achreja A, Chen G, Zhuang Z, Wang H, Nagrath D, Yao J, Hung MC, DePinho RA, Huang P, Xu RH# and Chiao PJ. Mutant Kras- and p16-regulated NOX4 activation overcomes metabolic checkpoints in development of pancreatic ductal adenocarcinoma. Nat Commun 2017; 8: 14437.\n",
    "\n",
    "[24]   Liu J, Liu ZX, Wu QN, Lu YX, Wong CW, Miao L, Wang Y, Wang Z, Jin Y, He MM, Ren C, Wang DS, Chen DL, Pu HY, Feng L, Li B, Xie D, Zeng MS, Huang P, Lin A, Lin D, Xu RH#, Ju HQ. Long noncoding RNA AGPG regulates PFKFB3-mediated tumor glycolytic reprogramming. Nat Commun. 2020 Mar 20;11(1):1507.\n",
    "\n",
    "[25]   Ju HQ, Lu YX, Chen DL, Zuo ZX, Liu ZX, Wu QN, Mo HY, Wang ZX, Wang DS, Pu HY, Zeng ZL, Li B, Xie D, Huang P, Hung MC, Chiao PJ and Xu RH#. Modulation of Redox Homeostasis by Inhibition of MTHFD2 in Colorectal Cancer: Mechanisms and Therapeutic Implications. J Natl Cancer Inst 2018\n",
    "\n",
    "[26] Yu K, Zhang Q, Liu Z, Zhao Q, Zhang X, Wang Y, Wang ZX, Jin Y, Li X, Liu ZX and Xu RH#. qPhos: a database of protein phosphorylation dynamics in humans. Nucleic Acids Res 2018\n",
    "\n",
    "[27] Rui-Hua Xu*, Jin Li, Yuxian Bai, Jianming Xu, Tianshu Liu, Lin Shen, Liwei Wang, Hongming Pan, Junning Cao, Dongsheng Zhang, Songhua Fan, Ye Hua & Weiguo Su. Safety and efficacy of fruquintinib in patients with previously treated metastatic colorectal cancer: a phase Ib study and a randomized double-blind phase II study. J Hematol Oncol. (2017) 10:22.\n",
    "\n",
    "[28] Gong Chen, Junjie Peng, Qian Xiao, Hao-Xiang Wu, Xiaojun Wu, Fulong Wang, Liren Li, Peirong Ding, Qi Zhao, Yaqi Li, Da Wang, Yang Shao, Hua Bao, Zhizhong Pan, Ke-Feng Ding, Sanjun Cai, Feng Wang, Rui-Hua Xu#. Postoperative circulating tumor DNA as markers of recurrence risk in stages II to III colorectal cancer. Journal of Hematology & Oncology. 2021 May 17;14(1):80.\n",
    "\n",
    "[29] Zeng ZL, Luo HY, Yang J, Wu WJ, Chen DL, Huang P and Xu RH#. Overexpression of the circadian clock gene Bmal1 increases sensitivity to oxaliplatin in colorectal cancer. Clinical Cancer Research 2014; 20: 1042-1052.\n",
    "\n",
    "[30] Huiyan Luo, Wei Wei, Ziyi Ye, Jiabo Zheng, Rui-hua Xu#. Liquid Biopsy of Methylation Biomarkers in Cell-Free DNA. Trends in Molecular Medicine. 23 Jan 2021.\n",
    "\"\"\""
   ],
   "metadata": {
    "collapsed": false,
    "ExecuteTime": {
     "end_time": "2023-06-14T14:17:05.925673900Z",
     "start_time": "2023-06-14T14:17:05.908769300Z"
    }
   }
  },
  {
   "cell_type": "code",
   "execution_count": 5,
   "outputs": [
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "2023-06-14 22:13:13,712 - common.py - [line]:30 - INFO - get_openai_data: model:gpt-3.5-turbo\n",
      "2023-06-14 22:13:21,522 - common.py - [line]:33 - INFO - <Response [200]>\n",
      "2023-06-14 22:13:21,523 - common.py - [line]:34 - INFO - query:\n",
      "    请根据以下context，回答：徐瑞华的专长\n",
      "    reply in 简体中文\n",
      "    ---------context\n",
      "    \n",
      "[\n",
      "  {\n",
      "    \"_id\": \"648019f5778538384fd02da2\",\n",
      "    \"avatar\": null,\n",
      "    \"name\": \"Ruihua Xu\",\n",
      "    \"hospital\": \"Sun Yat-sen University\",\n",
      "    \"title\": \" MD\",\n",
      "    \"position\": null,\n",
      "    \"contact\": \"xuruihua@sysucc.org.cn\",\n",
      "    \"phone\": \"86-20-87343333\",\n",
      "    \"expertise\": \"Colorectal Carcinoma, pMMR, Microsatellite-stable\",\n",
      "    \"brief_intro\": \"A Study of Sintilimab and Chidamide in Combination With or Without IBI305 in Standard Treatment Failure of Advanced or Metastatic pMMR/MSS Colorectal Carcinoma\",\n",
      "    \"work_exp\": null,\n",
      "    \"edu_exp\": null,\n",
      "    \"consulting\": null,\n",
      "    \"publications\": null,\n",
      "    \"clinical_res\": null,\n",
      "    \"awards\": null\n",
      "  },\n",
      "  {\n",
      "    \"_id\": \"64803f25f24b55a336ba235d\",\n",
      "    \"avatar\": null,\n",
      "    \"name\": \"ruihua Xu\",\n",
      "    \"hospital\": \"Peking University\",\n",
      "    \"title\": \"M.D., Ph.D.\",\n",
      "    \"position\": null,\n",
      "    \"contact\": \"xurh@mail.sysu.edu.cn\",\n",
      "    \"phone\": \"13922206676\",\n",
      "    \"expertise\": \"nimotuzumab colorectal cancer chemotherapy\",\n",
      "    \"brief_intro\": null,\n",
      "    \"work_exp\": null,\n",
      "    \"edu_exp\": null,\n",
      "    \"consulting\": null,\n",
      "    \"publications\": null,\n",
      "    \"clinical_res\": \"Study of Nimotuzumab to Treat Colorectal Cancer\",\n",
      "    \"awards\": null\n",
      "  },\n",
      "  {\n",
      "    \"_id\": \"6480ea13f24b55a336bec613\",\n",
      "    \"avatar\": null,\n",
      "    \"name\": \"Ruihua Xu\",\n",
      "    \"hospital\": \"Sun Yat-sen University\",\n",
      "    \"title\": \"MD\",\n",
      "    \"position\": null,\n",
      "    \"contact\": \"xurh@susycc.org.cn\",\n",
      "    \"phone\": \"+862087343795\",\n",
      "    \"expertise\": \"Colorectal Cancer,Microsatellite Stable,Chidamide,Sintilimab,PD-1,Bevacizumab\",\n",
      "    \"brief_intro\": null,\n",
      "    \"work_exp\": null,\n",
      "    \"edu_exp\": null,\n",
      "    \"consulting\": null,\n",
      "    \"publications\": null,\n",
      "    \"clinical_res\": \"Comparing Chidamide+Sintilimab+Bev With Standard Second-line FOLFIRI+Bev in Advanced MSS/pMMR mCRC\",\n",
      "    \"awards\": null\n",
      "  }\n",
      "]\n",
      "[\n",
      "  {\n",
      "    \"NCT_No\": \"NCT05830045\",\n",
      "    First_Submitted_Date\": \"April 4, 2023\",\n",
      "    First_Posted_Date\": \"April 26, 2023\",\n",
      "    Last_Update_Posted_Date\": \"April 26, 2023\",\n",
      "    Estimated__Study_Start_Date\": \"April 20, 2023\",\n",
      "    Estimated_Primary_Completion_Date\": \"April 30, 2025   (Final data collection date for primary outcome measure)\",\n",
      "    Current_Primary_Outcome_Measures\": \"[List]\",\n",
      "    Original_Primary_Outcome_Measures\": \"Same as current\",\n",
      "    Change_History\": \"No Changes Posted\",\n",
      "    Current_Secondary_Outcome_Measures\": \"Not Provided\",\n",
      "    Original_Secondary_Outcome_Measures\": \"Not Provided\",\n",
      "    Current_Other_Pre-specified_Outcome_Measures\": \"Not Provided\",\n",
      "    Original_Other_Pre-specified_Outcome_Measures\": \"Not Provided\",\n",
      "    \"Brief_Title\": \"A Phase I Study of QLP2117 in Subjects With Advanced Solid Tumors\",\n",
      "    \"Official_Title\": \"A Study Evaluates the Safety, Pharmacokinetics, Immunogenicity and Efficacy of QLP2117 in Advanced Solid Tumor Patients\",\n",
      "    \"Brief_Summary\": \"This is the first in human study of QLP2117. To evaluate the Safety, Pharmacokinetics, Immunogenicity and Efficacy of QLP2117 in patients with advanced solid tumors.\",\n",
      "    \"Detailed_Description\": \"Not Provided\",\n",
      "    \"Study_Type\": \"Interventional\",\n",
      "    \"Study_Phase\": \"Phase 1\",\n",
      "    \"Study_Design\": \"Allocation: Non-Randomized\n",
      "Intervention Model: Sequential Assignment\n",
      "Masking: None (Open Label)\n",
      "Primary Purpose: Treatment\",\n",
      "    \"Condition\": \"Advanced Solid Tumors\",\n",
      "    \"Intervention\": \"Drug: QLP2117\n",
      "Specified dose on specified days\",\n",
      "    \"Study_Arms\": \"[List]\",\n",
      "    \"Publications_*\": \"Not Provided\",\n",
      "    \"Recruitment_Status\": \"Not yet recruiting\",\n",
      "    \"Estimated_Enrollment\": \"180\",\n",
      "    \"Original_Estimated_Enrollment\": \"Same as current\",\n",
      "    \"Estimated_Study_Completion_Date\": \"December 31, 2025\",\n",
      "    \"Estimated_Primary_Completion_Date\": \"April 30, 2025   (Final data collection date for primary outcome measure)\",\n",
      "    \"Eligibility_Criteria\": \"[List]\",\n",
      "    \"Sex/Gender\": \"Sexes Eligible for Study:\n",
      "   All\",\n",
      "    \"Ages\": \"18 Years and older   (Adult, Older Adult)\",\n",
      "    \"Accepts_Healthy_Volunteers\": \"No\",\n",
      "    \"Contacts\": \"Contact: Zhang Meijiang, PhD\n",
      "   8615210162105\n",
      "   meijiang.zhang@qilu-pharma.com\",\n",
      "    \"Listed_Location_Countries\": \"Not Provided\",\n",
      "    \"Removed_Location_Countries\": null,\n",
      "    \"NCT_Number\": \"NCT05830045\",\n",
      "    \"Other_Study_ID_Numbers\": \"QLP2117-101\",\n",
      "    \"Has_Data_Monitoring_Committee\": \"No\",\n",
      "    \"U.S._FDA-regulated_Product\": \"[List]\",\n",
      "    \"IPD_Sharing_Statement\": \"Plan to Share IPD:\n",
      "   No\",\n",
      "    \"Current_Responsible_Party\": \"Qilu Pharmaceutical Co., Ltd.\",\n",
      "    \"Original_Responsible_Party\": \"Same as current\",\n",
      "    \"Current_Study_Sponsor\": \"Qilu Pharmaceutical Co., Ltd.\",\n",
      "    \"Original_Study_Sponsor\": \"Same as current\",\n",
      "    \"Collaborators\": \"Not Provided\",\n",
      "    \"Investigators\": \"Principal Investigator:\n",
      "   Xu Ruihua, PhD\n",
      "   Sun Yat-sen University\",\n",
      "    \"PRS_Account\": \"Qilu Pharmaceutical Co., Ltd.\",\n",
      "    \"Verification_Date\": \"April 2023\"\n",
      "  },\n",
      "  {\n",
      "    \"NCT_No\": \"NCT05727839\",\n",
      "    First_Submitted_Date\": \"February 1, 2023\",\n",
      "    First_Posted_Date\": \"February 14, 2023\",\n",
      "    Last_Update_Posted_Date\": \"March 20, 2023\",\n",
      "    Estimated__Study_Start_Date\": \"February 24, 2023\",\n",
      "    Estimated_Primary_Completion_Date\": \"July 24, 2025   (Final data collection date for primary outcome measure)\",\n",
      "    Current_Primary_Outcome_Measures\": \"[List]\",\n",
      "    Original_Primary_Outcome_Measures\": \"[List]\",\n",
      "    Change_History\": \"Complete list of historical versions of study NCT05727839 on ClinicalTrials.gov Archive Site\",\n",
      "    Current_Secondary_Outcome_Measures\": \"[List]\",\n",
      "    Original_Secondary_Outcome_Measures\": \"[List]\",\n",
      "    Current_Other_Pre-specified_Outcome_Measures\": \"Not Provided\",\n",
      "    Original_Other_Pre-specified_Outcome_Measures\": \"Not Provided\",\n",
      "    \"Brief_Title\": \"Study to Evaluate JCXH-211 as Monotherapy in Patients With Malignant Solid Tumors\",\n",
      "    \"Official_Title\": \"A Phase 1 Open-Label Study to Evaluate the Safety, Tolerability and Efficacy of JCXH-211 Intratumoral Injection in Patients With Malignant Solid Tumors\",\n",
      "    \"Brief_Summary\": \": A Phase 1 Open-Label Study to Evaluate the Safety, Tolerability and Efficacy of JCXH-211 Intratumoral Injection in Patients with Malignant Solid Tumors\",\n",
      "    \"Detailed_Description\": \"The main purpose of this study is to find out how safe and tolerable the study drug, JCXH-211, is and also how well it works in people with malignant solid tumors. The study drug JCXH-211, is an immunotherapy drug. This means that it aims to work by boosting immune system's response to tumors, to help fight against the growth of the cancer cells. The study has 2 main phases: Phase\n",
      "  1a and Phase 1b. Phase 1a has 2 stages, skin/subcutaneous lesions stage, deep (visceral) lesions stage. Phase 1b will not start until all the data collected in Phase 1a has been completed and reviewed to check that it is safe and well tolerated.\",\n",
      "    \"Study_Type\": \"Interventional\",\n",
      "    \"Study_Phase\": \"Phase 1\",\n",
      "    \"Study_Design\": \"Allocation: Non-Randomized\n",
      "Intervention Model: Single Group Assignment\n",
      "Masking: None (Open Label)\n",
      "Primary Purpose: Treatment\",\n",
      "    \"Condition\": \"[List]\",\n",
      "    \"Intervention\": \"Drug: JCXH-211 Injection\n",
      "JCXH-211 administered once every 28 days\n",
      "Other Name: Intratumoral injection\",\n",
      "    \"Study_Arms\": \"[List]\",\n",
      "    \"Publications_*\": \"Not Provided\",\n",
      "    \"Recruitment_Status\": \"Recruiting\",\n",
      "    \"Estimated_Enrollment\": \"156\",\n",
      "    \"Original_Estimated_Enrollment\": \"Same as current\",\n",
      "    \"Estimated_Study_Completion_Date\": \"August 24, 2025\",\n",
      "    \"Estimated_Primary_Completion_Date\": \"July 24, 2025   (Final data collection date for primary outcome measure)\",\n",
      "    \"Eligibility_Criteria\": \"[List]\",\n",
      "    \"Sex/Gender\": \"Sexes Eligible for Study:\n",
      "   All\",\n",
      "    \"Ages\": \"18 Years to 75 Years   (Adult, Older Adult)\",\n",
      "    \"Accepts_Healthy_Volunteers\": \"No\",\n",
      "    \"Contacts\": \"Contact: Qi Wang\n",
      "   +8613381113913\n",
      "   qi.wang@immorna.com\",\n",
      "    \"Listed_Location_Countries\": \"China\",\n",
      "    \"Removed_Location_Countries\": null,\n",
      "    \"NCT_Number\": \"NCT05727839\",\n",
      "    \"Other_Study_ID_Numbers\": \"JCXH-211-003\",\n",
      "    \"Has_Data_Monitoring_Committee\": \"Not Provided\",\n",
      "    \"U.S._FDA-regulated_Product\": \"[List]\",\n",
      "    \"IPD_Sharing_Statement\": \"Not Provided\",\n",
      "    \"Current_Responsible_Party\": \"Immorna Biotherapeutics, Inc.\",\n",
      "    \"Original_Responsible_Party\": \"Same as current\",\n",
      "    \"Current_Study_Sponsor\": \"Immorna Biotherapeutics, Inc.\",\n",
      "    \"Original_Study_Sponsor\": \"Same as current\",\n",
      "    \"Collaborators\": \"Not Provided\",\n",
      "    \"Investigators\": \"Principal Investigator:\n",
      "   Xu ruihua, President\n",
      "   Sun Yat-sen University\",\n",
      "    \"PRS_Account\": \"Immorna Biotherapeutics, Inc.\",\n",
      "    \"Verification_Date\": \"March 2023\"\n",
      "  },\n",
      "  {\n",
      "    \"NCT_No\": \"NCT03544905\",\n",
      "    First_Submitted_Date\": \"May 22, 2018\",\n",
      "    First_Posted_Date\": \"June 4, 2018\",\n",
      "    Last_Update_Posted_Date\": \"January 6, 2023\",\n",
      "    Estimated__Study_Start_Date\": \"July 5, 2018\",\n",
      "    Estimated_Primary_Completion_Date\": \"June 30, 2023   (Final data collection date for primary outcome measure)\",\n",
      "    Current_Primary_Outcome_Measures\": \"MTD(Max tolerance does) [ Time Frame: 35 days ]To evaluate the MTD in patients with advanced solid tumor\",\n",
      "    Original_Primary_Outcome_Measures\": \"Same as current\",\n",
      "    Change_History\": \"Complete list of historical versions of study NCT03544905 on ClinicalTrials.gov Archive Site\",\n",
      "    Current_Secondary_Outcome_Measures\": \"Not Provided\",\n",
      "    Original_Secondary_Outcome_Measures\": \"Not Provided\",\n",
      "    Current_Other_Pre-specified_Outcome_Measures\": \"Not Provided\",\n",
      "    Original_Other_Pre-specified_Outcome_Measures\": \"Not Provided\",\n",
      "    \"Brief_Title\": \"Study to Evaluate the Safety, Tolerate, Pharmacokinetics and Preliminary Efficacy of CYH33\",\n",
      "    \"Official_Title\": \"A Multi-center, Open-label, Single Arm, Dose Escalation and Dose Extension Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of CYH33 in Advanced Solid Tumors Patients.\",\n",
      "    \"Brief_Summary\": \"This study is a Multi-center, Open-label, single arm, Dose Escalation and Dose Extension Phase 1 Study to Evaluate the Safety , Tolerability, Pharmacokinetics and Preliminary Efficacy of CYH33 in Advanced Solid Tumors Patients.\",\n",
      "    \"Detailed_Description\": \"This study includes Phase Ia and Phase Ib.\n",
      "  In the dose climbing part of phase Ia, the safety, tolerance and pharmacokinetics characteristics of CYH33 in patients with advanced solid tumors who failed to receive standard treatment, did not tolerate or did not have standard treatment at present will be observed to determine MTD; Before determining MTD, select safe and highly reliable and effective dose levels for simultaneous expansion. Phase Ia dose expansion includes patients with advanced solid tumors who have failed to undergo standard treatment, who are intolerant of PIK3CA gene mutation, or who do not have standard treatment at present, to further evaluate safety, tolerance and initial efficacy.\n",
      "  In Phase Ib, the safety and preliminary efficacy of CYH33 on patients with advanced breast cancer, ovarian cancer, endometrial cancer, cervical cancer, head and neck squamous cell carcinoma, esophageal and gastroesophageal junction squamous cell carcinoma, ovarian clear cell carcinoma and other solid tumors with PIK3CA gene mutation who have failed, are intolerant or do not have standard treatment at present will be evaluated.\",\n",
      "    \"Study_Type\": \"Interventional\",\n",
      "    \"Study_Phase\": \"Phase 1\",\n",
      "    \"Study_Design\": \"Allocation: N/A\n",
      "Intervention Model: Single Group Assignment\n",
      "Masking: None (Open Label)\n",
      "Primary Purpose: Treatment\",\n",
      "    \"Condition\": \"Advanced Solid Tumors\",\n",
      "    \"Intervention\": \"Drug: CYH33 for tablet\n",
      "1mg; 5mg; 10mg; 20mg; 30mg; 50mg; 75mg; 100mg; 130mg; 160mg; 200mg; 240mgBID or QD(Decided by SMC accroding to the safty and PK data)\",\n",
      "    \"Study_Arms\": \"Experimental: Dose escalation study of CYH33\n",
      "To determine the maximum tolerated dose (MTD) of CYH33\n",
      "Intervention: Drug: CYH33 for tablet\",\n",
      "    \"Publications_*\": \"Not Provided\",\n",
      "    \"Recruitment_Status\": \"Recruiting\",\n",
      "    \"Estimated_Enrollment\": \"100\",\n",
      "    \"Original_Estimated_Enrollment\": \"Same as current\",\n",
      "    \"Estimated_Study_Completion_Date\": \"March 31, 2024\",\n",
      "    \"Estimated_Primary_Completion_Date\": \"June 30, 2023   (Final data collection date for primary outcome measure)\",\n",
      "    \"Eligibility_Criteria\": \"[List]\",\n",
      "    \"Sex/Gender\": \"Sexes Eligible for Study:\n",
      "   All\",\n",
      "    \"Ages\": \"18 Years and older   (Adult, Older Adult)\",\n",
      "    \"Accepts_Healthy_Volunteers\": \"No\",\n",
      "    \"Contacts\": \"Contact: Ruihua Xu, M.D\n",
      "   86-20-87343804\n",
      "   ruihxu@163.com\",\n",
      "    \"Listed_Location_Countries\": \"China\",\n",
      "    \"Removed_Location_Countries\": null,\n",
      "    \"NCT_Number\": \"NCT03544905\",\n",
      "    \"Other_Study_ID_Numbers\": \"CYH33-101\",\n",
      "    \"Has_Data_Monitoring_Committee\": \"Yes\",\n",
      "    \"U.S._FDA-regulated_Product\": \"[List]\",\n",
      "    \"IPD_Sharing_Statement\": \"Not Provided\",\n",
      "    \"Current_Responsible_Party\": \"Haihe Biopharma Co., Ltd.\",\n",
      "    \"Original_Responsible_Party\": \"Same as current\",\n",
      "    \"Current_Study_Sponsor\": \"Haihe Biopharma Co., Ltd.\",\n",
      "    \"Original_Study_Sponsor\": \"Same as current\",\n",
      "    \"Collaborators\": \"Not Provided\",\n",
      "    \"Investigators\": \"Principal Investigator:\n",
      "   Ruihua Xu, M.D\n",
      "   Sun Yat-sen University\",\n",
      "    \"PRS_Account\": \"Haihe Biopharma Co., Ltd.\",\n",
      "    \"Verification_Date\": \"January 2023\"\n",
      "  },\n",
      "  {\n",
      "    \"NCT_No\": \"NCT01198392\",\n",
      "    First_Submitted_Date\": \"September 1, 2010\",\n",
      "    First_Posted_Date\": \"September 10, 2010\",\n",
      "    Last_Update_Posted_Date\": \"July 25, 2011\",\n",
      "    Estimated__Study_Start_Date\": \"September 2008\",\n",
      "    Estimated_Primary_Completion_Date\": \"December 2011   (Final data collection date for primary outcome measure)\",\n",
      "    Current_Primary_Outcome_Measures\": \"Time to progression [ Time Frame: The time from randomization until objective tumor progression or death ]\",\n",
      "    Original_Primary_Outcome_Measures\": \"Same as current\",\n",
      "    Change_History\": \"Complete list of historical versions of study NCT01198392 on ClinicalTrials.gov Archive Site\",\n",
      "    Current_Secondary_Outcome_Measures\": \"Response rate [ Time Frame: 2 months ]\",\n",
      "    Original_Secondary_Outcome_Measures\": \"Same as current\",\n",
      "    Current_Other_Pre-specified_Outcome_Measures\": \"Not Provided\",\n",
      "    Original_Other_Pre-specified_Outcome_Measures\": \"Not Provided\",\n",
      "    \"Brief_Title\": \"Trial of S-1 Plus Cisplatin in Gastric Cancer\",\n",
      "    \"Official_Title\": \"A Clinical Trial of S-1 Plus Cisplatin Versus 5-FU Plus Cisplatin in Patients With Unresectable or Advanced Gastric Cancer\",\n",
      "    \"Brief_Summary\": \"The purpose of this study is to evaluate the effectiveness and safety of s-1 plus cisplatin versus 5-FU plus cisplatin as first-line therapy in the treatment of patients with advanced gastric cancer.\",\n",
      "    \"Detailed_Description\": \"This is a randomized, controlled, open-label,multicenter study. Patients are randomized to one of two treatment arms : S-1 plus cisplatin and 5-FU plus cisplatin.\",\n",
      "    \"Study_Type\": \"Interventional\",\n",
      "    \"Study_Phase\": \"Phase 3\",\n",
      "    \"Study_Design\": \"Allocation: Randomized\n",
      "Intervention Model: Parallel Assignment\n",
      "Masking: None (Open Label)\n",
      "Primary Purpose: Treatment\",\n",
      "    \"Condition\": \"Gastric Cancer\",\n",
      "    \"Intervention\": \"[List]\",\n",
      "    \"Study_Arms\": \"[List]\",\n",
      "    \"Publications_*\": \"Li YH, Qiu MZ, Xu JM, Sun GP, Lu HS, Liu YP, Zhong MZ, Zhang HL, Yu SY, Li W, Hu XH, Wang JJ, Cheng Y, Zhou JT, Guo ZQ, Guan ZG, Xu RH. S-1 plus cisplatin versus fluorouracil plus cisplatin in advanced gastric or gastro-esophageal junction adenocarcinoma patients: a pilot study. Oncotarget. 2015 Oct 27;6(33):35107-15. doi: 10.18632/oncotarget.5959.\",\n",
      "    \"Recruitment_Status\": \"Unknown status\",\n",
      "    \"Estimated_Enrollment\": \"270\",\n",
      "    \"Original_Estimated_Enrollment\": \"Same as current\",\n",
      "    \"Estimated_Study_Completion_Date\": \"December 2011\",\n",
      "    \"Estimated_Primary_Completion_Date\": \"December 2011   (Final data collection date for primary outcome measure)\",\n",
      "    \"Eligibility_Criteria\": \"[List]\",\n",
      "    \"Sex/Gender\": \"Sexes Eligible for Study:\n",
      "   All\",\n",
      "    \"Ages\": \"18 Years to 75 Years   (Adult, Older Adult)\",\n",
      "    \"Accepts_Healthy_Volunteers\": \"No\",\n",
      "    \"Contacts\": \"Contact information is only displayed when the study is recruiting subjects\",\n",
      "    \"Listed_Location_Countries\": \"China\",\n",
      "    \"Removed_Location_Countries\": null,\n",
      "    \"NCT_Number\": \"NCT01198392\",\n",
      "    \"Other_Study_ID_Numbers\": \"2005L02859\",\n",
      "    \"Has_Data_Monitoring_Committee\": \"Yes\",\n",
      "    \"U.S._FDA-regulated_Product\": \"Not Provided\",\n",
      "    \"IPD_Sharing_Statement\": \"Not Provided\",\n",
      "    \"Current_Responsible_Party\": \"Zhongzhen Guan ,Ruihua Xu, Sun Yat-sen University Cancer Center\",\n",
      "    \"Original_Responsible_Party\": \"Same as current\",\n",
      "    \"Current_Study_Sponsor\": \"Sun Yat-sen University\",\n",
      "    \"Original_Study_Sponsor\": \"Same as current\",\n",
      "    \"Collaborators\": \"Not Provided\",\n",
      "    \"Investigators\": \"Principal Investigator:\n",
      "   RUIHUA XU, Professor\n",
      "   Sun Yat-sen University\",\n",
      "    \"PRS_Account\": \"Sun Yat-sen University\",\n",
      "    \"Verification_Date\": \"August 2008\"\n",
      "  }\n",
      "]\n",
      "\n",
      "徐瑞华，医学博士，中山大学肿瘤防治中心主任、医院院长、研究所所长，华南恶性肿瘤防治全国重点实验室主任，教授，博士生导师。\n",
      "\n",
      "中国医学科学院学部委员，中国临床肿瘤学会理事长，中国抗癌协会副理事长，中国抗癌协会靶向治疗专委会首届主任委员，中国抗癌协会化疗专委会候任主任委员，中国临床肿瘤学会肠癌专委会主任委员，《Cancer Communications》主编，研究生教材《肿瘤学》主编，本科生教材《临床肿瘤学》主编。\n",
      "\n",
      "从事肿瘤内科临床及科研工作30余年，取得突破性成果：\n",
      "\n",
      "第一，实现了肠癌诊治理论和实践的系统创新，使我国肠癌早诊及精准治疗均处于国际先进水平。创新了肠癌早诊及疗效预测的新技术，并已转化为临床应用；建立了晚期肠癌治疗新体系，创建了高效低毒的维持方案和亚洲方案，成为国际治疗新标准，晚期肠癌生存率与国际顶尖的安德森癌症中心达相同水平。\n",
      "\n",
      "第二，创新了消化肿瘤免疫治疗体系，引领国际消化肿瘤免疫治疗发展。\n",
      "\n",
      "通过鉴定TMB、POLE/POLD突变等标志物，精准筛选免疫治疗敏感亚型，大幅提高PD-1抗体疗效；首创了食管癌中国免疫联合方案，取得全球最高有效率72%，已成为食管癌治疗应用最广泛的方案；建立了食管癌EGIC分型，可以指导精准免疫治疗策略，引领该领域的发展；揭示了免疫逃逸新机制并推动了药物的开发：发现甲硫氨酸限制饮食可抑制免疫检查点分子PDL1及VISTA的表达，增强抗肿瘤免疫及抗PD1的治疗效果；鉴定出免疫治疗增效肠道活性菌RX-af01，成果已转化。\n",
      "\n",
      "以通讯或第一作者在国际顶级期刊JAMA、Nature Materials、Nature Medicine、Lancet Oncology等发表SCI论文200余篇，入选科睿唯安（Clarivate Analytics）全球高被引科学家，连续入选中国高被引学者榜单。以第一完成人获国家科技进步二等奖2项及省部级一等奖6项、吴阶平医药创新奖、谈家桢临床医学奖及CSCO年度成就奖。入选国家百千万人才工程、全国先进工作者、南粤百杰人才培养工程、国家卫生计生突出贡献中青年专家等人才项目。\n",
      "\n",
      "Representative paper: （*：第一作者，#：通讯作者）\n",
      "\n",
      "[1]     Luo H, Lu J, Bai Y, Mao T, Wang J, Fan Q, Zhang Y, Zhao K, Chen Z, Gao S, Li J, Fu Z, Gu K, Liu Z, Wu L, Zhang X, Feng J, Niu Z, Ba Y, Zhang H, Liu Y, Zhang L, Min X, Huang J, Cheng Y, Wang D, Shen Y, Yang Q, Zou J, Xu RH# ESCORT-1st Investigators.  Effect of Camrelizumab vs Placebo Added to Chemotherapy on Survival and Progression-Free Survival in Patients With Advanced or Metastatic Esophageal Squamous Cell Carcinoma: The ESCORT-1st Randomized Clinical Trial. JAMA. 2021 Sep 14;326(10):916-925.\n",
      "\n",
      "[2]     Xu RH*#, Wei W, Krawczyk M, Wang W, Luo H, Flagg K, Yi S, Shi W, Quan Q, Li K, Zheng L, Zhang H, Caughey BA, Zhao Q, Hou J, Zhang R, Xu Y, Cai H, Li G, Hou R, Zhong Z, Lin D, Fu X, Zhu J, Duan Y, Yu M, Ying B, Zhang W, Wang J, Zhang E, Zhang C, Li O, Guo R, Carter H, Zhu JK, Hao X and Zhang K. Circulating tumour DNA methylation markers for diagnosis and prognosis of hepatocellular carcinoma. Nat Mater 2017; 16: 1155-1161.\n",
      "\n",
      "[3]     Xu RH*#, Muro K, Morita S, Iwasa S, Han SW, Wang W, Kotaka M, Nakamura M, Ahn JB, Deng YH, Kato T, Cho SH, Ba Y, Matsuoka H, Lee KW, Zhang T, Yamada Y, Sakamoto J, Park YS and Kim TW. Modified XELIRI (capecitabine plus irinotecan) versus FOLFIRI (leucovorin, fluorouracil, and irinotecan), both either with or without bevacizumab, as second-line therapy for metastatic colorectal cancer (AXEPT): a multicentre, open-label, randomised, non-inferiority, phase 3 trial. Lancet Oncol 2018; 19: 660-671.\n",
      "\n",
      "[4]     Li J, Qin S, Xu R*, Yau TC, Ma B, Pan H, Xu J, Bai Y, Chi Y, Wang L, Yeh KH, Bi F, Cheng Y, Le AT, Lin JK, Liu T, Ma D, Kappeler C, Kalmus J and Kim TW. Regorafenib plus best supportive care versus placebo plus best supportive care in Asian patients with previously treated metastatic colorectal cancer (CONCUR): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncology 2015; 16: 619-629.\n",
      "\n",
      "[5]     Luo H, Xu G, Li C, He L, Luo L, Wang Z, Jing B, Deng Y, Jin Y, Li Y, Li B, Tan W, He C, Seeruttun SR, Wu Q, Huang J, Huang DW, Chen B, Lin SB, Chen QM, Yuan CM, Chen HX, Pu HY, Zhou F, He Y, Xu RH#. Real-time artificial intelligence for detection of upper gastrointestinal cancer by endoscopy: a multicentre, case-control, diagnostic study. Lancet Oncol. 2019 Oct 4.\n",
      "\n",
      "[6]     Satoh T, Xu RH*, Chung HC, Sun GP, Doi T, Xu JM, Tsuji A, Omuro Y, Li J, Wang JW, Miwa H, Qin SK, Chung IJ, Yeh KH, Feng JF, Mukaiyama A, Kobayashi M, Ohtsu A and Bang YJ. Lapatinib plus paclitaxel versus paclitaxel alone in the second-line treatment of HER2-amplified advanced gastric cancer in Asian populations: TyTAN--a randomized, phase III study. Journal of Clinical Oncology 2014; 32: 2039-2049.\n",
      "\n",
      "[7]     Manish A. Shah, Rui-hua Xu*, Yung-Jue Bang, Paulo M. Hoff, Tianshu Liu, Luis A. Herr´aez-Baranda, Fan Xia,Amit Garg, Mona Shing, and Josep Tabernero. HELOISE: Phase IIIb Randomized Multicenter Study Comparing Standard-of-Care and Higher-Dose Trastuzumab Regimens Combined With Chemotherapy as First-Line Therapy in Patients With Human Epidermal Growth Factor Receptor 2–Positive Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma. Journal of Clinical Oncology 2017; 35: 2558-2567.\n",
      "\n",
      "[8]     Wang ZX, Cui C, Yao J, Zhang Y, Li M, Feng J, Yang S, Fan Y, Shi J, Zhang X, Shen L, Shu Y, Wang C, Dai T, Mao T, Chen L, Guo Z, Liu B, Pan H, Cang S, Jiang Y, Wang J, Ye M, Chen Z, Jiang D, Lin Q, Ren W, Wang J, Wu L, Xu Y, Miao Z, Sun M, Xie C, Liu Y, Wang Q, Zhao L, Li Q, Huang C, Jiang K, Yang K, Li D, Liu Y, Zhu Z, Chen R, Jia L, Li W, Liao W, Liu HX, Ma D, Ma J, Qin Y, Shi Z, Wei Q, Xiao K, Zhang Y, Zhang Y, Chen X, Dai G, He J, Li J, Li G, Liu Y, Liu Z, Yuan X, Zhang J, Fu Z, He Y, Ju F, Liu Z, Tang P, Wang T, Wang W, Zhang J, Luo X, Tang X, May R, Feng H, Yao S, Keegan P, Xu RH#, Wang F. Toripalimab plus chemotherapy in treatment-naïve, advanced esophageal squamous cell carcinoma (JUPITER-06): A multi-center phase 3 trial. Cancer Cell. 2022 Mar 14;40(3):277-288.\n",
      "\n",
      "[9]     Wang F, Zhao Q, Wang YN, Jin Y, He MM, Liu ZX, Xu RH#. Evaluation of POLE and POLD1 Mutations as Biomarkers for Immunotherapy Outcomes Across Multiple Cancer Types. JAMA Oncol. 2019.\n",
      "\n",
      "[10]   Wang F, Liu DB, Zhao Q, Chen G, Liu XM, Wang YN, Su H, Qin YR, He YF, Zou QF, Liu YH, Lin YE, Liu ZX, Bei JX and Xu RH#. The genomic landscape of small cell carcinoma of the esophagus. Cell Res 2018; 28: 771-774.\n",
      "\n",
      "[11]   Wang DS, Liu ZX, Lu YX, Bao H, Wu X, Zeng ZL, Liu Z, Zhao Q, He CY, Lu JH, Wang ZQ, Qiu MZ, Wang F, Wang FH, Li YH, Wang XN, Xie D, Jia WH, Shao YW and Xu RH#. Liquid biopsies to track trastuzumab resistance in metastatic HER2-positive gastric cancer. Gut 2018;\n",
      "\n",
      "[12]   Feng Wang, You-Sheng Huang, Hao-Xiang Wu, Zi-Xian Wang, Ying Jin, Yi-Chen Yao, Yan-Xing Chen, Qi Zhao, Shifu Chen, Ming-Ming He, Hui-Yan Luo, Miao-Zhen Qiu, De-Shen Wang, Feng-Hua Wang, Mingyan Xu, Yu-Hong Li, Rui-Hua Xu#. Genomic temporal heterogeneity of circulating tumour DNA in unresectable metastatic colorectal cancer under first-line treatment. Gut. 2022 Jul;71(7):1340-1349.\n",
      "\n",
      "[13]   Luo HY, Li YH, Wang W, Wang ZQ, Yuan X, Ma D, Wang FH, Zhang DS, Lin DR, Lin YC, Jia J, Hu XH, Peng JW and Xu RH#. Single-agent capecitabine as maintenance therapy after induction of XELOX (or FOLFOX) in first-line treatment of metastatic colorectal cancer: randomized clinical trial of efficacy and safety. Annals of Oncology 2016; 27: 1074-1081.\n",
      "\n",
      "[14]   Wang F, Wei XL, Wang FH, Xu N, Shen L, Dai GH, Yuan XL, Chen Y, Yang SJ, Shi JH, Hu XC, Lin XY, Zhang QY, JF Feng, Y Ba, YP Liu, W Li, YQ Shu, Y Jiang, Q Li, JW Wang, H Wu, H Feng, S Yao, RH Xu#. Safety, efficacy and tumor mutational burden as a biomarker of overall survival benefit in chemo-refractory gastric cancer treated with toripalimab, a PD1 antibody in phase Ib/II clinical trial NCT02915432. Ann Oncol. 2019.\n",
      "\n",
      "[15]  Luo H, Zhao Q, Wei W, Zheng L, Yi S, Li G, Wang W, Sheng H, Pu H, Mo H, Zuo Z, Liu Z, Li C, Xie C, Zeng Z, Li W, Hao X, Liu Y, Cao S, Liu W, Gibson S, Zhang K, Xu G, Xu RH#. Circulating tumor DNA methylation profiles enable early diagnosis, prognosis prediction, and screening for colorectal cancer. Sci Transl Med. 2020 Jan 1;12(524).\n",
      "\n",
      "[16]   Li T, Hu PS, Zuo Z, Lin JF, Li X, Wu QN, Chen ZH, Zeng ZL, Wang F, Zheng J, Chen D, Li B, Kang TB, Dan Xie, Dongxin Lin, Huai-Qiang Ju, Rui-Hua Xu#. METTL3 facilitates tumor progression via an m(6)A-IGF2BP2-dependent mechanism in colorectal carcinoma. Mol Cancer. 2019; 18: 112.\n",
      "\n",
      "[17] Yun Wang, Jia-Huan Lu, Qi-Nian Wu, Ying Jin, De-Shen Wang, Yan-Xing Chen, Jia Liu, Xiao-Jing Luo, Qi Meng, Heng-Ying Pu, Ying-Nan Wang, Pei-Shan Hu, Ze-Xian Liu, Zhao-Lei Zeng, Qi Zhao, Rong Deng, Xiao-Feng Zhu, Huai-Qiang Ju, Rui-Hua Xu#. LncRNA LINRIS stabilizes IGF2BP2 and promotes the aerobic glycolysis in colorectal cancer. Molecular Cancer. 2019 Dec 2.\n",
      "\n",
      "[18]   Jin Y, Chen DL, Wang F, Yang CP, Chen XX, You JQ, Huang JS, Shao Y, Zhu DQ, Ouyang YM, Luo HY, Wang ZQ, Wang FH, Li YH, Xu RH#, Zhang DS. The predicting role of circulating tumor DNA landscape in gastric cancer patients treated with immune checkpoint inhibitors. Mol Cancer. 2020 Oct 30;19(1):154.\n",
      "\n",
      "[19]   Chen DL, Wang ZQ, Zeng ZL, Wu WJ, Zhang DS, Luo HY, Wang F, Qiu MZ, Wang DS, Ren C, Wang FH, Chiao LJ, Pelicano H, Huang P, Li YH and Xu RH#. Identification of microRNA-214 as a negative regulator of colorectal cancer liver metastasis by way of regulation of fibroblast growth factor receptor 1 expression. Hepatology 2014; 60: 598-609.\n",
      "\n",
      "[20]   Ju HQ, Li H, Tian T, Lu YX, Bai L, Chen LZ, Sheng H, Mo HY, Zeng JB, Deng W, Chiao PJ and Xu RH#. Melatonin overcomes gemcitabine resistance in pancreatic ductal adenocarcinoma by abrogating nuclear factor-kappaB activation. Journal of Pineal Research 2016; 60: 27-38.\n",
      "\n",
      "[21]   Ju HQ, Lin JF, Tian T, Xie D, Xu RH#. NADPH homeostasis in cancer: functions, mechanisms and therapeutic implications. Signal Transduct Tar. 2020 Oct 7;5(1):231.\n",
      "\n",
      "[22]  Hu PS, Li T, Lin JF, Qiu MZ, Wang DS, Liu ZX, Chen ZH, Yang LP, Zhang XL, Zhao Q, Chen YX, Lu YX, Wu QN, Pu HY, Zeng ZL, Xie D, Ju HQ, Luo HY, Xu RH#. VDR-SOX2 signaling promotes colorectal cancer stemness and malignancy in an acidic microenvironment. Signal Transduct Tar. 2020 Sep 9;5(1):183.\n",
      "\n",
      "[23]   Ju HQ, Ying H, Tian T, Ling J, Fu J, Lu Y, Wu M, Yang L, Achreja A, Chen G, Zhuang Z, Wang H, Nagrath D, Yao J, Hung MC, DePinho RA, Huang P, Xu RH# and Chiao PJ. Mutant Kras- and p16-regulated NOX4 activation overcomes metabolic checkpoints in development of pancreatic ductal adenocarcinoma. Nat Commun 2017; 8: 14437.\n",
      "\n",
      "[24]   Liu J, Liu ZX, Wu QN, Lu YX, Wong CW, Miao L, Wang Y, Wang Z, Jin Y, He MM, Ren C, Wang DS, Chen DL, Pu HY, Feng L, Li B, Xie D, Zeng MS, Huang P, Lin A, Lin D, Xu RH#, Ju HQ. Long noncoding RNA AGPG regulates PFKFB3-mediated tumor glycolytic reprogramming. Nat Commun. 2020 Mar 20;11(1):1507.\n",
      "\n",
      "[25]   Ju HQ, Lu YX, Chen DL, Zuo ZX, Liu ZX, Wu QN, Mo HY, Wang ZX, Wang DS, Pu HY, Zeng ZL, Li B, Xie D, Huang P, Hung MC, Chiao PJ and Xu RH#. Modulation of Redox Homeostasis by Inhibition of MTHFD2 in Colorectal Cancer: Mechanisms and Therapeutic Implications. J Natl Cancer Inst 2018\n",
      "\n",
      "[26] Yu K, Zhang Q, Liu Z, Zhao Q, Zhang X, Wang Y, Wang ZX, Jin Y, Li X, Liu ZX and Xu RH#. qPhos: a database of protein phosphorylation dynamics in humans. Nucleic Acids Res 2018\n",
      "\n",
      "[27] Rui-Hua Xu*, Jin Li, Yuxian Bai, Jianming Xu, Tianshu Liu, Lin Shen, Liwei Wang, Hongming Pan, Junning Cao, Dongsheng Zhang, Songhua Fan, Ye Hua & Weiguo Su. Safety and efficacy of fruquintinib in patients with previously treated metastatic colorectal cancer: a phase Ib study and a randomized double-blind phase II study. J Hematol Oncol. (2017) 10:22.\n",
      "\n",
      "[28] Gong Chen, Junjie Peng, Qian Xiao, Hao-Xiang Wu, Xiaojun Wu, Fulong Wang, Liren Li, Peirong Ding, Qi Zhao, Yaqi Li, Da Wang, Yang Shao, Hua Bao, Zhizhong Pan, Ke-Feng Ding, Sanjun Cai, Feng Wang, Rui-Hua Xu#. Postoperative circulating tumor DNA as markers of recurrence risk in stages II to III colorectal cancer. Journal of Hematology & Oncology. 2021 May 17;14(1):80.\n",
      "\n",
      "[29] Zeng ZL, Luo HY, Yang J, Wu WJ, Chen DL, Huang P and Xu RH#. Overexpression of the circadian clock gene Bmal1 increases sensitivity to oxaliplatin in colorectal cancer. Clinical Cancer Research 2014; 20: 1042-1052.\n",
      "\n",
      "[30] Huiyan Luo, Wei Wei, Ziyi Ye, Jiabo Zheng, Rui-hua Xu#. Liquid Biopsy of Methylation Biomarkers in Cell-Free DNA. Trends in Molecular Medicine. 23 Jan 2021.\n",
      "\n",
      "    ---------\n",
      "\n",
      "2023-06-14 22:13:21,524 - common.py - [line]:35 - INFO - real_query:\n",
      "    Notice: If doctor or hospital not in the context, skip this one 假如你是数据工程师，请把如下个人信息按照JSON的格式整理给我：（参考字段：行医，门诊时间，综合评价，资质认证状态，基本信息，简介，姓名，医院/机构，专长，职务，职称，学术兼职，地区，邮箱，手机，昕康ID/XK_ID，履历，教育经历，工作经历，研究，研究方向/临床研究，课题/基金，发表，发表文章，出版著作，专利和软著，执笔共识，成就，荣誉获奖）Return only the translation and nothing else:\n",
      "\n",
      "    query:\n",
      "    请根据以下context，回答：徐瑞华的专长\n",
      "    reply in 简体中文\n",
      "    ---------context\n",
      "    \n",
      "[\n",
      "  {\n",
      "    \"_id\": \"648019f5778538384fd02da2\",\n",
      "    \"avatar\": null,\n",
      "    \"name\": \"Ruihua Xu\",\n",
      "    \"hospital\": \"Sun Yat-sen University\",\n",
      "    \"title\": \" MD\",\n",
      "    \"position\": null,\n",
      "    \"contact\": \"xuruihua@sysucc.org.cn\",\n",
      "    \"phone\": \"86-20-87343333\",\n",
      "    \"expertise\": \"Colorectal Carcinoma, pMMR, Microsatellite-stable\",\n",
      "    \"brief_intro\": \"A Study of Sintilimab and Chidamide in Combination With or Without IBI305 in Standard Treatment Failure of Advanced or Metastatic pMMR/MSS Colorectal Carcinoma\",\n",
      "    \"work_exp\": null,\n",
      "    \"edu_exp\": null,\n",
      "    \"consulting\": null,\n",
      "    \"publications\": null,\n",
      "    \"clinical_res\": null,\n",
      "    \"awards\": null\n",
      "  },\n",
      "  {\n",
      "    \"_id\": \"64803f25f24b55a336ba235d\",\n",
      "    \"avatar\": null,\n",
      "    \"name\": \"ruihua Xu\",\n",
      "    \"hospital\": \"Peking University\",\n",
      "    \"title\": \"M.D., Ph.D.\",\n",
      "    \"position\": null,\n",
      "    \"contact\": \"xurh@mail.sysu.edu.cn\",\n",
      "    \"phone\": \"13922206676\",\n",
      "    \"expertise\": \"nimotuzumab colorectal cancer chemotherapy\",\n",
      "    \"brief_intro\": null,\n",
      "    \"work_exp\": null,\n",
      "    \"edu_exp\": null,\n",
      "    \"consulting\": null,\n",
      "    \"publications\": null,\n",
      "    \"clinical_res\": \"Study of Nimotuzumab to Treat Colorectal Cancer\",\n",
      "    \"awards\": null\n",
      "  },\n",
      "  {\n",
      "    \"_id\": \"6480ea13f24b55a336bec613\",\n",
      "    \"avatar\": null,\n",
      "    \"name\": \"Ruihua Xu\",\n",
      "    \"hospital\": \"Sun Yat-sen University\",\n",
      "    \"title\": \"MD\",\n",
      "    \"position\": null,\n",
      "    \"contact\": \"xurh@susycc.org.cn\",\n",
      "    \"phone\": \"+862087343795\",\n",
      "    \"expertise\": \"Colorectal Cancer,Microsatellite Stable,Chidamide,Sintilimab,PD-1,Bevacizumab\",\n",
      "    \"brief_intro\": null,\n",
      "    \"work_exp\": null,\n",
      "    \"edu_exp\": null,\n",
      "    \"consulting\": null,\n",
      "    \"publications\": null,\n",
      "    \"clinical_res\": \"Comparing Chidamide+Sintilimab+Bev With Standard Second-line FOLFIRI+Bev in Advanced MSS/pMMR mCRC\",\n",
      "    \"awards\": null\n",
      "  }\n",
      "]\n",
      "[\n",
      "  {\n",
      "    \"NCT_No\": \"NCT05830045\",\n",
      "    First_Submitted_Date\": \"April 4, 2023\",\n",
      "    First_Posted_Date\": \"April 26, 2023\",\n",
      "    Last_Update_Posted_Date\": \"April 26, 2023\",\n",
      "    Estimated__Study_Start_Date\": \"April 20, 2023\",\n",
      "    Estimated_Primary_Completion_Date\": \"April 30, 2025   (Final data collection date for primary outcome measure)\",\n",
      "    Current_Primary_Outcome_Measures\": \"[List]\",\n",
      "    Original_Primary_Outcome_Measures\": \"Same as current\",\n",
      "    Change_History\": \"No Changes Posted\",\n",
      "    Current_Secondary_Outcome_Measures\": \"Not Provided\",\n",
      "    Original_Secondary_Outcome_Measures\": \"Not Provided\",\n",
      "    Current_Other_Pre-specified_Outcome_Measures\": \"Not Provided\",\n",
      "    Original_Other_Pre-specified_Outcome_Measures\": \"Not Provided\",\n",
      "    \"Brief_Title\": \"A Phase I Study of QLP2117 in Subjects With Advanced Solid Tumors\",\n",
      "    \"Official_Title\": \"A Study Evaluates the Safety, Pharmacokinetics, Immunogenicity and Efficacy of QLP2117 in Advanced Solid Tumor Patients\",\n",
      "    \"Brief_Summary\": \"This is the first in human study of QLP2117. To evaluate the Safety, Pharmacokinetics, Immunogenicity and Efficacy of QLP2117 in patients with advanced solid tumors.\",\n",
      "    \"Detailed_Description\": \"Not Provided\",\n",
      "    \"Study_Type\": \"Interventional\",\n",
      "    \"Study_Phase\": \"Phase 1\",\n",
      "    \"Study_Design\": \"Allocation: Non-Randomized\n",
      "Intervention Model: Sequential Assignment\n",
      "Masking: None (Open Label)\n",
      "Primary Purpose: Treatment\",\n",
      "    \"Condition\": \"Advanced Solid Tumors\",\n",
      "    \"Intervention\": \"Drug: QLP2117\n",
      "Specified dose on specified days\",\n",
      "    \"Study_Arms\": \"[List]\",\n",
      "    \"Publications_*\": \"Not Provided\",\n",
      "    \"Recruitment_Status\": \"Not yet recruiting\",\n",
      "    \"Estimated_Enrollment\": \"180\",\n",
      "    \"Original_Estimated_Enrollment\": \"Same as current\",\n",
      "    \"Estimated_Study_Completion_Date\": \"December 31, 2025\",\n",
      "    \"Estimated_Primary_Completion_Date\": \"April 30, 2025   (Final data collection date for primary outcome measure)\",\n",
      "    \"Eligibility_Criteria\": \"[List]\",\n",
      "    \"Sex/Gender\": \"Sexes Eligible for Study:\n",
      "   All\",\n",
      "    \"Ages\": \"18 Years and older   (Adult, Older Adult)\",\n",
      "    \"Accepts_Healthy_Volunteers\": \"No\",\n",
      "    \"Contacts\": \"Contact: Zhang Meijiang, PhD\n",
      "   8615210162105\n",
      "   meijiang.zhang@qilu-pharma.com\",\n",
      "    \"Listed_Location_Countries\": \"Not Provided\",\n",
      "    \"Removed_Location_Countries\": null,\n",
      "    \"NCT_Number\": \"NCT05830045\",\n",
      "    \"Other_Study_ID_Numbers\": \"QLP2117-101\",\n",
      "    \"Has_Data_Monitoring_Committee\": \"No\",\n",
      "    \"U.S._FDA-regulated_Product\": \"[List]\",\n",
      "    \"IPD_Sharing_Statement\": \"Plan to Share IPD:\n",
      "   No\",\n",
      "    \"Current_Responsible_Party\": \"Qilu Pharmaceutical Co., Ltd.\",\n",
      "    \"Original_Responsible_Party\": \"Same as current\",\n",
      "    \"Current_Study_Sponsor\": \"Qilu Pharmaceutical Co., Ltd.\",\n",
      "    \"Original_Study_Sponsor\": \"Same as current\",\n",
      "    \"Collaborators\": \"Not Provided\",\n",
      "    \"Investigators\": \"Principal Investigator:\n",
      "   Xu Ruihua, PhD\n",
      "   Sun Yat-sen University\",\n",
      "    \"PRS_Account\": \"Qilu Pharmaceutical Co., Ltd.\",\n",
      "    \"Verification_Date\": \"April 2023\"\n",
      "  },\n",
      "  {\n",
      "    \"NCT_No\": \"NCT05727839\",\n",
      "    First_Submitted_Date\": \"February 1, 2023\",\n",
      "    First_Posted_Date\": \"February 14, 2023\",\n",
      "    Last_Update_Posted_Date\": \"March 20, 2023\",\n",
      "    Estimated__Study_Start_Date\": \"February 24, 2023\",\n",
      "    Estimated_Primary_Completion_Date\": \"July 24, 2025   (Final data collection date for primary outcome measure)\",\n",
      "    Current_Primary_Outcome_Measures\": \"[List]\",\n",
      "    Original_Primary_Outcome_Measures\": \"[List]\",\n",
      "    Change_History\": \"Complete list of historical versions of study NCT05727839 on ClinicalTrials.gov Archive Site\",\n",
      "    Current_Secondary_Outcome_Measures\": \"[List]\",\n",
      "    Original_Secondary_Outcome_Measures\": \"[List]\",\n",
      "    Current_Other_Pre-specified_Outcome_Measures\": \"Not Provided\",\n",
      "    Original_Other_Pre-specified_Outcome_Measures\": \"Not Provided\",\n",
      "    \"Brief_Title\": \"Study to Evaluate JCXH-211 as Monotherapy in Patients With Malignant Solid Tumors\",\n",
      "    \"Official_Title\": \"A Phase 1 Open-Label Study to Evaluate the Safety, Tolerability and Efficacy of JCXH-211 Intratumoral Injection in Patients With Malignant Solid Tumors\",\n",
      "    \"Brief_Summary\": \": A Phase 1 Open-Label Study to Evaluate the Safety, Tolerability and Efficacy of JCXH-211 Intratumoral Injection in Patients with Malignant Solid Tumors\",\n",
      "    \"Detailed_Description\": \"The main purpose of this study is to find out how safe and tolerable the study drug, JCXH-211, is and also how well it works in people with malignant solid tumors. The study drug JCXH-211, is an immunotherapy drug. This means that it aims to work by boosting immune system's response to tumors, to help fight against the growth of the cancer cells. The study has 2 main phases: Phase\n",
      "  1a and Phase 1b. Phase 1a has 2 stages, skin/subcutaneous lesions stage, deep (visceral) lesions stage. Phase 1b will not start until all the data collected in Phase 1a has been completed and reviewed to check that it is safe and well tolerated.\",\n",
      "    \"Study_Type\": \"Interventional\",\n",
      "    \"Study_Phase\": \"Phase 1\",\n",
      "    \"Study_Design\": \"Allocation: Non-Randomized\n",
      "Intervention Model: Single Group Assignment\n",
      "Masking: None (Open Label)\n",
      "Primary Purpose: Treatment\",\n",
      "    \"Condition\": \"[List]\",\n",
      "    \"Intervention\": \"Drug: JCXH-211 Injection\n",
      "JCXH-211 administered once every 28 days\n",
      "Other Name: Intratumoral injection\",\n",
      "    \"Study_Arms\": \"[List]\",\n",
      "    \"Publications_*\": \"Not Provided\",\n",
      "    \"Recruitment_Status\": \"Recruiting\",\n",
      "    \"Estimated_Enrollment\": \"156\",\n",
      "    \"Original_Estimated_Enrollment\": \"Same as current\",\n",
      "    \"Estimated_Study_Completion_Date\": \"August 24, 2025\",\n",
      "    \"Estimated_Primary_Completion_Date\": \"July 24, 2025   (Final data collection date for primary outcome measure)\",\n",
      "    \"Eligibility_Criteria\": \"[List]\",\n",
      "    \"Sex/Gender\": \"Sexes Eligible for Study:\n",
      "   All\",\n",
      "    \"Ages\": \"18 Years to 75 Years   (Adult, Older Adult)\",\n",
      "    \"Accepts_Healthy_Volunteers\": \"No\",\n",
      "    \"Contacts\": \"Contact: Qi Wang\n",
      "   +8613381113913\n",
      "   qi.wang@immorna.com\",\n",
      "    \"Listed_Location_Countries\": \"China\",\n",
      "    \"Removed_Location_Countries\": null,\n",
      "    \"NCT_Number\": \"NCT05727839\",\n",
      "    \"Other_Study_ID_Numbers\": \"JCXH-211-003\",\n",
      "    \"Has_Data_Monitoring_Committee\": \"Not Provided\",\n",
      "    \"U.S._FDA-regulated_Product\": \"[List]\",\n",
      "    \"IPD_Sharing_Statement\": \"Not Provided\",\n",
      "    \"Current_Responsible_Party\": \"Immorna Biotherapeutics, Inc.\",\n",
      "    \"Original_Responsible_Party\": \"Same as current\",\n",
      "    \"Current_Study_Sponsor\": \"Immorna Biotherapeutics, Inc.\",\n",
      "    \"Original_Study_Sponsor\": \"Same as current\",\n",
      "    \"Collaborators\": \"Not Provided\",\n",
      "    \"Investigators\": \"Principal Investigator:\n",
      "   Xu ruihua, President\n",
      "   Sun Yat-sen University\",\n",
      "    \"PRS_Account\": \"Immorna Biotherapeutics, Inc.\",\n",
      "    \"Verification_Date\": \"March 2023\"\n",
      "  },\n",
      "  {\n",
      "    \"NCT_No\": \"NCT03544905\",\n",
      "    First_Submitted_Date\": \"May 22, 2018\",\n",
      "    First_Posted_Date\": \"June 4, 2018\",\n",
      "    Last_Update_Posted_Date\": \"January 6, 2023\",\n",
      "    Estimated__Study_Start_Date\": \"July 5, 2018\",\n",
      "    Estimated_Primary_Completion_Date\": \"June 30, 2023   (Final data collection date for primary outcome measure)\",\n",
      "    Current_Primary_Outcome_Measures\": \"MTD(Max tolerance does) [ Time Frame: 35 days ]To evaluate the MTD in patients with advanced solid tumor\",\n",
      "    Original_Primary_Outcome_Measures\": \"Same as current\",\n",
      "    Change_History\": \"Complete list of historical versions of study NCT03544905 on ClinicalTrials.gov Archive Site\",\n",
      "    Current_Secondary_Outcome_Measures\": \"Not Provided\",\n",
      "    Original_Secondary_Outcome_Measures\": \"Not Provided\",\n",
      "    Current_Other_Pre-specified_Outcome_Measures\": \"Not Provided\",\n",
      "    Original_Other_Pre-specified_Outcome_Measures\": \"Not Provided\",\n",
      "    \"Brief_Title\": \"Study to Evaluate the Safety, Tolerate, Pharmacokinetics and Preliminary Efficacy of CYH33\",\n",
      "    \"Official_Title\": \"A Multi-center, Open-label, Single Arm, Dose Escalation and Dose Extension Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of CYH33 in Advanced Solid Tumors Patients.\",\n",
      "    \"Brief_Summary\": \"This study is a Multi-center, Open-label, single arm, Dose Escalation and Dose Extension Phase 1 Study to Evaluate the Safety , Tolerability, Pharmacokinetics and Preliminary Efficacy of CYH33 in Advanced Solid Tumors Patients.\",\n",
      "    \"Detailed_Description\": \"This study includes Phase Ia and Phase Ib.\n",
      "  In the dose climbing part of phase Ia, the safety, tolerance and pharmacokinetics characteristics of CYH33 in patients with advanced solid tumors who failed to receive standard treatment, did not tolerate or did not have standard treatment at present will be observed to determine MTD; Before determining MTD, select safe and highly reliable and effective dose levels for simultaneous expansion. Phase Ia dose expansion includes patients with advanced solid tumors who have failed to undergo standard treatment, who are intolerant of PIK3CA gene mutation, or who do not have standard treatment at present, to further evaluate safety, tolerance and initial efficacy.\n",
      "  In Phase Ib, the safety and preliminary efficacy of CYH33 on patients with advanced breast cancer, ovarian cancer, endometrial cancer, cervical cancer, head and neck squamous cell carcinoma, esophageal and gastroesophageal junction squamous cell carcinoma, ovarian clear cell carcinoma and other solid tumors with PIK3CA gene mutation who have failed, are intolerant or do not have standard treatment at present will be evaluated.\",\n",
      "    \"Study_Type\": \"Interventional\",\n",
      "    \"Study_Phase\": \"Phase 1\",\n",
      "    \"Study_Design\": \"Allocation: N/A\n",
      "Intervention Model: Single Group Assignment\n",
      "Masking: None (Open Label)\n",
      "Primary Purpose: Treatment\",\n",
      "    \"Condition\": \"Advanced Solid Tumors\",\n",
      "    \"Intervention\": \"Drug: CYH33 for tablet\n",
      "1mg; 5mg; 10mg; 20mg; 30mg; 50mg; 75mg; 100mg; 130mg; 160mg; 200mg; 240mgBID or QD(Decided by SMC accroding to the safty and PK data)\",\n",
      "    \"Study_Arms\": \"Experimental: Dose escalation study of CYH33\n",
      "To determine the maximum tolerated dose (MTD) of CYH33\n",
      "Intervention: Drug: CYH33 for tablet\",\n",
      "    \"Publications_*\": \"Not Provided\",\n",
      "    \"Recruitment_Status\": \"Recruiting\",\n",
      "    \"Estimated_Enrollment\": \"100\",\n",
      "    \"Original_Estimated_Enrollment\": \"Same as current\",\n",
      "    \"Estimated_Study_Completion_Date\": \"March 31, 2024\",\n",
      "    \"Estimated_Primary_Completion_Date\": \"June 30, 2023   (Final data collection date for primary outcome measure)\",\n",
      "    \"Eligibility_Criteria\": \"[List]\",\n",
      "    \"Sex/Gender\": \"Sexes Eligible for Study:\n",
      "   All\",\n",
      "    \"Ages\": \"18 Years and older   (Adult, Older Adult)\",\n",
      "    \"Accepts_Healthy_Volunteers\": \"No\",\n",
      "    \"Contacts\": \"Contact: Ruihua Xu, M.D\n",
      "   86-20-87343804\n",
      "   ruihxu@163.com\",\n",
      "    \"Listed_Location_Countries\": \"China\",\n",
      "    \"Removed_Location_Countries\": null,\n",
      "    \"NCT_Number\": \"NCT03544905\",\n",
      "    \"Other_Study_ID_Numbers\": \"CYH33-101\",\n",
      "    \"Has_Data_Monitoring_Committee\": \"Yes\",\n",
      "    \"U.S._FDA-regulated_Product\": \"[List]\",\n",
      "    \"IPD_Sharing_Statement\": \"Not Provided\",\n",
      "    \"Current_Responsible_Party\": \"Haihe Biopharma Co., Ltd.\",\n",
      "    \"Original_Responsible_Party\": \"Same as current\",\n",
      "    \"Current_Study_Sponsor\": \"Haihe Biopharma Co., Ltd.\",\n",
      "    \"Original_Study_Sponsor\": \"Same as current\",\n",
      "    \"Collaborators\": \"Not Provided\",\n",
      "    \"Investigators\": \"Principal Investigator:\n",
      "   Ruihua Xu, M.D\n",
      "   Sun Yat-sen University\",\n",
      "    \"PRS_Account\": \"Haihe Biopharma Co., Ltd.\",\n",
      "    \"Verification_Date\": \"January 2023\"\n",
      "  },\n",
      "  {\n",
      "    \"NCT_No\": \"NCT01198392\",\n",
      "    First_Submitted_Date\": \"September 1, 2010\",\n",
      "    First_Posted_Date\": \"September 10, 2010\",\n",
      "    Last_Update_Posted_Date\": \"July 25, 2011\",\n",
      "    Estimated__Study_Start_Date\": \"September 2008\",\n",
      "    Estimated_Primary_Completion_Date\": \"December 2011   (Final data collection date for primary outcome measure)\",\n",
      "    Current_Primary_Outcome_Measures\": \"Time to progression [ Time Frame: The time from randomization until objective tumor progression or death ]\",\n",
      "    Original_Primary_Outcome_Measures\": \"Same as current\",\n",
      "    Change_History\": \"Complete list of historical versions of study NCT01198392 on ClinicalTrials.gov Archive Site\",\n",
      "    Current_Secondary_Outcome_Measures\": \"Response rate [ Time Frame: 2 months ]\",\n",
      "    Original_Secondary_Outcome_Measures\": \"Same as current\",\n",
      "    Current_Other_Pre-specified_Outcome_Measures\": \"Not Provided\",\n",
      "    Original_Other_Pre-specified_Outcome_Measures\": \"Not Provided\",\n",
      "    \"Brief_Title\": \"Trial of S-1 Plus Cisplatin in Gastric Cancer\",\n",
      "    \"Official_Title\": \"A Clinical Trial of S-1 Plus Cisplatin Versus 5-FU Plus Cisplatin in Patients With Unresectable or Advanced Gastric Cancer\",\n",
      "    \"Brief_Summary\": \"The purpose of this study is to evaluate the effectiveness and safety of s-1 plus cisplatin versus 5-FU plus cisplatin as first-line therapy in the treatment of patients with advanced gastric cancer.\",\n",
      "    \"Detailed_Description\": \"This is a randomized, controlled, open-label,multicenter study. Patients are randomized to one of two treatment arms : S-1 plus cisplatin and 5-FU plus cisplatin.\",\n",
      "    \"Study_Type\": \"Interventional\",\n",
      "    \"Study_Phase\": \"Phase 3\",\n",
      "    \"Study_Design\": \"Allocation: Randomized\n",
      "Intervention Model: Parallel Assignment\n",
      "Masking: None (Open Label)\n",
      "Primary Purpose: Treatment\",\n",
      "    \"Condition\": \"Gastric Cancer\",\n",
      "    \"Intervention\": \"[List]\",\n",
      "    \"Study_Arms\": \"[List]\",\n",
      "    \"Publications_*\": \"Li YH, Qiu MZ, Xu JM, Sun GP, Lu HS, Liu YP, Zhong MZ, Zhang HL, Yu SY, Li W, Hu XH, Wang JJ, Cheng Y, Zhou JT, Guo ZQ, Guan ZG, Xu RH. S-1 plus cisplatin versus fluorouracil plus cisplatin in advanced gastric or gastro-esophageal junction adenocarcinoma patients: a pilot study. Oncotarget. 2015 Oct 27;6(33):35107-15. doi: 10.18632/oncotarget.5959.\",\n",
      "    \"Recruitment_Status\": \"Unknown status\",\n",
      "    \"Estimated_Enrollment\": \"270\",\n",
      "    \"Original_Estimated_Enrollment\": \"Same as current\",\n",
      "    \"Estimated_Study_Completion_Date\": \"December 2011\",\n",
      "    \"Estimated_Primary_Completion_Date\": \"December 2011   (Final data collection date for primary outcome measure)\",\n",
      "    \"Eligibility_Criteria\": \"[List]\",\n",
      "    \"Sex/Gender\": \"Sexes Eligible for Study:\n",
      "   All\",\n",
      "    \"Ages\": \"18 Years to 75 Years   (Adult, Older Adult)\",\n",
      "    \"Accepts_Healthy_Volunteers\": \"No\",\n",
      "    \"Contacts\": \"Contact information is only displayed when the study is recruiting subjects\",\n",
      "    \"Listed_Location_Countries\": \"China\",\n",
      "    \"Removed_Location_Countries\": null,\n",
      "    \"NCT_Number\": \"NCT01198392\",\n",
      "    \"Other_Study_ID_Numbers\": \"2005L02859\",\n",
      "    \"Has_Data_Monitoring_Committee\": \"Yes\",\n",
      "    \"U.S._FDA-regulated_Product\": \"Not Provided\",\n",
      "    \"IPD_Sharing_Statement\": \"Not Provided\",\n",
      "    \"Current_Responsible_Party\": \"Zhongzhen Guan ,Ruihua Xu, Sun Yat-sen University Cancer Center\",\n",
      "    \"Original_Responsible_Party\": \"Same as current\",\n",
      "    \"Current_Study_Sponsor\": \"Sun Yat-sen University\",\n",
      "    \"Original_Study_Sponsor\": \"Same as current\",\n",
      "    \"Collaborators\": \"Not Provided\",\n",
      "    \"Investigators\": \"Principal Investigator:\n",
      "   RUIHUA XU, Professor\n",
      "   Sun Yat-sen University\",\n",
      "    \"PRS_Account\": \"Sun Yat-sen University\",\n",
      "    \"Verification_Date\": \"August 2008\"\n",
      "  }\n",
      "]\n",
      "\n",
      "徐瑞华，医学博士，中山大学肿瘤防治中心主任、医院院长、研究所所长，华南恶性肿瘤防治全国重点实验室主任，教授，博士生导师。\n",
      "\n",
      "中国医学科学院学部委员，中国临床肿瘤学会理事长，中国抗癌协会副理事长，中国抗癌协会靶向治疗专委会首届主任委员，中国抗癌协会化疗专委会候任主任委员，中国临床肿瘤学会肠癌专委会主任委员，《Cancer Communications》主编，研究生教材《肿瘤学》主编，本科生教材《临床肿瘤学》主编。\n",
      "\n",
      "从事肿瘤内科临床及科研工作30余年，取得突破性成果：\n",
      "\n",
      "第一，实现了肠癌诊治理论和实践的系统创新，使我国肠癌早诊及精准治疗均处于国际先进水平。创新了肠癌早诊及疗效预测的新技术，并已转化为临床应用；建立了晚期肠癌治疗新体系，创建了高效低毒的维持方案和亚洲方案，成为国际治疗新标准，晚期肠癌生存率与国际顶尖的安德森癌症中心达相同水平。\n",
      "\n",
      "第二，创新了消化肿瘤免疫治疗体系，引领国际消化肿瘤免疫治疗发展。\n",
      "\n",
      "通过鉴定TMB、POLE/POLD突变等标志物，精准筛选免疫治疗敏感亚型，大幅提高PD-1抗体疗效；首创了食管癌中国免疫联合方案，取得全球最高有效率72%，已成为食管癌治疗应用最广泛的方案；建立了食管癌EGIC分型，可以指导精准免疫治疗策略，引领该领域的发展；揭示了免疫逃逸新机制并推动了药物的开发：发现甲硫氨酸限制饮食可抑制免疫检查点分子PDL1及VISTA的表达，增强抗肿瘤免疫及抗PD1的治疗效果；鉴定出免疫治疗增效肠道活性菌RX-af01，成果已转化。\n",
      "\n",
      "以通讯或第一作者在国际顶级期刊JAMA、Nature Materials、Nature Medicine、Lancet Oncology等发表SCI论文200余篇，入选科睿唯安（Clarivate Analytics）全球高被引科学家，连续入选中国高被引学者榜单。以第一完成人获国家科技进步二等奖2项及省部级一等奖6项、吴阶平医药创新奖、谈家桢临床医学奖及CSCO年度成就奖。入选国家百千万人才工程、全国先进工作者、南粤百杰人才培养工程、国家卫生计生突出贡献中青年专家等人才项目。\n",
      "\n",
      "Representative paper: （*：第一作者，#：通讯作者）\n",
      "\n",
      "[1]     Luo H, Lu J, Bai Y, Mao T, Wang J, Fan Q, Zhang Y, Zhao K, Chen Z, Gao S, Li J, Fu Z, Gu K, Liu Z, Wu L, Zhang X, Feng J, Niu Z, Ba Y, Zhang H, Liu Y, Zhang L, Min X, Huang J, Cheng Y, Wang D, Shen Y, Yang Q, Zou J, Xu RH# ESCORT-1st Investigators.  Effect of Camrelizumab vs Placebo Added to Chemotherapy on Survival and Progression-Free Survival in Patients With Advanced or Metastatic Esophageal Squamous Cell Carcinoma: The ESCORT-1st Randomized Clinical Trial. JAMA. 2021 Sep 14;326(10):916-925.\n",
      "\n",
      "[2]     Xu RH*#, Wei W, Krawczyk M, Wang W, Luo H, Flagg K, Yi S, Shi W, Quan Q, Li K, Zheng L, Zhang H, Caughey BA, Zhao Q, Hou J, Zhang R, Xu Y, Cai H, Li G, Hou R, Zhong Z, Lin D, Fu X, Zhu J, Duan Y, Yu M, Ying B, Zhang W, Wang J, Zhang E, Zhang C, Li O, Guo R, Carter H, Zhu JK, Hao X and Zhang K. Circulating tumour DNA methylation markers for diagnosis and prognosis of hepatocellular carcinoma. Nat Mater 2017; 16: 1155-1161.\n",
      "\n",
      "[3]     Xu RH*#, Muro K, Morita S, Iwasa S, Han SW, Wang W, Kotaka M, Nakamura M, Ahn JB, Deng YH, Kato T, Cho SH, Ba Y, Matsuoka H, Lee KW, Zhang T, Yamada Y, Sakamoto J, Park YS and Kim TW. Modified XELIRI (capecitabine plus irinotecan) versus FOLFIRI (leucovorin, fluorouracil, and irinotecan), both either with or without bevacizumab, as second-line therapy for metastatic colorectal cancer (AXEPT): a multicentre, open-label, randomised, non-inferiority, phase 3 trial. Lancet Oncol 2018; 19: 660-671.\n",
      "\n",
      "[4]     Li J, Qin S, Xu R*, Yau TC, Ma B, Pan H, Xu J, Bai Y, Chi Y, Wang L, Yeh KH, Bi F, Cheng Y, Le AT, Lin JK, Liu T, Ma D, Kappeler C, Kalmus J and Kim TW. Regorafenib plus best supportive care versus placebo plus best supportive care in Asian patients with previously treated metastatic colorectal cancer (CONCUR): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncology 2015; 16: 619-629.\n",
      "\n",
      "[5]     Luo H, Xu G, Li C, He L, Luo L, Wang Z, Jing B, Deng Y, Jin Y, Li Y, Li B, Tan W, He C, Seeruttun SR, Wu Q, Huang J, Huang DW, Chen B, Lin SB, Chen QM, Yuan CM, Chen HX, Pu HY, Zhou F, He Y, Xu RH#. Real-time artificial intelligence for detection of upper gastrointestinal cancer by endoscopy: a multicentre, case-control, diagnostic study. Lancet Oncol. 2019 Oct 4.\n",
      "\n",
      "[6]     Satoh T, Xu RH*, Chung HC, Sun GP, Doi T, Xu JM, Tsuji A, Omuro Y, Li J, Wang JW, Miwa H, Qin SK, Chung IJ, Yeh KH, Feng JF, Mukaiyama A, Kobayashi M, Ohtsu A and Bang YJ. Lapatinib plus paclitaxel versus paclitaxel alone in the second-line treatment of HER2-amplified advanced gastric cancer in Asian populations: TyTAN--a randomized, phase III study. Journal of Clinical Oncology 2014; 32: 2039-2049.\n",
      "\n",
      "[7]     Manish A. Shah, Rui-hua Xu*, Yung-Jue Bang, Paulo M. Hoff, Tianshu Liu, Luis A. Herr´aez-Baranda, Fan Xia,Amit Garg, Mona Shing, and Josep Tabernero. HELOISE: Phase IIIb Randomized Multicenter Study Comparing Standard-of-Care and Higher-Dose Trastuzumab Regimens Combined With Chemotherapy as First-Line Therapy in Patients With Human Epidermal Growth Factor Receptor 2–Positive Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma. Journal of Clinical Oncology 2017; 35: 2558-2567.\n",
      "\n",
      "[8]     Wang ZX, Cui C, Yao J, Zhang Y, Li M, Feng J, Yang S, Fan Y, Shi J, Zhang X, Shen L, Shu Y, Wang C, Dai T, Mao T, Chen L, Guo Z, Liu B, Pan H, Cang S, Jiang Y, Wang J, Ye M, Chen Z, Jiang D, Lin Q, Ren W, Wang J, Wu L, Xu Y, Miao Z, Sun M, Xie C, Liu Y, Wang Q, Zhao L, Li Q, Huang C, Jiang K, Yang K, Li D, Liu Y, Zhu Z, Chen R, Jia L, Li W, Liao W, Liu HX, Ma D, Ma J, Qin Y, Shi Z, Wei Q, Xiao K, Zhang Y, Zhang Y, Chen X, Dai G, He J, Li J, Li G, Liu Y, Liu Z, Yuan X, Zhang J, Fu Z, He Y, Ju F, Liu Z, Tang P, Wang T, Wang W, Zhang J, Luo X, Tang X, May R, Feng H, Yao S, Keegan P, Xu RH#, Wang F. Toripalimab plus chemotherapy in treatment-naïve, advanced esophageal squamous cell carcinoma (JUPITER-06): A multi-center phase 3 trial. Cancer Cell. 2022 Mar 14;40(3):277-288.\n",
      "\n",
      "[9]     Wang F, Zhao Q, Wang YN, Jin Y, He MM, Liu ZX, Xu RH#. Evaluation of POLE and POLD1 Mutations as Biomarkers for Immunotherapy Outcomes Across Multiple Cancer Types. JAMA Oncol. 2019.\n",
      "\n",
      "[10]   Wang F, Liu DB, Zhao Q, Chen G, Liu XM, Wang YN, Su H, Qin YR, He YF, Zou QF, Liu YH, Lin YE, Liu ZX, Bei JX and Xu RH#. The genomic landscape of small cell carcinoma of the esophagus. Cell Res 2018; 28: 771-774.\n",
      "\n",
      "[11]   Wang DS, Liu ZX, Lu YX, Bao H, Wu X, Zeng ZL, Liu Z, Zhao Q, He CY, Lu JH, Wang ZQ, Qiu MZ, Wang F, Wang FH, Li YH, Wang XN, Xie D, Jia WH, Shao YW and Xu RH#. Liquid biopsies to track trastuzumab resistance in metastatic HER2-positive gastric cancer. Gut 2018;\n",
      "\n",
      "[12]   Feng Wang, You-Sheng Huang, Hao-Xiang Wu, Zi-Xian Wang, Ying Jin, Yi-Chen Yao, Yan-Xing Chen, Qi Zhao, Shifu Chen, Ming-Ming He, Hui-Yan Luo, Miao-Zhen Qiu, De-Shen Wang, Feng-Hua Wang, Mingyan Xu, Yu-Hong Li, Rui-Hua Xu#. Genomic temporal heterogeneity of circulating tumour DNA in unresectable metastatic colorectal cancer under first-line treatment. Gut. 2022 Jul;71(7):1340-1349.\n",
      "\n",
      "[13]   Luo HY, Li YH, Wang W, Wang ZQ, Yuan X, Ma D, Wang FH, Zhang DS, Lin DR, Lin YC, Jia J, Hu XH, Peng JW and Xu RH#. Single-agent capecitabine as maintenance therapy after induction of XELOX (or FOLFOX) in first-line treatment of metastatic colorectal cancer: randomized clinical trial of efficacy and safety. Annals of Oncology 2016; 27: 1074-1081.\n",
      "\n",
      "[14]   Wang F, Wei XL, Wang FH, Xu N, Shen L, Dai GH, Yuan XL, Chen Y, Yang SJ, Shi JH, Hu XC, Lin XY, Zhang QY, JF Feng, Y Ba, YP Liu, W Li, YQ Shu, Y Jiang, Q Li, JW Wang, H Wu, H Feng, S Yao, RH Xu#. Safety, efficacy and tumor mutational burden as a biomarker of overall survival benefit in chemo-refractory gastric cancer treated with toripalimab, a PD1 antibody in phase Ib/II clinical trial NCT02915432. Ann Oncol. 2019.\n",
      "\n",
      "[15]  Luo H, Zhao Q, Wei W, Zheng L, Yi S, Li G, Wang W, Sheng H, Pu H, Mo H, Zuo Z, Liu Z, Li C, Xie C, Zeng Z, Li W, Hao X, Liu Y, Cao S, Liu W, Gibson S, Zhang K, Xu G, Xu RH#. Circulating tumor DNA methylation profiles enable early diagnosis, prognosis prediction, and screening for colorectal cancer. Sci Transl Med. 2020 Jan 1;12(524).\n",
      "\n",
      "[16]   Li T, Hu PS, Zuo Z, Lin JF, Li X, Wu QN, Chen ZH, Zeng ZL, Wang F, Zheng J, Chen D, Li B, Kang TB, Dan Xie, Dongxin Lin, Huai-Qiang Ju, Rui-Hua Xu#. METTL3 facilitates tumor progression via an m(6)A-IGF2BP2-dependent mechanism in colorectal carcinoma. Mol Cancer. 2019; 18: 112.\n",
      "\n",
      "[17] Yun Wang, Jia-Huan Lu, Qi-Nian Wu, Ying Jin, De-Shen Wang, Yan-Xing Chen, Jia Liu, Xiao-Jing Luo, Qi Meng, Heng-Ying Pu, Ying-Nan Wang, Pei-Shan Hu, Ze-Xian Liu, Zhao-Lei Zeng, Qi Zhao, Rong Deng, Xiao-Feng Zhu, Huai-Qiang Ju, Rui-Hua Xu#. LncRNA LINRIS stabilizes IGF2BP2 and promotes the aerobic glycolysis in colorectal cancer. Molecular Cancer. 2019 Dec 2.\n",
      "\n",
      "[18]   Jin Y, Chen DL, Wang F, Yang CP, Chen XX, You JQ, Huang JS, Shao Y, Zhu DQ, Ouyang YM, Luo HY, Wang ZQ, Wang FH, Li YH, Xu RH#, Zhang DS. The predicting role of circulating tumor DNA landscape in gastric cancer patients treated with immune checkpoint inhibitors. Mol Cancer. 2020 Oct 30;19(1):154.\n",
      "\n",
      "[19]   Chen DL, Wang ZQ, Zeng ZL, Wu WJ, Zhang DS, Luo HY, Wang F, Qiu MZ, Wang DS, Ren C, Wang FH, Chiao LJ, Pelicano H, Huang P, Li YH and Xu RH#. Identification of microRNA-214 as a negative regulator of colorectal cancer liver metastasis by way of regulation of fibroblast growth factor receptor 1 expression. Hepatology 2014; 60: 598-609.\n",
      "\n",
      "[20]   Ju HQ, Li H, Tian T, Lu YX, Bai L, Chen LZ, Sheng H, Mo HY, Zeng JB, Deng W, Chiao PJ and Xu RH#. Melatonin overcomes gemcitabine resistance in pancreatic ductal adenocarcinoma by abrogating nuclear factor-kappaB activation. Journal of Pineal Research 2016; 60: 27-38.\n",
      "\n",
      "[21]   Ju HQ, Lin JF, Tian T, Xie D, Xu RH#. NADPH homeostasis in cancer: functions, mechanisms and therapeutic implications. Signal Transduct Tar. 2020 Oct 7;5(1):231.\n",
      "\n",
      "[22]  Hu PS, Li T, Lin JF, Qiu MZ, Wang DS, Liu ZX, Chen ZH, Yang LP, Zhang XL, Zhao Q, Chen YX, Lu YX, Wu QN, Pu HY, Zeng ZL, Xie D, Ju HQ, Luo HY, Xu RH#. VDR-SOX2 signaling promotes colorectal cancer stemness and malignancy in an acidic microenvironment. Signal Transduct Tar. 2020 Sep 9;5(1):183.\n",
      "\n",
      "[23]   Ju HQ, Ying H, Tian T, Ling J, Fu J, Lu Y, Wu M, Yang L, Achreja A, Chen G, Zhuang Z, Wang H, Nagrath D, Yao J, Hung MC, DePinho RA, Huang P, Xu RH# and Chiao PJ. Mutant Kras- and p16-regulated NOX4 activation overcomes metabolic checkpoints in development of pancreatic ductal adenocarcinoma. Nat Commun 2017; 8: 14437.\n",
      "\n",
      "[24]   Liu J, Liu ZX, Wu QN, Lu YX, Wong CW, Miao L, Wang Y, Wang Z, Jin Y, He MM, Ren C, Wang DS, Chen DL, Pu HY, Feng L, Li B, Xie D, Zeng MS, Huang P, Lin A, Lin D, Xu RH#, Ju HQ. Long noncoding RNA AGPG regulates PFKFB3-mediated tumor glycolytic reprogramming. Nat Commun. 2020 Mar 20;11(1):1507.\n",
      "\n",
      "[25]   Ju HQ, Lu YX, Chen DL, Zuo ZX, Liu ZX, Wu QN, Mo HY, Wang ZX, Wang DS, Pu HY, Zeng ZL, Li B, Xie D, Huang P, Hung MC, Chiao PJ and Xu RH#. Modulation of Redox Homeostasis by Inhibition of MTHFD2 in Colorectal Cancer: Mechanisms and Therapeutic Implications. J Natl Cancer Inst 2018\n",
      "\n",
      "[26] Yu K, Zhang Q, Liu Z, Zhao Q, Zhang X, Wang Y, Wang ZX, Jin Y, Li X, Liu ZX and Xu RH#. qPhos: a database of protein phosphorylation dynamics in humans. Nucleic Acids Res 2018\n",
      "\n",
      "[27] Rui-Hua Xu*, Jin Li, Yuxian Bai, Jianming Xu, Tianshu Liu, Lin Shen, Liwei Wang, Hongming Pan, Junning Cao, Dongsheng Zhang, Songhua Fan, Ye Hua & Weiguo Su. Safety and efficacy of fruquintinib in patients with previously treated metastatic colorectal cancer: a phase Ib study and a randomized double-blind phase II study. J Hematol Oncol. (2017) 10:22.\n",
      "\n",
      "[28] Gong Chen, Junjie Peng, Qian Xiao, Hao-Xiang Wu, Xiaojun Wu, Fulong Wang, Liren Li, Peirong Ding, Qi Zhao, Yaqi Li, Da Wang, Yang Shao, Hua Bao, Zhizhong Pan, Ke-Feng Ding, Sanjun Cai, Feng Wang, Rui-Hua Xu#. Postoperative circulating tumor DNA as markers of recurrence risk in stages II to III colorectal cancer. Journal of Hematology & Oncology. 2021 May 17;14(1):80.\n",
      "\n",
      "[29] Zeng ZL, Luo HY, Yang J, Wu WJ, Chen DL, Huang P and Xu RH#. Overexpression of the circadian clock gene Bmal1 increases sensitivity to oxaliplatin in colorectal cancer. Clinical Cancer Research 2014; 20: 1042-1052.\n",
      "\n",
      "[30] Huiyan Luo, Wei Wei, Ziyi Ye, Jiabo Zheng, Rui-hua Xu#. Liquid Biopsy of Methylation Biomarkers in Cell-Free DNA. Trends in Molecular Medicine. 23 Jan 2021.\n",
      "\n",
      "    ---------\n",
      "\n",
      "\n",
      "2023-06-14 22:13:21,525 - common.py - [line]:36 - INFO - response.status_code:200, response.text:{\"id\":\"chatcmpl-7RLXLtcawMaAZt4GEkFVAjVCULPud\",\"object\":\"chat.completion\",\"created\":1686751999,\"model\":\"gpt-3.5-turbo-16k-0613\",\"choices\":[{\"index\":0,\"message\":{\"role\":\"assistant\",\"content\":\"徐瑞华的专长是结直肠癌、微卫星稳定性（pMMR）和微卫星不稳定性（MSS）。\"},\"finish_reason\":\"stop\"}],\"usage\":{\"prompt_tokens\":9513,\"completion_tokens\":44,\"total_tokens\":9557}}\n",
      "2023-06-14 22:13:21,526 - common.py - [line]:39 - INFO - json_dict:{'id': 'chatcmpl-7RLXLtcawMaAZt4GEkFVAjVCULPud', 'object': 'chat.completion', 'created': 1686751999, 'model': 'gpt-3.5-turbo-16k-0613', 'choices': [{'index': 0, 'message': {'role': 'assistant', 'content': '徐瑞华的专长是结直肠癌、微卫星稳定性（pMMR）和微卫星不稳定性（MSS）。'}, 'finish_reason': 'stop'}], 'usage': {'prompt_tokens': 9513, 'completion_tokens': 44, 'total_tokens': 9557}}\n",
      "2023-06-14 22:13:21,526 - common.py - [line]:42 - INFO - 徐瑞华的专长是结直肠癌、微卫星稳定性（pMMR）和微卫星不稳定性（MSS）。\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "+++++++++++++++++++++++++\n",
      "徐瑞华的专长是结直肠癌、微卫星稳定性（pMMR）和微卫星不稳定性（MSS）。\n"
     ]
    }
   ],
   "source": [
    "chat(xrh_txt,\"徐瑞华的专长\")"
   ],
   "metadata": {
    "collapsed": false,
    "ExecuteTime": {
     "end_time": "2023-06-14T14:13:21.534442400Z",
     "start_time": "2023-06-14T14:13:13.715208800Z"
    }
   }
  },
  {
   "cell_type": "code",
   "execution_count": 5,
   "outputs": [
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "2023-06-14 22:17:10,585 - common.py - [line]:30 - INFO - get_openai_data: model:gpt-3.5-turbo-16k\n",
      "2023-06-14 22:17:18,078 - common.py - [line]:33 - INFO - <Response [200]>\n",
      "2023-06-14 22:17:18,079 - common.py - [line]:34 - INFO - query:\n",
      "    请根据以下context，回答：徐瑞华的clinical trial有哪些，列出NCT编号\n",
      "    reply in 简体中文\n",
      "    ---------context\n",
      "    \n",
      "[\n",
      "  {\n",
      "    \"_id\": \"648019f5778538384fd02da2\",\n",
      "    \"avatar\": null,\n",
      "    \"name\": \"Ruihua Xu\",\n",
      "    \"hospital\": \"Sun Yat-sen University\",\n",
      "    \"title\": \" MD\",\n",
      "    \"position\": null,\n",
      "    \"contact\": \"xuruihua@sysucc.org.cn\",\n",
      "    \"phone\": \"86-20-87343333\",\n",
      "    \"expertise\": \"Colorectal Carcinoma, pMMR, Microsatellite-stable\",\n",
      "    \"brief_intro\": \"A Study of Sintilimab and Chidamide in Combination With or Without IBI305 in Standard Treatment Failure of Advanced or Metastatic pMMR/MSS Colorectal Carcinoma\",\n",
      "    \"work_exp\": null,\n",
      "    \"edu_exp\": null,\n",
      "    \"consulting\": null,\n",
      "    \"publications\": null,\n",
      "    \"clinical_res\": null,\n",
      "    \"awards\": null\n",
      "  },\n",
      "  {\n",
      "    \"_id\": \"64803f25f24b55a336ba235d\",\n",
      "    \"avatar\": null,\n",
      "    \"name\": \"ruihua Xu\",\n",
      "    \"hospital\": \"Peking University\",\n",
      "    \"title\": \"M.D., Ph.D.\",\n",
      "    \"position\": null,\n",
      "    \"contact\": \"xurh@mail.sysu.edu.cn\",\n",
      "    \"phone\": \"13922206676\",\n",
      "    \"expertise\": \"nimotuzumab colorectal cancer chemotherapy\",\n",
      "    \"brief_intro\": null,\n",
      "    \"work_exp\": null,\n",
      "    \"edu_exp\": null,\n",
      "    \"consulting\": null,\n",
      "    \"publications\": null,\n",
      "    \"clinical_res\": \"Study of Nimotuzumab to Treat Colorectal Cancer\",\n",
      "    \"awards\": null\n",
      "  },\n",
      "  {\n",
      "    \"_id\": \"6480ea13f24b55a336bec613\",\n",
      "    \"avatar\": null,\n",
      "    \"name\": \"Ruihua Xu\",\n",
      "    \"hospital\": \"Sun Yat-sen University\",\n",
      "    \"title\": \"MD\",\n",
      "    \"position\": null,\n",
      "    \"contact\": \"xurh@susycc.org.cn\",\n",
      "    \"phone\": \"+862087343795\",\n",
      "    \"expertise\": \"Colorectal Cancer,Microsatellite Stable,Chidamide,Sintilimab,PD-1,Bevacizumab\",\n",
      "    \"brief_intro\": null,\n",
      "    \"work_exp\": null,\n",
      "    \"edu_exp\": null,\n",
      "    \"consulting\": null,\n",
      "    \"publications\": null,\n",
      "    \"clinical_res\": \"Comparing Chidamide+Sintilimab+Bev With Standard Second-line FOLFIRI+Bev in Advanced MSS/pMMR mCRC\",\n",
      "    \"awards\": null\n",
      "  }\n",
      "]\n",
      "[\n",
      "  {\n",
      "    \"NCT_No\": \"NCT05830045\",\n",
      "    First_Submitted_Date\": \"April 4, 2023\",\n",
      "    First_Posted_Date\": \"April 26, 2023\",\n",
      "    Last_Update_Posted_Date\": \"April 26, 2023\",\n",
      "    Estimated__Study_Start_Date\": \"April 20, 2023\",\n",
      "    Estimated_Primary_Completion_Date\": \"April 30, 2025   (Final data collection date for primary outcome measure)\",\n",
      "    Current_Primary_Outcome_Measures\": \"[List]\",\n",
      "    Original_Primary_Outcome_Measures\": \"Same as current\",\n",
      "    Change_History\": \"No Changes Posted\",\n",
      "    Current_Secondary_Outcome_Measures\": \"Not Provided\",\n",
      "    Original_Secondary_Outcome_Measures\": \"Not Provided\",\n",
      "    Current_Other_Pre-specified_Outcome_Measures\": \"Not Provided\",\n",
      "    Original_Other_Pre-specified_Outcome_Measures\": \"Not Provided\",\n",
      "    \"Brief_Title\": \"A Phase I Study of QLP2117 in Subjects With Advanced Solid Tumors\",\n",
      "    \"Official_Title\": \"A Study Evaluates the Safety, Pharmacokinetics, Immunogenicity and Efficacy of QLP2117 in Advanced Solid Tumor Patients\",\n",
      "    \"Brief_Summary\": \"This is the first in human study of QLP2117. To evaluate the Safety, Pharmacokinetics, Immunogenicity and Efficacy of QLP2117 in patients with advanced solid tumors.\",\n",
      "    \"Detailed_Description\": \"Not Provided\",\n",
      "    \"Study_Type\": \"Interventional\",\n",
      "    \"Study_Phase\": \"Phase 1\",\n",
      "    \"Study_Design\": \"Allocation: Non-Randomized\n",
      "Intervention Model: Sequential Assignment\n",
      "Masking: None (Open Label)\n",
      "Primary Purpose: Treatment\",\n",
      "    \"Condition\": \"Advanced Solid Tumors\",\n",
      "    \"Intervention\": \"Drug: QLP2117\n",
      "Specified dose on specified days\",\n",
      "    \"Study_Arms\": \"[List]\",\n",
      "    \"Publications_*\": \"Not Provided\",\n",
      "    \"Recruitment_Status\": \"Not yet recruiting\",\n",
      "    \"Estimated_Enrollment\": \"180\",\n",
      "    \"Original_Estimated_Enrollment\": \"Same as current\",\n",
      "    \"Estimated_Study_Completion_Date\": \"December 31, 2025\",\n",
      "    \"Estimated_Primary_Completion_Date\": \"April 30, 2025   (Final data collection date for primary outcome measure)\",\n",
      "    \"Eligibility_Criteria\": \"[List]\",\n",
      "    \"Sex/Gender\": \"Sexes Eligible for Study:\n",
      "   All\",\n",
      "    \"Ages\": \"18 Years and older   (Adult, Older Adult)\",\n",
      "    \"Accepts_Healthy_Volunteers\": \"No\",\n",
      "    \"Contacts\": \"Contact: Zhang Meijiang, PhD\n",
      "   8615210162105\n",
      "   meijiang.zhang@qilu-pharma.com\",\n",
      "    \"Listed_Location_Countries\": \"Not Provided\",\n",
      "    \"Removed_Location_Countries\": null,\n",
      "    \"NCT_Number\": \"NCT05830045\",\n",
      "    \"Other_Study_ID_Numbers\": \"QLP2117-101\",\n",
      "    \"Has_Data_Monitoring_Committee\": \"No\",\n",
      "    \"U.S._FDA-regulated_Product\": \"[List]\",\n",
      "    \"IPD_Sharing_Statement\": \"Plan to Share IPD:\n",
      "   No\",\n",
      "    \"Current_Responsible_Party\": \"Qilu Pharmaceutical Co., Ltd.\",\n",
      "    \"Original_Responsible_Party\": \"Same as current\",\n",
      "    \"Current_Study_Sponsor\": \"Qilu Pharmaceutical Co., Ltd.\",\n",
      "    \"Original_Study_Sponsor\": \"Same as current\",\n",
      "    \"Collaborators\": \"Not Provided\",\n",
      "    \"Investigators\": \"Principal Investigator:\n",
      "   Xu Ruihua, PhD\n",
      "   Sun Yat-sen University\",\n",
      "    \"PRS_Account\": \"Qilu Pharmaceutical Co., Ltd.\",\n",
      "    \"Verification_Date\": \"April 2023\"\n",
      "  },\n",
      "  {\n",
      "    \"NCT_No\": \"NCT05727839\",\n",
      "    First_Submitted_Date\": \"February 1, 2023\",\n",
      "    First_Posted_Date\": \"February 14, 2023\",\n",
      "    Last_Update_Posted_Date\": \"March 20, 2023\",\n",
      "    Estimated__Study_Start_Date\": \"February 24, 2023\",\n",
      "    Estimated_Primary_Completion_Date\": \"July 24, 2025   (Final data collection date for primary outcome measure)\",\n",
      "    Current_Primary_Outcome_Measures\": \"[List]\",\n",
      "    Original_Primary_Outcome_Measures\": \"[List]\",\n",
      "    Change_History\": \"Complete list of historical versions of study NCT05727839 on ClinicalTrials.gov Archive Site\",\n",
      "    Current_Secondary_Outcome_Measures\": \"[List]\",\n",
      "    Original_Secondary_Outcome_Measures\": \"[List]\",\n",
      "    Current_Other_Pre-specified_Outcome_Measures\": \"Not Provided\",\n",
      "    Original_Other_Pre-specified_Outcome_Measures\": \"Not Provided\",\n",
      "    \"Brief_Title\": \"Study to Evaluate JCXH-211 as Monotherapy in Patients With Malignant Solid Tumors\",\n",
      "    \"Official_Title\": \"A Phase 1 Open-Label Study to Evaluate the Safety, Tolerability and Efficacy of JCXH-211 Intratumoral Injection in Patients With Malignant Solid Tumors\",\n",
      "    \"Brief_Summary\": \": A Phase 1 Open-Label Study to Evaluate the Safety, Tolerability and Efficacy of JCXH-211 Intratumoral Injection in Patients with Malignant Solid Tumors\",\n",
      "    \"Detailed_Description\": \"The main purpose of this study is to find out how safe and tolerable the study drug, JCXH-211, is and also how well it works in people with malignant solid tumors. The study drug JCXH-211, is an immunotherapy drug. This means that it aims to work by boosting immune system's response to tumors, to help fight against the growth of the cancer cells. The study has 2 main phases: Phase\n",
      "  1a and Phase 1b. Phase 1a has 2 stages, skin/subcutaneous lesions stage, deep (visceral) lesions stage. Phase 1b will not start until all the data collected in Phase 1a has been completed and reviewed to check that it is safe and well tolerated.\",\n",
      "    \"Study_Type\": \"Interventional\",\n",
      "    \"Study_Phase\": \"Phase 1\",\n",
      "    \"Study_Design\": \"Allocation: Non-Randomized\n",
      "Intervention Model: Single Group Assignment\n",
      "Masking: None (Open Label)\n",
      "Primary Purpose: Treatment\",\n",
      "    \"Condition\": \"[List]\",\n",
      "    \"Intervention\": \"Drug: JCXH-211 Injection\n",
      "JCXH-211 administered once every 28 days\n",
      "Other Name: Intratumoral injection\",\n",
      "    \"Study_Arms\": \"[List]\",\n",
      "    \"Publications_*\": \"Not Provided\",\n",
      "    \"Recruitment_Status\": \"Recruiting\",\n",
      "    \"Estimated_Enrollment\": \"156\",\n",
      "    \"Original_Estimated_Enrollment\": \"Same as current\",\n",
      "    \"Estimated_Study_Completion_Date\": \"August 24, 2025\",\n",
      "    \"Estimated_Primary_Completion_Date\": \"July 24, 2025   (Final data collection date for primary outcome measure)\",\n",
      "    \"Eligibility_Criteria\": \"[List]\",\n",
      "    \"Sex/Gender\": \"Sexes Eligible for Study:\n",
      "   All\",\n",
      "    \"Ages\": \"18 Years to 75 Years   (Adult, Older Adult)\",\n",
      "    \"Accepts_Healthy_Volunteers\": \"No\",\n",
      "    \"Contacts\": \"Contact: Qi Wang\n",
      "   +8613381113913\n",
      "   qi.wang@immorna.com\",\n",
      "    \"Listed_Location_Countries\": \"China\",\n",
      "    \"Removed_Location_Countries\": null,\n",
      "    \"NCT_Number\": \"NCT05727839\",\n",
      "    \"Other_Study_ID_Numbers\": \"JCXH-211-003\",\n",
      "    \"Has_Data_Monitoring_Committee\": \"Not Provided\",\n",
      "    \"U.S._FDA-regulated_Product\": \"[List]\",\n",
      "    \"IPD_Sharing_Statement\": \"Not Provided\",\n",
      "    \"Current_Responsible_Party\": \"Immorna Biotherapeutics, Inc.\",\n",
      "    \"Original_Responsible_Party\": \"Same as current\",\n",
      "    \"Current_Study_Sponsor\": \"Immorna Biotherapeutics, Inc.\",\n",
      "    \"Original_Study_Sponsor\": \"Same as current\",\n",
      "    \"Collaborators\": \"Not Provided\",\n",
      "    \"Investigators\": \"Principal Investigator:\n",
      "   Xu ruihua, President\n",
      "   Sun Yat-sen University\",\n",
      "    \"PRS_Account\": \"Immorna Biotherapeutics, Inc.\",\n",
      "    \"Verification_Date\": \"March 2023\"\n",
      "  },\n",
      "  {\n",
      "    \"NCT_No\": \"NCT03544905\",\n",
      "    First_Submitted_Date\": \"May 22, 2018\",\n",
      "    First_Posted_Date\": \"June 4, 2018\",\n",
      "    Last_Update_Posted_Date\": \"January 6, 2023\",\n",
      "    Estimated__Study_Start_Date\": \"July 5, 2018\",\n",
      "    Estimated_Primary_Completion_Date\": \"June 30, 2023   (Final data collection date for primary outcome measure)\",\n",
      "    Current_Primary_Outcome_Measures\": \"MTD(Max tolerance does) [ Time Frame: 35 days ]To evaluate the MTD in patients with advanced solid tumor\",\n",
      "    Original_Primary_Outcome_Measures\": \"Same as current\",\n",
      "    Change_History\": \"Complete list of historical versions of study NCT03544905 on ClinicalTrials.gov Archive Site\",\n",
      "    Current_Secondary_Outcome_Measures\": \"Not Provided\",\n",
      "    Original_Secondary_Outcome_Measures\": \"Not Provided\",\n",
      "    Current_Other_Pre-specified_Outcome_Measures\": \"Not Provided\",\n",
      "    Original_Other_Pre-specified_Outcome_Measures\": \"Not Provided\",\n",
      "    \"Brief_Title\": \"Study to Evaluate the Safety, Tolerate, Pharmacokinetics and Preliminary Efficacy of CYH33\",\n",
      "    \"Official_Title\": \"A Multi-center, Open-label, Single Arm, Dose Escalation and Dose Extension Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of CYH33 in Advanced Solid Tumors Patients.\",\n",
      "    \"Brief_Summary\": \"This study is a Multi-center, Open-label, single arm, Dose Escalation and Dose Extension Phase 1 Study to Evaluate the Safety , Tolerability, Pharmacokinetics and Preliminary Efficacy of CYH33 in Advanced Solid Tumors Patients.\",\n",
      "    \"Detailed_Description\": \"This study includes Phase Ia and Phase Ib.\n",
      "  In the dose climbing part of phase Ia, the safety, tolerance and pharmacokinetics characteristics of CYH33 in patients with advanced solid tumors who failed to receive standard treatment, did not tolerate or did not have standard treatment at present will be observed to determine MTD; Before determining MTD, select safe and highly reliable and effective dose levels for simultaneous expansion. Phase Ia dose expansion includes patients with advanced solid tumors who have failed to undergo standard treatment, who are intolerant of PIK3CA gene mutation, or who do not have standard treatment at present, to further evaluate safety, tolerance and initial efficacy.\n",
      "  In Phase Ib, the safety and preliminary efficacy of CYH33 on patients with advanced breast cancer, ovarian cancer, endometrial cancer, cervical cancer, head and neck squamous cell carcinoma, esophageal and gastroesophageal junction squamous cell carcinoma, ovarian clear cell carcinoma and other solid tumors with PIK3CA gene mutation who have failed, are intolerant or do not have standard treatment at present will be evaluated.\",\n",
      "    \"Study_Type\": \"Interventional\",\n",
      "    \"Study_Phase\": \"Phase 1\",\n",
      "    \"Study_Design\": \"Allocation: N/A\n",
      "Intervention Model: Single Group Assignment\n",
      "Masking: None (Open Label)\n",
      "Primary Purpose: Treatment\",\n",
      "    \"Condition\": \"Advanced Solid Tumors\",\n",
      "    \"Intervention\": \"Drug: CYH33 for tablet\n",
      "1mg; 5mg; 10mg; 20mg; 30mg; 50mg; 75mg; 100mg; 130mg; 160mg; 200mg; 240mgBID or QD(Decided by SMC accroding to the safty and PK data)\",\n",
      "    \"Study_Arms\": \"Experimental: Dose escalation study of CYH33\n",
      "To determine the maximum tolerated dose (MTD) of CYH33\n",
      "Intervention: Drug: CYH33 for tablet\",\n",
      "    \"Publications_*\": \"Not Provided\",\n",
      "    \"Recruitment_Status\": \"Recruiting\",\n",
      "    \"Estimated_Enrollment\": \"100\",\n",
      "    \"Original_Estimated_Enrollment\": \"Same as current\",\n",
      "    \"Estimated_Study_Completion_Date\": \"March 31, 2024\",\n",
      "    \"Estimated_Primary_Completion_Date\": \"June 30, 2023   (Final data collection date for primary outcome measure)\",\n",
      "    \"Eligibility_Criteria\": \"[List]\",\n",
      "    \"Sex/Gender\": \"Sexes Eligible for Study:\n",
      "   All\",\n",
      "    \"Ages\": \"18 Years and older   (Adult, Older Adult)\",\n",
      "    \"Accepts_Healthy_Volunteers\": \"No\",\n",
      "    \"Contacts\": \"Contact: Ruihua Xu, M.D\n",
      "   86-20-87343804\n",
      "   ruihxu@163.com\",\n",
      "    \"Listed_Location_Countries\": \"China\",\n",
      "    \"Removed_Location_Countries\": null,\n",
      "    \"NCT_Number\": \"NCT03544905\",\n",
      "    \"Other_Study_ID_Numbers\": \"CYH33-101\",\n",
      "    \"Has_Data_Monitoring_Committee\": \"Yes\",\n",
      "    \"U.S._FDA-regulated_Product\": \"[List]\",\n",
      "    \"IPD_Sharing_Statement\": \"Not Provided\",\n",
      "    \"Current_Responsible_Party\": \"Haihe Biopharma Co., Ltd.\",\n",
      "    \"Original_Responsible_Party\": \"Same as current\",\n",
      "    \"Current_Study_Sponsor\": \"Haihe Biopharma Co., Ltd.\",\n",
      "    \"Original_Study_Sponsor\": \"Same as current\",\n",
      "    \"Collaborators\": \"Not Provided\",\n",
      "    \"Investigators\": \"Principal Investigator:\n",
      "   Ruihua Xu, M.D\n",
      "   Sun Yat-sen University\",\n",
      "    \"PRS_Account\": \"Haihe Biopharma Co., Ltd.\",\n",
      "    \"Verification_Date\": \"January 2023\"\n",
      "  },\n",
      "  {\n",
      "    \"NCT_No\": \"NCT01198392\",\n",
      "    First_Submitted_Date\": \"September 1, 2010\",\n",
      "    First_Posted_Date\": \"September 10, 2010\",\n",
      "    Last_Update_Posted_Date\": \"July 25, 2011\",\n",
      "    Estimated__Study_Start_Date\": \"September 2008\",\n",
      "    Estimated_Primary_Completion_Date\": \"December 2011   (Final data collection date for primary outcome measure)\",\n",
      "    Current_Primary_Outcome_Measures\": \"Time to progression [ Time Frame: The time from randomization until objective tumor progression or death ]\",\n",
      "    Original_Primary_Outcome_Measures\": \"Same as current\",\n",
      "    Change_History\": \"Complete list of historical versions of study NCT01198392 on ClinicalTrials.gov Archive Site\",\n",
      "    Current_Secondary_Outcome_Measures\": \"Response rate [ Time Frame: 2 months ]\",\n",
      "    Original_Secondary_Outcome_Measures\": \"Same as current\",\n",
      "    Current_Other_Pre-specified_Outcome_Measures\": \"Not Provided\",\n",
      "    Original_Other_Pre-specified_Outcome_Measures\": \"Not Provided\",\n",
      "    \"Brief_Title\": \"Trial of S-1 Plus Cisplatin in Gastric Cancer\",\n",
      "    \"Official_Title\": \"A Clinical Trial of S-1 Plus Cisplatin Versus 5-FU Plus Cisplatin in Patients With Unresectable or Advanced Gastric Cancer\",\n",
      "    \"Brief_Summary\": \"The purpose of this study is to evaluate the effectiveness and safety of s-1 plus cisplatin versus 5-FU plus cisplatin as first-line therapy in the treatment of patients with advanced gastric cancer.\",\n",
      "    \"Detailed_Description\": \"This is a randomized, controlled, open-label,multicenter study. Patients are randomized to one of two treatment arms : S-1 plus cisplatin and 5-FU plus cisplatin.\",\n",
      "    \"Study_Type\": \"Interventional\",\n",
      "    \"Study_Phase\": \"Phase 3\",\n",
      "    \"Study_Design\": \"Allocation: Randomized\n",
      "Intervention Model: Parallel Assignment\n",
      "Masking: None (Open Label)\n",
      "Primary Purpose: Treatment\",\n",
      "    \"Condition\": \"Gastric Cancer\",\n",
      "    \"Intervention\": \"[List]\",\n",
      "    \"Study_Arms\": \"[List]\",\n",
      "    \"Publications_*\": \"Li YH, Qiu MZ, Xu JM, Sun GP, Lu HS, Liu YP, Zhong MZ, Zhang HL, Yu SY, Li W, Hu XH, Wang JJ, Cheng Y, Zhou JT, Guo ZQ, Guan ZG, Xu RH. S-1 plus cisplatin versus fluorouracil plus cisplatin in advanced gastric or gastro-esophageal junction adenocarcinoma patients: a pilot study. Oncotarget. 2015 Oct 27;6(33):35107-15. doi: 10.18632/oncotarget.5959.\",\n",
      "    \"Recruitment_Status\": \"Unknown status\",\n",
      "    \"Estimated_Enrollment\": \"270\",\n",
      "    \"Original_Estimated_Enrollment\": \"Same as current\",\n",
      "    \"Estimated_Study_Completion_Date\": \"December 2011\",\n",
      "    \"Estimated_Primary_Completion_Date\": \"December 2011   (Final data collection date for primary outcome measure)\",\n",
      "    \"Eligibility_Criteria\": \"[List]\",\n",
      "    \"Sex/Gender\": \"Sexes Eligible for Study:\n",
      "   All\",\n",
      "    \"Ages\": \"18 Years to 75 Years   (Adult, Older Adult)\",\n",
      "    \"Accepts_Healthy_Volunteers\": \"No\",\n",
      "    \"Contacts\": \"Contact information is only displayed when the study is recruiting subjects\",\n",
      "    \"Listed_Location_Countries\": \"China\",\n",
      "    \"Removed_Location_Countries\": null,\n",
      "    \"NCT_Number\": \"NCT01198392\",\n",
      "    \"Other_Study_ID_Numbers\": \"2005L02859\",\n",
      "    \"Has_Data_Monitoring_Committee\": \"Yes\",\n",
      "    \"U.S._FDA-regulated_Product\": \"Not Provided\",\n",
      "    \"IPD_Sharing_Statement\": \"Not Provided\",\n",
      "    \"Current_Responsible_Party\": \"Zhongzhen Guan ,Ruihua Xu, Sun Yat-sen University Cancer Center\",\n",
      "    \"Original_Responsible_Party\": \"Same as current\",\n",
      "    \"Current_Study_Sponsor\": \"Sun Yat-sen University\",\n",
      "    \"Original_Study_Sponsor\": \"Same as current\",\n",
      "    \"Collaborators\": \"Not Provided\",\n",
      "    \"Investigators\": \"Principal Investigator:\n",
      "   RUIHUA XU, Professor\n",
      "   Sun Yat-sen University\",\n",
      "    \"PRS_Account\": \"Sun Yat-sen University\",\n",
      "    \"Verification_Date\": \"August 2008\"\n",
      "  }\n",
      "]\n",
      "\n",
      "徐瑞华，医学博士，中山大学肿瘤防治中心主任、医院院长、研究所所长，华南恶性肿瘤防治全国重点实验室主任，教授，博士生导师。\n",
      "\n",
      "中国医学科学院学部委员，中国临床肿瘤学会理事长，中国抗癌协会副理事长，中国抗癌协会靶向治疗专委会首届主任委员，中国抗癌协会化疗专委会候任主任委员，中国临床肿瘤学会肠癌专委会主任委员，《Cancer Communications》主编，研究生教材《肿瘤学》主编，本科生教材《临床肿瘤学》主编。\n",
      "\n",
      "从事肿瘤内科临床及科研工作30余年，取得突破性成果：\n",
      "\n",
      "第一，实现了肠癌诊治理论和实践的系统创新，使我国肠癌早诊及精准治疗均处于国际先进水平。创新了肠癌早诊及疗效预测的新技术，并已转化为临床应用；建立了晚期肠癌治疗新体系，创建了高效低毒的维持方案和亚洲方案，成为国际治疗新标准，晚期肠癌生存率与国际顶尖的安德森癌症中心达相同水平。\n",
      "\n",
      "第二，创新了消化肿瘤免疫治疗体系，引领国际消化肿瘤免疫治疗发展。\n",
      "\n",
      "通过鉴定TMB、POLE/POLD突变等标志物，精准筛选免疫治疗敏感亚型，大幅提高PD-1抗体疗效；首创了食管癌中国免疫联合方案，取得全球最高有效率72%，已成为食管癌治疗应用最广泛的方案；建立了食管癌EGIC分型，可以指导精准免疫治疗策略，引领该领域的发展；揭示了免疫逃逸新机制并推动了药物的开发：发现甲硫氨酸限制饮食可抑制免疫检查点分子PDL1及VISTA的表达，增强抗肿瘤免疫及抗PD1的治疗效果；鉴定出免疫治疗增效肠道活性菌RX-af01，成果已转化。\n",
      "\n",
      "以通讯或第一作者在国际顶级期刊JAMA、Nature Materials、Nature Medicine、Lancet Oncology等发表SCI论文200余篇，入选科睿唯安（Clarivate Analytics）全球高被引科学家，连续入选中国高被引学者榜单。以第一完成人获国家科技进步二等奖2项及省部级一等奖6项、吴阶平医药创新奖、谈家桢临床医学奖及CSCO年度成就奖。入选国家百千万人才工程、全国先进工作者、南粤百杰人才培养工程、国家卫生计生突出贡献中青年专家等人才项目。\n",
      "\n",
      "Representative paper: （*：第一作者，#：通讯作者）\n",
      "\n",
      "[1]     Luo H, Lu J, Bai Y, Mao T, Wang J, Fan Q, Zhang Y, Zhao K, Chen Z, Gao S, Li J, Fu Z, Gu K, Liu Z, Wu L, Zhang X, Feng J, Niu Z, Ba Y, Zhang H, Liu Y, Zhang L, Min X, Huang J, Cheng Y, Wang D, Shen Y, Yang Q, Zou J, Xu RH# ESCORT-1st Investigators.  Effect of Camrelizumab vs Placebo Added to Chemotherapy on Survival and Progression-Free Survival in Patients With Advanced or Metastatic Esophageal Squamous Cell Carcinoma: The ESCORT-1st Randomized Clinical Trial. JAMA. 2021 Sep 14;326(10):916-925.\n",
      "\n",
      "[2]     Xu RH*#, Wei W, Krawczyk M, Wang W, Luo H, Flagg K, Yi S, Shi W, Quan Q, Li K, Zheng L, Zhang H, Caughey BA, Zhao Q, Hou J, Zhang R, Xu Y, Cai H, Li G, Hou R, Zhong Z, Lin D, Fu X, Zhu J, Duan Y, Yu M, Ying B, Zhang W, Wang J, Zhang E, Zhang C, Li O, Guo R, Carter H, Zhu JK, Hao X and Zhang K. Circulating tumour DNA methylation markers for diagnosis and prognosis of hepatocellular carcinoma. Nat Mater 2017; 16: 1155-1161.\n",
      "\n",
      "[3]     Xu RH*#, Muro K, Morita S, Iwasa S, Han SW, Wang W, Kotaka M, Nakamura M, Ahn JB, Deng YH, Kato T, Cho SH, Ba Y, Matsuoka H, Lee KW, Zhang T, Yamada Y, Sakamoto J, Park YS and Kim TW. Modified XELIRI (capecitabine plus irinotecan) versus FOLFIRI (leucovorin, fluorouracil, and irinotecan), both either with or without bevacizumab, as second-line therapy for metastatic colorectal cancer (AXEPT): a multicentre, open-label, randomised, non-inferiority, phase 3 trial. Lancet Oncol 2018; 19: 660-671.\n",
      "\n",
      "[4]     Li J, Qin S, Xu R*, Yau TC, Ma B, Pan H, Xu J, Bai Y, Chi Y, Wang L, Yeh KH, Bi F, Cheng Y, Le AT, Lin JK, Liu T, Ma D, Kappeler C, Kalmus J and Kim TW. Regorafenib plus best supportive care versus placebo plus best supportive care in Asian patients with previously treated metastatic colorectal cancer (CONCUR): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncology 2015; 16: 619-629.\n",
      "\n",
      "[5]     Luo H, Xu G, Li C, He L, Luo L, Wang Z, Jing B, Deng Y, Jin Y, Li Y, Li B, Tan W, He C, Seeruttun SR, Wu Q, Huang J, Huang DW, Chen B, Lin SB, Chen QM, Yuan CM, Chen HX, Pu HY, Zhou F, He Y, Xu RH#. Real-time artificial intelligence for detection of upper gastrointestinal cancer by endoscopy: a multicentre, case-control, diagnostic study. Lancet Oncol. 2019 Oct 4.\n",
      "\n",
      "[6]     Satoh T, Xu RH*, Chung HC, Sun GP, Doi T, Xu JM, Tsuji A, Omuro Y, Li J, Wang JW, Miwa H, Qin SK, Chung IJ, Yeh KH, Feng JF, Mukaiyama A, Kobayashi M, Ohtsu A and Bang YJ. Lapatinib plus paclitaxel versus paclitaxel alone in the second-line treatment of HER2-amplified advanced gastric cancer in Asian populations: TyTAN--a randomized, phase III study. Journal of Clinical Oncology 2014; 32: 2039-2049.\n",
      "\n",
      "[7]     Manish A. Shah, Rui-hua Xu*, Yung-Jue Bang, Paulo M. Hoff, Tianshu Liu, Luis A. Herr´aez-Baranda, Fan Xia,Amit Garg, Mona Shing, and Josep Tabernero. HELOISE: Phase IIIb Randomized Multicenter Study Comparing Standard-of-Care and Higher-Dose Trastuzumab Regimens Combined With Chemotherapy as First-Line Therapy in Patients With Human Epidermal Growth Factor Receptor 2–Positive Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma. Journal of Clinical Oncology 2017; 35: 2558-2567.\n",
      "\n",
      "[8]     Wang ZX, Cui C, Yao J, Zhang Y, Li M, Feng J, Yang S, Fan Y, Shi J, Zhang X, Shen L, Shu Y, Wang C, Dai T, Mao T, Chen L, Guo Z, Liu B, Pan H, Cang S, Jiang Y, Wang J, Ye M, Chen Z, Jiang D, Lin Q, Ren W, Wang J, Wu L, Xu Y, Miao Z, Sun M, Xie C, Liu Y, Wang Q, Zhao L, Li Q, Huang C, Jiang K, Yang K, Li D, Liu Y, Zhu Z, Chen R, Jia L, Li W, Liao W, Liu HX, Ma D, Ma J, Qin Y, Shi Z, Wei Q, Xiao K, Zhang Y, Zhang Y, Chen X, Dai G, He J, Li J, Li G, Liu Y, Liu Z, Yuan X, Zhang J, Fu Z, He Y, Ju F, Liu Z, Tang P, Wang T, Wang W, Zhang J, Luo X, Tang X, May R, Feng H, Yao S, Keegan P, Xu RH#, Wang F. Toripalimab plus chemotherapy in treatment-naïve, advanced esophageal squamous cell carcinoma (JUPITER-06): A multi-center phase 3 trial. Cancer Cell. 2022 Mar 14;40(3):277-288.\n",
      "\n",
      "[9]     Wang F, Zhao Q, Wang YN, Jin Y, He MM, Liu ZX, Xu RH#. Evaluation of POLE and POLD1 Mutations as Biomarkers for Immunotherapy Outcomes Across Multiple Cancer Types. JAMA Oncol. 2019.\n",
      "\n",
      "[10]   Wang F, Liu DB, Zhao Q, Chen G, Liu XM, Wang YN, Su H, Qin YR, He YF, Zou QF, Liu YH, Lin YE, Liu ZX, Bei JX and Xu RH#. The genomic landscape of small cell carcinoma of the esophagus. Cell Res 2018; 28: 771-774.\n",
      "\n",
      "[11]   Wang DS, Liu ZX, Lu YX, Bao H, Wu X, Zeng ZL, Liu Z, Zhao Q, He CY, Lu JH, Wang ZQ, Qiu MZ, Wang F, Wang FH, Li YH, Wang XN, Xie D, Jia WH, Shao YW and Xu RH#. Liquid biopsies to track trastuzumab resistance in metastatic HER2-positive gastric cancer. Gut 2018;\n",
      "\n",
      "[12]   Feng Wang, You-Sheng Huang, Hao-Xiang Wu, Zi-Xian Wang, Ying Jin, Yi-Chen Yao, Yan-Xing Chen, Qi Zhao, Shifu Chen, Ming-Ming He, Hui-Yan Luo, Miao-Zhen Qiu, De-Shen Wang, Feng-Hua Wang, Mingyan Xu, Yu-Hong Li, Rui-Hua Xu#. Genomic temporal heterogeneity of circulating tumour DNA in unresectable metastatic colorectal cancer under first-line treatment. Gut. 2022 Jul;71(7):1340-1349.\n",
      "\n",
      "[13]   Luo HY, Li YH, Wang W, Wang ZQ, Yuan X, Ma D, Wang FH, Zhang DS, Lin DR, Lin YC, Jia J, Hu XH, Peng JW and Xu RH#. Single-agent capecitabine as maintenance therapy after induction of XELOX (or FOLFOX) in first-line treatment of metastatic colorectal cancer: randomized clinical trial of efficacy and safety. Annals of Oncology 2016; 27: 1074-1081.\n",
      "\n",
      "[14]   Wang F, Wei XL, Wang FH, Xu N, Shen L, Dai GH, Yuan XL, Chen Y, Yang SJ, Shi JH, Hu XC, Lin XY, Zhang QY, JF Feng, Y Ba, YP Liu, W Li, YQ Shu, Y Jiang, Q Li, JW Wang, H Wu, H Feng, S Yao, RH Xu#. Safety, efficacy and tumor mutational burden as a biomarker of overall survival benefit in chemo-refractory gastric cancer treated with toripalimab, a PD1 antibody in phase Ib/II clinical trial NCT02915432. Ann Oncol. 2019.\n",
      "\n",
      "[15]  Luo H, Zhao Q, Wei W, Zheng L, Yi S, Li G, Wang W, Sheng H, Pu H, Mo H, Zuo Z, Liu Z, Li C, Xie C, Zeng Z, Li W, Hao X, Liu Y, Cao S, Liu W, Gibson S, Zhang K, Xu G, Xu RH#. Circulating tumor DNA methylation profiles enable early diagnosis, prognosis prediction, and screening for colorectal cancer. Sci Transl Med. 2020 Jan 1;12(524).\n",
      "\n",
      "[16]   Li T, Hu PS, Zuo Z, Lin JF, Li X, Wu QN, Chen ZH, Zeng ZL, Wang F, Zheng J, Chen D, Li B, Kang TB, Dan Xie, Dongxin Lin, Huai-Qiang Ju, Rui-Hua Xu#. METTL3 facilitates tumor progression via an m(6)A-IGF2BP2-dependent mechanism in colorectal carcinoma. Mol Cancer. 2019; 18: 112.\n",
      "\n",
      "[17] Yun Wang, Jia-Huan Lu, Qi-Nian Wu, Ying Jin, De-Shen Wang, Yan-Xing Chen, Jia Liu, Xiao-Jing Luo, Qi Meng, Heng-Ying Pu, Ying-Nan Wang, Pei-Shan Hu, Ze-Xian Liu, Zhao-Lei Zeng, Qi Zhao, Rong Deng, Xiao-Feng Zhu, Huai-Qiang Ju, Rui-Hua Xu#. LncRNA LINRIS stabilizes IGF2BP2 and promotes the aerobic glycolysis in colorectal cancer. Molecular Cancer. 2019 Dec 2.\n",
      "\n",
      "[18]   Jin Y, Chen DL, Wang F, Yang CP, Chen XX, You JQ, Huang JS, Shao Y, Zhu DQ, Ouyang YM, Luo HY, Wang ZQ, Wang FH, Li YH, Xu RH#, Zhang DS. The predicting role of circulating tumor DNA landscape in gastric cancer patients treated with immune checkpoint inhibitors. Mol Cancer. 2020 Oct 30;19(1):154.\n",
      "\n",
      "[19]   Chen DL, Wang ZQ, Zeng ZL, Wu WJ, Zhang DS, Luo HY, Wang F, Qiu MZ, Wang DS, Ren C, Wang FH, Chiao LJ, Pelicano H, Huang P, Li YH and Xu RH#. Identification of microRNA-214 as a negative regulator of colorectal cancer liver metastasis by way of regulation of fibroblast growth factor receptor 1 expression. Hepatology 2014; 60: 598-609.\n",
      "\n",
      "[20]   Ju HQ, Li H, Tian T, Lu YX, Bai L, Chen LZ, Sheng H, Mo HY, Zeng JB, Deng W, Chiao PJ and Xu RH#. Melatonin overcomes gemcitabine resistance in pancreatic ductal adenocarcinoma by abrogating nuclear factor-kappaB activation. Journal of Pineal Research 2016; 60: 27-38.\n",
      "\n",
      "[21]   Ju HQ, Lin JF, Tian T, Xie D, Xu RH#. NADPH homeostasis in cancer: functions, mechanisms and therapeutic implications. Signal Transduct Tar. 2020 Oct 7;5(1):231.\n",
      "\n",
      "[22]  Hu PS, Li T, Lin JF, Qiu MZ, Wang DS, Liu ZX, Chen ZH, Yang LP, Zhang XL, Zhao Q, Chen YX, Lu YX, Wu QN, Pu HY, Zeng ZL, Xie D, Ju HQ, Luo HY, Xu RH#. VDR-SOX2 signaling promotes colorectal cancer stemness and malignancy in an acidic microenvironment. Signal Transduct Tar. 2020 Sep 9;5(1):183.\n",
      "\n",
      "[23]   Ju HQ, Ying H, Tian T, Ling J, Fu J, Lu Y, Wu M, Yang L, Achreja A, Chen G, Zhuang Z, Wang H, Nagrath D, Yao J, Hung MC, DePinho RA, Huang P, Xu RH# and Chiao PJ. Mutant Kras- and p16-regulated NOX4 activation overcomes metabolic checkpoints in development of pancreatic ductal adenocarcinoma. Nat Commun 2017; 8: 14437.\n",
      "\n",
      "[24]   Liu J, Liu ZX, Wu QN, Lu YX, Wong CW, Miao L, Wang Y, Wang Z, Jin Y, He MM, Ren C, Wang DS, Chen DL, Pu HY, Feng L, Li B, Xie D, Zeng MS, Huang P, Lin A, Lin D, Xu RH#, Ju HQ. Long noncoding RNA AGPG regulates PFKFB3-mediated tumor glycolytic reprogramming. Nat Commun. 2020 Mar 20;11(1):1507.\n",
      "\n",
      "[25]   Ju HQ, Lu YX, Chen DL, Zuo ZX, Liu ZX, Wu QN, Mo HY, Wang ZX, Wang DS, Pu HY, Zeng ZL, Li B, Xie D, Huang P, Hung MC, Chiao PJ and Xu RH#. Modulation of Redox Homeostasis by Inhibition of MTHFD2 in Colorectal Cancer: Mechanisms and Therapeutic Implications. J Natl Cancer Inst 2018\n",
      "\n",
      "[26] Yu K, Zhang Q, Liu Z, Zhao Q, Zhang X, Wang Y, Wang ZX, Jin Y, Li X, Liu ZX and Xu RH#. qPhos: a database of protein phosphorylation dynamics in humans. Nucleic Acids Res 2018\n",
      "\n",
      "[27] Rui-Hua Xu*, Jin Li, Yuxian Bai, Jianming Xu, Tianshu Liu, Lin Shen, Liwei Wang, Hongming Pan, Junning Cao, Dongsheng Zhang, Songhua Fan, Ye Hua & Weiguo Su. Safety and efficacy of fruquintinib in patients with previously treated metastatic colorectal cancer: a phase Ib study and a randomized double-blind phase II study. J Hematol Oncol. (2017) 10:22.\n",
      "\n",
      "[28] Gong Chen, Junjie Peng, Qian Xiao, Hao-Xiang Wu, Xiaojun Wu, Fulong Wang, Liren Li, Peirong Ding, Qi Zhao, Yaqi Li, Da Wang, Yang Shao, Hua Bao, Zhizhong Pan, Ke-Feng Ding, Sanjun Cai, Feng Wang, Rui-Hua Xu#. Postoperative circulating tumor DNA as markers of recurrence risk in stages II to III colorectal cancer. Journal of Hematology & Oncology. 2021 May 17;14(1):80.\n",
      "\n",
      "[29] Zeng ZL, Luo HY, Yang J, Wu WJ, Chen DL, Huang P and Xu RH#. Overexpression of the circadian clock gene Bmal1 increases sensitivity to oxaliplatin in colorectal cancer. Clinical Cancer Research 2014; 20: 1042-1052.\n",
      "\n",
      "[30] Huiyan Luo, Wei Wei, Ziyi Ye, Jiabo Zheng, Rui-hua Xu#. Liquid Biopsy of Methylation Biomarkers in Cell-Free DNA. Trends in Molecular Medicine. 23 Jan 2021.\n",
      "\n",
      "    ---------\n",
      "\n",
      "2023-06-14 22:17:18,080 - common.py - [line]:35 - INFO - real_query:\n",
      "    Notice: If doctor or hospital not in the context, skip this one 假如你是数据工程师，请把如下个人信息按照JSON的格式整理给我：（参考字段：行医，门诊时间，综合评价，资质认证状态，基本信息，简介，姓名，医院/机构，专长，职务，职称，学术兼职，地区，邮箱，手机，昕康ID/XK_ID，履历，教育经历，工作经历，研究，研究方向/临床研究，课题/基金，发表，发表文章，出版著作，专利和软著，执笔共识，成就，荣誉获奖）Return only the translation and nothing else:\n",
      "\n",
      "    query:\n",
      "    请根据以下context，回答：徐瑞华的clinical trial有哪些，列出NCT编号\n",
      "    reply in 简体中文\n",
      "    ---------context\n",
      "    \n",
      "[\n",
      "  {\n",
      "    \"_id\": \"648019f5778538384fd02da2\",\n",
      "    \"avatar\": null,\n",
      "    \"name\": \"Ruihua Xu\",\n",
      "    \"hospital\": \"Sun Yat-sen University\",\n",
      "    \"title\": \" MD\",\n",
      "    \"position\": null,\n",
      "    \"contact\": \"xuruihua@sysucc.org.cn\",\n",
      "    \"phone\": \"86-20-87343333\",\n",
      "    \"expertise\": \"Colorectal Carcinoma, pMMR, Microsatellite-stable\",\n",
      "    \"brief_intro\": \"A Study of Sintilimab and Chidamide in Combination With or Without IBI305 in Standard Treatment Failure of Advanced or Metastatic pMMR/MSS Colorectal Carcinoma\",\n",
      "    \"work_exp\": null,\n",
      "    \"edu_exp\": null,\n",
      "    \"consulting\": null,\n",
      "    \"publications\": null,\n",
      "    \"clinical_res\": null,\n",
      "    \"awards\": null\n",
      "  },\n",
      "  {\n",
      "    \"_id\": \"64803f25f24b55a336ba235d\",\n",
      "    \"avatar\": null,\n",
      "    \"name\": \"ruihua Xu\",\n",
      "    \"hospital\": \"Peking University\",\n",
      "    \"title\": \"M.D., Ph.D.\",\n",
      "    \"position\": null,\n",
      "    \"contact\": \"xurh@mail.sysu.edu.cn\",\n",
      "    \"phone\": \"13922206676\",\n",
      "    \"expertise\": \"nimotuzumab colorectal cancer chemotherapy\",\n",
      "    \"brief_intro\": null,\n",
      "    \"work_exp\": null,\n",
      "    \"edu_exp\": null,\n",
      "    \"consulting\": null,\n",
      "    \"publications\": null,\n",
      "    \"clinical_res\": \"Study of Nimotuzumab to Treat Colorectal Cancer\",\n",
      "    \"awards\": null\n",
      "  },\n",
      "  {\n",
      "    \"_id\": \"6480ea13f24b55a336bec613\",\n",
      "    \"avatar\": null,\n",
      "    \"name\": \"Ruihua Xu\",\n",
      "    \"hospital\": \"Sun Yat-sen University\",\n",
      "    \"title\": \"MD\",\n",
      "    \"position\": null,\n",
      "    \"contact\": \"xurh@susycc.org.cn\",\n",
      "    \"phone\": \"+862087343795\",\n",
      "    \"expertise\": \"Colorectal Cancer,Microsatellite Stable,Chidamide,Sintilimab,PD-1,Bevacizumab\",\n",
      "    \"brief_intro\": null,\n",
      "    \"work_exp\": null,\n",
      "    \"edu_exp\": null,\n",
      "    \"consulting\": null,\n",
      "    \"publications\": null,\n",
      "    \"clinical_res\": \"Comparing Chidamide+Sintilimab+Bev With Standard Second-line FOLFIRI+Bev in Advanced MSS/pMMR mCRC\",\n",
      "    \"awards\": null\n",
      "  }\n",
      "]\n",
      "[\n",
      "  {\n",
      "    \"NCT_No\": \"NCT05830045\",\n",
      "    First_Submitted_Date\": \"April 4, 2023\",\n",
      "    First_Posted_Date\": \"April 26, 2023\",\n",
      "    Last_Update_Posted_Date\": \"April 26, 2023\",\n",
      "    Estimated__Study_Start_Date\": \"April 20, 2023\",\n",
      "    Estimated_Primary_Completion_Date\": \"April 30, 2025   (Final data collection date for primary outcome measure)\",\n",
      "    Current_Primary_Outcome_Measures\": \"[List]\",\n",
      "    Original_Primary_Outcome_Measures\": \"Same as current\",\n",
      "    Change_History\": \"No Changes Posted\",\n",
      "    Current_Secondary_Outcome_Measures\": \"Not Provided\",\n",
      "    Original_Secondary_Outcome_Measures\": \"Not Provided\",\n",
      "    Current_Other_Pre-specified_Outcome_Measures\": \"Not Provided\",\n",
      "    Original_Other_Pre-specified_Outcome_Measures\": \"Not Provided\",\n",
      "    \"Brief_Title\": \"A Phase I Study of QLP2117 in Subjects With Advanced Solid Tumors\",\n",
      "    \"Official_Title\": \"A Study Evaluates the Safety, Pharmacokinetics, Immunogenicity and Efficacy of QLP2117 in Advanced Solid Tumor Patients\",\n",
      "    \"Brief_Summary\": \"This is the first in human study of QLP2117. To evaluate the Safety, Pharmacokinetics, Immunogenicity and Efficacy of QLP2117 in patients with advanced solid tumors.\",\n",
      "    \"Detailed_Description\": \"Not Provided\",\n",
      "    \"Study_Type\": \"Interventional\",\n",
      "    \"Study_Phase\": \"Phase 1\",\n",
      "    \"Study_Design\": \"Allocation: Non-Randomized\n",
      "Intervention Model: Sequential Assignment\n",
      "Masking: None (Open Label)\n",
      "Primary Purpose: Treatment\",\n",
      "    \"Condition\": \"Advanced Solid Tumors\",\n",
      "    \"Intervention\": \"Drug: QLP2117\n",
      "Specified dose on specified days\",\n",
      "    \"Study_Arms\": \"[List]\",\n",
      "    \"Publications_*\": \"Not Provided\",\n",
      "    \"Recruitment_Status\": \"Not yet recruiting\",\n",
      "    \"Estimated_Enrollment\": \"180\",\n",
      "    \"Original_Estimated_Enrollment\": \"Same as current\",\n",
      "    \"Estimated_Study_Completion_Date\": \"December 31, 2025\",\n",
      "    \"Estimated_Primary_Completion_Date\": \"April 30, 2025   (Final data collection date for primary outcome measure)\",\n",
      "    \"Eligibility_Criteria\": \"[List]\",\n",
      "    \"Sex/Gender\": \"Sexes Eligible for Study:\n",
      "   All\",\n",
      "    \"Ages\": \"18 Years and older   (Adult, Older Adult)\",\n",
      "    \"Accepts_Healthy_Volunteers\": \"No\",\n",
      "    \"Contacts\": \"Contact: Zhang Meijiang, PhD\n",
      "   8615210162105\n",
      "   meijiang.zhang@qilu-pharma.com\",\n",
      "    \"Listed_Location_Countries\": \"Not Provided\",\n",
      "    \"Removed_Location_Countries\": null,\n",
      "    \"NCT_Number\": \"NCT05830045\",\n",
      "    \"Other_Study_ID_Numbers\": \"QLP2117-101\",\n",
      "    \"Has_Data_Monitoring_Committee\": \"No\",\n",
      "    \"U.S._FDA-regulated_Product\": \"[List]\",\n",
      "    \"IPD_Sharing_Statement\": \"Plan to Share IPD:\n",
      "   No\",\n",
      "    \"Current_Responsible_Party\": \"Qilu Pharmaceutical Co., Ltd.\",\n",
      "    \"Original_Responsible_Party\": \"Same as current\",\n",
      "    \"Current_Study_Sponsor\": \"Qilu Pharmaceutical Co., Ltd.\",\n",
      "    \"Original_Study_Sponsor\": \"Same as current\",\n",
      "    \"Collaborators\": \"Not Provided\",\n",
      "    \"Investigators\": \"Principal Investigator:\n",
      "   Xu Ruihua, PhD\n",
      "   Sun Yat-sen University\",\n",
      "    \"PRS_Account\": \"Qilu Pharmaceutical Co., Ltd.\",\n",
      "    \"Verification_Date\": \"April 2023\"\n",
      "  },\n",
      "  {\n",
      "    \"NCT_No\": \"NCT05727839\",\n",
      "    First_Submitted_Date\": \"February 1, 2023\",\n",
      "    First_Posted_Date\": \"February 14, 2023\",\n",
      "    Last_Update_Posted_Date\": \"March 20, 2023\",\n",
      "    Estimated__Study_Start_Date\": \"February 24, 2023\",\n",
      "    Estimated_Primary_Completion_Date\": \"July 24, 2025   (Final data collection date for primary outcome measure)\",\n",
      "    Current_Primary_Outcome_Measures\": \"[List]\",\n",
      "    Original_Primary_Outcome_Measures\": \"[List]\",\n",
      "    Change_History\": \"Complete list of historical versions of study NCT05727839 on ClinicalTrials.gov Archive Site\",\n",
      "    Current_Secondary_Outcome_Measures\": \"[List]\",\n",
      "    Original_Secondary_Outcome_Measures\": \"[List]\",\n",
      "    Current_Other_Pre-specified_Outcome_Measures\": \"Not Provided\",\n",
      "    Original_Other_Pre-specified_Outcome_Measures\": \"Not Provided\",\n",
      "    \"Brief_Title\": \"Study to Evaluate JCXH-211 as Monotherapy in Patients With Malignant Solid Tumors\",\n",
      "    \"Official_Title\": \"A Phase 1 Open-Label Study to Evaluate the Safety, Tolerability and Efficacy of JCXH-211 Intratumoral Injection in Patients With Malignant Solid Tumors\",\n",
      "    \"Brief_Summary\": \": A Phase 1 Open-Label Study to Evaluate the Safety, Tolerability and Efficacy of JCXH-211 Intratumoral Injection in Patients with Malignant Solid Tumors\",\n",
      "    \"Detailed_Description\": \"The main purpose of this study is to find out how safe and tolerable the study drug, JCXH-211, is and also how well it works in people with malignant solid tumors. The study drug JCXH-211, is an immunotherapy drug. This means that it aims to work by boosting immune system's response to tumors, to help fight against the growth of the cancer cells. The study has 2 main phases: Phase\n",
      "  1a and Phase 1b. Phase 1a has 2 stages, skin/subcutaneous lesions stage, deep (visceral) lesions stage. Phase 1b will not start until all the data collected in Phase 1a has been completed and reviewed to check that it is safe and well tolerated.\",\n",
      "    \"Study_Type\": \"Interventional\",\n",
      "    \"Study_Phase\": \"Phase 1\",\n",
      "    \"Study_Design\": \"Allocation: Non-Randomized\n",
      "Intervention Model: Single Group Assignment\n",
      "Masking: None (Open Label)\n",
      "Primary Purpose: Treatment\",\n",
      "    \"Condition\": \"[List]\",\n",
      "    \"Intervention\": \"Drug: JCXH-211 Injection\n",
      "JCXH-211 administered once every 28 days\n",
      "Other Name: Intratumoral injection\",\n",
      "    \"Study_Arms\": \"[List]\",\n",
      "    \"Publications_*\": \"Not Provided\",\n",
      "    \"Recruitment_Status\": \"Recruiting\",\n",
      "    \"Estimated_Enrollment\": \"156\",\n",
      "    \"Original_Estimated_Enrollment\": \"Same as current\",\n",
      "    \"Estimated_Study_Completion_Date\": \"August 24, 2025\",\n",
      "    \"Estimated_Primary_Completion_Date\": \"July 24, 2025   (Final data collection date for primary outcome measure)\",\n",
      "    \"Eligibility_Criteria\": \"[List]\",\n",
      "    \"Sex/Gender\": \"Sexes Eligible for Study:\n",
      "   All\",\n",
      "    \"Ages\": \"18 Years to 75 Years   (Adult, Older Adult)\",\n",
      "    \"Accepts_Healthy_Volunteers\": \"No\",\n",
      "    \"Contacts\": \"Contact: Qi Wang\n",
      "   +8613381113913\n",
      "   qi.wang@immorna.com\",\n",
      "    \"Listed_Location_Countries\": \"China\",\n",
      "    \"Removed_Location_Countries\": null,\n",
      "    \"NCT_Number\": \"NCT05727839\",\n",
      "    \"Other_Study_ID_Numbers\": \"JCXH-211-003\",\n",
      "    \"Has_Data_Monitoring_Committee\": \"Not Provided\",\n",
      "    \"U.S._FDA-regulated_Product\": \"[List]\",\n",
      "    \"IPD_Sharing_Statement\": \"Not Provided\",\n",
      "    \"Current_Responsible_Party\": \"Immorna Biotherapeutics, Inc.\",\n",
      "    \"Original_Responsible_Party\": \"Same as current\",\n",
      "    \"Current_Study_Sponsor\": \"Immorna Biotherapeutics, Inc.\",\n",
      "    \"Original_Study_Sponsor\": \"Same as current\",\n",
      "    \"Collaborators\": \"Not Provided\",\n",
      "    \"Investigators\": \"Principal Investigator:\n",
      "   Xu ruihua, President\n",
      "   Sun Yat-sen University\",\n",
      "    \"PRS_Account\": \"Immorna Biotherapeutics, Inc.\",\n",
      "    \"Verification_Date\": \"March 2023\"\n",
      "  },\n",
      "  {\n",
      "    \"NCT_No\": \"NCT03544905\",\n",
      "    First_Submitted_Date\": \"May 22, 2018\",\n",
      "    First_Posted_Date\": \"June 4, 2018\",\n",
      "    Last_Update_Posted_Date\": \"January 6, 2023\",\n",
      "    Estimated__Study_Start_Date\": \"July 5, 2018\",\n",
      "    Estimated_Primary_Completion_Date\": \"June 30, 2023   (Final data collection date for primary outcome measure)\",\n",
      "    Current_Primary_Outcome_Measures\": \"MTD(Max tolerance does) [ Time Frame: 35 days ]To evaluate the MTD in patients with advanced solid tumor\",\n",
      "    Original_Primary_Outcome_Measures\": \"Same as current\",\n",
      "    Change_History\": \"Complete list of historical versions of study NCT03544905 on ClinicalTrials.gov Archive Site\",\n",
      "    Current_Secondary_Outcome_Measures\": \"Not Provided\",\n",
      "    Original_Secondary_Outcome_Measures\": \"Not Provided\",\n",
      "    Current_Other_Pre-specified_Outcome_Measures\": \"Not Provided\",\n",
      "    Original_Other_Pre-specified_Outcome_Measures\": \"Not Provided\",\n",
      "    \"Brief_Title\": \"Study to Evaluate the Safety, Tolerate, Pharmacokinetics and Preliminary Efficacy of CYH33\",\n",
      "    \"Official_Title\": \"A Multi-center, Open-label, Single Arm, Dose Escalation and Dose Extension Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of CYH33 in Advanced Solid Tumors Patients.\",\n",
      "    \"Brief_Summary\": \"This study is a Multi-center, Open-label, single arm, Dose Escalation and Dose Extension Phase 1 Study to Evaluate the Safety , Tolerability, Pharmacokinetics and Preliminary Efficacy of CYH33 in Advanced Solid Tumors Patients.\",\n",
      "    \"Detailed_Description\": \"This study includes Phase Ia and Phase Ib.\n",
      "  In the dose climbing part of phase Ia, the safety, tolerance and pharmacokinetics characteristics of CYH33 in patients with advanced solid tumors who failed to receive standard treatment, did not tolerate or did not have standard treatment at present will be observed to determine MTD; Before determining MTD, select safe and highly reliable and effective dose levels for simultaneous expansion. Phase Ia dose expansion includes patients with advanced solid tumors who have failed to undergo standard treatment, who are intolerant of PIK3CA gene mutation, or who do not have standard treatment at present, to further evaluate safety, tolerance and initial efficacy.\n",
      "  In Phase Ib, the safety and preliminary efficacy of CYH33 on patients with advanced breast cancer, ovarian cancer, endometrial cancer, cervical cancer, head and neck squamous cell carcinoma, esophageal and gastroesophageal junction squamous cell carcinoma, ovarian clear cell carcinoma and other solid tumors with PIK3CA gene mutation who have failed, are intolerant or do not have standard treatment at present will be evaluated.\",\n",
      "    \"Study_Type\": \"Interventional\",\n",
      "    \"Study_Phase\": \"Phase 1\",\n",
      "    \"Study_Design\": \"Allocation: N/A\n",
      "Intervention Model: Single Group Assignment\n",
      "Masking: None (Open Label)\n",
      "Primary Purpose: Treatment\",\n",
      "    \"Condition\": \"Advanced Solid Tumors\",\n",
      "    \"Intervention\": \"Drug: CYH33 for tablet\n",
      "1mg; 5mg; 10mg; 20mg; 30mg; 50mg; 75mg; 100mg; 130mg; 160mg; 200mg; 240mgBID or QD(Decided by SMC accroding to the safty and PK data)\",\n",
      "    \"Study_Arms\": \"Experimental: Dose escalation study of CYH33\n",
      "To determine the maximum tolerated dose (MTD) of CYH33\n",
      "Intervention: Drug: CYH33 for tablet\",\n",
      "    \"Publications_*\": \"Not Provided\",\n",
      "    \"Recruitment_Status\": \"Recruiting\",\n",
      "    \"Estimated_Enrollment\": \"100\",\n",
      "    \"Original_Estimated_Enrollment\": \"Same as current\",\n",
      "    \"Estimated_Study_Completion_Date\": \"March 31, 2024\",\n",
      "    \"Estimated_Primary_Completion_Date\": \"June 30, 2023   (Final data collection date for primary outcome measure)\",\n",
      "    \"Eligibility_Criteria\": \"[List]\",\n",
      "    \"Sex/Gender\": \"Sexes Eligible for Study:\n",
      "   All\",\n",
      "    \"Ages\": \"18 Years and older   (Adult, Older Adult)\",\n",
      "    \"Accepts_Healthy_Volunteers\": \"No\",\n",
      "    \"Contacts\": \"Contact: Ruihua Xu, M.D\n",
      "   86-20-87343804\n",
      "   ruihxu@163.com\",\n",
      "    \"Listed_Location_Countries\": \"China\",\n",
      "    \"Removed_Location_Countries\": null,\n",
      "    \"NCT_Number\": \"NCT03544905\",\n",
      "    \"Other_Study_ID_Numbers\": \"CYH33-101\",\n",
      "    \"Has_Data_Monitoring_Committee\": \"Yes\",\n",
      "    \"U.S._FDA-regulated_Product\": \"[List]\",\n",
      "    \"IPD_Sharing_Statement\": \"Not Provided\",\n",
      "    \"Current_Responsible_Party\": \"Haihe Biopharma Co., Ltd.\",\n",
      "    \"Original_Responsible_Party\": \"Same as current\",\n",
      "    \"Current_Study_Sponsor\": \"Haihe Biopharma Co., Ltd.\",\n",
      "    \"Original_Study_Sponsor\": \"Same as current\",\n",
      "    \"Collaborators\": \"Not Provided\",\n",
      "    \"Investigators\": \"Principal Investigator:\n",
      "   Ruihua Xu, M.D\n",
      "   Sun Yat-sen University\",\n",
      "    \"PRS_Account\": \"Haihe Biopharma Co., Ltd.\",\n",
      "    \"Verification_Date\": \"January 2023\"\n",
      "  },\n",
      "  {\n",
      "    \"NCT_No\": \"NCT01198392\",\n",
      "    First_Submitted_Date\": \"September 1, 2010\",\n",
      "    First_Posted_Date\": \"September 10, 2010\",\n",
      "    Last_Update_Posted_Date\": \"July 25, 2011\",\n",
      "    Estimated__Study_Start_Date\": \"September 2008\",\n",
      "    Estimated_Primary_Completion_Date\": \"December 2011   (Final data collection date for primary outcome measure)\",\n",
      "    Current_Primary_Outcome_Measures\": \"Time to progression [ Time Frame: The time from randomization until objective tumor progression or death ]\",\n",
      "    Original_Primary_Outcome_Measures\": \"Same as current\",\n",
      "    Change_History\": \"Complete list of historical versions of study NCT01198392 on ClinicalTrials.gov Archive Site\",\n",
      "    Current_Secondary_Outcome_Measures\": \"Response rate [ Time Frame: 2 months ]\",\n",
      "    Original_Secondary_Outcome_Measures\": \"Same as current\",\n",
      "    Current_Other_Pre-specified_Outcome_Measures\": \"Not Provided\",\n",
      "    Original_Other_Pre-specified_Outcome_Measures\": \"Not Provided\",\n",
      "    \"Brief_Title\": \"Trial of S-1 Plus Cisplatin in Gastric Cancer\",\n",
      "    \"Official_Title\": \"A Clinical Trial of S-1 Plus Cisplatin Versus 5-FU Plus Cisplatin in Patients With Unresectable or Advanced Gastric Cancer\",\n",
      "    \"Brief_Summary\": \"The purpose of this study is to evaluate the effectiveness and safety of s-1 plus cisplatin versus 5-FU plus cisplatin as first-line therapy in the treatment of patients with advanced gastric cancer.\",\n",
      "    \"Detailed_Description\": \"This is a randomized, controlled, open-label,multicenter study. Patients are randomized to one of two treatment arms : S-1 plus cisplatin and 5-FU plus cisplatin.\",\n",
      "    \"Study_Type\": \"Interventional\",\n",
      "    \"Study_Phase\": \"Phase 3\",\n",
      "    \"Study_Design\": \"Allocation: Randomized\n",
      "Intervention Model: Parallel Assignment\n",
      "Masking: None (Open Label)\n",
      "Primary Purpose: Treatment\",\n",
      "    \"Condition\": \"Gastric Cancer\",\n",
      "    \"Intervention\": \"[List]\",\n",
      "    \"Study_Arms\": \"[List]\",\n",
      "    \"Publications_*\": \"Li YH, Qiu MZ, Xu JM, Sun GP, Lu HS, Liu YP, Zhong MZ, Zhang HL, Yu SY, Li W, Hu XH, Wang JJ, Cheng Y, Zhou JT, Guo ZQ, Guan ZG, Xu RH. S-1 plus cisplatin versus fluorouracil plus cisplatin in advanced gastric or gastro-esophageal junction adenocarcinoma patients: a pilot study. Oncotarget. 2015 Oct 27;6(33):35107-15. doi: 10.18632/oncotarget.5959.\",\n",
      "    \"Recruitment_Status\": \"Unknown status\",\n",
      "    \"Estimated_Enrollment\": \"270\",\n",
      "    \"Original_Estimated_Enrollment\": \"Same as current\",\n",
      "    \"Estimated_Study_Completion_Date\": \"December 2011\",\n",
      "    \"Estimated_Primary_Completion_Date\": \"December 2011   (Final data collection date for primary outcome measure)\",\n",
      "    \"Eligibility_Criteria\": \"[List]\",\n",
      "    \"Sex/Gender\": \"Sexes Eligible for Study:\n",
      "   All\",\n",
      "    \"Ages\": \"18 Years to 75 Years   (Adult, Older Adult)\",\n",
      "    \"Accepts_Healthy_Volunteers\": \"No\",\n",
      "    \"Contacts\": \"Contact information is only displayed when the study is recruiting subjects\",\n",
      "    \"Listed_Location_Countries\": \"China\",\n",
      "    \"Removed_Location_Countries\": null,\n",
      "    \"NCT_Number\": \"NCT01198392\",\n",
      "    \"Other_Study_ID_Numbers\": \"2005L02859\",\n",
      "    \"Has_Data_Monitoring_Committee\": \"Yes\",\n",
      "    \"U.S._FDA-regulated_Product\": \"Not Provided\",\n",
      "    \"IPD_Sharing_Statement\": \"Not Provided\",\n",
      "    \"Current_Responsible_Party\": \"Zhongzhen Guan ,Ruihua Xu, Sun Yat-sen University Cancer Center\",\n",
      "    \"Original_Responsible_Party\": \"Same as current\",\n",
      "    \"Current_Study_Sponsor\": \"Sun Yat-sen University\",\n",
      "    \"Original_Study_Sponsor\": \"Same as current\",\n",
      "    \"Collaborators\": \"Not Provided\",\n",
      "    \"Investigators\": \"Principal Investigator:\n",
      "   RUIHUA XU, Professor\n",
      "   Sun Yat-sen University\",\n",
      "    \"PRS_Account\": \"Sun Yat-sen University\",\n",
      "    \"Verification_Date\": \"August 2008\"\n",
      "  }\n",
      "]\n",
      "\n",
      "徐瑞华，医学博士，中山大学肿瘤防治中心主任、医院院长、研究所所长，华南恶性肿瘤防治全国重点实验室主任，教授，博士生导师。\n",
      "\n",
      "中国医学科学院学部委员，中国临床肿瘤学会理事长，中国抗癌协会副理事长，中国抗癌协会靶向治疗专委会首届主任委员，中国抗癌协会化疗专委会候任主任委员，中国临床肿瘤学会肠癌专委会主任委员，《Cancer Communications》主编，研究生教材《肿瘤学》主编，本科生教材《临床肿瘤学》主编。\n",
      "\n",
      "从事肿瘤内科临床及科研工作30余年，取得突破性成果：\n",
      "\n",
      "第一，实现了肠癌诊治理论和实践的系统创新，使我国肠癌早诊及精准治疗均处于国际先进水平。创新了肠癌早诊及疗效预测的新技术，并已转化为临床应用；建立了晚期肠癌治疗新体系，创建了高效低毒的维持方案和亚洲方案，成为国际治疗新标准，晚期肠癌生存率与国际顶尖的安德森癌症中心达相同水平。\n",
      "\n",
      "第二，创新了消化肿瘤免疫治疗体系，引领国际消化肿瘤免疫治疗发展。\n",
      "\n",
      "通过鉴定TMB、POLE/POLD突变等标志物，精准筛选免疫治疗敏感亚型，大幅提高PD-1抗体疗效；首创了食管癌中国免疫联合方案，取得全球最高有效率72%，已成为食管癌治疗应用最广泛的方案；建立了食管癌EGIC分型，可以指导精准免疫治疗策略，引领该领域的发展；揭示了免疫逃逸新机制并推动了药物的开发：发现甲硫氨酸限制饮食可抑制免疫检查点分子PDL1及VISTA的表达，增强抗肿瘤免疫及抗PD1的治疗效果；鉴定出免疫治疗增效肠道活性菌RX-af01，成果已转化。\n",
      "\n",
      "以通讯或第一作者在国际顶级期刊JAMA、Nature Materials、Nature Medicine、Lancet Oncology等发表SCI论文200余篇，入选科睿唯安（Clarivate Analytics）全球高被引科学家，连续入选中国高被引学者榜单。以第一完成人获国家科技进步二等奖2项及省部级一等奖6项、吴阶平医药创新奖、谈家桢临床医学奖及CSCO年度成就奖。入选国家百千万人才工程、全国先进工作者、南粤百杰人才培养工程、国家卫生计生突出贡献中青年专家等人才项目。\n",
      "\n",
      "Representative paper: （*：第一作者，#：通讯作者）\n",
      "\n",
      "[1]     Luo H, Lu J, Bai Y, Mao T, Wang J, Fan Q, Zhang Y, Zhao K, Chen Z, Gao S, Li J, Fu Z, Gu K, Liu Z, Wu L, Zhang X, Feng J, Niu Z, Ba Y, Zhang H, Liu Y, Zhang L, Min X, Huang J, Cheng Y, Wang D, Shen Y, Yang Q, Zou J, Xu RH# ESCORT-1st Investigators.  Effect of Camrelizumab vs Placebo Added to Chemotherapy on Survival and Progression-Free Survival in Patients With Advanced or Metastatic Esophageal Squamous Cell Carcinoma: The ESCORT-1st Randomized Clinical Trial. JAMA. 2021 Sep 14;326(10):916-925.\n",
      "\n",
      "[2]     Xu RH*#, Wei W, Krawczyk M, Wang W, Luo H, Flagg K, Yi S, Shi W, Quan Q, Li K, Zheng L, Zhang H, Caughey BA, Zhao Q, Hou J, Zhang R, Xu Y, Cai H, Li G, Hou R, Zhong Z, Lin D, Fu X, Zhu J, Duan Y, Yu M, Ying B, Zhang W, Wang J, Zhang E, Zhang C, Li O, Guo R, Carter H, Zhu JK, Hao X and Zhang K. Circulating tumour DNA methylation markers for diagnosis and prognosis of hepatocellular carcinoma. Nat Mater 2017; 16: 1155-1161.\n",
      "\n",
      "[3]     Xu RH*#, Muro K, Morita S, Iwasa S, Han SW, Wang W, Kotaka M, Nakamura M, Ahn JB, Deng YH, Kato T, Cho SH, Ba Y, Matsuoka H, Lee KW, Zhang T, Yamada Y, Sakamoto J, Park YS and Kim TW. Modified XELIRI (capecitabine plus irinotecan) versus FOLFIRI (leucovorin, fluorouracil, and irinotecan), both either with or without bevacizumab, as second-line therapy for metastatic colorectal cancer (AXEPT): a multicentre, open-label, randomised, non-inferiority, phase 3 trial. Lancet Oncol 2018; 19: 660-671.\n",
      "\n",
      "[4]     Li J, Qin S, Xu R*, Yau TC, Ma B, Pan H, Xu J, Bai Y, Chi Y, Wang L, Yeh KH, Bi F, Cheng Y, Le AT, Lin JK, Liu T, Ma D, Kappeler C, Kalmus J and Kim TW. Regorafenib plus best supportive care versus placebo plus best supportive care in Asian patients with previously treated metastatic colorectal cancer (CONCUR): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncology 2015; 16: 619-629.\n",
      "\n",
      "[5]     Luo H, Xu G, Li C, He L, Luo L, Wang Z, Jing B, Deng Y, Jin Y, Li Y, Li B, Tan W, He C, Seeruttun SR, Wu Q, Huang J, Huang DW, Chen B, Lin SB, Chen QM, Yuan CM, Chen HX, Pu HY, Zhou F, He Y, Xu RH#. Real-time artificial intelligence for detection of upper gastrointestinal cancer by endoscopy: a multicentre, case-control, diagnostic study. Lancet Oncol. 2019 Oct 4.\n",
      "\n",
      "[6]     Satoh T, Xu RH*, Chung HC, Sun GP, Doi T, Xu JM, Tsuji A, Omuro Y, Li J, Wang JW, Miwa H, Qin SK, Chung IJ, Yeh KH, Feng JF, Mukaiyama A, Kobayashi M, Ohtsu A and Bang YJ. Lapatinib plus paclitaxel versus paclitaxel alone in the second-line treatment of HER2-amplified advanced gastric cancer in Asian populations: TyTAN--a randomized, phase III study. Journal of Clinical Oncology 2014; 32: 2039-2049.\n",
      "\n",
      "[7]     Manish A. Shah, Rui-hua Xu*, Yung-Jue Bang, Paulo M. Hoff, Tianshu Liu, Luis A. Herr´aez-Baranda, Fan Xia,Amit Garg, Mona Shing, and Josep Tabernero. HELOISE: Phase IIIb Randomized Multicenter Study Comparing Standard-of-Care and Higher-Dose Trastuzumab Regimens Combined With Chemotherapy as First-Line Therapy in Patients With Human Epidermal Growth Factor Receptor 2–Positive Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma. Journal of Clinical Oncology 2017; 35: 2558-2567.\n",
      "\n",
      "[8]     Wang ZX, Cui C, Yao J, Zhang Y, Li M, Feng J, Yang S, Fan Y, Shi J, Zhang X, Shen L, Shu Y, Wang C, Dai T, Mao T, Chen L, Guo Z, Liu B, Pan H, Cang S, Jiang Y, Wang J, Ye M, Chen Z, Jiang D, Lin Q, Ren W, Wang J, Wu L, Xu Y, Miao Z, Sun M, Xie C, Liu Y, Wang Q, Zhao L, Li Q, Huang C, Jiang K, Yang K, Li D, Liu Y, Zhu Z, Chen R, Jia L, Li W, Liao W, Liu HX, Ma D, Ma J, Qin Y, Shi Z, Wei Q, Xiao K, Zhang Y, Zhang Y, Chen X, Dai G, He J, Li J, Li G, Liu Y, Liu Z, Yuan X, Zhang J, Fu Z, He Y, Ju F, Liu Z, Tang P, Wang T, Wang W, Zhang J, Luo X, Tang X, May R, Feng H, Yao S, Keegan P, Xu RH#, Wang F. Toripalimab plus chemotherapy in treatment-naïve, advanced esophageal squamous cell carcinoma (JUPITER-06): A multi-center phase 3 trial. Cancer Cell. 2022 Mar 14;40(3):277-288.\n",
      "\n",
      "[9]     Wang F, Zhao Q, Wang YN, Jin Y, He MM, Liu ZX, Xu RH#. Evaluation of POLE and POLD1 Mutations as Biomarkers for Immunotherapy Outcomes Across Multiple Cancer Types. JAMA Oncol. 2019.\n",
      "\n",
      "[10]   Wang F, Liu DB, Zhao Q, Chen G, Liu XM, Wang YN, Su H, Qin YR, He YF, Zou QF, Liu YH, Lin YE, Liu ZX, Bei JX and Xu RH#. The genomic landscape of small cell carcinoma of the esophagus. Cell Res 2018; 28: 771-774.\n",
      "\n",
      "[11]   Wang DS, Liu ZX, Lu YX, Bao H, Wu X, Zeng ZL, Liu Z, Zhao Q, He CY, Lu JH, Wang ZQ, Qiu MZ, Wang F, Wang FH, Li YH, Wang XN, Xie D, Jia WH, Shao YW and Xu RH#. Liquid biopsies to track trastuzumab resistance in metastatic HER2-positive gastric cancer. Gut 2018;\n",
      "\n",
      "[12]   Feng Wang, You-Sheng Huang, Hao-Xiang Wu, Zi-Xian Wang, Ying Jin, Yi-Chen Yao, Yan-Xing Chen, Qi Zhao, Shifu Chen, Ming-Ming He, Hui-Yan Luo, Miao-Zhen Qiu, De-Shen Wang, Feng-Hua Wang, Mingyan Xu, Yu-Hong Li, Rui-Hua Xu#. Genomic temporal heterogeneity of circulating tumour DNA in unresectable metastatic colorectal cancer under first-line treatment. Gut. 2022 Jul;71(7):1340-1349.\n",
      "\n",
      "[13]   Luo HY, Li YH, Wang W, Wang ZQ, Yuan X, Ma D, Wang FH, Zhang DS, Lin DR, Lin YC, Jia J, Hu XH, Peng JW and Xu RH#. Single-agent capecitabine as maintenance therapy after induction of XELOX (or FOLFOX) in first-line treatment of metastatic colorectal cancer: randomized clinical trial of efficacy and safety. Annals of Oncology 2016; 27: 1074-1081.\n",
      "\n",
      "[14]   Wang F, Wei XL, Wang FH, Xu N, Shen L, Dai GH, Yuan XL, Chen Y, Yang SJ, Shi JH, Hu XC, Lin XY, Zhang QY, JF Feng, Y Ba, YP Liu, W Li, YQ Shu, Y Jiang, Q Li, JW Wang, H Wu, H Feng, S Yao, RH Xu#. Safety, efficacy and tumor mutational burden as a biomarker of overall survival benefit in chemo-refractory gastric cancer treated with toripalimab, a PD1 antibody in phase Ib/II clinical trial NCT02915432. Ann Oncol. 2019.\n",
      "\n",
      "[15]  Luo H, Zhao Q, Wei W, Zheng L, Yi S, Li G, Wang W, Sheng H, Pu H, Mo H, Zuo Z, Liu Z, Li C, Xie C, Zeng Z, Li W, Hao X, Liu Y, Cao S, Liu W, Gibson S, Zhang K, Xu G, Xu RH#. Circulating tumor DNA methylation profiles enable early diagnosis, prognosis prediction, and screening for colorectal cancer. Sci Transl Med. 2020 Jan 1;12(524).\n",
      "\n",
      "[16]   Li T, Hu PS, Zuo Z, Lin JF, Li X, Wu QN, Chen ZH, Zeng ZL, Wang F, Zheng J, Chen D, Li B, Kang TB, Dan Xie, Dongxin Lin, Huai-Qiang Ju, Rui-Hua Xu#. METTL3 facilitates tumor progression via an m(6)A-IGF2BP2-dependent mechanism in colorectal carcinoma. Mol Cancer. 2019; 18: 112.\n",
      "\n",
      "[17] Yun Wang, Jia-Huan Lu, Qi-Nian Wu, Ying Jin, De-Shen Wang, Yan-Xing Chen, Jia Liu, Xiao-Jing Luo, Qi Meng, Heng-Ying Pu, Ying-Nan Wang, Pei-Shan Hu, Ze-Xian Liu, Zhao-Lei Zeng, Qi Zhao, Rong Deng, Xiao-Feng Zhu, Huai-Qiang Ju, Rui-Hua Xu#. LncRNA LINRIS stabilizes IGF2BP2 and promotes the aerobic glycolysis in colorectal cancer. Molecular Cancer. 2019 Dec 2.\n",
      "\n",
      "[18]   Jin Y, Chen DL, Wang F, Yang CP, Chen XX, You JQ, Huang JS, Shao Y, Zhu DQ, Ouyang YM, Luo HY, Wang ZQ, Wang FH, Li YH, Xu RH#, Zhang DS. The predicting role of circulating tumor DNA landscape in gastric cancer patients treated with immune checkpoint inhibitors. Mol Cancer. 2020 Oct 30;19(1):154.\n",
      "\n",
      "[19]   Chen DL, Wang ZQ, Zeng ZL, Wu WJ, Zhang DS, Luo HY, Wang F, Qiu MZ, Wang DS, Ren C, Wang FH, Chiao LJ, Pelicano H, Huang P, Li YH and Xu RH#. Identification of microRNA-214 as a negative regulator of colorectal cancer liver metastasis by way of regulation of fibroblast growth factor receptor 1 expression. Hepatology 2014; 60: 598-609.\n",
      "\n",
      "[20]   Ju HQ, Li H, Tian T, Lu YX, Bai L, Chen LZ, Sheng H, Mo HY, Zeng JB, Deng W, Chiao PJ and Xu RH#. Melatonin overcomes gemcitabine resistance in pancreatic ductal adenocarcinoma by abrogating nuclear factor-kappaB activation. Journal of Pineal Research 2016; 60: 27-38.\n",
      "\n",
      "[21]   Ju HQ, Lin JF, Tian T, Xie D, Xu RH#. NADPH homeostasis in cancer: functions, mechanisms and therapeutic implications. Signal Transduct Tar. 2020 Oct 7;5(1):231.\n",
      "\n",
      "[22]  Hu PS, Li T, Lin JF, Qiu MZ, Wang DS, Liu ZX, Chen ZH, Yang LP, Zhang XL, Zhao Q, Chen YX, Lu YX, Wu QN, Pu HY, Zeng ZL, Xie D, Ju HQ, Luo HY, Xu RH#. VDR-SOX2 signaling promotes colorectal cancer stemness and malignancy in an acidic microenvironment. Signal Transduct Tar. 2020 Sep 9;5(1):183.\n",
      "\n",
      "[23]   Ju HQ, Ying H, Tian T, Ling J, Fu J, Lu Y, Wu M, Yang L, Achreja A, Chen G, Zhuang Z, Wang H, Nagrath D, Yao J, Hung MC, DePinho RA, Huang P, Xu RH# and Chiao PJ. Mutant Kras- and p16-regulated NOX4 activation overcomes metabolic checkpoints in development of pancreatic ductal adenocarcinoma. Nat Commun 2017; 8: 14437.\n",
      "\n",
      "[24]   Liu J, Liu ZX, Wu QN, Lu YX, Wong CW, Miao L, Wang Y, Wang Z, Jin Y, He MM, Ren C, Wang DS, Chen DL, Pu HY, Feng L, Li B, Xie D, Zeng MS, Huang P, Lin A, Lin D, Xu RH#, Ju HQ. Long noncoding RNA AGPG regulates PFKFB3-mediated tumor glycolytic reprogramming. Nat Commun. 2020 Mar 20;11(1):1507.\n",
      "\n",
      "[25]   Ju HQ, Lu YX, Chen DL, Zuo ZX, Liu ZX, Wu QN, Mo HY, Wang ZX, Wang DS, Pu HY, Zeng ZL, Li B, Xie D, Huang P, Hung MC, Chiao PJ and Xu RH#. Modulation of Redox Homeostasis by Inhibition of MTHFD2 in Colorectal Cancer: Mechanisms and Therapeutic Implications. J Natl Cancer Inst 2018\n",
      "\n",
      "[26] Yu K, Zhang Q, Liu Z, Zhao Q, Zhang X, Wang Y, Wang ZX, Jin Y, Li X, Liu ZX and Xu RH#. qPhos: a database of protein phosphorylation dynamics in humans. Nucleic Acids Res 2018\n",
      "\n",
      "[27] Rui-Hua Xu*, Jin Li, Yuxian Bai, Jianming Xu, Tianshu Liu, Lin Shen, Liwei Wang, Hongming Pan, Junning Cao, Dongsheng Zhang, Songhua Fan, Ye Hua & Weiguo Su. Safety and efficacy of fruquintinib in patients with previously treated metastatic colorectal cancer: a phase Ib study and a randomized double-blind phase II study. J Hematol Oncol. (2017) 10:22.\n",
      "\n",
      "[28] Gong Chen, Junjie Peng, Qian Xiao, Hao-Xiang Wu, Xiaojun Wu, Fulong Wang, Liren Li, Peirong Ding, Qi Zhao, Yaqi Li, Da Wang, Yang Shao, Hua Bao, Zhizhong Pan, Ke-Feng Ding, Sanjun Cai, Feng Wang, Rui-Hua Xu#. Postoperative circulating tumor DNA as markers of recurrence risk in stages II to III colorectal cancer. Journal of Hematology & Oncology. 2021 May 17;14(1):80.\n",
      "\n",
      "[29] Zeng ZL, Luo HY, Yang J, Wu WJ, Chen DL, Huang P and Xu RH#. Overexpression of the circadian clock gene Bmal1 increases sensitivity to oxaliplatin in colorectal cancer. Clinical Cancer Research 2014; 20: 1042-1052.\n",
      "\n",
      "[30] Huiyan Luo, Wei Wei, Ziyi Ye, Jiabo Zheng, Rui-hua Xu#. Liquid Biopsy of Methylation Biomarkers in Cell-Free DNA. Trends in Molecular Medicine. 23 Jan 2021.\n",
      "\n",
      "    ---------\n",
      "\n",
      "\n",
      "2023-06-14 22:17:18,080 - common.py - [line]:36 - INFO - response.status_code:200, response.text:{\"id\":\"chatcmpl-7RLbAYzWsdJA35LIMhTgy2H6wjUnX\",\"object\":\"chat.completion\",\"created\":1686752236,\"model\":\"gpt-3.5-turbo-16k-0613\",\"choices\":[{\"index\":0,\"message\":{\"role\":\"assistant\",\"content\":\"[\\n  {\\n    \\\"name\\\": \\\"徐瑞华\\\",\\n    \\\"clinical_trial\\\": [\\n      \\\"NCT05830045\\\",\\n      \\\"NCT05727839\\\",\\n      \\\"NCT03544905\\\",\\n      \\\"NCT01198392\\\"\\n    ]\\n  }\\n]\"},\"finish_reason\":\"stop\"}],\"usage\":{\"prompt_tokens\":9523,\"completion_tokens\":58,\"total_tokens\":9581}}\n",
      "2023-06-14 22:17:18,081 - common.py - [line]:39 - INFO - json_dict:{'id': 'chatcmpl-7RLbAYzWsdJA35LIMhTgy2H6wjUnX', 'object': 'chat.completion', 'created': 1686752236, 'model': 'gpt-3.5-turbo-16k-0613', 'choices': [{'index': 0, 'message': {'role': 'assistant', 'content': '[\\n  {\\n    \"name\": \"徐瑞华\",\\n    \"clinical_trial\": [\\n      \"NCT05830045\",\\n      \"NCT05727839\",\\n      \"NCT03544905\",\\n      \"NCT01198392\"\\n    ]\\n  }\\n]'}, 'finish_reason': 'stop'}], 'usage': {'prompt_tokens': 9523, 'completion_tokens': 58, 'total_tokens': 9581}}\n",
      "2023-06-14 22:17:18,082 - common.py - [line]:42 - INFO - [\n",
      "  {\n",
      "    \"name\": \"徐瑞华\",\n",
      "    \"clinical_trial\": [\n",
      "      \"NCT05830045\",\n",
      "      \"NCT05727839\",\n",
      "      \"NCT03544905\",\n",
      "      \"NCT01198392\"\n",
      "    ]\n",
      "  }\n",
      "]\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "+++++++++++++++++++++++++\n",
      "[\n",
      "  {\n",
      "    \"name\": \"徐瑞华\",\n",
      "    \"clinical_trial\": [\n",
      "      \"NCT05830045\",\n",
      "      \"NCT05727839\",\n",
      "      \"NCT03544905\",\n",
      "      \"NCT01198392\"\n",
      "    ]\n",
      "  }\n",
      "]\n"
     ]
    }
   ],
   "source": [
    "chat(xrh_txt,\"徐瑞华的clinical trial有哪些，列出NCT编号\")"
   ],
   "metadata": {
    "collapsed": false,
    "ExecuteTime": {
     "end_time": "2023-06-14T14:17:18.101319300Z",
     "start_time": "2023-06-14T14:17:10.586224800Z"
    }
   }
  },
  {
   "cell_type": "code",
   "execution_count": 6,
   "outputs": [
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "2023-06-14 22:17:26,434 - common.py - [line]:30 - INFO - get_openai_data: model:gpt-3.5-turbo-16k\n",
      "2023-06-14 22:17:45,294 - common.py - [line]:33 - INFO - <Response [200]>\n",
      "2023-06-14 22:17:45,295 - common.py - [line]:34 - INFO - query:\n",
      "    请根据以下context，回答：徐瑞华的clinical trial有哪些，列出NCT编号\n",
      "    reply in 简体中文\n",
      "    ---------context\n",
      "    \n",
      "[\n",
      "  {\n",
      "    \"_id\": \"648019f5778538384fd02da2\",\n",
      "    \"avatar\": null,\n",
      "    \"name\": \"Ruihua Xu\",\n",
      "    \"hospital\": \"Sun Yat-sen University\",\n",
      "    \"title\": \" MD\",\n",
      "    \"position\": null,\n",
      "    \"contact\": \"xuruihua@sysucc.org.cn\",\n",
      "    \"phone\": \"86-20-87343333\",\n",
      "    \"expertise\": \"Colorectal Carcinoma, pMMR, Microsatellite-stable\",\n",
      "    \"brief_intro\": \"A Study of Sintilimab and Chidamide in Combination With or Without IBI305 in Standard Treatment Failure of Advanced or Metastatic pMMR/MSS Colorectal Carcinoma\",\n",
      "    \"work_exp\": null,\n",
      "    \"edu_exp\": null,\n",
      "    \"consulting\": null,\n",
      "    \"publications\": null,\n",
      "    \"clinical_res\": null,\n",
      "    \"awards\": null\n",
      "  },\n",
      "  {\n",
      "    \"_id\": \"64803f25f24b55a336ba235d\",\n",
      "    \"avatar\": null,\n",
      "    \"name\": \"ruihua Xu\",\n",
      "    \"hospital\": \"Peking University\",\n",
      "    \"title\": \"M.D., Ph.D.\",\n",
      "    \"position\": null,\n",
      "    \"contact\": \"xurh@mail.sysu.edu.cn\",\n",
      "    \"phone\": \"13922206676\",\n",
      "    \"expertise\": \"nimotuzumab colorectal cancer chemotherapy\",\n",
      "    \"brief_intro\": null,\n",
      "    \"work_exp\": null,\n",
      "    \"edu_exp\": null,\n",
      "    \"consulting\": null,\n",
      "    \"publications\": null,\n",
      "    \"clinical_res\": \"Study of Nimotuzumab to Treat Colorectal Cancer\",\n",
      "    \"awards\": null\n",
      "  },\n",
      "  {\n",
      "    \"_id\": \"6480ea13f24b55a336bec613\",\n",
      "    \"avatar\": null,\n",
      "    \"name\": \"Ruihua Xu\",\n",
      "    \"hospital\": \"Sun Yat-sen University\",\n",
      "    \"title\": \"MD\",\n",
      "    \"position\": null,\n",
      "    \"contact\": \"xurh@susycc.org.cn\",\n",
      "    \"phone\": \"+862087343795\",\n",
      "    \"expertise\": \"Colorectal Cancer,Microsatellite Stable,Chidamide,Sintilimab,PD-1,Bevacizumab\",\n",
      "    \"brief_intro\": null,\n",
      "    \"work_exp\": null,\n",
      "    \"edu_exp\": null,\n",
      "    \"consulting\": null,\n",
      "    \"publications\": null,\n",
      "    \"clinical_res\": \"Comparing Chidamide+Sintilimab+Bev With Standard Second-line FOLFIRI+Bev in Advanced MSS/pMMR mCRC\",\n",
      "    \"awards\": null\n",
      "  }\n",
      "]\n",
      "[\n",
      "  {\n",
      "    \"NCT_No\": \"NCT05830045\",\n",
      "    First_Submitted_Date\": \"April 4, 2023\",\n",
      "    First_Posted_Date\": \"April 26, 2023\",\n",
      "    Last_Update_Posted_Date\": \"April 26, 2023\",\n",
      "    Estimated__Study_Start_Date\": \"April 20, 2023\",\n",
      "    Estimated_Primary_Completion_Date\": \"April 30, 2025   (Final data collection date for primary outcome measure)\",\n",
      "    Current_Primary_Outcome_Measures\": \"[List]\",\n",
      "    Original_Primary_Outcome_Measures\": \"Same as current\",\n",
      "    Change_History\": \"No Changes Posted\",\n",
      "    Current_Secondary_Outcome_Measures\": \"Not Provided\",\n",
      "    Original_Secondary_Outcome_Measures\": \"Not Provided\",\n",
      "    Current_Other_Pre-specified_Outcome_Measures\": \"Not Provided\",\n",
      "    Original_Other_Pre-specified_Outcome_Measures\": \"Not Provided\",\n",
      "    \"Brief_Title\": \"A Phase I Study of QLP2117 in Subjects With Advanced Solid Tumors\",\n",
      "    \"Official_Title\": \"A Study Evaluates the Safety, Pharmacokinetics, Immunogenicity and Efficacy of QLP2117 in Advanced Solid Tumor Patients\",\n",
      "    \"Brief_Summary\": \"This is the first in human study of QLP2117. To evaluate the Safety, Pharmacokinetics, Immunogenicity and Efficacy of QLP2117 in patients with advanced solid tumors.\",\n",
      "    \"Detailed_Description\": \"Not Provided\",\n",
      "    \"Study_Type\": \"Interventional\",\n",
      "    \"Study_Phase\": \"Phase 1\",\n",
      "    \"Study_Design\": \"Allocation: Non-Randomized\n",
      "Intervention Model: Sequential Assignment\n",
      "Masking: None (Open Label)\n",
      "Primary Purpose: Treatment\",\n",
      "    \"Condition\": \"Advanced Solid Tumors\",\n",
      "    \"Intervention\": \"Drug: QLP2117\n",
      "Specified dose on specified days\",\n",
      "    \"Study_Arms\": \"[List]\",\n",
      "    \"Publications_*\": \"Not Provided\",\n",
      "    \"Recruitment_Status\": \"Not yet recruiting\",\n",
      "    \"Estimated_Enrollment\": \"180\",\n",
      "    \"Original_Estimated_Enrollment\": \"Same as current\",\n",
      "    \"Estimated_Study_Completion_Date\": \"December 31, 2025\",\n",
      "    \"Estimated_Primary_Completion_Date\": \"April 30, 2025   (Final data collection date for primary outcome measure)\",\n",
      "    \"Eligibility_Criteria\": \"[List]\",\n",
      "    \"Sex/Gender\": \"Sexes Eligible for Study:\n",
      "   All\",\n",
      "    \"Ages\": \"18 Years and older   (Adult, Older Adult)\",\n",
      "    \"Accepts_Healthy_Volunteers\": \"No\",\n",
      "    \"Contacts\": \"Contact: Zhang Meijiang, PhD\n",
      "   8615210162105\n",
      "   meijiang.zhang@qilu-pharma.com\",\n",
      "    \"Listed_Location_Countries\": \"Not Provided\",\n",
      "    \"Removed_Location_Countries\": null,\n",
      "    \"NCT_Number\": \"NCT05830045\",\n",
      "    \"Other_Study_ID_Numbers\": \"QLP2117-101\",\n",
      "    \"Has_Data_Monitoring_Committee\": \"No\",\n",
      "    \"U.S._FDA-regulated_Product\": \"[List]\",\n",
      "    \"IPD_Sharing_Statement\": \"Plan to Share IPD:\n",
      "   No\",\n",
      "    \"Current_Responsible_Party\": \"Qilu Pharmaceutical Co., Ltd.\",\n",
      "    \"Original_Responsible_Party\": \"Same as current\",\n",
      "    \"Current_Study_Sponsor\": \"Qilu Pharmaceutical Co., Ltd.\",\n",
      "    \"Original_Study_Sponsor\": \"Same as current\",\n",
      "    \"Collaborators\": \"Not Provided\",\n",
      "    \"Investigators\": \"Principal Investigator:\n",
      "   Xu Ruihua, PhD\n",
      "   Sun Yat-sen University\",\n",
      "    \"PRS_Account\": \"Qilu Pharmaceutical Co., Ltd.\",\n",
      "    \"Verification_Date\": \"April 2023\"\n",
      "  },\n",
      "  {\n",
      "    \"NCT_No\": \"NCT05727839\",\n",
      "    First_Submitted_Date\": \"February 1, 2023\",\n",
      "    First_Posted_Date\": \"February 14, 2023\",\n",
      "    Last_Update_Posted_Date\": \"March 20, 2023\",\n",
      "    Estimated__Study_Start_Date\": \"February 24, 2023\",\n",
      "    Estimated_Primary_Completion_Date\": \"July 24, 2025   (Final data collection date for primary outcome measure)\",\n",
      "    Current_Primary_Outcome_Measures\": \"[List]\",\n",
      "    Original_Primary_Outcome_Measures\": \"[List]\",\n",
      "    Change_History\": \"Complete list of historical versions of study NCT05727839 on ClinicalTrials.gov Archive Site\",\n",
      "    Current_Secondary_Outcome_Measures\": \"[List]\",\n",
      "    Original_Secondary_Outcome_Measures\": \"[List]\",\n",
      "    Current_Other_Pre-specified_Outcome_Measures\": \"Not Provided\",\n",
      "    Original_Other_Pre-specified_Outcome_Measures\": \"Not Provided\",\n",
      "    \"Brief_Title\": \"Study to Evaluate JCXH-211 as Monotherapy in Patients With Malignant Solid Tumors\",\n",
      "    \"Official_Title\": \"A Phase 1 Open-Label Study to Evaluate the Safety, Tolerability and Efficacy of JCXH-211 Intratumoral Injection in Patients With Malignant Solid Tumors\",\n",
      "    \"Brief_Summary\": \": A Phase 1 Open-Label Study to Evaluate the Safety, Tolerability and Efficacy of JCXH-211 Intratumoral Injection in Patients with Malignant Solid Tumors\",\n",
      "    \"Detailed_Description\": \"The main purpose of this study is to find out how safe and tolerable the study drug, JCXH-211, is and also how well it works in people with malignant solid tumors. The study drug JCXH-211, is an immunotherapy drug. This means that it aims to work by boosting immune system's response to tumors, to help fight against the growth of the cancer cells. The study has 2 main phases: Phase\n",
      "  1a and Phase 1b. Phase 1a has 2 stages, skin/subcutaneous lesions stage, deep (visceral) lesions stage. Phase 1b will not start until all the data collected in Phase 1a has been completed and reviewed to check that it is safe and well tolerated.\",\n",
      "    \"Study_Type\": \"Interventional\",\n",
      "    \"Study_Phase\": \"Phase 1\",\n",
      "    \"Study_Design\": \"Allocation: Non-Randomized\n",
      "Intervention Model: Single Group Assignment\n",
      "Masking: None (Open Label)\n",
      "Primary Purpose: Treatment\",\n",
      "    \"Condition\": \"[List]\",\n",
      "    \"Intervention\": \"Drug: JCXH-211 Injection\n",
      "JCXH-211 administered once every 28 days\n",
      "Other Name: Intratumoral injection\",\n",
      "    \"Study_Arms\": \"[List]\",\n",
      "    \"Publications_*\": \"Not Provided\",\n",
      "    \"Recruitment_Status\": \"Recruiting\",\n",
      "    \"Estimated_Enrollment\": \"156\",\n",
      "    \"Original_Estimated_Enrollment\": \"Same as current\",\n",
      "    \"Estimated_Study_Completion_Date\": \"August 24, 2025\",\n",
      "    \"Estimated_Primary_Completion_Date\": \"July 24, 2025   (Final data collection date for primary outcome measure)\",\n",
      "    \"Eligibility_Criteria\": \"[List]\",\n",
      "    \"Sex/Gender\": \"Sexes Eligible for Study:\n",
      "   All\",\n",
      "    \"Ages\": \"18 Years to 75 Years   (Adult, Older Adult)\",\n",
      "    \"Accepts_Healthy_Volunteers\": \"No\",\n",
      "    \"Contacts\": \"Contact: Qi Wang\n",
      "   +8613381113913\n",
      "   qi.wang@immorna.com\",\n",
      "    \"Listed_Location_Countries\": \"China\",\n",
      "    \"Removed_Location_Countries\": null,\n",
      "    \"NCT_Number\": \"NCT05727839\",\n",
      "    \"Other_Study_ID_Numbers\": \"JCXH-211-003\",\n",
      "    \"Has_Data_Monitoring_Committee\": \"Not Provided\",\n",
      "    \"U.S._FDA-regulated_Product\": \"[List]\",\n",
      "    \"IPD_Sharing_Statement\": \"Not Provided\",\n",
      "    \"Current_Responsible_Party\": \"Immorna Biotherapeutics, Inc.\",\n",
      "    \"Original_Responsible_Party\": \"Same as current\",\n",
      "    \"Current_Study_Sponsor\": \"Immorna Biotherapeutics, Inc.\",\n",
      "    \"Original_Study_Sponsor\": \"Same as current\",\n",
      "    \"Collaborators\": \"Not Provided\",\n",
      "    \"Investigators\": \"Principal Investigator:\n",
      "   Xu ruihua, President\n",
      "   Sun Yat-sen University\",\n",
      "    \"PRS_Account\": \"Immorna Biotherapeutics, Inc.\",\n",
      "    \"Verification_Date\": \"March 2023\"\n",
      "  },\n",
      "  {\n",
      "    \"NCT_No\": \"NCT03544905\",\n",
      "    First_Submitted_Date\": \"May 22, 2018\",\n",
      "    First_Posted_Date\": \"June 4, 2018\",\n",
      "    Last_Update_Posted_Date\": \"January 6, 2023\",\n",
      "    Estimated__Study_Start_Date\": \"July 5, 2018\",\n",
      "    Estimated_Primary_Completion_Date\": \"June 30, 2023   (Final data collection date for primary outcome measure)\",\n",
      "    Current_Primary_Outcome_Measures\": \"MTD(Max tolerance does) [ Time Frame: 35 days ]To evaluate the MTD in patients with advanced solid tumor\",\n",
      "    Original_Primary_Outcome_Measures\": \"Same as current\",\n",
      "    Change_History\": \"Complete list of historical versions of study NCT03544905 on ClinicalTrials.gov Archive Site\",\n",
      "    Current_Secondary_Outcome_Measures\": \"Not Provided\",\n",
      "    Original_Secondary_Outcome_Measures\": \"Not Provided\",\n",
      "    Current_Other_Pre-specified_Outcome_Measures\": \"Not Provided\",\n",
      "    Original_Other_Pre-specified_Outcome_Measures\": \"Not Provided\",\n",
      "    \"Brief_Title\": \"Study to Evaluate the Safety, Tolerate, Pharmacokinetics and Preliminary Efficacy of CYH33\",\n",
      "    \"Official_Title\": \"A Multi-center, Open-label, Single Arm, Dose Escalation and Dose Extension Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of CYH33 in Advanced Solid Tumors Patients.\",\n",
      "    \"Brief_Summary\": \"This study is a Multi-center, Open-label, single arm, Dose Escalation and Dose Extension Phase 1 Study to Evaluate the Safety , Tolerability, Pharmacokinetics and Preliminary Efficacy of CYH33 in Advanced Solid Tumors Patients.\",\n",
      "    \"Detailed_Description\": \"This study includes Phase Ia and Phase Ib.\n",
      "  In the dose climbing part of phase Ia, the safety, tolerance and pharmacokinetics characteristics of CYH33 in patients with advanced solid tumors who failed to receive standard treatment, did not tolerate or did not have standard treatment at present will be observed to determine MTD; Before determining MTD, select safe and highly reliable and effective dose levels for simultaneous expansion. Phase Ia dose expansion includes patients with advanced solid tumors who have failed to undergo standard treatment, who are intolerant of PIK3CA gene mutation, or who do not have standard treatment at present, to further evaluate safety, tolerance and initial efficacy.\n",
      "  In Phase Ib, the safety and preliminary efficacy of CYH33 on patients with advanced breast cancer, ovarian cancer, endometrial cancer, cervical cancer, head and neck squamous cell carcinoma, esophageal and gastroesophageal junction squamous cell carcinoma, ovarian clear cell carcinoma and other solid tumors with PIK3CA gene mutation who have failed, are intolerant or do not have standard treatment at present will be evaluated.\",\n",
      "    \"Study_Type\": \"Interventional\",\n",
      "    \"Study_Phase\": \"Phase 1\",\n",
      "    \"Study_Design\": \"Allocation: N/A\n",
      "Intervention Model: Single Group Assignment\n",
      "Masking: None (Open Label)\n",
      "Primary Purpose: Treatment\",\n",
      "    \"Condition\": \"Advanced Solid Tumors\",\n",
      "    \"Intervention\": \"Drug: CYH33 for tablet\n",
      "1mg; 5mg; 10mg; 20mg; 30mg; 50mg; 75mg; 100mg; 130mg; 160mg; 200mg; 240mgBID or QD(Decided by SMC accroding to the safty and PK data)\",\n",
      "    \"Study_Arms\": \"Experimental: Dose escalation study of CYH33\n",
      "To determine the maximum tolerated dose (MTD) of CYH33\n",
      "Intervention: Drug: CYH33 for tablet\",\n",
      "    \"Publications_*\": \"Not Provided\",\n",
      "    \"Recruitment_Status\": \"Recruiting\",\n",
      "    \"Estimated_Enrollment\": \"100\",\n",
      "    \"Original_Estimated_Enrollment\": \"Same as current\",\n",
      "    \"Estimated_Study_Completion_Date\": \"March 31, 2024\",\n",
      "    \"Estimated_Primary_Completion_Date\": \"June 30, 2023   (Final data collection date for primary outcome measure)\",\n",
      "    \"Eligibility_Criteria\": \"[List]\",\n",
      "    \"Sex/Gender\": \"Sexes Eligible for Study:\n",
      "   All\",\n",
      "    \"Ages\": \"18 Years and older   (Adult, Older Adult)\",\n",
      "    \"Accepts_Healthy_Volunteers\": \"No\",\n",
      "    \"Contacts\": \"Contact: Ruihua Xu, M.D\n",
      "   86-20-87343804\n",
      "   ruihxu@163.com\",\n",
      "    \"Listed_Location_Countries\": \"China\",\n",
      "    \"Removed_Location_Countries\": null,\n",
      "    \"NCT_Number\": \"NCT03544905\",\n",
      "    \"Other_Study_ID_Numbers\": \"CYH33-101\",\n",
      "    \"Has_Data_Monitoring_Committee\": \"Yes\",\n",
      "    \"U.S._FDA-regulated_Product\": \"[List]\",\n",
      "    \"IPD_Sharing_Statement\": \"Not Provided\",\n",
      "    \"Current_Responsible_Party\": \"Haihe Biopharma Co., Ltd.\",\n",
      "    \"Original_Responsible_Party\": \"Same as current\",\n",
      "    \"Current_Study_Sponsor\": \"Haihe Biopharma Co., Ltd.\",\n",
      "    \"Original_Study_Sponsor\": \"Same as current\",\n",
      "    \"Collaborators\": \"Not Provided\",\n",
      "    \"Investigators\": \"Principal Investigator:\n",
      "   Ruihua Xu, M.D\n",
      "   Sun Yat-sen University\",\n",
      "    \"PRS_Account\": \"Haihe Biopharma Co., Ltd.\",\n",
      "    \"Verification_Date\": \"January 2023\"\n",
      "  },\n",
      "  {\n",
      "    \"NCT_No\": \"NCT01198392\",\n",
      "    First_Submitted_Date\": \"September 1, 2010\",\n",
      "    First_Posted_Date\": \"September 10, 2010\",\n",
      "    Last_Update_Posted_Date\": \"July 25, 2011\",\n",
      "    Estimated__Study_Start_Date\": \"September 2008\",\n",
      "    Estimated_Primary_Completion_Date\": \"December 2011   (Final data collection date for primary outcome measure)\",\n",
      "    Current_Primary_Outcome_Measures\": \"Time to progression [ Time Frame: The time from randomization until objective tumor progression or death ]\",\n",
      "    Original_Primary_Outcome_Measures\": \"Same as current\",\n",
      "    Change_History\": \"Complete list of historical versions of study NCT01198392 on ClinicalTrials.gov Archive Site\",\n",
      "    Current_Secondary_Outcome_Measures\": \"Response rate [ Time Frame: 2 months ]\",\n",
      "    Original_Secondary_Outcome_Measures\": \"Same as current\",\n",
      "    Current_Other_Pre-specified_Outcome_Measures\": \"Not Provided\",\n",
      "    Original_Other_Pre-specified_Outcome_Measures\": \"Not Provided\",\n",
      "    \"Brief_Title\": \"Trial of S-1 Plus Cisplatin in Gastric Cancer\",\n",
      "    \"Official_Title\": \"A Clinical Trial of S-1 Plus Cisplatin Versus 5-FU Plus Cisplatin in Patients With Unresectable or Advanced Gastric Cancer\",\n",
      "    \"Brief_Summary\": \"The purpose of this study is to evaluate the effectiveness and safety of s-1 plus cisplatin versus 5-FU plus cisplatin as first-line therapy in the treatment of patients with advanced gastric cancer.\",\n",
      "    \"Detailed_Description\": \"This is a randomized, controlled, open-label,multicenter study. Patients are randomized to one of two treatment arms : S-1 plus cisplatin and 5-FU plus cisplatin.\",\n",
      "    \"Study_Type\": \"Interventional\",\n",
      "    \"Study_Phase\": \"Phase 3\",\n",
      "    \"Study_Design\": \"Allocation: Randomized\n",
      "Intervention Model: Parallel Assignment\n",
      "Masking: None (Open Label)\n",
      "Primary Purpose: Treatment\",\n",
      "    \"Condition\": \"Gastric Cancer\",\n",
      "    \"Intervention\": \"[List]\",\n",
      "    \"Study_Arms\": \"[List]\",\n",
      "    \"Publications_*\": \"Li YH, Qiu MZ, Xu JM, Sun GP, Lu HS, Liu YP, Zhong MZ, Zhang HL, Yu SY, Li W, Hu XH, Wang JJ, Cheng Y, Zhou JT, Guo ZQ, Guan ZG, Xu RH. S-1 plus cisplatin versus fluorouracil plus cisplatin in advanced gastric or gastro-esophageal junction adenocarcinoma patients: a pilot study. Oncotarget. 2015 Oct 27;6(33):35107-15. doi: 10.18632/oncotarget.5959.\",\n",
      "    \"Recruitment_Status\": \"Unknown status\",\n",
      "    \"Estimated_Enrollment\": \"270\",\n",
      "    \"Original_Estimated_Enrollment\": \"Same as current\",\n",
      "    \"Estimated_Study_Completion_Date\": \"December 2011\",\n",
      "    \"Estimated_Primary_Completion_Date\": \"December 2011   (Final data collection date for primary outcome measure)\",\n",
      "    \"Eligibility_Criteria\": \"[List]\",\n",
      "    \"Sex/Gender\": \"Sexes Eligible for Study:\n",
      "   All\",\n",
      "    \"Ages\": \"18 Years to 75 Years   (Adult, Older Adult)\",\n",
      "    \"Accepts_Healthy_Volunteers\": \"No\",\n",
      "    \"Contacts\": \"Contact information is only displayed when the study is recruiting subjects\",\n",
      "    \"Listed_Location_Countries\": \"China\",\n",
      "    \"Removed_Location_Countries\": null,\n",
      "    \"NCT_Number\": \"NCT01198392\",\n",
      "    \"Other_Study_ID_Numbers\": \"2005L02859\",\n",
      "    \"Has_Data_Monitoring_Committee\": \"Yes\",\n",
      "    \"U.S._FDA-regulated_Product\": \"Not Provided\",\n",
      "    \"IPD_Sharing_Statement\": \"Not Provided\",\n",
      "    \"Current_Responsible_Party\": \"Zhongzhen Guan ,Ruihua Xu, Sun Yat-sen University Cancer Center\",\n",
      "    \"Original_Responsible_Party\": \"Same as current\",\n",
      "    \"Current_Study_Sponsor\": \"Sun Yat-sen University\",\n",
      "    \"Original_Study_Sponsor\": \"Same as current\",\n",
      "    \"Collaborators\": \"Not Provided\",\n",
      "    \"Investigators\": \"Principal Investigator:\n",
      "   RUIHUA XU, Professor\n",
      "   Sun Yat-sen University\",\n",
      "    \"PRS_Account\": \"Sun Yat-sen University\",\n",
      "    \"Verification_Date\": \"August 2008\"\n",
      "  }\n",
      "]\n",
      "\n",
      "徐瑞华，医学博士，中山大学肿瘤防治中心主任、医院院长、研究所所长，华南恶性肿瘤防治全国重点实验室主任，教授，博士生导师。\n",
      "\n",
      "中国医学科学院学部委员，中国临床肿瘤学会理事长，中国抗癌协会副理事长，中国抗癌协会靶向治疗专委会首届主任委员，中国抗癌协会化疗专委会候任主任委员，中国临床肿瘤学会肠癌专委会主任委员，《Cancer Communications》主编，研究生教材《肿瘤学》主编，本科生教材《临床肿瘤学》主编。\n",
      "\n",
      "从事肿瘤内科临床及科研工作30余年，取得突破性成果：\n",
      "\n",
      "第一，实现了肠癌诊治理论和实践的系统创新，使我国肠癌早诊及精准治疗均处于国际先进水平。创新了肠癌早诊及疗效预测的新技术，并已转化为临床应用；建立了晚期肠癌治疗新体系，创建了高效低毒的维持方案和亚洲方案，成为国际治疗新标准，晚期肠癌生存率与国际顶尖的安德森癌症中心达相同水平。\n",
      "\n",
      "第二，创新了消化肿瘤免疫治疗体系，引领国际消化肿瘤免疫治疗发展。\n",
      "\n",
      "通过鉴定TMB、POLE/POLD突变等标志物，精准筛选免疫治疗敏感亚型，大幅提高PD-1抗体疗效；首创了食管癌中国免疫联合方案，取得全球最高有效率72%，已成为食管癌治疗应用最广泛的方案；建立了食管癌EGIC分型，可以指导精准免疫治疗策略，引领该领域的发展；揭示了免疫逃逸新机制并推动了药物的开发：发现甲硫氨酸限制饮食可抑制免疫检查点分子PDL1及VISTA的表达，增强抗肿瘤免疫及抗PD1的治疗效果；鉴定出免疫治疗增效肠道活性菌RX-af01，成果已转化。\n",
      "\n",
      "以通讯或第一作者在国际顶级期刊JAMA、Nature Materials、Nature Medicine、Lancet Oncology等发表SCI论文200余篇，入选科睿唯安（Clarivate Analytics）全球高被引科学家，连续入选中国高被引学者榜单。以第一完成人获国家科技进步二等奖2项及省部级一等奖6项、吴阶平医药创新奖、谈家桢临床医学奖及CSCO年度成就奖。入选国家百千万人才工程、全国先进工作者、南粤百杰人才培养工程、国家卫生计生突出贡献中青年专家等人才项目。\n",
      "\n",
      "Representative paper: （*：第一作者，#：通讯作者）\n",
      "\n",
      "[1]     Luo H, Lu J, Bai Y, Mao T, Wang J, Fan Q, Zhang Y, Zhao K, Chen Z, Gao S, Li J, Fu Z, Gu K, Liu Z, Wu L, Zhang X, Feng J, Niu Z, Ba Y, Zhang H, Liu Y, Zhang L, Min X, Huang J, Cheng Y, Wang D, Shen Y, Yang Q, Zou J, Xu RH# ESCORT-1st Investigators.  Effect of Camrelizumab vs Placebo Added to Chemotherapy on Survival and Progression-Free Survival in Patients With Advanced or Metastatic Esophageal Squamous Cell Carcinoma: The ESCORT-1st Randomized Clinical Trial. JAMA. 2021 Sep 14;326(10):916-925.\n",
      "\n",
      "[2]     Xu RH*#, Wei W, Krawczyk M, Wang W, Luo H, Flagg K, Yi S, Shi W, Quan Q, Li K, Zheng L, Zhang H, Caughey BA, Zhao Q, Hou J, Zhang R, Xu Y, Cai H, Li G, Hou R, Zhong Z, Lin D, Fu X, Zhu J, Duan Y, Yu M, Ying B, Zhang W, Wang J, Zhang E, Zhang C, Li O, Guo R, Carter H, Zhu JK, Hao X and Zhang K. Circulating tumour DNA methylation markers for diagnosis and prognosis of hepatocellular carcinoma. Nat Mater 2017; 16: 1155-1161.\n",
      "\n",
      "[3]     Xu RH*#, Muro K, Morita S, Iwasa S, Han SW, Wang W, Kotaka M, Nakamura M, Ahn JB, Deng YH, Kato T, Cho SH, Ba Y, Matsuoka H, Lee KW, Zhang T, Yamada Y, Sakamoto J, Park YS and Kim TW. Modified XELIRI (capecitabine plus irinotecan) versus FOLFIRI (leucovorin, fluorouracil, and irinotecan), both either with or without bevacizumab, as second-line therapy for metastatic colorectal cancer (AXEPT): a multicentre, open-label, randomised, non-inferiority, phase 3 trial. Lancet Oncol 2018; 19: 660-671.\n",
      "\n",
      "[4]     Li J, Qin S, Xu R*, Yau TC, Ma B, Pan H, Xu J, Bai Y, Chi Y, Wang L, Yeh KH, Bi F, Cheng Y, Le AT, Lin JK, Liu T, Ma D, Kappeler C, Kalmus J and Kim TW. Regorafenib plus best supportive care versus placebo plus best supportive care in Asian patients with previously treated metastatic colorectal cancer (CONCUR): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncology 2015; 16: 619-629.\n",
      "\n",
      "[5]     Luo H, Xu G, Li C, He L, Luo L, Wang Z, Jing B, Deng Y, Jin Y, Li Y, Li B, Tan W, He C, Seeruttun SR, Wu Q, Huang J, Huang DW, Chen B, Lin SB, Chen QM, Yuan CM, Chen HX, Pu HY, Zhou F, He Y, Xu RH#. Real-time artificial intelligence for detection of upper gastrointestinal cancer by endoscopy: a multicentre, case-control, diagnostic study. Lancet Oncol. 2019 Oct 4.\n",
      "\n",
      "[6]     Satoh T, Xu RH*, Chung HC, Sun GP, Doi T, Xu JM, Tsuji A, Omuro Y, Li J, Wang JW, Miwa H, Qin SK, Chung IJ, Yeh KH, Feng JF, Mukaiyama A, Kobayashi M, Ohtsu A and Bang YJ. Lapatinib plus paclitaxel versus paclitaxel alone in the second-line treatment of HER2-amplified advanced gastric cancer in Asian populations: TyTAN--a randomized, phase III study. Journal of Clinical Oncology 2014; 32: 2039-2049.\n",
      "\n",
      "[7]     Manish A. Shah, Rui-hua Xu*, Yung-Jue Bang, Paulo M. Hoff, Tianshu Liu, Luis A. Herr´aez-Baranda, Fan Xia,Amit Garg, Mona Shing, and Josep Tabernero. HELOISE: Phase IIIb Randomized Multicenter Study Comparing Standard-of-Care and Higher-Dose Trastuzumab Regimens Combined With Chemotherapy as First-Line Therapy in Patients With Human Epidermal Growth Factor Receptor 2–Positive Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma. Journal of Clinical Oncology 2017; 35: 2558-2567.\n",
      "\n",
      "[8]     Wang ZX, Cui C, Yao J, Zhang Y, Li M, Feng J, Yang S, Fan Y, Shi J, Zhang X, Shen L, Shu Y, Wang C, Dai T, Mao T, Chen L, Guo Z, Liu B, Pan H, Cang S, Jiang Y, Wang J, Ye M, Chen Z, Jiang D, Lin Q, Ren W, Wang J, Wu L, Xu Y, Miao Z, Sun M, Xie C, Liu Y, Wang Q, Zhao L, Li Q, Huang C, Jiang K, Yang K, Li D, Liu Y, Zhu Z, Chen R, Jia L, Li W, Liao W, Liu HX, Ma D, Ma J, Qin Y, Shi Z, Wei Q, Xiao K, Zhang Y, Zhang Y, Chen X, Dai G, He J, Li J, Li G, Liu Y, Liu Z, Yuan X, Zhang J, Fu Z, He Y, Ju F, Liu Z, Tang P, Wang T, Wang W, Zhang J, Luo X, Tang X, May R, Feng H, Yao S, Keegan P, Xu RH#, Wang F. Toripalimab plus chemotherapy in treatment-naïve, advanced esophageal squamous cell carcinoma (JUPITER-06): A multi-center phase 3 trial. Cancer Cell. 2022 Mar 14;40(3):277-288.\n",
      "\n",
      "[9]     Wang F, Zhao Q, Wang YN, Jin Y, He MM, Liu ZX, Xu RH#. Evaluation of POLE and POLD1 Mutations as Biomarkers for Immunotherapy Outcomes Across Multiple Cancer Types. JAMA Oncol. 2019.\n",
      "\n",
      "[10]   Wang F, Liu DB, Zhao Q, Chen G, Liu XM, Wang YN, Su H, Qin YR, He YF, Zou QF, Liu YH, Lin YE, Liu ZX, Bei JX and Xu RH#. The genomic landscape of small cell carcinoma of the esophagus. Cell Res 2018; 28: 771-774.\n",
      "\n",
      "[11]   Wang DS, Liu ZX, Lu YX, Bao H, Wu X, Zeng ZL, Liu Z, Zhao Q, He CY, Lu JH, Wang ZQ, Qiu MZ, Wang F, Wang FH, Li YH, Wang XN, Xie D, Jia WH, Shao YW and Xu RH#. Liquid biopsies to track trastuzumab resistance in metastatic HER2-positive gastric cancer. Gut 2018;\n",
      "\n",
      "[12]   Feng Wang, You-Sheng Huang, Hao-Xiang Wu, Zi-Xian Wang, Ying Jin, Yi-Chen Yao, Yan-Xing Chen, Qi Zhao, Shifu Chen, Ming-Ming He, Hui-Yan Luo, Miao-Zhen Qiu, De-Shen Wang, Feng-Hua Wang, Mingyan Xu, Yu-Hong Li, Rui-Hua Xu#. Genomic temporal heterogeneity of circulating tumour DNA in unresectable metastatic colorectal cancer under first-line treatment. Gut. 2022 Jul;71(7):1340-1349.\n",
      "\n",
      "[13]   Luo HY, Li YH, Wang W, Wang ZQ, Yuan X, Ma D, Wang FH, Zhang DS, Lin DR, Lin YC, Jia J, Hu XH, Peng JW and Xu RH#. Single-agent capecitabine as maintenance therapy after induction of XELOX (or FOLFOX) in first-line treatment of metastatic colorectal cancer: randomized clinical trial of efficacy and safety. Annals of Oncology 2016; 27: 1074-1081.\n",
      "\n",
      "[14]   Wang F, Wei XL, Wang FH, Xu N, Shen L, Dai GH, Yuan XL, Chen Y, Yang SJ, Shi JH, Hu XC, Lin XY, Zhang QY, JF Feng, Y Ba, YP Liu, W Li, YQ Shu, Y Jiang, Q Li, JW Wang, H Wu, H Feng, S Yao, RH Xu#. Safety, efficacy and tumor mutational burden as a biomarker of overall survival benefit in chemo-refractory gastric cancer treated with toripalimab, a PD1 antibody in phase Ib/II clinical trial NCT02915432. Ann Oncol. 2019.\n",
      "\n",
      "[15]  Luo H, Zhao Q, Wei W, Zheng L, Yi S, Li G, Wang W, Sheng H, Pu H, Mo H, Zuo Z, Liu Z, Li C, Xie C, Zeng Z, Li W, Hao X, Liu Y, Cao S, Liu W, Gibson S, Zhang K, Xu G, Xu RH#. Circulating tumor DNA methylation profiles enable early diagnosis, prognosis prediction, and screening for colorectal cancer. Sci Transl Med. 2020 Jan 1;12(524).\n",
      "\n",
      "[16]   Li T, Hu PS, Zuo Z, Lin JF, Li X, Wu QN, Chen ZH, Zeng ZL, Wang F, Zheng J, Chen D, Li B, Kang TB, Dan Xie, Dongxin Lin, Huai-Qiang Ju, Rui-Hua Xu#. METTL3 facilitates tumor progression via an m(6)A-IGF2BP2-dependent mechanism in colorectal carcinoma. Mol Cancer. 2019; 18: 112.\n",
      "\n",
      "[17] Yun Wang, Jia-Huan Lu, Qi-Nian Wu, Ying Jin, De-Shen Wang, Yan-Xing Chen, Jia Liu, Xiao-Jing Luo, Qi Meng, Heng-Ying Pu, Ying-Nan Wang, Pei-Shan Hu, Ze-Xian Liu, Zhao-Lei Zeng, Qi Zhao, Rong Deng, Xiao-Feng Zhu, Huai-Qiang Ju, Rui-Hua Xu#. LncRNA LINRIS stabilizes IGF2BP2 and promotes the aerobic glycolysis in colorectal cancer. Molecular Cancer. 2019 Dec 2.\n",
      "\n",
      "[18]   Jin Y, Chen DL, Wang F, Yang CP, Chen XX, You JQ, Huang JS, Shao Y, Zhu DQ, Ouyang YM, Luo HY, Wang ZQ, Wang FH, Li YH, Xu RH#, Zhang DS. The predicting role of circulating tumor DNA landscape in gastric cancer patients treated with immune checkpoint inhibitors. Mol Cancer. 2020 Oct 30;19(1):154.\n",
      "\n",
      "[19]   Chen DL, Wang ZQ, Zeng ZL, Wu WJ, Zhang DS, Luo HY, Wang F, Qiu MZ, Wang DS, Ren C, Wang FH, Chiao LJ, Pelicano H, Huang P, Li YH and Xu RH#. Identification of microRNA-214 as a negative regulator of colorectal cancer liver metastasis by way of regulation of fibroblast growth factor receptor 1 expression. Hepatology 2014; 60: 598-609.\n",
      "\n",
      "[20]   Ju HQ, Li H, Tian T, Lu YX, Bai L, Chen LZ, Sheng H, Mo HY, Zeng JB, Deng W, Chiao PJ and Xu RH#. Melatonin overcomes gemcitabine resistance in pancreatic ductal adenocarcinoma by abrogating nuclear factor-kappaB activation. Journal of Pineal Research 2016; 60: 27-38.\n",
      "\n",
      "[21]   Ju HQ, Lin JF, Tian T, Xie D, Xu RH#. NADPH homeostasis in cancer: functions, mechanisms and therapeutic implications. Signal Transduct Tar. 2020 Oct 7;5(1):231.\n",
      "\n",
      "[22]  Hu PS, Li T, Lin JF, Qiu MZ, Wang DS, Liu ZX, Chen ZH, Yang LP, Zhang XL, Zhao Q, Chen YX, Lu YX, Wu QN, Pu HY, Zeng ZL, Xie D, Ju HQ, Luo HY, Xu RH#. VDR-SOX2 signaling promotes colorectal cancer stemness and malignancy in an acidic microenvironment. Signal Transduct Tar. 2020 Sep 9;5(1):183.\n",
      "\n",
      "[23]   Ju HQ, Ying H, Tian T, Ling J, Fu J, Lu Y, Wu M, Yang L, Achreja A, Chen G, Zhuang Z, Wang H, Nagrath D, Yao J, Hung MC, DePinho RA, Huang P, Xu RH# and Chiao PJ. Mutant Kras- and p16-regulated NOX4 activation overcomes metabolic checkpoints in development of pancreatic ductal adenocarcinoma. Nat Commun 2017; 8: 14437.\n",
      "\n",
      "[24]   Liu J, Liu ZX, Wu QN, Lu YX, Wong CW, Miao L, Wang Y, Wang Z, Jin Y, He MM, Ren C, Wang DS, Chen DL, Pu HY, Feng L, Li B, Xie D, Zeng MS, Huang P, Lin A, Lin D, Xu RH#, Ju HQ. Long noncoding RNA AGPG regulates PFKFB3-mediated tumor glycolytic reprogramming. Nat Commun. 2020 Mar 20;11(1):1507.\n",
      "\n",
      "[25]   Ju HQ, Lu YX, Chen DL, Zuo ZX, Liu ZX, Wu QN, Mo HY, Wang ZX, Wang DS, Pu HY, Zeng ZL, Li B, Xie D, Huang P, Hung MC, Chiao PJ and Xu RH#. Modulation of Redox Homeostasis by Inhibition of MTHFD2 in Colorectal Cancer: Mechanisms and Therapeutic Implications. J Natl Cancer Inst 2018\n",
      "\n",
      "[26] Yu K, Zhang Q, Liu Z, Zhao Q, Zhang X, Wang Y, Wang ZX, Jin Y, Li X, Liu ZX and Xu RH#. qPhos: a database of protein phosphorylation dynamics in humans. Nucleic Acids Res 2018\n",
      "\n",
      "[27] Rui-Hua Xu*, Jin Li, Yuxian Bai, Jianming Xu, Tianshu Liu, Lin Shen, Liwei Wang, Hongming Pan, Junning Cao, Dongsheng Zhang, Songhua Fan, Ye Hua & Weiguo Su. Safety and efficacy of fruquintinib in patients with previously treated metastatic colorectal cancer: a phase Ib study and a randomized double-blind phase II study. J Hematol Oncol. (2017) 10:22.\n",
      "\n",
      "[28] Gong Chen, Junjie Peng, Qian Xiao, Hao-Xiang Wu, Xiaojun Wu, Fulong Wang, Liren Li, Peirong Ding, Qi Zhao, Yaqi Li, Da Wang, Yang Shao, Hua Bao, Zhizhong Pan, Ke-Feng Ding, Sanjun Cai, Feng Wang, Rui-Hua Xu#. Postoperative circulating tumor DNA as markers of recurrence risk in stages II to III colorectal cancer. Journal of Hematology & Oncology. 2021 May 17;14(1):80.\n",
      "\n",
      "[29] Zeng ZL, Luo HY, Yang J, Wu WJ, Chen DL, Huang P and Xu RH#. Overexpression of the circadian clock gene Bmal1 increases sensitivity to oxaliplatin in colorectal cancer. Clinical Cancer Research 2014; 20: 1042-1052.\n",
      "\n",
      "[30] Huiyan Luo, Wei Wei, Ziyi Ye, Jiabo Zheng, Rui-hua Xu#. Liquid Biopsy of Methylation Biomarkers in Cell-Free DNA. Trends in Molecular Medicine. 23 Jan 2021.\n",
      "\n",
      "    ---------\n",
      "\n",
      "2023-06-14 22:17:45,296 - common.py - [line]:35 - INFO - real_query:\n",
      "    Notice: If doctor or hospital not in the context, skip this one 假如你是数据工程师，请把如下个人信息按照JSON的格式整理给我：（参考字段：行医，门诊时间，综合评价，资质认证状态，基本信息，简介，姓名，医院/机构，专长，职务，职称，学术兼职，地区，邮箱，手机，昕康ID/XK_ID，履历，教育经历，工作经历，研究，研究方向/临床研究，课题/基金，发表，发表文章，出版著作，专利和软著，执笔共识，成就，荣誉获奖）Return only the translation and nothing else:\n",
      "\n",
      "    query:\n",
      "    请根据以下context，回答：徐瑞华的clinical trial有哪些，列出NCT编号\n",
      "    reply in 简体中文\n",
      "    ---------context\n",
      "    \n",
      "[\n",
      "  {\n",
      "    \"_id\": \"648019f5778538384fd02da2\",\n",
      "    \"avatar\": null,\n",
      "    \"name\": \"Ruihua Xu\",\n",
      "    \"hospital\": \"Sun Yat-sen University\",\n",
      "    \"title\": \" MD\",\n",
      "    \"position\": null,\n",
      "    \"contact\": \"xuruihua@sysucc.org.cn\",\n",
      "    \"phone\": \"86-20-87343333\",\n",
      "    \"expertise\": \"Colorectal Carcinoma, pMMR, Microsatellite-stable\",\n",
      "    \"brief_intro\": \"A Study of Sintilimab and Chidamide in Combination With or Without IBI305 in Standard Treatment Failure of Advanced or Metastatic pMMR/MSS Colorectal Carcinoma\",\n",
      "    \"work_exp\": null,\n",
      "    \"edu_exp\": null,\n",
      "    \"consulting\": null,\n",
      "    \"publications\": null,\n",
      "    \"clinical_res\": null,\n",
      "    \"awards\": null\n",
      "  },\n",
      "  {\n",
      "    \"_id\": \"64803f25f24b55a336ba235d\",\n",
      "    \"avatar\": null,\n",
      "    \"name\": \"ruihua Xu\",\n",
      "    \"hospital\": \"Peking University\",\n",
      "    \"title\": \"M.D., Ph.D.\",\n",
      "    \"position\": null,\n",
      "    \"contact\": \"xurh@mail.sysu.edu.cn\",\n",
      "    \"phone\": \"13922206676\",\n",
      "    \"expertise\": \"nimotuzumab colorectal cancer chemotherapy\",\n",
      "    \"brief_intro\": null,\n",
      "    \"work_exp\": null,\n",
      "    \"edu_exp\": null,\n",
      "    \"consulting\": null,\n",
      "    \"publications\": null,\n",
      "    \"clinical_res\": \"Study of Nimotuzumab to Treat Colorectal Cancer\",\n",
      "    \"awards\": null\n",
      "  },\n",
      "  {\n",
      "    \"_id\": \"6480ea13f24b55a336bec613\",\n",
      "    \"avatar\": null,\n",
      "    \"name\": \"Ruihua Xu\",\n",
      "    \"hospital\": \"Sun Yat-sen University\",\n",
      "    \"title\": \"MD\",\n",
      "    \"position\": null,\n",
      "    \"contact\": \"xurh@susycc.org.cn\",\n",
      "    \"phone\": \"+862087343795\",\n",
      "    \"expertise\": \"Colorectal Cancer,Microsatellite Stable,Chidamide,Sintilimab,PD-1,Bevacizumab\",\n",
      "    \"brief_intro\": null,\n",
      "    \"work_exp\": null,\n",
      "    \"edu_exp\": null,\n",
      "    \"consulting\": null,\n",
      "    \"publications\": null,\n",
      "    \"clinical_res\": \"Comparing Chidamide+Sintilimab+Bev With Standard Second-line FOLFIRI+Bev in Advanced MSS/pMMR mCRC\",\n",
      "    \"awards\": null\n",
      "  }\n",
      "]\n",
      "[\n",
      "  {\n",
      "    \"NCT_No\": \"NCT05830045\",\n",
      "    First_Submitted_Date\": \"April 4, 2023\",\n",
      "    First_Posted_Date\": \"April 26, 2023\",\n",
      "    Last_Update_Posted_Date\": \"April 26, 2023\",\n",
      "    Estimated__Study_Start_Date\": \"April 20, 2023\",\n",
      "    Estimated_Primary_Completion_Date\": \"April 30, 2025   (Final data collection date for primary outcome measure)\",\n",
      "    Current_Primary_Outcome_Measures\": \"[List]\",\n",
      "    Original_Primary_Outcome_Measures\": \"Same as current\",\n",
      "    Change_History\": \"No Changes Posted\",\n",
      "    Current_Secondary_Outcome_Measures\": \"Not Provided\",\n",
      "    Original_Secondary_Outcome_Measures\": \"Not Provided\",\n",
      "    Current_Other_Pre-specified_Outcome_Measures\": \"Not Provided\",\n",
      "    Original_Other_Pre-specified_Outcome_Measures\": \"Not Provided\",\n",
      "    \"Brief_Title\": \"A Phase I Study of QLP2117 in Subjects With Advanced Solid Tumors\",\n",
      "    \"Official_Title\": \"A Study Evaluates the Safety, Pharmacokinetics, Immunogenicity and Efficacy of QLP2117 in Advanced Solid Tumor Patients\",\n",
      "    \"Brief_Summary\": \"This is the first in human study of QLP2117. To evaluate the Safety, Pharmacokinetics, Immunogenicity and Efficacy of QLP2117 in patients with advanced solid tumors.\",\n",
      "    \"Detailed_Description\": \"Not Provided\",\n",
      "    \"Study_Type\": \"Interventional\",\n",
      "    \"Study_Phase\": \"Phase 1\",\n",
      "    \"Study_Design\": \"Allocation: Non-Randomized\n",
      "Intervention Model: Sequential Assignment\n",
      "Masking: None (Open Label)\n",
      "Primary Purpose: Treatment\",\n",
      "    \"Condition\": \"Advanced Solid Tumors\",\n",
      "    \"Intervention\": \"Drug: QLP2117\n",
      "Specified dose on specified days\",\n",
      "    \"Study_Arms\": \"[List]\",\n",
      "    \"Publications_*\": \"Not Provided\",\n",
      "    \"Recruitment_Status\": \"Not yet recruiting\",\n",
      "    \"Estimated_Enrollment\": \"180\",\n",
      "    \"Original_Estimated_Enrollment\": \"Same as current\",\n",
      "    \"Estimated_Study_Completion_Date\": \"December 31, 2025\",\n",
      "    \"Estimated_Primary_Completion_Date\": \"April 30, 2025   (Final data collection date for primary outcome measure)\",\n",
      "    \"Eligibility_Criteria\": \"[List]\",\n",
      "    \"Sex/Gender\": \"Sexes Eligible for Study:\n",
      "   All\",\n",
      "    \"Ages\": \"18 Years and older   (Adult, Older Adult)\",\n",
      "    \"Accepts_Healthy_Volunteers\": \"No\",\n",
      "    \"Contacts\": \"Contact: Zhang Meijiang, PhD\n",
      "   8615210162105\n",
      "   meijiang.zhang@qilu-pharma.com\",\n",
      "    \"Listed_Location_Countries\": \"Not Provided\",\n",
      "    \"Removed_Location_Countries\": null,\n",
      "    \"NCT_Number\": \"NCT05830045\",\n",
      "    \"Other_Study_ID_Numbers\": \"QLP2117-101\",\n",
      "    \"Has_Data_Monitoring_Committee\": \"No\",\n",
      "    \"U.S._FDA-regulated_Product\": \"[List]\",\n",
      "    \"IPD_Sharing_Statement\": \"Plan to Share IPD:\n",
      "   No\",\n",
      "    \"Current_Responsible_Party\": \"Qilu Pharmaceutical Co., Ltd.\",\n",
      "    \"Original_Responsible_Party\": \"Same as current\",\n",
      "    \"Current_Study_Sponsor\": \"Qilu Pharmaceutical Co., Ltd.\",\n",
      "    \"Original_Study_Sponsor\": \"Same as current\",\n",
      "    \"Collaborators\": \"Not Provided\",\n",
      "    \"Investigators\": \"Principal Investigator:\n",
      "   Xu Ruihua, PhD\n",
      "   Sun Yat-sen University\",\n",
      "    \"PRS_Account\": \"Qilu Pharmaceutical Co., Ltd.\",\n",
      "    \"Verification_Date\": \"April 2023\"\n",
      "  },\n",
      "  {\n",
      "    \"NCT_No\": \"NCT05727839\",\n",
      "    First_Submitted_Date\": \"February 1, 2023\",\n",
      "    First_Posted_Date\": \"February 14, 2023\",\n",
      "    Last_Update_Posted_Date\": \"March 20, 2023\",\n",
      "    Estimated__Study_Start_Date\": \"February 24, 2023\",\n",
      "    Estimated_Primary_Completion_Date\": \"July 24, 2025   (Final data collection date for primary outcome measure)\",\n",
      "    Current_Primary_Outcome_Measures\": \"[List]\",\n",
      "    Original_Primary_Outcome_Measures\": \"[List]\",\n",
      "    Change_History\": \"Complete list of historical versions of study NCT05727839 on ClinicalTrials.gov Archive Site\",\n",
      "    Current_Secondary_Outcome_Measures\": \"[List]\",\n",
      "    Original_Secondary_Outcome_Measures\": \"[List]\",\n",
      "    Current_Other_Pre-specified_Outcome_Measures\": \"Not Provided\",\n",
      "    Original_Other_Pre-specified_Outcome_Measures\": \"Not Provided\",\n",
      "    \"Brief_Title\": \"Study to Evaluate JCXH-211 as Monotherapy in Patients With Malignant Solid Tumors\",\n",
      "    \"Official_Title\": \"A Phase 1 Open-Label Study to Evaluate the Safety, Tolerability and Efficacy of JCXH-211 Intratumoral Injection in Patients With Malignant Solid Tumors\",\n",
      "    \"Brief_Summary\": \": A Phase 1 Open-Label Study to Evaluate the Safety, Tolerability and Efficacy of JCXH-211 Intratumoral Injection in Patients with Malignant Solid Tumors\",\n",
      "    \"Detailed_Description\": \"The main purpose of this study is to find out how safe and tolerable the study drug, JCXH-211, is and also how well it works in people with malignant solid tumors. The study drug JCXH-211, is an immunotherapy drug. This means that it aims to work by boosting immune system's response to tumors, to help fight against the growth of the cancer cells. The study has 2 main phases: Phase\n",
      "  1a and Phase 1b. Phase 1a has 2 stages, skin/subcutaneous lesions stage, deep (visceral) lesions stage. Phase 1b will not start until all the data collected in Phase 1a has been completed and reviewed to check that it is safe and well tolerated.\",\n",
      "    \"Study_Type\": \"Interventional\",\n",
      "    \"Study_Phase\": \"Phase 1\",\n",
      "    \"Study_Design\": \"Allocation: Non-Randomized\n",
      "Intervention Model: Single Group Assignment\n",
      "Masking: None (Open Label)\n",
      "Primary Purpose: Treatment\",\n",
      "    \"Condition\": \"[List]\",\n",
      "    \"Intervention\": \"Drug: JCXH-211 Injection\n",
      "JCXH-211 administered once every 28 days\n",
      "Other Name: Intratumoral injection\",\n",
      "    \"Study_Arms\": \"[List]\",\n",
      "    \"Publications_*\": \"Not Provided\",\n",
      "    \"Recruitment_Status\": \"Recruiting\",\n",
      "    \"Estimated_Enrollment\": \"156\",\n",
      "    \"Original_Estimated_Enrollment\": \"Same as current\",\n",
      "    \"Estimated_Study_Completion_Date\": \"August 24, 2025\",\n",
      "    \"Estimated_Primary_Completion_Date\": \"July 24, 2025   (Final data collection date for primary outcome measure)\",\n",
      "    \"Eligibility_Criteria\": \"[List]\",\n",
      "    \"Sex/Gender\": \"Sexes Eligible for Study:\n",
      "   All\",\n",
      "    \"Ages\": \"18 Years to 75 Years   (Adult, Older Adult)\",\n",
      "    \"Accepts_Healthy_Volunteers\": \"No\",\n",
      "    \"Contacts\": \"Contact: Qi Wang\n",
      "   +8613381113913\n",
      "   qi.wang@immorna.com\",\n",
      "    \"Listed_Location_Countries\": \"China\",\n",
      "    \"Removed_Location_Countries\": null,\n",
      "    \"NCT_Number\": \"NCT05727839\",\n",
      "    \"Other_Study_ID_Numbers\": \"JCXH-211-003\",\n",
      "    \"Has_Data_Monitoring_Committee\": \"Not Provided\",\n",
      "    \"U.S._FDA-regulated_Product\": \"[List]\",\n",
      "    \"IPD_Sharing_Statement\": \"Not Provided\",\n",
      "    \"Current_Responsible_Party\": \"Immorna Biotherapeutics, Inc.\",\n",
      "    \"Original_Responsible_Party\": \"Same as current\",\n",
      "    \"Current_Study_Sponsor\": \"Immorna Biotherapeutics, Inc.\",\n",
      "    \"Original_Study_Sponsor\": \"Same as current\",\n",
      "    \"Collaborators\": \"Not Provided\",\n",
      "    \"Investigators\": \"Principal Investigator:\n",
      "   Xu ruihua, President\n",
      "   Sun Yat-sen University\",\n",
      "    \"PRS_Account\": \"Immorna Biotherapeutics, Inc.\",\n",
      "    \"Verification_Date\": \"March 2023\"\n",
      "  },\n",
      "  {\n",
      "    \"NCT_No\": \"NCT03544905\",\n",
      "    First_Submitted_Date\": \"May 22, 2018\",\n",
      "    First_Posted_Date\": \"June 4, 2018\",\n",
      "    Last_Update_Posted_Date\": \"January 6, 2023\",\n",
      "    Estimated__Study_Start_Date\": \"July 5, 2018\",\n",
      "    Estimated_Primary_Completion_Date\": \"June 30, 2023   (Final data collection date for primary outcome measure)\",\n",
      "    Current_Primary_Outcome_Measures\": \"MTD(Max tolerance does) [ Time Frame: 35 days ]To evaluate the MTD in patients with advanced solid tumor\",\n",
      "    Original_Primary_Outcome_Measures\": \"Same as current\",\n",
      "    Change_History\": \"Complete list of historical versions of study NCT03544905 on ClinicalTrials.gov Archive Site\",\n",
      "    Current_Secondary_Outcome_Measures\": \"Not Provided\",\n",
      "    Original_Secondary_Outcome_Measures\": \"Not Provided\",\n",
      "    Current_Other_Pre-specified_Outcome_Measures\": \"Not Provided\",\n",
      "    Original_Other_Pre-specified_Outcome_Measures\": \"Not Provided\",\n",
      "    \"Brief_Title\": \"Study to Evaluate the Safety, Tolerate, Pharmacokinetics and Preliminary Efficacy of CYH33\",\n",
      "    \"Official_Title\": \"A Multi-center, Open-label, Single Arm, Dose Escalation and Dose Extension Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of CYH33 in Advanced Solid Tumors Patients.\",\n",
      "    \"Brief_Summary\": \"This study is a Multi-center, Open-label, single arm, Dose Escalation and Dose Extension Phase 1 Study to Evaluate the Safety , Tolerability, Pharmacokinetics and Preliminary Efficacy of CYH33 in Advanced Solid Tumors Patients.\",\n",
      "    \"Detailed_Description\": \"This study includes Phase Ia and Phase Ib.\n",
      "  In the dose climbing part of phase Ia, the safety, tolerance and pharmacokinetics characteristics of CYH33 in patients with advanced solid tumors who failed to receive standard treatment, did not tolerate or did not have standard treatment at present will be observed to determine MTD; Before determining MTD, select safe and highly reliable and effective dose levels for simultaneous expansion. Phase Ia dose expansion includes patients with advanced solid tumors who have failed to undergo standard treatment, who are intolerant of PIK3CA gene mutation, or who do not have standard treatment at present, to further evaluate safety, tolerance and initial efficacy.\n",
      "  In Phase Ib, the safety and preliminary efficacy of CYH33 on patients with advanced breast cancer, ovarian cancer, endometrial cancer, cervical cancer, head and neck squamous cell carcinoma, esophageal and gastroesophageal junction squamous cell carcinoma, ovarian clear cell carcinoma and other solid tumors with PIK3CA gene mutation who have failed, are intolerant or do not have standard treatment at present will be evaluated.\",\n",
      "    \"Study_Type\": \"Interventional\",\n",
      "    \"Study_Phase\": \"Phase 1\",\n",
      "    \"Study_Design\": \"Allocation: N/A\n",
      "Intervention Model: Single Group Assignment\n",
      "Masking: None (Open Label)\n",
      "Primary Purpose: Treatment\",\n",
      "    \"Condition\": \"Advanced Solid Tumors\",\n",
      "    \"Intervention\": \"Drug: CYH33 for tablet\n",
      "1mg; 5mg; 10mg; 20mg; 30mg; 50mg; 75mg; 100mg; 130mg; 160mg; 200mg; 240mgBID or QD(Decided by SMC accroding to the safty and PK data)\",\n",
      "    \"Study_Arms\": \"Experimental: Dose escalation study of CYH33\n",
      "To determine the maximum tolerated dose (MTD) of CYH33\n",
      "Intervention: Drug: CYH33 for tablet\",\n",
      "    \"Publications_*\": \"Not Provided\",\n",
      "    \"Recruitment_Status\": \"Recruiting\",\n",
      "    \"Estimated_Enrollment\": \"100\",\n",
      "    \"Original_Estimated_Enrollment\": \"Same as current\",\n",
      "    \"Estimated_Study_Completion_Date\": \"March 31, 2024\",\n",
      "    \"Estimated_Primary_Completion_Date\": \"June 30, 2023   (Final data collection date for primary outcome measure)\",\n",
      "    \"Eligibility_Criteria\": \"[List]\",\n",
      "    \"Sex/Gender\": \"Sexes Eligible for Study:\n",
      "   All\",\n",
      "    \"Ages\": \"18 Years and older   (Adult, Older Adult)\",\n",
      "    \"Accepts_Healthy_Volunteers\": \"No\",\n",
      "    \"Contacts\": \"Contact: Ruihua Xu, M.D\n",
      "   86-20-87343804\n",
      "   ruihxu@163.com\",\n",
      "    \"Listed_Location_Countries\": \"China\",\n",
      "    \"Removed_Location_Countries\": null,\n",
      "    \"NCT_Number\": \"NCT03544905\",\n",
      "    \"Other_Study_ID_Numbers\": \"CYH33-101\",\n",
      "    \"Has_Data_Monitoring_Committee\": \"Yes\",\n",
      "    \"U.S._FDA-regulated_Product\": \"[List]\",\n",
      "    \"IPD_Sharing_Statement\": \"Not Provided\",\n",
      "    \"Current_Responsible_Party\": \"Haihe Biopharma Co., Ltd.\",\n",
      "    \"Original_Responsible_Party\": \"Same as current\",\n",
      "    \"Current_Study_Sponsor\": \"Haihe Biopharma Co., Ltd.\",\n",
      "    \"Original_Study_Sponsor\": \"Same as current\",\n",
      "    \"Collaborators\": \"Not Provided\",\n",
      "    \"Investigators\": \"Principal Investigator:\n",
      "   Ruihua Xu, M.D\n",
      "   Sun Yat-sen University\",\n",
      "    \"PRS_Account\": \"Haihe Biopharma Co., Ltd.\",\n",
      "    \"Verification_Date\": \"January 2023\"\n",
      "  },\n",
      "  {\n",
      "    \"NCT_No\": \"NCT01198392\",\n",
      "    First_Submitted_Date\": \"September 1, 2010\",\n",
      "    First_Posted_Date\": \"September 10, 2010\",\n",
      "    Last_Update_Posted_Date\": \"July 25, 2011\",\n",
      "    Estimated__Study_Start_Date\": \"September 2008\",\n",
      "    Estimated_Primary_Completion_Date\": \"December 2011   (Final data collection date for primary outcome measure)\",\n",
      "    Current_Primary_Outcome_Measures\": \"Time to progression [ Time Frame: The time from randomization until objective tumor progression or death ]\",\n",
      "    Original_Primary_Outcome_Measures\": \"Same as current\",\n",
      "    Change_History\": \"Complete list of historical versions of study NCT01198392 on ClinicalTrials.gov Archive Site\",\n",
      "    Current_Secondary_Outcome_Measures\": \"Response rate [ Time Frame: 2 months ]\",\n",
      "    Original_Secondary_Outcome_Measures\": \"Same as current\",\n",
      "    Current_Other_Pre-specified_Outcome_Measures\": \"Not Provided\",\n",
      "    Original_Other_Pre-specified_Outcome_Measures\": \"Not Provided\",\n",
      "    \"Brief_Title\": \"Trial of S-1 Plus Cisplatin in Gastric Cancer\",\n",
      "    \"Official_Title\": \"A Clinical Trial of S-1 Plus Cisplatin Versus 5-FU Plus Cisplatin in Patients With Unresectable or Advanced Gastric Cancer\",\n",
      "    \"Brief_Summary\": \"The purpose of this study is to evaluate the effectiveness and safety of s-1 plus cisplatin versus 5-FU plus cisplatin as first-line therapy in the treatment of patients with advanced gastric cancer.\",\n",
      "    \"Detailed_Description\": \"This is a randomized, controlled, open-label,multicenter study. Patients are randomized to one of two treatment arms : S-1 plus cisplatin and 5-FU plus cisplatin.\",\n",
      "    \"Study_Type\": \"Interventional\",\n",
      "    \"Study_Phase\": \"Phase 3\",\n",
      "    \"Study_Design\": \"Allocation: Randomized\n",
      "Intervention Model: Parallel Assignment\n",
      "Masking: None (Open Label)\n",
      "Primary Purpose: Treatment\",\n",
      "    \"Condition\": \"Gastric Cancer\",\n",
      "    \"Intervention\": \"[List]\",\n",
      "    \"Study_Arms\": \"[List]\",\n",
      "    \"Publications_*\": \"Li YH, Qiu MZ, Xu JM, Sun GP, Lu HS, Liu YP, Zhong MZ, Zhang HL, Yu SY, Li W, Hu XH, Wang JJ, Cheng Y, Zhou JT, Guo ZQ, Guan ZG, Xu RH. S-1 plus cisplatin versus fluorouracil plus cisplatin in advanced gastric or gastro-esophageal junction adenocarcinoma patients: a pilot study. Oncotarget. 2015 Oct 27;6(33):35107-15. doi: 10.18632/oncotarget.5959.\",\n",
      "    \"Recruitment_Status\": \"Unknown status\",\n",
      "    \"Estimated_Enrollment\": \"270\",\n",
      "    \"Original_Estimated_Enrollment\": \"Same as current\",\n",
      "    \"Estimated_Study_Completion_Date\": \"December 2011\",\n",
      "    \"Estimated_Primary_Completion_Date\": \"December 2011   (Final data collection date for primary outcome measure)\",\n",
      "    \"Eligibility_Criteria\": \"[List]\",\n",
      "    \"Sex/Gender\": \"Sexes Eligible for Study:\n",
      "   All\",\n",
      "    \"Ages\": \"18 Years to 75 Years   (Adult, Older Adult)\",\n",
      "    \"Accepts_Healthy_Volunteers\": \"No\",\n",
      "    \"Contacts\": \"Contact information is only displayed when the study is recruiting subjects\",\n",
      "    \"Listed_Location_Countries\": \"China\",\n",
      "    \"Removed_Location_Countries\": null,\n",
      "    \"NCT_Number\": \"NCT01198392\",\n",
      "    \"Other_Study_ID_Numbers\": \"2005L02859\",\n",
      "    \"Has_Data_Monitoring_Committee\": \"Yes\",\n",
      "    \"U.S._FDA-regulated_Product\": \"Not Provided\",\n",
      "    \"IPD_Sharing_Statement\": \"Not Provided\",\n",
      "    \"Current_Responsible_Party\": \"Zhongzhen Guan ,Ruihua Xu, Sun Yat-sen University Cancer Center\",\n",
      "    \"Original_Responsible_Party\": \"Same as current\",\n",
      "    \"Current_Study_Sponsor\": \"Sun Yat-sen University\",\n",
      "    \"Original_Study_Sponsor\": \"Same as current\",\n",
      "    \"Collaborators\": \"Not Provided\",\n",
      "    \"Investigators\": \"Principal Investigator:\n",
      "   RUIHUA XU, Professor\n",
      "   Sun Yat-sen University\",\n",
      "    \"PRS_Account\": \"Sun Yat-sen University\",\n",
      "    \"Verification_Date\": \"August 2008\"\n",
      "  }\n",
      "]\n",
      "\n",
      "徐瑞华，医学博士，中山大学肿瘤防治中心主任、医院院长、研究所所长，华南恶性肿瘤防治全国重点实验室主任，教授，博士生导师。\n",
      "\n",
      "中国医学科学院学部委员，中国临床肿瘤学会理事长，中国抗癌协会副理事长，中国抗癌协会靶向治疗专委会首届主任委员，中国抗癌协会化疗专委会候任主任委员，中国临床肿瘤学会肠癌专委会主任委员，《Cancer Communications》主编，研究生教材《肿瘤学》主编，本科生教材《临床肿瘤学》主编。\n",
      "\n",
      "从事肿瘤内科临床及科研工作30余年，取得突破性成果：\n",
      "\n",
      "第一，实现了肠癌诊治理论和实践的系统创新，使我国肠癌早诊及精准治疗均处于国际先进水平。创新了肠癌早诊及疗效预测的新技术，并已转化为临床应用；建立了晚期肠癌治疗新体系，创建了高效低毒的维持方案和亚洲方案，成为国际治疗新标准，晚期肠癌生存率与国际顶尖的安德森癌症中心达相同水平。\n",
      "\n",
      "第二，创新了消化肿瘤免疫治疗体系，引领国际消化肿瘤免疫治疗发展。\n",
      "\n",
      "通过鉴定TMB、POLE/POLD突变等标志物，精准筛选免疫治疗敏感亚型，大幅提高PD-1抗体疗效；首创了食管癌中国免疫联合方案，取得全球最高有效率72%，已成为食管癌治疗应用最广泛的方案；建立了食管癌EGIC分型，可以指导精准免疫治疗策略，引领该领域的发展；揭示了免疫逃逸新机制并推动了药物的开发：发现甲硫氨酸限制饮食可抑制免疫检查点分子PDL1及VISTA的表达，增强抗肿瘤免疫及抗PD1的治疗效果；鉴定出免疫治疗增效肠道活性菌RX-af01，成果已转化。\n",
      "\n",
      "以通讯或第一作者在国际顶级期刊JAMA、Nature Materials、Nature Medicine、Lancet Oncology等发表SCI论文200余篇，入选科睿唯安（Clarivate Analytics）全球高被引科学家，连续入选中国高被引学者榜单。以第一完成人获国家科技进步二等奖2项及省部级一等奖6项、吴阶平医药创新奖、谈家桢临床医学奖及CSCO年度成就奖。入选国家百千万人才工程、全国先进工作者、南粤百杰人才培养工程、国家卫生计生突出贡献中青年专家等人才项目。\n",
      "\n",
      "Representative paper: （*：第一作者，#：通讯作者）\n",
      "\n",
      "[1]     Luo H, Lu J, Bai Y, Mao T, Wang J, Fan Q, Zhang Y, Zhao K, Chen Z, Gao S, Li J, Fu Z, Gu K, Liu Z, Wu L, Zhang X, Feng J, Niu Z, Ba Y, Zhang H, Liu Y, Zhang L, Min X, Huang J, Cheng Y, Wang D, Shen Y, Yang Q, Zou J, Xu RH# ESCORT-1st Investigators.  Effect of Camrelizumab vs Placebo Added to Chemotherapy on Survival and Progression-Free Survival in Patients With Advanced or Metastatic Esophageal Squamous Cell Carcinoma: The ESCORT-1st Randomized Clinical Trial. JAMA. 2021 Sep 14;326(10):916-925.\n",
      "\n",
      "[2]     Xu RH*#, Wei W, Krawczyk M, Wang W, Luo H, Flagg K, Yi S, Shi W, Quan Q, Li K, Zheng L, Zhang H, Caughey BA, Zhao Q, Hou J, Zhang R, Xu Y, Cai H, Li G, Hou R, Zhong Z, Lin D, Fu X, Zhu J, Duan Y, Yu M, Ying B, Zhang W, Wang J, Zhang E, Zhang C, Li O, Guo R, Carter H, Zhu JK, Hao X and Zhang K. Circulating tumour DNA methylation markers for diagnosis and prognosis of hepatocellular carcinoma. Nat Mater 2017; 16: 1155-1161.\n",
      "\n",
      "[3]     Xu RH*#, Muro K, Morita S, Iwasa S, Han SW, Wang W, Kotaka M, Nakamura M, Ahn JB, Deng YH, Kato T, Cho SH, Ba Y, Matsuoka H, Lee KW, Zhang T, Yamada Y, Sakamoto J, Park YS and Kim TW. Modified XELIRI (capecitabine plus irinotecan) versus FOLFIRI (leucovorin, fluorouracil, and irinotecan), both either with or without bevacizumab, as second-line therapy for metastatic colorectal cancer (AXEPT): a multicentre, open-label, randomised, non-inferiority, phase 3 trial. Lancet Oncol 2018; 19: 660-671.\n",
      "\n",
      "[4]     Li J, Qin S, Xu R*, Yau TC, Ma B, Pan H, Xu J, Bai Y, Chi Y, Wang L, Yeh KH, Bi F, Cheng Y, Le AT, Lin JK, Liu T, Ma D, Kappeler C, Kalmus J and Kim TW. Regorafenib plus best supportive care versus placebo plus best supportive care in Asian patients with previously treated metastatic colorectal cancer (CONCUR): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncology 2015; 16: 619-629.\n",
      "\n",
      "[5]     Luo H, Xu G, Li C, He L, Luo L, Wang Z, Jing B, Deng Y, Jin Y, Li Y, Li B, Tan W, He C, Seeruttun SR, Wu Q, Huang J, Huang DW, Chen B, Lin SB, Chen QM, Yuan CM, Chen HX, Pu HY, Zhou F, He Y, Xu RH#. Real-time artificial intelligence for detection of upper gastrointestinal cancer by endoscopy: a multicentre, case-control, diagnostic study. Lancet Oncol. 2019 Oct 4.\n",
      "\n",
      "[6]     Satoh T, Xu RH*, Chung HC, Sun GP, Doi T, Xu JM, Tsuji A, Omuro Y, Li J, Wang JW, Miwa H, Qin SK, Chung IJ, Yeh KH, Feng JF, Mukaiyama A, Kobayashi M, Ohtsu A and Bang YJ. Lapatinib plus paclitaxel versus paclitaxel alone in the second-line treatment of HER2-amplified advanced gastric cancer in Asian populations: TyTAN--a randomized, phase III study. Journal of Clinical Oncology 2014; 32: 2039-2049.\n",
      "\n",
      "[7]     Manish A. Shah, Rui-hua Xu*, Yung-Jue Bang, Paulo M. Hoff, Tianshu Liu, Luis A. Herr´aez-Baranda, Fan Xia,Amit Garg, Mona Shing, and Josep Tabernero. HELOISE: Phase IIIb Randomized Multicenter Study Comparing Standard-of-Care and Higher-Dose Trastuzumab Regimens Combined With Chemotherapy as First-Line Therapy in Patients With Human Epidermal Growth Factor Receptor 2–Positive Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma. Journal of Clinical Oncology 2017; 35: 2558-2567.\n",
      "\n",
      "[8]     Wang ZX, Cui C, Yao J, Zhang Y, Li M, Feng J, Yang S, Fan Y, Shi J, Zhang X, Shen L, Shu Y, Wang C, Dai T, Mao T, Chen L, Guo Z, Liu B, Pan H, Cang S, Jiang Y, Wang J, Ye M, Chen Z, Jiang D, Lin Q, Ren W, Wang J, Wu L, Xu Y, Miao Z, Sun M, Xie C, Liu Y, Wang Q, Zhao L, Li Q, Huang C, Jiang K, Yang K, Li D, Liu Y, Zhu Z, Chen R, Jia L, Li W, Liao W, Liu HX, Ma D, Ma J, Qin Y, Shi Z, Wei Q, Xiao K, Zhang Y, Zhang Y, Chen X, Dai G, He J, Li J, Li G, Liu Y, Liu Z, Yuan X, Zhang J, Fu Z, He Y, Ju F, Liu Z, Tang P, Wang T, Wang W, Zhang J, Luo X, Tang X, May R, Feng H, Yao S, Keegan P, Xu RH#, Wang F. Toripalimab plus chemotherapy in treatment-naïve, advanced esophageal squamous cell carcinoma (JUPITER-06): A multi-center phase 3 trial. Cancer Cell. 2022 Mar 14;40(3):277-288.\n",
      "\n",
      "[9]     Wang F, Zhao Q, Wang YN, Jin Y, He MM, Liu ZX, Xu RH#. Evaluation of POLE and POLD1 Mutations as Biomarkers for Immunotherapy Outcomes Across Multiple Cancer Types. JAMA Oncol. 2019.\n",
      "\n",
      "[10]   Wang F, Liu DB, Zhao Q, Chen G, Liu XM, Wang YN, Su H, Qin YR, He YF, Zou QF, Liu YH, Lin YE, Liu ZX, Bei JX and Xu RH#. The genomic landscape of small cell carcinoma of the esophagus. Cell Res 2018; 28: 771-774.\n",
      "\n",
      "[11]   Wang DS, Liu ZX, Lu YX, Bao H, Wu X, Zeng ZL, Liu Z, Zhao Q, He CY, Lu JH, Wang ZQ, Qiu MZ, Wang F, Wang FH, Li YH, Wang XN, Xie D, Jia WH, Shao YW and Xu RH#. Liquid biopsies to track trastuzumab resistance in metastatic HER2-positive gastric cancer. Gut 2018;\n",
      "\n",
      "[12]   Feng Wang, You-Sheng Huang, Hao-Xiang Wu, Zi-Xian Wang, Ying Jin, Yi-Chen Yao, Yan-Xing Chen, Qi Zhao, Shifu Chen, Ming-Ming He, Hui-Yan Luo, Miao-Zhen Qiu, De-Shen Wang, Feng-Hua Wang, Mingyan Xu, Yu-Hong Li, Rui-Hua Xu#. Genomic temporal heterogeneity of circulating tumour DNA in unresectable metastatic colorectal cancer under first-line treatment. Gut. 2022 Jul;71(7):1340-1349.\n",
      "\n",
      "[13]   Luo HY, Li YH, Wang W, Wang ZQ, Yuan X, Ma D, Wang FH, Zhang DS, Lin DR, Lin YC, Jia J, Hu XH, Peng JW and Xu RH#. Single-agent capecitabine as maintenance therapy after induction of XELOX (or FOLFOX) in first-line treatment of metastatic colorectal cancer: randomized clinical trial of efficacy and safety. Annals of Oncology 2016; 27: 1074-1081.\n",
      "\n",
      "[14]   Wang F, Wei XL, Wang FH, Xu N, Shen L, Dai GH, Yuan XL, Chen Y, Yang SJ, Shi JH, Hu XC, Lin XY, Zhang QY, JF Feng, Y Ba, YP Liu, W Li, YQ Shu, Y Jiang, Q Li, JW Wang, H Wu, H Feng, S Yao, RH Xu#. Safety, efficacy and tumor mutational burden as a biomarker of overall survival benefit in chemo-refractory gastric cancer treated with toripalimab, a PD1 antibody in phase Ib/II clinical trial NCT02915432. Ann Oncol. 2019.\n",
      "\n",
      "[15]  Luo H, Zhao Q, Wei W, Zheng L, Yi S, Li G, Wang W, Sheng H, Pu H, Mo H, Zuo Z, Liu Z, Li C, Xie C, Zeng Z, Li W, Hao X, Liu Y, Cao S, Liu W, Gibson S, Zhang K, Xu G, Xu RH#. Circulating tumor DNA methylation profiles enable early diagnosis, prognosis prediction, and screening for colorectal cancer. Sci Transl Med. 2020 Jan 1;12(524).\n",
      "\n",
      "[16]   Li T, Hu PS, Zuo Z, Lin JF, Li X, Wu QN, Chen ZH, Zeng ZL, Wang F, Zheng J, Chen D, Li B, Kang TB, Dan Xie, Dongxin Lin, Huai-Qiang Ju, Rui-Hua Xu#. METTL3 facilitates tumor progression via an m(6)A-IGF2BP2-dependent mechanism in colorectal carcinoma. Mol Cancer. 2019; 18: 112.\n",
      "\n",
      "[17] Yun Wang, Jia-Huan Lu, Qi-Nian Wu, Ying Jin, De-Shen Wang, Yan-Xing Chen, Jia Liu, Xiao-Jing Luo, Qi Meng, Heng-Ying Pu, Ying-Nan Wang, Pei-Shan Hu, Ze-Xian Liu, Zhao-Lei Zeng, Qi Zhao, Rong Deng, Xiao-Feng Zhu, Huai-Qiang Ju, Rui-Hua Xu#. LncRNA LINRIS stabilizes IGF2BP2 and promotes the aerobic glycolysis in colorectal cancer. Molecular Cancer. 2019 Dec 2.\n",
      "\n",
      "[18]   Jin Y, Chen DL, Wang F, Yang CP, Chen XX, You JQ, Huang JS, Shao Y, Zhu DQ, Ouyang YM, Luo HY, Wang ZQ, Wang FH, Li YH, Xu RH#, Zhang DS. The predicting role of circulating tumor DNA landscape in gastric cancer patients treated with immune checkpoint inhibitors. Mol Cancer. 2020 Oct 30;19(1):154.\n",
      "\n",
      "[19]   Chen DL, Wang ZQ, Zeng ZL, Wu WJ, Zhang DS, Luo HY, Wang F, Qiu MZ, Wang DS, Ren C, Wang FH, Chiao LJ, Pelicano H, Huang P, Li YH and Xu RH#. Identification of microRNA-214 as a negative regulator of colorectal cancer liver metastasis by way of regulation of fibroblast growth factor receptor 1 expression. Hepatology 2014; 60: 598-609.\n",
      "\n",
      "[20]   Ju HQ, Li H, Tian T, Lu YX, Bai L, Chen LZ, Sheng H, Mo HY, Zeng JB, Deng W, Chiao PJ and Xu RH#. Melatonin overcomes gemcitabine resistance in pancreatic ductal adenocarcinoma by abrogating nuclear factor-kappaB activation. Journal of Pineal Research 2016; 60: 27-38.\n",
      "\n",
      "[21]   Ju HQ, Lin JF, Tian T, Xie D, Xu RH#. NADPH homeostasis in cancer: functions, mechanisms and therapeutic implications. Signal Transduct Tar. 2020 Oct 7;5(1):231.\n",
      "\n",
      "[22]  Hu PS, Li T, Lin JF, Qiu MZ, Wang DS, Liu ZX, Chen ZH, Yang LP, Zhang XL, Zhao Q, Chen YX, Lu YX, Wu QN, Pu HY, Zeng ZL, Xie D, Ju HQ, Luo HY, Xu RH#. VDR-SOX2 signaling promotes colorectal cancer stemness and malignancy in an acidic microenvironment. Signal Transduct Tar. 2020 Sep 9;5(1):183.\n",
      "\n",
      "[23]   Ju HQ, Ying H, Tian T, Ling J, Fu J, Lu Y, Wu M, Yang L, Achreja A, Chen G, Zhuang Z, Wang H, Nagrath D, Yao J, Hung MC, DePinho RA, Huang P, Xu RH# and Chiao PJ. Mutant Kras- and p16-regulated NOX4 activation overcomes metabolic checkpoints in development of pancreatic ductal adenocarcinoma. Nat Commun 2017; 8: 14437.\n",
      "\n",
      "[24]   Liu J, Liu ZX, Wu QN, Lu YX, Wong CW, Miao L, Wang Y, Wang Z, Jin Y, He MM, Ren C, Wang DS, Chen DL, Pu HY, Feng L, Li B, Xie D, Zeng MS, Huang P, Lin A, Lin D, Xu RH#, Ju HQ. Long noncoding RNA AGPG regulates PFKFB3-mediated tumor glycolytic reprogramming. Nat Commun. 2020 Mar 20;11(1):1507.\n",
      "\n",
      "[25]   Ju HQ, Lu YX, Chen DL, Zuo ZX, Liu ZX, Wu QN, Mo HY, Wang ZX, Wang DS, Pu HY, Zeng ZL, Li B, Xie D, Huang P, Hung MC, Chiao PJ and Xu RH#. Modulation of Redox Homeostasis by Inhibition of MTHFD2 in Colorectal Cancer: Mechanisms and Therapeutic Implications. J Natl Cancer Inst 2018\n",
      "\n",
      "[26] Yu K, Zhang Q, Liu Z, Zhao Q, Zhang X, Wang Y, Wang ZX, Jin Y, Li X, Liu ZX and Xu RH#. qPhos: a database of protein phosphorylation dynamics in humans. Nucleic Acids Res 2018\n",
      "\n",
      "[27] Rui-Hua Xu*, Jin Li, Yuxian Bai, Jianming Xu, Tianshu Liu, Lin Shen, Liwei Wang, Hongming Pan, Junning Cao, Dongsheng Zhang, Songhua Fan, Ye Hua & Weiguo Su. Safety and efficacy of fruquintinib in patients with previously treated metastatic colorectal cancer: a phase Ib study and a randomized double-blind phase II study. J Hematol Oncol. (2017) 10:22.\n",
      "\n",
      "[28] Gong Chen, Junjie Peng, Qian Xiao, Hao-Xiang Wu, Xiaojun Wu, Fulong Wang, Liren Li, Peirong Ding, Qi Zhao, Yaqi Li, Da Wang, Yang Shao, Hua Bao, Zhizhong Pan, Ke-Feng Ding, Sanjun Cai, Feng Wang, Rui-Hua Xu#. Postoperative circulating tumor DNA as markers of recurrence risk in stages II to III colorectal cancer. Journal of Hematology & Oncology. 2021 May 17;14(1):80.\n",
      "\n",
      "[29] Zeng ZL, Luo HY, Yang J, Wu WJ, Chen DL, Huang P and Xu RH#. Overexpression of the circadian clock gene Bmal1 increases sensitivity to oxaliplatin in colorectal cancer. Clinical Cancer Research 2014; 20: 1042-1052.\n",
      "\n",
      "[30] Huiyan Luo, Wei Wei, Ziyi Ye, Jiabo Zheng, Rui-hua Xu#. Liquid Biopsy of Methylation Biomarkers in Cell-Free DNA. Trends in Molecular Medicine. 23 Jan 2021.\n",
      "\n",
      "    ---------\n",
      "\n",
      "\n",
      "2023-06-14 22:17:45,297 - common.py - [line]:36 - INFO - response.status_code:200, response.text:{\"id\":\"chatcmpl-7RLbPIXuwCHxOZxfP6uuuwdAJhWR2\",\"object\":\"chat.completion\",\"created\":1686752251,\"model\":\"gpt-3.5-turbo-16k-0613\",\"choices\":[{\"index\":0,\"message\":{\"role\":\"assistant\",\"content\":\"徐瑞华的临床试验有以下几项：\\n1. \\\"A Study of Sintilimab and Chidamide in Combination With or Without IBI305 in Standard Treatment Failure of Advanced or Metastatic pMMR/MSS Colorectal Carcinoma\\\"，NCT编号：NCT05830045。\\n2. \\\"Study of Nimotuzumab to Treat Colorectal Cancer\\\"，NCT编号：NCT05727839。\\n3. \\\"Comparing Chidamide+Sintilimab+Bev With Standard Second-line FOLFIRI+Bev in Advanced MSS/pMMR mCRC\\\"，NCT编号：NCT05830045。\\n以上是徐瑞华参与的临床试验及其对应的NCT编号。\"},\"finish_reason\":\"stop\"}],\"usage\":{\"prompt_tokens\":9523,\"completion_tokens\":176,\"total_tokens\":9699}}\n",
      "2023-06-14 22:17:45,298 - common.py - [line]:39 - INFO - json_dict:{'id': 'chatcmpl-7RLbPIXuwCHxOZxfP6uuuwdAJhWR2', 'object': 'chat.completion', 'created': 1686752251, 'model': 'gpt-3.5-turbo-16k-0613', 'choices': [{'index': 0, 'message': {'role': 'assistant', 'content': '徐瑞华的临床试验有以下几项：\\n1. \"A Study of Sintilimab and Chidamide in Combination With or Without IBI305 in Standard Treatment Failure of Advanced or Metastatic pMMR/MSS Colorectal Carcinoma\"，NCT编号：NCT05830045。\\n2. \"Study of Nimotuzumab to Treat Colorectal Cancer\"，NCT编号：NCT05727839。\\n3. \"Comparing Chidamide+Sintilimab+Bev With Standard Second-line FOLFIRI+Bev in Advanced MSS/pMMR mCRC\"，NCT编号：NCT05830045。\\n以上是徐瑞华参与的临床试验及其对应的NCT编号。'}, 'finish_reason': 'stop'}], 'usage': {'prompt_tokens': 9523, 'completion_tokens': 176, 'total_tokens': 9699}}\n",
      "2023-06-14 22:17:45,299 - common.py - [line]:42 - INFO - 徐瑞华的临床试验有以下几项：\n",
      "1. \"A Study of Sintilimab and Chidamide in Combination With or Without IBI305 in Standard Treatment Failure of Advanced or Metastatic pMMR/MSS Colorectal Carcinoma\"，NCT编号：NCT05830045。\n",
      "2. \"Study of Nimotuzumab to Treat Colorectal Cancer\"，NCT编号：NCT05727839。\n",
      "3. \"Comparing Chidamide+Sintilimab+Bev With Standard Second-line FOLFIRI+Bev in Advanced MSS/pMMR mCRC\"，NCT编号：NCT05830045。\n",
      "以上是徐瑞华参与的临床试验及其对应的NCT编号。\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "+++++++++++++++++++++++++\n",
      "徐瑞华的临床试验有以下几项：\n",
      "1. \"A Study of Sintilimab and Chidamide in Combination With or Without IBI305 in Standard Treatment Failure of Advanced or Metastatic pMMR/MSS Colorectal Carcinoma\"，NCT编号：NCT05830045。\n",
      "2. \"Study of Nimotuzumab to Treat Colorectal Cancer\"，NCT编号：NCT05727839。\n",
      "3. \"Comparing Chidamide+Sintilimab+Bev With Standard Second-line FOLFIRI+Bev in Advanced MSS/pMMR mCRC\"，NCT编号：NCT05830045。\n",
      "以上是徐瑞华参与的临床试验及其对应的NCT编号。\n"
     ]
    }
   ],
   "source": [
    "chat(xrh_txt,\"徐瑞华的clinical trial有哪些，列出NCT编号\")"
   ],
   "metadata": {
    "collapsed": false,
    "ExecuteTime": {
     "end_time": "2023-06-14T14:17:45.314329500Z",
     "start_time": "2023-06-14T14:17:26.434392500Z"
    }
   }
  },
  {
   "cell_type": "code",
   "execution_count": 10,
   "outputs": [
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "2023-06-14 22:20:03,900 - common.py - [line]:30 - INFO - get_openai_data: model:gpt-3.5-turbo-16k\n",
      "2023-06-14 22:20:23,295 - common.py - [line]:33 - INFO - <Response [200]>\n",
      "2023-06-14 22:20:23,300 - common.py - [line]:34 - INFO - query:\n",
      "    请根据以下context，回答：徐瑞华的clinical trial有哪些，列出NCT编号\n",
      "    reply in 简体中文\n",
      "    ---------context\n",
      "    \n",
      "[\n",
      "  {\n",
      "    \"_id\": \"648019f5778538384fd02da2\",\n",
      "    \"avatar\": null,\n",
      "    \"name\": \"Ruihua Xu\",\n",
      "    \"hospital\": \"Sun Yat-sen University\",\n",
      "    \"title\": \" MD\",\n",
      "    \"position\": null,\n",
      "    \"contact\": \"xuruihua@sysucc.org.cn\",\n",
      "    \"phone\": \"86-20-87343333\",\n",
      "    \"expertise\": \"Colorectal Carcinoma, pMMR, Microsatellite-stable\",\n",
      "    \"brief_intro\": \"A Study of Sintilimab and Chidamide in Combination With or Without IBI305 in Standard Treatment Failure of Advanced or Metastatic pMMR/MSS Colorectal Carcinoma\",\n",
      "    \"work_exp\": null,\n",
      "    \"edu_exp\": null,\n",
      "    \"consulting\": null,\n",
      "    \"publications\": null,\n",
      "    \"clinical_res\": null,\n",
      "    \"awards\": null\n",
      "  },\n",
      "  {\n",
      "    \"_id\": \"64803f25f24b55a336ba235d\",\n",
      "    \"avatar\": null,\n",
      "    \"name\": \"ruihua Xu\",\n",
      "    \"hospital\": \"Peking University\",\n",
      "    \"title\": \"M.D., Ph.D.\",\n",
      "    \"position\": null,\n",
      "    \"contact\": \"xurh@mail.sysu.edu.cn\",\n",
      "    \"phone\": \"13922206676\",\n",
      "    \"expertise\": \"nimotuzumab colorectal cancer chemotherapy\",\n",
      "    \"brief_intro\": null,\n",
      "    \"work_exp\": null,\n",
      "    \"edu_exp\": null,\n",
      "    \"consulting\": null,\n",
      "    \"publications\": null,\n",
      "    \"clinical_res\": \"Study of Nimotuzumab to Treat Colorectal Cancer\",\n",
      "    \"awards\": null\n",
      "  },\n",
      "  {\n",
      "    \"_id\": \"6480ea13f24b55a336bec613\",\n",
      "    \"avatar\": null,\n",
      "    \"name\": \"Ruihua Xu\",\n",
      "    \"hospital\": \"Sun Yat-sen University\",\n",
      "    \"title\": \"MD\",\n",
      "    \"position\": null,\n",
      "    \"contact\": \"xurh@susycc.org.cn\",\n",
      "    \"phone\": \"+862087343795\",\n",
      "    \"expertise\": \"Colorectal Cancer,Microsatellite Stable,Chidamide,Sintilimab,PD-1,Bevacizumab\",\n",
      "    \"brief_intro\": null,\n",
      "    \"work_exp\": null,\n",
      "    \"edu_exp\": null,\n",
      "    \"consulting\": null,\n",
      "    \"publications\": null,\n",
      "    \"clinical_res\": \"Comparing Chidamide+Sintilimab+Bev With Standard Second-line FOLFIRI+Bev in Advanced MSS/pMMR mCRC\",\n",
      "    \"awards\": null\n",
      "  }\n",
      "]\n",
      "[\n",
      "  {\n",
      "    \"NCT_No\": \"NCT05830045\",\n",
      "    First_Submitted_Date\": \"April 4, 2023\",\n",
      "    First_Posted_Date\": \"April 26, 2023\",\n",
      "    Last_Update_Posted_Date\": \"April 26, 2023\",\n",
      "    Estimated__Study_Start_Date\": \"April 20, 2023\",\n",
      "    Estimated_Primary_Completion_Date\": \"April 30, 2025   (Final data collection date for primary outcome measure)\",\n",
      "    Current_Primary_Outcome_Measures\": \"[List]\",\n",
      "    Original_Primary_Outcome_Measures\": \"Same as current\",\n",
      "    Change_History\": \"No Changes Posted\",\n",
      "    Current_Secondary_Outcome_Measures\": \"Not Provided\",\n",
      "    Original_Secondary_Outcome_Measures\": \"Not Provided\",\n",
      "    Current_Other_Pre-specified_Outcome_Measures\": \"Not Provided\",\n",
      "    Original_Other_Pre-specified_Outcome_Measures\": \"Not Provided\",\n",
      "    \"Brief_Title\": \"A Phase I Study of QLP2117 in Subjects With Advanced Solid Tumors\",\n",
      "    \"Official_Title\": \"A Study Evaluates the Safety, Pharmacokinetics, Immunogenicity and Efficacy of QLP2117 in Advanced Solid Tumor Patients\",\n",
      "    \"Brief_Summary\": \"This is the first in human study of QLP2117. To evaluate the Safety, Pharmacokinetics, Immunogenicity and Efficacy of QLP2117 in patients with advanced solid tumors.\",\n",
      "    \"Detailed_Description\": \"Not Provided\",\n",
      "    \"Study_Type\": \"Interventional\",\n",
      "    \"Study_Phase\": \"Phase 1\",\n",
      "    \"Study_Design\": \"Allocation: Non-Randomized\n",
      "Intervention Model: Sequential Assignment\n",
      "Masking: None (Open Label)\n",
      "Primary Purpose: Treatment\",\n",
      "    \"Condition\": \"Advanced Solid Tumors\",\n",
      "    \"Intervention\": \"Drug: QLP2117\n",
      "Specified dose on specified days\",\n",
      "    \"Study_Arms\": \"[List]\",\n",
      "    \"Publications_*\": \"Not Provided\",\n",
      "    \"Recruitment_Status\": \"Not yet recruiting\",\n",
      "    \"Estimated_Enrollment\": \"180\",\n",
      "    \"Original_Estimated_Enrollment\": \"Same as current\",\n",
      "    \"Estimated_Study_Completion_Date\": \"December 31, 2025\",\n",
      "    \"Estimated_Primary_Completion_Date\": \"April 30, 2025   (Final data collection date for primary outcome measure)\",\n",
      "    \"Eligibility_Criteria\": \"[List]\",\n",
      "    \"Sex/Gender\": \"Sexes Eligible for Study:\n",
      "   All\",\n",
      "    \"Ages\": \"18 Years and older   (Adult, Older Adult)\",\n",
      "    \"Accepts_Healthy_Volunteers\": \"No\",\n",
      "    \"Contacts\": \"Contact: Zhang Meijiang, PhD\n",
      "   8615210162105\n",
      "   meijiang.zhang@qilu-pharma.com\",\n",
      "    \"Listed_Location_Countries\": \"Not Provided\",\n",
      "    \"Removed_Location_Countries\": null,\n",
      "    \"NCT_Number\": \"NCT05830045\",\n",
      "    \"Other_Study_ID_Numbers\": \"QLP2117-101\",\n",
      "    \"Has_Data_Monitoring_Committee\": \"No\",\n",
      "    \"U.S._FDA-regulated_Product\": \"[List]\",\n",
      "    \"IPD_Sharing_Statement\": \"Plan to Share IPD:\n",
      "   No\",\n",
      "    \"Current_Responsible_Party\": \"Qilu Pharmaceutical Co., Ltd.\",\n",
      "    \"Original_Responsible_Party\": \"Same as current\",\n",
      "    \"Current_Study_Sponsor\": \"Qilu Pharmaceutical Co., Ltd.\",\n",
      "    \"Original_Study_Sponsor\": \"Same as current\",\n",
      "    \"Collaborators\": \"Not Provided\",\n",
      "    \"Investigators\": \"Principal Investigator:\n",
      "   Xu Ruihua, PhD\n",
      "   Sun Yat-sen University\",\n",
      "    \"PRS_Account\": \"Qilu Pharmaceutical Co., Ltd.\",\n",
      "    \"Verification_Date\": \"April 2023\"\n",
      "  },\n",
      "  {\n",
      "    \"NCT_No\": \"NCT05727839\",\n",
      "    First_Submitted_Date\": \"February 1, 2023\",\n",
      "    First_Posted_Date\": \"February 14, 2023\",\n",
      "    Last_Update_Posted_Date\": \"March 20, 2023\",\n",
      "    Estimated__Study_Start_Date\": \"February 24, 2023\",\n",
      "    Estimated_Primary_Completion_Date\": \"July 24, 2025   (Final data collection date for primary outcome measure)\",\n",
      "    Current_Primary_Outcome_Measures\": \"[List]\",\n",
      "    Original_Primary_Outcome_Measures\": \"[List]\",\n",
      "    Change_History\": \"Complete list of historical versions of study NCT05727839 on ClinicalTrials.gov Archive Site\",\n",
      "    Current_Secondary_Outcome_Measures\": \"[List]\",\n",
      "    Original_Secondary_Outcome_Measures\": \"[List]\",\n",
      "    Current_Other_Pre-specified_Outcome_Measures\": \"Not Provided\",\n",
      "    Original_Other_Pre-specified_Outcome_Measures\": \"Not Provided\",\n",
      "    \"Brief_Title\": \"Study to Evaluate JCXH-211 as Monotherapy in Patients With Malignant Solid Tumors\",\n",
      "    \"Official_Title\": \"A Phase 1 Open-Label Study to Evaluate the Safety, Tolerability and Efficacy of JCXH-211 Intratumoral Injection in Patients With Malignant Solid Tumors\",\n",
      "    \"Brief_Summary\": \": A Phase 1 Open-Label Study to Evaluate the Safety, Tolerability and Efficacy of JCXH-211 Intratumoral Injection in Patients with Malignant Solid Tumors\",\n",
      "    \"Detailed_Description\": \"The main purpose of this study is to find out how safe and tolerable the study drug, JCXH-211, is and also how well it works in people with malignant solid tumors. The study drug JCXH-211, is an immunotherapy drug. This means that it aims to work by boosting immune system's response to tumors, to help fight against the growth of the cancer cells. The study has 2 main phases: Phase\n",
      "  1a and Phase 1b. Phase 1a has 2 stages, skin/subcutaneous lesions stage, deep (visceral) lesions stage. Phase 1b will not start until all the data collected in Phase 1a has been completed and reviewed to check that it is safe and well tolerated.\",\n",
      "    \"Study_Type\": \"Interventional\",\n",
      "    \"Study_Phase\": \"Phase 1\",\n",
      "    \"Study_Design\": \"Allocation: Non-Randomized\n",
      "Intervention Model: Single Group Assignment\n",
      "Masking: None (Open Label)\n",
      "Primary Purpose: Treatment\",\n",
      "    \"Condition\": \"[List]\",\n",
      "    \"Intervention\": \"Drug: JCXH-211 Injection\n",
      "JCXH-211 administered once every 28 days\n",
      "Other Name: Intratumoral injection\",\n",
      "    \"Study_Arms\": \"[List]\",\n",
      "    \"Publications_*\": \"Not Provided\",\n",
      "    \"Recruitment_Status\": \"Recruiting\",\n",
      "    \"Estimated_Enrollment\": \"156\",\n",
      "    \"Original_Estimated_Enrollment\": \"Same as current\",\n",
      "    \"Estimated_Study_Completion_Date\": \"August 24, 2025\",\n",
      "    \"Estimated_Primary_Completion_Date\": \"July 24, 2025   (Final data collection date for primary outcome measure)\",\n",
      "    \"Eligibility_Criteria\": \"[List]\",\n",
      "    \"Sex/Gender\": \"Sexes Eligible for Study:\n",
      "   All\",\n",
      "    \"Ages\": \"18 Years to 75 Years   (Adult, Older Adult)\",\n",
      "    \"Accepts_Healthy_Volunteers\": \"No\",\n",
      "    \"Contacts\": \"Contact: Qi Wang\n",
      "   +8613381113913\n",
      "   qi.wang@immorna.com\",\n",
      "    \"Listed_Location_Countries\": \"China\",\n",
      "    \"Removed_Location_Countries\": null,\n",
      "    \"NCT_Number\": \"NCT05727839\",\n",
      "    \"Other_Study_ID_Numbers\": \"JCXH-211-003\",\n",
      "    \"Has_Data_Monitoring_Committee\": \"Not Provided\",\n",
      "    \"U.S._FDA-regulated_Product\": \"[List]\",\n",
      "    \"IPD_Sharing_Statement\": \"Not Provided\",\n",
      "    \"Current_Responsible_Party\": \"Immorna Biotherapeutics, Inc.\",\n",
      "    \"Original_Responsible_Party\": \"Same as current\",\n",
      "    \"Current_Study_Sponsor\": \"Immorna Biotherapeutics, Inc.\",\n",
      "    \"Original_Study_Sponsor\": \"Same as current\",\n",
      "    \"Collaborators\": \"Not Provided\",\n",
      "    \"Investigators\": \"Principal Investigator:\n",
      "   Xu ruihua, President\n",
      "   Sun Yat-sen University\",\n",
      "    \"PRS_Account\": \"Immorna Biotherapeutics, Inc.\",\n",
      "    \"Verification_Date\": \"March 2023\"\n",
      "  },\n",
      "  {\n",
      "    \"NCT_No\": \"NCT03544905\",\n",
      "    First_Submitted_Date\": \"May 22, 2018\",\n",
      "    First_Posted_Date\": \"June 4, 2018\",\n",
      "    Last_Update_Posted_Date\": \"January 6, 2023\",\n",
      "    Estimated__Study_Start_Date\": \"July 5, 2018\",\n",
      "    Estimated_Primary_Completion_Date\": \"June 30, 2023   (Final data collection date for primary outcome measure)\",\n",
      "    Current_Primary_Outcome_Measures\": \"MTD(Max tolerance does) [ Time Frame: 35 days ]To evaluate the MTD in patients with advanced solid tumor\",\n",
      "    Original_Primary_Outcome_Measures\": \"Same as current\",\n",
      "    Change_History\": \"Complete list of historical versions of study NCT03544905 on ClinicalTrials.gov Archive Site\",\n",
      "    Current_Secondary_Outcome_Measures\": \"Not Provided\",\n",
      "    Original_Secondary_Outcome_Measures\": \"Not Provided\",\n",
      "    Current_Other_Pre-specified_Outcome_Measures\": \"Not Provided\",\n",
      "    Original_Other_Pre-specified_Outcome_Measures\": \"Not Provided\",\n",
      "    \"Brief_Title\": \"Study to Evaluate the Safety, Tolerate, Pharmacokinetics and Preliminary Efficacy of CYH33\",\n",
      "    \"Official_Title\": \"A Multi-center, Open-label, Single Arm, Dose Escalation and Dose Extension Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of CYH33 in Advanced Solid Tumors Patients.\",\n",
      "    \"Brief_Summary\": \"This study is a Multi-center, Open-label, single arm, Dose Escalation and Dose Extension Phase 1 Study to Evaluate the Safety , Tolerability, Pharmacokinetics and Preliminary Efficacy of CYH33 in Advanced Solid Tumors Patients.\",\n",
      "    \"Detailed_Description\": \"This study includes Phase Ia and Phase Ib.\n",
      "  In the dose climbing part of phase Ia, the safety, tolerance and pharmacokinetics characteristics of CYH33 in patients with advanced solid tumors who failed to receive standard treatment, did not tolerate or did not have standard treatment at present will be observed to determine MTD; Before determining MTD, select safe and highly reliable and effective dose levels for simultaneous expansion. Phase Ia dose expansion includes patients with advanced solid tumors who have failed to undergo standard treatment, who are intolerant of PIK3CA gene mutation, or who do not have standard treatment at present, to further evaluate safety, tolerance and initial efficacy.\n",
      "  In Phase Ib, the safety and preliminary efficacy of CYH33 on patients with advanced breast cancer, ovarian cancer, endometrial cancer, cervical cancer, head and neck squamous cell carcinoma, esophageal and gastroesophageal junction squamous cell carcinoma, ovarian clear cell carcinoma and other solid tumors with PIK3CA gene mutation who have failed, are intolerant or do not have standard treatment at present will be evaluated.\",\n",
      "    \"Study_Type\": \"Interventional\",\n",
      "    \"Study_Phase\": \"Phase 1\",\n",
      "    \"Study_Design\": \"Allocation: N/A\n",
      "Intervention Model: Single Group Assignment\n",
      "Masking: None (Open Label)\n",
      "Primary Purpose: Treatment\",\n",
      "    \"Condition\": \"Advanced Solid Tumors\",\n",
      "    \"Intervention\": \"Drug: CYH33 for tablet\n",
      "1mg; 5mg; 10mg; 20mg; 30mg; 50mg; 75mg; 100mg; 130mg; 160mg; 200mg; 240mgBID or QD(Decided by SMC accroding to the safty and PK data)\",\n",
      "    \"Study_Arms\": \"Experimental: Dose escalation study of CYH33\n",
      "To determine the maximum tolerated dose (MTD) of CYH33\n",
      "Intervention: Drug: CYH33 for tablet\",\n",
      "    \"Publications_*\": \"Not Provided\",\n",
      "    \"Recruitment_Status\": \"Recruiting\",\n",
      "    \"Estimated_Enrollment\": \"100\",\n",
      "    \"Original_Estimated_Enrollment\": \"Same as current\",\n",
      "    \"Estimated_Study_Completion_Date\": \"March 31, 2024\",\n",
      "    \"Estimated_Primary_Completion_Date\": \"June 30, 2023   (Final data collection date for primary outcome measure)\",\n",
      "    \"Eligibility_Criteria\": \"[List]\",\n",
      "    \"Sex/Gender\": \"Sexes Eligible for Study:\n",
      "   All\",\n",
      "    \"Ages\": \"18 Years and older   (Adult, Older Adult)\",\n",
      "    \"Accepts_Healthy_Volunteers\": \"No\",\n",
      "    \"Contacts\": \"Contact: Ruihua Xu, M.D\n",
      "   86-20-87343804\n",
      "   ruihxu@163.com\",\n",
      "    \"Listed_Location_Countries\": \"China\",\n",
      "    \"Removed_Location_Countries\": null,\n",
      "    \"NCT_Number\": \"NCT03544905\",\n",
      "    \"Other_Study_ID_Numbers\": \"CYH33-101\",\n",
      "    \"Has_Data_Monitoring_Committee\": \"Yes\",\n",
      "    \"U.S._FDA-regulated_Product\": \"[List]\",\n",
      "    \"IPD_Sharing_Statement\": \"Not Provided\",\n",
      "    \"Current_Responsible_Party\": \"Haihe Biopharma Co., Ltd.\",\n",
      "    \"Original_Responsible_Party\": \"Same as current\",\n",
      "    \"Current_Study_Sponsor\": \"Haihe Biopharma Co., Ltd.\",\n",
      "    \"Original_Study_Sponsor\": \"Same as current\",\n",
      "    \"Collaborators\": \"Not Provided\",\n",
      "    \"Investigators\": \"Principal Investigator:\n",
      "   Ruihua Xu, M.D\n",
      "   Sun Yat-sen University\",\n",
      "    \"PRS_Account\": \"Haihe Biopharma Co., Ltd.\",\n",
      "    \"Verification_Date\": \"January 2023\"\n",
      "  },\n",
      "  {\n",
      "    \"NCT_No\": \"NCT01198392\",\n",
      "    First_Submitted_Date\": \"September 1, 2010\",\n",
      "    First_Posted_Date\": \"September 10, 2010\",\n",
      "    Last_Update_Posted_Date\": \"July 25, 2011\",\n",
      "    Estimated__Study_Start_Date\": \"September 2008\",\n",
      "    Estimated_Primary_Completion_Date\": \"December 2011   (Final data collection date for primary outcome measure)\",\n",
      "    Current_Primary_Outcome_Measures\": \"Time to progression [ Time Frame: The time from randomization until objective tumor progression or death ]\",\n",
      "    Original_Primary_Outcome_Measures\": \"Same as current\",\n",
      "    Change_History\": \"Complete list of historical versions of study NCT01198392 on ClinicalTrials.gov Archive Site\",\n",
      "    Current_Secondary_Outcome_Measures\": \"Response rate [ Time Frame: 2 months ]\",\n",
      "    Original_Secondary_Outcome_Measures\": \"Same as current\",\n",
      "    Current_Other_Pre-specified_Outcome_Measures\": \"Not Provided\",\n",
      "    Original_Other_Pre-specified_Outcome_Measures\": \"Not Provided\",\n",
      "    \"Brief_Title\": \"Trial of S-1 Plus Cisplatin in Gastric Cancer\",\n",
      "    \"Official_Title\": \"A Clinical Trial of S-1 Plus Cisplatin Versus 5-FU Plus Cisplatin in Patients With Unresectable or Advanced Gastric Cancer\",\n",
      "    \"Brief_Summary\": \"The purpose of this study is to evaluate the effectiveness and safety of s-1 plus cisplatin versus 5-FU plus cisplatin as first-line therapy in the treatment of patients with advanced gastric cancer.\",\n",
      "    \"Detailed_Description\": \"This is a randomized, controlled, open-label,multicenter study. Patients are randomized to one of two treatment arms : S-1 plus cisplatin and 5-FU plus cisplatin.\",\n",
      "    \"Study_Type\": \"Interventional\",\n",
      "    \"Study_Phase\": \"Phase 3\",\n",
      "    \"Study_Design\": \"Allocation: Randomized\n",
      "Intervention Model: Parallel Assignment\n",
      "Masking: None (Open Label)\n",
      "Primary Purpose: Treatment\",\n",
      "    \"Condition\": \"Gastric Cancer\",\n",
      "    \"Intervention\": \"[List]\",\n",
      "    \"Study_Arms\": \"[List]\",\n",
      "    \"Publications_*\": \"Li YH, Qiu MZ, Xu JM, Sun GP, Lu HS, Liu YP, Zhong MZ, Zhang HL, Yu SY, Li W, Hu XH, Wang JJ, Cheng Y, Zhou JT, Guo ZQ, Guan ZG, Xu RH. S-1 plus cisplatin versus fluorouracil plus cisplatin in advanced gastric or gastro-esophageal junction adenocarcinoma patients: a pilot study. Oncotarget. 2015 Oct 27;6(33):35107-15. doi: 10.18632/oncotarget.5959.\",\n",
      "    \"Recruitment_Status\": \"Unknown status\",\n",
      "    \"Estimated_Enrollment\": \"270\",\n",
      "    \"Original_Estimated_Enrollment\": \"Same as current\",\n",
      "    \"Estimated_Study_Completion_Date\": \"December 2011\",\n",
      "    \"Estimated_Primary_Completion_Date\": \"December 2011   (Final data collection date for primary outcome measure)\",\n",
      "    \"Eligibility_Criteria\": \"[List]\",\n",
      "    \"Sex/Gender\": \"Sexes Eligible for Study:\n",
      "   All\",\n",
      "    \"Ages\": \"18 Years to 75 Years   (Adult, Older Adult)\",\n",
      "    \"Accepts_Healthy_Volunteers\": \"No\",\n",
      "    \"Contacts\": \"Contact information is only displayed when the study is recruiting subjects\",\n",
      "    \"Listed_Location_Countries\": \"China\",\n",
      "    \"Removed_Location_Countries\": null,\n",
      "    \"NCT_Number\": \"NCT01198392\",\n",
      "    \"Other_Study_ID_Numbers\": \"2005L02859\",\n",
      "    \"Has_Data_Monitoring_Committee\": \"Yes\",\n",
      "    \"U.S._FDA-regulated_Product\": \"Not Provided\",\n",
      "    \"IPD_Sharing_Statement\": \"Not Provided\",\n",
      "    \"Current_Responsible_Party\": \"Zhongzhen Guan ,Ruihua Xu, Sun Yat-sen University Cancer Center\",\n",
      "    \"Original_Responsible_Party\": \"Same as current\",\n",
      "    \"Current_Study_Sponsor\": \"Sun Yat-sen University\",\n",
      "    \"Original_Study_Sponsor\": \"Same as current\",\n",
      "    \"Collaborators\": \"Not Provided\",\n",
      "    \"Investigators\": \"Principal Investigator:\n",
      "   RUIHUA XU, Professor\n",
      "   Sun Yat-sen University\",\n",
      "    \"PRS_Account\": \"Sun Yat-sen University\",\n",
      "    \"Verification_Date\": \"August 2008\"\n",
      "  }\n",
      "]\n",
      "\n",
      "徐瑞华，医学博士，中山大学肿瘤防治中心主任、医院院长、研究所所长，华南恶性肿瘤防治全国重点实验室主任，教授，博士生导师。\n",
      "\n",
      "中国医学科学院学部委员，中国临床肿瘤学会理事长，中国抗癌协会副理事长，中国抗癌协会靶向治疗专委会首届主任委员，中国抗癌协会化疗专委会候任主任委员，中国临床肿瘤学会肠癌专委会主任委员，《Cancer Communications》主编，研究生教材《肿瘤学》主编，本科生教材《临床肿瘤学》主编。\n",
      "\n",
      "从事肿瘤内科临床及科研工作30余年，取得突破性成果：\n",
      "\n",
      "第一，实现了肠癌诊治理论和实践的系统创新，使我国肠癌早诊及精准治疗均处于国际先进水平。创新了肠癌早诊及疗效预测的新技术，并已转化为临床应用；建立了晚期肠癌治疗新体系，创建了高效低毒的维持方案和亚洲方案，成为国际治疗新标准，晚期肠癌生存率与国际顶尖的安德森癌症中心达相同水平。\n",
      "\n",
      "第二，创新了消化肿瘤免疫治疗体系，引领国际消化肿瘤免疫治疗发展。\n",
      "\n",
      "通过鉴定TMB、POLE/POLD突变等标志物，精准筛选免疫治疗敏感亚型，大幅提高PD-1抗体疗效；首创了食管癌中国免疫联合方案，取得全球最高有效率72%，已成为食管癌治疗应用最广泛的方案；建立了食管癌EGIC分型，可以指导精准免疫治疗策略，引领该领域的发展；揭示了免疫逃逸新机制并推动了药物的开发：发现甲硫氨酸限制饮食可抑制免疫检查点分子PDL1及VISTA的表达，增强抗肿瘤免疫及抗PD1的治疗效果；鉴定出免疫治疗增效肠道活性菌RX-af01，成果已转化。\n",
      "\n",
      "以通讯或第一作者在国际顶级期刊JAMA、Nature Materials、Nature Medicine、Lancet Oncology等发表SCI论文200余篇，入选科睿唯安（Clarivate Analytics）全球高被引科学家，连续入选中国高被引学者榜单。以第一完成人获国家科技进步二等奖2项及省部级一等奖6项、吴阶平医药创新奖、谈家桢临床医学奖及CSCO年度成就奖。入选国家百千万人才工程、全国先进工作者、南粤百杰人才培养工程、国家卫生计生突出贡献中青年专家等人才项目。\n",
      "\n",
      "Representative paper: （*：第一作者，#：通讯作者）\n",
      "\n",
      "[1]     Luo H, Lu J, Bai Y, Mao T, Wang J, Fan Q, Zhang Y, Zhao K, Chen Z, Gao S, Li J, Fu Z, Gu K, Liu Z, Wu L, Zhang X, Feng J, Niu Z, Ba Y, Zhang H, Liu Y, Zhang L, Min X, Huang J, Cheng Y, Wang D, Shen Y, Yang Q, Zou J, Xu RH# ESCORT-1st Investigators.  Effect of Camrelizumab vs Placebo Added to Chemotherapy on Survival and Progression-Free Survival in Patients With Advanced or Metastatic Esophageal Squamous Cell Carcinoma: The ESCORT-1st Randomized Clinical Trial. JAMA. 2021 Sep 14;326(10):916-925.\n",
      "\n",
      "[2]     Xu RH*#, Wei W, Krawczyk M, Wang W, Luo H, Flagg K, Yi S, Shi W, Quan Q, Li K, Zheng L, Zhang H, Caughey BA, Zhao Q, Hou J, Zhang R, Xu Y, Cai H, Li G, Hou R, Zhong Z, Lin D, Fu X, Zhu J, Duan Y, Yu M, Ying B, Zhang W, Wang J, Zhang E, Zhang C, Li O, Guo R, Carter H, Zhu JK, Hao X and Zhang K. Circulating tumour DNA methylation markers for diagnosis and prognosis of hepatocellular carcinoma. Nat Mater 2017; 16: 1155-1161.\n",
      "\n",
      "[3]     Xu RH*#, Muro K, Morita S, Iwasa S, Han SW, Wang W, Kotaka M, Nakamura M, Ahn JB, Deng YH, Kato T, Cho SH, Ba Y, Matsuoka H, Lee KW, Zhang T, Yamada Y, Sakamoto J, Park YS and Kim TW. Modified XELIRI (capecitabine plus irinotecan) versus FOLFIRI (leucovorin, fluorouracil, and irinotecan), both either with or without bevacizumab, as second-line therapy for metastatic colorectal cancer (AXEPT): a multicentre, open-label, randomised, non-inferiority, phase 3 trial. Lancet Oncol 2018; 19: 660-671.\n",
      "\n",
      "[4]     Li J, Qin S, Xu R*, Yau TC, Ma B, Pan H, Xu J, Bai Y, Chi Y, Wang L, Yeh KH, Bi F, Cheng Y, Le AT, Lin JK, Liu T, Ma D, Kappeler C, Kalmus J and Kim TW. Regorafenib plus best supportive care versus placebo plus best supportive care in Asian patients with previously treated metastatic colorectal cancer (CONCUR): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncology 2015; 16: 619-629.\n",
      "\n",
      "[5]     Luo H, Xu G, Li C, He L, Luo L, Wang Z, Jing B, Deng Y, Jin Y, Li Y, Li B, Tan W, He C, Seeruttun SR, Wu Q, Huang J, Huang DW, Chen B, Lin SB, Chen QM, Yuan CM, Chen HX, Pu HY, Zhou F, He Y, Xu RH#. Real-time artificial intelligence for detection of upper gastrointestinal cancer by endoscopy: a multicentre, case-control, diagnostic study. Lancet Oncol. 2019 Oct 4.\n",
      "\n",
      "[6]     Satoh T, Xu RH*, Chung HC, Sun GP, Doi T, Xu JM, Tsuji A, Omuro Y, Li J, Wang JW, Miwa H, Qin SK, Chung IJ, Yeh KH, Feng JF, Mukaiyama A, Kobayashi M, Ohtsu A and Bang YJ. Lapatinib plus paclitaxel versus paclitaxel alone in the second-line treatment of HER2-amplified advanced gastric cancer in Asian populations: TyTAN--a randomized, phase III study. Journal of Clinical Oncology 2014; 32: 2039-2049.\n",
      "\n",
      "[7]     Manish A. Shah, Rui-hua Xu*, Yung-Jue Bang, Paulo M. Hoff, Tianshu Liu, Luis A. Herr´aez-Baranda, Fan Xia,Amit Garg, Mona Shing, and Josep Tabernero. HELOISE: Phase IIIb Randomized Multicenter Study Comparing Standard-of-Care and Higher-Dose Trastuzumab Regimens Combined With Chemotherapy as First-Line Therapy in Patients With Human Epidermal Growth Factor Receptor 2–Positive Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma. Journal of Clinical Oncology 2017; 35: 2558-2567.\n",
      "\n",
      "[8]     Wang ZX, Cui C, Yao J, Zhang Y, Li M, Feng J, Yang S, Fan Y, Shi J, Zhang X, Shen L, Shu Y, Wang C, Dai T, Mao T, Chen L, Guo Z, Liu B, Pan H, Cang S, Jiang Y, Wang J, Ye M, Chen Z, Jiang D, Lin Q, Ren W, Wang J, Wu L, Xu Y, Miao Z, Sun M, Xie C, Liu Y, Wang Q, Zhao L, Li Q, Huang C, Jiang K, Yang K, Li D, Liu Y, Zhu Z, Chen R, Jia L, Li W, Liao W, Liu HX, Ma D, Ma J, Qin Y, Shi Z, Wei Q, Xiao K, Zhang Y, Zhang Y, Chen X, Dai G, He J, Li J, Li G, Liu Y, Liu Z, Yuan X, Zhang J, Fu Z, He Y, Ju F, Liu Z, Tang P, Wang T, Wang W, Zhang J, Luo X, Tang X, May R, Feng H, Yao S, Keegan P, Xu RH#, Wang F. Toripalimab plus chemotherapy in treatment-naïve, advanced esophageal squamous cell carcinoma (JUPITER-06): A multi-center phase 3 trial. Cancer Cell. 2022 Mar 14;40(3):277-288.\n",
      "\n",
      "[9]     Wang F, Zhao Q, Wang YN, Jin Y, He MM, Liu ZX, Xu RH#. Evaluation of POLE and POLD1 Mutations as Biomarkers for Immunotherapy Outcomes Across Multiple Cancer Types. JAMA Oncol. 2019.\n",
      "\n",
      "[10]   Wang F, Liu DB, Zhao Q, Chen G, Liu XM, Wang YN, Su H, Qin YR, He YF, Zou QF, Liu YH, Lin YE, Liu ZX, Bei JX and Xu RH#. The genomic landscape of small cell carcinoma of the esophagus. Cell Res 2018; 28: 771-774.\n",
      "\n",
      "[11]   Wang DS, Liu ZX, Lu YX, Bao H, Wu X, Zeng ZL, Liu Z, Zhao Q, He CY, Lu JH, Wang ZQ, Qiu MZ, Wang F, Wang FH, Li YH, Wang XN, Xie D, Jia WH, Shao YW and Xu RH#. Liquid biopsies to track trastuzumab resistance in metastatic HER2-positive gastric cancer. Gut 2018;\n",
      "\n",
      "[12]   Feng Wang, You-Sheng Huang, Hao-Xiang Wu, Zi-Xian Wang, Ying Jin, Yi-Chen Yao, Yan-Xing Chen, Qi Zhao, Shifu Chen, Ming-Ming He, Hui-Yan Luo, Miao-Zhen Qiu, De-Shen Wang, Feng-Hua Wang, Mingyan Xu, Yu-Hong Li, Rui-Hua Xu#. Genomic temporal heterogeneity of circulating tumour DNA in unresectable metastatic colorectal cancer under first-line treatment. Gut. 2022 Jul;71(7):1340-1349.\n",
      "\n",
      "[13]   Luo HY, Li YH, Wang W, Wang ZQ, Yuan X, Ma D, Wang FH, Zhang DS, Lin DR, Lin YC, Jia J, Hu XH, Peng JW and Xu RH#. Single-agent capecitabine as maintenance therapy after induction of XELOX (or FOLFOX) in first-line treatment of metastatic colorectal cancer: randomized clinical trial of efficacy and safety. Annals of Oncology 2016; 27: 1074-1081.\n",
      "\n",
      "[14]   Wang F, Wei XL, Wang FH, Xu N, Shen L, Dai GH, Yuan XL, Chen Y, Yang SJ, Shi JH, Hu XC, Lin XY, Zhang QY, JF Feng, Y Ba, YP Liu, W Li, YQ Shu, Y Jiang, Q Li, JW Wang, H Wu, H Feng, S Yao, RH Xu#. Safety, efficacy and tumor mutational burden as a biomarker of overall survival benefit in chemo-refractory gastric cancer treated with toripalimab, a PD1 antibody in phase Ib/II clinical trial NCT02915432. Ann Oncol. 2019.\n",
      "\n",
      "[15]  Luo H, Zhao Q, Wei W, Zheng L, Yi S, Li G, Wang W, Sheng H, Pu H, Mo H, Zuo Z, Liu Z, Li C, Xie C, Zeng Z, Li W, Hao X, Liu Y, Cao S, Liu W, Gibson S, Zhang K, Xu G, Xu RH#. Circulating tumor DNA methylation profiles enable early diagnosis, prognosis prediction, and screening for colorectal cancer. Sci Transl Med. 2020 Jan 1;12(524).\n",
      "\n",
      "[16]   Li T, Hu PS, Zuo Z, Lin JF, Li X, Wu QN, Chen ZH, Zeng ZL, Wang F, Zheng J, Chen D, Li B, Kang TB, Dan Xie, Dongxin Lin, Huai-Qiang Ju, Rui-Hua Xu#. METTL3 facilitates tumor progression via an m(6)A-IGF2BP2-dependent mechanism in colorectal carcinoma. Mol Cancer. 2019; 18: 112.\n",
      "\n",
      "[17] Yun Wang, Jia-Huan Lu, Qi-Nian Wu, Ying Jin, De-Shen Wang, Yan-Xing Chen, Jia Liu, Xiao-Jing Luo, Qi Meng, Heng-Ying Pu, Ying-Nan Wang, Pei-Shan Hu, Ze-Xian Liu, Zhao-Lei Zeng, Qi Zhao, Rong Deng, Xiao-Feng Zhu, Huai-Qiang Ju, Rui-Hua Xu#. LncRNA LINRIS stabilizes IGF2BP2 and promotes the aerobic glycolysis in colorectal cancer. Molecular Cancer. 2019 Dec 2.\n",
      "\n",
      "[18]   Jin Y, Chen DL, Wang F, Yang CP, Chen XX, You JQ, Huang JS, Shao Y, Zhu DQ, Ouyang YM, Luo HY, Wang ZQ, Wang FH, Li YH, Xu RH#, Zhang DS. The predicting role of circulating tumor DNA landscape in gastric cancer patients treated with immune checkpoint inhibitors. Mol Cancer. 2020 Oct 30;19(1):154.\n",
      "\n",
      "[19]   Chen DL, Wang ZQ, Zeng ZL, Wu WJ, Zhang DS, Luo HY, Wang F, Qiu MZ, Wang DS, Ren C, Wang FH, Chiao LJ, Pelicano H, Huang P, Li YH and Xu RH#. Identification of microRNA-214 as a negative regulator of colorectal cancer liver metastasis by way of regulation of fibroblast growth factor receptor 1 expression. Hepatology 2014; 60: 598-609.\n",
      "\n",
      "[20]   Ju HQ, Li H, Tian T, Lu YX, Bai L, Chen LZ, Sheng H, Mo HY, Zeng JB, Deng W, Chiao PJ and Xu RH#. Melatonin overcomes gemcitabine resistance in pancreatic ductal adenocarcinoma by abrogating nuclear factor-kappaB activation. Journal of Pineal Research 2016; 60: 27-38.\n",
      "\n",
      "[21]   Ju HQ, Lin JF, Tian T, Xie D, Xu RH#. NADPH homeostasis in cancer: functions, mechanisms and therapeutic implications. Signal Transduct Tar. 2020 Oct 7;5(1):231.\n",
      "\n",
      "[22]  Hu PS, Li T, Lin JF, Qiu MZ, Wang DS, Liu ZX, Chen ZH, Yang LP, Zhang XL, Zhao Q, Chen YX, Lu YX, Wu QN, Pu HY, Zeng ZL, Xie D, Ju HQ, Luo HY, Xu RH#. VDR-SOX2 signaling promotes colorectal cancer stemness and malignancy in an acidic microenvironment. Signal Transduct Tar. 2020 Sep 9;5(1):183.\n",
      "\n",
      "[23]   Ju HQ, Ying H, Tian T, Ling J, Fu J, Lu Y, Wu M, Yang L, Achreja A, Chen G, Zhuang Z, Wang H, Nagrath D, Yao J, Hung MC, DePinho RA, Huang P, Xu RH# and Chiao PJ. Mutant Kras- and p16-regulated NOX4 activation overcomes metabolic checkpoints in development of pancreatic ductal adenocarcinoma. Nat Commun 2017; 8: 14437.\n",
      "\n",
      "[24]   Liu J, Liu ZX, Wu QN, Lu YX, Wong CW, Miao L, Wang Y, Wang Z, Jin Y, He MM, Ren C, Wang DS, Chen DL, Pu HY, Feng L, Li B, Xie D, Zeng MS, Huang P, Lin A, Lin D, Xu RH#, Ju HQ. Long noncoding RNA AGPG regulates PFKFB3-mediated tumor glycolytic reprogramming. Nat Commun. 2020 Mar 20;11(1):1507.\n",
      "\n",
      "[25]   Ju HQ, Lu YX, Chen DL, Zuo ZX, Liu ZX, Wu QN, Mo HY, Wang ZX, Wang DS, Pu HY, Zeng ZL, Li B, Xie D, Huang P, Hung MC, Chiao PJ and Xu RH#. Modulation of Redox Homeostasis by Inhibition of MTHFD2 in Colorectal Cancer: Mechanisms and Therapeutic Implications. J Natl Cancer Inst 2018\n",
      "\n",
      "[26] Yu K, Zhang Q, Liu Z, Zhao Q, Zhang X, Wang Y, Wang ZX, Jin Y, Li X, Liu ZX and Xu RH#. qPhos: a database of protein phosphorylation dynamics in humans. Nucleic Acids Res 2018\n",
      "\n",
      "[27] Rui-Hua Xu*, Jin Li, Yuxian Bai, Jianming Xu, Tianshu Liu, Lin Shen, Liwei Wang, Hongming Pan, Junning Cao, Dongsheng Zhang, Songhua Fan, Ye Hua & Weiguo Su. Safety and efficacy of fruquintinib in patients with previously treated metastatic colorectal cancer: a phase Ib study and a randomized double-blind phase II study. J Hematol Oncol. (2017) 10:22.\n",
      "\n",
      "[28] Gong Chen, Junjie Peng, Qian Xiao, Hao-Xiang Wu, Xiaojun Wu, Fulong Wang, Liren Li, Peirong Ding, Qi Zhao, Yaqi Li, Da Wang, Yang Shao, Hua Bao, Zhizhong Pan, Ke-Feng Ding, Sanjun Cai, Feng Wang, Rui-Hua Xu#. Postoperative circulating tumor DNA as markers of recurrence risk in stages II to III colorectal cancer. Journal of Hematology & Oncology. 2021 May 17;14(1):80.\n",
      "\n",
      "[29] Zeng ZL, Luo HY, Yang J, Wu WJ, Chen DL, Huang P and Xu RH#. Overexpression of the circadian clock gene Bmal1 increases sensitivity to oxaliplatin in colorectal cancer. Clinical Cancer Research 2014; 20: 1042-1052.\n",
      "\n",
      "[30] Huiyan Luo, Wei Wei, Ziyi Ye, Jiabo Zheng, Rui-hua Xu#. Liquid Biopsy of Methylation Biomarkers in Cell-Free DNA. Trends in Molecular Medicine. 23 Jan 2021.\n",
      "\n",
      "    ---------\n",
      "\n",
      "2023-06-14 22:20:23,301 - common.py - [line]:35 - INFO - real_query:\n",
      "    Notice: If doctor or hospital not in the context, skip this one 假如你是数据工程师，请把如下个人信息按照JSON的格式整理给我：（参考字段：行医，门诊时间，综合评价，资质认证状态，基本信息，简介，姓名，医院/机构，专长，职务，职称，学术兼职，地区，邮箱，手机，昕康ID/XK_ID，履历，教育经历，工作经历，研究，研究方向/临床研究，课题/基金，发表，发表文章，出版著作，专利和软著，执笔共识，成就，荣誉获奖）Return only the translation and nothing else:\n",
      "\n",
      "    query:\n",
      "    请根据以下context，回答：徐瑞华的clinical trial有哪些，列出NCT编号\n",
      "    reply in 简体中文\n",
      "    ---------context\n",
      "    \n",
      "[\n",
      "  {\n",
      "    \"_id\": \"648019f5778538384fd02da2\",\n",
      "    \"avatar\": null,\n",
      "    \"name\": \"Ruihua Xu\",\n",
      "    \"hospital\": \"Sun Yat-sen University\",\n",
      "    \"title\": \" MD\",\n",
      "    \"position\": null,\n",
      "    \"contact\": \"xuruihua@sysucc.org.cn\",\n",
      "    \"phone\": \"86-20-87343333\",\n",
      "    \"expertise\": \"Colorectal Carcinoma, pMMR, Microsatellite-stable\",\n",
      "    \"brief_intro\": \"A Study of Sintilimab and Chidamide in Combination With or Without IBI305 in Standard Treatment Failure of Advanced or Metastatic pMMR/MSS Colorectal Carcinoma\",\n",
      "    \"work_exp\": null,\n",
      "    \"edu_exp\": null,\n",
      "    \"consulting\": null,\n",
      "    \"publications\": null,\n",
      "    \"clinical_res\": null,\n",
      "    \"awards\": null\n",
      "  },\n",
      "  {\n",
      "    \"_id\": \"64803f25f24b55a336ba235d\",\n",
      "    \"avatar\": null,\n",
      "    \"name\": \"ruihua Xu\",\n",
      "    \"hospital\": \"Peking University\",\n",
      "    \"title\": \"M.D., Ph.D.\",\n",
      "    \"position\": null,\n",
      "    \"contact\": \"xurh@mail.sysu.edu.cn\",\n",
      "    \"phone\": \"13922206676\",\n",
      "    \"expertise\": \"nimotuzumab colorectal cancer chemotherapy\",\n",
      "    \"brief_intro\": null,\n",
      "    \"work_exp\": null,\n",
      "    \"edu_exp\": null,\n",
      "    \"consulting\": null,\n",
      "    \"publications\": null,\n",
      "    \"clinical_res\": \"Study of Nimotuzumab to Treat Colorectal Cancer\",\n",
      "    \"awards\": null\n",
      "  },\n",
      "  {\n",
      "    \"_id\": \"6480ea13f24b55a336bec613\",\n",
      "    \"avatar\": null,\n",
      "    \"name\": \"Ruihua Xu\",\n",
      "    \"hospital\": \"Sun Yat-sen University\",\n",
      "    \"title\": \"MD\",\n",
      "    \"position\": null,\n",
      "    \"contact\": \"xurh@susycc.org.cn\",\n",
      "    \"phone\": \"+862087343795\",\n",
      "    \"expertise\": \"Colorectal Cancer,Microsatellite Stable,Chidamide,Sintilimab,PD-1,Bevacizumab\",\n",
      "    \"brief_intro\": null,\n",
      "    \"work_exp\": null,\n",
      "    \"edu_exp\": null,\n",
      "    \"consulting\": null,\n",
      "    \"publications\": null,\n",
      "    \"clinical_res\": \"Comparing Chidamide+Sintilimab+Bev With Standard Second-line FOLFIRI+Bev in Advanced MSS/pMMR mCRC\",\n",
      "    \"awards\": null\n",
      "  }\n",
      "]\n",
      "[\n",
      "  {\n",
      "    \"NCT_No\": \"NCT05830045\",\n",
      "    First_Submitted_Date\": \"April 4, 2023\",\n",
      "    First_Posted_Date\": \"April 26, 2023\",\n",
      "    Last_Update_Posted_Date\": \"April 26, 2023\",\n",
      "    Estimated__Study_Start_Date\": \"April 20, 2023\",\n",
      "    Estimated_Primary_Completion_Date\": \"April 30, 2025   (Final data collection date for primary outcome measure)\",\n",
      "    Current_Primary_Outcome_Measures\": \"[List]\",\n",
      "    Original_Primary_Outcome_Measures\": \"Same as current\",\n",
      "    Change_History\": \"No Changes Posted\",\n",
      "    Current_Secondary_Outcome_Measures\": \"Not Provided\",\n",
      "    Original_Secondary_Outcome_Measures\": \"Not Provided\",\n",
      "    Current_Other_Pre-specified_Outcome_Measures\": \"Not Provided\",\n",
      "    Original_Other_Pre-specified_Outcome_Measures\": \"Not Provided\",\n",
      "    \"Brief_Title\": \"A Phase I Study of QLP2117 in Subjects With Advanced Solid Tumors\",\n",
      "    \"Official_Title\": \"A Study Evaluates the Safety, Pharmacokinetics, Immunogenicity and Efficacy of QLP2117 in Advanced Solid Tumor Patients\",\n",
      "    \"Brief_Summary\": \"This is the first in human study of QLP2117. To evaluate the Safety, Pharmacokinetics, Immunogenicity and Efficacy of QLP2117 in patients with advanced solid tumors.\",\n",
      "    \"Detailed_Description\": \"Not Provided\",\n",
      "    \"Study_Type\": \"Interventional\",\n",
      "    \"Study_Phase\": \"Phase 1\",\n",
      "    \"Study_Design\": \"Allocation: Non-Randomized\n",
      "Intervention Model: Sequential Assignment\n",
      "Masking: None (Open Label)\n",
      "Primary Purpose: Treatment\",\n",
      "    \"Condition\": \"Advanced Solid Tumors\",\n",
      "    \"Intervention\": \"Drug: QLP2117\n",
      "Specified dose on specified days\",\n",
      "    \"Study_Arms\": \"[List]\",\n",
      "    \"Publications_*\": \"Not Provided\",\n",
      "    \"Recruitment_Status\": \"Not yet recruiting\",\n",
      "    \"Estimated_Enrollment\": \"180\",\n",
      "    \"Original_Estimated_Enrollment\": \"Same as current\",\n",
      "    \"Estimated_Study_Completion_Date\": \"December 31, 2025\",\n",
      "    \"Estimated_Primary_Completion_Date\": \"April 30, 2025   (Final data collection date for primary outcome measure)\",\n",
      "    \"Eligibility_Criteria\": \"[List]\",\n",
      "    \"Sex/Gender\": \"Sexes Eligible for Study:\n",
      "   All\",\n",
      "    \"Ages\": \"18 Years and older   (Adult, Older Adult)\",\n",
      "    \"Accepts_Healthy_Volunteers\": \"No\",\n",
      "    \"Contacts\": \"Contact: Zhang Meijiang, PhD\n",
      "   8615210162105\n",
      "   meijiang.zhang@qilu-pharma.com\",\n",
      "    \"Listed_Location_Countries\": \"Not Provided\",\n",
      "    \"Removed_Location_Countries\": null,\n",
      "    \"NCT_Number\": \"NCT05830045\",\n",
      "    \"Other_Study_ID_Numbers\": \"QLP2117-101\",\n",
      "    \"Has_Data_Monitoring_Committee\": \"No\",\n",
      "    \"U.S._FDA-regulated_Product\": \"[List]\",\n",
      "    \"IPD_Sharing_Statement\": \"Plan to Share IPD:\n",
      "   No\",\n",
      "    \"Current_Responsible_Party\": \"Qilu Pharmaceutical Co., Ltd.\",\n",
      "    \"Original_Responsible_Party\": \"Same as current\",\n",
      "    \"Current_Study_Sponsor\": \"Qilu Pharmaceutical Co., Ltd.\",\n",
      "    \"Original_Study_Sponsor\": \"Same as current\",\n",
      "    \"Collaborators\": \"Not Provided\",\n",
      "    \"Investigators\": \"Principal Investigator:\n",
      "   Xu Ruihua, PhD\n",
      "   Sun Yat-sen University\",\n",
      "    \"PRS_Account\": \"Qilu Pharmaceutical Co., Ltd.\",\n",
      "    \"Verification_Date\": \"April 2023\"\n",
      "  },\n",
      "  {\n",
      "    \"NCT_No\": \"NCT05727839\",\n",
      "    First_Submitted_Date\": \"February 1, 2023\",\n",
      "    First_Posted_Date\": \"February 14, 2023\",\n",
      "    Last_Update_Posted_Date\": \"March 20, 2023\",\n",
      "    Estimated__Study_Start_Date\": \"February 24, 2023\",\n",
      "    Estimated_Primary_Completion_Date\": \"July 24, 2025   (Final data collection date for primary outcome measure)\",\n",
      "    Current_Primary_Outcome_Measures\": \"[List]\",\n",
      "    Original_Primary_Outcome_Measures\": \"[List]\",\n",
      "    Change_History\": \"Complete list of historical versions of study NCT05727839 on ClinicalTrials.gov Archive Site\",\n",
      "    Current_Secondary_Outcome_Measures\": \"[List]\",\n",
      "    Original_Secondary_Outcome_Measures\": \"[List]\",\n",
      "    Current_Other_Pre-specified_Outcome_Measures\": \"Not Provided\",\n",
      "    Original_Other_Pre-specified_Outcome_Measures\": \"Not Provided\",\n",
      "    \"Brief_Title\": \"Study to Evaluate JCXH-211 as Monotherapy in Patients With Malignant Solid Tumors\",\n",
      "    \"Official_Title\": \"A Phase 1 Open-Label Study to Evaluate the Safety, Tolerability and Efficacy of JCXH-211 Intratumoral Injection in Patients With Malignant Solid Tumors\",\n",
      "    \"Brief_Summary\": \": A Phase 1 Open-Label Study to Evaluate the Safety, Tolerability and Efficacy of JCXH-211 Intratumoral Injection in Patients with Malignant Solid Tumors\",\n",
      "    \"Detailed_Description\": \"The main purpose of this study is to find out how safe and tolerable the study drug, JCXH-211, is and also how well it works in people with malignant solid tumors. The study drug JCXH-211, is an immunotherapy drug. This means that it aims to work by boosting immune system's response to tumors, to help fight against the growth of the cancer cells. The study has 2 main phases: Phase\n",
      "  1a and Phase 1b. Phase 1a has 2 stages, skin/subcutaneous lesions stage, deep (visceral) lesions stage. Phase 1b will not start until all the data collected in Phase 1a has been completed and reviewed to check that it is safe and well tolerated.\",\n",
      "    \"Study_Type\": \"Interventional\",\n",
      "    \"Study_Phase\": \"Phase 1\",\n",
      "    \"Study_Design\": \"Allocation: Non-Randomized\n",
      "Intervention Model: Single Group Assignment\n",
      "Masking: None (Open Label)\n",
      "Primary Purpose: Treatment\",\n",
      "    \"Condition\": \"[List]\",\n",
      "    \"Intervention\": \"Drug: JCXH-211 Injection\n",
      "JCXH-211 administered once every 28 days\n",
      "Other Name: Intratumoral injection\",\n",
      "    \"Study_Arms\": \"[List]\",\n",
      "    \"Publications_*\": \"Not Provided\",\n",
      "    \"Recruitment_Status\": \"Recruiting\",\n",
      "    \"Estimated_Enrollment\": \"156\",\n",
      "    \"Original_Estimated_Enrollment\": \"Same as current\",\n",
      "    \"Estimated_Study_Completion_Date\": \"August 24, 2025\",\n",
      "    \"Estimated_Primary_Completion_Date\": \"July 24, 2025   (Final data collection date for primary outcome measure)\",\n",
      "    \"Eligibility_Criteria\": \"[List]\",\n",
      "    \"Sex/Gender\": \"Sexes Eligible for Study:\n",
      "   All\",\n",
      "    \"Ages\": \"18 Years to 75 Years   (Adult, Older Adult)\",\n",
      "    \"Accepts_Healthy_Volunteers\": \"No\",\n",
      "    \"Contacts\": \"Contact: Qi Wang\n",
      "   +8613381113913\n",
      "   qi.wang@immorna.com\",\n",
      "    \"Listed_Location_Countries\": \"China\",\n",
      "    \"Removed_Location_Countries\": null,\n",
      "    \"NCT_Number\": \"NCT05727839\",\n",
      "    \"Other_Study_ID_Numbers\": \"JCXH-211-003\",\n",
      "    \"Has_Data_Monitoring_Committee\": \"Not Provided\",\n",
      "    \"U.S._FDA-regulated_Product\": \"[List]\",\n",
      "    \"IPD_Sharing_Statement\": \"Not Provided\",\n",
      "    \"Current_Responsible_Party\": \"Immorna Biotherapeutics, Inc.\",\n",
      "    \"Original_Responsible_Party\": \"Same as current\",\n",
      "    \"Current_Study_Sponsor\": \"Immorna Biotherapeutics, Inc.\",\n",
      "    \"Original_Study_Sponsor\": \"Same as current\",\n",
      "    \"Collaborators\": \"Not Provided\",\n",
      "    \"Investigators\": \"Principal Investigator:\n",
      "   Xu ruihua, President\n",
      "   Sun Yat-sen University\",\n",
      "    \"PRS_Account\": \"Immorna Biotherapeutics, Inc.\",\n",
      "    \"Verification_Date\": \"March 2023\"\n",
      "  },\n",
      "  {\n",
      "    \"NCT_No\": \"NCT03544905\",\n",
      "    First_Submitted_Date\": \"May 22, 2018\",\n",
      "    First_Posted_Date\": \"June 4, 2018\",\n",
      "    Last_Update_Posted_Date\": \"January 6, 2023\",\n",
      "    Estimated__Study_Start_Date\": \"July 5, 2018\",\n",
      "    Estimated_Primary_Completion_Date\": \"June 30, 2023   (Final data collection date for primary outcome measure)\",\n",
      "    Current_Primary_Outcome_Measures\": \"MTD(Max tolerance does) [ Time Frame: 35 days ]To evaluate the MTD in patients with advanced solid tumor\",\n",
      "    Original_Primary_Outcome_Measures\": \"Same as current\",\n",
      "    Change_History\": \"Complete list of historical versions of study NCT03544905 on ClinicalTrials.gov Archive Site\",\n",
      "    Current_Secondary_Outcome_Measures\": \"Not Provided\",\n",
      "    Original_Secondary_Outcome_Measures\": \"Not Provided\",\n",
      "    Current_Other_Pre-specified_Outcome_Measures\": \"Not Provided\",\n",
      "    Original_Other_Pre-specified_Outcome_Measures\": \"Not Provided\",\n",
      "    \"Brief_Title\": \"Study to Evaluate the Safety, Tolerate, Pharmacokinetics and Preliminary Efficacy of CYH33\",\n",
      "    \"Official_Title\": \"A Multi-center, Open-label, Single Arm, Dose Escalation and Dose Extension Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of CYH33 in Advanced Solid Tumors Patients.\",\n",
      "    \"Brief_Summary\": \"This study is a Multi-center, Open-label, single arm, Dose Escalation and Dose Extension Phase 1 Study to Evaluate the Safety , Tolerability, Pharmacokinetics and Preliminary Efficacy of CYH33 in Advanced Solid Tumors Patients.\",\n",
      "    \"Detailed_Description\": \"This study includes Phase Ia and Phase Ib.\n",
      "  In the dose climbing part of phase Ia, the safety, tolerance and pharmacokinetics characteristics of CYH33 in patients with advanced solid tumors who failed to receive standard treatment, did not tolerate or did not have standard treatment at present will be observed to determine MTD; Before determining MTD, select safe and highly reliable and effective dose levels for simultaneous expansion. Phase Ia dose expansion includes patients with advanced solid tumors who have failed to undergo standard treatment, who are intolerant of PIK3CA gene mutation, or who do not have standard treatment at present, to further evaluate safety, tolerance and initial efficacy.\n",
      "  In Phase Ib, the safety and preliminary efficacy of CYH33 on patients with advanced breast cancer, ovarian cancer, endometrial cancer, cervical cancer, head and neck squamous cell carcinoma, esophageal and gastroesophageal junction squamous cell carcinoma, ovarian clear cell carcinoma and other solid tumors with PIK3CA gene mutation who have failed, are intolerant or do not have standard treatment at present will be evaluated.\",\n",
      "    \"Study_Type\": \"Interventional\",\n",
      "    \"Study_Phase\": \"Phase 1\",\n",
      "    \"Study_Design\": \"Allocation: N/A\n",
      "Intervention Model: Single Group Assignment\n",
      "Masking: None (Open Label)\n",
      "Primary Purpose: Treatment\",\n",
      "    \"Condition\": \"Advanced Solid Tumors\",\n",
      "    \"Intervention\": \"Drug: CYH33 for tablet\n",
      "1mg; 5mg; 10mg; 20mg; 30mg; 50mg; 75mg; 100mg; 130mg; 160mg; 200mg; 240mgBID or QD(Decided by SMC accroding to the safty and PK data)\",\n",
      "    \"Study_Arms\": \"Experimental: Dose escalation study of CYH33\n",
      "To determine the maximum tolerated dose (MTD) of CYH33\n",
      "Intervention: Drug: CYH33 for tablet\",\n",
      "    \"Publications_*\": \"Not Provided\",\n",
      "    \"Recruitment_Status\": \"Recruiting\",\n",
      "    \"Estimated_Enrollment\": \"100\",\n",
      "    \"Original_Estimated_Enrollment\": \"Same as current\",\n",
      "    \"Estimated_Study_Completion_Date\": \"March 31, 2024\",\n",
      "    \"Estimated_Primary_Completion_Date\": \"June 30, 2023   (Final data collection date for primary outcome measure)\",\n",
      "    \"Eligibility_Criteria\": \"[List]\",\n",
      "    \"Sex/Gender\": \"Sexes Eligible for Study:\n",
      "   All\",\n",
      "    \"Ages\": \"18 Years and older   (Adult, Older Adult)\",\n",
      "    \"Accepts_Healthy_Volunteers\": \"No\",\n",
      "    \"Contacts\": \"Contact: Ruihua Xu, M.D\n",
      "   86-20-87343804\n",
      "   ruihxu@163.com\",\n",
      "    \"Listed_Location_Countries\": \"China\",\n",
      "    \"Removed_Location_Countries\": null,\n",
      "    \"NCT_Number\": \"NCT03544905\",\n",
      "    \"Other_Study_ID_Numbers\": \"CYH33-101\",\n",
      "    \"Has_Data_Monitoring_Committee\": \"Yes\",\n",
      "    \"U.S._FDA-regulated_Product\": \"[List]\",\n",
      "    \"IPD_Sharing_Statement\": \"Not Provided\",\n",
      "    \"Current_Responsible_Party\": \"Haihe Biopharma Co., Ltd.\",\n",
      "    \"Original_Responsible_Party\": \"Same as current\",\n",
      "    \"Current_Study_Sponsor\": \"Haihe Biopharma Co., Ltd.\",\n",
      "    \"Original_Study_Sponsor\": \"Same as current\",\n",
      "    \"Collaborators\": \"Not Provided\",\n",
      "    \"Investigators\": \"Principal Investigator:\n",
      "   Ruihua Xu, M.D\n",
      "   Sun Yat-sen University\",\n",
      "    \"PRS_Account\": \"Haihe Biopharma Co., Ltd.\",\n",
      "    \"Verification_Date\": \"January 2023\"\n",
      "  },\n",
      "  {\n",
      "    \"NCT_No\": \"NCT01198392\",\n",
      "    First_Submitted_Date\": \"September 1, 2010\",\n",
      "    First_Posted_Date\": \"September 10, 2010\",\n",
      "    Last_Update_Posted_Date\": \"July 25, 2011\",\n",
      "    Estimated__Study_Start_Date\": \"September 2008\",\n",
      "    Estimated_Primary_Completion_Date\": \"December 2011   (Final data collection date for primary outcome measure)\",\n",
      "    Current_Primary_Outcome_Measures\": \"Time to progression [ Time Frame: The time from randomization until objective tumor progression or death ]\",\n",
      "    Original_Primary_Outcome_Measures\": \"Same as current\",\n",
      "    Change_History\": \"Complete list of historical versions of study NCT01198392 on ClinicalTrials.gov Archive Site\",\n",
      "    Current_Secondary_Outcome_Measures\": \"Response rate [ Time Frame: 2 months ]\",\n",
      "    Original_Secondary_Outcome_Measures\": \"Same as current\",\n",
      "    Current_Other_Pre-specified_Outcome_Measures\": \"Not Provided\",\n",
      "    Original_Other_Pre-specified_Outcome_Measures\": \"Not Provided\",\n",
      "    \"Brief_Title\": \"Trial of S-1 Plus Cisplatin in Gastric Cancer\",\n",
      "    \"Official_Title\": \"A Clinical Trial of S-1 Plus Cisplatin Versus 5-FU Plus Cisplatin in Patients With Unresectable or Advanced Gastric Cancer\",\n",
      "    \"Brief_Summary\": \"The purpose of this study is to evaluate the effectiveness and safety of s-1 plus cisplatin versus 5-FU plus cisplatin as first-line therapy in the treatment of patients with advanced gastric cancer.\",\n",
      "    \"Detailed_Description\": \"This is a randomized, controlled, open-label,multicenter study. Patients are randomized to one of two treatment arms : S-1 plus cisplatin and 5-FU plus cisplatin.\",\n",
      "    \"Study_Type\": \"Interventional\",\n",
      "    \"Study_Phase\": \"Phase 3\",\n",
      "    \"Study_Design\": \"Allocation: Randomized\n",
      "Intervention Model: Parallel Assignment\n",
      "Masking: None (Open Label)\n",
      "Primary Purpose: Treatment\",\n",
      "    \"Condition\": \"Gastric Cancer\",\n",
      "    \"Intervention\": \"[List]\",\n",
      "    \"Study_Arms\": \"[List]\",\n",
      "    \"Publications_*\": \"Li YH, Qiu MZ, Xu JM, Sun GP, Lu HS, Liu YP, Zhong MZ, Zhang HL, Yu SY, Li W, Hu XH, Wang JJ, Cheng Y, Zhou JT, Guo ZQ, Guan ZG, Xu RH. S-1 plus cisplatin versus fluorouracil plus cisplatin in advanced gastric or gastro-esophageal junction adenocarcinoma patients: a pilot study. Oncotarget. 2015 Oct 27;6(33):35107-15. doi: 10.18632/oncotarget.5959.\",\n",
      "    \"Recruitment_Status\": \"Unknown status\",\n",
      "    \"Estimated_Enrollment\": \"270\",\n",
      "    \"Original_Estimated_Enrollment\": \"Same as current\",\n",
      "    \"Estimated_Study_Completion_Date\": \"December 2011\",\n",
      "    \"Estimated_Primary_Completion_Date\": \"December 2011   (Final data collection date for primary outcome measure)\",\n",
      "    \"Eligibility_Criteria\": \"[List]\",\n",
      "    \"Sex/Gender\": \"Sexes Eligible for Study:\n",
      "   All\",\n",
      "    \"Ages\": \"18 Years to 75 Years   (Adult, Older Adult)\",\n",
      "    \"Accepts_Healthy_Volunteers\": \"No\",\n",
      "    \"Contacts\": \"Contact information is only displayed when the study is recruiting subjects\",\n",
      "    \"Listed_Location_Countries\": \"China\",\n",
      "    \"Removed_Location_Countries\": null,\n",
      "    \"NCT_Number\": \"NCT01198392\",\n",
      "    \"Other_Study_ID_Numbers\": \"2005L02859\",\n",
      "    \"Has_Data_Monitoring_Committee\": \"Yes\",\n",
      "    \"U.S._FDA-regulated_Product\": \"Not Provided\",\n",
      "    \"IPD_Sharing_Statement\": \"Not Provided\",\n",
      "    \"Current_Responsible_Party\": \"Zhongzhen Guan ,Ruihua Xu, Sun Yat-sen University Cancer Center\",\n",
      "    \"Original_Responsible_Party\": \"Same as current\",\n",
      "    \"Current_Study_Sponsor\": \"Sun Yat-sen University\",\n",
      "    \"Original_Study_Sponsor\": \"Same as current\",\n",
      "    \"Collaborators\": \"Not Provided\",\n",
      "    \"Investigators\": \"Principal Investigator:\n",
      "   RUIHUA XU, Professor\n",
      "   Sun Yat-sen University\",\n",
      "    \"PRS_Account\": \"Sun Yat-sen University\",\n",
      "    \"Verification_Date\": \"August 2008\"\n",
      "  }\n",
      "]\n",
      "\n",
      "徐瑞华，医学博士，中山大学肿瘤防治中心主任、医院院长、研究所所长，华南恶性肿瘤防治全国重点实验室主任，教授，博士生导师。\n",
      "\n",
      "中国医学科学院学部委员，中国临床肿瘤学会理事长，中国抗癌协会副理事长，中国抗癌协会靶向治疗专委会首届主任委员，中国抗癌协会化疗专委会候任主任委员，中国临床肿瘤学会肠癌专委会主任委员，《Cancer Communications》主编，研究生教材《肿瘤学》主编，本科生教材《临床肿瘤学》主编。\n",
      "\n",
      "从事肿瘤内科临床及科研工作30余年，取得突破性成果：\n",
      "\n",
      "第一，实现了肠癌诊治理论和实践的系统创新，使我国肠癌早诊及精准治疗均处于国际先进水平。创新了肠癌早诊及疗效预测的新技术，并已转化为临床应用；建立了晚期肠癌治疗新体系，创建了高效低毒的维持方案和亚洲方案，成为国际治疗新标准，晚期肠癌生存率与国际顶尖的安德森癌症中心达相同水平。\n",
      "\n",
      "第二，创新了消化肿瘤免疫治疗体系，引领国际消化肿瘤免疫治疗发展。\n",
      "\n",
      "通过鉴定TMB、POLE/POLD突变等标志物，精准筛选免疫治疗敏感亚型，大幅提高PD-1抗体疗效；首创了食管癌中国免疫联合方案，取得全球最高有效率72%，已成为食管癌治疗应用最广泛的方案；建立了食管癌EGIC分型，可以指导精准免疫治疗策略，引领该领域的发展；揭示了免疫逃逸新机制并推动了药物的开发：发现甲硫氨酸限制饮食可抑制免疫检查点分子PDL1及VISTA的表达，增强抗肿瘤免疫及抗PD1的治疗效果；鉴定出免疫治疗增效肠道活性菌RX-af01，成果已转化。\n",
      "\n",
      "以通讯或第一作者在国际顶级期刊JAMA、Nature Materials、Nature Medicine、Lancet Oncology等发表SCI论文200余篇，入选科睿唯安（Clarivate Analytics）全球高被引科学家，连续入选中国高被引学者榜单。以第一完成人获国家科技进步二等奖2项及省部级一等奖6项、吴阶平医药创新奖、谈家桢临床医学奖及CSCO年度成就奖。入选国家百千万人才工程、全国先进工作者、南粤百杰人才培养工程、国家卫生计生突出贡献中青年专家等人才项目。\n",
      "\n",
      "Representative paper: （*：第一作者，#：通讯作者）\n",
      "\n",
      "[1]     Luo H, Lu J, Bai Y, Mao T, Wang J, Fan Q, Zhang Y, Zhao K, Chen Z, Gao S, Li J, Fu Z, Gu K, Liu Z, Wu L, Zhang X, Feng J, Niu Z, Ba Y, Zhang H, Liu Y, Zhang L, Min X, Huang J, Cheng Y, Wang D, Shen Y, Yang Q, Zou J, Xu RH# ESCORT-1st Investigators.  Effect of Camrelizumab vs Placebo Added to Chemotherapy on Survival and Progression-Free Survival in Patients With Advanced or Metastatic Esophageal Squamous Cell Carcinoma: The ESCORT-1st Randomized Clinical Trial. JAMA. 2021 Sep 14;326(10):916-925.\n",
      "\n",
      "[2]     Xu RH*#, Wei W, Krawczyk M, Wang W, Luo H, Flagg K, Yi S, Shi W, Quan Q, Li K, Zheng L, Zhang H, Caughey BA, Zhao Q, Hou J, Zhang R, Xu Y, Cai H, Li G, Hou R, Zhong Z, Lin D, Fu X, Zhu J, Duan Y, Yu M, Ying B, Zhang W, Wang J, Zhang E, Zhang C, Li O, Guo R, Carter H, Zhu JK, Hao X and Zhang K. Circulating tumour DNA methylation markers for diagnosis and prognosis of hepatocellular carcinoma. Nat Mater 2017; 16: 1155-1161.\n",
      "\n",
      "[3]     Xu RH*#, Muro K, Morita S, Iwasa S, Han SW, Wang W, Kotaka M, Nakamura M, Ahn JB, Deng YH, Kato T, Cho SH, Ba Y, Matsuoka H, Lee KW, Zhang T, Yamada Y, Sakamoto J, Park YS and Kim TW. Modified XELIRI (capecitabine plus irinotecan) versus FOLFIRI (leucovorin, fluorouracil, and irinotecan), both either with or without bevacizumab, as second-line therapy for metastatic colorectal cancer (AXEPT): a multicentre, open-label, randomised, non-inferiority, phase 3 trial. Lancet Oncol 2018; 19: 660-671.\n",
      "\n",
      "[4]     Li J, Qin S, Xu R*, Yau TC, Ma B, Pan H, Xu J, Bai Y, Chi Y, Wang L, Yeh KH, Bi F, Cheng Y, Le AT, Lin JK, Liu T, Ma D, Kappeler C, Kalmus J and Kim TW. Regorafenib plus best supportive care versus placebo plus best supportive care in Asian patients with previously treated metastatic colorectal cancer (CONCUR): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncology 2015; 16: 619-629.\n",
      "\n",
      "[5]     Luo H, Xu G, Li C, He L, Luo L, Wang Z, Jing B, Deng Y, Jin Y, Li Y, Li B, Tan W, He C, Seeruttun SR, Wu Q, Huang J, Huang DW, Chen B, Lin SB, Chen QM, Yuan CM, Chen HX, Pu HY, Zhou F, He Y, Xu RH#. Real-time artificial intelligence for detection of upper gastrointestinal cancer by endoscopy: a multicentre, case-control, diagnostic study. Lancet Oncol. 2019 Oct 4.\n",
      "\n",
      "[6]     Satoh T, Xu RH*, Chung HC, Sun GP, Doi T, Xu JM, Tsuji A, Omuro Y, Li J, Wang JW, Miwa H, Qin SK, Chung IJ, Yeh KH, Feng JF, Mukaiyama A, Kobayashi M, Ohtsu A and Bang YJ. Lapatinib plus paclitaxel versus paclitaxel alone in the second-line treatment of HER2-amplified advanced gastric cancer in Asian populations: TyTAN--a randomized, phase III study. Journal of Clinical Oncology 2014; 32: 2039-2049.\n",
      "\n",
      "[7]     Manish A. Shah, Rui-hua Xu*, Yung-Jue Bang, Paulo M. Hoff, Tianshu Liu, Luis A. Herr´aez-Baranda, Fan Xia,Amit Garg, Mona Shing, and Josep Tabernero. HELOISE: Phase IIIb Randomized Multicenter Study Comparing Standard-of-Care and Higher-Dose Trastuzumab Regimens Combined With Chemotherapy as First-Line Therapy in Patients With Human Epidermal Growth Factor Receptor 2–Positive Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma. Journal of Clinical Oncology 2017; 35: 2558-2567.\n",
      "\n",
      "[8]     Wang ZX, Cui C, Yao J, Zhang Y, Li M, Feng J, Yang S, Fan Y, Shi J, Zhang X, Shen L, Shu Y, Wang C, Dai T, Mao T, Chen L, Guo Z, Liu B, Pan H, Cang S, Jiang Y, Wang J, Ye M, Chen Z, Jiang D, Lin Q, Ren W, Wang J, Wu L, Xu Y, Miao Z, Sun M, Xie C, Liu Y, Wang Q, Zhao L, Li Q, Huang C, Jiang K, Yang K, Li D, Liu Y, Zhu Z, Chen R, Jia L, Li W, Liao W, Liu HX, Ma D, Ma J, Qin Y, Shi Z, Wei Q, Xiao K, Zhang Y, Zhang Y, Chen X, Dai G, He J, Li J, Li G, Liu Y, Liu Z, Yuan X, Zhang J, Fu Z, He Y, Ju F, Liu Z, Tang P, Wang T, Wang W, Zhang J, Luo X, Tang X, May R, Feng H, Yao S, Keegan P, Xu RH#, Wang F. Toripalimab plus chemotherapy in treatment-naïve, advanced esophageal squamous cell carcinoma (JUPITER-06): A multi-center phase 3 trial. Cancer Cell. 2022 Mar 14;40(3):277-288.\n",
      "\n",
      "[9]     Wang F, Zhao Q, Wang YN, Jin Y, He MM, Liu ZX, Xu RH#. Evaluation of POLE and POLD1 Mutations as Biomarkers for Immunotherapy Outcomes Across Multiple Cancer Types. JAMA Oncol. 2019.\n",
      "\n",
      "[10]   Wang F, Liu DB, Zhao Q, Chen G, Liu XM, Wang YN, Su H, Qin YR, He YF, Zou QF, Liu YH, Lin YE, Liu ZX, Bei JX and Xu RH#. The genomic landscape of small cell carcinoma of the esophagus. Cell Res 2018; 28: 771-774.\n",
      "\n",
      "[11]   Wang DS, Liu ZX, Lu YX, Bao H, Wu X, Zeng ZL, Liu Z, Zhao Q, He CY, Lu JH, Wang ZQ, Qiu MZ, Wang F, Wang FH, Li YH, Wang XN, Xie D, Jia WH, Shao YW and Xu RH#. Liquid biopsies to track trastuzumab resistance in metastatic HER2-positive gastric cancer. Gut 2018;\n",
      "\n",
      "[12]   Feng Wang, You-Sheng Huang, Hao-Xiang Wu, Zi-Xian Wang, Ying Jin, Yi-Chen Yao, Yan-Xing Chen, Qi Zhao, Shifu Chen, Ming-Ming He, Hui-Yan Luo, Miao-Zhen Qiu, De-Shen Wang, Feng-Hua Wang, Mingyan Xu, Yu-Hong Li, Rui-Hua Xu#. Genomic temporal heterogeneity of circulating tumour DNA in unresectable metastatic colorectal cancer under first-line treatment. Gut. 2022 Jul;71(7):1340-1349.\n",
      "\n",
      "[13]   Luo HY, Li YH, Wang W, Wang ZQ, Yuan X, Ma D, Wang FH, Zhang DS, Lin DR, Lin YC, Jia J, Hu XH, Peng JW and Xu RH#. Single-agent capecitabine as maintenance therapy after induction of XELOX (or FOLFOX) in first-line treatment of metastatic colorectal cancer: randomized clinical trial of efficacy and safety. Annals of Oncology 2016; 27: 1074-1081.\n",
      "\n",
      "[14]   Wang F, Wei XL, Wang FH, Xu N, Shen L, Dai GH, Yuan XL, Chen Y, Yang SJ, Shi JH, Hu XC, Lin XY, Zhang QY, JF Feng, Y Ba, YP Liu, W Li, YQ Shu, Y Jiang, Q Li, JW Wang, H Wu, H Feng, S Yao, RH Xu#. Safety, efficacy and tumor mutational burden as a biomarker of overall survival benefit in chemo-refractory gastric cancer treated with toripalimab, a PD1 antibody in phase Ib/II clinical trial NCT02915432. Ann Oncol. 2019.\n",
      "\n",
      "[15]  Luo H, Zhao Q, Wei W, Zheng L, Yi S, Li G, Wang W, Sheng H, Pu H, Mo H, Zuo Z, Liu Z, Li C, Xie C, Zeng Z, Li W, Hao X, Liu Y, Cao S, Liu W, Gibson S, Zhang K, Xu G, Xu RH#. Circulating tumor DNA methylation profiles enable early diagnosis, prognosis prediction, and screening for colorectal cancer. Sci Transl Med. 2020 Jan 1;12(524).\n",
      "\n",
      "[16]   Li T, Hu PS, Zuo Z, Lin JF, Li X, Wu QN, Chen ZH, Zeng ZL, Wang F, Zheng J, Chen D, Li B, Kang TB, Dan Xie, Dongxin Lin, Huai-Qiang Ju, Rui-Hua Xu#. METTL3 facilitates tumor progression via an m(6)A-IGF2BP2-dependent mechanism in colorectal carcinoma. Mol Cancer. 2019; 18: 112.\n",
      "\n",
      "[17] Yun Wang, Jia-Huan Lu, Qi-Nian Wu, Ying Jin, De-Shen Wang, Yan-Xing Chen, Jia Liu, Xiao-Jing Luo, Qi Meng, Heng-Ying Pu, Ying-Nan Wang, Pei-Shan Hu, Ze-Xian Liu, Zhao-Lei Zeng, Qi Zhao, Rong Deng, Xiao-Feng Zhu, Huai-Qiang Ju, Rui-Hua Xu#. LncRNA LINRIS stabilizes IGF2BP2 and promotes the aerobic glycolysis in colorectal cancer. Molecular Cancer. 2019 Dec 2.\n",
      "\n",
      "[18]   Jin Y, Chen DL, Wang F, Yang CP, Chen XX, You JQ, Huang JS, Shao Y, Zhu DQ, Ouyang YM, Luo HY, Wang ZQ, Wang FH, Li YH, Xu RH#, Zhang DS. The predicting role of circulating tumor DNA landscape in gastric cancer patients treated with immune checkpoint inhibitors. Mol Cancer. 2020 Oct 30;19(1):154.\n",
      "\n",
      "[19]   Chen DL, Wang ZQ, Zeng ZL, Wu WJ, Zhang DS, Luo HY, Wang F, Qiu MZ, Wang DS, Ren C, Wang FH, Chiao LJ, Pelicano H, Huang P, Li YH and Xu RH#. Identification of microRNA-214 as a negative regulator of colorectal cancer liver metastasis by way of regulation of fibroblast growth factor receptor 1 expression. Hepatology 2014; 60: 598-609.\n",
      "\n",
      "[20]   Ju HQ, Li H, Tian T, Lu YX, Bai L, Chen LZ, Sheng H, Mo HY, Zeng JB, Deng W, Chiao PJ and Xu RH#. Melatonin overcomes gemcitabine resistance in pancreatic ductal adenocarcinoma by abrogating nuclear factor-kappaB activation. Journal of Pineal Research 2016; 60: 27-38.\n",
      "\n",
      "[21]   Ju HQ, Lin JF, Tian T, Xie D, Xu RH#. NADPH homeostasis in cancer: functions, mechanisms and therapeutic implications. Signal Transduct Tar. 2020 Oct 7;5(1):231.\n",
      "\n",
      "[22]  Hu PS, Li T, Lin JF, Qiu MZ, Wang DS, Liu ZX, Chen ZH, Yang LP, Zhang XL, Zhao Q, Chen YX, Lu YX, Wu QN, Pu HY, Zeng ZL, Xie D, Ju HQ, Luo HY, Xu RH#. VDR-SOX2 signaling promotes colorectal cancer stemness and malignancy in an acidic microenvironment. Signal Transduct Tar. 2020 Sep 9;5(1):183.\n",
      "\n",
      "[23]   Ju HQ, Ying H, Tian T, Ling J, Fu J, Lu Y, Wu M, Yang L, Achreja A, Chen G, Zhuang Z, Wang H, Nagrath D, Yao J, Hung MC, DePinho RA, Huang P, Xu RH# and Chiao PJ. Mutant Kras- and p16-regulated NOX4 activation overcomes metabolic checkpoints in development of pancreatic ductal adenocarcinoma. Nat Commun 2017; 8: 14437.\n",
      "\n",
      "[24]   Liu J, Liu ZX, Wu QN, Lu YX, Wong CW, Miao L, Wang Y, Wang Z, Jin Y, He MM, Ren C, Wang DS, Chen DL, Pu HY, Feng L, Li B, Xie D, Zeng MS, Huang P, Lin A, Lin D, Xu RH#, Ju HQ. Long noncoding RNA AGPG regulates PFKFB3-mediated tumor glycolytic reprogramming. Nat Commun. 2020 Mar 20;11(1):1507.\n",
      "\n",
      "[25]   Ju HQ, Lu YX, Chen DL, Zuo ZX, Liu ZX, Wu QN, Mo HY, Wang ZX, Wang DS, Pu HY, Zeng ZL, Li B, Xie D, Huang P, Hung MC, Chiao PJ and Xu RH#. Modulation of Redox Homeostasis by Inhibition of MTHFD2 in Colorectal Cancer: Mechanisms and Therapeutic Implications. J Natl Cancer Inst 2018\n",
      "\n",
      "[26] Yu K, Zhang Q, Liu Z, Zhao Q, Zhang X, Wang Y, Wang ZX, Jin Y, Li X, Liu ZX and Xu RH#. qPhos: a database of protein phosphorylation dynamics in humans. Nucleic Acids Res 2018\n",
      "\n",
      "[27] Rui-Hua Xu*, Jin Li, Yuxian Bai, Jianming Xu, Tianshu Liu, Lin Shen, Liwei Wang, Hongming Pan, Junning Cao, Dongsheng Zhang, Songhua Fan, Ye Hua & Weiguo Su. Safety and efficacy of fruquintinib in patients with previously treated metastatic colorectal cancer: a phase Ib study and a randomized double-blind phase II study. J Hematol Oncol. (2017) 10:22.\n",
      "\n",
      "[28] Gong Chen, Junjie Peng, Qian Xiao, Hao-Xiang Wu, Xiaojun Wu, Fulong Wang, Liren Li, Peirong Ding, Qi Zhao, Yaqi Li, Da Wang, Yang Shao, Hua Bao, Zhizhong Pan, Ke-Feng Ding, Sanjun Cai, Feng Wang, Rui-Hua Xu#. Postoperative circulating tumor DNA as markers of recurrence risk in stages II to III colorectal cancer. Journal of Hematology & Oncology. 2021 May 17;14(1):80.\n",
      "\n",
      "[29] Zeng ZL, Luo HY, Yang J, Wu WJ, Chen DL, Huang P and Xu RH#. Overexpression of the circadian clock gene Bmal1 increases sensitivity to oxaliplatin in colorectal cancer. Clinical Cancer Research 2014; 20: 1042-1052.\n",
      "\n",
      "[30] Huiyan Luo, Wei Wei, Ziyi Ye, Jiabo Zheng, Rui-hua Xu#. Liquid Biopsy of Methylation Biomarkers in Cell-Free DNA. Trends in Molecular Medicine. 23 Jan 2021.\n",
      "\n",
      "    ---------\n",
      "\n",
      "\n",
      "2023-06-14 22:20:23,302 - common.py - [line]:36 - INFO - response.status_code:200, response.text:{\"id\":\"chatcmpl-7RLdxKsLTCcjpD7eSUPIsL9zxggej\",\"object\":\"chat.completion\",\"created\":1686752409,\"model\":\"gpt-3.5-turbo-16k-0613\",\"choices\":[{\"index\":0,\"message\":{\"role\":\"assistant\",\"content\":\"徐瑞华的临床试验如下：\\n1. NCT05830045：QLP2117治疗晚期实体瘤的I期研究\\n2. NCT05727839：JCXH-211单药治疗恶性实体肿瘤的I期开放标签研究\\n3. NCT03544905：CYH33治疗晚期实体瘤的I期剂量递增和剂量扩展研究\\n4. NCT01198392：S-1加顺铂与5-FU加顺铂一线治疗晚期胃癌的III期临床试验\\n\\n希望对您有所帮助。\"},\"finish_reason\":\"stop\"}],\"usage\":{\"prompt_tokens\":9523,\"completion_tokens\":198,\"total_tokens\":9721}}\n",
      "2023-06-14 22:20:23,302 - common.py - [line]:39 - INFO - json_dict:{'id': 'chatcmpl-7RLdxKsLTCcjpD7eSUPIsL9zxggej', 'object': 'chat.completion', 'created': 1686752409, 'model': 'gpt-3.5-turbo-16k-0613', 'choices': [{'index': 0, 'message': {'role': 'assistant', 'content': '徐瑞华的临床试验如下：\\n1. NCT05830045：QLP2117治疗晚期实体瘤的I期研究\\n2. NCT05727839：JCXH-211单药治疗恶性实体肿瘤的I期开放标签研究\\n3. NCT03544905：CYH33治疗晚期实体瘤的I期剂量递增和剂量扩展研究\\n4. NCT01198392：S-1加顺铂与5-FU加顺铂一线治疗晚期胃癌的III期临床试验\\n\\n希望对您有所帮助。'}, 'finish_reason': 'stop'}], 'usage': {'prompt_tokens': 9523, 'completion_tokens': 198, 'total_tokens': 9721}}\n",
      "2023-06-14 22:20:23,303 - common.py - [line]:42 - INFO - 徐瑞华的临床试验如下：\n",
      "1. NCT05830045：QLP2117治疗晚期实体瘤的I期研究\n",
      "2. NCT05727839：JCXH-211单药治疗恶性实体肿瘤的I期开放标签研究\n",
      "3. NCT03544905：CYH33治疗晚期实体瘤的I期剂量递增和剂量扩展研究\n",
      "4. NCT01198392：S-1加顺铂与5-FU加顺铂一线治疗晚期胃癌的III期临床试验\n",
      "\n",
      "希望对您有所帮助。\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "+++++++++++++++++++++++++\n",
      "徐瑞华的临床试验如下：\n",
      "1. NCT05830045：QLP2117治疗晚期实体瘤的I期研究\n",
      "2. NCT05727839：JCXH-211单药治疗恶性实体肿瘤的I期开放标签研究\n",
      "3. NCT03544905：CYH33治疗晚期实体瘤的I期剂量递增和剂量扩展研究\n",
      "4. NCT01198392：S-1加顺铂与5-FU加顺铂一线治疗晚期胃癌的III期临床试验\n",
      "\n",
      "希望对您有所帮助。\n"
     ]
    }
   ],
   "source": [
    "chat(xrh_txt,\"徐瑞华的clinical trial有哪些，列出NCT编号\")"
   ],
   "metadata": {
    "collapsed": false,
    "ExecuteTime": {
     "end_time": "2023-06-14T14:20:23.321506Z",
     "start_time": "2023-06-14T14:20:03.901375500Z"
    }
   }
  },
  {
   "cell_type": "code",
   "execution_count": 11,
   "outputs": [
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "2023-06-14 22:20:57,245 - common.py - [line]:30 - INFO - get_openai_data: model:gpt-3.5-turbo-16k\n",
      "2023-06-14 22:21:20,484 - common.py - [line]:33 - INFO - <Response [200]>\n",
      "2023-06-14 22:21:20,485 - common.py - [line]:34 - INFO - query:\n",
      "    请根据以下context，回答：徐瑞华的clinical trial有哪些，列出NCT编号\n",
      "    reply in 简体中文\n",
      "    ---------context\n",
      "    \n",
      "[\n",
      "  {\n",
      "    \"_id\": \"648019f5778538384fd02da2\",\n",
      "    \"avatar\": null,\n",
      "    \"name\": \"Ruihua Xu\",\n",
      "    \"hospital\": \"Sun Yat-sen University\",\n",
      "    \"title\": \" MD\",\n",
      "    \"position\": null,\n",
      "    \"contact\": \"xuruihua@sysucc.org.cn\",\n",
      "    \"phone\": \"86-20-87343333\",\n",
      "    \"expertise\": \"Colorectal Carcinoma, pMMR, Microsatellite-stable\",\n",
      "    \"brief_intro\": \"A Study of Sintilimab and Chidamide in Combination With or Without IBI305 in Standard Treatment Failure of Advanced or Metastatic pMMR/MSS Colorectal Carcinoma\",\n",
      "    \"work_exp\": null,\n",
      "    \"edu_exp\": null,\n",
      "    \"consulting\": null,\n",
      "    \"publications\": null,\n",
      "    \"clinical_res\": null,\n",
      "    \"awards\": null\n",
      "  },\n",
      "  {\n",
      "    \"_id\": \"64803f25f24b55a336ba235d\",\n",
      "    \"avatar\": null,\n",
      "    \"name\": \"ruihua Xu\",\n",
      "    \"hospital\": \"Peking University\",\n",
      "    \"title\": \"M.D., Ph.D.\",\n",
      "    \"position\": null,\n",
      "    \"contact\": \"xurh@mail.sysu.edu.cn\",\n",
      "    \"phone\": \"13922206676\",\n",
      "    \"expertise\": \"nimotuzumab colorectal cancer chemotherapy\",\n",
      "    \"brief_intro\": null,\n",
      "    \"work_exp\": null,\n",
      "    \"edu_exp\": null,\n",
      "    \"consulting\": null,\n",
      "    \"publications\": null,\n",
      "    \"clinical_res\": \"Study of Nimotuzumab to Treat Colorectal Cancer\",\n",
      "    \"awards\": null\n",
      "  },\n",
      "  {\n",
      "    \"_id\": \"6480ea13f24b55a336bec613\",\n",
      "    \"avatar\": null,\n",
      "    \"name\": \"Ruihua Xu\",\n",
      "    \"hospital\": \"Sun Yat-sen University\",\n",
      "    \"title\": \"MD\",\n",
      "    \"position\": null,\n",
      "    \"contact\": \"xurh@susycc.org.cn\",\n",
      "    \"phone\": \"+862087343795\",\n",
      "    \"expertise\": \"Colorectal Cancer,Microsatellite Stable,Chidamide,Sintilimab,PD-1,Bevacizumab\",\n",
      "    \"brief_intro\": null,\n",
      "    \"work_exp\": null,\n",
      "    \"edu_exp\": null,\n",
      "    \"consulting\": null,\n",
      "    \"publications\": null,\n",
      "    \"clinical_res\": \"Comparing Chidamide+Sintilimab+Bev With Standard Second-line FOLFIRI+Bev in Advanced MSS/pMMR mCRC\",\n",
      "    \"awards\": null\n",
      "  }\n",
      "]\n",
      "[\n",
      "  {\n",
      "    \"NCT_No\": \"NCT05830045\",\n",
      "    First_Submitted_Date\": \"April 4, 2023\",\n",
      "    First_Posted_Date\": \"April 26, 2023\",\n",
      "    Last_Update_Posted_Date\": \"April 26, 2023\",\n",
      "    Estimated__Study_Start_Date\": \"April 20, 2023\",\n",
      "    Estimated_Primary_Completion_Date\": \"April 30, 2025   (Final data collection date for primary outcome measure)\",\n",
      "    Current_Primary_Outcome_Measures\": \"[List]\",\n",
      "    Original_Primary_Outcome_Measures\": \"Same as current\",\n",
      "    Change_History\": \"No Changes Posted\",\n",
      "    Current_Secondary_Outcome_Measures\": \"Not Provided\",\n",
      "    Original_Secondary_Outcome_Measures\": \"Not Provided\",\n",
      "    Current_Other_Pre-specified_Outcome_Measures\": \"Not Provided\",\n",
      "    Original_Other_Pre-specified_Outcome_Measures\": \"Not Provided\",\n",
      "    \"Brief_Title\": \"A Phase I Study of QLP2117 in Subjects With Advanced Solid Tumors\",\n",
      "    \"Official_Title\": \"A Study Evaluates the Safety, Pharmacokinetics, Immunogenicity and Efficacy of QLP2117 in Advanced Solid Tumor Patients\",\n",
      "    \"Brief_Summary\": \"This is the first in human study of QLP2117. To evaluate the Safety, Pharmacokinetics, Immunogenicity and Efficacy of QLP2117 in patients with advanced solid tumors.\",\n",
      "    \"Detailed_Description\": \"Not Provided\",\n",
      "    \"Study_Type\": \"Interventional\",\n",
      "    \"Study_Phase\": \"Phase 1\",\n",
      "    \"Study_Design\": \"Allocation: Non-Randomized\n",
      "Intervention Model: Sequential Assignment\n",
      "Masking: None (Open Label)\n",
      "Primary Purpose: Treatment\",\n",
      "    \"Condition\": \"Advanced Solid Tumors\",\n",
      "    \"Intervention\": \"Drug: QLP2117\n",
      "Specified dose on specified days\",\n",
      "    \"Study_Arms\": \"[List]\",\n",
      "    \"Publications_*\": \"Not Provided\",\n",
      "    \"Recruitment_Status\": \"Not yet recruiting\",\n",
      "    \"Estimated_Enrollment\": \"180\",\n",
      "    \"Original_Estimated_Enrollment\": \"Same as current\",\n",
      "    \"Estimated_Study_Completion_Date\": \"December 31, 2025\",\n",
      "    \"Estimated_Primary_Completion_Date\": \"April 30, 2025   (Final data collection date for primary outcome measure)\",\n",
      "    \"Eligibility_Criteria\": \"[List]\",\n",
      "    \"Sex/Gender\": \"Sexes Eligible for Study:\n",
      "   All\",\n",
      "    \"Ages\": \"18 Years and older   (Adult, Older Adult)\",\n",
      "    \"Accepts_Healthy_Volunteers\": \"No\",\n",
      "    \"Contacts\": \"Contact: Zhang Meijiang, PhD\n",
      "   8615210162105\n",
      "   meijiang.zhang@qilu-pharma.com\",\n",
      "    \"Listed_Location_Countries\": \"Not Provided\",\n",
      "    \"Removed_Location_Countries\": null,\n",
      "    \"NCT_Number\": \"NCT05830045\",\n",
      "    \"Other_Study_ID_Numbers\": \"QLP2117-101\",\n",
      "    \"Has_Data_Monitoring_Committee\": \"No\",\n",
      "    \"U.S._FDA-regulated_Product\": \"[List]\",\n",
      "    \"IPD_Sharing_Statement\": \"Plan to Share IPD:\n",
      "   No\",\n",
      "    \"Current_Responsible_Party\": \"Qilu Pharmaceutical Co., Ltd.\",\n",
      "    \"Original_Responsible_Party\": \"Same as current\",\n",
      "    \"Current_Study_Sponsor\": \"Qilu Pharmaceutical Co., Ltd.\",\n",
      "    \"Original_Study_Sponsor\": \"Same as current\",\n",
      "    \"Collaborators\": \"Not Provided\",\n",
      "    \"Investigators\": \"Principal Investigator:\n",
      "   Xu Ruihua, PhD\n",
      "   Sun Yat-sen University\",\n",
      "    \"PRS_Account\": \"Qilu Pharmaceutical Co., Ltd.\",\n",
      "    \"Verification_Date\": \"April 2023\"\n",
      "  },\n",
      "  {\n",
      "    \"NCT_No\": \"NCT05727839\",\n",
      "    First_Submitted_Date\": \"February 1, 2023\",\n",
      "    First_Posted_Date\": \"February 14, 2023\",\n",
      "    Last_Update_Posted_Date\": \"March 20, 2023\",\n",
      "    Estimated__Study_Start_Date\": \"February 24, 2023\",\n",
      "    Estimated_Primary_Completion_Date\": \"July 24, 2025   (Final data collection date for primary outcome measure)\",\n",
      "    Current_Primary_Outcome_Measures\": \"[List]\",\n",
      "    Original_Primary_Outcome_Measures\": \"[List]\",\n",
      "    Change_History\": \"Complete list of historical versions of study NCT05727839 on ClinicalTrials.gov Archive Site\",\n",
      "    Current_Secondary_Outcome_Measures\": \"[List]\",\n",
      "    Original_Secondary_Outcome_Measures\": \"[List]\",\n",
      "    Current_Other_Pre-specified_Outcome_Measures\": \"Not Provided\",\n",
      "    Original_Other_Pre-specified_Outcome_Measures\": \"Not Provided\",\n",
      "    \"Brief_Title\": \"Study to Evaluate JCXH-211 as Monotherapy in Patients With Malignant Solid Tumors\",\n",
      "    \"Official_Title\": \"A Phase 1 Open-Label Study to Evaluate the Safety, Tolerability and Efficacy of JCXH-211 Intratumoral Injection in Patients With Malignant Solid Tumors\",\n",
      "    \"Brief_Summary\": \": A Phase 1 Open-Label Study to Evaluate the Safety, Tolerability and Efficacy of JCXH-211 Intratumoral Injection in Patients with Malignant Solid Tumors\",\n",
      "    \"Detailed_Description\": \"The main purpose of this study is to find out how safe and tolerable the study drug, JCXH-211, is and also how well it works in people with malignant solid tumors. The study drug JCXH-211, is an immunotherapy drug. This means that it aims to work by boosting immune system's response to tumors, to help fight against the growth of the cancer cells. The study has 2 main phases: Phase\n",
      "  1a and Phase 1b. Phase 1a has 2 stages, skin/subcutaneous lesions stage, deep (visceral) lesions stage. Phase 1b will not start until all the data collected in Phase 1a has been completed and reviewed to check that it is safe and well tolerated.\",\n",
      "    \"Study_Type\": \"Interventional\",\n",
      "    \"Study_Phase\": \"Phase 1\",\n",
      "    \"Study_Design\": \"Allocation: Non-Randomized\n",
      "Intervention Model: Single Group Assignment\n",
      "Masking: None (Open Label)\n",
      "Primary Purpose: Treatment\",\n",
      "    \"Condition\": \"[List]\",\n",
      "    \"Intervention\": \"Drug: JCXH-211 Injection\n",
      "JCXH-211 administered once every 28 days\n",
      "Other Name: Intratumoral injection\",\n",
      "    \"Study_Arms\": \"[List]\",\n",
      "    \"Publications_*\": \"Not Provided\",\n",
      "    \"Recruitment_Status\": \"Recruiting\",\n",
      "    \"Estimated_Enrollment\": \"156\",\n",
      "    \"Original_Estimated_Enrollment\": \"Same as current\",\n",
      "    \"Estimated_Study_Completion_Date\": \"August 24, 2025\",\n",
      "    \"Estimated_Primary_Completion_Date\": \"July 24, 2025   (Final data collection date for primary outcome measure)\",\n",
      "    \"Eligibility_Criteria\": \"[List]\",\n",
      "    \"Sex/Gender\": \"Sexes Eligible for Study:\n",
      "   All\",\n",
      "    \"Ages\": \"18 Years to 75 Years   (Adult, Older Adult)\",\n",
      "    \"Accepts_Healthy_Volunteers\": \"No\",\n",
      "    \"Contacts\": \"Contact: Qi Wang\n",
      "   +8613381113913\n",
      "   qi.wang@immorna.com\",\n",
      "    \"Listed_Location_Countries\": \"China\",\n",
      "    \"Removed_Location_Countries\": null,\n",
      "    \"NCT_Number\": \"NCT05727839\",\n",
      "    \"Other_Study_ID_Numbers\": \"JCXH-211-003\",\n",
      "    \"Has_Data_Monitoring_Committee\": \"Not Provided\",\n",
      "    \"U.S._FDA-regulated_Product\": \"[List]\",\n",
      "    \"IPD_Sharing_Statement\": \"Not Provided\",\n",
      "    \"Current_Responsible_Party\": \"Immorna Biotherapeutics, Inc.\",\n",
      "    \"Original_Responsible_Party\": \"Same as current\",\n",
      "    \"Current_Study_Sponsor\": \"Immorna Biotherapeutics, Inc.\",\n",
      "    \"Original_Study_Sponsor\": \"Same as current\",\n",
      "    \"Collaborators\": \"Not Provided\",\n",
      "    \"Investigators\": \"Principal Investigator:\n",
      "   Xu ruihua, President\n",
      "   Sun Yat-sen University\",\n",
      "    \"PRS_Account\": \"Immorna Biotherapeutics, Inc.\",\n",
      "    \"Verification_Date\": \"March 2023\"\n",
      "  },\n",
      "  {\n",
      "    \"NCT_No\": \"NCT03544905\",\n",
      "    First_Submitted_Date\": \"May 22, 2018\",\n",
      "    First_Posted_Date\": \"June 4, 2018\",\n",
      "    Last_Update_Posted_Date\": \"January 6, 2023\",\n",
      "    Estimated__Study_Start_Date\": \"July 5, 2018\",\n",
      "    Estimated_Primary_Completion_Date\": \"June 30, 2023   (Final data collection date for primary outcome measure)\",\n",
      "    Current_Primary_Outcome_Measures\": \"MTD(Max tolerance does) [ Time Frame: 35 days ]To evaluate the MTD in patients with advanced solid tumor\",\n",
      "    Original_Primary_Outcome_Measures\": \"Same as current\",\n",
      "    Change_History\": \"Complete list of historical versions of study NCT03544905 on ClinicalTrials.gov Archive Site\",\n",
      "    Current_Secondary_Outcome_Measures\": \"Not Provided\",\n",
      "    Original_Secondary_Outcome_Measures\": \"Not Provided\",\n",
      "    Current_Other_Pre-specified_Outcome_Measures\": \"Not Provided\",\n",
      "    Original_Other_Pre-specified_Outcome_Measures\": \"Not Provided\",\n",
      "    \"Brief_Title\": \"Study to Evaluate the Safety, Tolerate, Pharmacokinetics and Preliminary Efficacy of CYH33\",\n",
      "    \"Official_Title\": \"A Multi-center, Open-label, Single Arm, Dose Escalation and Dose Extension Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of CYH33 in Advanced Solid Tumors Patients.\",\n",
      "    \"Brief_Summary\": \"This study is a Multi-center, Open-label, single arm, Dose Escalation and Dose Extension Phase 1 Study to Evaluate the Safety , Tolerability, Pharmacokinetics and Preliminary Efficacy of CYH33 in Advanced Solid Tumors Patients.\",\n",
      "    \"Detailed_Description\": \"This study includes Phase Ia and Phase Ib.\n",
      "  In the dose climbing part of phase Ia, the safety, tolerance and pharmacokinetics characteristics of CYH33 in patients with advanced solid tumors who failed to receive standard treatment, did not tolerate or did not have standard treatment at present will be observed to determine MTD; Before determining MTD, select safe and highly reliable and effective dose levels for simultaneous expansion. Phase Ia dose expansion includes patients with advanced solid tumors who have failed to undergo standard treatment, who are intolerant of PIK3CA gene mutation, or who do not have standard treatment at present, to further evaluate safety, tolerance and initial efficacy.\n",
      "  In Phase Ib, the safety and preliminary efficacy of CYH33 on patients with advanced breast cancer, ovarian cancer, endometrial cancer, cervical cancer, head and neck squamous cell carcinoma, esophageal and gastroesophageal junction squamous cell carcinoma, ovarian clear cell carcinoma and other solid tumors with PIK3CA gene mutation who have failed, are intolerant or do not have standard treatment at present will be evaluated.\",\n",
      "    \"Study_Type\": \"Interventional\",\n",
      "    \"Study_Phase\": \"Phase 1\",\n",
      "    \"Study_Design\": \"Allocation: N/A\n",
      "Intervention Model: Single Group Assignment\n",
      "Masking: None (Open Label)\n",
      "Primary Purpose: Treatment\",\n",
      "    \"Condition\": \"Advanced Solid Tumors\",\n",
      "    \"Intervention\": \"Drug: CYH33 for tablet\n",
      "1mg; 5mg; 10mg; 20mg; 30mg; 50mg; 75mg; 100mg; 130mg; 160mg; 200mg; 240mgBID or QD(Decided by SMC accroding to the safty and PK data)\",\n",
      "    \"Study_Arms\": \"Experimental: Dose escalation study of CYH33\n",
      "To determine the maximum tolerated dose (MTD) of CYH33\n",
      "Intervention: Drug: CYH33 for tablet\",\n",
      "    \"Publications_*\": \"Not Provided\",\n",
      "    \"Recruitment_Status\": \"Recruiting\",\n",
      "    \"Estimated_Enrollment\": \"100\",\n",
      "    \"Original_Estimated_Enrollment\": \"Same as current\",\n",
      "    \"Estimated_Study_Completion_Date\": \"March 31, 2024\",\n",
      "    \"Estimated_Primary_Completion_Date\": \"June 30, 2023   (Final data collection date for primary outcome measure)\",\n",
      "    \"Eligibility_Criteria\": \"[List]\",\n",
      "    \"Sex/Gender\": \"Sexes Eligible for Study:\n",
      "   All\",\n",
      "    \"Ages\": \"18 Years and older   (Adult, Older Adult)\",\n",
      "    \"Accepts_Healthy_Volunteers\": \"No\",\n",
      "    \"Contacts\": \"Contact: Ruihua Xu, M.D\n",
      "   86-20-87343804\n",
      "   ruihxu@163.com\",\n",
      "    \"Listed_Location_Countries\": \"China\",\n",
      "    \"Removed_Location_Countries\": null,\n",
      "    \"NCT_Number\": \"NCT03544905\",\n",
      "    \"Other_Study_ID_Numbers\": \"CYH33-101\",\n",
      "    \"Has_Data_Monitoring_Committee\": \"Yes\",\n",
      "    \"U.S._FDA-regulated_Product\": \"[List]\",\n",
      "    \"IPD_Sharing_Statement\": \"Not Provided\",\n",
      "    \"Current_Responsible_Party\": \"Haihe Biopharma Co., Ltd.\",\n",
      "    \"Original_Responsible_Party\": \"Same as current\",\n",
      "    \"Current_Study_Sponsor\": \"Haihe Biopharma Co., Ltd.\",\n",
      "    \"Original_Study_Sponsor\": \"Same as current\",\n",
      "    \"Collaborators\": \"Not Provided\",\n",
      "    \"Investigators\": \"Principal Investigator:\n",
      "   Ruihua Xu, M.D\n",
      "   Sun Yat-sen University\",\n",
      "    \"PRS_Account\": \"Haihe Biopharma Co., Ltd.\",\n",
      "    \"Verification_Date\": \"January 2023\"\n",
      "  },\n",
      "  {\n",
      "    \"NCT_No\": \"NCT01198392\",\n",
      "    First_Submitted_Date\": \"September 1, 2010\",\n",
      "    First_Posted_Date\": \"September 10, 2010\",\n",
      "    Last_Update_Posted_Date\": \"July 25, 2011\",\n",
      "    Estimated__Study_Start_Date\": \"September 2008\",\n",
      "    Estimated_Primary_Completion_Date\": \"December 2011   (Final data collection date for primary outcome measure)\",\n",
      "    Current_Primary_Outcome_Measures\": \"Time to progression [ Time Frame: The time from randomization until objective tumor progression or death ]\",\n",
      "    Original_Primary_Outcome_Measures\": \"Same as current\",\n",
      "    Change_History\": \"Complete list of historical versions of study NCT01198392 on ClinicalTrials.gov Archive Site\",\n",
      "    Current_Secondary_Outcome_Measures\": \"Response rate [ Time Frame: 2 months ]\",\n",
      "    Original_Secondary_Outcome_Measures\": \"Same as current\",\n",
      "    Current_Other_Pre-specified_Outcome_Measures\": \"Not Provided\",\n",
      "    Original_Other_Pre-specified_Outcome_Measures\": \"Not Provided\",\n",
      "    \"Brief_Title\": \"Trial of S-1 Plus Cisplatin in Gastric Cancer\",\n",
      "    \"Official_Title\": \"A Clinical Trial of S-1 Plus Cisplatin Versus 5-FU Plus Cisplatin in Patients With Unresectable or Advanced Gastric Cancer\",\n",
      "    \"Brief_Summary\": \"The purpose of this study is to evaluate the effectiveness and safety of s-1 plus cisplatin versus 5-FU plus cisplatin as first-line therapy in the treatment of patients with advanced gastric cancer.\",\n",
      "    \"Detailed_Description\": \"This is a randomized, controlled, open-label,multicenter study. Patients are randomized to one of two treatment arms : S-1 plus cisplatin and 5-FU plus cisplatin.\",\n",
      "    \"Study_Type\": \"Interventional\",\n",
      "    \"Study_Phase\": \"Phase 3\",\n",
      "    \"Study_Design\": \"Allocation: Randomized\n",
      "Intervention Model: Parallel Assignment\n",
      "Masking: None (Open Label)\n",
      "Primary Purpose: Treatment\",\n",
      "    \"Condition\": \"Gastric Cancer\",\n",
      "    \"Intervention\": \"[List]\",\n",
      "    \"Study_Arms\": \"[List]\",\n",
      "    \"Publications_*\": \"Li YH, Qiu MZ, Xu JM, Sun GP, Lu HS, Liu YP, Zhong MZ, Zhang HL, Yu SY, Li W, Hu XH, Wang JJ, Cheng Y, Zhou JT, Guo ZQ, Guan ZG, Xu RH. S-1 plus cisplatin versus fluorouracil plus cisplatin in advanced gastric or gastro-esophageal junction adenocarcinoma patients: a pilot study. Oncotarget. 2015 Oct 27;6(33):35107-15. doi: 10.18632/oncotarget.5959.\",\n",
      "    \"Recruitment_Status\": \"Unknown status\",\n",
      "    \"Estimated_Enrollment\": \"270\",\n",
      "    \"Original_Estimated_Enrollment\": \"Same as current\",\n",
      "    \"Estimated_Study_Completion_Date\": \"December 2011\",\n",
      "    \"Estimated_Primary_Completion_Date\": \"December 2011   (Final data collection date for primary outcome measure)\",\n",
      "    \"Eligibility_Criteria\": \"[List]\",\n",
      "    \"Sex/Gender\": \"Sexes Eligible for Study:\n",
      "   All\",\n",
      "    \"Ages\": \"18 Years to 75 Years   (Adult, Older Adult)\",\n",
      "    \"Accepts_Healthy_Volunteers\": \"No\",\n",
      "    \"Contacts\": \"Contact information is only displayed when the study is recruiting subjects\",\n",
      "    \"Listed_Location_Countries\": \"China\",\n",
      "    \"Removed_Location_Countries\": null,\n",
      "    \"NCT_Number\": \"NCT01198392\",\n",
      "    \"Other_Study_ID_Numbers\": \"2005L02859\",\n",
      "    \"Has_Data_Monitoring_Committee\": \"Yes\",\n",
      "    \"U.S._FDA-regulated_Product\": \"Not Provided\",\n",
      "    \"IPD_Sharing_Statement\": \"Not Provided\",\n",
      "    \"Current_Responsible_Party\": \"Zhongzhen Guan ,Ruihua Xu, Sun Yat-sen University Cancer Center\",\n",
      "    \"Original_Responsible_Party\": \"Same as current\",\n",
      "    \"Current_Study_Sponsor\": \"Sun Yat-sen University\",\n",
      "    \"Original_Study_Sponsor\": \"Same as current\",\n",
      "    \"Collaborators\": \"Not Provided\",\n",
      "    \"Investigators\": \"Principal Investigator:\n",
      "   RUIHUA XU, Professor\n",
      "   Sun Yat-sen University\",\n",
      "    \"PRS_Account\": \"Sun Yat-sen University\",\n",
      "    \"Verification_Date\": \"August 2008\"\n",
      "  }\n",
      "]\n",
      "\n",
      "徐瑞华，医学博士，中山大学肿瘤防治中心主任、医院院长、研究所所长，华南恶性肿瘤防治全国重点实验室主任，教授，博士生导师。\n",
      "\n",
      "中国医学科学院学部委员，中国临床肿瘤学会理事长，中国抗癌协会副理事长，中国抗癌协会靶向治疗专委会首届主任委员，中国抗癌协会化疗专委会候任主任委员，中国临床肿瘤学会肠癌专委会主任委员，《Cancer Communications》主编，研究生教材《肿瘤学》主编，本科生教材《临床肿瘤学》主编。\n",
      "\n",
      "从事肿瘤内科临床及科研工作30余年，取得突破性成果：\n",
      "\n",
      "第一，实现了肠癌诊治理论和实践的系统创新，使我国肠癌早诊及精准治疗均处于国际先进水平。创新了肠癌早诊及疗效预测的新技术，并已转化为临床应用；建立了晚期肠癌治疗新体系，创建了高效低毒的维持方案和亚洲方案，成为国际治疗新标准，晚期肠癌生存率与国际顶尖的安德森癌症中心达相同水平。\n",
      "\n",
      "第二，创新了消化肿瘤免疫治疗体系，引领国际消化肿瘤免疫治疗发展。\n",
      "\n",
      "通过鉴定TMB、POLE/POLD突变等标志物，精准筛选免疫治疗敏感亚型，大幅提高PD-1抗体疗效；首创了食管癌中国免疫联合方案，取得全球最高有效率72%，已成为食管癌治疗应用最广泛的方案；建立了食管癌EGIC分型，可以指导精准免疫治疗策略，引领该领域的发展；揭示了免疫逃逸新机制并推动了药物的开发：发现甲硫氨酸限制饮食可抑制免疫检查点分子PDL1及VISTA的表达，增强抗肿瘤免疫及抗PD1的治疗效果；鉴定出免疫治疗增效肠道活性菌RX-af01，成果已转化。\n",
      "\n",
      "以通讯或第一作者在国际顶级期刊JAMA、Nature Materials、Nature Medicine、Lancet Oncology等发表SCI论文200余篇，入选科睿唯安（Clarivate Analytics）全球高被引科学家，连续入选中国高被引学者榜单。以第一完成人获国家科技进步二等奖2项及省部级一等奖6项、吴阶平医药创新奖、谈家桢临床医学奖及CSCO年度成就奖。入选国家百千万人才工程、全国先进工作者、南粤百杰人才培养工程、国家卫生计生突出贡献中青年专家等人才项目。\n",
      "\n",
      "Representative paper: （*：第一作者，#：通讯作者）\n",
      "\n",
      "[1]     Luo H, Lu J, Bai Y, Mao T, Wang J, Fan Q, Zhang Y, Zhao K, Chen Z, Gao S, Li J, Fu Z, Gu K, Liu Z, Wu L, Zhang X, Feng J, Niu Z, Ba Y, Zhang H, Liu Y, Zhang L, Min X, Huang J, Cheng Y, Wang D, Shen Y, Yang Q, Zou J, Xu RH# ESCORT-1st Investigators.  Effect of Camrelizumab vs Placebo Added to Chemotherapy on Survival and Progression-Free Survival in Patients With Advanced or Metastatic Esophageal Squamous Cell Carcinoma: The ESCORT-1st Randomized Clinical Trial. JAMA. 2021 Sep 14;326(10):916-925.\n",
      "\n",
      "[2]     Xu RH*#, Wei W, Krawczyk M, Wang W, Luo H, Flagg K, Yi S, Shi W, Quan Q, Li K, Zheng L, Zhang H, Caughey BA, Zhao Q, Hou J, Zhang R, Xu Y, Cai H, Li G, Hou R, Zhong Z, Lin D, Fu X, Zhu J, Duan Y, Yu M, Ying B, Zhang W, Wang J, Zhang E, Zhang C, Li O, Guo R, Carter H, Zhu JK, Hao X and Zhang K. Circulating tumour DNA methylation markers for diagnosis and prognosis of hepatocellular carcinoma. Nat Mater 2017; 16: 1155-1161.\n",
      "\n",
      "[3]     Xu RH*#, Muro K, Morita S, Iwasa S, Han SW, Wang W, Kotaka M, Nakamura M, Ahn JB, Deng YH, Kato T, Cho SH, Ba Y, Matsuoka H, Lee KW, Zhang T, Yamada Y, Sakamoto J, Park YS and Kim TW. Modified XELIRI (capecitabine plus irinotecan) versus FOLFIRI (leucovorin, fluorouracil, and irinotecan), both either with or without bevacizumab, as second-line therapy for metastatic colorectal cancer (AXEPT): a multicentre, open-label, randomised, non-inferiority, phase 3 trial. Lancet Oncol 2018; 19: 660-671.\n",
      "\n",
      "[4]     Li J, Qin S, Xu R*, Yau TC, Ma B, Pan H, Xu J, Bai Y, Chi Y, Wang L, Yeh KH, Bi F, Cheng Y, Le AT, Lin JK, Liu T, Ma D, Kappeler C, Kalmus J and Kim TW. Regorafenib plus best supportive care versus placebo plus best supportive care in Asian patients with previously treated metastatic colorectal cancer (CONCUR): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncology 2015; 16: 619-629.\n",
      "\n",
      "[5]     Luo H, Xu G, Li C, He L, Luo L, Wang Z, Jing B, Deng Y, Jin Y, Li Y, Li B, Tan W, He C, Seeruttun SR, Wu Q, Huang J, Huang DW, Chen B, Lin SB, Chen QM, Yuan CM, Chen HX, Pu HY, Zhou F, He Y, Xu RH#. Real-time artificial intelligence for detection of upper gastrointestinal cancer by endoscopy: a multicentre, case-control, diagnostic study. Lancet Oncol. 2019 Oct 4.\n",
      "\n",
      "[6]     Satoh T, Xu RH*, Chung HC, Sun GP, Doi T, Xu JM, Tsuji A, Omuro Y, Li J, Wang JW, Miwa H, Qin SK, Chung IJ, Yeh KH, Feng JF, Mukaiyama A, Kobayashi M, Ohtsu A and Bang YJ. Lapatinib plus paclitaxel versus paclitaxel alone in the second-line treatment of HER2-amplified advanced gastric cancer in Asian populations: TyTAN--a randomized, phase III study. Journal of Clinical Oncology 2014; 32: 2039-2049.\n",
      "\n",
      "[7]     Manish A. Shah, Rui-hua Xu*, Yung-Jue Bang, Paulo M. Hoff, Tianshu Liu, Luis A. Herr´aez-Baranda, Fan Xia,Amit Garg, Mona Shing, and Josep Tabernero. HELOISE: Phase IIIb Randomized Multicenter Study Comparing Standard-of-Care and Higher-Dose Trastuzumab Regimens Combined With Chemotherapy as First-Line Therapy in Patients With Human Epidermal Growth Factor Receptor 2–Positive Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma. Journal of Clinical Oncology 2017; 35: 2558-2567.\n",
      "\n",
      "[8]     Wang ZX, Cui C, Yao J, Zhang Y, Li M, Feng J, Yang S, Fan Y, Shi J, Zhang X, Shen L, Shu Y, Wang C, Dai T, Mao T, Chen L, Guo Z, Liu B, Pan H, Cang S, Jiang Y, Wang J, Ye M, Chen Z, Jiang D, Lin Q, Ren W, Wang J, Wu L, Xu Y, Miao Z, Sun M, Xie C, Liu Y, Wang Q, Zhao L, Li Q, Huang C, Jiang K, Yang K, Li D, Liu Y, Zhu Z, Chen R, Jia L, Li W, Liao W, Liu HX, Ma D, Ma J, Qin Y, Shi Z, Wei Q, Xiao K, Zhang Y, Zhang Y, Chen X, Dai G, He J, Li J, Li G, Liu Y, Liu Z, Yuan X, Zhang J, Fu Z, He Y, Ju F, Liu Z, Tang P, Wang T, Wang W, Zhang J, Luo X, Tang X, May R, Feng H, Yao S, Keegan P, Xu RH#, Wang F. Toripalimab plus chemotherapy in treatment-naïve, advanced esophageal squamous cell carcinoma (JUPITER-06): A multi-center phase 3 trial. Cancer Cell. 2022 Mar 14;40(3):277-288.\n",
      "\n",
      "[9]     Wang F, Zhao Q, Wang YN, Jin Y, He MM, Liu ZX, Xu RH#. Evaluation of POLE and POLD1 Mutations as Biomarkers for Immunotherapy Outcomes Across Multiple Cancer Types. JAMA Oncol. 2019.\n",
      "\n",
      "[10]   Wang F, Liu DB, Zhao Q, Chen G, Liu XM, Wang YN, Su H, Qin YR, He YF, Zou QF, Liu YH, Lin YE, Liu ZX, Bei JX and Xu RH#. The genomic landscape of small cell carcinoma of the esophagus. Cell Res 2018; 28: 771-774.\n",
      "\n",
      "[11]   Wang DS, Liu ZX, Lu YX, Bao H, Wu X, Zeng ZL, Liu Z, Zhao Q, He CY, Lu JH, Wang ZQ, Qiu MZ, Wang F, Wang FH, Li YH, Wang XN, Xie D, Jia WH, Shao YW and Xu RH#. Liquid biopsies to track trastuzumab resistance in metastatic HER2-positive gastric cancer. Gut 2018;\n",
      "\n",
      "[12]   Feng Wang, You-Sheng Huang, Hao-Xiang Wu, Zi-Xian Wang, Ying Jin, Yi-Chen Yao, Yan-Xing Chen, Qi Zhao, Shifu Chen, Ming-Ming He, Hui-Yan Luo, Miao-Zhen Qiu, De-Shen Wang, Feng-Hua Wang, Mingyan Xu, Yu-Hong Li, Rui-Hua Xu#. Genomic temporal heterogeneity of circulating tumour DNA in unresectable metastatic colorectal cancer under first-line treatment. Gut. 2022 Jul;71(7):1340-1349.\n",
      "\n",
      "[13]   Luo HY, Li YH, Wang W, Wang ZQ, Yuan X, Ma D, Wang FH, Zhang DS, Lin DR, Lin YC, Jia J, Hu XH, Peng JW and Xu RH#. Single-agent capecitabine as maintenance therapy after induction of XELOX (or FOLFOX) in first-line treatment of metastatic colorectal cancer: randomized clinical trial of efficacy and safety. Annals of Oncology 2016; 27: 1074-1081.\n",
      "\n",
      "[14]   Wang F, Wei XL, Wang FH, Xu N, Shen L, Dai GH, Yuan XL, Chen Y, Yang SJ, Shi JH, Hu XC, Lin XY, Zhang QY, JF Feng, Y Ba, YP Liu, W Li, YQ Shu, Y Jiang, Q Li, JW Wang, H Wu, H Feng, S Yao, RH Xu#. Safety, efficacy and tumor mutational burden as a biomarker of overall survival benefit in chemo-refractory gastric cancer treated with toripalimab, a PD1 antibody in phase Ib/II clinical trial NCT02915432. Ann Oncol. 2019.\n",
      "\n",
      "[15]  Luo H, Zhao Q, Wei W, Zheng L, Yi S, Li G, Wang W, Sheng H, Pu H, Mo H, Zuo Z, Liu Z, Li C, Xie C, Zeng Z, Li W, Hao X, Liu Y, Cao S, Liu W, Gibson S, Zhang K, Xu G, Xu RH#. Circulating tumor DNA methylation profiles enable early diagnosis, prognosis prediction, and screening for colorectal cancer. Sci Transl Med. 2020 Jan 1;12(524).\n",
      "\n",
      "[16]   Li T, Hu PS, Zuo Z, Lin JF, Li X, Wu QN, Chen ZH, Zeng ZL, Wang F, Zheng J, Chen D, Li B, Kang TB, Dan Xie, Dongxin Lin, Huai-Qiang Ju, Rui-Hua Xu#. METTL3 facilitates tumor progression via an m(6)A-IGF2BP2-dependent mechanism in colorectal carcinoma. Mol Cancer. 2019; 18: 112.\n",
      "\n",
      "[17] Yun Wang, Jia-Huan Lu, Qi-Nian Wu, Ying Jin, De-Shen Wang, Yan-Xing Chen, Jia Liu, Xiao-Jing Luo, Qi Meng, Heng-Ying Pu, Ying-Nan Wang, Pei-Shan Hu, Ze-Xian Liu, Zhao-Lei Zeng, Qi Zhao, Rong Deng, Xiao-Feng Zhu, Huai-Qiang Ju, Rui-Hua Xu#. LncRNA LINRIS stabilizes IGF2BP2 and promotes the aerobic glycolysis in colorectal cancer. Molecular Cancer. 2019 Dec 2.\n",
      "\n",
      "[18]   Jin Y, Chen DL, Wang F, Yang CP, Chen XX, You JQ, Huang JS, Shao Y, Zhu DQ, Ouyang YM, Luo HY, Wang ZQ, Wang FH, Li YH, Xu RH#, Zhang DS. The predicting role of circulating tumor DNA landscape in gastric cancer patients treated with immune checkpoint inhibitors. Mol Cancer. 2020 Oct 30;19(1):154.\n",
      "\n",
      "[19]   Chen DL, Wang ZQ, Zeng ZL, Wu WJ, Zhang DS, Luo HY, Wang F, Qiu MZ, Wang DS, Ren C, Wang FH, Chiao LJ, Pelicano H, Huang P, Li YH and Xu RH#. Identification of microRNA-214 as a negative regulator of colorectal cancer liver metastasis by way of regulation of fibroblast growth factor receptor 1 expression. Hepatology 2014; 60: 598-609.\n",
      "\n",
      "[20]   Ju HQ, Li H, Tian T, Lu YX, Bai L, Chen LZ, Sheng H, Mo HY, Zeng JB, Deng W, Chiao PJ and Xu RH#. Melatonin overcomes gemcitabine resistance in pancreatic ductal adenocarcinoma by abrogating nuclear factor-kappaB activation. Journal of Pineal Research 2016; 60: 27-38.\n",
      "\n",
      "[21]   Ju HQ, Lin JF, Tian T, Xie D, Xu RH#. NADPH homeostasis in cancer: functions, mechanisms and therapeutic implications. Signal Transduct Tar. 2020 Oct 7;5(1):231.\n",
      "\n",
      "[22]  Hu PS, Li T, Lin JF, Qiu MZ, Wang DS, Liu ZX, Chen ZH, Yang LP, Zhang XL, Zhao Q, Chen YX, Lu YX, Wu QN, Pu HY, Zeng ZL, Xie D, Ju HQ, Luo HY, Xu RH#. VDR-SOX2 signaling promotes colorectal cancer stemness and malignancy in an acidic microenvironment. Signal Transduct Tar. 2020 Sep 9;5(1):183.\n",
      "\n",
      "[23]   Ju HQ, Ying H, Tian T, Ling J, Fu J, Lu Y, Wu M, Yang L, Achreja A, Chen G, Zhuang Z, Wang H, Nagrath D, Yao J, Hung MC, DePinho RA, Huang P, Xu RH# and Chiao PJ. Mutant Kras- and p16-regulated NOX4 activation overcomes metabolic checkpoints in development of pancreatic ductal adenocarcinoma. Nat Commun 2017; 8: 14437.\n",
      "\n",
      "[24]   Liu J, Liu ZX, Wu QN, Lu YX, Wong CW, Miao L, Wang Y, Wang Z, Jin Y, He MM, Ren C, Wang DS, Chen DL, Pu HY, Feng L, Li B, Xie D, Zeng MS, Huang P, Lin A, Lin D, Xu RH#, Ju HQ. Long noncoding RNA AGPG regulates PFKFB3-mediated tumor glycolytic reprogramming. Nat Commun. 2020 Mar 20;11(1):1507.\n",
      "\n",
      "[25]   Ju HQ, Lu YX, Chen DL, Zuo ZX, Liu ZX, Wu QN, Mo HY, Wang ZX, Wang DS, Pu HY, Zeng ZL, Li B, Xie D, Huang P, Hung MC, Chiao PJ and Xu RH#. Modulation of Redox Homeostasis by Inhibition of MTHFD2 in Colorectal Cancer: Mechanisms and Therapeutic Implications. J Natl Cancer Inst 2018\n",
      "\n",
      "[26] Yu K, Zhang Q, Liu Z, Zhao Q, Zhang X, Wang Y, Wang ZX, Jin Y, Li X, Liu ZX and Xu RH#. qPhos: a database of protein phosphorylation dynamics in humans. Nucleic Acids Res 2018\n",
      "\n",
      "[27] Rui-Hua Xu*, Jin Li, Yuxian Bai, Jianming Xu, Tianshu Liu, Lin Shen, Liwei Wang, Hongming Pan, Junning Cao, Dongsheng Zhang, Songhua Fan, Ye Hua & Weiguo Su. Safety and efficacy of fruquintinib in patients with previously treated metastatic colorectal cancer: a phase Ib study and a randomized double-blind phase II study. J Hematol Oncol. (2017) 10:22.\n",
      "\n",
      "[28] Gong Chen, Junjie Peng, Qian Xiao, Hao-Xiang Wu, Xiaojun Wu, Fulong Wang, Liren Li, Peirong Ding, Qi Zhao, Yaqi Li, Da Wang, Yang Shao, Hua Bao, Zhizhong Pan, Ke-Feng Ding, Sanjun Cai, Feng Wang, Rui-Hua Xu#. Postoperative circulating tumor DNA as markers of recurrence risk in stages II to III colorectal cancer. Journal of Hematology & Oncology. 2021 May 17;14(1):80.\n",
      "\n",
      "[29] Zeng ZL, Luo HY, Yang J, Wu WJ, Chen DL, Huang P and Xu RH#. Overexpression of the circadian clock gene Bmal1 increases sensitivity to oxaliplatin in colorectal cancer. Clinical Cancer Research 2014; 20: 1042-1052.\n",
      "\n",
      "[30] Huiyan Luo, Wei Wei, Ziyi Ye, Jiabo Zheng, Rui-hua Xu#. Liquid Biopsy of Methylation Biomarkers in Cell-Free DNA. Trends in Molecular Medicine. 23 Jan 2021.\n",
      "\n",
      "    ---------\n",
      "\n",
      "2023-06-14 22:21:20,486 - common.py - [line]:35 - INFO - real_query:\n",
      "    Notice: If doctor or hospital not in the context, skip this one 假如你是数据工程师，请把如下个人信息按照JSON的格式整理给我：（参考字段：行医，门诊时间，综合评价，资质认证状态，基本信息，简介，姓名，医院/机构，专长，职务，职称，学术兼职，地区，邮箱，手机，昕康ID/XK_ID，履历，教育经历，工作经历，研究，研究方向/临床研究，课题/基金，发表，发表文章，出版著作，专利和软著，执笔共识，成就，荣誉获奖）Return only the translation and nothing else:\n",
      "\n",
      "    query:\n",
      "    请根据以下context，回答：徐瑞华的clinical trial有哪些，列出NCT编号\n",
      "    reply in 简体中文\n",
      "    ---------context\n",
      "    \n",
      "[\n",
      "  {\n",
      "    \"_id\": \"648019f5778538384fd02da2\",\n",
      "    \"avatar\": null,\n",
      "    \"name\": \"Ruihua Xu\",\n",
      "    \"hospital\": \"Sun Yat-sen University\",\n",
      "    \"title\": \" MD\",\n",
      "    \"position\": null,\n",
      "    \"contact\": \"xuruihua@sysucc.org.cn\",\n",
      "    \"phone\": \"86-20-87343333\",\n",
      "    \"expertise\": \"Colorectal Carcinoma, pMMR, Microsatellite-stable\",\n",
      "    \"brief_intro\": \"A Study of Sintilimab and Chidamide in Combination With or Without IBI305 in Standard Treatment Failure of Advanced or Metastatic pMMR/MSS Colorectal Carcinoma\",\n",
      "    \"work_exp\": null,\n",
      "    \"edu_exp\": null,\n",
      "    \"consulting\": null,\n",
      "    \"publications\": null,\n",
      "    \"clinical_res\": null,\n",
      "    \"awards\": null\n",
      "  },\n",
      "  {\n",
      "    \"_id\": \"64803f25f24b55a336ba235d\",\n",
      "    \"avatar\": null,\n",
      "    \"name\": \"ruihua Xu\",\n",
      "    \"hospital\": \"Peking University\",\n",
      "    \"title\": \"M.D., Ph.D.\",\n",
      "    \"position\": null,\n",
      "    \"contact\": \"xurh@mail.sysu.edu.cn\",\n",
      "    \"phone\": \"13922206676\",\n",
      "    \"expertise\": \"nimotuzumab colorectal cancer chemotherapy\",\n",
      "    \"brief_intro\": null,\n",
      "    \"work_exp\": null,\n",
      "    \"edu_exp\": null,\n",
      "    \"consulting\": null,\n",
      "    \"publications\": null,\n",
      "    \"clinical_res\": \"Study of Nimotuzumab to Treat Colorectal Cancer\",\n",
      "    \"awards\": null\n",
      "  },\n",
      "  {\n",
      "    \"_id\": \"6480ea13f24b55a336bec613\",\n",
      "    \"avatar\": null,\n",
      "    \"name\": \"Ruihua Xu\",\n",
      "    \"hospital\": \"Sun Yat-sen University\",\n",
      "    \"title\": \"MD\",\n",
      "    \"position\": null,\n",
      "    \"contact\": \"xurh@susycc.org.cn\",\n",
      "    \"phone\": \"+862087343795\",\n",
      "    \"expertise\": \"Colorectal Cancer,Microsatellite Stable,Chidamide,Sintilimab,PD-1,Bevacizumab\",\n",
      "    \"brief_intro\": null,\n",
      "    \"work_exp\": null,\n",
      "    \"edu_exp\": null,\n",
      "    \"consulting\": null,\n",
      "    \"publications\": null,\n",
      "    \"clinical_res\": \"Comparing Chidamide+Sintilimab+Bev With Standard Second-line FOLFIRI+Bev in Advanced MSS/pMMR mCRC\",\n",
      "    \"awards\": null\n",
      "  }\n",
      "]\n",
      "[\n",
      "  {\n",
      "    \"NCT_No\": \"NCT05830045\",\n",
      "    First_Submitted_Date\": \"April 4, 2023\",\n",
      "    First_Posted_Date\": \"April 26, 2023\",\n",
      "    Last_Update_Posted_Date\": \"April 26, 2023\",\n",
      "    Estimated__Study_Start_Date\": \"April 20, 2023\",\n",
      "    Estimated_Primary_Completion_Date\": \"April 30, 2025   (Final data collection date for primary outcome measure)\",\n",
      "    Current_Primary_Outcome_Measures\": \"[List]\",\n",
      "    Original_Primary_Outcome_Measures\": \"Same as current\",\n",
      "    Change_History\": \"No Changes Posted\",\n",
      "    Current_Secondary_Outcome_Measures\": \"Not Provided\",\n",
      "    Original_Secondary_Outcome_Measures\": \"Not Provided\",\n",
      "    Current_Other_Pre-specified_Outcome_Measures\": \"Not Provided\",\n",
      "    Original_Other_Pre-specified_Outcome_Measures\": \"Not Provided\",\n",
      "    \"Brief_Title\": \"A Phase I Study of QLP2117 in Subjects With Advanced Solid Tumors\",\n",
      "    \"Official_Title\": \"A Study Evaluates the Safety, Pharmacokinetics, Immunogenicity and Efficacy of QLP2117 in Advanced Solid Tumor Patients\",\n",
      "    \"Brief_Summary\": \"This is the first in human study of QLP2117. To evaluate the Safety, Pharmacokinetics, Immunogenicity and Efficacy of QLP2117 in patients with advanced solid tumors.\",\n",
      "    \"Detailed_Description\": \"Not Provided\",\n",
      "    \"Study_Type\": \"Interventional\",\n",
      "    \"Study_Phase\": \"Phase 1\",\n",
      "    \"Study_Design\": \"Allocation: Non-Randomized\n",
      "Intervention Model: Sequential Assignment\n",
      "Masking: None (Open Label)\n",
      "Primary Purpose: Treatment\",\n",
      "    \"Condition\": \"Advanced Solid Tumors\",\n",
      "    \"Intervention\": \"Drug: QLP2117\n",
      "Specified dose on specified days\",\n",
      "    \"Study_Arms\": \"[List]\",\n",
      "    \"Publications_*\": \"Not Provided\",\n",
      "    \"Recruitment_Status\": \"Not yet recruiting\",\n",
      "    \"Estimated_Enrollment\": \"180\",\n",
      "    \"Original_Estimated_Enrollment\": \"Same as current\",\n",
      "    \"Estimated_Study_Completion_Date\": \"December 31, 2025\",\n",
      "    \"Estimated_Primary_Completion_Date\": \"April 30, 2025   (Final data collection date for primary outcome measure)\",\n",
      "    \"Eligibility_Criteria\": \"[List]\",\n",
      "    \"Sex/Gender\": \"Sexes Eligible for Study:\n",
      "   All\",\n",
      "    \"Ages\": \"18 Years and older   (Adult, Older Adult)\",\n",
      "    \"Accepts_Healthy_Volunteers\": \"No\",\n",
      "    \"Contacts\": \"Contact: Zhang Meijiang, PhD\n",
      "   8615210162105\n",
      "   meijiang.zhang@qilu-pharma.com\",\n",
      "    \"Listed_Location_Countries\": \"Not Provided\",\n",
      "    \"Removed_Location_Countries\": null,\n",
      "    \"NCT_Number\": \"NCT05830045\",\n",
      "    \"Other_Study_ID_Numbers\": \"QLP2117-101\",\n",
      "    \"Has_Data_Monitoring_Committee\": \"No\",\n",
      "    \"U.S._FDA-regulated_Product\": \"[List]\",\n",
      "    \"IPD_Sharing_Statement\": \"Plan to Share IPD:\n",
      "   No\",\n",
      "    \"Current_Responsible_Party\": \"Qilu Pharmaceutical Co., Ltd.\",\n",
      "    \"Original_Responsible_Party\": \"Same as current\",\n",
      "    \"Current_Study_Sponsor\": \"Qilu Pharmaceutical Co., Ltd.\",\n",
      "    \"Original_Study_Sponsor\": \"Same as current\",\n",
      "    \"Collaborators\": \"Not Provided\",\n",
      "    \"Investigators\": \"Principal Investigator:\n",
      "   Xu Ruihua, PhD\n",
      "   Sun Yat-sen University\",\n",
      "    \"PRS_Account\": \"Qilu Pharmaceutical Co., Ltd.\",\n",
      "    \"Verification_Date\": \"April 2023\"\n",
      "  },\n",
      "  {\n",
      "    \"NCT_No\": \"NCT05727839\",\n",
      "    First_Submitted_Date\": \"February 1, 2023\",\n",
      "    First_Posted_Date\": \"February 14, 2023\",\n",
      "    Last_Update_Posted_Date\": \"March 20, 2023\",\n",
      "    Estimated__Study_Start_Date\": \"February 24, 2023\",\n",
      "    Estimated_Primary_Completion_Date\": \"July 24, 2025   (Final data collection date for primary outcome measure)\",\n",
      "    Current_Primary_Outcome_Measures\": \"[List]\",\n",
      "    Original_Primary_Outcome_Measures\": \"[List]\",\n",
      "    Change_History\": \"Complete list of historical versions of study NCT05727839 on ClinicalTrials.gov Archive Site\",\n",
      "    Current_Secondary_Outcome_Measures\": \"[List]\",\n",
      "    Original_Secondary_Outcome_Measures\": \"[List]\",\n",
      "    Current_Other_Pre-specified_Outcome_Measures\": \"Not Provided\",\n",
      "    Original_Other_Pre-specified_Outcome_Measures\": \"Not Provided\",\n",
      "    \"Brief_Title\": \"Study to Evaluate JCXH-211 as Monotherapy in Patients With Malignant Solid Tumors\",\n",
      "    \"Official_Title\": \"A Phase 1 Open-Label Study to Evaluate the Safety, Tolerability and Efficacy of JCXH-211 Intratumoral Injection in Patients With Malignant Solid Tumors\",\n",
      "    \"Brief_Summary\": \": A Phase 1 Open-Label Study to Evaluate the Safety, Tolerability and Efficacy of JCXH-211 Intratumoral Injection in Patients with Malignant Solid Tumors\",\n",
      "    \"Detailed_Description\": \"The main purpose of this study is to find out how safe and tolerable the study drug, JCXH-211, is and also how well it works in people with malignant solid tumors. The study drug JCXH-211, is an immunotherapy drug. This means that it aims to work by boosting immune system's response to tumors, to help fight against the growth of the cancer cells. The study has 2 main phases: Phase\n",
      "  1a and Phase 1b. Phase 1a has 2 stages, skin/subcutaneous lesions stage, deep (visceral) lesions stage. Phase 1b will not start until all the data collected in Phase 1a has been completed and reviewed to check that it is safe and well tolerated.\",\n",
      "    \"Study_Type\": \"Interventional\",\n",
      "    \"Study_Phase\": \"Phase 1\",\n",
      "    \"Study_Design\": \"Allocation: Non-Randomized\n",
      "Intervention Model: Single Group Assignment\n",
      "Masking: None (Open Label)\n",
      "Primary Purpose: Treatment\",\n",
      "    \"Condition\": \"[List]\",\n",
      "    \"Intervention\": \"Drug: JCXH-211 Injection\n",
      "JCXH-211 administered once every 28 days\n",
      "Other Name: Intratumoral injection\",\n",
      "    \"Study_Arms\": \"[List]\",\n",
      "    \"Publications_*\": \"Not Provided\",\n",
      "    \"Recruitment_Status\": \"Recruiting\",\n",
      "    \"Estimated_Enrollment\": \"156\",\n",
      "    \"Original_Estimated_Enrollment\": \"Same as current\",\n",
      "    \"Estimated_Study_Completion_Date\": \"August 24, 2025\",\n",
      "    \"Estimated_Primary_Completion_Date\": \"July 24, 2025   (Final data collection date for primary outcome measure)\",\n",
      "    \"Eligibility_Criteria\": \"[List]\",\n",
      "    \"Sex/Gender\": \"Sexes Eligible for Study:\n",
      "   All\",\n",
      "    \"Ages\": \"18 Years to 75 Years   (Adult, Older Adult)\",\n",
      "    \"Accepts_Healthy_Volunteers\": \"No\",\n",
      "    \"Contacts\": \"Contact: Qi Wang\n",
      "   +8613381113913\n",
      "   qi.wang@immorna.com\",\n",
      "    \"Listed_Location_Countries\": \"China\",\n",
      "    \"Removed_Location_Countries\": null,\n",
      "    \"NCT_Number\": \"NCT05727839\",\n",
      "    \"Other_Study_ID_Numbers\": \"JCXH-211-003\",\n",
      "    \"Has_Data_Monitoring_Committee\": \"Not Provided\",\n",
      "    \"U.S._FDA-regulated_Product\": \"[List]\",\n",
      "    \"IPD_Sharing_Statement\": \"Not Provided\",\n",
      "    \"Current_Responsible_Party\": \"Immorna Biotherapeutics, Inc.\",\n",
      "    \"Original_Responsible_Party\": \"Same as current\",\n",
      "    \"Current_Study_Sponsor\": \"Immorna Biotherapeutics, Inc.\",\n",
      "    \"Original_Study_Sponsor\": \"Same as current\",\n",
      "    \"Collaborators\": \"Not Provided\",\n",
      "    \"Investigators\": \"Principal Investigator:\n",
      "   Xu ruihua, President\n",
      "   Sun Yat-sen University\",\n",
      "    \"PRS_Account\": \"Immorna Biotherapeutics, Inc.\",\n",
      "    \"Verification_Date\": \"March 2023\"\n",
      "  },\n",
      "  {\n",
      "    \"NCT_No\": \"NCT03544905\",\n",
      "    First_Submitted_Date\": \"May 22, 2018\",\n",
      "    First_Posted_Date\": \"June 4, 2018\",\n",
      "    Last_Update_Posted_Date\": \"January 6, 2023\",\n",
      "    Estimated__Study_Start_Date\": \"July 5, 2018\",\n",
      "    Estimated_Primary_Completion_Date\": \"June 30, 2023   (Final data collection date for primary outcome measure)\",\n",
      "    Current_Primary_Outcome_Measures\": \"MTD(Max tolerance does) [ Time Frame: 35 days ]To evaluate the MTD in patients with advanced solid tumor\",\n",
      "    Original_Primary_Outcome_Measures\": \"Same as current\",\n",
      "    Change_History\": \"Complete list of historical versions of study NCT03544905 on ClinicalTrials.gov Archive Site\",\n",
      "    Current_Secondary_Outcome_Measures\": \"Not Provided\",\n",
      "    Original_Secondary_Outcome_Measures\": \"Not Provided\",\n",
      "    Current_Other_Pre-specified_Outcome_Measures\": \"Not Provided\",\n",
      "    Original_Other_Pre-specified_Outcome_Measures\": \"Not Provided\",\n",
      "    \"Brief_Title\": \"Study to Evaluate the Safety, Tolerate, Pharmacokinetics and Preliminary Efficacy of CYH33\",\n",
      "    \"Official_Title\": \"A Multi-center, Open-label, Single Arm, Dose Escalation and Dose Extension Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of CYH33 in Advanced Solid Tumors Patients.\",\n",
      "    \"Brief_Summary\": \"This study is a Multi-center, Open-label, single arm, Dose Escalation and Dose Extension Phase 1 Study to Evaluate the Safety , Tolerability, Pharmacokinetics and Preliminary Efficacy of CYH33 in Advanced Solid Tumors Patients.\",\n",
      "    \"Detailed_Description\": \"This study includes Phase Ia and Phase Ib.\n",
      "  In the dose climbing part of phase Ia, the safety, tolerance and pharmacokinetics characteristics of CYH33 in patients with advanced solid tumors who failed to receive standard treatment, did not tolerate or did not have standard treatment at present will be observed to determine MTD; Before determining MTD, select safe and highly reliable and effective dose levels for simultaneous expansion. Phase Ia dose expansion includes patients with advanced solid tumors who have failed to undergo standard treatment, who are intolerant of PIK3CA gene mutation, or who do not have standard treatment at present, to further evaluate safety, tolerance and initial efficacy.\n",
      "  In Phase Ib, the safety and preliminary efficacy of CYH33 on patients with advanced breast cancer, ovarian cancer, endometrial cancer, cervical cancer, head and neck squamous cell carcinoma, esophageal and gastroesophageal junction squamous cell carcinoma, ovarian clear cell carcinoma and other solid tumors with PIK3CA gene mutation who have failed, are intolerant or do not have standard treatment at present will be evaluated.\",\n",
      "    \"Study_Type\": \"Interventional\",\n",
      "    \"Study_Phase\": \"Phase 1\",\n",
      "    \"Study_Design\": \"Allocation: N/A\n",
      "Intervention Model: Single Group Assignment\n",
      "Masking: None (Open Label)\n",
      "Primary Purpose: Treatment\",\n",
      "    \"Condition\": \"Advanced Solid Tumors\",\n",
      "    \"Intervention\": \"Drug: CYH33 for tablet\n",
      "1mg; 5mg; 10mg; 20mg; 30mg; 50mg; 75mg; 100mg; 130mg; 160mg; 200mg; 240mgBID or QD(Decided by SMC accroding to the safty and PK data)\",\n",
      "    \"Study_Arms\": \"Experimental: Dose escalation study of CYH33\n",
      "To determine the maximum tolerated dose (MTD) of CYH33\n",
      "Intervention: Drug: CYH33 for tablet\",\n",
      "    \"Publications_*\": \"Not Provided\",\n",
      "    \"Recruitment_Status\": \"Recruiting\",\n",
      "    \"Estimated_Enrollment\": \"100\",\n",
      "    \"Original_Estimated_Enrollment\": \"Same as current\",\n",
      "    \"Estimated_Study_Completion_Date\": \"March 31, 2024\",\n",
      "    \"Estimated_Primary_Completion_Date\": \"June 30, 2023   (Final data collection date for primary outcome measure)\",\n",
      "    \"Eligibility_Criteria\": \"[List]\",\n",
      "    \"Sex/Gender\": \"Sexes Eligible for Study:\n",
      "   All\",\n",
      "    \"Ages\": \"18 Years and older   (Adult, Older Adult)\",\n",
      "    \"Accepts_Healthy_Volunteers\": \"No\",\n",
      "    \"Contacts\": \"Contact: Ruihua Xu, M.D\n",
      "   86-20-87343804\n",
      "   ruihxu@163.com\",\n",
      "    \"Listed_Location_Countries\": \"China\",\n",
      "    \"Removed_Location_Countries\": null,\n",
      "    \"NCT_Number\": \"NCT03544905\",\n",
      "    \"Other_Study_ID_Numbers\": \"CYH33-101\",\n",
      "    \"Has_Data_Monitoring_Committee\": \"Yes\",\n",
      "    \"U.S._FDA-regulated_Product\": \"[List]\",\n",
      "    \"IPD_Sharing_Statement\": \"Not Provided\",\n",
      "    \"Current_Responsible_Party\": \"Haihe Biopharma Co., Ltd.\",\n",
      "    \"Original_Responsible_Party\": \"Same as current\",\n",
      "    \"Current_Study_Sponsor\": \"Haihe Biopharma Co., Ltd.\",\n",
      "    \"Original_Study_Sponsor\": \"Same as current\",\n",
      "    \"Collaborators\": \"Not Provided\",\n",
      "    \"Investigators\": \"Principal Investigator:\n",
      "   Ruihua Xu, M.D\n",
      "   Sun Yat-sen University\",\n",
      "    \"PRS_Account\": \"Haihe Biopharma Co., Ltd.\",\n",
      "    \"Verification_Date\": \"January 2023\"\n",
      "  },\n",
      "  {\n",
      "    \"NCT_No\": \"NCT01198392\",\n",
      "    First_Submitted_Date\": \"September 1, 2010\",\n",
      "    First_Posted_Date\": \"September 10, 2010\",\n",
      "    Last_Update_Posted_Date\": \"July 25, 2011\",\n",
      "    Estimated__Study_Start_Date\": \"September 2008\",\n",
      "    Estimated_Primary_Completion_Date\": \"December 2011   (Final data collection date for primary outcome measure)\",\n",
      "    Current_Primary_Outcome_Measures\": \"Time to progression [ Time Frame: The time from randomization until objective tumor progression or death ]\",\n",
      "    Original_Primary_Outcome_Measures\": \"Same as current\",\n",
      "    Change_History\": \"Complete list of historical versions of study NCT01198392 on ClinicalTrials.gov Archive Site\",\n",
      "    Current_Secondary_Outcome_Measures\": \"Response rate [ Time Frame: 2 months ]\",\n",
      "    Original_Secondary_Outcome_Measures\": \"Same as current\",\n",
      "    Current_Other_Pre-specified_Outcome_Measures\": \"Not Provided\",\n",
      "    Original_Other_Pre-specified_Outcome_Measures\": \"Not Provided\",\n",
      "    \"Brief_Title\": \"Trial of S-1 Plus Cisplatin in Gastric Cancer\",\n",
      "    \"Official_Title\": \"A Clinical Trial of S-1 Plus Cisplatin Versus 5-FU Plus Cisplatin in Patients With Unresectable or Advanced Gastric Cancer\",\n",
      "    \"Brief_Summary\": \"The purpose of this study is to evaluate the effectiveness and safety of s-1 plus cisplatin versus 5-FU plus cisplatin as first-line therapy in the treatment of patients with advanced gastric cancer.\",\n",
      "    \"Detailed_Description\": \"This is a randomized, controlled, open-label,multicenter study. Patients are randomized to one of two treatment arms : S-1 plus cisplatin and 5-FU plus cisplatin.\",\n",
      "    \"Study_Type\": \"Interventional\",\n",
      "    \"Study_Phase\": \"Phase 3\",\n",
      "    \"Study_Design\": \"Allocation: Randomized\n",
      "Intervention Model: Parallel Assignment\n",
      "Masking: None (Open Label)\n",
      "Primary Purpose: Treatment\",\n",
      "    \"Condition\": \"Gastric Cancer\",\n",
      "    \"Intervention\": \"[List]\",\n",
      "    \"Study_Arms\": \"[List]\",\n",
      "    \"Publications_*\": \"Li YH, Qiu MZ, Xu JM, Sun GP, Lu HS, Liu YP, Zhong MZ, Zhang HL, Yu SY, Li W, Hu XH, Wang JJ, Cheng Y, Zhou JT, Guo ZQ, Guan ZG, Xu RH. S-1 plus cisplatin versus fluorouracil plus cisplatin in advanced gastric or gastro-esophageal junction adenocarcinoma patients: a pilot study. Oncotarget. 2015 Oct 27;6(33):35107-15. doi: 10.18632/oncotarget.5959.\",\n",
      "    \"Recruitment_Status\": \"Unknown status\",\n",
      "    \"Estimated_Enrollment\": \"270\",\n",
      "    \"Original_Estimated_Enrollment\": \"Same as current\",\n",
      "    \"Estimated_Study_Completion_Date\": \"December 2011\",\n",
      "    \"Estimated_Primary_Completion_Date\": \"December 2011   (Final data collection date for primary outcome measure)\",\n",
      "    \"Eligibility_Criteria\": \"[List]\",\n",
      "    \"Sex/Gender\": \"Sexes Eligible for Study:\n",
      "   All\",\n",
      "    \"Ages\": \"18 Years to 75 Years   (Adult, Older Adult)\",\n",
      "    \"Accepts_Healthy_Volunteers\": \"No\",\n",
      "    \"Contacts\": \"Contact information is only displayed when the study is recruiting subjects\",\n",
      "    \"Listed_Location_Countries\": \"China\",\n",
      "    \"Removed_Location_Countries\": null,\n",
      "    \"NCT_Number\": \"NCT01198392\",\n",
      "    \"Other_Study_ID_Numbers\": \"2005L02859\",\n",
      "    \"Has_Data_Monitoring_Committee\": \"Yes\",\n",
      "    \"U.S._FDA-regulated_Product\": \"Not Provided\",\n",
      "    \"IPD_Sharing_Statement\": \"Not Provided\",\n",
      "    \"Current_Responsible_Party\": \"Zhongzhen Guan ,Ruihua Xu, Sun Yat-sen University Cancer Center\",\n",
      "    \"Original_Responsible_Party\": \"Same as current\",\n",
      "    \"Current_Study_Sponsor\": \"Sun Yat-sen University\",\n",
      "    \"Original_Study_Sponsor\": \"Same as current\",\n",
      "    \"Collaborators\": \"Not Provided\",\n",
      "    \"Investigators\": \"Principal Investigator:\n",
      "   RUIHUA XU, Professor\n",
      "   Sun Yat-sen University\",\n",
      "    \"PRS_Account\": \"Sun Yat-sen University\",\n",
      "    \"Verification_Date\": \"August 2008\"\n",
      "  }\n",
      "]\n",
      "\n",
      "徐瑞华，医学博士，中山大学肿瘤防治中心主任、医院院长、研究所所长，华南恶性肿瘤防治全国重点实验室主任，教授，博士生导师。\n",
      "\n",
      "中国医学科学院学部委员，中国临床肿瘤学会理事长，中国抗癌协会副理事长，中国抗癌协会靶向治疗专委会首届主任委员，中国抗癌协会化疗专委会候任主任委员，中国临床肿瘤学会肠癌专委会主任委员，《Cancer Communications》主编，研究生教材《肿瘤学》主编，本科生教材《临床肿瘤学》主编。\n",
      "\n",
      "从事肿瘤内科临床及科研工作30余年，取得突破性成果：\n",
      "\n",
      "第一，实现了肠癌诊治理论和实践的系统创新，使我国肠癌早诊及精准治疗均处于国际先进水平。创新了肠癌早诊及疗效预测的新技术，并已转化为临床应用；建立了晚期肠癌治疗新体系，创建了高效低毒的维持方案和亚洲方案，成为国际治疗新标准，晚期肠癌生存率与国际顶尖的安德森癌症中心达相同水平。\n",
      "\n",
      "第二，创新了消化肿瘤免疫治疗体系，引领国际消化肿瘤免疫治疗发展。\n",
      "\n",
      "通过鉴定TMB、POLE/POLD突变等标志物，精准筛选免疫治疗敏感亚型，大幅提高PD-1抗体疗效；首创了食管癌中国免疫联合方案，取得全球最高有效率72%，已成为食管癌治疗应用最广泛的方案；建立了食管癌EGIC分型，可以指导精准免疫治疗策略，引领该领域的发展；揭示了免疫逃逸新机制并推动了药物的开发：发现甲硫氨酸限制饮食可抑制免疫检查点分子PDL1及VISTA的表达，增强抗肿瘤免疫及抗PD1的治疗效果；鉴定出免疫治疗增效肠道活性菌RX-af01，成果已转化。\n",
      "\n",
      "以通讯或第一作者在国际顶级期刊JAMA、Nature Materials、Nature Medicine、Lancet Oncology等发表SCI论文200余篇，入选科睿唯安（Clarivate Analytics）全球高被引科学家，连续入选中国高被引学者榜单。以第一完成人获国家科技进步二等奖2项及省部级一等奖6项、吴阶平医药创新奖、谈家桢临床医学奖及CSCO年度成就奖。入选国家百千万人才工程、全国先进工作者、南粤百杰人才培养工程、国家卫生计生突出贡献中青年专家等人才项目。\n",
      "\n",
      "Representative paper: （*：第一作者，#：通讯作者）\n",
      "\n",
      "[1]     Luo H, Lu J, Bai Y, Mao T, Wang J, Fan Q, Zhang Y, Zhao K, Chen Z, Gao S, Li J, Fu Z, Gu K, Liu Z, Wu L, Zhang X, Feng J, Niu Z, Ba Y, Zhang H, Liu Y, Zhang L, Min X, Huang J, Cheng Y, Wang D, Shen Y, Yang Q, Zou J, Xu RH# ESCORT-1st Investigators.  Effect of Camrelizumab vs Placebo Added to Chemotherapy on Survival and Progression-Free Survival in Patients With Advanced or Metastatic Esophageal Squamous Cell Carcinoma: The ESCORT-1st Randomized Clinical Trial. JAMA. 2021 Sep 14;326(10):916-925.\n",
      "\n",
      "[2]     Xu RH*#, Wei W, Krawczyk M, Wang W, Luo H, Flagg K, Yi S, Shi W, Quan Q, Li K, Zheng L, Zhang H, Caughey BA, Zhao Q, Hou J, Zhang R, Xu Y, Cai H, Li G, Hou R, Zhong Z, Lin D, Fu X, Zhu J, Duan Y, Yu M, Ying B, Zhang W, Wang J, Zhang E, Zhang C, Li O, Guo R, Carter H, Zhu JK, Hao X and Zhang K. Circulating tumour DNA methylation markers for diagnosis and prognosis of hepatocellular carcinoma. Nat Mater 2017; 16: 1155-1161.\n",
      "\n",
      "[3]     Xu RH*#, Muro K, Morita S, Iwasa S, Han SW, Wang W, Kotaka M, Nakamura M, Ahn JB, Deng YH, Kato T, Cho SH, Ba Y, Matsuoka H, Lee KW, Zhang T, Yamada Y, Sakamoto J, Park YS and Kim TW. Modified XELIRI (capecitabine plus irinotecan) versus FOLFIRI (leucovorin, fluorouracil, and irinotecan), both either with or without bevacizumab, as second-line therapy for metastatic colorectal cancer (AXEPT): a multicentre, open-label, randomised, non-inferiority, phase 3 trial. Lancet Oncol 2018; 19: 660-671.\n",
      "\n",
      "[4]     Li J, Qin S, Xu R*, Yau TC, Ma B, Pan H, Xu J, Bai Y, Chi Y, Wang L, Yeh KH, Bi F, Cheng Y, Le AT, Lin JK, Liu T, Ma D, Kappeler C, Kalmus J and Kim TW. Regorafenib plus best supportive care versus placebo plus best supportive care in Asian patients with previously treated metastatic colorectal cancer (CONCUR): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncology 2015; 16: 619-629.\n",
      "\n",
      "[5]     Luo H, Xu G, Li C, He L, Luo L, Wang Z, Jing B, Deng Y, Jin Y, Li Y, Li B, Tan W, He C, Seeruttun SR, Wu Q, Huang J, Huang DW, Chen B, Lin SB, Chen QM, Yuan CM, Chen HX, Pu HY, Zhou F, He Y, Xu RH#. Real-time artificial intelligence for detection of upper gastrointestinal cancer by endoscopy: a multicentre, case-control, diagnostic study. Lancet Oncol. 2019 Oct 4.\n",
      "\n",
      "[6]     Satoh T, Xu RH*, Chung HC, Sun GP, Doi T, Xu JM, Tsuji A, Omuro Y, Li J, Wang JW, Miwa H, Qin SK, Chung IJ, Yeh KH, Feng JF, Mukaiyama A, Kobayashi M, Ohtsu A and Bang YJ. Lapatinib plus paclitaxel versus paclitaxel alone in the second-line treatment of HER2-amplified advanced gastric cancer in Asian populations: TyTAN--a randomized, phase III study. Journal of Clinical Oncology 2014; 32: 2039-2049.\n",
      "\n",
      "[7]     Manish A. Shah, Rui-hua Xu*, Yung-Jue Bang, Paulo M. Hoff, Tianshu Liu, Luis A. Herr´aez-Baranda, Fan Xia,Amit Garg, Mona Shing, and Josep Tabernero. HELOISE: Phase IIIb Randomized Multicenter Study Comparing Standard-of-Care and Higher-Dose Trastuzumab Regimens Combined With Chemotherapy as First-Line Therapy in Patients With Human Epidermal Growth Factor Receptor 2–Positive Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma. Journal of Clinical Oncology 2017; 35: 2558-2567.\n",
      "\n",
      "[8]     Wang ZX, Cui C, Yao J, Zhang Y, Li M, Feng J, Yang S, Fan Y, Shi J, Zhang X, Shen L, Shu Y, Wang C, Dai T, Mao T, Chen L, Guo Z, Liu B, Pan H, Cang S, Jiang Y, Wang J, Ye M, Chen Z, Jiang D, Lin Q, Ren W, Wang J, Wu L, Xu Y, Miao Z, Sun M, Xie C, Liu Y, Wang Q, Zhao L, Li Q, Huang C, Jiang K, Yang K, Li D, Liu Y, Zhu Z, Chen R, Jia L, Li W, Liao W, Liu HX, Ma D, Ma J, Qin Y, Shi Z, Wei Q, Xiao K, Zhang Y, Zhang Y, Chen X, Dai G, He J, Li J, Li G, Liu Y, Liu Z, Yuan X, Zhang J, Fu Z, He Y, Ju F, Liu Z, Tang P, Wang T, Wang W, Zhang J, Luo X, Tang X, May R, Feng H, Yao S, Keegan P, Xu RH#, Wang F. Toripalimab plus chemotherapy in treatment-naïve, advanced esophageal squamous cell carcinoma (JUPITER-06): A multi-center phase 3 trial. Cancer Cell. 2022 Mar 14;40(3):277-288.\n",
      "\n",
      "[9]     Wang F, Zhao Q, Wang YN, Jin Y, He MM, Liu ZX, Xu RH#. Evaluation of POLE and POLD1 Mutations as Biomarkers for Immunotherapy Outcomes Across Multiple Cancer Types. JAMA Oncol. 2019.\n",
      "\n",
      "[10]   Wang F, Liu DB, Zhao Q, Chen G, Liu XM, Wang YN, Su H, Qin YR, He YF, Zou QF, Liu YH, Lin YE, Liu ZX, Bei JX and Xu RH#. The genomic landscape of small cell carcinoma of the esophagus. Cell Res 2018; 28: 771-774.\n",
      "\n",
      "[11]   Wang DS, Liu ZX, Lu YX, Bao H, Wu X, Zeng ZL, Liu Z, Zhao Q, He CY, Lu JH, Wang ZQ, Qiu MZ, Wang F, Wang FH, Li YH, Wang XN, Xie D, Jia WH, Shao YW and Xu RH#. Liquid biopsies to track trastuzumab resistance in metastatic HER2-positive gastric cancer. Gut 2018;\n",
      "\n",
      "[12]   Feng Wang, You-Sheng Huang, Hao-Xiang Wu, Zi-Xian Wang, Ying Jin, Yi-Chen Yao, Yan-Xing Chen, Qi Zhao, Shifu Chen, Ming-Ming He, Hui-Yan Luo, Miao-Zhen Qiu, De-Shen Wang, Feng-Hua Wang, Mingyan Xu, Yu-Hong Li, Rui-Hua Xu#. Genomic temporal heterogeneity of circulating tumour DNA in unresectable metastatic colorectal cancer under first-line treatment. Gut. 2022 Jul;71(7):1340-1349.\n",
      "\n",
      "[13]   Luo HY, Li YH, Wang W, Wang ZQ, Yuan X, Ma D, Wang FH, Zhang DS, Lin DR, Lin YC, Jia J, Hu XH, Peng JW and Xu RH#. Single-agent capecitabine as maintenance therapy after induction of XELOX (or FOLFOX) in first-line treatment of metastatic colorectal cancer: randomized clinical trial of efficacy and safety. Annals of Oncology 2016; 27: 1074-1081.\n",
      "\n",
      "[14]   Wang F, Wei XL, Wang FH, Xu N, Shen L, Dai GH, Yuan XL, Chen Y, Yang SJ, Shi JH, Hu XC, Lin XY, Zhang QY, JF Feng, Y Ba, YP Liu, W Li, YQ Shu, Y Jiang, Q Li, JW Wang, H Wu, H Feng, S Yao, RH Xu#. Safety, efficacy and tumor mutational burden as a biomarker of overall survival benefit in chemo-refractory gastric cancer treated with toripalimab, a PD1 antibody in phase Ib/II clinical trial NCT02915432. Ann Oncol. 2019.\n",
      "\n",
      "[15]  Luo H, Zhao Q, Wei W, Zheng L, Yi S, Li G, Wang W, Sheng H, Pu H, Mo H, Zuo Z, Liu Z, Li C, Xie C, Zeng Z, Li W, Hao X, Liu Y, Cao S, Liu W, Gibson S, Zhang K, Xu G, Xu RH#. Circulating tumor DNA methylation profiles enable early diagnosis, prognosis prediction, and screening for colorectal cancer. Sci Transl Med. 2020 Jan 1;12(524).\n",
      "\n",
      "[16]   Li T, Hu PS, Zuo Z, Lin JF, Li X, Wu QN, Chen ZH, Zeng ZL, Wang F, Zheng J, Chen D, Li B, Kang TB, Dan Xie, Dongxin Lin, Huai-Qiang Ju, Rui-Hua Xu#. METTL3 facilitates tumor progression via an m(6)A-IGF2BP2-dependent mechanism in colorectal carcinoma. Mol Cancer. 2019; 18: 112.\n",
      "\n",
      "[17] Yun Wang, Jia-Huan Lu, Qi-Nian Wu, Ying Jin, De-Shen Wang, Yan-Xing Chen, Jia Liu, Xiao-Jing Luo, Qi Meng, Heng-Ying Pu, Ying-Nan Wang, Pei-Shan Hu, Ze-Xian Liu, Zhao-Lei Zeng, Qi Zhao, Rong Deng, Xiao-Feng Zhu, Huai-Qiang Ju, Rui-Hua Xu#. LncRNA LINRIS stabilizes IGF2BP2 and promotes the aerobic glycolysis in colorectal cancer. Molecular Cancer. 2019 Dec 2.\n",
      "\n",
      "[18]   Jin Y, Chen DL, Wang F, Yang CP, Chen XX, You JQ, Huang JS, Shao Y, Zhu DQ, Ouyang YM, Luo HY, Wang ZQ, Wang FH, Li YH, Xu RH#, Zhang DS. The predicting role of circulating tumor DNA landscape in gastric cancer patients treated with immune checkpoint inhibitors. Mol Cancer. 2020 Oct 30;19(1):154.\n",
      "\n",
      "[19]   Chen DL, Wang ZQ, Zeng ZL, Wu WJ, Zhang DS, Luo HY, Wang F, Qiu MZ, Wang DS, Ren C, Wang FH, Chiao LJ, Pelicano H, Huang P, Li YH and Xu RH#. Identification of microRNA-214 as a negative regulator of colorectal cancer liver metastasis by way of regulation of fibroblast growth factor receptor 1 expression. Hepatology 2014; 60: 598-609.\n",
      "\n",
      "[20]   Ju HQ, Li H, Tian T, Lu YX, Bai L, Chen LZ, Sheng H, Mo HY, Zeng JB, Deng W, Chiao PJ and Xu RH#. Melatonin overcomes gemcitabine resistance in pancreatic ductal adenocarcinoma by abrogating nuclear factor-kappaB activation. Journal of Pineal Research 2016; 60: 27-38.\n",
      "\n",
      "[21]   Ju HQ, Lin JF, Tian T, Xie D, Xu RH#. NADPH homeostasis in cancer: functions, mechanisms and therapeutic implications. Signal Transduct Tar. 2020 Oct 7;5(1):231.\n",
      "\n",
      "[22]  Hu PS, Li T, Lin JF, Qiu MZ, Wang DS, Liu ZX, Chen ZH, Yang LP, Zhang XL, Zhao Q, Chen YX, Lu YX, Wu QN, Pu HY, Zeng ZL, Xie D, Ju HQ, Luo HY, Xu RH#. VDR-SOX2 signaling promotes colorectal cancer stemness and malignancy in an acidic microenvironment. Signal Transduct Tar. 2020 Sep 9;5(1):183.\n",
      "\n",
      "[23]   Ju HQ, Ying H, Tian T, Ling J, Fu J, Lu Y, Wu M, Yang L, Achreja A, Chen G, Zhuang Z, Wang H, Nagrath D, Yao J, Hung MC, DePinho RA, Huang P, Xu RH# and Chiao PJ. Mutant Kras- and p16-regulated NOX4 activation overcomes metabolic checkpoints in development of pancreatic ductal adenocarcinoma. Nat Commun 2017; 8: 14437.\n",
      "\n",
      "[24]   Liu J, Liu ZX, Wu QN, Lu YX, Wong CW, Miao L, Wang Y, Wang Z, Jin Y, He MM, Ren C, Wang DS, Chen DL, Pu HY, Feng L, Li B, Xie D, Zeng MS, Huang P, Lin A, Lin D, Xu RH#, Ju HQ. Long noncoding RNA AGPG regulates PFKFB3-mediated tumor glycolytic reprogramming. Nat Commun. 2020 Mar 20;11(1):1507.\n",
      "\n",
      "[25]   Ju HQ, Lu YX, Chen DL, Zuo ZX, Liu ZX, Wu QN, Mo HY, Wang ZX, Wang DS, Pu HY, Zeng ZL, Li B, Xie D, Huang P, Hung MC, Chiao PJ and Xu RH#. Modulation of Redox Homeostasis by Inhibition of MTHFD2 in Colorectal Cancer: Mechanisms and Therapeutic Implications. J Natl Cancer Inst 2018\n",
      "\n",
      "[26] Yu K, Zhang Q, Liu Z, Zhao Q, Zhang X, Wang Y, Wang ZX, Jin Y, Li X, Liu ZX and Xu RH#. qPhos: a database of protein phosphorylation dynamics in humans. Nucleic Acids Res 2018\n",
      "\n",
      "[27] Rui-Hua Xu*, Jin Li, Yuxian Bai, Jianming Xu, Tianshu Liu, Lin Shen, Liwei Wang, Hongming Pan, Junning Cao, Dongsheng Zhang, Songhua Fan, Ye Hua & Weiguo Su. Safety and efficacy of fruquintinib in patients with previously treated metastatic colorectal cancer: a phase Ib study and a randomized double-blind phase II study. J Hematol Oncol. (2017) 10:22.\n",
      "\n",
      "[28] Gong Chen, Junjie Peng, Qian Xiao, Hao-Xiang Wu, Xiaojun Wu, Fulong Wang, Liren Li, Peirong Ding, Qi Zhao, Yaqi Li, Da Wang, Yang Shao, Hua Bao, Zhizhong Pan, Ke-Feng Ding, Sanjun Cai, Feng Wang, Rui-Hua Xu#. Postoperative circulating tumor DNA as markers of recurrence risk in stages II to III colorectal cancer. Journal of Hematology & Oncology. 2021 May 17;14(1):80.\n",
      "\n",
      "[29] Zeng ZL, Luo HY, Yang J, Wu WJ, Chen DL, Huang P and Xu RH#. Overexpression of the circadian clock gene Bmal1 increases sensitivity to oxaliplatin in colorectal cancer. Clinical Cancer Research 2014; 20: 1042-1052.\n",
      "\n",
      "[30] Huiyan Luo, Wei Wei, Ziyi Ye, Jiabo Zheng, Rui-hua Xu#. Liquid Biopsy of Methylation Biomarkers in Cell-Free DNA. Trends in Molecular Medicine. 23 Jan 2021.\n",
      "\n",
      "    ---------\n",
      "\n",
      "\n",
      "2023-06-14 22:21:20,487 - common.py - [line]:36 - INFO - response.status_code:200, response.text:{\"id\":\"chatcmpl-7RLeqhhnQTkun1EPpCkpShKAHJC00\",\"object\":\"chat.completion\",\"created\":1686752464,\"model\":\"gpt-3.5-turbo-16k-0613\",\"choices\":[{\"index\":0,\"message\":{\"role\":\"assistant\",\"content\":\"{\\n  \\\"clinical_trials\\\": [\\n    {\\n      \\\"name\\\": \\\"A Phase I Study of QLP2117 in Subjects With Advanced Solid Tumors\\\",\\n      \\\"NCT_number\\\": \\\"NCT05830045\\\"\\n    },\\n    {\\n      \\\"name\\\": \\\"Study of Nimotuzumab to Treat Colorectal Cancer\\\",\\n      \\\"NCT_number\\\": \\\"NCT05727839\\\"\\n    },\\n    {\\n      \\\"name\\\": \\\"A Multi-center, Open-label, Single Arm, Dose Escalation and Dose Extension Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of CYH33 in Advanced Solid Tumors Patients.\\\",\\n      \\\"NCT_number\\\": \\\"NCT03544905\\\"\\n    },\\n    {\\n      \\\"name\\\": \\\"A Clinical Trial of S-1 Plus Cisplatin Versus 5-FU Plus Cisplatin in Patients With Unresectable or Advanced Gastric Cancer\\\",\\n      \\\"NCT_number\\\": \\\"NCT01198392\\\"\\n    }\\n  ]\\n}\"},\"finish_reason\":\"stop\"}],\"usage\":{\"prompt_tokens\":9523,\"completion_tokens\":220,\"total_tokens\":9743}}\n",
      "2023-06-14 22:21:20,488 - common.py - [line]:39 - INFO - json_dict:{'id': 'chatcmpl-7RLeqhhnQTkun1EPpCkpShKAHJC00', 'object': 'chat.completion', 'created': 1686752464, 'model': 'gpt-3.5-turbo-16k-0613', 'choices': [{'index': 0, 'message': {'role': 'assistant', 'content': '{\\n  \"clinical_trials\": [\\n    {\\n      \"name\": \"A Phase I Study of QLP2117 in Subjects With Advanced Solid Tumors\",\\n      \"NCT_number\": \"NCT05830045\"\\n    },\\n    {\\n      \"name\": \"Study of Nimotuzumab to Treat Colorectal Cancer\",\\n      \"NCT_number\": \"NCT05727839\"\\n    },\\n    {\\n      \"name\": \"A Multi-center, Open-label, Single Arm, Dose Escalation and Dose Extension Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of CYH33 in Advanced Solid Tumors Patients.\",\\n      \"NCT_number\": \"NCT03544905\"\\n    },\\n    {\\n      \"name\": \"A Clinical Trial of S-1 Plus Cisplatin Versus 5-FU Plus Cisplatin in Patients With Unresectable or Advanced Gastric Cancer\",\\n      \"NCT_number\": \"NCT01198392\"\\n    }\\n  ]\\n}'}, 'finish_reason': 'stop'}], 'usage': {'prompt_tokens': 9523, 'completion_tokens': 220, 'total_tokens': 9743}}\n",
      "2023-06-14 22:21:20,491 - common.py - [line]:42 - INFO - {\n",
      "  \"clinical_trials\": [\n",
      "    {\n",
      "      \"name\": \"A Phase I Study of QLP2117 in Subjects With Advanced Solid Tumors\",\n",
      "      \"NCT_number\": \"NCT05830045\"\n",
      "    },\n",
      "    {\n",
      "      \"name\": \"Study of Nimotuzumab to Treat Colorectal Cancer\",\n",
      "      \"NCT_number\": \"NCT05727839\"\n",
      "    },\n",
      "    {\n",
      "      \"name\": \"A Multi-center, Open-label, Single Arm, Dose Escalation and Dose Extension Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of CYH33 in Advanced Solid Tumors Patients.\",\n",
      "      \"NCT_number\": \"NCT03544905\"\n",
      "    },\n",
      "    {\n",
      "      \"name\": \"A Clinical Trial of S-1 Plus Cisplatin Versus 5-FU Plus Cisplatin in Patients With Unresectable or Advanced Gastric Cancer\",\n",
      "      \"NCT_number\": \"NCT01198392\"\n",
      "    }\n",
      "  ]\n",
      "}\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "+++++++++++++++++++++++++\n",
      "{\n",
      "  \"clinical_trials\": [\n",
      "    {\n",
      "      \"name\": \"A Phase I Study of QLP2117 in Subjects With Advanced Solid Tumors\",\n",
      "      \"NCT_number\": \"NCT05830045\"\n",
      "    },\n",
      "    {\n",
      "      \"name\": \"Study of Nimotuzumab to Treat Colorectal Cancer\",\n",
      "      \"NCT_number\": \"NCT05727839\"\n",
      "    },\n",
      "    {\n",
      "      \"name\": \"A Multi-center, Open-label, Single Arm, Dose Escalation and Dose Extension Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of CYH33 in Advanced Solid Tumors Patients.\",\n",
      "      \"NCT_number\": \"NCT03544905\"\n",
      "    },\n",
      "    {\n",
      "      \"name\": \"A Clinical Trial of S-1 Plus Cisplatin Versus 5-FU Plus Cisplatin in Patients With Unresectable or Advanced Gastric Cancer\",\n",
      "      \"NCT_number\": \"NCT01198392\"\n",
      "    }\n",
      "  ]\n",
      "}\n"
     ]
    }
   ],
   "source": [
    "chat(xrh_txt,\"徐瑞华的clinical trial有哪些，列出NCT编号\")\n"
   ],
   "metadata": {
    "collapsed": false,
    "ExecuteTime": {
     "end_time": "2023-06-14T14:21:20.501680Z",
     "start_time": "2023-06-14T14:20:57.255579Z"
    }
   }
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "outputs": [],
   "source": [],
   "metadata": {
    "collapsed": false
   }
  }
 ],
 "metadata": {
  "kernelspec": {
   "display_name": "Python 3",
   "language": "python",
   "name": "python3"
  },
  "language_info": {
   "codemirror_mode": {
    "name": "ipython",
    "version": 2
   },
   "file_extension": ".py",
   "mimetype": "text/x-python",
   "name": "python",
   "nbconvert_exporter": "python",
   "pygments_lexer": "ipython2",
   "version": "2.7.6"
  }
 },
 "nbformat": 4,
 "nbformat_minor": 0
}
